assay_id,doc_id,description,assay_type,assay_test_type,assay_category,assay_organism,assay_tax_id,assay_strain,assay_tissue,assay_cell_type,assay_subcellular_fraction,tid,relationship_type,confidence_score,curated_by,src_id,src_assay_id,chembl_id,cell_id,bao_format,tissue_id,variant_id
1,11087,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615117,,BAO_0000019,,
2,684,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615118,,BAO_0000219,,
3,15453,,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615119,,BAO_0000019,,
4,17841,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,B,,,Bos taurus,9913.0,,,,,104729,H,4,Autocuration,1,,CHEMBL615120,,BAO_0000249,,
5,17430,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615121,163.0,BAO_0000219,,
6,17430,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615122,163.0,BAO_0000219,,
7,13799,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,F,,,Mus musculus,10090.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615123,163.0,BAO_0000219,,
8,17774,In vitro cell cytotoxicity was determined against 143B cell line,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Expert,1,,CHEMBL615124,163.0,BAO_0000219,,
9,3801,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615125,163.0,BAO_0000219,,
10,17430,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615126,163.0,BAO_0000219,,
11,17430,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615127,163.0,BAO_0000219,,
12,17774,In vitro cell cytotoxicity was determined against 143B-LTK cell line,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Expert,1,,CHEMBL615128,163.0,BAO_0000219,,
13,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Intermediate,1,,CHEMBL857900,,BAO_0000218,,
14,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Intermediate,1,,CHEMBL615129,,BAO_0000218,,
15,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Intermediate,1,,CHEMBL615130,,BAO_0000218,,
16,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Intermediate,1,,CHEMBL615131,,BAO_0000218,,
17,11347,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,A,,,Rattus norvegicus,10116.0,,,,,100122,D,9,Expert,1,,CHEMBL884521,,BAO_0000357,,
18,16474,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615132,,BAO_0000357,,
19,10091,Inhibition of partially purified 15-lipoxygenase from human leukocytes,B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615133,,BAO_0000019,,
20,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615134,,BAO_0000357,,
21,16474,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615135,,BAO_0000357,,
22,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615136,,BAO_0000357,,
23,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615137,,BAO_0000357,,
24,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615138,,BAO_0000357,,
25,14352,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL836324,,BAO_0000219,,
26,5646,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,B,,,Oryctolagus cuniculus,9986.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615139,,BAO_0000357,,
27,5646,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),B,,,Oryctolagus cuniculus,9986.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615140,,BAO_0000357,,
28,10997,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,B,,,,,,,,,12426,H,8,Autocuration,1,,CHEMBL615141,,BAO_0000219,,
29,6309,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,B,,,soya bean,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615142,,BAO_0000357,,
30,167,Inhibitory activity against soybean 15-lipoxygenase was evaluated,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615143,,BAO_0000357,,
31,167,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615144,,BAO_0000357,,
32,11087,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL872867,,BAO_0000357,,
33,11087,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615145,,BAO_0000357,,
34,13622,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615146,,BAO_0000357,,
35,13622,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615147,,BAO_0000357,,
36,11347,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,A,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615148,,BAO_0000019,,
37,5926,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,B,,,Escherichia coli,562.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615149,,BAO_0000019,,
38,4567,Dissociation constant with dimeric 16S rRNA RNA construct B,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615150,,BAO_0000019,,
39,3782,Dissociation constant towards 16S rRNA construct A,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615151,,BAO_0000225,,
40,3782,Dissociation constant towards 16S rRNA construct B,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615152,,BAO_0000225,,
41,4466,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,B,,,Escherichia coli,562.0,,,,,100263,M,3,Expert,1,,CHEMBL615153,,BAO_0000225,,
42,6592,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,B,,,Escherichia coli,562.0,,,,,100263,M,3,Expert,1,,CHEMBL615154,,BAO_0000225,,
43,898,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,,,,,13053,H,8,Autocuration,1,,CHEMBL615155,,BAO_0000019,,
44,898,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,,,,,13053,H,8,Autocuration,1,,CHEMBL615156,,BAO_0000019,,
45,13163,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,,Homo sapiens,9606.0,,,,,20001,H,8,Autocuration,1,,CHEMBL615157,,BAO_0000019,,
46,13163,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,,Homo sapiens,9606.0,,,,,20001,H,8,Autocuration,1,,CHEMBL615158,,BAO_0000019,,
47,10691,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,,Rattus norvegicus,10116.0,,,,,12971,D,9,Expert,1,,CHEMBL615159,,BAO_0000019,,
48,10691,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,,Rattus norvegicus,10116.0,,,,,12971,D,9,Expert,1,,CHEMBL615172,,BAO_0000019,,
49,10691,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,,Rattus norvegicus,10116.0,,,,,12971,D,9,Expert,1,,CHEMBL615173,,BAO_0000019,,
50,10691,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,,Rattus norvegicus,10116.0,,,,,12971,D,9,Expert,1,,CHEMBL615174,,BAO_0000019,,
51,898,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,,,,,13053,H,8,Autocuration,1,,CHEMBL884518,,BAO_0000019,,
52,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),B,,,,,,,,,11512,H,8,Autocuration,1,,CHEMBL615175,,BAO_0000357,,
53,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,B,,,,,,,,,11512,H,8,Autocuration,1,,CHEMBL615176,,BAO_0000357,,
54,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,B,,,,,,,,,11512,H,8,Autocuration,1,,CHEMBL615177,,BAO_0000357,,
55,15103,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,104740,D,5,Autocuration,1,,CHEMBL615178,,BAO_0000249,,
56,5116,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615179,506.0,BAO_0000219,,
57,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,F,,,Rattus norvegicus,10116.0,,,Oocytes,,104835,D,7,Autocuration,1,,CHEMBL615180,,BAO_0000219,,
58,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,F,,,Rattus norvegicus,10116.0,,,Oocytes,,104821,D,7,Autocuration,1,,CHEMBL615181,,BAO_0000219,,
59,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,F,,,Rattus norvegicus,10116.0,,,Oocytes,,104848,D,7,Autocuration,1,,CHEMBL615182,,BAO_0000219,,
60,4787,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL615183,506.0,BAO_0000219,,
61,4787,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615184,506.0,BAO_0000219,,
62,3547,Cytotoxic activity against human ovarian cancer (1A9) cell line,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615185,506.0,BAO_0000219,,
63,3547,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615186,506.0,BAO_0000219,,
64,6726,Effective dose of compound against replication of 1A9 cell line was evaluated,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615187,506.0,BAO_0000219,,
65,3455,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL885343,506.0,BAO_0000219,,
66,5726,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615188,506.0,BAO_0000219,,
67,5726,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615189,506.0,BAO_0000219,,
68,5726,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615190,506.0,BAO_0000219,,
69,3395,Inhibitory activity against Taxol resistant 1A9 cell lines,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615191,506.0,BAO_0000219,,
70,3415,Cytotoxicity against human ovarian cancer (1A9) cell lines.,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL615192,506.0,BAO_0000219,,
71,3415,Percentage inhibition of human ovarian cancer (1A9) cell lines.,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL827083,506.0,BAO_0000219,,
72,17099,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL615193,506.0,BAO_0000219,,
73,17099,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615194,506.0,BAO_0000219,,
74,17099,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615195,506.0,BAO_0000219,,
75,17099,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615196,506.0,BAO_0000219,,
76,17721,Inhibitory concentration against Jurkat cells,F,,,Homo sapiens,9606.0,,,Jurkat,,81072,N,1,Intermediate,1,,CHEMBL615197,503.0,BAO_0000219,,
77,1229,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL615198,,BAO_0000019,,
78,11347,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,A,,,Rattus norvegicus,10116.0,,,,,100121,D,9,Expert,1,,CHEMBL615199,,BAO_0000357,,
79,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,,,,,,11231,H,8,Expert,1,,CHEMBL615200,,BAO_0000357,,
80,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,,,,,,11231,H,8,Expert,1,,CHEMBL615201,,BAO_0000357,,
81,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",B,,,,,,,,,11231,H,8,Expert,1,,CHEMBL615202,,BAO_0000357,,
82,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",B,,,Candida albicans,5476.0,,,,Microsomes,11231,H,8,Autocuration,1,,CHEMBL615203,,BAO_0000251,,
83,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",B,,,Candida albicans,5476.0,,,,Microsomes,11231,H,8,Autocuration,1,,CHEMBL615204,,BAO_0000251,,
84,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",B,,,Saccharomyces cerevisiae,4932.0,,,,Microsomes,11231,H,8,Autocuration,1,,CHEMBL615205,,BAO_0000251,,
85,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",B,,,Saccharomyces cerevisiae,4932.0,,,,Microsomes,11231,H,8,Autocuration,1,,CHEMBL615206,,BAO_0000251,,
86,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",B,,,Sus scrofa,9823.0,,Liver,,Microsomes,12083,H,8,Autocuration,1,,CHEMBL615207,,BAO_0000251,2107.0,
87,791,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",B,,,Rattus norvegicus,10116.0,,,,,11231,H,8,Autocuration,1,,CHEMBL827084,,BAO_0000019,,
88,791,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",B,,,Rattus norvegicus,10116.0,,,,,11231,H,8,Autocuration,1,,CHEMBL615208,,BAO_0000019,,
89,791,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",B,,,Rattus norvegicus,10116.0,,,,,11231,H,8,Autocuration,1,,CHEMBL615209,,BAO_0000019,,
90,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12083,D,9,Autocuration,1,,CHEMBL615210,,BAO_0000251,2107.0,
91,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12083,D,9,Autocuration,1,,CHEMBL615211,,BAO_0000251,2107.0,
92,153,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12083,D,9,Autocuration,1,,CHEMBL615212,,BAO_0000251,2107.0,
93,8269,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),B,,,,,,,,,11377,H,8,Expert,1,,CHEMBL615213,,BAO_0000357,,
94,8269,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,B,,,,,,,,,11377,H,8,Expert,1,,CHEMBL615273,,BAO_0000357,,
95,17653,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Expert,1,,CHEMBL615274,726.0,BAO_0000219,,
96,14277,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615275,726.0,BAO_0000219,,
97,1717,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615276,726.0,BAO_0000219,,
98,14091,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615277,726.0,BAO_0000219,,
99,14091,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615326,726.0,BAO_0000219,,
100,17653,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,,Hepatitis B virus,10407.0,,,,,50606,N,1,Expert,1,,CHEMBL883130,,BAO_0000218,,
101,13105,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL884519,726.0,BAO_0000219,,
102,1717,Concentration required to inhibit 50% of 2.2.15 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615327,726.0,BAO_0000219,,
103,13105,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,A,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615328,726.0,BAO_0000219,,
104,13600,Cytotoxic activity of compound against uninfected 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615329,,BAO_0000218,,
105,13467,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615330,,BAO_0000218,,
106,17477,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",F,,,Hepatitis B virus,10407.0,,,2.2.15,,50606,N,1,Expert,1,,CHEMBL615331,,BAO_0000218,,
107,1593,In vitro anti-HBV activity in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615332,,BAO_0000218,,
108,1593,In vitro anti-HBV activity in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615333,,BAO_0000218,,
109,15089,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615334,,BAO_0000218,,
110,15089,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615335,,BAO_0000218,,
111,1593,Cytotoxicity in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615336,,BAO_0000218,,
112,1593,Cytotoxicity in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615337,,BAO_0000218,,
113,13600,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615338,,BAO_0000218,,
114,13467,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615339,,BAO_0000218,,
115,13467,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615340,,BAO_0000218,,
116,14764,Antiviral activity against HBV was determined in 2.215 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615341,726.0,BAO_0000219,,
117,6531,Inhibition of 20-HETE synthesis in human renal microsomes,B,,,Homo sapiens,9606.0,,,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL615342,,BAO_0000251,,
118,17322,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615343,,BAO_0000019,,
119,17072,Inhibitory concentration against 2008 (ovarian) cells,F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615344,388.0,BAO_0000219,,
120,16936,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615345,388.0,BAO_0000219,,
121,16936,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615346,388.0,BAO_0000219,,
122,17146,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615347,388.0,BAO_0000219,,
123,17146,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615348,388.0,BAO_0000219,,
124,10797,In vitro inhibition of 2008/R ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,2008/R,,80613,N,1,Intermediate,1,,CHEMBL827085,561.0,BAO_0000219,,
125,10797,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,F,,,Homo sapiens,9606.0,,,2008/R,,80613,N,1,Intermediate,1,,CHEMBL615349,561.0,BAO_0000219,,
126,10797,In vitro inhibition of 2008/S ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,2008/S,,80614,N,1,Intermediate,1,,CHEMBL615350,389.0,BAO_0000219,,
127,10797,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,F,,,Homo sapiens,9606.0,,,2008/S,,80614,N,1,Intermediate,1,,CHEMBL615351,389.0,BAO_0000219,,
128,4823,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,B,,,Homo sapiens,9606.0,,,,,100256,S,2,Expert,1,,CHEMBL615352,,BAO_0000220,,
129,12912,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,B,,,Homo sapiens,9606.0,,,,,100256,S,2,Intermediate,1,,CHEMBL615353,,BAO_0000220,,
130,2957,Inhibition of chymotrypsin-like activity of 20S proteasome,B,,,,,,,,,100256,S,2,Expert,1,,CHEMBL615354,,BAO_0000220,,
131,2957,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,B,,,,,,,,,100256,S,2,Expert,1,,CHEMBL615355,,BAO_0000220,,
132,3260,Inhibitory activity against 20S proteosome,B,,,,,,,,,100256,S,2,Intermediate,1,,CHEMBL615356,,BAO_0000220,,
133,3451,Compound was tested for inhibitory activity against tryptase,B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615357,,BAO_0000019,,
134,13885,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615358,726.0,BAO_0000219,,
135,13885,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL827086,726.0,BAO_0000219,,
136,3676,Compound was tested for the inhibition of Alpha-glucosidase,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615359,,BAO_0000019,,
137,6043,Inhibitory concentration against human neutrophil elastase (HNE),B,,,,,,,,,235,H,8,Autocuration,1,,CHEMBL615360,,BAO_0000357,,
138,11140,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,F,,,Rattus norvegicus,10116.0,,Heart,,,22226,U,0,Autocuration,1,,CHEMBL615361,,BAO_0000218,948.0,
139,10543,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,,,,,19640,H,8,Autocuration,1,,CHEMBL615362,,BAO_0000019,,
140,10543,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,,,,,19640,H,8,Expert,1,,CHEMBL615363,,BAO_0000019,,
141,10543,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,B,,,,,,,,,19640,H,8,Autocuration,1,,CHEMBL615364,,BAO_0000357,,
142,10543,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,,,,,19640,H,8,Expert,1,,CHEMBL615365,,BAO_0000019,,
143,11365,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,F,,,Mus musculus,10090.0,,,P338,,80360,N,1,Intermediate,1,,CHEMBL615366,524.0,BAO_0000219,,
144,11365,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,F,,,Mus musculus,10090.0,,,P338,,80360,N,1,Intermediate,1,,CHEMBL615367,524.0,BAO_0000219,,
145,11803,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,F,,,Homo sapiens,9606.0,,,PBL,,80384,N,1,Intermediate,1,,CHEMBL615368,554.0,BAO_0000219,,
146,11803,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,F,,,Ovis aries,9940.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615369,,BAO_0000019,,
147,11803,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,F,,,Ovis aries,9940.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615370,,BAO_0000019,,
148,12278,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),B,,,,,,,,,191,H,8,Autocuration,1,,CHEMBL615673,,BAO_0000357,,
149,8249,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615674,,BAO_0000019,,
150,8249,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615675,,BAO_0000019,,
151,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226,U,0,Autocuration,1,,CHEMBL615676,635.0,BAO_0000219,,
152,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226,U,0,Autocuration,1,,CHEMBL615677,635.0,BAO_0000219,,
153,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226,U,0,Autocuration,1,,CHEMBL615678,635.0,BAO_0000219,,
154,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226,U,0,Autocuration,1,,CHEMBL615679,635.0,BAO_0000219,,
155,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615680,,BAO_0000019,,
156,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615681,,BAO_0000019,,
157,16992,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,B,,,,,,,,,104290,H,6,Autocuration,1,,CHEMBL857972,,BAO_0000249,,
158,10543,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,F,,,Streptococcus pyogenes,1314.0,,,,,50264,N,1,Intermediate,1,,CHEMBL857899,,BAO_0000218,,
159,17833,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),F,,,Human herpesvirus 3,10335.0,,,,,50527,N,1,Intermediate,1,,CHEMBL615371,,BAO_0000218,,
160,17290,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,F,,,vericilla zoster virus,10335.0,,,HEL,,50527,N,1,Expert,1,,CHEMBL615372,468.0,BAO_0000218,,
161,17290,Antiviral activity against 07/1 strain of VZV; ND: No data,F,,,vericilla zoster virus,10335.0,,,,,50527,N,1,Intermediate,1,,CHEMBL615373,,BAO_0000218,,
162,17290,Antiviral activity against 07/1 strain of VZV; ND=No data,F,,,vericilla zoster virus,10335.0,,,,,50527,N,1,Intermediate,1,,CHEMBL615374,,BAO_0000218,,
163,10932,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",F,,,escherichia cloac,561.0,,,,,50145,N,1,Intermediate,1,,CHEMBL615375,,BAO_0000218,,
164,9707,Ratio of Ki at A2 to Ki at A1 receptors,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615376,,BAO_0000019,,
165,2346,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",B,,,Candida albicans,5476.0,,,,,11143,H,8,Expert,1,,CHEMBL615377,,BAO_0000249,,
166,2205,"Inhibition of 1,3-beta-glucan synthase",B,,,Candida glabrata CBS 138,284593.0,,,,,18077,H,8,Expert,1,,CHEMBL615378,,BAO_0000357,,
167,11900,Inhibition of growth of 1-87 human tumor cell line,F,,,Homo sapiens,9606.0,,,1-87 tumor cell line,,80609,N,1,Intermediate,1,,CHEMBL615379,832.0,BAO_0000219,,
168,14864,Inhibition of 1-lipoxygenase (LOX)in RBL cells,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL615380,,BAO_0000219,,
169,16474,Inhibitory activity against soybean 1-lipoxygenase (SLO),B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615381,,BAO_0000357,,
170,16474,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615382,,BAO_0000357,,
171,16474,% inhibition against soybean 1-lipoxygenase (SLO),B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615383,,BAO_0000357,,
172,16474,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615384,,BAO_0000357,,
173,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615385,,BAO_0000357,,
174,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615386,,BAO_0000357,,
175,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615387,,BAO_0000357,,
176,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615388,,BAO_0000357,,
177,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615214,,BAO_0000357,,
178,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL827087,,BAO_0000357,,
179,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615215,,BAO_0000357,,
180,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615216,,BAO_0000357,,
181,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615217,,BAO_0000357,,
182,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615218,,BAO_0000357,,
183,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615219,,BAO_0000357,,
184,10413,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,B,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615220,,BAO_0000019,,
185,16929,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),F,,,Mus musculus,10090.0,,,C3H 10T1/2,,80049,N,1,Intermediate,1,,CHEMBL615221,294.0,BAO_0000219,,
186,1229,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL615222,,BAO_0000019,,
187,16587,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,,,,,,11489,H,8,Autocuration,1,,CHEMBL615223,,BAO_0000357,,
188,16587,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,,,,,,11862,H,8,Autocuration,1,,CHEMBL615224,,BAO_0000357,,
189,16587,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,B,,,,,,,,,11862,H,8,Autocuration,1,,CHEMBL615225,,BAO_0000357,,
190,16587,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,B,,,,,,,,,11489,H,8,Autocuration,1,,CHEMBL615226,,BAO_0000357,,
191,16587,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,B,,,,,,,,,11862,H,8,Autocuration,1,,CHEMBL615227,,BAO_0000357,,
192,8058,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,F,,,Bos taurus,9913.0,,,,,12347,D,9,Expert,1,,CHEMBL615228,,BAO_0000019,,
193,9065,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,B,,,Rattus norvegicus,10116.0,,,,,100120,D,9,Expert,1,,CHEMBL615229,,BAO_0000357,,
194,8865,Inhibition of 11 beta-hydroxylase from rat adrenal gland,B,,,Rattus norvegicus,10116.0,,Adrenal gland,,,100120,D,9,Expert,1,,CHEMBL615230,,BAO_0000357,2369.0,
195,9066,Inhibition of rat adrenal 11-beta-hydroxylase,B,,,Rattus norvegicus,10116.0,,,,,100120,D,9,Expert,1,,CHEMBL615231,,BAO_0000357,,
196,8394,Inhibition of rat adrenal 11-beta-hydroxylase,B,,,Rattus norvegicus,10116.0,,,,,100120,D,9,Expert,1,,CHEMBL884520,,BAO_0000357,,
197,8394,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,B,,,Rattus norvegicus,10116.0,,,,,100120,D,9,Expert,1,,CHEMBL615232,,BAO_0000357,,
198,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,B,,,,,,,,,10328,H,8,Autocuration,1,,CHEMBL615233,,BAO_0000019,,
199,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,,,,,,11490,H,8,Autocuration,1,,CHEMBL827088,,BAO_0000357,,
200,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,,,,,,11490,H,8,Autocuration,1,,CHEMBL615234,,BAO_0000357,,
201,9295,Compound was tested for the percent of inhibition against 12-LO at 10 uM,F,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615235,,BAO_0000019,,
202,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615236,,BAO_0000019,,
203,13622,Compound was tested in vitro for inhibition of 12-LO human platelet,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615237,,BAO_0000019,,
204,12079,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615238,,BAO_0000019,,
205,13622,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615239,,BAO_0000019,,
206,12079,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,Homo sapiens,9606.0,,,,,11134,D,9,Autocuration,1,,CHEMBL615240,,BAO_0000019,,
207,13500,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,B,,,,,,,,,11835,H,8,Expert,1,,CHEMBL615241,,BAO_0000019,,
208,13723,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,B,,,,,,,,,11601,H,8,Expert,1,,CHEMBL615242,,BAO_0000357,,
209,16474,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615243,,BAO_0000019,,
210,1630,Inhibitory activity against human platelet 12-lipoxygenase,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615244,,BAO_0000019,,
211,167,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615245,,BAO_0000019,,
212,16474,% inhibition against human platelet 12-lipoxygenase (12-HLO),B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615246,,BAO_0000019,,
213,167,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615247,,BAO_0000019,,
214,16474,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615248,,BAO_0000019,,
215,10091,Inhibitory activity towards porcine 12-lipoxygenase,B,,,,,,,,,11601,H,8,Autocuration,1,,CHEMBL615249,,BAO_0000357,,
216,11966,Tested for inhibition against porcine 12-LO,B,,,,,,,,,11601,H,8,Autocuration,1,,CHEMBL615250,,BAO_0000357,,
217,951,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615251,,BAO_0000019,,
218,10997,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615252,,BAO_0000019,,
219,10193,In vitro inhibition of rat platelet 12-lipoxygenase,B,,,,,,,,,12052,H,8,Expert,1,,CHEMBL828340,,BAO_0000019,,
220,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615253,,BAO_0000019,,
221,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615254,,BAO_0000019,,
222,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615255,,BAO_0000019,,
223,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615256,,BAO_0000019,,
224,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615257,,BAO_0000019,,
225,11087,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615258,,BAO_0000019,,
226,15569,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Intermediate,1,,CHEMBL615259,621.0,BAO_0000219,,
227,12989,In vitro antitumor activity against 41M cell line.,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Expert,1,,CHEMBL615260,621.0,BAO_0000219,,
228,16745,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Intermediate,1,,CHEMBL615261,621.0,BAO_0000219,,
229,15569,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Intermediate,1,,CHEMBL615262,621.0,BAO_0000219,,
230,12989,In vitro antitumor activity against 41McisR cell line.,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Expert,1,,CHEMBL615263,621.0,BAO_0000219,,
231,12989,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Expert,1,,CHEMBL838393,621.0,BAO_0000219,,
232,16745,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Intermediate,1,,CHEMBL615264,621.0,BAO_0000219,,
233,6210,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),B,,,Homo sapiens,9606.0,,,,,84,D,9,Expert,1,,CHEMBL615265,,BAO_0000357,,
234,6210,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,Homo sapiens,9606.0,,,,,68,D,9,Expert,1,,CHEMBL615266,,BAO_0000357,,
235,6226,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,,,,,,,68,H,8,Expert,1,,CHEMBL615267,,BAO_0000357,,
236,17855,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,,,,,,10201,H,8,Expert,1,,CHEMBL615268,,BAO_0000357,,
237,17855,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,B,,,,,,,,,10201,H,8,Expert,1,,CHEMBL615269,,BAO_0000357,,
238,17855,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,,,,,,10201,H,8,Expert,1,,CHEMBL615270,,BAO_0000357,,
239,10413,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,,,,,,12220,H,8,Autocuration,1,,CHEMBL615271,,BAO_0000357,,
240,10413,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,,Escherichia coli,562.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615272,,BAO_0000357,,
241,10413,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,,Escherichia coli,562.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615103,,BAO_0000357,,
242,10413,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",B,,,Escherichia coli,562.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615104,,BAO_0000357,,
243,10413,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,,,,,,12220,H,8,Autocuration,1,,CHEMBL615105,,BAO_0000357,,
244,10413,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",B,,,,,,,,,12220,H,8,Autocuration,1,,CHEMBL872866,,BAO_0000357,,
245,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615106,,BAO_0000357,,
246,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615107,,BAO_0000019,,
247,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615108,,BAO_0000357,,
248,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615109,,BAO_0000357,,
249,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615110,,BAO_0000357,,
250,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL840105,,BAO_0000019,,
251,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615111,,BAO_0000019,,
252,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615112,,BAO_0000019,,
253,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615113,,BAO_0000019,,
254,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615114,,BAO_0000019,,
255,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615115,,BAO_0000357,,
256,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615116,,BAO_0000019,,
257,7323,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",B,,,,,,,,,11303,H,8,Autocuration,1,,CHEMBL615698,,BAO_0000357,,
258,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615699,,BAO_0000019,,
259,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",B,,,Sus scrofa,9823.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615700,,BAO_0000019,,
260,13750,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,B,,,Saccharomyces cerevisiae,4932.0,,,,,100249,H,8,Expert,1,,CHEMBL615701,,BAO_0000357,,
261,7662,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615702,,BAO_0000019,,
262,7662,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615703,,BAO_0000019,,
263,7662,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615704,,BAO_0000019,,
264,12211,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL615705,,BAO_0000019,,
265,12211,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL615706,,BAO_0000019,,
266,12211,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL615707,,BAO_0000221,2116.0,
267,12211,Stimulatory activity of intragastric pressure was tested in the rat,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL615708,,BAO_0000019,,
268,15453,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,B,,,,,,,,,121,H,8,Autocuration,1,,CHEMBL615709,,BAO_0000357,,
269,11884,Dose to reduce neuronal firing against 5-HT cells in rats (iv),F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615710,,BAO_0000218,,
270,7185,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL615711,,BAO_0000019,,
271,6876,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,B,,,Homo sapiens,9606.0,,,,,121,D,9,Expert,1,,CHEMBL615712,,BAO_0000357,,
272,6876,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,B,,,Homo sapiens,9606.0,,,,,121,D,9,Expert,1,,CHEMBL836325,,BAO_0000357,,
273,11863,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,F,,,,,,,,,12198,H,8,Autocuration,1,,CHEMBL615713,,BAO_0000019,,
274,11863,Inhibition constant of high-affinity 5-HT uptake,B,,,,,,,,,12198,H,8,Autocuration,1,,CHEMBL615714,,BAO_0000357,,
275,11863,Michaelis-Menten constant was reported for high affinity transport of 5-HT,F,,,,,,,,,12198,H,8,Autocuration,1,,CHEMBL615715,,BAO_0000019,,
276,11863,Maximum rate was determined for high affinity transport of 5-HT,F,,,,,,,,,12198,H,8,Autocuration,1,,CHEMBL615716,,BAO_0000019,,
277,4639,Compound was tested for agonistic activity against 5-HT uptake,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL615717,,BAO_0000019,,
278,15796,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL881818,,BAO_0000019,,
279,15796,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,B,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL884540,,BAO_0000357,,
280,12801,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615718,,BAO_0000224,,
281,12801,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615719,,BAO_0000224,,
282,12120,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,B,,,,,,,,Membranes,104744,H,4,Autocuration,1,,CHEMBL615720,,BAO_0000249,,
283,12120,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,B,,,,,,,,Membranes,104744,H,4,Autocuration,1,,CHEMBL615721,,BAO_0000249,,
284,11963,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615722,,BAO_0000019,,
285,11701,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615723,,BAO_0000019,,
286,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615724,,BAO_0000221,10000000.0,
287,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615725,,BAO_0000221,10000000.0,
288,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615726,,BAO_0000221,10000000.0,
289,16394,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615727,,BAO_0000218,,
290,11574,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL615728,,BAO_0000019,,
291,15779,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL857971,449.0,BAO_0000219,,
292,15363,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL615729,,BAO_0000357,,
293,15363,Efficacy against 5-hydroxytryptamine 2A receptor,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL615730,,BAO_0000019,,
294,15329,Intrinsic activity towards 5-HT2A receptor of rat tail artery,F,,,,,,,,,12687,H,8,Expert,1,,CHEMBL615731,,BAO_0000019,,
295,15329,Relative potency towards 5-HT2A receptor of rat tail artery,F,,,,,,,,,12687,H,8,Expert,1,,CHEMBL615732,,BAO_0000019,,
296,15329,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,,,,,,12687,H,8,Expert,1,,CHEMBL615733,,BAO_0000019,,
297,15329,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,F,,,,,,,,,12687,H,8,Expert,1,,CHEMBL615734,,BAO_0000019,,
298,15329,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL615735,,BAO_0000019,,
299,15329,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,,,,,,12687,H,8,Expert,1,,CHEMBL615736,,BAO_0000019,,
300,273,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL615737,,BAO_0000221,2116.0,
301,273,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL615738,,BAO_0000221,2116.0,
302,273,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL615739,,BAO_0000221,2116.0,
303,12092,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL615278,,BAO_0000357,,
304,1317,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL615279,,BAO_0000019,,
305,12409,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Expert,1,,CHEMBL615280,,BAO_0000357,,
306,11126,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,B,,,Gallus gallus,9031.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615281,,BAO_0000019,,
307,11126,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615282,,BAO_0000019,,
308,11126,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615283,,BAO_0000019,,
309,11126,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,B,,,Homo sapiens,9606.0,,,HL-60,,80156,N,1,Autocuration,1,,CHEMBL615284,649.0,BAO_0000219,,
310,11126,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615285,,BAO_0000019,,
311,11126,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615286,,BAO_0000019,,
312,17807,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,B,,,Homo sapiens,9606.0,,,Oocytes,,104703,D,7,Autocuration,1,,CHEMBL615287,,BAO_0000219,,
313,16575,Chymotryptic inhibitory activity against 26S proteasome,F,,,,,,,,,100256,S,2,Intermediate,1,,CHEMBL615288,,BAO_0000220,,
314,15407,Inhibitory activity against 26S proteasome degradation of IkB,B,,,,,,,,,100256,S,2,Intermediate,1,,CHEMBL615289,,BAO_0000220,,
315,10797,In vitro inhibition of 2780/DOX ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL615290,478.0,BAO_0000219,,
316,10797,In vitro inhibition of 2780/S ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL884522,478.0,BAO_0000219,,
317,3469,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615291,,BAO_0000019,,
318,16037,Association constant for binding to AATT 28-mer AATT hairpin,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615292,,BAO_0000225,,
319,16037,Kinetically Defined Association Constant for 28-mer AATT hairpin.,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615293,,BAO_0000225,,
320,16037,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615294,,BAO_0000225,,
321,16037,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615295,,BAO_0000225,,
322,16524,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL825021,,BAO_0000019,,
323,16524,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615296,,BAO_0000019,,
324,16524,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615297,,BAO_0000019,,
325,16758,Cytotoxicity against cell line 2SC/20 determined by MTT test,F,,,Cricetulus griseus,10029.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615298,,BAO_0000019,,
326,16758,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,F,,,Cricetulus griseus,10029.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615299,,BAO_0000019,,
327,16758,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,F,,,Cricetulus griseus,10029.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615300,,BAO_0000019,,
328,14360,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,B,,,,,,,,,241,H,8,Autocuration,1,,CHEMBL615301,,BAO_0000357,,
329,14360,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,B,,,Homo sapiens,9606.0,,,,,241,D,9,Expert,1,,CHEMBL615302,,BAO_0000357,,
330,9964,Selectivity ratio of ID50 in liver and heart,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615303,,BAO_0000019,,
331,9964,"Selectivity, ratio of relative ID50 in liver and heart",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615304,,BAO_0000019,,
332,9964,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615305,,BAO_0000019,,
333,9964,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615306,,BAO_0000218,,
334,9964,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615307,,BAO_0000218,,
335,9964,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,In vivo,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615308,,BAO_0000218,,
336,9964,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",F,In vivo,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615309,,BAO_0000218,,
337,9964,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615310,,BAO_0000019,,
338,9964,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615311,,BAO_0000019,,
339,9964,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615312,,BAO_0000019,,
340,9964,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615313,,BAO_0000019,,
341,9964,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,F,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615314,,BAO_0000019,,
342,9964,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615315,,BAO_0000019,,
343,9964,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615316,,BAO_0000218,,
344,9964,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,B,In vivo,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615317,,BAO_0000218,,
345,9964,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615318,,BAO_0000218,,
346,9964,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615319,,BAO_0000218,,
347,9964,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615320,,BAO_0000019,,
348,9964,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",F,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615321,,BAO_0000019,,
349,3796,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615322,,BAO_0000019,,
350,4251,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690,H,8,Autocuration,1,,CHEMBL615323,,BAO_0000357,,
351,4251,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690,H,8,Autocuration,1,,CHEMBL615407,,BAO_0000357,,
352,4251,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690,H,8,Autocuration,1,,CHEMBL857267,,BAO_0000357,,
353,4251,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690,H,8,Autocuration,1,,CHEMBL615408,,BAO_0000357,,
354,166,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615409,,BAO_0000357,,
355,17861,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615410,,BAO_0000357,,
356,166,Inhibition constant against 3-dehydroquinate synthase,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615411,,BAO_0000357,,
357,166,Association rate constant against 3-dehydroquinate synthase,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615412,,BAO_0000357,,
358,166,Rate constant against 3-dehydroquinate synthase,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615413,,BAO_0000357,,
359,3548,Inhibitory activity against fuc-TVII,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615414,,BAO_0000019,,
360,9877,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615415,,BAO_0000251,2107.0,
361,9877,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615416,,BAO_0000251,2107.0,
362,9877,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615417,,BAO_0000251,2107.0,
363,9877,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615418,,BAO_0000251,2107.0,
364,9877,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615419,,BAO_0000251,2107.0,
365,9877,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615420,,BAO_0000251,2107.0,
366,9877,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615421,,BAO_0000251,2107.0,
367,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615422,,BAO_0000251,2107.0,
368,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615423,,BAO_0000251,2107.0,
369,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL872868,,BAO_0000251,2107.0,
370,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615424,,BAO_0000251,2107.0,
371,3003,Inhibitory activity against 3-phosphoglycerate kinase.,B,,,,,,,,,104832,H,4,Autocuration,1,,CHEMBL825022,,BAO_0000224,,
372,3003,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,B,,,,,,,,,104832,H,4,Autocuration,1,,CHEMBL615425,,BAO_0000224,,
373,3003,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",B,,,,,,,,,104832,H,4,Autocuration,1,,CHEMBL615426,,BAO_0000224,,
374,17185,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,B,,,Homo sapiens,9606.0,,,,,10612,D,9,Expert,1,,CHEMBL615427,,BAO_0000357,,
375,6072,Cytotoxicity on 3677 melanoma cells,F,,,Homo sapiens,9606.0,,,3677 melanoma cell line,,80616,N,1,Intermediate,1,,CHEMBL615428,844.0,BAO_0000219,,
376,6072,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,F,,,Homo sapiens,9606.0,,,3677 melanoma cell line,,80616,N,1,Intermediate,1,,CHEMBL615429,844.0,BAO_0000219,,
377,5018,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,F,,,Mus musculus,10090.0,,,MC-38,,80617,N,1,Intermediate,1,,CHEMBL615430,700.0,BAO_0000219,,
378,2852,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Intermediate,1,,CHEMBL615431,,BAO_0000019,,
379,8663,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,F,,,,,,,B16,,22226,U,0,Autocuration,1,,CHEMBL615432,798.0,BAO_0000218,,
380,8663,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,F,,,,,,,B16,,22226,U,0,Autocuration,1,,CHEMBL615433,798.0,BAO_0000218,,
381,3245,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,F,,,Human rhinovirus 14,12131.0,,,,,12464,D,9,Expert,1,,CHEMBL615434,,BAO_0000019,,
382,3245,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,F,,,Human rhinovirus sp.,169066.0,,,,,50085,N,1,Intermediate,1,,CHEMBL615435,,BAO_0000218,,
383,3877,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,F,,,human rhinovirus type 14,169066.0,,,,,50679,N,1,Intermediate,1,,CHEMBL615436,,BAO_0000218,,
384,3877,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,F,,,human rhinovirus type 14,169066.0,,,,,50679,N,1,Intermediate,1,,CHEMBL615437,,BAO_0000218,,
385,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Human rhinovirus 14,12131.0,,,,,12464,D,9,Expert,1,,CHEMBL615438,,BAO_0000019,,
386,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Human rhinovirus 14,12131.0,,,,,12464,D,9,Expert,1,,CHEMBL615439,,BAO_0000019,,
387,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Human rhinovirus 14,12131.0,,,,,12464,D,9,Expert,1,,CHEMBL615440,,BAO_0000019,,
388,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,F,,,Human rhinovirus 14,12131.0,,,,,12464,D,9,Expert,1,,CHEMBL615441,,BAO_0000019,,
389,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,F,,,Enterovirus,12059.0,,,,,50665,N,1,Intermediate,1,,CHEMBL615641,,BAO_0000218,,
390,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,F,,,Enterovirus,12059.0,,,,,50665,N,1,Intermediate,1,,CHEMBL872065,,BAO_0000218,,
391,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,F,,,Enterovirus,12059.0,,,,,50665,N,1,Intermediate,1,,CHEMBL825023,,BAO_0000218,,
392,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,F,,,Enterovirus,12059.0,,,,,50665,N,1,Intermediate,1,,CHEMBL615642,,BAO_0000218,,
393,13748,Inhibition of human rhinovirus 3C protease,B,,,Human rhinovirus B,147712.0,,,,,12464,H,8,Expert,1,,CHEMBL615643,,BAO_0000357,,
394,17699,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615644,,BAO_0000019,,
395,7145,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615645,833.0,BAO_0000218,,
396,7145,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615646,833.0,BAO_0000218,,
397,7145,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615647,833.0,BAO_0000218,,
398,7145,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615648,833.0,BAO_0000218,,
399,7145,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615649,833.0,BAO_0000218,,
400,7145,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615650,833.0,BAO_0000218,,
401,5325,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615651,847.0,BAO_0000218,,
402,5325,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615652,847.0,BAO_0000218,,
403,5325,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Expert,1,,CHEMBL615653,847.0,BAO_0000218,,
404,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615654,847.0,BAO_0000219,,
405,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615655,847.0,BAO_0000219,,
406,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL825024,847.0,BAO_0000219,,
407,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615656,847.0,BAO_0000219,,
408,16169,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615657,847.0,BAO_0000219,,
409,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615658,847.0,BAO_0000219,,
410,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615659,847.0,BAO_0000219,,
411,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615660,847.0,BAO_0000219,,
412,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615661,847.0,BAO_0000219,,
413,16169,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615662,847.0,BAO_0000219,,
414,16169,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615663,847.0,BAO_0000219,,
415,16169,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615664,847.0,BAO_0000219,,
416,16169,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615665,847.0,BAO_0000219,,
417,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615666,847.0,BAO_0000219,,
418,16169,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615667,847.0,BAO_0000219,,
419,16169,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615668,847.0,BAO_0000219,,
420,16169,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615669,847.0,BAO_0000219,,
421,16169,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615670,847.0,BAO_0000219,,
422,16169,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL836739,847.0,BAO_0000219,,
423,16169,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615671,847.0,BAO_0000219,,
424,16169,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615672,847.0,BAO_0000219,,
425,16169,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615791,847.0,BAO_0000219,,
426,16169,spermine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615792,847.0,BAO_0000219,,
427,16169,spermine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615793,847.0,BAO_0000219,,
428,16169,spermine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615794,847.0,BAO_0000219,,
429,16169,spermine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615795,847.0,BAO_0000219,,
430,15547,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,F,,,Homo sapiens,9606.0,,,3LLD122,,80621,N,1,Intermediate,1,,CHEMBL615590,971.0,BAO_0000219,,
431,8663,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615591,,BAO_0000218,,
432,8663,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615592,,BAO_0000218,,
433,8663,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615593,,BAO_0000218,,
434,8663,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615594,,BAO_0000218,,
435,4504,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615595,723.0,BAO_0000219,,
436,4504,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615596,723.0,BAO_0000219,,
437,12695,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,F,,,,,,,NIH3T3,,11169,H,8,Expert,1,,CHEMBL615597,723.0,BAO_0000219,,
438,12695,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615598,723.0,BAO_0000219,,
439,12695,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615599,723.0,BAO_0000219,,
440,17642,Effective dose against murine 3T3 fibroblasts cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615600,723.0,BAO_0000219,,
441,17642,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615601,723.0,BAO_0000219,,
442,12340,Cytotoxic effect on 3T3 cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615602,723.0,BAO_0000219,,
443,12340,Cytotoxic effect on 3T3 cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615603,723.0,BAO_0000219,,
444,12716,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615604,723.0,BAO_0000219,,
445,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615605,723.0,BAO_0000219,,
446,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615606,723.0,BAO_0000219,,
447,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL884526,723.0,BAO_0000219,,
448,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615607,723.0,BAO_0000219,,
449,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615608,723.0,BAO_0000219,,
450,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615609,723.0,BAO_0000219,,
451,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615682,723.0,BAO_0000219,,
452,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615683,723.0,BAO_0000219,,
453,17780,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615684,723.0,BAO_0000218,,
454,12751,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,F,,,Mus musculus,10090.0,,,,,104860,D,7,Autocuration,1,,CHEMBL615685,,BAO_0000219,,
455,12380,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615686,723.0,BAO_0000219,,
456,14892,Inhibitory activity against 3T3 cell line,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615687,723.0,BAO_0000219,,
457,12695,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL884523,723.0,BAO_0000219,,
458,12695,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,F,,,,,,,,,11169,H,8,Expert,1,,CHEMBL615688,,BAO_0000019,,
459,12695,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615689,723.0,BAO_0000219,,
460,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615690,723.0,BAO_0000219,,
461,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,F,,,,,,,,,11169,H,8,Expert,1,,CHEMBL615691,,BAO_0000019,,
462,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,F,,,,,,,,,11169,H,8,Expert,1,,CHEMBL615692,,BAO_0000019,,
463,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615693,723.0,BAO_0000219,,
464,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615324,723.0,BAO_0000219,,
465,4959,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,F,,,Homo sapiens,9606.0,,,NIH3T3,,9,D,9,Expert,1,,CHEMBL615325,723.0,BAO_0000219,,
466,4959,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),F,,,Homo sapiens,9606.0,,,NIH3T3,,9,D,9,Expert,1,,CHEMBL615490,723.0,BAO_0000219,,
467,4959,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,F,,,Homo sapiens,9606.0,,,NIH3T3,,188,D,9,Expert,1,,CHEMBL615491,723.0,BAO_0000219,,
468,4959,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),F,,,Homo sapiens,9606.0,,,NIH3T3,,188,D,9,Expert,1,,CHEMBL615492,723.0,BAO_0000219,,
469,12082,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615493,723.0,BAO_0000219,,
470,12082,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615494,723.0,BAO_0000219,,
471,12082,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615495,723.0,BAO_0000219,,
472,12082,Inhibitory concentration was calculated on 3T3 cells by using growth assay,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615496,723.0,BAO_0000219,,
473,2643,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615497,723.0,BAO_0000219,,
474,11926,Inhibition of Swiss 3T3 mouse fibroblast proliferation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615498,723.0,BAO_0000219,,
475,15204,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,A,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615499,723.0,BAO_0000219,,
476,15992,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL835522,723.0,BAO_0000219,,
477,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615500,723.0,BAO_0000219,,
478,16279,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615501,723.0,BAO_0000219,,
479,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615502,723.0,BAO_0000219,,
480,16279,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615503,723.0,BAO_0000219,,
481,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615504,723.0,BAO_0000219,,
482,16279,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615505,723.0,BAO_0000219,,
483,12831,Inhibition of swiss 3T3 mouse fibroblast proliferation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615506,723.0,BAO_0000219,,
484,13497,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615507,723.0,BAO_0000219,,
485,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615508,620.0,BAO_0000218,,
486,13618,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615509,620.0,BAO_0000219,,
487,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615510,620.0,BAO_0000219,,
488,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615511,620.0,BAO_0000219,,
489,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615512,620.0,BAO_0000219,,
490,14840,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615513,620.0,BAO_0000218,,
491,14840,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615514,620.0,BAO_0000218,,
492,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615515,620.0,BAO_0000219,,
493,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615516,620.0,BAO_0000219,,
494,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615517,620.0,BAO_0000219,,
495,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615518,620.0,BAO_0000219,,
496,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615519,620.0,BAO_0000219,,
497,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615520,620.0,BAO_0000218,,
498,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615521,620.0,BAO_0000218,,
499,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615522,620.0,BAO_0000218,,
500,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615523,620.0,BAO_0000218,,
501,13715,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615524,620.0,BAO_0000218,,
502,13715,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615525,620.0,BAO_0000218,,
503,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615526,620.0,BAO_0000218,,
504,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615527,620.0,BAO_0000218,,
505,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615528,620.0,BAO_0000218,,
506,13715,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615529,620.0,BAO_0000218,,
507,13715,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615530,620.0,BAO_0000218,,
508,13715,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615531,620.0,BAO_0000218,,
509,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615532,620.0,BAO_0000219,,
510,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615533,620.0,BAO_0000219,,
511,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615534,620.0,BAO_0000219,,
512,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615535,620.0,BAO_0000218,,
513,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615536,620.0,BAO_0000218,,
514,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615537,620.0,BAO_0000218,,
515,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615538,620.0,BAO_0000218,,
516,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL836166,620.0,BAO_0000218,,
517,6411,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,F,,,,,,,3T3-L1,,11214,H,8,Expert,1,,CHEMBL615539,620.0,BAO_0000219,,
518,6411,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615540,620.0,BAO_0000219,,
519,6411,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,F,,,,,,,3T3-L1,,11214,H,8,Expert,1,,CHEMBL615541,620.0,BAO_0000219,,
520,3966,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615542,620.0,BAO_0000219,,
521,3966,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615543,620.0,BAO_0000219,,
522,15556,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615544,620.0,BAO_0000219,,
523,5845,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615545,620.0,BAO_0000219,,
524,14422,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615546,620.0,BAO_0000219,,
525,5845,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615547,620.0,BAO_0000219,,
526,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615548,620.0,BAO_0000219,,
527,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615549,620.0,BAO_0000219,,
528,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615550,620.0,BAO_0000219,,
529,6349,Inhibitory activity against rat fibroblast (3Y1) cell line,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Intermediate,1,,CHEMBL615551,1118.0,BAO_0000219,,
530,15899,Mean concentration causing inhibition of cell growth in 3Y1 cells.,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Expert,1,,CHEMBL615552,1118.0,BAO_0000219,,
531,15899,Cytotoxicity in 3Y1 cells.,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Expert,1,,CHEMBL615553,1118.0,BAO_0000219,,
532,15899,Cytostatic effect in 3Y1 cells.,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Expert,1,,CHEMBL615554,1118.0,BAO_0000219,,
533,15899,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Intermediate,1,,CHEMBL615555,1118.0,BAO_0000219,,
534,17038,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Expert,1,,CHEMBL615556,1118.0,BAO_0000219,,
535,12421,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615557,,BAO_0000019,,
536,12947,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615558,,BAO_0000019,,
537,12947,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL872066,,BAO_0000019,,
538,4896,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,B,,,Sus scrofa,9823.0,,,,,11607,D,9,Expert,1,,CHEMBL615559,,BAO_0000019,,
539,6148,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615560,,BAO_0000019,,
540,16432,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615561,,BAO_0000019,,
541,4978,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,B,,,,,,,,,11607,H,8,Expert,1,,CHEMBL857062,,BAO_0000019,,
542,4978,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),B,,,,,,,,,11607,H,8,Expert,1,,CHEMBL615562,,BAO_0000019,,
543,3723,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615563,,BAO_0000019,,
544,3518,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615564,,BAO_0000357,,
545,4164,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615565,,BAO_0000019,,
546,3518,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615566,,BAO_0000019,,
547,4164,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,B,,,Sus scrofa,9823.0,,,,,11607,D,9,Expert,1,,CHEMBL615567,,BAO_0000019,,
548,3518,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615568,,BAO_0000019,,
549,3518,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615569,,BAO_0000357,,
550,4978,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615570,,BAO_0000019,,
551,4978,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615571,,BAO_0000019,,
552,6455,Binding affinity against melatonin (MT1) receptor (pC1),B,,,,,,,,,104733,H,4,Autocuration,1,,CHEMBL615572,,BAO_0000224,,
553,2222,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615573,,BAO_0000019,,
554,13020,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615574,,BAO_0000019,,
555,13021,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615575,,BAO_0000019,,
556,14532,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,B,,,,,,,,,10619,H,8,Autocuration,1,,CHEMBL615576,,BAO_0000357,,
557,14118,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,,,,,,,10619,H,8,Autocuration,1,,CHEMBL615577,,BAO_0000357,,
558,11884,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615578,,BAO_0000221,10000000.0,
559,13969,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615579,,BAO_0000357,,
560,13392,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615580,,BAO_0000357,,
561,14430,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615581,,BAO_0000019,,
562,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615582,,BAO_0000221,10000000.0,
563,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615583,,BAO_0000221,10000000.0,
564,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615584,,BAO_0000221,10000000.0,
565,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL833691,,BAO_0000221,10000000.0,
566,9995,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615585,,BAO_0000221,10000000.0,
567,9995,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615586,,BAO_0000221,10000000.0,
568,9995,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL884524,,BAO_0000221,10000000.0,
569,12249,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615587,,BAO_0000221,10000000.0,
570,11799,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615588,,BAO_0000221,10000000.0,
571,14331,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL615589,,BAO_0000249,,
572,11884,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,B,,,Bos taurus,9913.0,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615442,,BAO_0000221,10000000.0,
573,14331,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615443,,BAO_0000221,10000000.0,
574,11701,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615444,,BAO_0000221,10000000.0,
575,11701,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615445,,BAO_0000221,10000000.0,
576,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615446,,BAO_0000221,10000000.0,
577,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615447,449.0,BAO_0000219,,
578,12248,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615448,,BAO_0000221,10000000.0,
579,12249,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615449,,BAO_0000221,10000000.0,
580,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615450,449.0,BAO_0000219,,
581,11799,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615451,,BAO_0000221,10000000.0,
582,634,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615452,,BAO_0000357,,
583,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615453,,BAO_0000221,10000000.0,
584,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615454,,BAO_0000221,10000000.0,
585,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615455,,BAO_0000221,10000000.0,
586,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615456,,BAO_0000221,10000000.0,
587,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615457,,BAO_0000221,10000000.0,
588,12210,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615458,,BAO_0000218,10000000.0,
589,13311,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615459,,BAO_0000221,10000000.0,
590,2331,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615460,449.0,BAO_0000219,,
591,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,F,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615461,,BAO_0000019,,
592,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,F,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615462,,BAO_0000019,,
593,11574,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,F,,,Cavia porcellus,10141.0,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615463,,BAO_0000221,10000000.0,
594,12867,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615464,,BAO_0000221,2116.0,
595,12867,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615465,,BAO_0000221,2116.0,
596,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615466,,BAO_0000221,2116.0,
597,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615467,,BAO_0000221,2116.0,
598,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615468,,BAO_0000221,2116.0,
599,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615469,,BAO_0000221,2116.0,
600,11574,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615470,,BAO_0000357,,
601,13114,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615471,,BAO_0000357,,
602,13181,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615472,,BAO_0000357,,
603,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,B,,,Cavia porcellus,10141.0,,Hippocampus,,,106,H,8,Autocuration,1,,CHEMBL883242,,BAO_0000221,10000000.0,
604,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,F,,,Cavia porcellus,10141.0,,Hippocampus,,,106,H,8,Autocuration,1,,CHEMBL615473,,BAO_0000221,10000000.0,
605,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,,Cricetulus griseus,10029.0,,,CHO,,11863,H,8,Autocuration,1,,CHEMBL615474,449.0,BAO_0000218,,
606,17785,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615475,,BAO_0000357,,
607,1558,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,F,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL615476,308.0,BAO_0000219,,
608,1558,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,F,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL615477,308.0,BAO_0000219,,
609,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615478,,BAO_0000019,,
610,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615160,449.0,BAO_0000219,,
611,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615161,449.0,BAO_0000219,,
612,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615162,449.0,BAO_0000219,,
613,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615163,449.0,BAO_0000219,,
614,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615164,449.0,BAO_0000219,,
615,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615165,449.0,BAO_0000219,,
616,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615166,449.0,BAO_0000219,,
617,14256,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615167,,BAO_0000219,,
618,3445,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL615168,308.0,BAO_0000219,,
619,3445,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL615169,308.0,BAO_0000219,,
620,17200,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615170,449.0,BAO_0000219,,
621,17200,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615171,449.0,BAO_0000219,,
622,15180,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615694,,BAO_0000019,,
623,15180,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615695,,BAO_0000019,,
624,16026,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615696,,BAO_0000019,,
625,2759,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615697,449.0,BAO_0000219,,
626,2759,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL859410,449.0,BAO_0000219,,
627,2759,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615841,449.0,BAO_0000219,,
628,2759,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615842,449.0,BAO_0000219,,
629,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL835003,449.0,BAO_0000219,,
630,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615843,449.0,BAO_0000219,,
631,2759,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615979,449.0,BAO_0000219,,
632,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615980,449.0,BAO_0000219,,
633,2759,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615981,449.0,BAO_0000219,,
634,3445,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615982,,BAO_0000019,,
635,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615983,,BAO_0000019,,
636,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615984,,BAO_0000019,,
637,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615985,,BAO_0000019,,
638,17624,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615986,449.0,BAO_0000219,,
639,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615987,449.0,BAO_0000219,,
640,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615988,449.0,BAO_0000219,,
641,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615989,449.0,BAO_0000219,,
642,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615990,449.0,BAO_0000219,,
643,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615991,449.0,BAO_0000219,,
644,17624,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615992,449.0,BAO_0000219,,
645,17624,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615993,449.0,BAO_0000219,,
646,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615994,449.0,BAO_0000219,,
647,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615995,449.0,BAO_0000219,,
648,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615996,449.0,BAO_0000219,,
649,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615997,449.0,BAO_0000219,,
650,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615998,,BAO_0000019,,
651,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615999,,BAO_0000019,,
652,6563,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616000,,BAO_0000019,,
653,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616001,722.0,BAO_0000219,,
654,6876,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616002,,BAO_0000019,,
655,6876,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616003,,BAO_0000019,,
656,5272,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616004,,BAO_0000019,,
657,5272,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616005,,BAO_0000019,,
658,5548,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616006,,BAO_0000019,,
659,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616007,,BAO_0000019,,
660,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616008,,BAO_0000019,,
661,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616009,,BAO_0000019,,
662,5929,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616010,,BAO_0000019,,
663,5929,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616011,,BAO_0000019,,
664,5929,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615740,,BAO_0000019,,
665,16245,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615741,,BAO_0000019,,
666,5640,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL615742,,BAO_0000019,,
667,5640,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615743,,BAO_0000019,,
668,14509,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615744,449.0,BAO_0000219,,
669,14509,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,F,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615745,449.0,BAO_0000219,,
670,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615746,,BAO_0000357,,
671,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615747,,BAO_0000357,,
672,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615748,,BAO_0000019,,
673,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615749,,BAO_0000019,,
674,6563,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615750,,BAO_0000019,,
675,6563,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616259,,BAO_0000019,,
676,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616260,,BAO_0000019,,
677,5272,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616261,,BAO_0000019,,
678,5272,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616262,,BAO_0000019,,
679,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616263,,BAO_0000019,,
680,5272,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616264,,BAO_0000019,,
681,5272,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616265,,BAO_0000019,,
682,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616266,,BAO_0000019,,
683,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616267,,BAO_0000019,,
684,5272,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616268,,BAO_0000019,,
685,16146,Inhibition of human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616269,,BAO_0000357,,
686,17624,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL884528,449.0,BAO_0000219,,
687,13706,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,B,,,,,,,HEK293,,105,D,9,Expert,1,,CHEMBL616270,722.0,BAO_0000219,,
688,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616271,449.0,BAO_0000219,,
689,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616272,449.0,BAO_0000219,,
690,6861,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616273,,BAO_0000357,,
691,17200,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616274,,BAO_0000357,,
692,17624,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616275,449.0,BAO_0000219,,
693,17624,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616276,449.0,BAO_0000219,,
694,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616277,,BAO_0000218,,
695,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616278,,BAO_0000218,,
696,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616279,,BAO_0000218,,
697,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616280,,BAO_0000218,,
698,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616281,,BAO_0000218,,
699,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616282,,BAO_0000218,,
700,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616283,,BAO_0000218,,
701,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616284,,BAO_0000218,,
702,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616285,,BAO_0000218,,
703,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616286,,BAO_0000218,,
704,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616287,,BAO_0000218,,
705,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616288,,BAO_0000218,,
706,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616289,,BAO_0000218,,
707,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615610,,BAO_0000218,,
708,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615611,,BAO_0000218,,
709,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615612,,BAO_0000218,,
710,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615613,,BAO_0000218,,
711,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615614,,BAO_0000218,,
712,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615615,,BAO_0000218,,
713,11440,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,B,,,,,,,,,105093,H,4,Autocuration,1,,CHEMBL615616,,BAO_0000019,,
714,6238,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,B,,,,,,Hypothalamus,,,11923,H,8,Autocuration,1,,CHEMBL615617,,BAO_0000249,1898.0,
715,10046,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL615618,,BAO_0000019,,
716,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL615619,,BAO_0000019,,
717,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL615620,,BAO_0000019,,
718,167,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL615621,,BAO_0000357,,
719,167,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL615622,,BAO_0000357,,
720,11520,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615623,,BAO_0000019,,
721,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615624,,BAO_0000019,,
722,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615625,,BAO_0000019,,
723,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL767045,,BAO_0000019,,
724,135,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,F,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL615626,,BAO_0000019,,
725,135,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,F,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL615627,,BAO_0000019,,
726,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL615628,,BAO_0000019,,
727,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL615629,,BAO_0000357,,
728,12281,Inhibitory concentration against 5-lipoxygenase from human whole blood,B,,,Homo sapiens,9606.0,,,,,55,D,9,Expert,1,,CHEMBL615630,,BAO_0000357,,
729,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL615631,,BAO_0000219,,
730,12576,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL615632,,BAO_0000218,,
731,12281,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,B,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL615633,,BAO_0000357,,
732,12576,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL615634,,BAO_0000218,,
733,11089,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,,Sus scrofa,9823.0,,,,,55,H,8,Expert,1,,CHEMBL615635,,BAO_0000019,,
734,11006,In vitro inhibition of rat 5-Lipoxygenase,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL615636,,BAO_0000357,,
735,11481,Inhibitory activity against 5-Lipoxygenase,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL615637,,BAO_0000357,,
736,10864,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL615638,702.0,BAO_0000219,,
737,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL615639,702.0,BAO_0000219,,
738,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL615640,702.0,BAO_0000219,,
739,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615796,,BAO_0000019,,
740,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615845,,BAO_0000219,,
741,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615846,,BAO_0000357,,
742,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL615847,702.0,BAO_0000219,,
743,11311,The compound was tested for inhibition of isolated 5-Lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615848,,BAO_0000357,,
744,11481,Ratio of IC50 against 5-LO and COX,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615849,,BAO_0000019,,
745,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615850,,BAO_0000357,,
746,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615851,,BAO_0000357,,
747,11311,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615852,,BAO_0000219,,
748,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615853,,BAO_0000019,,
749,4288,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,B,,,,,,Prostate gland,,,120,H,8,Autocuration,1,,CHEMBL884527,,BAO_0000357,2367.0,
750,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,B,,,Columba livia,8932.0,,,,,22226,U,0,Autocuration,1,,CHEMBL872871,,BAO_0000019,,
751,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,B,,,Columba livia,8932.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615854,,BAO_0000019,,
752,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,B,,,Columba livia,8932.0,,,,,22226,U,0,Autocuration,1,,CHEMBL767046,,BAO_0000019,,
753,11249,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,B,,,,,,,,,10732,H,8,Autocuration,1,,CHEMBL615855,,BAO_0000357,,
754,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,F,,,Rattus norvegicus,10116.0,,,,,12198,D,9,Expert,1,,CHEMBL615856,,BAO_0000019,,
755,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,,Rattus norvegicus,10116.0,,,,,12198,D,9,Expert,1,,CHEMBL615857,,BAO_0000019,,
756,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,,Rattus norvegicus,10116.0,,,,,12198,D,9,Expert,1,,CHEMBL615858,,BAO_0000019,,
757,12416,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615859,,BAO_0000221,10000000.0,
758,16293,Binding affinity towards human 5-hydroxytryptamine 1 receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615860,,BAO_0000357,,
759,13047,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615861,,BAO_0000019,,
760,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615862,,BAO_0000019,,
761,13047,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615863,,BAO_0000019,,
762,13047,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615864,,BAO_0000019,,
763,10085,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL615865,,BAO_0000221,10000000.0,
764,10085,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL615866,,BAO_0000221,10000000.0,
765,10085,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL615867,,BAO_0000221,10000000.0,
766,9841,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,B,,,,,,,,Membranes,104744,H,4,Autocuration,1,,CHEMBL615868,,BAO_0000249,,
767,8822,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615869,,BAO_0000249,,
768,9806,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615870,,BAO_0000019,,
769,9806,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615871,,BAO_0000019,,
770,8868,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615872,,BAO_0000224,,
771,9036,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL833492,,BAO_0000221,10000000.0,
772,11374,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL615873,,BAO_0000221,10000000.0,
773,10881,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615479,,BAO_0000224,,
774,8822,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615480,,BAO_0000019,,
775,9806,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615481,,BAO_0000249,,
776,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL872869,,BAO_0000019,,
777,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615482,,BAO_0000019,,
778,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615483,,BAO_0000221,955.0,
779,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615484,,BAO_0000221,955.0,
780,8569,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615485,,BAO_0000019,,
781,10062,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615486,,BAO_0000224,,
782,4771,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615487,,BAO_0000224,,
783,10062,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615488,,BAO_0000224,,
784,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615489,,BAO_0000224,,
785,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615389,,BAO_0000224,,
786,15463,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615390,,BAO_0000019,,
787,15463,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615391,,BAO_0000019,,
788,9098,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615392,,BAO_0000224,,
789,3070,Affinity for 5-hydroxytryptamine 1 receptor,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615393,,BAO_0000019,,
790,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615394,,BAO_0000221,955.0,
791,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615395,,BAO_0000221,955.0,
792,6398,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615396,,BAO_0000224,,
793,1344,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615397,,BAO_0000221,955.0,
794,11963,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615398,,BAO_0000019,,
795,8908,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615399,,BAO_0000019,,
796,9098,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615400,,BAO_0000019,,
797,8841,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615401,,BAO_0000019,,
798,8814,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615402,,BAO_0000019,,
799,11752,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615403,,BAO_0000019,,
800,11642,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615404,,BAO_0000221,955.0,
801,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615781,,BAO_0000019,,
802,9231,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615782,,BAO_0000220,955.0,
803,11351,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615783,,BAO_0000221,955.0,
804,4639,Compound was tested for binding affinity against 5-HT1 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL873481,,BAO_0000019,,
805,1205,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615784,,BAO_0000019,,
806,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615785,,BAO_0000357,,
807,13241,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615786,,BAO_0000249,,
808,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615787,,BAO_0000218,,
809,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615788,,BAO_0000218,,
810,12438,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL767044,,BAO_0000019,,
811,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615789,,BAO_0000218,,
812,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615790,,BAO_0000218,,
813,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615813,,BAO_0000019,,
814,15535,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615814,,BAO_0000219,,
815,15535,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,F,,,,,,,,,51,H,8,Expert,1,,CHEMBL615815,,BAO_0000219,,
816,15535,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615816,,BAO_0000219,,
817,9888,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615817,,BAO_0000249,,
818,10085,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615818,,BAO_0000221,10000000.0,
819,10085,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615819,,BAO_0000221,10000000.0,
820,17331,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,B,,,,,,,,Membranes,10576,H,8,Expert,1,,CHEMBL615820,,BAO_0000249,,
821,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615821,,BAO_0000221,10000000.0,
822,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615822,,BAO_0000221,10000000.0,
823,10845,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615823,,BAO_0000221,10000000.0,
824,10845,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615824,,BAO_0000221,10000000.0,
825,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615825,,BAO_0000221,10000000.0,
826,13730,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615826,,BAO_0000357,,
827,13508,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615827,,BAO_0000249,,
828,13508,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615828,,BAO_0000249,10000000.0,
829,12073,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615829,,BAO_0000221,10000000.0,
830,4671,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615830,,BAO_0000221,10000000.0,
831,13631,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615831,,BAO_0000221,10000000.0,
832,12438,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615832,,BAO_0000357,,
833,10483,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615833,,BAO_0000019,,
834,10483,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615834,,BAO_0000221,10000000.0,
835,12352,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,B,,,,,,,,,10576,H,8,Intermediate,1,,CHEMBL615835,,BAO_0000249,,
836,14732,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615836,,BAO_0000249,10000000.0,
837,11049,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615837,,BAO_0000019,,
838,11049,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615838,,BAO_0000019,,
839,13657,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615839,,BAO_0000249,,
840,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL884525,,BAO_0000019,,
841,2014,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615840,,BAO_0000249,,
842,3086,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615405,,BAO_0000221,10000000.0,
843,15854,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615406,,BAO_0000019,,
844,10922,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615900,,BAO_0000221,10000000.0,
845,13346,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615901,,BAO_0000221,10000000.0,
846,15311,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615902,,BAO_0000357,,
847,10922,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615903,,BAO_0000221,10000000.0,
848,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615904,,BAO_0000357,,
849,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615905,,BAO_0000357,,
850,9742,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615906,,BAO_0000019,,
851,9742,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615907,,BAO_0000019,,
852,12304,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615908,,BAO_0000019,,
853,15789,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615909,,BAO_0000221,10000000.0,
854,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615910,,BAO_0000019,,
855,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615911,,BAO_0000019,,
856,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615912,,BAO_0000019,,
857,16693,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615913,,BAO_0000019,,
858,13276,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615914,,BAO_0000357,,
859,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615915,,BAO_0000221,10000000.0,
860,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615916,,BAO_0000357,,
861,12443,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615917,,BAO_0000357,,
862,13830,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615918,,BAO_0000357,,
863,14286,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615919,,BAO_0000249,10000000.0,
864,14356,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615920,,BAO_0000221,10000000.0,
865,15306,Inhibition concentration against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615921,,BAO_0000357,,
866,15306,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615922,,BAO_0000357,,
867,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL881290,,BAO_0000249,,
868,3651,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615923,,BAO_0000221,10000000.0,
869,14331,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615924,,BAO_0000221,10000000.0,
870,14331,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615925,,BAO_0000221,10000000.0,
871,14178,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615926,,BAO_0000357,,
872,10639,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615927,,BAO_0000019,,
873,12306,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615928,,BAO_0000221,10000000.0,
874,1348,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615929,,BAO_0000357,,
875,13605,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615930,,BAO_0000221,10000000.0,
876,17624,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615931,449.0,BAO_0000219,,
877,17624,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615932,449.0,BAO_0000219,,
878,17624,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615933,449.0,BAO_0000219,,
879,15267,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615934,,BAO_0000357,,
880,16532,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615935,,BAO_0000357,,
881,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615936,,BAO_0000019,,
882,4751,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615937,449.0,BAO_0000219,,
883,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615938,,BAO_0000357,,
884,3805,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615797,,BAO_0000357,,
885,5640,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615798,,BAO_0000357,,
886,6563,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL872870,,BAO_0000357,,
887,5548,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615799,,BAO_0000357,,
888,6347,Percent binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615800,,BAO_0000357,,
889,17296,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL615801,722.0,BAO_0000219,,
890,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615802,,BAO_0000019,,
891,15740,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615803,,BAO_0000357,,
892,5640,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL835002,,BAO_0000019,,
893,5640,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615804,,BAO_0000019,,
894,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,B,,,,,,,HeLa,,51,H,8,Expert,1,,CHEMBL615805,308.0,BAO_0000219,,
895,4751,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615806,449.0,BAO_0000219,,
896,6491,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615807,,BAO_0000357,,
897,4707,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615808,,BAO_0000357,,
898,13910,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615809,,BAO_0000357,,
899,16190,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL615810,308.0,BAO_0000219,,
900,16633,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615811,,BAO_0000357,,
901,11898,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615812,449.0,BAO_0000219,,
902,11898,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615751,449.0,BAO_0000219,,
903,14331,Binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615752,,BAO_0000357,,
904,17624,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615753,449.0,BAO_0000219,,
905,17624,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615754,449.0,BAO_0000219,,
906,3307,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615755,,BAO_0000357,,
907,6563,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615756,449.0,BAO_0000219,,
908,14165,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615757,,BAO_0000019,,
909,5732,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615758,,BAO_0000357,,
910,13366,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615759,,BAO_0000357,,
911,17626,Binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615760,,BAO_0000357,,
912,6588,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,B,,,,,,,HeLa,,51,H,8,Expert,1,,CHEMBL615761,308.0,BAO_0000219,,
913,16209,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL872104,,BAO_0000357,,
914,15463,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615762,,BAO_0000357,,
915,15463,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615763,,BAO_0000357,,
916,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615764,,BAO_0000357,,
917,16245,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),B,,,,,,,Cell line,,51,H,8,Autocuration,1,,CHEMBL615765,1167.0,BAO_0000219,,
918,16245,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615766,,BAO_0000019,,
919,5548,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615767,,BAO_0000357,,
920,5548,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615768,,BAO_0000357,,
921,5548,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615769,,BAO_0000357,,
922,6876,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615770,,BAO_0000357,,
923,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615771,,BAO_0000357,,
924,17785,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615772,,BAO_0000357,,
925,6013,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615773,,BAO_0000357,,
926,5929,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615774,,BAO_0000357,,
927,16633,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615775,,BAO_0000357,,
928,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615776,,BAO_0000357,,
929,16026,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615777,,BAO_0000357,,
930,12469,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615778,,BAO_0000219,,
931,15874,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615779,,BAO_0000357,,
932,15874,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615780,,BAO_0000357,,
933,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616298,,BAO_0000357,,
934,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616299,,BAO_0000357,,
935,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,51,H,8,Autocuration,1,,CHEMBL616300,485.0,BAO_0000219,,
936,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,F,,,,,,,CHO-K1,,51,H,8,Expert,1,,CHEMBL616301,485.0,BAO_0000219,,
937,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616302,,BAO_0000019,,
938,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616117,,BAO_0000019,,
939,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616118,,BAO_0000019,,
940,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616119,,BAO_0000019,,
941,3445,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616120,308.0,BAO_0000219,,
942,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616121,,BAO_0000357,,
943,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616122,,BAO_0000357,,
944,17626,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616123,,BAO_0000357,,
945,4234,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616124,,BAO_0000357,,
946,5640,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616125,,BAO_0000357,,
947,5272,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,,,,51,H,8,Expert,1,,CHEMBL616126,,BAO_0000357,,
948,4622,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616127,449.0,BAO_0000219,,
949,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616128,,BAO_0000019,,
950,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616129,,BAO_0000357,,
951,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616130,,BAO_0000357,,
952,15267,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616131,,BAO_0000357,,
953,17158,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616132,308.0,BAO_0000219,,
954,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616133,308.0,BAO_0000219,,
955,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616134,,BAO_0000357,,
956,16532,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616135,,BAO_0000357,,
957,2391,Affinity for 5-hydroxytryptamine 1A receptor subtype,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616136,,BAO_0000357,,
958,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616137,,BAO_0000019,,
959,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL872105,,BAO_0000019,,
960,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616138,,BAO_0000357,,
961,13051,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616139,,BAO_0000357,,
962,16026,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616140,,BAO_0000019,,
963,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616141,,BAO_0000019,,
964,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616142,,BAO_0000357,,
965,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616143,,BAO_0000357,,
966,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616144,308.0,BAO_0000219,,
967,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616145,308.0,BAO_0000219,,
968,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616012,308.0,BAO_0000219,,
969,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616013,308.0,BAO_0000219,,
970,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616014,,BAO_0000019,,
971,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616015,,BAO_0000019,,
972,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616016,,BAO_0000019,,
973,16394,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,F,In vivo,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616017,,BAO_0000218,,
974,16394,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616018,,BAO_0000019,,
975,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616019,,BAO_0000019,,
976,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616020,,BAO_0000019,,
977,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL858018,,BAO_0000357,,
978,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616021,722.0,BAO_0000219,,
979,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616022,,BAO_0000019,,
980,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616023,,BAO_0000019,,
981,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616024,,BAO_0000019,,
982,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616025,,BAO_0000019,,
983,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616026,449.0,BAO_0000219,,
984,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616027,,BAO_0000019,,
985,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616028,,BAO_0000019,,
986,3445,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616029,,BAO_0000019,,
987,4316,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL616030,449.0,BAO_0000219,,
988,4316,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616031,,BAO_0000019,,
989,15180,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616032,,BAO_0000019,,
990,15180,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616033,,BAO_0000019,,
991,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616034,,BAO_0000019,,
992,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616035,,BAO_0000019,,
993,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616036,,BAO_0000019,,
994,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616037,,BAO_0000019,,
995,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616038,,BAO_0000019,,
996,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616039,,BAO_0000019,,
997,15042,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616040,,BAO_0000019,,
998,15180,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616041,308.0,BAO_0000219,,
999,15180,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616042,308.0,BAO_0000219,,
1000,15180,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616043,308.0,BAO_0000219,,
1001,16245,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616044,,BAO_0000019,,
1002,16026,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616045,,BAO_0000019,,
1003,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616046,722.0,BAO_0000219,,
1004,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616047,449.0,BAO_0000219,,
1005,2759,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616048,449.0,BAO_0000219,,
1006,2759,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL616049,449.0,BAO_0000219,,
1007,2759,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616050,449.0,BAO_0000219,,
1008,15419,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616051,,BAO_0000219,,
1009,15419,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616212,,BAO_0000219,,
1010,16026,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616213,,BAO_0000019,,
1011,1414,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,B,In vitro,,,,,,,,51,H,8,Expert,1,,CHEMBL616214,,BAO_0000219,,
1012,1414,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,B,In vitro,,,,,,,,51,H,8,Expert,1,,CHEMBL616215,,BAO_0000219,,
1013,12861,Binding activity radioligand.,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616216,,BAO_0000357,,
1014,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616217,,BAO_0000019,,
1015,5104,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616218,,BAO_0000357,,
1016,5105,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616219,,BAO_0000357,,
1017,16312,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616220,,BAO_0000357,,
1018,15180,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL833493,,BAO_0000357,,
1019,5033,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616221,,BAO_0000357,,
1020,16909,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL616222,449.0,BAO_0000219,,
1021,2590,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616223,,BAO_0000019,,
1022,2590,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616224,,BAO_0000019,,
1023,16394,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616225,,BAO_0000019,,
1024,4540,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,51,D,9,Expert,1,,CHEMBL616226,722.0,BAO_0000219,,
1025,17296,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616227,722.0,BAO_0000219,,
1026,17296,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616228,722.0,BAO_0000219,,
1027,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616229,722.0,BAO_0000219,,
1028,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616230,722.0,BAO_0000219,,
1029,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616231,722.0,BAO_0000219,,
1030,6166,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616232,,BAO_0000357,,
1031,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616233,722.0,BAO_0000219,,
1032,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL857973,722.0,BAO_0000219,,
1033,15316,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616234,,BAO_0000219,,
1034,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616235,,BAO_0000357,,
1035,14727,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,,,,HeLa,,51,H,8,Expert,1,,CHEMBL616236,308.0,BAO_0000219,,
1036,14727,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616237,,BAO_0000019,,
1037,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616238,722.0,BAO_0000219,,
1038,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616239,722.0,BAO_0000219,,
1039,16429,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616240,,BAO_0000219,,
1040,15042,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616241,308.0,BAO_0000219,,
1041,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616242,722.0,BAO_0000219,,
1042,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616243,722.0,BAO_0000219,,
1043,17200,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,D,9,Expert,1,,CHEMBL616244,,BAO_0000357,,
1044,13051,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Autocuration,1,,CHEMBL616245,,BAO_0000357,,
1045,5486,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616246,,BAO_0000357,,
1046,5254,Binding affinity against 5-HT1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616247,,BAO_0000357,,
1047,5254,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616248,,BAO_0000357,,
1048,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL616249,,BAO_0000357,,
1049,13506,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,Homo sapiens,9606.0,,,,,10576,H,8,Autocuration,1,,CHEMBL616250,,BAO_0000357,,
1050,15267,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616251,,BAO_0000357,,
1051,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,F,In vivo,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616252,,BAO_0000218,,
1052,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,F,In vivo,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616253,,BAO_0000218,,
1053,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,F,In vivo,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616254,,BAO_0000218,,
1054,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616255,,BAO_0000218,,
1055,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL832872,,BAO_0000218,,
1056,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616256,,BAO_0000218,,
1057,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616257,,BAO_0000218,,
1058,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616258,,BAO_0000218,,
1059,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616384,,BAO_0000218,,
1060,10297,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,,,,,Hippocampus,,,11863,H,8,Autocuration,1,,CHEMBL616385,,BAO_0000221,10000000.0,
1061,13704,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,B,,,,,,,,,11863,H,8,Expert,1,,CHEMBL616386,,BAO_0000357,,
1062,10297,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,,Mus musculus,10090.0,,Hippocampus,,,11863,D,9,Expert,1,,CHEMBL616387,,BAO_0000221,10000000.0,
1063,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,,,,Hippocampus,,,11863,H,8,Autocuration,1,,CHEMBL616388,,BAO_0000221,10000000.0,
1064,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,,Mus musculus,10090.0,,Hippocampus,,,11863,D,9,Expert,1,,CHEMBL616389,,BAO_0000221,10000000.0,
1065,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,,,,Hippocampus,,,11863,H,8,Autocuration,1,,CHEMBL616390,,BAO_0000221,10000000.0,
1066,217,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616391,,BAO_0000357,,
1067,10297,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,,Mus musculus,10090.0,,Hippocampus,,,11863,D,9,Expert,1,,CHEMBL616392,,BAO_0000221,10000000.0,
1068,4921,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616393,,BAO_0000357,,
1069,4921,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616394,,BAO_0000357,,
1070,4996,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616395,,BAO_0000019,,
1071,12918,Compound was evaluated for the binding affinity at 5- HT1A receptor,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616396,,BAO_0000357,,
1072,5333,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL872907,,BAO_0000019,,
1073,4437,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616397,,BAO_0000019,,
1074,1742,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616398,,BAO_0000019,,
1075,16688,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0,,,,,51,H,8,Expert,1,,CHEMBL616399,,BAO_0000357,,
1076,12861,Binding activity radioligand.,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL857065,,BAO_0000357,,
1077,12861,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,,Sus scrofa,9823.0,,,,,51,H,8,Expert,1,,CHEMBL616400,,BAO_0000019,,
1078,12861,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616401,,BAO_0000019,,
1079,12490,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL616402,,BAO_0000019,,
1080,11828,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0,,,,,51,H,8,Expert,1,,CHEMBL616403,,BAO_0000019,,
1081,11866,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,B,,,Sus scrofa,9823.0,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL616404,,BAO_0000221,10000000.0,
1082,12827,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616405,,BAO_0000249,,
1083,12918,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616406,,BAO_0000019,,
1084,12919,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,F,,,Sus scrofa,9823.0,,,,,51,H,8,Expert,1,,CHEMBL616407,,BAO_0000019,,
1085,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,B,,,Oryctolagus cuniculus,9986.0,,,,,51,H,8,Autocuration,1,,CHEMBL616408,,BAO_0000019,,
1086,15796,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616409,,BAO_0000249,,
1087,3651,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616410,,BAO_0000221,10000000.0,
1088,188,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616411,,BAO_0000357,,
1089,16616,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616412,,BAO_0000249,,
1090,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,Hippocampus,,Membranes,10576,D,9,Expert,1,,CHEMBL616413,,BAO_0000249,10000000.0,
1091,12306,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616414,,BAO_0000221,10000000.0,
1092,17167,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616415,,BAO_0000221,10000000.0,
1093,14776,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616416,,BAO_0000019,,
1094,12158,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616417,,BAO_0000357,,
1095,13481,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616418,,BAO_0000357,,
1096,13427,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616419,,BAO_0000219,,
1097,10210,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616420,,BAO_0000357,,
1098,10205,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,,,,,,Membranes,10576,H,8,Autocuration,1,,CHEMBL616421,,BAO_0000249,,
1099,10205,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,,,,,,Membranes,10576,H,8,Autocuration,1,,CHEMBL616422,,BAO_0000249,,
1100,10205,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,B,,,,,,,,Membranes,10576,H,8,Expert,1,,CHEMBL616423,,BAO_0000249,,
1101,12280,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616424,,BAO_0000357,,
1102,17386,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616425,,BAO_0000357,,
1103,13654,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616426,,BAO_0000357,,
1104,14423,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616427,,BAO_0000221,10000000.0,
1105,15412,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616428,,BAO_0000221,10000000.0,
1106,12073,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616290,,BAO_0000221,10000000.0,
1107,4101,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616052,,BAO_0000357,,
1108,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616053,,BAO_0000357,,
1109,6238,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616054,,BAO_0000249,,
1110,16273,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616055,,BAO_0000357,,
1111,11139,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616056,,BAO_0000357,,
1112,16796,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616057,,BAO_0000019,,
1113,9548,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,Rattus norvegicus,10116.0,,Brain,,,10576,D,9,Expert,1,,CHEMBL616058,,BAO_0000221,955.0,
1114,10381,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616059,,BAO_0000221,955.0,
1115,13408,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616060,,BAO_0000249,,
1116,13825,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616061,,BAO_0000221,10000000.0,
1117,11147,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616062,,BAO_0000221,10000000.0,
1118,10552,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616063,,BAO_0000249,,
1119,10552,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,,,,Striatum,,,10576,H,8,Autocuration,1,,CHEMBL616064,,BAO_0000249,2435.0,
1120,17136,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616065,,BAO_0000249,,
1121,5778,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616066,,BAO_0000249,,
1122,13481,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616067,,BAO_0000221,10000000.0,
1123,13481,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616068,,BAO_0000221,10000000.0,
1124,13630,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Intermediate,1,,CHEMBL616069,,BAO_0000221,10000000.0,
1125,16245,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616070,,BAO_0000249,,
1126,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616071,,BAO_0000221,10000000.0,
1127,14509,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616072,,BAO_0000221,10000000.0,
1128,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616073,,BAO_0000221,10000000.0,
1129,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616074,,BAO_0000221,10000000.0,
1130,14256,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616075,,BAO_0000019,,
1131,11139,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616076,,BAO_0000357,,
1132,11047,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616077,,BAO_0000019,,
1133,11047,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616078,,BAO_0000019,,
1134,11047,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616079,,BAO_0000019,,
1135,2395,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,10576,D,9,Expert,1,,CHEMBL616080,485.0,BAO_0000219,,
1136,9699,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616081,,BAO_0000357,,
1137,12028,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616082,,BAO_0000221,10000000.0,
1138,12028,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616083,,BAO_0000221,10000000.0,
1139,5815,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616084,,BAO_0000019,,
1140,16616,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616085,,BAO_0000019,,
1141,5815,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616086,,BAO_0000019,,
1142,2761,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616087,,BAO_0000221,10000000.0,
1143,13133,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616088,,BAO_0000357,,
1144,10444,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616089,,BAO_0000019,,
1145,13278,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616090,,BAO_0000357,,
1146,15874,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616091,,BAO_0000357,,
1147,10552,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,,,,Striatum,,Membranes,10576,H,8,Autocuration,1,,CHEMBL616092,,BAO_0000249,2435.0,
1148,11130,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616093,,BAO_0000357,,
1149,11130,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),B,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616094,,BAO_0000218,,
1150,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616095,,BAO_0000221,955.0,
1151,13670,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616096,,BAO_0000357,,
1152,9888,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616097,,BAO_0000249,,
1153,3678,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616098,,BAO_0000249,,
1154,11332,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616099,,BAO_0000221,10000000.0,
1155,11332,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616100,,BAO_0000221,10000000.0,
1156,1185,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616101,,BAO_0000357,,
1157,2014,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616102,,BAO_0000249,,
1158,1185,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616103,,BAO_0000357,,
1159,14429,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616104,,BAO_0000019,,
1160,16288,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616105,,BAO_0000019,,
1161,5432,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616106,,BAO_0000019,,
1162,14429,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616107,,BAO_0000019,,
1163,13672,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616108,,BAO_0000357,,
1164,11296,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616109,,BAO_0000221,10000000.0,
1165,11296,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616110,,BAO_0000357,,
1166,14749,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,B,,,,,,,CHO,,10576,H,8,Expert,1,,CHEMBL616111,449.0,BAO_0000219,,
1167,15086,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616112,,BAO_0000019,,
1168,13462,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616113,,BAO_0000221,10000000.0,
1169,15363,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616114,,BAO_0000019,,
1170,15363,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616115,,BAO_0000019,,
1171,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616116,,BAO_0000357,,
1172,12816,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL615844,,BAO_0000221,955.0,
1173,13542,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615939,,BAO_0000221,10000000.0,
1174,13308,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615940,,BAO_0000019,,
1175,13541,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615941,,BAO_0000221,10000000.0,
1176,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615942,,BAO_0000221,10000000.0,
1177,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615943,,BAO_0000221,10000000.0,
1178,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615944,,BAO_0000221,10000000.0,
1179,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615945,,BAO_0000221,10000000.0,
1180,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615946,,BAO_0000221,10000000.0,
1181,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615947,,BAO_0000221,10000000.0,
1182,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615948,,BAO_0000221,10000000.0,
1183,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615949,,BAO_0000221,10000000.0,
1184,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615950,,BAO_0000221,10000000.0,
1185,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615951,,BAO_0000221,10000000.0,
1186,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615952,,BAO_0000221,10000000.0,
1187,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615953,,BAO_0000221,10000000.0,
1188,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615954,,BAO_0000221,10000000.0,
1189,10058,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615955,,BAO_0000221,10000000.0,
1190,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615956,,BAO_0000221,10000000.0,
1191,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615957,,BAO_0000221,10000000.0,
1192,12879,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615958,,BAO_0000019,,
1193,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615959,,BAO_0000019,,
1194,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615960,,BAO_0000019,,
1195,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615961,,BAO_0000019,,
1196,9548,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL615962,,BAO_0000221,955.0,
1197,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615963,,BAO_0000019,,
1198,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615964,,BAO_0000019,,
1199,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615965,,BAO_0000019,,
1200,13248,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,B,,,,,,,CHO,,10576,H,8,Expert,1,,CHEMBL615966,449.0,BAO_0000219,,
1201,3147,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615967,,BAO_0000249,,
1202,13949,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615968,,BAO_0000019,,
1203,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,,,,,,CHO,,10576,H,8,Autocuration,1,,CHEMBL615969,449.0,BAO_0000218,,
1204,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615970,,BAO_0000218,,
1205,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615971,,BAO_0000357,,
1206,15535,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,,,,Membranes,10576,H,8,Expert,1,,CHEMBL615972,,BAO_0000249,,
1207,15535,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615973,,BAO_0000249,,
1208,15535,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615974,,BAO_0000249,,
1209,16372,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615975,449.0,BAO_0000219,,
1210,14608,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615976,,BAO_0000249,,
1211,4795,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL872106,,BAO_0000221,10000000.0,
1212,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615977,,BAO_0000357,,
1213,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615978,,BAO_0000357,,
1214,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616166,,BAO_0000357,,
1215,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616167,,BAO_0000357,,
1216,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616168,,BAO_0000357,,
1217,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616169,,BAO_0000357,,
1218,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616170,,BAO_0000357,,
1219,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616171,,BAO_0000357,,
1220,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616172,,BAO_0000357,,
1221,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616173,,BAO_0000357,,
1222,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616174,,BAO_0000357,,
1223,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616175,,BAO_0000357,,
1224,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616176,,BAO_0000357,,
1225,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616177,,BAO_0000357,,
1226,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616178,,BAO_0000357,,
1227,9742,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616179,,BAO_0000019,,
1228,12073,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616180,,BAO_0000357,,
1229,4101,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616181,,BAO_0000357,,
1230,15360,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616182,,BAO_0000019,,
1231,11576,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616183,,BAO_0000221,10000000.0,
1232,5834,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615874,,BAO_0000019,,
1233,2395,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,10576,D,9,Expert,1,,CHEMBL615875,485.0,BAO_0000219,,
1234,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615876,,BAO_0000019,,
1235,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615877,,BAO_0000019,,
1236,3967,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615878,,BAO_0000357,,
1237,12884,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615879,,BAO_0000357,,
1238,2343,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615880,,BAO_0000357,,
1239,11511,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615881,,BAO_0000019,,
1240,11511,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615882,,BAO_0000019,,
1241,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615883,,BAO_0000218,,
1242,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615884,,BAO_0000218,,
1243,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615885,,BAO_0000218,,
1244,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615886,,BAO_0000218,,
1245,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615887,,BAO_0000218,,
1246,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615888,,BAO_0000218,,
1247,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615889,,BAO_0000218,,
1248,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615890,,BAO_0000218,,
1249,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615891,,BAO_0000218,,
1250,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615892,,BAO_0000218,,
1251,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615893,,BAO_0000218,,
1252,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615894,,BAO_0000218,,
1253,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615895,,BAO_0000218,,
1254,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615896,,BAO_0000218,,
1255,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615897,,BAO_0000218,,
1256,16616,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL615898,,BAO_0000249,,
1257,16796,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615899,,BAO_0000019,,
1258,16796,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616291,,BAO_0000019,,
1259,15629,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616292,,BAO_0000357,,
1260,13241,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616293,,BAO_0000249,,
1261,12073,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616294,,BAO_0000221,10000000.0,
1262,14286,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616295,,BAO_0000249,10000000.0,
1263,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616296,,BAO_0000221,955.0,
1264,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616297,,BAO_0000019,,
1265,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616605,,BAO_0000019,,
1266,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616606,,BAO_0000019,,
1267,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616607,,BAO_0000019,,
1268,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616608,,BAO_0000019,,
1269,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616609,,BAO_0000019,,
1270,13630,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,F,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616610,,BAO_0000019,,
1271,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616611,,BAO_0000019,,
1272,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616612,,BAO_0000019,,
1273,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616613,,BAO_0000019,,
1274,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616614,,BAO_0000019,,
1275,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616615,,BAO_0000019,,
1276,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616616,,BAO_0000019,,
1277,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616617,,BAO_0000019,,
1278,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616618,,BAO_0000019,,
1279,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616619,,BAO_0000019,,
1280,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616620,,BAO_0000019,,
1281,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616621,,BAO_0000019,,
1282,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616622,,BAO_0000019,,
1283,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616146,,BAO_0000019,,
1284,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL832873,,BAO_0000019,,
1285,13630,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616147,,BAO_0000019,,
1286,13630,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL872872,,BAO_0000019,,
1287,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616148,,BAO_0000019,,
1288,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616149,,BAO_0000221,10000000.0,
1289,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616150,,BAO_0000221,10000000.0,
1290,14331,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616151,,BAO_0000249,,
1291,15260,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL872873,,BAO_0000221,10000000.0,
1292,15260,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616670,,BAO_0000221,10000000.0,
1293,15260,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616671,,BAO_0000221,10000000.0,
1294,16616,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL884861,,BAO_0000249,,
1295,15629,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616672,,BAO_0000357,,
1296,15086,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616673,,BAO_0000019,,
1297,5717,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616674,,BAO_0000019,,
1298,12652,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616675,,BAO_0000357,,
1299,14608,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616676,,BAO_0000221,10000000.0,
1300,12306,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616677,,BAO_0000221,10000000.0,
1301,12306,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616678,,BAO_0000221,10000000.0,
1302,15247,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616679,,BAO_0000357,,
1303,17529,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616680,,BAO_0000221,10000000.0,
1304,14826,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616681,,BAO_0000221,10000000.0,
1305,14826,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616682,,BAO_0000221,10000000.0,
1306,13241,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616683,,BAO_0000221,10000000.0,
1307,14093,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616684,,BAO_0000221,10000000.0,
1308,14093,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616685,,BAO_0000221,10000000.0,
1309,14442,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616686,,BAO_0000221,955.0,
1310,9919,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616687,,BAO_0000357,,
1311,9919,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616688,,BAO_0000357,,
1312,11440,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616689,,BAO_0000221,10000000.0,
1313,11257,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616690,,BAO_0000357,,
1314,10330,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616691,,BAO_0000357,,
1315,17331,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616692,,BAO_0000221,10000000.0,
1316,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616693,,BAO_0000249,,
1317,12058,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616694,,BAO_0000019,,
1318,9699,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616695,,BAO_0000221,10000000.0,
1319,9547,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616696,,BAO_0000357,,
1320,10330,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616697,,BAO_0000357,,
1321,14331,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616698,,BAO_0000357,,
1322,14060,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616949,,BAO_0000019,,
1323,14744,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616950,,BAO_0000221,10000000.0,
1324,13506,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL832875,,BAO_0000357,,
1325,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL616951,,BAO_0000221,955.0,
1326,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL616952,,BAO_0000221,955.0,
1327,10062,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616953,,BAO_0000357,,
1328,12073,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616954,,BAO_0000357,,
1329,14875,GTPgammaS radioligand binding assay,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616955,,BAO_0000357,,
1330,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616956,,BAO_0000357,,
1331,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616957,,BAO_0000019,,
1332,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616958,,BAO_0000019,,
1333,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616959,,BAO_0000357,,
1334,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616960,,BAO_0000357,,
1335,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616961,,BAO_0000019,,
1336,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,B,,,,,,,HeLa,,106,H,8,Expert,1,,CHEMBL616962,308.0,BAO_0000219,,
1337,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,B,,,,,,,HeLa,,106,H,8,Autocuration,1,,CHEMBL616963,308.0,BAO_0000219,,
1338,6491,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616524,,BAO_0000357,,
1339,16190,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616525,449.0,BAO_0000219,,
1340,14165,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL872908,,BAO_0000019,,
1341,14165,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616526,,BAO_0000019,,
1342,4234,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616527,,BAO_0000357,,
1343,6328,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616528,,BAO_0000219,,
1344,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616529,,BAO_0000357,,
1345,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616530,,BAO_0000357,,
1346,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616531,,BAO_0000357,,
1347,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616532,,BAO_0000357,,
1348,6013,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616533,,BAO_0000357,,
1349,5843,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616534,,BAO_0000357,,
1350,14454,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616535,,BAO_0000357,,
1351,16209,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616536,,BAO_0000357,,
1352,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616537,,BAO_0000357,,
1353,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,F,,,,,,,CHO-K1,,106,H,8,Expert,1,,CHEMBL616538,485.0,BAO_0000219,,
1354,14251,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,F,,,,,,,,,106,H,8,Expert,1,,CHEMBL616539,,BAO_0000019,,
1355,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616540,,BAO_0000019,,
1356,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616429,,BAO_0000357,,
1357,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616430,,BAO_0000357,,
1358,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616431,,BAO_0000219,,
1359,3804,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616432,,BAO_0000357,,
1360,2391,Affinity for 5-hydroxytryptamine 1B receptor subtype,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616433,,BAO_0000357,,
1361,4175,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616434,,BAO_0000357,,
1362,17296,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616435,449.0,BAO_0000219,,
1363,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616436,,BAO_0000019,,
1364,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,,,,HeLa,,106,H,8,Autocuration,1,,CHEMBL616437,308.0,BAO_0000219,,
1365,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,B,,,,,,,HeLa,,106,H,8,Autocuration,1,,CHEMBL616438,308.0,BAO_0000219,,
1366,17211,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,,,,HeLa,,106,H,8,Autocuration,1,,CHEMBL616439,308.0,BAO_0000219,,
1367,15926,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616440,,BAO_0000357,,
1368,16312,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,B,,,,,,,CHO-K1,,106,H,8,Autocuration,1,,CHEMBL616441,485.0,BAO_0000219,,
1369,5843,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616442,,BAO_0000357,,
1370,5843,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616443,,BAO_0000357,,
1371,16312,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,B,,,,,,,CHO-K1,,106,H,8,Expert,1,,CHEMBL616444,485.0,BAO_0000219,,
1372,15926,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616445,,BAO_0000357,,
1373,15926,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616446,,BAO_0000357,,
1374,4540,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,,Homo sapiens,9606.0,,,CHO,,106,D,9,Expert,1,,CHEMBL616447,449.0,BAO_0000219,,
1375,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616448,,BAO_0000357,,
1376,17296,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616449,449.0,BAO_0000219,,
1377,17296,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616450,449.0,BAO_0000219,,
1378,17296,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL857974,449.0,BAO_0000219,,
1379,15779,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616451,449.0,BAO_0000219,,
1380,15779,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616452,449.0,BAO_0000219,,
1381,15779,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616453,449.0,BAO_0000219,,
1382,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616454,449.0,BAO_0000219,,
1383,14875,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616455,,BAO_0000357,,
1384,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616456,449.0,BAO_0000219,,
1385,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616457,,BAO_0000357,,
1386,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616458,449.0,BAO_0000219,,
1387,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616459,449.0,BAO_0000219,,
1388,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,F,,,,,,,,,106,H,8,Expert,1,,CHEMBL616460,,BAO_0000019,,
1389,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,F,,,,,,,,,106,H,8,Expert,1,,CHEMBL616461,,BAO_0000019,,
1390,14875,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616462,449.0,BAO_0000219,,
1391,14875,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616463,449.0,BAO_0000219,,
1392,15250,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616464,,BAO_0000019,,
1393,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616465,449.0,BAO_0000219,,
1394,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,17105,H,8,Autocuration,1,,CHEMBL832874,,BAO_0000357,,
1395,3025,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,F,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Autocuration,1,,CHEMBL616184,,BAO_0000019,,
1396,14998,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Autocuration,1,,CHEMBL616185,,BAO_0000019,,
1397,14998,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Intermediate,1,,CHEMBL616186,,BAO_0000019,,
1398,14998,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Autocuration,1,,CHEMBL616187,,BAO_0000019,,
1399,13969,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616188,,BAO_0000357,,
1400,13392,Binding affinity for 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,D,9,Intermediate,1,,CHEMBL873475,,BAO_0000357,,
1401,3651,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,B,,,Rattus norvegicus,10116.0,,Striatum,,,10577,D,9,Expert,1,,CHEMBL616189,,BAO_0000019,2435.0,
1402,10025,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616190,,BAO_0000357,,
1403,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616191,,BAO_0000357,,
1404,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616192,,BAO_0000357,,
1405,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616193,,BAO_0000357,,
1406,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616194,,BAO_0000357,,
1407,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616195,,BAO_0000357,,
1408,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616196,,BAO_0000357,,
1409,4622,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616197,,BAO_0000249,10000000.0,
1410,14911,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Intermediate,1,,CHEMBL616198,,BAO_0000019,,
1411,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616199,,BAO_0000221,10000000.0,
1412,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616200,,BAO_0000221,10000000.0,
1413,14235,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616201,,BAO_0000221,10000000.0,
1414,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616202,,BAO_0000221,10000000.0,
1415,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616203,,BAO_0000221,10000000.0,
1416,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616204,,BAO_0000221,10000000.0,
1417,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616205,,BAO_0000221,10000000.0,
1418,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616206,,BAO_0000221,10000000.0,
1419,16118,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616207,,BAO_0000249,,
1420,3268,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616208,,BAO_0000249,,
1421,3268,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616209,,BAO_0000249,,
1422,16117,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616210,,BAO_0000357,,
1423,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616211,,BAO_0000221,10000000.0,
1424,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616504,,BAO_0000221,10000000.0,
1425,14356,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616505,,BAO_0000221,10000000.0,
1426,15740,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616506,,BAO_0000019,,
1427,12306,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL872107,,BAO_0000221,10000000.0,
1428,13348,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616507,,BAO_0000221,10000000.0,
1429,10394,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616303,,BAO_0000249,,
1430,15260,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616304,,BAO_0000221,10000000.0,
1431,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616305,,BAO_0000221,10000000.0,
1432,15260,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,F,,,,,,Hippocampus,,,10576,H,8,Intermediate,1,,CHEMBL616306,,BAO_0000221,10000000.0,
1433,12851,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616307,,BAO_0000357,,
1434,2148,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL881829,,BAO_0000221,10000000.0,
1435,13134,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616308,,BAO_0000357,,
1436,12462,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616309,,BAO_0000019,,
1437,12462,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616310,,BAO_0000019,,
1438,12462,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,B,,,,,,,CHO,,10576,H,8,Autocuration,1,,CHEMBL616311,449.0,BAO_0000219,,
1439,11933,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616312,,BAO_0000357,,
1440,11933,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616313,,BAO_0000357,,
1441,403,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616314,,BAO_0000221,10000000.0,
1442,15538,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616315,,BAO_0000221,10000000.0,
1443,15538,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616567,,BAO_0000221,10000000.0,
1444,15538,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616568,,BAO_0000221,10000000.0,
1445,12464,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,B,,,,,,,,,10576,H,8,Intermediate,1,,CHEMBL616569,,BAO_0000019,,
1446,1455,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616570,,BAO_0000357,,
1447,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616571,,BAO_0000357,,
1448,12639,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616572,,BAO_0000221,10000000.0,
1449,13949,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616573,,BAO_0000249,,
1450,12463,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616574,,BAO_0000357,,
1451,14829,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616575,,BAO_0000221,10000000.0,
1452,14829,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL872108,,BAO_0000221,10000000.0,
1453,12092,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616576,,BAO_0000357,,
1454,403,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616577,,BAO_0000249,,
1455,403,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616578,,BAO_0000249,,
1456,3967,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616579,,BAO_0000357,,
1457,12771,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616580,,BAO_0000019,,
1458,15086,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616581,,BAO_0000019,,
1459,14909,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616582,,BAO_0000221,10000000.0,
1460,14949,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616583,,BAO_0000221,10000000.0,
1461,2309,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616584,,BAO_0000221,10000000.0,
1462,4170,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616585,,BAO_0000357,,
1463,11642,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616586,,BAO_0000221,10000000.0,
1464,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616587,,BAO_0000221,10000000.0,
1465,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616588,,BAO_0000221,10000000.0,
1466,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616589,,BAO_0000221,10000000.0,
1467,12953,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616590,,BAO_0000221,10000000.0,
1468,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",B,,,,,,,CHO,,10576,H,8,Expert,1,,CHEMBL616591,449.0,BAO_0000219,,
1469,12536,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616592,,BAO_0000357,,
1470,10058,The inhibition activity of 5-HT1A at 1 uM,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616593,,BAO_0000357,,
1471,12902,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",B,,,,,,,CHO-K1,,10576,H,8,Expert,1,,CHEMBL616594,485.0,BAO_0000219,,
1472,14057,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616595,,BAO_0000249,,
1473,11296,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616596,,BAO_0000357,,
1474,11296,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616597,,BAO_0000221,10000000.0,
1475,11296,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616598,,BAO_0000221,10000000.0,
1476,16616,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,F,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616599,,BAO_0000249,,
1477,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,Hippocampus,,Membranes,10576,D,9,Expert,1,,CHEMBL616600,,BAO_0000249,10000000.0,
1478,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616601,,BAO_0000019,,
1479,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616602,,BAO_0000019,,
1480,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616603,,BAO_0000019,,
1481,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616604,,BAO_0000019,,
1482,17136,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616316,,BAO_0000249,,
1483,17136,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616317,,BAO_0000249,,
1484,16616,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616318,,BAO_0000019,,
1485,17331,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616319,,BAO_0000221,10000000.0,
1486,17331,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616320,,BAO_0000221,10000000.0,
1487,17167,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616321,,BAO_0000221,10000000.0,
1488,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616322,,BAO_0000019,,
1489,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616323,,BAO_0000019,,
1490,4671,Ratio of binding affinity to 5-HT 1A and D2 receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616324,,BAO_0000357,,
1491,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616325,,BAO_0000221,10000000.0,
1492,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616326,,BAO_0000221,10000000.0,
1493,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616327,,BAO_0000221,10000000.0,
1494,12073,Percentage inhibition against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616328,,BAO_0000357,,
1495,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL858110,,BAO_0000249,,
1496,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616329,,BAO_0000249,,
1497,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616330,,BAO_0000249,,
1498,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616331,,BAO_0000249,,
1499,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616332,,BAO_0000249,,
1500,9737,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL857063,,BAO_0000249,955.0,
1501,9737,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616333,,BAO_0000019,,
1502,5717,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616334,,BAO_0000019,,
1503,12253,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616335,,BAO_0000221,10000000.0,
1504,14025,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616336,,BAO_0000019,,
1505,10425,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616337,,BAO_0000249,,
1506,14998,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616338,,BAO_0000019,,
1507,13694,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616339,,BAO_0000221,10000000.0,
1508,13694,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616340,,BAO_0000221,10000000.0,
1509,4342,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616341,,BAO_0000357,,
1510,12936,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616342,,BAO_0000357,,
1511,13144,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616343,,BAO_0000019,,
1512,13343,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616344,,BAO_0000019,,
1513,12132,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616345,,BAO_0000357,,
1514,15419,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616346,,BAO_0000019,,
1515,1479,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616347,,BAO_0000221,10000000.0,
1516,14287,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616348,,BAO_0000019,,
1517,13116,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616349,,BAO_0000357,,
1518,2759,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616152,,BAO_0000249,,
1519,2759,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616153,,BAO_0000249,,
1520,14748,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616154,,BAO_0000019,,
1521,12304,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616155,,BAO_0000019,,
1522,12409,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616156,,BAO_0000221,10000000.0,
1523,12409,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616157,,BAO_0000221,10000000.0,
1524,13267,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616158,,BAO_0000221,10000000.0,
1525,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616159,,BAO_0000357,,
1526,14256,pKi value against rat 5-hydroxytryptamine 1A receptor.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616160,,BAO_0000357,,
1527,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616161,,BAO_0000019,,
1528,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616162,,BAO_0000019,,
1529,13278,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL616163,,BAO_0000357,,
1530,1970,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,,,,Membranes,10626,H,8,Expert,1,,CHEMBL616164,,BAO_0000249,,
1531,10034,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616165,,BAO_0000221,955.0,
1532,13348,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,B,,,Rattus norvegicus,10116.0,,,,,51,H,8,Autocuration,1,,CHEMBL616355,,BAO_0000019,,
1533,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616356,,BAO_0000019,,
1534,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616357,,BAO_0000221,955.0,
1535,12058,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616358,,BAO_0000019,,
1536,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616359,,BAO_0000357,,
1537,15453,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616360,,BAO_0000357,,
1538,4820,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616361,,BAO_0000357,,
1539,1089,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616362,,BAO_0000357,,
1540,386,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,B,,,,,,,,Brain membranes,51,H,8,Autocuration,1,,CHEMBL616363,,BAO_0000249,,
1541,6011,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616364,,BAO_0000357,,
1542,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616365,,BAO_0000357,,
1543,4402,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616366,,BAO_0000357,,
1544,17066,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL872906,,BAO_0000357,,
1545,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616367,,BAO_0000357,,
1546,2474,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616368,,BAO_0000357,,
1547,4775,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616369,,BAO_0000357,,
1548,14294,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616370,,BAO_0000357,,
1549,14294,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616371,,BAO_0000357,,
1550,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616372,449.0,BAO_0000219,,
1551,11376,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616373,,BAO_0000219,,
1552,2474,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,In vivo,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616374,,BAO_0000218,,
1553,13311,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL616375,,BAO_0000221,10000000.0,
1554,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616376,,BAO_0000357,,
1555,1633,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL857064,,BAO_0000357,,
1556,11866,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616377,,BAO_0000357,,
1557,4373,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616378,,BAO_0000357,,
1558,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616379,,BAO_0000357,,
1559,16946,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616380,,BAO_0000357,,
1560,13291,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616381,,BAO_0000357,,
1561,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616382,,BAO_0000357,,
1562,10812,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616383,,BAO_0000357,,
1563,3032,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,B,,,Mus musculus,10090.0,,,CHO,,11863,D,9,Expert,1,,CHEMBL616350,449.0,BAO_0000219,,
1564,16655,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616351,,BAO_0000357,,
1565,14532,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616352,,BAO_0000357,,
1566,13944,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616353,,BAO_0000357,,
1567,13033,Binding affinity against serotonergic 5-HT1a receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616354,,BAO_0000357,,
1568,10321,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616508,,BAO_0000357,,
1569,2968,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616559,,BAO_0000357,,
1570,13964,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616560,,BAO_0000357,,
1571,15527,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616561,,BAO_0000357,,
1572,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,11863,H,8,Autocuration,1,,CHEMBL616562,449.0,BAO_0000219,,
1573,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,11863,H,8,Autocuration,1,,CHEMBL616563,449.0,BAO_0000219,,
1574,15120,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616564,,BAO_0000357,,
1575,13313,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616565,,BAO_0000357,,
1576,2613,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616566,,BAO_0000218,,
1577,16700,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616989,,BAO_0000357,,
1578,2201,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL857975,,BAO_0000357,,
1579,1274,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616990,,BAO_0000357,,
1580,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616991,,BAO_0000357,,
1581,12146,Tested against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616992,,BAO_0000357,,
1582,14059,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616993,,BAO_0000357,,
1583,14025,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Expert,1,,CHEMBL616994,,BAO_0000019,,
1584,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Autocuration,1,,CHEMBL616995,,BAO_0000019,,
1585,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,,Gorilla gorilla,9593.0,,,HEK293,,105571,D,9,Intermediate,1,,CHEMBL616996,722.0,BAO_0000219,,
1586,3025,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,In vivo,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL616997,,BAO_0000218,,
1587,3025,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,In vivo,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL616998,,BAO_0000218,,
1588,15329,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,F,,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL616999,,BAO_0000019,,
1589,15329,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,F,,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL617000,,BAO_0000019,,
1590,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,F,,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL617001,,BAO_0000019,,
1591,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,F,,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL858111,,BAO_0000019,,
1592,14165,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617002,,BAO_0000019,,
1593,14214,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617003,,BAO_0000019,,
1594,14214,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617004,,BAO_0000019,,
1595,14214,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,F,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL617005,,BAO_0000019,,
1596,13729,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,F,,,Homo sapiens,9606.0,,,CHO-K1,,106,D,9,Expert,1,,CHEMBL616623,485.0,BAO_0000219,,
1597,3025,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616624,449.0,BAO_0000219,,
1598,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL883243,,BAO_0000357,,
1599,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616625,,BAO_0000019,,
1600,14956,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",F,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616626,449.0,BAO_0000219,,
1601,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616627,449.0,BAO_0000219,,
1602,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616628,449.0,BAO_0000219,,
1603,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616629,449.0,BAO_0000219,,
1604,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616630,449.0,BAO_0000219,,
1605,14956,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,,,,,106,H,8,Expert,1,,CHEMBL616631,,BAO_0000019,,
1606,14956,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616632,,BAO_0000019,,
1607,14214,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616633,,BAO_0000357,,
1608,3463,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616634,449.0,BAO_0000219,,
1609,15331,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616635,,BAO_0000357,,
1610,16146,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL885358,,BAO_0000357,,
1611,14159,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,106,D,9,Expert,1,,CHEMBL616636,449.0,BAO_0000219,,
1612,14158,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616637,449.0,BAO_0000219,,
1613,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616638,,BAO_0000357,,
1614,15250,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616639,449.0,BAO_0000219,,
1615,15250,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616640,449.0,BAO_0000219,,
1616,15331,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616641,449.0,BAO_0000219,,
1617,15332,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616642,449.0,BAO_0000219,,
1618,14956,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616643,449.0,BAO_0000219,,
1619,3805,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616644,,BAO_0000357,,
1620,14875,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616645,,BAO_0000357,,
1621,14454,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Autocuration,1,,CHEMBL616646,,BAO_0000019,,
1622,14454,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Expert,1,,CHEMBL616647,,BAO_0000019,,
1623,16288,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616509,,BAO_0000357,,
1624,16288,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616510,,BAO_0000357,,
1625,16312,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616511,,BAO_0000357,,
1626,1348,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,B,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616512,,BAO_0000357,,
1627,5834,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616513,,BAO_0000357,,
1628,13366,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,,Bos taurus,9913.0,,Striatum,,,105,H,8,Autocuration,1,,CHEMBL616514,,BAO_0000019,2435.0,
1629,1414,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,B,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616515,,BAO_0000357,,
1630,14998,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616516,,BAO_0000019,,
1631,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616517,,BAO_0000357,,
1632,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616518,,BAO_0000357,,
1633,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616519,,BAO_0000357,,
1634,10639,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616520,,BAO_0000357,,
1635,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616521,,BAO_0000357,,
1636,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616522,,BAO_0000357,,
1637,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL884531,,BAO_0000357,,
1638,11147,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616523,,BAO_0000357,,
1639,13366,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,,Bos taurus,9913.0,,Striatum,,,105,H,8,Autocuration,1,,CHEMBL616731,,BAO_0000019,2435.0,
1640,10444,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616732,,BAO_0000019,,
1641,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616733,,BAO_0000357,,
1642,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616734,,BAO_0000357,,
1643,12827,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616735,,BAO_0000249,,
1644,12827,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616736,,BAO_0000249,,
1645,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616737,,BAO_0000019,,
1646,14025,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616738,,BAO_0000019,,
1647,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616739,,BAO_0000019,,
1648,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616740,,BAO_0000019,,
1649,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616741,,BAO_0000019,,
1650,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,,Gorilla gorilla,9593.0,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL616742,722.0,BAO_0000219,,
1651,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616743,,BAO_0000019,,
1652,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616744,,BAO_0000019,,
1653,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616745,,BAO_0000019,,
1654,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616746,,BAO_0000019,,
1655,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616747,,BAO_0000019,,
1656,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616748,,BAO_0000019,,
1657,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616648,,BAO_0000019,,
1658,11574,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616649,,BAO_0000357,,
1659,1558,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616650,,BAO_0000357,,
1660,12409,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616651,,BAO_0000218,,
1661,12409,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616652,,BAO_0000218,,
1662,12409,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616653,,BAO_0000218,,
1663,12409,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616654,,BAO_0000218,,
1664,12253,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616655,,BAO_0000019,,
1665,12936,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616656,,BAO_0000357,,
1666,13181,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,B,,,Cavia porcellus,10141.0,,,,,105,H,8,Autocuration,1,,CHEMBL616657,,BAO_0000019,,
1667,12409,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,B,,,Cavia porcellus,10141.0,,Striatum,,,105570,D,9,Intermediate,1,,CHEMBL616658,,BAO_0000357,2435.0,
1668,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616659,,BAO_0000357,,
1669,5254,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616660,,BAO_0000357,,
1670,13051,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616661,,BAO_0000357,,
1671,3463,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Expert,1,,CHEMBL616662,,BAO_0000019,,
1672,15315,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616663,,BAO_0000019,,
1673,6011,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616664,,BAO_0000019,,
1674,14159,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL881820,449.0,BAO_0000219,,
1675,14159,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",F,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616665,449.0,BAO_0000219,,
1676,15250,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616666,449.0,BAO_0000219,,
1677,15250,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616667,449.0,BAO_0000219,,
1678,15331,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616668,449.0,BAO_0000219,,
1679,15332,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616669,449.0,BAO_0000219,,
1680,15332,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617040,449.0,BAO_0000219,,
1681,3294,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",F,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL617041,449.0,BAO_0000219,,
1682,14158,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617042,449.0,BAO_0000219,,
1683,14956,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617043,449.0,BAO_0000219,,
1684,12469,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617044,,BAO_0000019,,
1685,3463,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617045,449.0,BAO_0000219,,
1686,15250,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL617046,449.0,BAO_0000219,,
1687,15250,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL617047,449.0,BAO_0000219,,
1688,14956,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,,,,,105,H,8,Expert,1,,CHEMBL617048,,BAO_0000019,,
1689,14159,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616897,,BAO_0000019,,
1690,14159,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",F,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616898,,BAO_0000019,,
1691,14499,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL858201,449.0,BAO_0000219,,
1692,15315,Intrinsic activity for 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616899,,BAO_0000019,,
1693,3294,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),B,In vitro,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616900,,BAO_0000219,,
1694,3463,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616901,449.0,BAO_0000219,,
1695,15331,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616902,,BAO_0000357,,
1696,14159,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616903,449.0,BAO_0000219,,
1697,14158,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616904,449.0,BAO_0000219,,
1698,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616905,,BAO_0000357,,
1699,15250,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616906,449.0,BAO_0000219,,
1700,15250,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616907,449.0,BAO_0000219,,
1701,15331,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616908,449.0,BAO_0000219,,
1702,15332,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616909,449.0,BAO_0000219,,
1703,14499,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616910,449.0,BAO_0000219,,
1704,15332,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616911,449.0,BAO_0000219,,
1705,14956,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616912,449.0,BAO_0000219,,
1706,3805,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616913,,BAO_0000357,,
1707,6011,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616914,449.0,BAO_0000219,,
1708,16190,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616915,449.0,BAO_0000219,,
1709,14165,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616916,,BAO_0000019,,
1710,4234,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616917,,BAO_0000357,,
1711,15527,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616918,,BAO_0000357,,
1712,6328,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616919,,BAO_0000219,,
1713,16209,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616920,,BAO_0000357,,
1714,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL872914,,BAO_0000357,,
1715,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616921,,BAO_0000357,,
1716,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616922,,BAO_0000357,,
1717,6013,Binding affinity towards 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616923,,BAO_0000357,,
1718,5843,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616924,,BAO_0000357,,
1719,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL875909,,BAO_0000357,,
1720,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616925,,BAO_0000357,,
1721,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616926,,BAO_0000357,,
1722,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616927,,BAO_0000357,,
1723,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,F,,,,,,,CHO-K1,,105,H,8,Expert,1,,CHEMBL616928,485.0,BAO_0000219,,
1724,6011,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),B,In vitro,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616929,,BAO_0000219,,
1725,4234,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616930,,BAO_0000357,,
1726,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616931,,BAO_0000019,,
1727,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616932,,BAO_0000357,,
1728,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616933,,BAO_0000357,,
1729,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616934,,BAO_0000219,,
1730,3804,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616935,,BAO_0000357,,
1731,16700,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616936,,BAO_0000357,,
1732,2391,Affinity for 5-hydroxytryptamine 1D receptor subtype,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616937,,BAO_0000357,,
1733,4175,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616938,,BAO_0000357,,
1734,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616939,,BAO_0000019,,
1735,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616940,,BAO_0000019,,
1736,15926,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616941,,BAO_0000357,,
1737,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,B,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616942,485.0,BAO_0000219,,
1738,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,B,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616943,485.0,BAO_0000219,,
1739,14956,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,B,,,,,,,CHO,,104802,H,4,Autocuration,1,,CHEMBL616944,449.0,BAO_0000219,,
1740,3294,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616945,,BAO_0000019,,
1741,12861,Binding activity radioligand.,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616946,,BAO_0000357,,
1742,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616947,,BAO_0000019,,
1743,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,B,,,,,,,CHO-K1,,105,H,8,Expert,1,,CHEMBL616948,485.0,BAO_0000219,,
1744,5104,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616851,,BAO_0000357,,
1745,5105,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616852,,BAO_0000357,,
1746,14499,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616853,,BAO_0000357,,
1747,15926,Binding activity against human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616854,,BAO_0000357,,
1748,4540,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616855,449.0,BAO_0000219,,
1749,15779,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616856,449.0,BAO_0000219,,
1750,15779,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616857,449.0,BAO_0000219,,
1751,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616858,,BAO_0000357,,
1752,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616859,449.0,BAO_0000219,,
1753,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616860,449.0,BAO_0000219,,
1754,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL616861,722.0,BAO_0000219,,
1755,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL616541,722.0,BAO_0000219,,
1756,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL616542,722.0,BAO_0000219,,
1757,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616543,449.0,BAO_0000219,,
1758,14875,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616544,,BAO_0000357,,
1759,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616545,449.0,BAO_0000219,,
1760,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616546,,BAO_0000357,,
1761,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616547,449.0,BAO_0000219,,
1762,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616548,449.0,BAO_0000219,,
1763,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,F,,,,,,,,,105,H,8,Expert,1,,CHEMBL616549,,BAO_0000019,,
1764,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,F,,,,,,,,,105,H,8,Expert,1,,CHEMBL616550,,BAO_0000019,,
1765,5254,Binding affinity against 5-HT2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL857066,,BAO_0000357,,
1766,5254,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL616551,,BAO_0000357,,
1767,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616552,,BAO_0000357,,
1768,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,F,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL832876,,BAO_0000019,,
1769,12352,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616553,,BAO_0000019,,
1770,9098,Binding affinity towards 5-HT1B was determined,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616554,,BAO_0000357,,
1771,14430,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616555,,BAO_0000019,,
1772,13657,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616556,,BAO_0000019,,
1773,13657,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616557,,BAO_0000019,,
1774,15854,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616558,,BAO_0000019,,
1775,10639,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616749,,BAO_0000019,,
1776,10025,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616750,,BAO_0000357,,
1777,10025,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616751,,BAO_0000357,,
1778,14286,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616752,,BAO_0000249,,
1779,3651,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616753,,BAO_0000019,2435.0,
1780,14178,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616754,,BAO_0000357,,
1781,10639,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616755,,BAO_0000019,,
1782,13605,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616756,,BAO_0000019,2435.0,
1783,5834,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616757,,BAO_0000019,2435.0,
1784,10922,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616758,,BAO_0000357,2435.0,
1785,14286,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616759,,BAO_0000249,,
1786,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616760,,BAO_0000357,,
1787,14826,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616761,,BAO_0000019,2435.0,
1788,9699,Binding affinity against 5-HT1B serotonin receptor in rat striatum,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616762,,BAO_0000019,2435.0,
1789,14423,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616763,,BAO_0000019,,
1790,10062,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL872909,,BAO_0000357,,
1791,10062,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616764,,BAO_0000357,,
1792,12280,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616765,,BAO_0000357,,
1793,15412,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616766,,BAO_0000357,2435.0,
1794,15412,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616767,,BAO_0000357,2435.0,
1795,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616768,,BAO_0000357,,
1796,11147,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616769,,BAO_0000357,,
1797,9547,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616770,,BAO_0000019,,
1798,10444,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616771,,BAO_0000019,,
1799,12469,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616772,,BAO_0000019,2435.0,
1800,9098,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616773,,BAO_0000019,,
1801,9098,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616774,,BAO_0000019,,
1802,9699,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616775,,BAO_0000357,,
1803,10394,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616776,,BAO_0000249,,
1804,12092,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616777,,BAO_0000357,,
1805,16700,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616778,,BAO_0000357,,
1806,403,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616779,,BAO_0000249,,
1807,12771,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616780,,BAO_0000357,,
1808,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616781,,BAO_0000019,,
1809,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616782,,BAO_0000357,,
1810,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616783,,BAO_0000357,,
1811,12953,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,B,,,,,,Striatum,,,10577,H,8,Expert,1,,CHEMBL616784,,BAO_0000019,2435.0,
1812,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616785,,BAO_0000357,,
1813,9737,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,,10577,H,8,Autocuration,1,,CHEMBL857067,,BAO_0000249,955.0,
1814,9737,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616786,,BAO_0000019,,
1815,9737,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,,10577,H,8,Autocuration,1,,CHEMBL616787,,BAO_0000249,955.0,
1816,12827,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616788,,BAO_0000357,,
1817,5033,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616789,,BAO_0000357,,
1818,9786,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616790,,BAO_0000019,,
1819,13116,Binding affinity at 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616791,,BAO_0000357,,
1820,16429,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616792,,BAO_0000019,,
1821,12409,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616793,,BAO_0000249,,
1822,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616794,,BAO_0000357,,
1823,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616795,,BAO_0000357,,
1824,5486,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616796,,BAO_0000019,,
1825,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616797,,BAO_0000357,,
1826,386,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,B,,,,,,,,Brain membranes,106,H,8,Autocuration,1,,CHEMBL616798,,BAO_0000249,,
1827,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616799,,BAO_0000357,,
1828,6011,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616800,,BAO_0000357,,
1829,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616801,,BAO_0000357,,
1830,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616802,,BAO_0000357,,
1831,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616803,,BAO_0000357,,
1832,1633,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL857068,,BAO_0000357,,
1833,1633,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616804,,BAO_0000357,,
1834,4373,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616805,,BAO_0000357,,
1835,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616806,,BAO_0000357,,
1836,11574,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616807,,BAO_0000357,,
1837,10321,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616808,,BAO_0000357,,
1838,15527,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616809,,BAO_0000357,,
1839,17200,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616810,,BAO_0000357,,
1840,14423,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,B,,,,,,,,,104802,H,4,Autocuration,1,,CHEMBL616811,,BAO_0000224,,
1841,5834,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL616812,,BAO_0000357,,
1842,11473,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616813,,BAO_0000357,,
1843,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616814,,BAO_0000357,,
1844,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616815,,BAO_0000357,,
1845,10639,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616816,,BAO_0000357,,
1846,14331,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616817,,BAO_0000357,,
1847,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616818,,BAO_0000357,,
1848,9098,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,B,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL616819,,BAO_0000357,,
1849,14331,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,B,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL616820,,BAO_0000357,,
1850,11828,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,B,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL616821,,BAO_0000019,,
1851,11866,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616822,,BAO_0000357,,
1852,13047,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,108,H,8,Autocuration,1,,CHEMBL616823,,BAO_0000019,,
1853,188,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616824,,BAO_0000357,,
1854,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616825,,BAO_0000357,,
1855,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616826,,BAO_0000357,,
1856,11624,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL616827,,BAO_0000019,,
1857,11139,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616828,,BAO_0000357,,
1858,11147,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616829,,BAO_0000357,,
1859,10444,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616830,,BAO_0000019,,
1860,11624,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL616831,,BAO_0000357,,
1861,11662,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616832,,BAO_0000019,,
1862,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616833,,BAO_0000019,,
1863,11662,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL616834,,BAO_0000019,,
1864,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL829595,,BAO_0000019,,
1865,9098,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616835,,BAO_0000357,,
1866,10394,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL872910,,BAO_0000249,,
1867,11933,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL616836,,BAO_0000357,,
1868,12092,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616837,,BAO_0000357,,
1869,12253,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616466,,BAO_0000019,,
1870,12253,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,B,,,Rattus norvegicus,10116.0,,,HEK293,,12689,D,9,Autocuration,1,,CHEMBL616467,722.0,BAO_0000219,,
1871,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL616468,,BAO_0000357,,
1872,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL616469,,BAO_0000357,,
1873,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL616470,,BAO_0000357,,
1874,11574,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616471,,BAO_0000357,,
1875,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616472,,BAO_0000357,,
1876,13944,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616473,,BAO_0000357,,
1877,13033,Binding affinity against serotonergic 5-HT1c receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616474,,BAO_0000357,,
1878,10321,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616475,,BAO_0000357,,
1879,11866,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616476,,BAO_0000357,,
1880,14454,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Autocuration,1,,CHEMBL616477,,BAO_0000019,,
1881,11574,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616478,,BAO_0000224,,
1882,11574,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616479,,BAO_0000224,,
1883,13631,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616480,,BAO_0000019,,
1884,9630,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL616481,,BAO_0000019,,
1885,8822,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL616482,,BAO_0000249,,
1886,9064,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0,,Brain,,,104686,D,5,Autocuration,1,,CHEMBL884713,,BAO_0000221,955.0,
1887,8868,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616483,,BAO_0000224,,
1888,9064,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616484,,BAO_0000224,,
1889,9806,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616485,,BAO_0000019,,
1890,9098,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616486,,BAO_0000224,,
1891,8868,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616487,,BAO_0000224,,
1892,12765,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616488,,BAO_0000224,,
1893,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616489,,BAO_0000019,,
1894,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616490,,BAO_0000019,,
1895,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616491,,BAO_0000019,,
1896,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616492,,BAO_0000019,,
1897,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616493,,BAO_0000019,,
1898,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616494,,BAO_0000019,,
1899,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616495,,BAO_0000019,,
1900,3086,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616496,,BAO_0000019,,
1901,11049,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616497,,BAO_0000019,,
1902,11049,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616498,,BAO_0000019,,
1903,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616499,,BAO_0000019,,
1904,10922,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616500,,BAO_0000019,,
1905,9064,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0,,Brain,,,104686,D,5,Autocuration,1,,CHEMBL616501,,BAO_0000221,955.0,
1906,10748,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL616502,,BAO_0000221,955.0,
1907,11614,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL884529,,BAO_0000249,,
1908,11615,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL616503,,BAO_0000249,,
1909,11615,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616964,,BAO_0000224,,
1910,11614,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL616965,,BAO_0000249,,
1911,11702,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616966,,BAO_0000224,,
1912,11702,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616967,,BAO_0000224,,
1913,11702,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL616968,,BAO_0000224,,
1914,11702,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616969,,BAO_0000224,,
1915,13346,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL884530,,BAO_0000019,,
1916,10025,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616970,,BAO_0000224,,
1917,10025,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616971,,BAO_0000224,,
1918,10025,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616972,,BAO_0000224,,
1919,9036,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616973,,BAO_0000224,,
1920,9036,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616974,,BAO_0000224,,
1921,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616975,,BAO_0000019,,
1922,12304,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616976,,BAO_0000019,,
1923,13276,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616977,,BAO_0000224,,
1924,11825,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616978,,BAO_0000224,,
1925,12443,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616979,,BAO_0000224,,
1926,13830,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616980,,BAO_0000224,,
1927,9592,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL616981,,BAO_0000249,,
1928,9592,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL616982,,BAO_0000249,,
1929,10881,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616983,,BAO_0000224,,
1930,13605,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616984,,BAO_0000019,,
1931,11624,Inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL616985,,BAO_0000224,,
1932,4101,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616986,,BAO_0000224,,
1933,4101,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616987,,BAO_0000224,,
1934,15360,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616988,,BAO_0000019,,
1935,11576,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617243,,BAO_0000019,,
1936,5834,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617244,,BAO_0000019,,
1937,2395,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,104686,D,5,Autocuration,1,,CHEMBL617245,485.0,BAO_0000219,,
1938,11965,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL617246,,BAO_0000249,,
1939,3967,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617546,,BAO_0000224,,
1940,11130,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),B,,,,,,,,Brain membranes,104686,H,4,Autocuration,1,,CHEMBL617547,,BAO_0000249,,
1941,13427,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617548,,BAO_0000219,,
1942,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617549,,BAO_0000224,,
1943,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617550,,BAO_0000224,,
1944,11825,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617551,,BAO_0000224,,
1945,12120,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL617552,,BAO_0000249,,
1946,12120,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL617553,,BAO_0000249,,
1947,11963,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,F,,,,,,Thoracic aorta,,,104686,H,4,Autocuration,1,,CHEMBL617554,,BAO_0000019,1515.0,
1948,9069,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617555,,BAO_0000019,,
1949,8868,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617556,,BAO_0000224,,
1950,17200,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL617557,,BAO_0000357,,
1951,17200,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL617558,,BAO_0000357,,
1952,13969,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL617559,,BAO_0000357,,
1953,13392,Binding affinity for 5-hydroxytryptamine 1D receptor,B,,,,,,,,,17106,D,9,Expert,1,,CHEMBL617560,,BAO_0000357,,
1954,1742,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617561,,BAO_0000249,,
1955,1742,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617562,,BAO_0000249,,
1956,14331,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,B,,,,,,Striatum,,,17106,H,8,Autocuration,1,,CHEMBL617563,,BAO_0000357,2435.0,
1957,12861,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,F,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617564,,BAO_0000019,,
1958,12861,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL617565,,BAO_0000019,,
1959,12861,Binding activity radioligand.,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL856076,,BAO_0000357,,
1960,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617566,,BAO_0000019,,
1961,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL875911,,BAO_0000019,,
1962,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617567,,BAO_0000019,,
1963,675,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617568,,BAO_0000249,,
1964,12490,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL617569,,BAO_0000019,,
1965,11828,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL617570,,BAO_0000249,,
1966,11866,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617571,,BAO_0000357,,
1967,773,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,B,,,Sus scrofa,9823.0,,,,,105,H,8,Autocuration,1,,CHEMBL617572,,BAO_0000357,,
1968,13047,The compound was tested for intrinsic activity against 5-HT1D receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Expert,1,,CHEMBL617573,,BAO_0000357,,
1969,13047,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Autocuration,1,,CHEMBL617574,,BAO_0000019,,
1970,13047,The compound was tested for binding affinity against 5-HT1D receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Expert,1,,CHEMBL617575,,BAO_0000357,,
1971,188,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,B,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617576,,BAO_0000357,,
1972,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,F,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617577,,BAO_0000019,,
1973,12438,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,F,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617578,,BAO_0000019,,
1974,12438,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,B,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617579,,BAO_0000357,,
1975,15854,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,,,,,10578,H,8,Expert,1,,CHEMBL617580,,BAO_0000019,,
1976,10394,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617581,,BAO_0000249,,
1977,12092,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,B,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617582,,BAO_0000357,,
1978,3389,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,B,,,,,,,,,10578,H,8,Expert,1,,CHEMBL617583,,BAO_0000019,,
1979,6011,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617584,,BAO_0000357,,
1980,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617585,,BAO_0000357,,
1981,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL875912,,BAO_0000357,,
1982,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617586,,BAO_0000357,,
1983,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617587,,BAO_0000357,,
1984,11866,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617588,,BAO_0000357,,
1985,4687,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL857980,,BAO_0000357,,
1986,12146,Tested against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617589,,BAO_0000357,,
1987,10321,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617590,,BAO_0000357,,
1988,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL617591,722.0,BAO_0000219,,
1989,1274,Binding affinity against 5-Hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL617592,,BAO_0000357,,
1990,15250,,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617593,,BAO_0000357,,
1991,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,106,H,8,Autocuration,1,,CHEMBL617594,485.0,BAO_0000219,,
1992,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL617595,485.0,BAO_0000219,,
1993,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL617596,722.0,BAO_0000219,,
1994,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL617597,722.0,BAO_0000219,,
1995,13047,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617598,,BAO_0000019,,
1996,13366,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL872916,,BAO_0000357,,
1997,13366,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL617599,,BAO_0000357,,
1998,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617091,,BAO_0000357,,
1999,12902,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",B,,,,,,,CHO-K1,,105,H,8,Expert,1,,CHEMBL617092,485.0,BAO_0000219,,
2000,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL617093,485.0,BAO_0000219,,
2001,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617094,,BAO_0000019,,
2002,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617095,,BAO_0000019,,
2003,14251,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617096,,BAO_0000019,,
2004,14251,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617097,,BAO_0000019,,
2005,14251,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617098,,BAO_0000019,,
2006,13313,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617301,,BAO_0000357,,
2007,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617302,,BAO_0000357,,
2008,13366,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617303,,BAO_0000357,,
2009,13051,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL617304,,BAO_0000357,,
2010,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617305,449.0,BAO_0000219,,
2011,12469,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,B,,,Homo sapiens,9606.0,,,,,105,D,9,Autocuration,1,,CHEMBL617306,,BAO_0000219,,
2012,5619,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617307,,BAO_0000357,,
2013,13047,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Autocuration,1,,CHEMBL617308,,BAO_0000019,,
2014,16633,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617309,,BAO_0000357,,
2015,16633,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617310,,BAO_0000357,,
2016,16633,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617311,,BAO_0000357,,
2017,16633,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617312,,BAO_0000357,,
2018,3269,Affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617313,,BAO_0000357,,
2019,12409,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL617314,,BAO_0000357,,
2020,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617315,,BAO_0000019,,
2021,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,,,,HEK293,,106,H,8,Autocuration,1,,CHEMBL617316,722.0,BAO_0000219,,
2022,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,,,,HEK293,,106,H,8,Autocuration,1,,CHEMBL617317,722.0,BAO_0000219,,
2023,12903,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL617318,449.0,BAO_0000219,,
2024,13047,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617319,,BAO_0000019,,
2025,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106,D,9,Expert,1,,CHEMBL617320,,BAO_0000357,,
2026,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106,D,9,Expert,1,,CHEMBL617321,,BAO_0000357,,
2027,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106,D,9,Expert,1,,CHEMBL617322,,BAO_0000357,,
2028,13366,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616862,,BAO_0000357,,
2029,13366,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616863,,BAO_0000357,,
2030,12469,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616864,449.0,BAO_0000219,,
2031,13706,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,106,H,8,Autocuration,1,,CHEMBL616865,485.0,BAO_0000219,,
2032,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,106,H,8,Autocuration,1,,CHEMBL616866,485.0,BAO_0000219,,
2033,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616867,,BAO_0000019,,
2034,12902,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",B,,,,,,,CHO-K1,,106,H,8,Expert,1,,CHEMBL616868,485.0,BAO_0000219,,
2035,13051,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616869,,BAO_0000357,,
2036,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616870,449.0,BAO_0000219,,
2037,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,F,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616871,485.0,BAO_0000219,,
2038,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,F,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616872,485.0,BAO_0000219,,
2039,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,F,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616873,485.0,BAO_0000219,,
2040,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,F,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616838,485.0,BAO_0000219,,
2041,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616839,,BAO_0000357,,
2042,13047,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Autocuration,1,,CHEMBL616840,,BAO_0000019,,
2043,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616841,,BAO_0000357,,
2044,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616842,,BAO_0000357,,
2045,12409,Binding affinity against 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL857976,,BAO_0000357,,
2046,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616843,449.0,BAO_0000219,,
2047,1348,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,B,,,Homo sapiens,9606.0,,,,,10618,D,9,Expert,1,,CHEMBL616844,,BAO_0000357,,
2048,1348,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616845,,BAO_0000357,,
2049,4234,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,B,,,Homo sapiens,9606.0,,,,,10618,D,9,Expert,1,,CHEMBL616846,,BAO_0000357,,
2050,16209,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616847,,BAO_0000357,,
2051,10444,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616848,,BAO_0000019,,
2052,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616849,,BAO_0000357,,
2053,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL872911,,BAO_0000357,,
2054,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616850,,BAO_0000019,,
2055,12936,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,10618,D,9,Expert,1,,CHEMBL616699,449.0,BAO_0000219,,
2056,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616700,,BAO_0000357,,
2057,15779,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616701,449.0,BAO_0000219,,
2058,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616702,449.0,BAO_0000219,,
2059,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616703,449.0,BAO_0000219,,
2060,13181,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616704,,BAO_0000357,,
2061,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616705,449.0,BAO_0000219,,
2062,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616706,,BAO_0000357,,
2063,15146,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616707,449.0,BAO_0000219,,
2064,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616708,,BAO_0000357,,
2065,12146,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616709,,BAO_0000357,,
2066,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616710,449.0,BAO_0000219,,
2067,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616711,449.0,BAO_0000219,,
2068,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616712,449.0,BAO_0000219,,
2069,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616713,,BAO_0000357,,
2070,4373,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616714,,BAO_0000357,,
2071,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616715,,BAO_0000357,,
2072,16633,Binding affinity towards 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616716,,BAO_0000357,,
2073,17085,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",F,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616717,,BAO_0000019,,
2074,17085,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",F,,,,,,,,,279,H,8,Expert,1,,CHEMBL616718,,BAO_0000019,,
2075,16209,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,F,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL875905,,BAO_0000019,,
2076,16209,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,F,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616719,,BAO_0000019,,
2077,17085,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",F,,,,,,,,,279,H,8,Expert,1,,CHEMBL616720,,BAO_0000019,,
2078,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616721,,BAO_0000357,,
2079,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL616722,449.0,BAO_0000219,,
2080,3805,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616723,,BAO_0000357,,
2081,16190,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL616724,449.0,BAO_0000219,,
2082,16190,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616725,,BAO_0000357,,
2083,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616726,,BAO_0000357,,
2084,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616727,,BAO_0000357,,
2085,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616728,,BAO_0000357,,
2086,6866,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616729,,BAO_0000357,,
2087,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Expert,1,,CHEMBL616730,,BAO_0000019,,
2088,16312,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617125,,BAO_0000357,,
2089,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL857977,,BAO_0000357,,
2090,15779,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617126,449.0,BAO_0000219,,
2091,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617127,449.0,BAO_0000219,,
2092,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617128,,BAO_0000357,,
2093,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617129,449.0,BAO_0000219,,
2094,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617130,,BAO_0000357,,
2095,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617131,449.0,BAO_0000219,,
2096,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617132,449.0,BAO_0000219,,
2097,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617133,449.0,BAO_0000219,,
2098,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617134,,BAO_0000357,,
2099,4373,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617135,,BAO_0000357,,
2100,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617136,,BAO_0000357,,
2101,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617137,,BAO_0000019,,
2102,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617138,,BAO_0000019,,
2103,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617139,,BAO_0000019,,
2104,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617140,,BAO_0000019,,
2105,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617141,,BAO_0000218,,
2106,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL858112,,BAO_0000019,,
2107,12352,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,B,,,,,,,,,17005,H,8,Intermediate,1,,CHEMBL617142,,BAO_0000019,,
2108,13657,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",B,,,Bos taurus,9913.0,,,,,22226,U,0,Autocuration,1,,CHEMBL617143,,BAO_0000019,,
2109,14331,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,B,,,Bos taurus,9913.0,,,,,22226,U,0,Autocuration,1,,CHEMBL617144,,BAO_0000019,,
2110,14331,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,B,,,Bos taurus,9913.0,,,,,22226,U,0,Autocuration,1,,CHEMBL617145,,BAO_0000019,,
2111,14331,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617146,,BAO_0000019,,
2112,12685,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,B,,,Cavia porcellus,10141.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617147,,BAO_0000019,,
2113,14389,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,B,,,Cavia porcellus,10141.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617148,,BAO_0000019,,
2114,14386,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,B,,,Cavia porcellus,10141.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617149,,BAO_0000019,,
2115,5732,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617150,,BAO_0000224,,
2116,16293,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617151,,BAO_0000224,,
2117,2078,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617201,,BAO_0000224,,
2118,5486,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL617202,,BAO_0000357,,
2119,11820,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,In vivo,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617203,,BAO_0000218,,
2120,10297,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617204,,BAO_0000019,,
2121,13704,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617205,,BAO_0000224,,
2122,10297,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,B,,,Mus musculus,10090.0,,,,,104826,D,5,Autocuration,1,,CHEMBL617206,,BAO_0000019,,
2123,11820,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,In vivo,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617207,,BAO_0000218,,
2124,10297,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,B,,,Mus musculus,10090.0,,,,,104826,D,5,Autocuration,1,,CHEMBL617208,,BAO_0000019,,
2125,11555,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617209,,BAO_0000224,,
2126,11555,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617210,,BAO_0000224,,
2127,11555,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617211,,BAO_0000224,,
2128,10297,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,Mus musculus,10090.0,,,,,104826,D,5,Autocuration,1,,CHEMBL617212,,BAO_0000019,,
2129,16688,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,B,,,Sus scrofa,9823.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617213,,BAO_0000224,,
2130,16688,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,B,,,Sus scrofa,9823.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617214,,BAO_0000224,,
2131,5333,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617215,,BAO_0000221,,
2132,4437,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617216,,BAO_0000221,,
2133,5033,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,B,,,Sus scrofa,9823.0,,,,,17005,H,8,Autocuration,1,,CHEMBL617217,,BAO_0000357,,
2134,15267,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617218,,BAO_0000019,,
2135,15267,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL872913,,BAO_0000019,,
2136,11820,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617219,,BAO_0000019,,
2137,9069,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL873482,,BAO_0000224,,
2138,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617220,,BAO_0000019,,
2139,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617221,,BAO_0000019,,
2140,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617222,,BAO_0000019,,
2141,10428,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL875906,,BAO_0000019,,
2142,9628,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617223,,BAO_0000019,,
2143,12704,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617224,,BAO_0000224,,
2144,15453,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617225,,BAO_0000224,,
2145,188,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617226,,BAO_0000224,,
2146,10349,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617227,,BAO_0000224,,
2147,10349,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617228,,BAO_0000224,,
2148,8868,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617229,,BAO_0000224,,
2149,10025,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617230,,BAO_0000224,,
2150,10025,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617231,,BAO_0000224,,
2151,11702,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617232,,BAO_0000224,,
2152,11702,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617233,,BAO_0000224,,
2153,11702,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617234,,BAO_0000224,,
2154,11702,Compound was tested for the inhibition of quipazine induced head twitches in rats,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617235,,BAO_0000019,,
2155,11702,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617236,,BAO_0000019,,
2156,10085,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,B,,,,,,Hippocampus,,,104686,H,4,Autocuration,1,,CHEMBL617237,,BAO_0000221,10000000.0,
2157,10085,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,B,,,,,,Hippocampus,,,104686,H,4,Autocuration,1,,CHEMBL617238,,BAO_0000221,10000000.0,
2158,9630,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,B,,,Rattus norvegicus,10116.0,,Brain,,,104686,D,5,Autocuration,1,,CHEMBL617239,,BAO_0000221,955.0,
2159,11070,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617240,,BAO_0000019,,
2160,9841,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL617241,,BAO_0000249,,
2161,9841,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL875907,,BAO_0000249,,
2162,13291,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617242,,BAO_0000019,,
2163,10590,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617152,,BAO_0000019,,
2164,9064,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0,,Brain,,,104686,D,5,Autocuration,1,,CHEMBL617153,,BAO_0000221,955.0,
2165,12268,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,104686,D,5,Autocuration,1,,CHEMBL617154,,BAO_0000249,,
2166,13508,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617155,,BAO_0000221,955.0,
2167,11279,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617156,,BAO_0000019,,
2168,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617157,,BAO_0000019,,
2169,11200,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617158,,BAO_0000019,,
2170,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617159,,BAO_0000019,,
2171,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617160,,BAO_0000019,,
2172,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL858113,,BAO_0000019,,
2173,9231,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617247,,BAO_0000220,955.0,
2174,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617248,,BAO_0000019,,
2175,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617249,,BAO_0000249,955.0,
2176,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617250,,BAO_0000019,,
2177,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617251,,BAO_0000019,,
2178,11828,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617252,,BAO_0000019,,
2179,12253,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617006,,BAO_0000019,,
2180,12253,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617007,,BAO_0000019,,
2181,11279,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617008,,BAO_0000019,,
2182,11866,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617009,,BAO_0000019,,
2183,14424,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617010,,BAO_0000224,,
2184,15180,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL857978,,BAO_0000019,,
2185,15180,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617011,,BAO_0000019,,
2186,9786,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617012,,BAO_0000019,,
2187,12132,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617013,,BAO_0000224,,
2188,5486,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617014,,BAO_0000249,,
2189,15316,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617015,,BAO_0000019,,
2190,16429,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617016,,BAO_0000019,,
2191,14617,pKi value for 5-hydroxytryptamine 2 receptor binding site,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617017,,BAO_0000224,,
2192,11351,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617018,,BAO_0000221,955.0,
2193,11279,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617019,,BAO_0000019,,
2194,9523,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617020,,BAO_0000019,,
2195,9523,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617021,,BAO_0000019,,
2196,9523,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617022,,BAO_0000019,,
2197,9523,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617023,,BAO_0000019,,
2198,9523,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617024,,BAO_0000019,,
2199,9523,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617025,,BAO_0000019,,
2200,9523,Hill coefficient of compound was determined,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617026,,BAO_0000224,,
2201,4771,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617027,,BAO_0000019,,
2202,5033,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617028,,BAO_0000019,,
2203,10845,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617029,,BAO_0000019,,
2204,10845,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL875908,,BAO_0000019,,
2205,16288,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617030,,BAO_0000357,,
2206,16288,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617031,,BAO_0000019,,
2207,16190,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617032,,BAO_0000019,,
2208,12463,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617033,,BAO_0000224,,
2209,9699,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617034,,BAO_0000224,,
2210,9699,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617035,,BAO_0000224,,
2211,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617036,,BAO_0000019,,
2212,1205,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617037,,BAO_0000224,,
2213,11376,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617038,,BAO_0000219,,
2214,11376,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617039,,BAO_0000219,,
2215,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617161,,BAO_0000224,,
2216,2222,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617162,,BAO_0000224,,
2217,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617163,,BAO_0000224,,
2218,1089,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617164,,BAO_0000224,,
2219,386,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,B,,,,,,,,Brain membranes,104784,H,4,Autocuration,1,,CHEMBL617165,,BAO_0000249,,
2220,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617166,,BAO_0000224,,
2221,17066,Binding affinity towards 5-HT2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617167,,BAO_0000224,,
2222,959,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL872912,,BAO_0000224,,
2223,6398,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617168,,BAO_0000224,,
2224,11889,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617169,,BAO_0000224,,
2225,4221,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617170,,BAO_0000224,,
2226,11026,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617171,,BAO_0000224,,
2227,11866,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617172,,BAO_0000224,,
2228,4221,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617173,,BAO_0000224,,
2229,13950,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617174,,BAO_0000019,,
2230,1263,5-hydroxytryptamine 2 receptor binding affinity,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617175,,BAO_0000224,,
2231,13291,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617176,,BAO_0000357,,
2232,10812,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617177,,BAO_0000357,,
2233,13020,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617178,,BAO_0000224,,
2234,13021,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617179,,BAO_0000224,,
2235,13020,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617180,,BAO_0000224,,
2236,14532,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617181,,BAO_0000357,,
2237,13944,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617182,,BAO_0000357,,
2238,14331,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617183,,BAO_0000357,,
2239,14118,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617184,,BAO_0000357,,
2240,13033,Binding affinity against serotonergic 5-HT2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617185,,BAO_0000357,,
2241,10321,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617186,,BAO_0000357,,
2242,12918,Compound was evaluated for the binding affinity at 5- HT2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617187,,BAO_0000357,,
2243,15120,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617188,,BAO_0000357,,
2244,2613,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617189,,BAO_0000218,,
2245,13378,Inhibitory activity against cloned human 5-HT2 receptor,B,,,Homo sapiens,9606.0,,,,,104784,D,5,Autocuration,1,,CHEMBL617190,,BAO_0000224,,
2246,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",B,,,Homo sapiens,9606.0,,,CHO,,104784,D,5,Autocuration,1,,CHEMBL617191,449.0,BAO_0000219,,
2247,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",B,,,Homo sapiens,9606.0,,,CHO,,104784,D,5,Autocuration,1,,CHEMBL617192,449.0,BAO_0000219,,
2248,2331,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",B,,,Homo sapiens,9606.0,,,CHO,,104784,D,5,Autocuration,1,,CHEMBL617193,449.0,BAO_0000219,,
2249,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",B,,,Homo sapiens,9606.0,,,CHO,,104784,D,5,Autocuration,1,,CHEMBL617194,449.0,BAO_0000219,,
2250,4170,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617195,,BAO_0000224,,
2251,15453,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL881830,,BAO_0000224,,
2252,1479,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617196,,BAO_0000357,,
2253,11139,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617197,,BAO_0000224,,
2254,13969,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,B,,,,,,,,,17005,H,8,Expert,1,,CHEMBL617198,,BAO_0000357,,
2255,13392,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,17005,H,8,Expert,1,,CHEMBL873476,,BAO_0000357,,
2256,14430,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,B,,,,,,,,,17005,H,8,Expert,1,,CHEMBL617199,,BAO_0000019,,
2257,13181,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,,Cavia porcellus,10141.0,,,,,107,H,8,Autocuration,1,,CHEMBL617200,,BAO_0000357,,
2258,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL617484,,BAO_0000357,,
2259,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617485,,BAO_0000357,,
2260,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL617486,,BAO_0000357,,
2261,13463,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL858022,,BAO_0000357,,
2262,6347,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617049,449.0,BAO_0000219,,
2263,6857,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0,,,CHO,,107,D,9,Expert,1,,CHEMBL617050,449.0,BAO_0000219,,
2264,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617051,,BAO_0000219,,
2265,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617052,,BAO_0000219,,
2266,4176,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617053,,BAO_0000219,,
2267,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617054,449.0,BAO_0000219,,
2268,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617055,449.0,BAO_0000219,,
2269,15331,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL882924,,BAO_0000357,,
2270,16146,Inhibition of human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617056,,BAO_0000357,,
2271,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617057,449.0,BAO_0000219,,
2272,13631,Inhibitory concentration against human 5-HT2A receptor in BEK cells,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617058,,BAO_0000219,,
2273,3805,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617059,,BAO_0000357,,
2274,4011,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617060,449.0,BAO_0000219,,
2275,4012,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,B,,,,,,,CHO,,107,H,8,Expert,1,,CHEMBL617061,449.0,BAO_0000219,,
2276,6366,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,B,,,,,,,L929,,107,H,8,Expert,1,,CHEMBL617062,307.0,BAO_0000219,,
2277,15949,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,107,H,8,Expert,1,,CHEMBL617063,449.0,BAO_0000219,,
2278,14093,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617064,,BAO_0000019,,
2279,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617065,,BAO_0000019,,
2280,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617066,449.0,BAO_0000219,,
2281,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617067,449.0,BAO_0000219,,
2282,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617068,,BAO_0000019,,
2283,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617069,,BAO_0000019,,
2284,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617070,,BAO_0000019,,
2285,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617071,,BAO_0000357,,
2286,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL872915,,BAO_0000357,,
2287,14755,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617072,,BAO_0000357,,
2288,16441,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617073,,BAO_0000357,,
2289,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617074,,BAO_0000357,,
2290,16659,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,107,H,8,Expert,1,,CHEMBL617075,449.0,BAO_0000219,,
2291,3307,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617076,,BAO_0000357,,
2292,6857,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617077,,BAO_0000019,,
2293,5635,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617078,,BAO_0000357,,
2294,4234,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617079,,BAO_0000357,,
2295,15527,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617080,,BAO_0000357,,
2296,6588,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,B,,,,,,,CHO,,107,H,8,Expert,1,,CHEMBL617081,449.0,BAO_0000219,,
2297,13631,Binding affinity towards human 5-HT2A receptor in BEK cells,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617082,,BAO_0000219,,
2298,17723,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617083,,BAO_0000357,,
2299,14770,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617084,,BAO_0000357,,
2300,16293,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617085,,BAO_0000357,,
2301,16209,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617086,,BAO_0000357,,
2302,12469,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617087,,BAO_0000219,,
2303,15363,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617088,,BAO_0000357,,
2304,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617089,,BAO_0000357,,
2305,16441,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617090,,BAO_0000019,,
2306,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617513,,BAO_0000357,,
2307,4176,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617514,722.0,BAO_0000219,,
2308,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617515,,BAO_0000019,,
2309,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617516,,BAO_0000357,,
2310,17200,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617517,,BAO_0000357,,
2311,4013,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,107,D,9,Expert,1,,CHEMBL617518,449.0,BAO_0000219,,
2312,5088,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617519,,BAO_0000357,,
2313,5088,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617520,,BAO_0000357,,
2314,5088,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617521,,BAO_0000357,,
2315,5088,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617522,,BAO_0000357,,
2316,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617523,,BAO_0000357,,
2317,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617524,,BAO_0000357,,
2318,9786,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617525,,BAO_0000019,,
2319,9205,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617526,,BAO_0000019,,
2320,11257,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617527,,BAO_0000224,,
2321,9362,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617528,,BAO_0000019,,
2322,9362,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617529,,BAO_0000019,,
2323,10590,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617530,,BAO_0000224,,
2324,10468,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617531,,BAO_0000019,,
2325,13050,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617532,,BAO_0000019,,
2326,11624,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617533,,BAO_0000019,,
2327,10468,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617534,,BAO_0000019,,
2328,10330,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617535,,BAO_0000224,,
2329,10062,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617536,,BAO_0000224,,
2330,11642,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617537,,BAO_0000224,,
2331,10062,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617538,,BAO_0000224,,
2332,13427,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617539,,BAO_0000219,,
2333,12280,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617540,,BAO_0000224,,
2334,4101,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617541,,BAO_0000224,,
2335,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617542,,BAO_0000224,,
2336,11147,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617543,,BAO_0000224,,
2337,2395,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,104686,D,5,Autocuration,1,,CHEMBL617544,485.0,BAO_0000219,,
2338,2395,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,104686,D,5,Autocuration,1,,CHEMBL617545,485.0,BAO_0000219,,
2339,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617413,,BAO_0000019,,
2340,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617414,,BAO_0000019,,
2341,9098,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617415,,BAO_0000019,,
2342,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617416,,BAO_0000224,,
2343,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617417,,BAO_0000224,,
2344,9699,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617418,,BAO_0000019,,
2345,9699,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617419,,BAO_0000019,,
2346,9098,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617420,,BAO_0000224,,
2347,3070,Affinity for 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617421,,BAO_0000224,,
2348,9547,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617422,,BAO_0000224,,
2349,10444,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617423,,BAO_0000019,,
2350,14617,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617424,,BAO_0000019,,
2351,14617,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617425,,BAO_0000019,,
2352,11130,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617426,,BAO_0000224,,
2353,11130,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),B,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617427,,BAO_0000218,,
2354,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617428,,BAO_0000221,955.0,
2355,2797,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617429,,BAO_0000224,,
2356,11332,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617430,,BAO_0000019,,
2357,11332,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617431,,BAO_0000019,,
2358,10752,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,B,,,,,,Frontal cortex,,,104686,H,4,Autocuration,1,,CHEMBL617432,,BAO_0000019,1870.0,
2359,1185,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617433,,BAO_0000224,,
2360,1185,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617434,,BAO_0000224,,
2361,11624,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617435,,BAO_0000224,,
2362,1344,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617436,,BAO_0000019,,
2363,15453,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,B,,,Rattus norvegicus,10116.0,,Striatum,,,104686,D,5,Autocuration,1,,CHEMBL617437,,BAO_0000019,2435.0,
2364,11662,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617438,,BAO_0000019,,
2365,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617439,,BAO_0000019,,
2366,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617440,,BAO_0000224,,
2367,9069,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617441,,BAO_0000224,,
2368,8814,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL872918,,BAO_0000019,,
2369,8908,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617442,,BAO_0000019,,
2370,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617443,,BAO_0000019,,
2371,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617444,,BAO_0000019,,
2372,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617445,,BAO_0000019,,
2373,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617446,,BAO_0000019,,
2374,9098,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617447,,BAO_0000249,,
2375,9098,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617448,,BAO_0000019,,
2376,9098,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617449,,BAO_0000019,,
2377,9161,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617450,,BAO_0000019,,
2378,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617451,,BAO_0000019,,
2379,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617452,,BAO_0000019,,
2380,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617453,,BAO_0000019,,
2381,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617660,,BAO_0000019,,
2382,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617661,,BAO_0000019,,
2383,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617662,,BAO_0000019,,
2384,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL872919,,BAO_0000019,,
2385,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617663,,BAO_0000019,,
2386,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617664,,BAO_0000019,,
2387,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617665,,BAO_0000019,,
2388,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617666,,BAO_0000019,,
2389,12094,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617667,,BAO_0000019,,
2390,12018,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617668,,BAO_0000249,,
2391,10394,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617669,,BAO_0000249,,
2392,15260,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617670,,BAO_0000224,,
2393,11624,Inhibitory constant against 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617671,,BAO_0000224,,
2394,13654,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617672,,BAO_0000224,,
2395,9541,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617673,,BAO_0000019,,
2396,11933,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617674,,BAO_0000224,,
2397,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617675,,BAO_0000019,,
2398,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617676,,BAO_0000019,,
2399,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617677,,BAO_0000019,,
2400,8841,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,D,5,Autocuration,1,,CHEMBL617678,,BAO_0000019,,
2401,1455,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617679,,BAO_0000224,,
2402,1455,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617680,,BAO_0000224,,
2403,11752,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617681,,BAO_0000019,,
2404,11642,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617682,,BAO_0000221,955.0,
2405,12092,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617683,,BAO_0000224,,
2406,3967,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617684,,BAO_0000224,,
2407,12771,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617685,,BAO_0000224,,
2408,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617686,,BAO_0000019,,
2409,11628,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617687,,BAO_0000224,,
2410,13654,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617688,,BAO_0000224,,
2411,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617689,,BAO_0000019,,
2412,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617690,,BAO_0000019,,
2413,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617691,,BAO_0000218,,
2414,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617692,,BAO_0000218,,
2415,11200,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617693,,BAO_0000218,,
2416,11200,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617694,,BAO_0000218,,
2417,15436,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,B,,,,,,Brain,,,12687,H,8,Expert,1,,CHEMBL857985,,BAO_0000221,955.0,
2418,15436,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617695,,BAO_0000019,,
2419,14025,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617696,,BAO_0000019,,
2420,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617697,,BAO_0000357,,
2421,13735,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617257,,BAO_0000019,,
2422,5816,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617258,,BAO_0000357,,
2423,14287,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617259,,BAO_0000019,,
2424,15738,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617260,,BAO_0000357,,
2425,15738,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617261,,BAO_0000357,,
2426,15026,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617262,,BAO_0000019,,
2427,16647,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617263,,BAO_0000019,,
2428,16647,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617264,,BAO_0000019,,
2429,13345,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617265,,BAO_0000019,,
2430,1543,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,B,,,,,,,,Membranes,12687,H,8,Autocuration,1,,CHEMBL617266,,BAO_0000249,,
2431,12444,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617267,,BAO_0000019,,
2432,16404,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617268,,BAO_0000019,,
2433,16404,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,,,,,,CHO,,12687,H,8,Autocuration,1,,CHEMBL617269,449.0,BAO_0000219,,
2434,15577,Kinetic inhibition constant evaluated by measuring serotonergic activity,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617323,,BAO_0000357,,
2435,15577,Serotonergic activity of the compound.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617324,,BAO_0000357,,
2436,2495,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617325,,BAO_0000249,,
2437,15042,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617326,,BAO_0000019,,
2438,15026,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617327,,BAO_0000249,,
2439,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617328,,BAO_0000019,,
2440,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617329,,BAO_0000019,,
2441,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617330,,BAO_0000019,,
2442,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617331,,BAO_0000357,,
2443,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617332,,BAO_0000357,,
2444,4820,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617333,,BAO_0000357,,
2445,6736,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617334,,BAO_0000357,,
2446,5163,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617335,,BAO_0000357,,
2447,5163,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617336,,BAO_0000357,,
2448,6011,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617337,,BAO_0000357,,
2449,14294,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617338,,BAO_0000357,,
2450,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617339,,BAO_0000357,,
2451,17066,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617340,,BAO_0000357,,
2452,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617341,,BAO_0000357,,
2453,6736,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617342,,BAO_0000357,,
2454,5163,Affinity for 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617343,,BAO_0000357,,
2455,16911,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,B,,,,,,,NIH3T3,,107,H,8,Expert,1,,CHEMBL617344,723.0,BAO_0000219,,
2456,6841,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617345,,BAO_0000357,,
2457,6119,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617346,,BAO_0000357,,
2458,3962,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617347,,BAO_0000357,,
2459,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617348,,BAO_0000357,,
2460,4373,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617349,,BAO_0000357,,
2461,3962,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617350,,BAO_0000019,,
2462,1633,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL872339,,BAO_0000357,,
2463,4373,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617351,,BAO_0000357,,
2464,6576,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617352,,BAO_0000357,,
2465,4687,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617353,,BAO_0000357,,
2466,16946,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617354,,BAO_0000357,,
2467,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617355,,BAO_0000357,,
2468,3032,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,B,,,Mus musculus,10090.0,,,CHO,,107,H,8,Expert,1,,CHEMBL617356,449.0,BAO_0000219,,
2469,16655,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617357,,BAO_0000357,,
2470,13964,Binding affinity at 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617358,,BAO_0000357,,
2471,16989,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617359,,BAO_0000357,,
2472,16117,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617360,,BAO_0000357,,
2473,16700,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL875913,,BAO_0000357,,
2474,3269,Affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617361,,BAO_0000357,,
2475,1274,Binding affinity against 5-Hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617362,,BAO_0000357,,
2476,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617363,,BAO_0000357,,
2477,12146,Tested against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617364,,BAO_0000357,,
2478,12652,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617365,,BAO_0000224,,
2479,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617366,,BAO_0000224,,
2480,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617367,,BAO_0000224,,
2481,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617368,,BAO_0000224,,
2482,16647,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617369,,BAO_0000357,,
2483,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617370,722.0,BAO_0000219,,
2484,6857,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0,,,CHO,,227,D,9,Expert,1,,CHEMBL617371,449.0,BAO_0000219,,
2485,3805,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617372,,BAO_0000357,,
2486,6491,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,B,,,Homo sapiens,9606.0,,,,,227,D,9,Expert,1,,CHEMBL617373,,BAO_0000357,,
2487,14093,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617374,,BAO_0000019,,
2488,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617375,,BAO_0000019,,
2489,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617376,,BAO_0000019,,
2490,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617377,,BAO_0000019,,
2491,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617378,,BAO_0000019,,
2492,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617379,,BAO_0000019,,
2493,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617380,,BAO_0000357,,
2494,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617381,,BAO_0000357,,
2495,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617382,,BAO_0000357,,
2496,12369,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617383,,BAO_0000357,,
2497,12369,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617384,,BAO_0000357,,
2498,12369,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617385,,BAO_0000357,,
2499,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617386,,BAO_0000019,,
2500,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617387,,BAO_0000019,,
2501,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,107,H,8,Autocuration,1,,CHEMBL617388,723.0,BAO_0000219,,
2502,6857,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617389,449.0,BAO_0000219,,
2503,6857,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,107,D,9,Expert,1,,CHEMBL617390,449.0,BAO_0000219,,
2504,5635,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,B,,,,,,,,,104817,H,4,Autocuration,1,,CHEMBL617391,,BAO_0000224,,
2505,12861,Binding activity radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617392,,BAO_0000357,,
2506,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617393,,BAO_0000019,,
2507,5105,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,,,,L929,,107,H,8,Autocuration,1,,CHEMBL617394,307.0,BAO_0000219,,
2508,5104,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,,,,L929,,107,H,8,Expert,1,,CHEMBL617395,307.0,BAO_0000219,,
2509,5105,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,B,,,,,,,L929,,107,H,8,Expert,1,,CHEMBL617396,307.0,BAO_0000219,,
2510,5105,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,B,,,,,,,L929,,107,H,8,Autocuration,1,,CHEMBL617397,307.0,BAO_0000219,,
2511,5254,Binding affinity against 5-HT2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617398,,BAO_0000357,,
2512,5254,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617399,,BAO_0000357,,
2513,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617400,722.0,BAO_0000219,,
2514,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617401,722.0,BAO_0000219,,
2515,14157,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL617402,722.0,BAO_0000219,,
2516,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL617403,722.0,BAO_0000219,,
2517,14068,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617404,,BAO_0000357,,
2518,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL857981,722.0,BAO_0000219,,
2519,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL617405,722.0,BAO_0000219,,
2520,4540,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL617253,722.0,BAO_0000219,,
2521,6166,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617254,,BAO_0000357,,
2522,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617255,722.0,BAO_0000219,,
2523,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617256,722.0,BAO_0000219,,
2524,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616874,722.0,BAO_0000219,,
2525,15779,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL616875,722.0,BAO_0000219,,
2526,14391,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Expert,1,,CHEMBL616876,722.0,BAO_0000219,,
2527,15851,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",B,,,,,,,HEK293,,107,H,8,Expert,1,,CHEMBL616877,722.0,BAO_0000219,,
2528,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL616878,722.0,BAO_0000219,,
2529,3832,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,B,,,,,,,HEK293,,107,H,8,Expert,1,,CHEMBL616879,722.0,BAO_0000219,,
2530,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,B,,,,,,,HEK293,,107,H,8,Expert,1,,CHEMBL616880,722.0,BAO_0000219,,
2531,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL616881,722.0,BAO_0000219,,
2532,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,,,,NIH3T3,,107,H,8,Autocuration,1,,CHEMBL616882,723.0,BAO_0000219,,
2533,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,107,H,8,Autocuration,1,,CHEMBL616883,723.0,BAO_0000219,,
2534,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,107,H,8,Autocuration,1,,CHEMBL616884,723.0,BAO_0000219,,
2535,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616885,722.0,BAO_0000219,,
2536,1883,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,B,,,,,,,CHO-K1,,107,H,8,Autocuration,1,,CHEMBL616886,485.0,BAO_0000219,,
2537,1883,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,107,H,8,Expert,1,,CHEMBL616887,485.0,BAO_0000219,,
2538,14875,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL616888,,BAO_0000357,,
2539,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616889,722.0,BAO_0000219,,
2540,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616890,722.0,BAO_0000219,,
2541,16404,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,107,D,9,Expert,1,,CHEMBL616891,449.0,BAO_0000219,,
2542,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616892,722.0,BAO_0000219,,
2543,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616893,722.0,BAO_0000219,,
2544,12652,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,F,,,,,,,NIH3T3,,10620,H,8,Autocuration,1,,CHEMBL616894,723.0,BAO_0000219,,
2545,4682,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,B,,,,,,,NIH3T3,,107,H,8,Expert,1,,CHEMBL616895,723.0,BAO_0000219,,
2546,12652,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,F,,,,,,,,,10620,H,8,Autocuration,1,,CHEMBL616896,,BAO_0000019,,
2547,4921,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,B,,,,,,,,,10621,H,8,Autocuration,1,,CHEMBL617099,,BAO_0000357,,
2548,4921,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,B,,,,,,,,,10621,H,8,Autocuration,1,,CHEMBL617100,,BAO_0000357,,
2549,16312,Binding affinity against rabbit aorta 5-HT2A receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Autocuration,1,,CHEMBL884532,,BAO_0000357,,
2550,14998,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Expert,1,,CHEMBL617101,,BAO_0000357,,
2551,14025,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Expert,1,,CHEMBL617102,,BAO_0000357,,
2552,13047,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Autocuration,1,,CHEMBL617103,,BAO_0000019,,
2553,13047,The compound was tested for binding affinity against 5-HT2A receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Expert,1,,CHEMBL617104,,BAO_0000357,,
2554,1883,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,B,,,,,,,CHO-K1,,10576,H,8,Autocuration,1,,CHEMBL857979,485.0,BAO_0000219,,
2555,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL857502,,BAO_0000019,,
2556,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617105,,BAO_0000019,,
2557,13463,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,B,,,,,,Stomach,,,12687,H,8,Autocuration,1,,CHEMBL858021,,BAO_0000019,945.0,
2558,13463,Binding affinity for 5-HT 2A in rat stomach fundus,B,,,Rattus norvegicus,10116.0,,Stomach,,,12687,D,9,Expert,1,,CHEMBL875910,,BAO_0000019,945.0,
2559,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617106,,BAO_0000019,,
2560,16326,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL617107,723.0,BAO_0000219,,
2561,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617108,,BAO_0000019,,
2562,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617109,,BAO_0000019,,
2563,15740,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617110,,BAO_0000357,,
2564,16633,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617111,,BAO_0000357,,
2565,17200,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617112,,BAO_0000019,,
2566,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617113,,BAO_0000357,,
2567,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617114,,BAO_0000357,,
2568,17133,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617115,,BAO_0000357,,
2569,17200,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617116,,BAO_0000219,,
2570,15363,Efficacy at 5-hydroxytryptamine 2A receptor,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617117,,BAO_0000019,,
2571,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617118,,BAO_0000357,,
2572,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617119,,BAO_0000357,,
2573,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617120,,BAO_0000357,,
2574,17200,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617121,,BAO_0000219,,
2575,17200,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617122,,BAO_0000219,,
2576,17211,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617123,,BAO_0000019,,
2577,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617124,,BAO_0000019,,
2578,13565,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617600,,BAO_0000249,,
2579,13730,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617601,,BAO_0000357,,
2580,12416,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL882923,,BAO_0000019,,
2581,15295,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617602,,BAO_0000357,,
2582,1742,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617603,,BAO_0000019,,
2583,15295,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617604,,BAO_0000357,,
2584,14970,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617605,,BAO_0000019,,
2585,16693,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617606,,BAO_0000019,,
2586,14776,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617607,,BAO_0000019,,
2587,14286,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617455,,BAO_0000249,,
2588,17200,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617456,,BAO_0000019,,
2589,15306,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617457,,BAO_0000357,,
2590,14178,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617458,,BAO_0000357,,
2591,14229,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617459,,BAO_0000019,,
2592,12884,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617460,,BAO_0000357,,
2593,13149,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617461,,BAO_0000357,,
2594,15295,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617462,,BAO_0000019,,
2595,15740,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617463,,BAO_0000357,,
2596,15185,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617464,,BAO_0000019,,
2597,15185,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617465,,BAO_0000019,,
2598,17529,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617466,,BAO_0000019,,
2599,14826,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617467,,BAO_0000019,,
2600,17211,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617468,,BAO_0000019,,
2601,14826,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617469,,BAO_0000019,,
2602,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617470,,BAO_0000019,,
2603,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617471,,BAO_0000019,,
2604,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL617472,723.0,BAO_0000219,,
2605,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617473,,BAO_0000357,,
2606,15436,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617474,,BAO_0000019,,
2607,15436,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617475,,BAO_0000019,,
2608,14442,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,B,,,,,,Brain,,,12687,H,8,Autocuration,1,,CHEMBL617476,,BAO_0000221,955.0,
2609,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617477,,BAO_0000357,,
2610,12457,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL617478,723.0,BAO_0000219,,
2611,14755,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617479,,BAO_0000221,,
2612,4707,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617480,,BAO_0000357,,
2613,13297,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617481,,BAO_0000357,,
2614,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617482,,BAO_0000019,,
2615,4664,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617483,,BAO_0000019,,
2616,16633,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621528,,BAO_0000357,,
2617,4664,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,NIH3T3,,12687,D,9,Expert,1,,CHEMBL621529,723.0,BAO_0000219,,
2618,16133,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621530,,BAO_0000357,,
2619,16133,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621531,,BAO_0000357,,
2620,14060,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL621532,,BAO_0000019,,
2621,16326,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621533,,BAO_0000357,,
2622,16659,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,12687,H,8,Expert,1,,CHEMBL621534,449.0,BAO_0000219,,
2623,14776,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621535,,BAO_0000019,,
2624,13481,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621536,,BAO_0000357,,
2625,17386,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621537,,BAO_0000357,,
2626,6611,Binding affinity for 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL621538,,BAO_0000357,,
2627,14423,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621539,,BAO_0000019,,
2628,15412,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621540,,BAO_0000019,,
2629,15412,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621541,,BAO_0000019,,
2630,6238,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621542,,BAO_0000019,,
2631,6648,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621543,,BAO_0000357,,
2632,5667,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621544,,BAO_0000357,,
2633,6611,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL621545,,BAO_0000357,,
2634,13481,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621546,,BAO_0000357,,
2635,13481,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621547,,BAO_0000357,,
2636,15558,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL618692,723.0,BAO_0000219,,
2637,6013,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618693,,BAO_0000357,,
2638,16633,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL872922,,BAO_0000357,,
2639,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618694,,BAO_0000357,,
2640,6013,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL618695,,BAO_0000357,,
2641,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618696,,BAO_0000357,,
2642,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL618697,,BAO_0000357,,
2643,6013,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618892,,BAO_0000357,,
2644,6013,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618893,,BAO_0000357,,
2645,16293,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618894,,BAO_0000357,,
2646,17175,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL618895,723.0,BAO_0000219,,
2647,13278,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL618896,,BAO_0000357,,
2648,3682,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,B,,,,,,Caudate-putamen,,,12687,H,8,Autocuration,1,,CHEMBL618897,,BAO_0000019,5383.0,
2649,2014,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618898,,BAO_0000357,,
2650,2014,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618899,,BAO_0000357,,
2651,4932,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618900,,BAO_0000357,,
2652,4932,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618901,,BAO_0000019,,
2653,3935,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618902,,BAO_0000357,,
2654,5432,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,12687,D,9,Expert,1,,CHEMBL618903,,BAO_0000221,10000000.0,
2655,15818,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618904,,BAO_0000357,,
2656,13672,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618905,,BAO_0000357,,
2657,13672,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618906,,BAO_0000357,,
2658,14749,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL618907,723.0,BAO_0000219,,
2659,13462,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618908,,BAO_0000019,,
2660,15740,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617909,,BAO_0000357,,
2661,16647,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617910,,BAO_0000019,,
2662,13345,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,B,,,,,,Brain,,,12687,H,8,Autocuration,1,,CHEMBL617911,,BAO_0000221,955.0,
2663,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL872923,,BAO_0000249,,
2664,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617912,,BAO_0000249,,
2665,15535,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617913,,BAO_0000019,,
2666,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617914,,BAO_0000249,,
2667,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617915,,BAO_0000249,,
2668,16740,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617916,,BAO_0000249,,
2669,4795,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617917,,BAO_0000019,,
2670,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617918,,BAO_0000019,,
2671,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617919,,BAO_0000019,,
2672,17200,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617920,,BAO_0000019,,
2673,2148,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617921,,BAO_0000019,,
2674,13345,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",B,,,Rattus norvegicus,10116.0,,,,,105102,D,5,Expert,1,,CHEMBL617922,,BAO_0000224,,
2675,5088,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617923,,BAO_0000357,,
2676,5088,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617924,,BAO_0000357,,
2677,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617925,,BAO_0000357,,
2678,17133,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617926,,BAO_0000357,,
2679,16532,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617927,,BAO_0000357,,
2680,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617928,,BAO_0000357,,
2681,2309,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617929,,BAO_0000019,,
2682,12953,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617930,,BAO_0000019,,
2683,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617931,,BAO_0000019,,
2684,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617932,,BAO_0000019,,
2685,16659,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,B,,,,,,,CHO,,12687,H,8,Autocuration,1,,CHEMBL617933,449.0,BAO_0000219,,
2686,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617934,,BAO_0000019,,
2687,16740,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617935,,BAO_0000019,,
2688,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617936,,BAO_0000357,,
2689,17211,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617937,,BAO_0000019,,
2690,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617938,,BAO_0000019,,
2691,16633,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617939,,BAO_0000218,,
2692,16633,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617940,,BAO_0000218,,
2693,16633,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617941,,BAO_0000218,,
2694,15026,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617942,,BAO_0000357,,
2695,15026,Ratio of pKi of 5-HT2A to that of D2 receptor,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617943,,BAO_0000357,,
2696,16404,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,,,,,,105093,H,4,Expert,1,,CHEMBL617944,,BAO_0000224,,
2697,16404,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,,,,,,105093,H,4,Expert,1,,CHEMBL617945,,BAO_0000224,,
2698,16404,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,B,,,,,,,,,105075,H,4,Expert,1,,CHEMBL617946,,BAO_0000224,,
2699,16404,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617947,,BAO_0000357,,
2700,16326,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617948,,BAO_0000357,,
2701,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL858116,,BAO_0000019,,
2702,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617949,,BAO_0000019,,
2703,15329,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617950,,BAO_0000019,,
2704,16404,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,F,,,,,,Thoracic aorta,,,12687,H,8,Expert,1,,CHEMBL617951,,BAO_0000019,1515.0,
2705,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,F,,,,,,Thoracic aorta,,,12687,H,8,Expert,1,,CHEMBL617952,,BAO_0000019,1515.0,
2706,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,F,,,,,,Thoracic aorta,,,12687,H,8,Autocuration,1,,CHEMBL617953,,BAO_0000019,1515.0,
2707,12861,Binding activity radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617954,,BAO_0000357,,
2708,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617955,,BAO_0000019,,
2709,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL857071,,BAO_0000019,,
2710,12490,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617270,,BAO_0000019,,
2711,12827,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,B,,,,,,,N1E-115,,12687,H,8,Autocuration,1,,CHEMBL617271,339.0,BAO_0000219,,
2712,12827,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,B,,,,,,,N1E-115,,12687,H,8,Autocuration,1,,CHEMBL617272,339.0,BAO_0000219,,
2713,12918,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617273,,BAO_0000019,,
2714,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617274,,BAO_0000019,,
2715,17723,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617275,,BAO_0000357,,
2716,6013,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617276,,BAO_0000357,,
2717,16293,Binding affinity towards human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617277,,BAO_0000357,,
2718,3857,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617278,,BAO_0000019,,
2719,3857,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617279,,BAO_0000019,,
2720,3857,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617280,,BAO_0000019,,
2721,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617281,,BAO_0000357,,
2722,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617282,,BAO_0000357,,
2723,16441,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617283,,BAO_0000019,,
2724,16441,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617284,,BAO_0000019,,
2725,4176,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617285,722.0,BAO_0000219,,
2726,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617286,,BAO_0000019,,
2727,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL617287,,BAO_0000357,,
2728,5088,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617288,,BAO_0000357,,
2729,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617289,,BAO_0000357,,
2730,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL872917,,BAO_0000357,,
2731,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617290,,BAO_0000357,,
2732,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617291,449.0,BAO_0000219,,
2733,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617292,449.0,BAO_0000219,,
2734,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,108,H,8,Autocuration,1,,CHEMBL617293,723.0,BAO_0000219,,
2735,6857,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,108,D,9,Expert,1,,CHEMBL617294,449.0,BAO_0000219,,
2736,3857,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617295,,BAO_0000019,,
2737,12861,Binding activity radioligand.,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617296,,BAO_0000357,,
2738,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617297,,BAO_0000019,,
2739,5104,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617298,449.0,BAO_0000219,,
2740,5105,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617299,449.0,BAO_0000219,,
2741,5105,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617300,449.0,BAO_0000219,,
2742,5254,Binding affinity against 5-HT2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617454,,BAO_0000357,,
2743,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617505,722.0,BAO_0000219,,
2744,14157,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617506,722.0,BAO_0000219,,
2745,12936,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617507,722.0,BAO_0000219,,
2746,14068,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617508,,BAO_0000357,,
2747,12936,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL857982,722.0,BAO_0000219,,
2748,4540,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617509,722.0,BAO_0000219,,
2749,4540,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617510,722.0,BAO_0000219,,
2750,6166,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617511,,BAO_0000357,,
2751,17296,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617512,722.0,BAO_0000219,,
2752,17296,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617749,722.0,BAO_0000219,,
2753,15779,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617750,722.0,BAO_0000219,,
2754,15779,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617751,722.0,BAO_0000219,,
2755,14391,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Expert,1,,CHEMBL617752,722.0,BAO_0000219,,
2756,15779,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617753,722.0,BAO_0000219,,
2757,15851,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",B,,,,,,,HEK293,,108,H,8,Expert,1,,CHEMBL617754,722.0,BAO_0000219,,
2758,15851,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617755,722.0,BAO_0000219,,
2759,15779,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617756,722.0,BAO_0000219,,
2760,3832,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,B,,,,,,,HEK293,,108,H,8,Expert,1,,CHEMBL617757,722.0,BAO_0000219,,
2761,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,B,,,,,,,HEK293,,108,H,8,Expert,1,,CHEMBL617758,722.0,BAO_0000219,,
2762,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,,,,NIH3T3,,108,H,8,Autocuration,1,,CHEMBL617759,723.0,BAO_0000219,,
2763,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617760,722.0,BAO_0000219,,
2764,1883,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,B,,,,,,,CHO-K1,,108,H,8,Expert,1,,CHEMBL617761,485.0,BAO_0000219,,
2765,4321,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL617762,,BAO_0000357,,
2766,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617763,,BAO_0000357,,
2767,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL857983,722.0,BAO_0000219,,
2768,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617764,722.0,BAO_0000219,,
2769,16404,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,B,,,,,,,HeLa,,108,H,8,Autocuration,1,,CHEMBL617765,308.0,BAO_0000219,,
2770,13267,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617766,,BAO_0000019,,
2771,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,F,,,,,,Hippocampus,,,108,H,8,Autocuration,1,,CHEMBL617767,,BAO_0000221,10000000.0,
2772,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617768,722.0,BAO_0000219,,
2773,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617769,722.0,BAO_0000219,,
2774,13463,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,B,,,,,,,,,11864,H,8,Autocuration,1,,CHEMBL858023,,BAO_0000357,,
2775,13463,Binding affinity analysed on 5-HT 2C in rat stomach fundus,B,,,,,,Stomach,,,11864,H,8,Autocuration,1,,CHEMBL617770,,BAO_0000019,945.0,
2776,13463,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,B,,,,,,Stomach,,,11864,H,8,Autocuration,1,,CHEMBL617771,,BAO_0000019,945.0,
2777,12652,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,F,,,,,,,A9,,11864,H,8,Autocuration,1,,CHEMBL617772,625.0,BAO_0000219,,
2778,4682,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,,,,NIH3T3,,11864,H,8,Autocuration,1,,CHEMBL617773,723.0,BAO_0000219,,
2779,4682,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,B,,,,,,,NIH3T3,,11864,H,8,Autocuration,1,,CHEMBL617850,723.0,BAO_0000219,,
2780,4682,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,,,,NIH3T3,,11864,H,8,Autocuration,1,,CHEMBL617851,723.0,BAO_0000219,,
2781,12652,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,F,,,,,,,,,11864,H,8,Autocuration,1,,CHEMBL617852,,BAO_0000019,,
2782,13463,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,B,,,Mus musculus,10090.0,,Stomach,,,12689,H,8,Autocuration,1,,CHEMBL858024,,BAO_0000019,945.0,
2783,13463,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,B,,,Rattus norvegicus,10116.0,,Stomach,,,12689,D,9,Expert,1,,CHEMBL617853,,BAO_0000019,945.0,
2784,13969,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617854,,BAO_0000357,,
2785,13392,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL873477,,BAO_0000357,,
2786,13392,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617855,,BAO_0000357,,
2787,14430,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617856,,BAO_0000019,,
2788,1742,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617857,,BAO_0000019,,
2789,14286,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617858,,BAO_0000249,,
2790,5619,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617859,,BAO_0000357,,
2791,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617860,,BAO_0000357,,
2792,12861,Binding activity radioligand.,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617861,,BAO_0000357,,
2793,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617862,,BAO_0000019,,
2794,12861,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617863,,BAO_0000019,,
2795,12827,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617864,,BAO_0000249,,
2796,12827,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617649,,BAO_0000249,,
2797,12919,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL617650,,BAO_0000019,,
2798,12919,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL617651,,BAO_0000019,,
2799,16429,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL617652,,BAO_0000357,,
2800,773,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL857072,,BAO_0000019,,
2801,5033,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL617653,,BAO_0000357,,
2802,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617654,,BAO_0000019,,
2803,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,F,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617655,,BAO_0000019,,
2804,14970,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617656,,BAO_0000357,,
2805,14970,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617657,,BAO_0000357,,
2806,14970,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617658,,BAO_0000357,,
2807,14178,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL617659,,BAO_0000357,,
2808,14178,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL617838,,BAO_0000357,,
2809,14229,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,B,,,Rattus norvegicus,10116.0,,,,Brain membranes,12689,D,9,Expert,1,,CHEMBL617839,,BAO_0000249,,
2810,16532,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617840,,BAO_0000357,,
2811,14826,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617841,,BAO_0000019,,
2812,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL875915,,BAO_0000019,,
2813,17211,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,B,In vitro,,,,,,,,12689,H,8,Expert,1,,CHEMBL617842,,BAO_0000219,,
2814,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,B,,,,,,,NIH3T3,,12689,H,8,Expert,1,,CHEMBL617843,723.0,BAO_0000219,,
2815,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617844,,BAO_0000357,,
2816,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617845,,BAO_0000357,,
2817,12457,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,B,,,,,,,NIH3T3,,12689,H,8,Expert,1,,CHEMBL617846,723.0,BAO_0000219,,
2818,4707,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617847,,BAO_0000357,,
2819,13297,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617848,,BAO_0000357,,
2820,16633,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617849,,BAO_0000357,,
2821,16133,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621507,,BAO_0000357,,
2822,16326,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621508,,BAO_0000357,,
2823,14423,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621509,,BAO_0000019,,
2824,15412,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621510,,BAO_0000019,,
2825,15412,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621511,,BAO_0000019,,
2826,15558,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,B,,,,,,,A9,,12689,H,8,Expert,1,,CHEMBL621512,625.0,BAO_0000219,,
2827,16633,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621513,,BAO_0000357,,
2828,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621514,,BAO_0000357,,
2829,17175,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,B,In vitro,,,,,,,,12689,H,8,Expert,1,,CHEMBL621515,,BAO_0000219,,
2830,12469,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621516,,BAO_0000219,,
2831,3682,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,B,,,,,,Caudate-putamen,,,12689,H,8,Autocuration,1,,CHEMBL621517,,BAO_0000019,5383.0,
2832,4932,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621518,,BAO_0000357,,
2833,4932,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621519,,BAO_0000019,,
2834,3935,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621520,,BAO_0000357,,
2835,15818,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621521,,BAO_0000357,,
2836,15818,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621522,,BAO_0000357,,
2837,14749,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621523,,BAO_0000219,,
2838,15740,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621524,,BAO_0000357,,
2839,17133,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL621525,,BAO_0000357,,
2840,16532,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL872921,,BAO_0000357,,
2841,12369,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621526,,BAO_0000357,,
2842,12369,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621527,,BAO_0000219,,
2843,2309,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL617865,,BAO_0000019,,
2844,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617866,,BAO_0000357,,
2845,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617867,,BAO_0000019,,
2846,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617487,,BAO_0000357,,
2847,12953,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617488,,BAO_0000357,,
2848,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617489,,BAO_0000357,,
2849,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617490,,BAO_0000019,,
2850,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617491,,BAO_0000019,,
2851,14025,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617492,,BAO_0000019,,
2852,14998,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617493,,BAO_0000019,,
2853,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617494,,BAO_0000357,,
2854,13735,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL617495,,BAO_0000019,,
2855,13181,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617496,,BAO_0000357,,
2856,1883,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,B,,,,,,,CHO-K1,,12689,H,8,Autocuration,1,,CHEMBL617497,485.0,BAO_0000219,,
2857,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617498,,BAO_0000357,,
2858,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617499,,BAO_0000357,,
2859,14579,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,F,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617500,,BAO_0000019,,
2860,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617501,,BAO_0000357,,
2861,4820,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617502,,BAO_0000357,,
2862,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617503,,BAO_0000357,,
2863,14755,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617504,,BAO_0000357,,
2864,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617406,,BAO_0000357,,
2865,6857,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0,,,,,227,D,9,Expert,1,,CHEMBL617407,,BAO_0000019,,
2866,16209,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617408,,BAO_0000357,,
2867,15363,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617409,,BAO_0000357,,
2868,15363,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617410,,BAO_0000357,,
2869,15363,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617411,,BAO_0000357,,
2870,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617412,,BAO_0000019,,
2871,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0,,,,,227,D,9,Expert,1,,CHEMBL617774,,BAO_0000357,,
2872,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617775,722.0,BAO_0000219,,
2873,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617776,722.0,BAO_0000219,,
2874,6857,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,227,D,9,Expert,1,,CHEMBL617777,449.0,BAO_0000219,,
2875,6857,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,227,D,9,Expert,1,,CHEMBL617778,449.0,BAO_0000219,,
2876,15779,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617779,722.0,BAO_0000219,,
2877,15851,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,B,,,,,,,HEK293,,227,H,8,Expert,1,,CHEMBL617780,722.0,BAO_0000219,,
2878,15779,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617781,722.0,BAO_0000219,,
2879,14157,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617782,722.0,BAO_0000219,,
2880,4540,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617783,722.0,BAO_0000219,,
2881,6166,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617784,,BAO_0000357,,
2882,15779,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617785,722.0,BAO_0000219,,
2883,14391,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,B,,,,,,,HEK293,,227,H,8,Expert,1,,CHEMBL857984,722.0,BAO_0000219,,
2884,3832,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,B,,,,,,,HEK293,,227,H,8,Expert,1,,CHEMBL617786,722.0,BAO_0000219,,
2885,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,B,,,,,,,HEK293,,227,H,8,Expert,1,,CHEMBL617787,722.0,BAO_0000219,,
2886,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617788,722.0,BAO_0000219,,
2887,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617789,722.0,BAO_0000219,,
2888,4199,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617790,722.0,BAO_0000219,,
2889,1883,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,B,,,,,,,CHO-K1,,227,H,8,Expert,1,,CHEMBL617791,485.0,BAO_0000219,,
2890,4321,Binding affinity against 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Expert,1,,CHEMBL617608,,BAO_0000357,,
2891,15146,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617609,722.0,BAO_0000219,,
2892,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617610,722.0,BAO_0000219,,
2893,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617611,722.0,BAO_0000219,,
2894,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617612,722.0,BAO_0000219,,
2895,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617613,722.0,BAO_0000219,,
2896,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,B,,,Oryctolagus cuniculus,9986.0,,,,,227,H,8,Autocuration,1,,CHEMBL617614,,BAO_0000019,,
2897,13463,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,B,,,,,,Stomach,,,12688,H,8,Expert,1,,CHEMBL617615,,BAO_0000019,945.0,
2898,7259,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,B,,,,,,Stomach,,,12688,H,8,Expert,1,,CHEMBL858114,,BAO_0000357,945.0,
2899,7259,Affinity against serotonergic receptor in the isolated rat stomach fundus,B,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL617616,,BAO_0000357,945.0,
2900,7185,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,F,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617617,,BAO_0000019,945.0,
2901,7185,Antagonistic against 5-hydroxytryptamine 2B receptor,F,,,Rattus norvegicus,10116.0,,,,,12688,D,9,Expert,1,,CHEMBL875914,,BAO_0000019,,
2902,13267,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,F,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL617618,,BAO_0000019,945.0,
2903,13735,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617619,,BAO_0000357,945.0,
2904,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,F,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617620,,BAO_0000019,,
2905,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,F,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617621,,BAO_0000019,,
2906,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,F,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617622,,BAO_0000019,,
2907,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617623,,BAO_0000357,945.0,
2908,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617624,,BAO_0000357,945.0,
2909,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617625,,BAO_0000357,945.0,
2910,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617626,,BAO_0000357,945.0,
2911,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL617627,,BAO_0000019,945.0,
2912,16404,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,,,,Stomach,,,12688,H,8,Expert,1,,CHEMBL617628,,BAO_0000019,945.0,
2913,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,F,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL617629,,BAO_0000019,945.0,
2914,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,F,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL858115,,BAO_0000019,945.0,
2915,16404,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,F,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617630,,BAO_0000019,945.0,
2916,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,F,,,,,,Thoracic aorta,,,12688,H,8,Autocuration,1,,CHEMBL617631,,BAO_0000019,1515.0,
2917,7483,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617632,,BAO_0000357,,
2918,7483,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,B,,,,,,,,,12688,H,8,Expert,1,,CHEMBL617633,,BAO_0000357,,
2919,7483,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617634,,BAO_0000357,,
2920,7483,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617635,,BAO_0000357,,
2922,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Autocuration,1,,CHEMBL617637,,BAO_0000019,945.0,
2923,6347,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617638,,BAO_0000357,,
2924,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617639,,BAO_0000357,,
2925,4373,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617640,,BAO_0000357,,
2926,4687,Evaluated for the binding affinity to 5-HT 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617641,,BAO_0000357,,
2927,16946,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617642,,BAO_0000357,,
2928,16633,Binding affinities against 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617643,,BAO_0000357,,
2929,16633,Binding affinities towards 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617644,,BAO_0000357,,
2930,16633,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617645,,BAO_0000357,,
2931,15026,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617646,,BAO_0000357,,
2932,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617647,,BAO_0000357,,
2933,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617648,,BAO_0000357,,
2934,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617875,,BAO_0000357,,
2935,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617876,,BAO_0000357,,
2936,16404,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,B,,,Bos taurus,9913.0,,,,,108,H,8,Expert,1,,CHEMBL617877,,BAO_0000357,,
2937,15026,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,Bos taurus,9913.0,,,,,108,H,8,Expert,1,,CHEMBL617878,,BAO_0000357,,
2938,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617879,,BAO_0000357,,
2939,16312,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,B,,,Cavia porcellus,10141.0,,,,,108,H,8,Autocuration,1,,CHEMBL617880,,BAO_0000019,,
2940,5486,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617881,,BAO_0000357,2435.0,
2941,5254,Binding affinity against 5-HT1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL857073,,BAO_0000357,,
2942,3857,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,F,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617882,449.0,BAO_0000219,,
2943,6857,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0,,,CHO,,108,D,9,Expert,1,,CHEMBL617883,449.0,BAO_0000219,,
2944,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617884,,BAO_0000219,,
2945,6347,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617885,449.0,BAO_0000219,,
2946,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617886,449.0,BAO_0000219,,
2947,16146,Inhibition of human 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL617887,,BAO_0000357,,
2948,3805,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617888,,BAO_0000357,,
2949,3857,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617889,,BAO_0000019,,
2950,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617890,,BAO_0000357,,
2951,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617891,,BAO_0000357,,
2952,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617892,,BAO_0000357,,
2953,4012,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617893,449.0,BAO_0000219,,
2954,6366,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617894,449.0,BAO_0000219,,
2955,15949,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617895,449.0,BAO_0000219,,
2956,17211,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617896,449.0,BAO_0000219,,
2957,6491,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL617897,,BAO_0000357,,
2958,14093,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617898,,BAO_0000019,,
2959,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617899,,BAO_0000019,,
2960,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,B,,,Rattus norvegicus,10116.0,,,CHO,,108,H,8,Expert,1,,CHEMBL617900,449.0,BAO_0000219,,
2961,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617901,,BAO_0000019,,
2962,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617902,,BAO_0000019,,
2963,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617903,,BAO_0000019,,
2964,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617904,,BAO_0000357,,
2965,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617905,,BAO_0000357,,
2966,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617906,,BAO_0000357,,
2967,14755,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617907,,BAO_0000357,,
2968,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617908,,BAO_0000357,,
2969,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL620617,449.0,BAO_0000219,,
2970,6857,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL620618,,BAO_0000019,,
2971,5635,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620619,,BAO_0000357,,
2972,4234,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL620620,,BAO_0000357,,
2973,16209,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620621,,BAO_0000357,,
2974,5778,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,104698,D,7,Autocuration,1,,CHEMBL872920,,BAO_0000249,,
2975,5094,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620622,,BAO_0000223,,
2976,809,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL620623,,BAO_0000019,,
2977,1578,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620624,,BAO_0000019,,
2978,809,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620625,,BAO_0000019,,
2979,12469,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620626,,BAO_0000219,,
2980,14290,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621307,,BAO_0000019,,
2981,14290,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621308,,BAO_0000019,,
2982,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621309,,BAO_0000223,,
2983,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621310,,BAO_0000223,,
2984,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621311,,BAO_0000223,,
2985,15253,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621502,,BAO_0000249,,
2986,15253,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621503,,BAO_0000249,,
2987,11683,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,B,,,,,,,,Membranes,104698,H,6,Autocuration,1,,CHEMBL621504,,BAO_0000249,,
2988,12092,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621505,,BAO_0000223,,
2989,1946,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621506,,BAO_0000019,,
2990,11623,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619781,,BAO_0000223,,
2991,11623,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619782,,BAO_0000223,,
2992,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619783,,BAO_0000019,,
2993,5432,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619784,,BAO_0000019,,
2994,14826,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619785,,BAO_0000249,,
2995,2222,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619786,,BAO_0000223,,
2996,11963,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619787,,BAO_0000019,,
2997,14145,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL872925,,BAO_0000019,,
2998,17819,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619788,,BAO_0000019,,
2999,10394,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619789,,BAO_0000249,,
3000,10394,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619790,,BAO_0000249,,
3001,15034,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619791,,BAO_0000019,,
3002,691,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619792,,BAO_0000019,,
3003,12092,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,B,,,,,,,,Membranes,104698,H,6,Autocuration,1,,CHEMBL619793,,BAO_0000249,,
3004,11752,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619794,,BAO_0000223,,
3005,11752,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,B,,,,,,Brain,,,104698,H,6,Autocuration,1,,CHEMBL619795,,BAO_0000221,955.0,
3006,301,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619796,,BAO_0000019,,
3007,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620448,,BAO_0000223,,
3008,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620449,,BAO_0000223,,
3009,12092,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620450,,BAO_0000223,,
3010,11684,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620451,,BAO_0000223,,
3011,11684,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620631,,BAO_0000223,,
3012,12953,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620632,,BAO_0000019,,
3013,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620633,,BAO_0000019,,
3014,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620634,,BAO_0000223,,
3015,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620635,,BAO_0000019,,
3016,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620636,,BAO_0000218,,
3017,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620637,,BAO_0000218,,
3018,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620638,,BAO_0000218,,
3019,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620639,,BAO_0000218,,
3020,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620640,,BAO_0000218,,
3021,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620641,,BAO_0000218,,
3022,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620642,,BAO_0000218,,
3023,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620643,,BAO_0000218,,
3024,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620644,,BAO_0000218,,
3025,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620645,,BAO_0000218,,
3026,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620646,,BAO_0000218,,
3027,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620647,,BAO_0000218,,
3028,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620648,,BAO_0000218,,
3029,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620649,,BAO_0000218,,
3030,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620650,,BAO_0000218,,
3031,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620651,,BAO_0000218,,
3032,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL872875,,BAO_0000218,,
3033,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620652,,BAO_0000218,,
3034,10609,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620653,,BAO_0000019,,
3035,12861,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL857076,,BAO_0000019,,
3036,12861,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL620654,,BAO_0000019,,
3037,12861,Binding activity radioligand.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620655,,BAO_0000223,,
3038,10728,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,B,,,,,,,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL620656,,BAO_0000249,,
3039,10728,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,B,,,,,,,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL620657,,BAO_0000249,,
3040,5163,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620658,,BAO_0000357,,
3041,5163,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620659,,BAO_0000357,,
3042,6011,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620660,,BAO_0000357,,
3043,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620661,,BAO_0000357,,
3044,5635,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620662,,BAO_0000357,,
3045,5163,Affinity for 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620663,,BAO_0000357,,
3046,6841,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620664,,BAO_0000357,,
3047,6119,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620665,,BAO_0000357,,
3048,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620666,,BAO_0000357,,
3049,1633,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620667,,BAO_0000357,,
3050,1633,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620668,,BAO_0000357,,
3051,4373,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620669,,BAO_0000357,,
3052,6576,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620670,,BAO_0000357,,
3053,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620671,,BAO_0000357,,
3054,12146,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620672,,BAO_0000357,,
3055,12146,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620673,,BAO_0000357,,
3056,16946,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620674,,BAO_0000357,,
3057,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620675,,BAO_0000357,,
3058,16700,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620676,,BAO_0000357,,
3059,3269,Affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL621382,,BAO_0000357,,
3060,1274,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL621383,,BAO_0000357,,
3061,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL621384,,BAO_0000357,,
3062,5834,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,B,,,Bos taurus,9913.0,,,,,144,H,8,Autocuration,1,,CHEMBL621385,,BAO_0000357,,
3063,11147,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,B,,,Bos taurus,9913.0,,,,,144,H,8,Autocuration,1,,CHEMBL617989,,BAO_0000357,,
3064,14145,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Expert,1,,CHEMBL617990,,BAO_0000019,,
3065,10561,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL875085,,BAO_0000221,2116.0,
3066,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617991,,BAO_0000019,,
3067,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617992,,BAO_0000019,,
3068,10561,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617993,,BAO_0000221,2116.0,
3069,11454,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617994,,BAO_0000221,2116.0,
3070,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617995,,BAO_0000019,,
3071,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617996,,BAO_0000019,,
3072,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617997,,BAO_0000019,,
3073,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617998,,BAO_0000019,,
3074,4639,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617999,,BAO_0000019,,
3075,4639,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618000,,BAO_0000019,,
3076,15253,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617815,,BAO_0000221,2116.0,
3077,15253,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617816,,BAO_0000221,2116.0,
3078,11963,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617817,,BAO_0000221,2116.0,
3079,1946,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617818,,BAO_0000221,2116.0,
3080,1946,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617819,,BAO_0000221,2116.0,
3081,12045,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,B,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617820,,BAO_0000223,,
3082,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617821,,BAO_0000221,2116.0,
3083,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617822,,BAO_0000221,2116.0,
3084,273,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617823,,BAO_0000221,2116.0,
3085,188,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617824,,BAO_0000221,2116.0,
3086,12919,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617825,,BAO_0000221,2116.0,
3087,12918,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617826,,BAO_0000221,2116.0,
3088,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617827,,BAO_0000221,2116.0,
3089,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617828,,BAO_0000221,2116.0,
3090,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617829,,BAO_0000221,2116.0,
3091,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617830,,BAO_0000221,2116.0,
3092,1559,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617831,,BAO_0000221,2116.0,
3093,14424,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617832,,BAO_0000221,2116.0,
3094,13181,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,,Cavia porcellus,10141.0,,,,,22226,U,0,Autocuration,1,,CHEMBL617833,,BAO_0000019,,
3095,5486,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL617834,,BAO_0000357,,
3096,6491,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,B,,,Homo sapiens,9606.0,,,,,104714,D,5,Expert,1,,CHEMBL617835,,BAO_0000223,,
3097,6013,Binding affinity towards 5-HT3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL617836,,BAO_0000223,,
3098,12861,Binding activity radioligand.,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL617837,,BAO_0000223,,
3099,12861,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620392,,BAO_0000019,,
3100,5104,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620393,,BAO_0000223,,
3101,5105,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620394,,BAO_0000223,,
3102,5104,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620395,,BAO_0000223,,
3103,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620396,,BAO_0000019,,
3104,13657,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,B,,,,,,,NG108-15,,105030,H,4,Expert,1,,CHEMBL620582,433.0,BAO_0000219,,
3105,10369,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",B,In vivo,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620583,,BAO_0000218,,
3106,10369,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620584,,BAO_0000019,,
3107,12918,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620585,,BAO_0000224,,
3108,12918,Compound was evaluated for the binding affinity at 5- HT3 receptor,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620586,,BAO_0000224,,
3109,10369,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620587,,BAO_0000019,,
3110,773,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620588,,BAO_0000019,,
3111,12918,5-hydroxytryptamine 3 receptor agonism in mouse,F,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620589,,BAO_0000218,,
3112,10561,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620590,,BAO_0000219,,
3113,12827,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617956,,BAO_0000019,,
3114,12827,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617957,,BAO_0000019,,
3115,12918,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617958,,BAO_0000224,,
3116,273,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617959,,BAO_0000219,,
3117,273,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617960,,BAO_0000219,,
3118,10561,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617961,,BAO_0000224,,
3119,5033,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,B,In vitro,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617962,,BAO_0000219,,
3120,16429,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,B,,,,,,,N1E-115,,105030,H,4,Autocuration,1,,CHEMBL617963,339.0,BAO_0000219,,
3121,10322,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,,,,,,11765,H,8,Autocuration,1,,CHEMBL617964,,BAO_0000019,,
3122,14331,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,B,,,,,,,,,11765,H,8,Autocuration,1,,CHEMBL617965,,BAO_0000219,,
3123,13462,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,B,,,Mus musculus,10090.0,,,,,10630,D,9,Autocuration,1,,CHEMBL617966,,BAO_0000357,,
3124,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL857074,,BAO_0000019,,
3125,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,Sus scrofa,9823.0,,,,,144,H,8,Autocuration,1,,CHEMBL617967,,BAO_0000357,,
3126,12861,Binding activity radioligand.,B,,,Sus scrofa,9823.0,,,,,144,H,8,Autocuration,1,,CHEMBL617968,,BAO_0000357,,
3127,10561,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,B,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617969,,BAO_0000223,,
3128,10561,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617970,,BAO_0000223,,
3129,10561,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,B,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617971,,BAO_0000223,,
3130,10561,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617972,,BAO_0000019,,
3131,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617973,,BAO_0000019,,
3132,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617974,,BAO_0000019,,
3133,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Oryctolagus cuniculus,9986.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617975,,BAO_0000221,2116.0,
3134,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617976,,BAO_0000019,,
3135,273,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617977,,BAO_0000019,,
3136,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617978,,BAO_0000019,,
3137,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617979,,BAO_0000019,,
3138,13047,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,B,,,Oryctolagus cuniculus,9986.0,,,CHO,,104714,H,4,Autocuration,1,,CHEMBL617980,449.0,BAO_0000219,,
3139,1650,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617981,,BAO_0000019,,
3140,16288,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL617982,,BAO_0000019,,
3141,16288,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL617983,,BAO_0000357,,
3142,10254,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617984,,BAO_0000019,,
3143,14532,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617985,,BAO_0000019,,
3144,13392,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,In vivo,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617986,,BAO_0000218,948.0,
3145,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617987,,BAO_0000019,948.0,
3146,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617988,,BAO_0000019,948.0,
3147,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617792,,BAO_0000019,948.0,
3148,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617793,,BAO_0000019,948.0,
3149,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617794,,BAO_0000019,,
3150,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617795,,BAO_0000019,,
3151,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617796,,BAO_0000019,,
3152,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617797,,BAO_0000019,,
3153,1089,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),F,In vivo,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617798,,BAO_0000218,,
3154,1089,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617799,,BAO_0000218,,
3155,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617800,,BAO_0000218,,
3156,11454,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,F,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617801,,BAO_0000019,,
3157,12205,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617802,,BAO_0000218,,
3158,1089,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),F,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617803,,BAO_0000019,,
3159,5094,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617804,,BAO_0000019,,
3160,2622,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617805,,BAO_0000019,,
3161,245,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617806,,BAO_0000223,,
3162,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617807,,BAO_0000019,,
3163,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617808,,BAO_0000019,,
3164,3020,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617809,,BAO_0000249,,
3165,1742,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617810,,BAO_0000019,,
3166,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,B,,,,,,Brain,,,104698,H,6,Autocuration,1,,CHEMBL617811,,BAO_0000249,955.0,
3167,17394,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,B,,,,,,Brain,,,104698,H,6,Autocuration,1,,CHEMBL617812,,BAO_0000221,955.0,
3168,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617813,,BAO_0000249,,
3169,14286,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617814,,BAO_0000249,,
3170,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617698,,BAO_0000019,,
3171,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617699,,BAO_0000019,,
3172,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617700,,BAO_0000019,,
3173,14178,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617701,,BAO_0000223,,
3174,15034,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617702,,BAO_0000019,,
3175,1089,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",B,,,,,,,,Membranes,104698,H,6,Autocuration,1,,CHEMBL617703,,BAO_0000249,,
3176,1089,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617704,,BAO_0000019,,
3177,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617705,,BAO_0000223,,
3178,12801,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617706,,BAO_0000223,,
3179,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),B,,,,,,,NG108-15,,104698,H,6,Autocuration,1,,CHEMBL617707,433.0,BAO_0000219,,
3180,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,B,,,,,,,NG108-15,,104698,H,6,Autocuration,1,,CHEMBL617708,433.0,BAO_0000219,,
3181,15194,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617709,,BAO_0000019,,
3182,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617710,,BAO_0000019,,
3183,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL882925,,BAO_0000019,,
3184,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617711,,BAO_0000019,,
3185,10610,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617712,,BAO_0000019,,
3186,10355,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,F,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617713,,BAO_0000019,,
3187,691,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617714,,BAO_0000019,,
3188,10611,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617715,,BAO_0000218,,
3189,12801,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617716,,BAO_0000218,,
3190,10609,Inhibition of 5-HT evoked reflex bradycardia in rat.,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617717,,BAO_0000218,,
3191,11454,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617718,,BAO_0000218,,
3192,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617719,,BAO_0000218,,
3193,11454,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617720,,BAO_0000218,,
3194,11454,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617721,,BAO_0000218,,
3195,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617722,,BAO_0000218,,
3196,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617723,,BAO_0000218,,
3197,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617724,,BAO_0000218,,
3198,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617725,,BAO_0000218,,
3199,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617726,,BAO_0000218,,
3200,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617727,,BAO_0000218,,
3201,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617728,,BAO_0000218,,
3202,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617729,,BAO_0000218,,
3203,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617730,,BAO_0000218,,
3204,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617731,,BAO_0000218,,
3205,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617732,,BAO_0000218,,
3206,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617733,,BAO_0000218,,
3207,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617734,,BAO_0000218,,
3208,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL872874,,BAO_0000218,,
3209,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617735,,BAO_0000218,,
3210,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617736,,BAO_0000218,,
3211,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617737,,BAO_0000218,,
3212,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617738,,BAO_0000218,,
3213,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617739,,BAO_0000218,,
3214,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617740,,BAO_0000218,,
3215,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617741,,BAO_0000218,,
3216,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617742,,BAO_0000218,,
3217,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617743,,BAO_0000218,,
3218,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617744,,BAO_0000218,,
3219,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617745,,BAO_0000218,,
3220,670,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617746,,BAO_0000218,,
3221,670,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617747,,BAO_0000218,,
3222,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617748,,BAO_0000218,,
3223,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618909,,BAO_0000218,,
3224,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618910,,BAO_0000218,,
3225,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618911,,BAO_0000218,,
3226,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618912,,BAO_0000218,,
3227,10322,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618913,,BAO_0000218,,
3228,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618914,,BAO_0000019,,
3229,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618915,,BAO_0000019,,
3230,15412,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL618916,,BAO_0000223,,
3231,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618917,,BAO_0000019,,
3232,15412,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,B,,,,,,Hippocampus,,,104698,D,7,Intermediate,1,,CHEMBL618918,,BAO_0000221,10000000.0,
3233,15412,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL618919,,BAO_0000019,,
3234,17394,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL618920,,BAO_0000019,,
3235,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618921,,BAO_0000223,,
3236,12457,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618922,,BAO_0000019,,
3237,12205,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618923,,BAO_0000019,,
3238,14532,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618924,,BAO_0000019,,
3239,1122,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618925,,BAO_0000019,,
3240,5094,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618926,,BAO_0000019,,
3241,809,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618927,,BAO_0000221,2116.0,
3242,809,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618928,,BAO_0000221,2116.0,
3243,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618929,,BAO_0000221,2116.0,
3244,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618930,,BAO_0000221,2116.0,
3245,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618931,,BAO_0000221,2116.0,
3246,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619594,,BAO_0000221,2116.0,
3247,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619595,,BAO_0000221,2116.0,
3248,13961,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619596,,BAO_0000221,2116.0,
3249,13961,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619755,,BAO_0000221,2116.0,
3250,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619756,,BAO_0000221,2116.0,
3251,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619757,,BAO_0000221,2116.0,
3252,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619758,,BAO_0000221,2116.0,
3253,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619759,,BAO_0000221,2116.0,
3254,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619760,,BAO_0000221,2116.0,
3255,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619761,,BAO_0000221,2116.0,
3256,14290,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619762,,BAO_0000221,2116.0,
3257,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619763,,BAO_0000221,2116.0,
3258,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL617868,,BAO_0000221,2116.0,
3259,15034,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL617869,,BAO_0000357,,
3260,5094,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL882926,,BAO_0000249,2435.0,
3261,5094,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617870,,BAO_0000249,2435.0,
3262,5399,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617871,,BAO_0000357,2435.0,
3263,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617872,,BAO_0000357,2435.0,
3264,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617873,,BAO_0000357,2435.0,
3265,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617874,,BAO_0000357,2435.0,
3266,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619067,,BAO_0000221,2116.0,
3267,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619068,,BAO_0000221,2116.0,
3268,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619069,,BAO_0000221,2116.0,
3269,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619070,,BAO_0000357,,
3270,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619071,,BAO_0000357,,
3271,15034,Agonistic activity against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619072,,BAO_0000019,,
3272,15034,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619073,,BAO_0000019,,
3273,12918,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619074,,BAO_0000019,,
3274,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619075,,BAO_0000357,,
3275,17394,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619076,,BAO_0000357,2435.0,
3276,15034,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619077,,BAO_0000357,2435.0,
3277,5094,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619078,,BAO_0000249,2435.0,
3278,5094,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619079,,BAO_0000249,2435.0,
3279,17358,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,B,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619080,,BAO_0000221,2116.0,
3280,12953,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Expert,1,,CHEMBL619081,,BAO_0000357,,
3281,12953,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619082,,BAO_0000357,,
3282,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619083,,BAO_0000357,,
3283,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619084,,BAO_0000357,,
3284,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL859397,,BAO_0000221,2116.0,
3285,12918,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619085,,BAO_0000221,2116.0,
3286,12919,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619086,,BAO_0000221,2116.0,
3287,273,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619087,,BAO_0000221,2116.0,
3288,273,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619088,,BAO_0000221,2116.0,
3289,13181,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619089,,BAO_0000357,,
3290,13181,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,B,,,Cavia porcellus,10141.0,,,,,168,H,8,Autocuration,1,,CHEMBL619090,,BAO_0000357,,
3291,15034,Antagonistic activity against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619091,,BAO_0000019,,
3292,5033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619092,,BAO_0000357,,
3293,1980,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619093,,BAO_0000019,,
3294,13181,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,B,,,Cavia porcellus,10141.0,,,HEK293,,168,H,8,Autocuration,1,,CHEMBL619094,722.0,BAO_0000219,,
3295,14287,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619095,,BAO_0000019,,
3296,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL857988,,BAO_0000357,,
3297,15316,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619096,,BAO_0000357,,
3298,16429,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619097,,BAO_0000357,2435.0,
3299,14818,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,B,,,Cavia porcellus,10141.0,,Hippocampus,,,20033,D,9,Intermediate,1,,CHEMBL619098,,BAO_0000221,10000000.0,
3300,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619751,,BAO_0000357,,
3301,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619752,,BAO_0000357,,
3302,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL875096,,BAO_0000221,2116.0,
3303,5486,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL619004,,BAO_0000357,,
3304,16209,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL619005,,BAO_0000357,,
3305,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL619006,,BAO_0000019,,
3306,4199,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,B,,,,,,,HeLa,,168,H,8,Autocuration,1,,CHEMBL619007,308.0,BAO_0000219,,
3307,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL619008,,BAO_0000357,,
3308,5213,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL619009,,BAO_0000357,,
3309,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",B,,,,,,,HeLa,,168,H,8,Autocuration,1,,CHEMBL619010,308.0,BAO_0000219,,
3310,17358,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,B,,,,,,,,,10622,H,8,Autocuration,1,,CHEMBL619011,,BAO_0000357,,
3311,17358,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,B,,,,,,,,,10622,H,8,Autocuration,1,,CHEMBL619012,,BAO_0000357,,
3312,16946,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,B,,,,,,,,,10622,H,8,Autocuration,1,,CHEMBL619013,,BAO_0000219,,
3313,17358,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,B,,,,,,,,,10622,H,8,Autocuration,1,,CHEMBL619014,,BAO_0000357,,
3314,268,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,F,,,,,,Cardiac atrium,,,11249,H,8,Autocuration,1,,CHEMBL857503,,BAO_0000019,2081.0,
3315,268,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,F,,,,,,Cardiac atrium,,,11249,H,8,Autocuration,1,,CHEMBL619015,,BAO_0000019,2081.0,
3316,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,11249,H,8,Autocuration,1,,CHEMBL619016,,BAO_0000357,,
3317,14875,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,B,,,,,,Hippocampus,,,11249,H,8,Autocuration,1,,CHEMBL619017,,BAO_0000221,10000000.0,
3318,13267,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,B,,,Sus scrofa,9823.0,,Hippocampus,,,168,H,8,Autocuration,1,,CHEMBL619018,,BAO_0000221,10000000.0,
3319,13047,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,168,H,8,Autocuration,1,,CHEMBL619019,,BAO_0000019,,
3320,1650,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL619020,,BAO_0000357,,
3321,567,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619021,,BAO_0000019,,
3322,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619022,,BAO_0000357,,
3323,188,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619023,,BAO_0000357,,
3324,670,lntrinsic activity relative to 5-HT receptor,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619024,,BAO_0000019,,
3325,204,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619025,,BAO_0000019,,
3326,1946,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL619026,,BAO_0000019,,
3327,6398,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619027,,BAO_0000019,,
3328,6398,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619028,,BAO_0000019,,
3329,17358,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619029,,BAO_0000019,,
3330,6398,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619030,,BAO_0000019,,
3331,11752,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,B,,,,,,,,,10623,H,8,Expert,1,,CHEMBL619031,,BAO_0000357,,
3332,809,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619032,,BAO_0000019,,
3333,14178,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL619033,,BAO_0000357,,
3334,567,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619034,,BAO_0000357,,
3335,1946,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619035,,BAO_0000357,,
3336,1946,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619036,,BAO_0000357,,
3337,13961,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,B,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL619037,,BAO_0000019,,
3338,6238,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,B,,,,,,Striatum,,,10623,H,8,Autocuration,1,,CHEMBL619038,,BAO_0000249,2435.0,
3339,14290,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619039,,BAO_0000249,,
3340,14290,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,B,,,,,,,,,10623,H,8,Expert,1,,CHEMBL619040,,BAO_0000249,,
3341,809,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,,Rattus norvegicus,10116.0,,Striatum,,,10623,D,9,Expert,1,,CHEMBL619041,,BAO_0000019,2435.0,
3342,1578,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,,,,,Striatum,,,10623,H,8,Autocuration,1,,CHEMBL619042,,BAO_0000019,2435.0,
3343,16709,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL619043,,BAO_0000249,2435.0,
3344,1946,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL619044,,BAO_0000019,2435.0,
3345,15253,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL619045,,BAO_0000249,2435.0,
3346,4535,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL619046,,BAO_0000249,2435.0,
3347,13961,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,B,,,,,,,,,10623,H,8,Expert,1,,CHEMBL619047,,BAO_0000249,,
3348,17358,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,F,,,,,,Brain,,,10623,H,8,Autocuration,1,,CHEMBL619048,,BAO_0000221,955.0,
3349,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL859398,,BAO_0000019,,
3350,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619049,,BAO_0000019,,
3351,670,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL857886,,BAO_0000019,,
3352,670,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619050,,BAO_0000019,,
3353,1317,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL620591,,BAO_0000019,,
3354,12936,Binding affinity against rat 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL620592,,BAO_0000357,,
3355,4535,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL620593,,BAO_0000249,2435.0,
3356,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,F,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL620594,,BAO_0000019,,
3357,14424,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL875079,,BAO_0000019,,
3358,14424,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL620595,,BAO_0000019,,
3359,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,F,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL620596,,BAO_0000019,,
3360,14424,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL620597,,BAO_0000019,,
3361,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL620598,,BAO_0000019,,
3362,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL620599,,BAO_0000218,,
3363,14424,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL620600,,BAO_0000019,,
3364,1980,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,F,,,Rattus norvegicus,10116.0,,,,,168,H,8,Autocuration,1,,CHEMBL620601,,BAO_0000019,,
3365,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620602,,BAO_0000019,,
3366,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620603,,BAO_0000357,,
3367,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620604,,BAO_0000357,,
3368,17358,Compound was tested for 5-hydroxytryptamine 4 binding affinity,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620605,,BAO_0000357,,
3369,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620606,,BAO_0000357,,
3370,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620607,,BAO_0000019,,
3371,16117,In vitro binding affinity towards 5-HT4 receptor was determined,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620608,,BAO_0000357,,
3372,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620609,,BAO_0000019,,
3373,17358,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620610,,BAO_0000019,,
3374,17358,Tested for selectivity for 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620611,,BAO_0000357,,
3375,17358,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620612,,BAO_0000357,,
3376,17358,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620613,,BAO_0000357,,
3377,17358,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620614,,BAO_0000357,,
3378,1274,Binding affinity against 5-Hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Expert,1,,CHEMBL620615,,BAO_0000357,,
3379,10728,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,B,,,,,,,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL857075,,BAO_0000249,,
3380,11695,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,B,,,,,,,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL620616,,BAO_0000249,,
3381,11695,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,B,,,,,,,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL619411,,BAO_0000249,,
3382,12490,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619412,,BAO_0000019,,
3383,11828,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619413,,BAO_0000019,,
3384,12253,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,B,,,,,,Hippocampus,,,104698,H,6,Autocuration,1,,CHEMBL619414,,BAO_0000221,10000000.0,
3385,10561,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619415,,BAO_0000019,,
3386,10561,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619416,,BAO_0000019,,
3387,14432,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619417,,BAO_0000019,,
3388,12936,Binding affinity against rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619418,,BAO_0000223,,
3389,1274,Binding affinity against 5-Hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619419,,BAO_0000223,,
3390,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619420,,BAO_0000019,,
3391,670,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619421,,BAO_0000249,,
3392,968,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619422,,BAO_0000019,,
3393,14287,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619423,,BAO_0000019,,
3394,567,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL875080,,BAO_0000019,,
3395,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619424,,BAO_0000019,,
3396,14826,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619425,,BAO_0000249,,
3397,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619426,,BAO_0000223,,
3398,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619427,,BAO_0000223,,
3399,10394,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619645,,BAO_0000223,,
3400,13657,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",B,,,,,,,,,10576,D,9,Expert,1,,CHEMBL619646,,BAO_0000249,,
3401,1879,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,F,,,,,,Brain,,,12020,H,8,Autocuration,1,,CHEMBL619647,,BAO_0000221,955.0,
3402,1879,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,F,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL619648,,BAO_0000019,,
3403,1879,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,F,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL619165,,BAO_0000019,,
3404,204,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,F,In vivo,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620719,,BAO_0000218,,
3405,1879,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL872924,,BAO_0000019,,
3406,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620720,,BAO_0000357,,
3407,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620721,,BAO_0000019,,
3408,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620722,,BAO_0000019,,
3409,10641,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620723,,BAO_0000019,,
3410,773,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620724,,BAO_0000019,,
3411,11952,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620725,,BAO_0000249,,
3412,14145,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,F,,,Rattus norvegicus,10116.0,,,,,12020,D,9,Autocuration,1,,CHEMBL620726,,BAO_0000019,,
3413,17066,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Expert,1,,CHEMBL620727,,BAO_0000357,,
3414,6398,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620728,,BAO_0000223,,
3415,10321,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620729,,BAO_0000019,,
3416,511,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL858288,,BAO_0000019,,
3417,4639,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620730,,BAO_0000223,,
3418,4639,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620731,,BAO_0000223,,
3419,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL620732,,BAO_0000019,,
3420,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618042,,BAO_0000019,,
3421,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618043,,BAO_0000019,,
3422,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618044,,BAO_0000223,,
3423,268,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618045,,BAO_0000019,,
3424,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618046,,BAO_0000223,,
3425,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618047,,BAO_0000019,,
3426,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL875084,,BAO_0000019,,
3427,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618048,,BAO_0000019,,
3428,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618049,,BAO_0000223,,
3429,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619764,,BAO_0000019,,
3430,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619765,,BAO_0000019,,
3431,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619766,,BAO_0000019,,
3432,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619767,,BAO_0000223,,
3433,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619768,,BAO_0000223,,
3434,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619769,,BAO_0000019,,
3435,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619770,,BAO_0000223,,
3436,5067,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619771,,BAO_0000223,,
3437,14331,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619772,,BAO_0000219,,
3438,5067,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619773,,BAO_0000223,,
3439,6179,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,B,,,,,,,NG108-15,,104714,H,4,Autocuration,1,,CHEMBL619774,433.0,BAO_0000219,,
3440,4265,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL875083,,BAO_0000019,,
3441,4265,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,B,,,,,,,NG108-15,,104714,H,4,Autocuration,1,,CHEMBL620718,433.0,BAO_0000219,,
3442,17358,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618127,,BAO_0000223,,
3443,17358,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618128,,BAO_0000223,,
3444,13628,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,B,In vitro,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618129,,BAO_0000219,,
3445,4612,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618130,,BAO_0000223,,
3446,17358,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618131,,BAO_0000019,,
3447,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618132,,BAO_0000019,,
3448,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618133,,BAO_0000019,,
3449,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618134,,BAO_0000019,,
3450,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618135,,BAO_0000019,,
3451,511,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618136,,BAO_0000223,,
3452,1479,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618137,,BAO_0000223,,
3453,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618138,,BAO_0000223,,
3454,12146,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618139,,BAO_0000223,,
3455,12146,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618140,,BAO_0000223,,
3456,13969,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618141,,BAO_0000223,,
3457,13392,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL873478,,BAO_0000357,,
3458,13392,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618142,,BAO_0000223,,
3459,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618143,,BAO_0000357,,
3460,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618144,,BAO_0000357,,
3461,16655,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618145,,BAO_0000357,,
3462,13020,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618146,,BAO_0000223,,
3463,13021,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618147,,BAO_0000223,,
3464,13020,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618148,,BAO_0000223,,
3465,10321,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618149,,BAO_0000019,,
3466,15818,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL872927,,BAO_0000357,,
3467,15818,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618150,,BAO_0000357,,
3468,17358,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618151,,BAO_0000357,,
3469,2222,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL875094,,BAO_0000357,,
3470,10322,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618152,,BAO_0000019,,
3471,16117,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618153,,BAO_0000357,,
3472,17200,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618888,,BAO_0000357,,
3473,17358,Tested for 5-hydroxytryptamine 3 receptor agonist activity,F,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618889,,BAO_0000019,,
3474,16700,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618890,,BAO_0000357,,
3475,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618891,,BAO_0000019,,
3476,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL619054,,BAO_0000019,,
3477,12409,Binding affinity against the 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619055,,BAO_0000223,,
3478,4365,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL619056,,BAO_0000357,,
3479,4365,Percent efficacy against 5-hydroxytryptamine 3A receptor,F,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL619057,,BAO_0000019,,
3480,4365,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL619058,,BAO_0000357,,
3481,6769,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,F,,,Rattus norvegicus,10116.0,,,Oocytes,,12020,D,9,Expert,1,,CHEMBL619059,,BAO_0000219,,
3482,6769,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,F,,,Rattus norvegicus,10116.0,,,Oocytes,,12020,D,9,Expert,1,,CHEMBL619060,,BAO_0000219,,
3483,6769,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,F,,,Rattus norvegicus,10116.0,,,Oocytes,,12020,D,9,Expert,1,,CHEMBL875095,,BAO_0000219,,
3484,809,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619061,,BAO_0000221,2116.0,
3485,809,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619062,,BAO_0000221,2116.0,
3486,14290,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619063,,BAO_0000019,,
3487,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619064,,BAO_0000221,2116.0,
3488,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619065,,BAO_0000357,,
3489,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,B,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619066,,BAO_0000221,2116.0,
3490,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,B,,,,,,Ileum,,,10209,H,8,Autocuration,1,,CHEMBL619775,,BAO_0000221,2116.0,
3491,3269,Affinity against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619776,,BAO_0000357,,
3492,7721,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619777,,BAO_0000224,,
3493,7721,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619778,,BAO_0000224,,
3494,9117,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,B,,,Cavia porcellus,10141.0,,Ileum,,,104841,H,4,Autocuration,1,,CHEMBL619779,,BAO_0000221,2116.0,
3495,7721,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619780,,BAO_0000224,,
3496,7721,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619166,,BAO_0000224,,
3497,15796,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619167,,BAO_0000019,,
3498,15796,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619168,,BAO_0000019,,
3499,15650,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,B,,,Homo sapiens,9606.0,,Cardiac atrium,,,168,D,9,Expert,1,,CHEMBL619169,,BAO_0000219,2081.0,
3500,15650,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,B,,,Homo sapiens,9606.0,,Cardiac atrium,,,168,D,9,Expert,1,,CHEMBL619170,,BAO_0000219,2081.0,
3501,6866,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",F,,,Homo sapiens,9606.0,,,,,104841,D,5,Autocuration,1,,CHEMBL619171,,BAO_0000019,,
3502,15650,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",F,,,Homo sapiens,9606.0,,Cardiac atrium,,,168,D,9,Expert,1,,CHEMBL619172,,BAO_0000219,2081.0,
3503,10063,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,B,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619173,,BAO_0000019,,
3504,12665,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,B,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619174,,BAO_0000019,,
3505,7504,5-hydroxytryptamine receptor binding affinity was determined in rats,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619175,,BAO_0000019,,
3506,7504,Binding affinity at rat 5-hydroxytryptamine receptor.,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619176,,BAO_0000224,,
3507,7038,Affinity against 5-hydroxytryptamine receptors in rat fundus model,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619177,,BAO_0000019,,
3508,7626,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619178,,BAO_0000224,,
3509,7626,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619179,,BAO_0000224,,
3510,7185,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,F,,,,,,Stomach,,,104705,H,4,Autocuration,1,,CHEMBL619180,,BAO_0000019,945.0,
3511,7185,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,F,,,,,,Stomach,,,104705,H,4,Autocuration,1,,CHEMBL619181,,BAO_0000019,945.0,
3512,7185,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619182,,BAO_0000019,,
3513,6960,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619183,,BAO_0000224,,
3514,6960,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619184,,BAO_0000224,,
3515,12416,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL619185,,BAO_0000221,10000000.0,
3516,15753,Binding affinity for rat 5-hydroxytryptamine transporter.,B,,,,,,,,,12198,H,8,Expert,1,,CHEMBL619186,,BAO_0000357,,
3517,8062,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619187,,BAO_0000019,,
3518,9036,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619188,,BAO_0000019,,
3519,15067,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619189,,BAO_0000224,,
3520,15753,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,F,,,Rattus norvegicus,10116.0,,Brain,,,12198,D,9,Expert,1,,CHEMBL619190,,BAO_0000019,955.0,
3521,15753,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,F,,,Rattus norvegicus,10116.0,,Cerebellum,,,12198,D,9,Expert,1,,CHEMBL619191,,BAO_0000221,2037.0,
3522,15295,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619192,,BAO_0000019,,
3523,6347,Percent binding affinity against 5-hydroxytryptamine receptor,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619193,,BAO_0000224,,
3524,6763,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL619194,,BAO_0000019,,
3525,12092,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619195,,BAO_0000224,,
3526,1579,Affinity against 5-hydroxytryptamine receptor was determined,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619196,,BAO_0000224,,
3527,1579,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,B,,,Rattus norvegicus,10116.0,,Stomach,,,104705,D,5,Autocuration,1,,CHEMBL619197,,BAO_0000019,945.0,
3528,5963,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,In vitro,,Homo sapiens,9606.0,,,,,121,D,9,Expert,1,,CHEMBL619198,,BAO_0000219,,
3529,5963,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,In vitro,,Homo sapiens,9606.0,,,,,121,D,9,Expert,1,,CHEMBL875081,,BAO_0000219,,
3530,5030,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,B,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL884712,,BAO_0000357,,
3531,15796,Inhibition of 5-hydroxytryptamine reuptake,B,,,,,,,,,121,H,8,Expert,1,,CHEMBL884710,,BAO_0000357,,
3532,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",F,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL619199,,BAO_0000019,,
3533,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",F,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL619200,,BAO_0000019,,
3534,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",F,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL619201,,BAO_0000019,,
3535,12409,Tested for 5-hydroxytryptamine receptor uptake,F,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL619202,,BAO_0000019,,
3536,16909,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL619203,449.0,BAO_0000219,,
3537,16909,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL619204,,BAO_0000019,,
3538,15629,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,B,,,Homo sapiens,9606.0,,,,,10576,H,8,Autocuration,1,,CHEMBL619205,,BAO_0000249,,
3539,15629,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL619206,,BAO_0000357,,
3540,15629,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL619207,,BAO_0000249,,
3541,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619208,,BAO_0000019,2435.0,
3542,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619209,,BAO_0000019,2435.0,
3543,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619210,,BAO_0000019,2435.0,
3544,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619211,,BAO_0000019,2435.0,
3545,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619212,,BAO_0000019,2435.0,
3546,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620681,,BAO_0000019,2435.0,
3547,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620682,,BAO_0000019,2435.0,
3548,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620683,,BAO_0000019,2435.0,
3549,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620684,,BAO_0000019,2435.0,
3550,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620685,,BAO_0000019,2435.0,
3551,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620686,,BAO_0000019,2435.0,
3552,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620687,,BAO_0000019,349.0,
3553,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620688,,BAO_0000019,349.0,
3554,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620689,,BAO_0000019,349.0,
3555,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620690,,BAO_0000019,349.0,
3556,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620691,,BAO_0000019,349.0,
3557,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620692,,BAO_0000019,349.0,
3558,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620693,,BAO_0000019,349.0,
3559,1274,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Expert,1,,CHEMBL620694,,BAO_0000357,,
3560,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL857986,,BAO_0000019,,
3561,14532,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620695,,BAO_0000357,,
3562,16989,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Expert,1,,CHEMBL620696,,BAO_0000357,,
3563,17200,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620697,,BAO_0000357,,
3564,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620698,,BAO_0000357,,
3565,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620699,,BAO_0000357,,
3566,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620700,,BAO_0000357,,
3567,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168,H,8,Autocuration,1,,CHEMBL620701,643.0,BAO_0000219,,
3568,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168,H,8,Autocuration,1,,CHEMBL875082,643.0,BAO_0000219,,
3569,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168,H,8,Autocuration,1,,CHEMBL620702,643.0,BAO_0000219,,
3570,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168,H,8,Autocuration,1,,CHEMBL620703,643.0,BAO_0000219,,
3571,17046,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,,,,C6,,168,H,8,Autocuration,1,,CHEMBL620704,673.0,BAO_0000219,,
3572,17046,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,,,,C6,,168,H,8,Expert,1,,CHEMBL620705,673.0,BAO_0000219,,
3573,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,B,,,,,,,C6,,168,H,8,Expert,1,,CHEMBL620706,673.0,BAO_0000219,,
3574,17046,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,B,,,,,,,C6,,168,H,8,Expert,1,,CHEMBL620707,673.0,BAO_0000219,,
3575,17066,Binding affinity towards 5-hydroxytryptamine 5 receptor,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL620708,,BAO_0000357,,
3576,17200,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL620709,,BAO_0000357,,
3577,16146,Binding affinity against 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620710,,BAO_0000357,,
3578,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,B,,,,,,,CHO,,10624,H,8,Autocuration,1,,CHEMBL620711,449.0,BAO_0000219,,
3579,6491,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620712,,BAO_0000357,,
3580,17066,Binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620713,,BAO_0000357,,
3581,17066,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620714,,BAO_0000357,,
3582,4234,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620715,,BAO_0000357,,
3583,6013,Binding affinity towards 5-HT5A receptor,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL620716,,BAO_0000357,,
3584,17175,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL620717,,BAO_0000357,,
3585,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL618072,,BAO_0000357,,
3586,6166,Binding affinity towards cloned human 5-HT5A receptor was determined,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL857987,,BAO_0000357,,
3587,15779,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,10624,H,8,Autocuration,1,,CHEMBL618073,722.0,BAO_0000219,,
3588,15779,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,,,,HEK293,,10624,H,8,Autocuration,1,,CHEMBL618074,722.0,BAO_0000219,,
3589,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),B,,,,,,,HEK293,,10624,H,8,Autocuration,1,,CHEMBL618075,722.0,BAO_0000219,,
3590,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL618076,,BAO_0000357,,
3591,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL618077,,BAO_0000357,,
3592,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL618078,,BAO_0000357,,
3593,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL881821,,BAO_0000357,,
3594,17066,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL618079,,BAO_0000357,,
3595,17175,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,,,,,,10625,H,8,Expert,1,,CHEMBL618080,,BAO_0000357,,
3596,16190,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,,,,HEK293,,10576,H,8,Autocuration,1,,CHEMBL618081,722.0,BAO_0000219,,
3597,16190,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,,,,HEK293,,10626,H,8,Autocuration,1,,CHEMBL618082,722.0,BAO_0000219,,
3598,4820,Binding affinity towards 5-HT5a receptor,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL618083,,BAO_0000357,,
3599,17066,Binding affinity towards 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL618084,,BAO_0000357,,
3600,17066,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL618085,,BAO_0000357,,
3601,17175,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL618086,,BAO_0000357,,
3602,16633,Binding affinities against 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL875092,,BAO_0000357,,
3603,16633,Binding affinities towards 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL618087,,BAO_0000357,,
3604,16700,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL872926,,BAO_0000357,,
3605,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618088,,BAO_0000019,,
3606,5486,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618089,,BAO_0000223,,
3607,16146,Inhibition of human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618090,,BAO_0000357,,
3608,17273,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618091,,BAO_0000357,,
3609,17687,Inhibition against human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618092,,BAO_0000357,,
3610,6491,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618093,,BAO_0000357,,
3611,16190,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,B,,,,,,,HeLa,,10627,H,8,Expert,1,,CHEMBL618094,308.0,BAO_0000219,,
3612,17066,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618095,,BAO_0000357,,
3613,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL875093,,BAO_0000357,,
3614,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618096,,BAO_0000357,,
3615,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618118,,BAO_0000357,,
3616,3555,Binding affinity against 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618119,,BAO_0000357,,
3617,5808,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL618120,,BAO_0000357,,
3618,6013,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618121,,BAO_0000357,,
3619,15818,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",B,,,,,,,HEK293,,10627,H,8,Expert,1,,CHEMBL618122,722.0,BAO_0000219,,
3620,16209,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618123,,BAO_0000357,,
3621,3935,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,B,,,,,,,HEK293,,10627,H,8,Expert,1,,CHEMBL618124,722.0,BAO_0000219,,
3622,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618125,,BAO_0000357,,
3623,3805,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,10627,D,9,Expert,1,,CHEMBL618126,722.0,BAO_0000219,,
3624,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL618236,,BAO_0000019,,
3625,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL618237,,BAO_0000019,,
3626,6786,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,B,,,,,,,COS-7,,10627,H,8,Expert,1,,CHEMBL618238,643.0,BAO_0000219,,
3627,4234,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618239,,BAO_0000357,,
3628,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618240,,BAO_0000019,,
3629,17200,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618241,,BAO_0000357,,
3630,17451,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,,,,,,HEK293,,10627,H,8,Autocuration,1,,CHEMBL859399,722.0,BAO_0000219,,
3631,3935,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,F,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618242,,BAO_0000019,,
3632,5033,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL857991,,BAO_0000357,,
3633,4540,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL619951,,BAO_0000357,,
3634,4540,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0,,,HeLa,,10627,D,9,Expert,1,,CHEMBL619952,308.0,BAO_0000219,,
3635,4540,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0,,,HeLa,,10627,D,9,Expert,1,,CHEMBL619953,308.0,BAO_0000219,,
3636,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL619954,308.0,BAO_0000219,,
3637,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL619955,308.0,BAO_0000219,,
3638,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL619956,308.0,BAO_0000219,,
3639,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,10627,H,8,Autocuration,1,,CHEMBL619957,449.0,BAO_0000219,,
3640,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,10627,H,8,Autocuration,1,,CHEMBL619958,722.0,BAO_0000219,,
3641,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,B,,,,,,,HEK293,,10627,H,8,Autocuration,1,,CHEMBL620627,722.0,BAO_0000219,,
3642,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,,,,HEK293,,10627,H,8,Autocuration,1,,CHEMBL620628,722.0,BAO_0000219,,
3643,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620629,308.0,BAO_0000219,,
3644,6166,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620630,,BAO_0000357,,
3645,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620782,308.0,BAO_0000219,,
3646,15316,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620783,,BAO_0000357,,
3647,4199,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620784,,BAO_0000357,,
3648,15146,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,B,,,,,,,HeLa,,10627,H,8,Expert,1,,CHEMBL620785,308.0,BAO_0000219,,
3649,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL857992,,BAO_0000357,,
3650,16429,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620786,,BAO_0000219,,
3651,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620787,308.0,BAO_0000219,,
3652,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620788,308.0,BAO_0000219,,
3653,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620789,308.0,BAO_0000219,,
3654,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620790,308.0,BAO_0000219,,
3655,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,B,,,,,,,CHO,,10628,H,8,Autocuration,1,,CHEMBL620791,449.0,BAO_0000219,,
3656,14423,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,B,,,,,,,,,10628,H,8,Autocuration,1,,CHEMBL620792,,BAO_0000019,,
3657,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10628,H,8,Autocuration,1,,CHEMBL620793,,BAO_0000357,,
3658,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,B,,,,,,,,,10628,H,8,Autocuration,1,,CHEMBL620794,,BAO_0000357,,
3659,16190,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,10627,D,9,Autocuration,1,,CHEMBL620795,308.0,BAO_0000219,,
3660,4820,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620796,,BAO_0000357,,
3661,4639,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620797,,BAO_0000357,,
3662,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL620798,,BAO_0000019,,
3663,6011,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620799,,BAO_0000357,,
3664,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620800,,BAO_0000357,,
3665,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620801,,BAO_0000357,,
3666,5014,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL875100,,BAO_0000357,,
3667,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620802,,BAO_0000357,,
3668,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,F,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620803,,BAO_0000019,,
3669,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620804,,BAO_0000019,,
3670,4373,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620805,,BAO_0000357,,
3671,4687,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620806,,BAO_0000357,,
3672,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620807,,BAO_0000357,,
3673,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620808,,BAO_0000357,,
3674,16633,Binding affinities against 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620809,,BAO_0000357,,
3675,16633,Binding affinities towards 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620810,,BAO_0000357,,
3676,17066,Binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL620811,,BAO_0000357,,
3677,16700,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620812,,BAO_0000357,,
3678,3269,Affinity against 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620813,,BAO_0000357,,
3679,5486,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620814,,BAO_0000357,,
3680,16146,Inhibition of human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620815,,BAO_0000357,,
3681,5014,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL620816,722.0,BAO_0000219,,
3682,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620817,,BAO_0000357,,
3683,3805,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620818,,BAO_0000357,,
3684,5014,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,B,,,,,,,HEK293,,10209,H,8,Expert,1,,CHEMBL620819,722.0,BAO_0000219,,
3685,6491,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620820,,BAO_0000357,,
3686,16190,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,B,,,,,,,CHO,,10209,H,8,Autocuration,1,,CHEMBL620821,449.0,BAO_0000219,,
3687,17066,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620822,,BAO_0000357,,
3688,17066,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620823,,BAO_0000357,,
3689,3555,Binding affinity against 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620824,,BAO_0000357,,
3690,6588,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,B,,,,,,,CHO,,10209,H,8,Expert,1,,CHEMBL620825,449.0,BAO_0000219,,
3691,15463,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL872930,,BAO_0000357,,
3692,6013,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620826,,BAO_0000357,,
3693,16209,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620827,,BAO_0000357,,
3694,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620828,,BAO_0000357,,
3695,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620829,,BAO_0000357,,
3696,5014,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,B,,,,,,,HEK293,,10209,H,8,Expert,1,,CHEMBL620830,722.0,BAO_0000219,,
3697,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL620831,,BAO_0000019,,
3698,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL620832,,BAO_0000019,,
3699,4234,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL621548,,BAO_0000357,,
3700,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL621549,,BAO_0000019,,
3701,17200,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL621550,,BAO_0000357,,
3702,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,B,,,,,,,CHO,,10209,H,8,Autocuration,1,,CHEMBL621551,449.0,BAO_0000219,,
3703,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL621552,,BAO_0000019,,
3704,5104,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL857077,,BAO_0000357,,
3705,5104,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL618158,,BAO_0000357,,
3706,5033,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,,Homo sapiens,9606.0,,,COS-7,,10209,D,9,Expert,1,,CHEMBL618159,643.0,BAO_0000219,,
3707,5486,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,,,,,,COS-7,,10209,H,8,Autocuration,1,,CHEMBL875101,643.0,BAO_0000219,,
3708,4540,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,10209,D,9,Expert,1,,CHEMBL618160,722.0,BAO_0000219,,
3709,6166,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL618161,,BAO_0000357,,
3710,17342,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,B,,,,,,,HEK293,,10209,H,8,Expert,1,,CHEMBL618162,722.0,BAO_0000219,,
3711,17342,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL618163,,BAO_0000357,,
3712,17296,Binding affinity against 5-hydroxytryptamine 7 human receptors,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL618164,,BAO_0000357,,
3713,16429,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL618165,,BAO_0000219,,
3714,15779,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL618166,722.0,BAO_0000219,,
3715,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL857989,722.0,BAO_0000219,,
3716,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619888,722.0,BAO_0000219,,
3717,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619889,722.0,BAO_0000219,,
3718,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619890,722.0,BAO_0000219,,
3719,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,B,,,,,,,CHO,,10209,H,8,Autocuration,1,,CHEMBL619891,449.0,BAO_0000219,,
3720,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619892,722.0,BAO_0000219,,
3721,4199,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,B,,,,,,,HEK293,,10209,D,9,Expert,1,,CHEMBL619893,722.0,BAO_0000219,,
3722,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619894,722.0,BAO_0000219,,
3723,3680,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,B,,,,,,,HEK293,,10209,D,9,Intermediate,1,,CHEMBL619895,722.0,BAO_0000219,,
3724,3680,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,B,,,,,,,,,10209,D,9,Intermediate,1,,CHEMBL619896,,BAO_0000357,,
3725,15316,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,B,,,,,,,COS-7,,10209,H,8,Autocuration,1,,CHEMBL619897,643.0,BAO_0000219,,
3726,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619898,722.0,BAO_0000219,,
3727,5213,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,,,,HEK293,,10209,H,8,Expert,1,,CHEMBL619899,722.0,BAO_0000219,,
3728,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619900,722.0,BAO_0000219,,
3729,14818,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,B,,,Homo sapiens,9606.0,,,HEK293,,10209,D,9,Expert,1,,CHEMBL619901,722.0,BAO_0000219,,
3730,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL620580,722.0,BAO_0000219,,
3731,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL620581,722.0,BAO_0000219,,
3732,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL620733,722.0,BAO_0000219,,
3733,17200,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Autocuration,1,,CHEMBL620734,,BAO_0000357,,
3734,17066,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,,Mus musculus,10090.0,,,,,10022,D,9,Expert,1,,CHEMBL620735,,BAO_0000357,,
3735,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,B,,,Oryctolagus cuniculus,9986.0,,,,,10209,H,8,Autocuration,1,,CHEMBL620736,,BAO_0000019,,
3736,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620737,449.0,BAO_0000219,,
3737,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620738,449.0,BAO_0000219,,
3738,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620739,449.0,BAO_0000219,,
3739,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620740,449.0,BAO_0000219,,
3740,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620741,449.0,BAO_0000219,,
3741,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620742,449.0,BAO_0000219,,
3742,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620743,449.0,BAO_0000219,,
3743,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620744,449.0,BAO_0000219,,
3744,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620745,449.0,BAO_0000219,,
3745,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620746,449.0,BAO_0000219,,
3746,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620747,449.0,BAO_0000219,,
3747,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620748,449.0,BAO_0000219,,
3748,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620749,449.0,BAO_0000219,,
3749,17066,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923,H,8,Expert,1,,CHEMBL620750,,BAO_0000357,,
3750,17066,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0,,,,,11923,D,9,Expert,1,,CHEMBL620751,,BAO_0000357,,
3751,17386,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923,H,8,Expert,1,,CHEMBL620752,,BAO_0000357,,
3752,14423,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL872929,,BAO_0000019,,
3753,15874,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,11923,D,9,Expert,1,,CHEMBL620753,,BAO_0000357,,
3754,15874,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,B,,,Rattus norvegicus,10116.0,,,,,11923,D,9,Expert,1,,CHEMBL620754,,BAO_0000357,,
3755,16372,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,B,,,Rattus norvegicus,10116.0,,,CHO,,11923,D,9,Expert,1,,CHEMBL620755,449.0,BAO_0000219,,
3756,4622,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL620756,,BAO_0000357,,
3757,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL620757,,BAO_0000357,,
3758,16372,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620758,449.0,BAO_0000219,,
3759,16372,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620759,449.0,BAO_0000219,,
3760,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620760,449.0,BAO_0000219,,
3761,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620761,449.0,BAO_0000219,,
3762,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,F,,,,,,Ileum,,,11923,H,8,Autocuration,1,,CHEMBL620762,,BAO_0000221,2116.0,
3763,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,F,,,,,,Ileum,,,11923,H,8,Autocuration,1,,CHEMBL620763,,BAO_0000221,2116.0,
3764,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,F,,,,,,Ileum,,,11923,H,8,Autocuration,1,,CHEMBL620764,,BAO_0000221,2116.0,
3765,5831,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,11923,D,9,Expert,1,,CHEMBL857990,,BAO_0000249,,
3766,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL620765,,BAO_0000357,,
3767,17319,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,B,,,,,,,,,11923,H,8,Expert,1,,CHEMBL620766,,BAO_0000357,,
3768,17342,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,B,,,,,,Hypothalamus,,,11923,H,8,Expert,1,,CHEMBL620767,,BAO_0000019,1898.0,
3769,17342,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL620768,,BAO_0000357,,
3770,3680,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,B,,,,,,Hypothalamus,,,11923,H,8,Expert,1,,CHEMBL619051,,BAO_0000249,1898.0,
3771,3680,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923,H,8,Expert,1,,CHEMBL619052,,BAO_0000357,,
3772,17319,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,F,,,Rattus norvegicus,10116.0,,,HEK293,,11923,D,9,Expert,1,,CHEMBL619053,722.0,BAO_0000219,,
3773,17319,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,F,,,Rattus norvegicus,10116.0,,,HEK293,,11923,D,9,Expert,1,,CHEMBL619703,722.0,BAO_0000219,,
3774,17319,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,F,,,Rattus norvegicus,10116.0,,,HEK293,,11923,D,9,Autocuration,1,,CHEMBL619704,722.0,BAO_0000219,,
3775,4820,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619851,,BAO_0000357,,
3776,4639,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619852,,BAO_0000357,,
3777,6011,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619853,,BAO_0000357,,
3778,17066,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL619854,,BAO_0000357,,
3779,17066,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619855,,BAO_0000357,,
3780,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619856,,BAO_0000357,,
3781,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619857,,BAO_0000357,,
3782,17066,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,F,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619858,,BAO_0000019,,
3783,4373,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619859,,BAO_0000357,,
3784,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619860,,BAO_0000357,,
3785,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619861,,BAO_0000357,,
3786,17342,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619862,,BAO_0000357,,
3787,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619863,,BAO_0000357,,
3788,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619864,,BAO_0000357,,
3789,16633,Binding affinities against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL872928,,BAO_0000357,,
3790,16633,Binding affinities towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619865,,BAO_0000357,,
3791,17066,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619866,,BAO_0000357,,
3792,16700,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619867,,BAO_0000357,,
3793,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,B,,,,,,Ileum,,,10209,H,8,Autocuration,1,,CHEMBL619868,,BAO_0000221,2116.0,
3794,14080,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,F,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619869,,BAO_0000019,,
3795,14080,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,F,,,Homo sapiens,9606.0,,,,,55,D,9,Expert,1,,CHEMBL619870,,BAO_0000019,,
3796,409,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619871,,BAO_0000357,,
3797,409,In vitro inhibition of human recombinant lipoxygenase enzyme,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619872,,BAO_0000357,,
3798,409,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619873,,BAO_0000357,,
3799,11090,Inhibition of 5-lipoxygenase in human whole blood.,B,,,,,,Blood,,,55,H,8,Expert,1,,CHEMBL619874,,BAO_0000357,178.0,
3800,11090,Inhibition of 5-lipoxygenase in human whole blood.,B,,,,,,Blood,,,55,H,8,Expert,1,,CHEMBL619875,,BAO_0000357,178.0,
3801,948,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619876,,BAO_0000357,,
3802,948,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619877,,BAO_0000357,,
3803,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,F,,,,,,,,,55,H,8,Expert,1,,CHEMBL619878,,BAO_0000219,,
3804,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,F,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619879,,BAO_0000019,178.0,
3805,9637,In vitro inhibition of 5-lipoxygenase from human polymorphs,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619880,,BAO_0000357,,
3806,11320,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619881,,BAO_0000357,,
3807,11320,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL619882,,BAO_0000357,,
3808,6838,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619883,,BAO_0000357,,
3809,17667,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),B,,,Homo sapiens,9606.0,,Blood,,,55,D,9,Expert,1,,CHEMBL619884,,BAO_0000357,178.0,
3810,12703,In vitro potency against human 5-Lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619885,,BAO_0000357,,
3811,14312,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,F,,,Homo sapiens,9606.0,,,,,55,D,9,Expert,1,,CHEMBL619886,,BAO_0000019,,
3812,14312,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,F,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619887,,BAO_0000019,178.0,
3813,5364,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL875097,,BAO_0000019,,
3814,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618001,,BAO_0000219,,
3815,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618002,,BAO_0000219,,
3816,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618003,,BAO_0000219,,
3817,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618004,,BAO_0000219,,
3818,12365,Inhibition of human 5-lipoxygenase in human cells,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618005,,BAO_0000219,,
3819,10603,Inhibition of human neutrophil 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618006,,BAO_0000357,,
3820,10501,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL875086,,BAO_0000019,,
3821,12281,Inhibition of 5-lipoxygenase from human whole blood,B,,,,,,Blood,,,55,H,8,Expert,1,,CHEMBL618007,,BAO_0000357,178.0,
3822,2567,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618008,,BAO_0000357,,
3823,2567,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618009,,BAO_0000219,,
3824,10193,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618010,,BAO_0000357,,
3825,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618011,,BAO_0000357,,
3826,13623,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618012,,BAO_0000357,,
3827,12780,Tested against 5-lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL882927,,BAO_0000357,,
3828,12780,Tested for activity against 5-Lipoxygenase (5-LO),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618013,,BAO_0000357,,
3829,12780,Tested for activity against 5-lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618014,,BAO_0000357,,
3830,11966,Tested for inhibition of 5-HPETE production by human 5-LO,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618015,,BAO_0000357,,
3831,5364,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618016,,BAO_0000019,,
3832,13165,Inhibition of Human 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618017,,BAO_0000357,,
3833,5364,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618018,,BAO_0000019,,
3834,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL875087,,BAO_0000219,,
3835,11311,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618019,,BAO_0000219,,
3836,14863,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618020,,BAO_0000019,,
3837,14863,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618021,,BAO_0000019,,
3838,11087,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),B,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL618022,,BAO_0000357,178.0,
3839,455,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618023,,BAO_0000357,,
3840,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618024,,BAO_0000357,,
3841,10319,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL873950,,BAO_0000019,,
3842,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618025,,BAO_0000357,,
3843,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618026,,BAO_0000219,,
3844,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618027,,BAO_0000219,,
3845,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618028,,BAO_0000219,,
3846,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618029,,BAO_0000219,,
3847,9859,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618030,,BAO_0000357,,
3848,9859,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618031,,BAO_0000357,,
3849,9859,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618032,,BAO_0000357,,
3850,2567,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618033,,BAO_0000357,,
3851,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618034,,BAO_0000357,,
3852,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL875088,,BAO_0000357,,
3853,949,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618035,,BAO_0000019,,
3854,949,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618036,,BAO_0000019,,
3855,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618037,,BAO_0000357,,
3856,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618038,,BAO_0000357,,
3857,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,F,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618761,,BAO_0000019,,
3858,10603,Inhibition of lipoxygenase at the concentration of 0.1 uM,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618762,,BAO_0000357,,
3859,10603,Inhibition of lipoxygenase at the concentration of 1 uM,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618763,,BAO_0000357,,
3860,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618764,,BAO_0000357,,
3861,14580,Inhibition of 5-Lipoxygenase (5-LOX),B,,,Homo sapiens,9606.0,,,,,55,D,9,Expert,1,,CHEMBL618765,,BAO_0000357,,
3862,11090,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,,,,,,,17087,H,8,Expert,1,,CHEMBL618766,,BAO_0000357,,
3863,11090,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,,,,,,,17087,H,8,Expert,1,,CHEMBL618767,,BAO_0000357,,
3864,6339,Inhibitory activity against lipoxygenase-2 in mice,B,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL619380,,BAO_0000357,,
3865,6339,Inhibitory activity against murine lipoxygenase-2.,B,,,,,,,,,17087,H,8,Expert,1,,CHEMBL619381,,BAO_0000357,,
3866,12281,Inhibition of 5-lipoxygenase from mouse macrophage,B,,,Mus musculus,10090.0,,,,,17087,D,9,Expert,1,,CHEMBL619382,,BAO_0000357,,
3867,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,B,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL619383,,BAO_0000357,,
3868,11089,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,,Sus scrofa,9823.0,,,,,55,H,8,Autocuration,1,,CHEMBL619384,,BAO_0000019,,
3869,10091,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,B,,,Sus scrofa,9823.0,,,,,55,H,8,Autocuration,1,,CHEMBL619385,,BAO_0000019,,
3870,14352,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,B,,,Oryctolagus cuniculus,9986.0,,,,,55,H,8,Autocuration,1,,CHEMBL882928,,BAO_0000019,,
3871,13329,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL619386,,BAO_0000019,,
3872,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619387,,BAO_0000019,,
3873,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619388,,BAO_0000019,,
3874,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619389,,BAO_0000019,,
3875,13329,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619390,,BAO_0000019,,
3876,13329,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619391,,BAO_0000019,,
3877,13329,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619392,,BAO_0000019,,
3878,11311,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619393,,BAO_0000019,,
3879,11311,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619394,,BAO_0000019,,
3880,105,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619395,702.0,BAO_0000219,,
3881,105,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619396,702.0,BAO_0000219,,
3882,9138,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619397,,BAO_0000357,,
3883,9138,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619398,,BAO_0000357,,
3884,9138,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619399,,BAO_0000357,,
3885,14427,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619400,,BAO_0000357,,
3886,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619401,,BAO_0000019,,
3887,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619402,,BAO_0000019,,
3888,14427,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,B,,,Rattus norvegicus,10116.0,,,RBL-2H3,,12166,D,9,Expert,1,,CHEMBL619403,663.0,BAO_0000219,,
3889,14427,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619404,,BAO_0000357,,
3890,14427,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619405,,BAO_0000357,,
3891,10293,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619406,702.0,BAO_0000219,,
3892,338,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL619407,702.0,BAO_0000219,,
3893,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619408,,BAO_0000357,,
3894,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619409,702.0,BAO_0000219,,
3895,9247,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619410,702.0,BAO_0000219,,
3896,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619753,702.0,BAO_0000219,,
3897,137,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619754,702.0,BAO_0000219,,
3898,11481,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619903,,BAO_0000357,,
3899,11481,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619904,,BAO_0000357,,
3900,9029,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619905,,BAO_0000357,,
3901,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619906,,BAO_0000019,,
3902,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619907,,BAO_0000019,,
3903,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619908,,BAO_0000019,,
3904,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619909,,BAO_0000019,,
3905,13358,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,F,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619910,702.0,BAO_0000219,,
3906,1175,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL882929,702.0,BAO_0000219,,
3907,8797,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619911,702.0,BAO_0000219,,
3908,8797,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619912,,BAO_0000019,,
3909,577,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL619913,,BAO_0000357,,
3910,9295,In vitro inhibitory activity against RBL-1 5-LO,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619914,702.0,BAO_0000219,,
3911,9295,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619915,702.0,BAO_0000219,,
3912,9295,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619916,702.0,BAO_0000219,,
3913,9295,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619917,,BAO_0000218,,
3914,9295,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619918,,BAO_0000357,,
3915,216,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619919,,BAO_0000218,,
3916,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL883710,702.0,BAO_0000219,,
3917,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,B,,,,,,Blood,,,12166,H,8,Autocuration,1,,CHEMBL619920,,BAO_0000019,178.0,
3918,10091,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619921,,BAO_0000357,,
3919,10274,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619922,,BAO_0000019,,
3920,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619923,,BAO_0000219,,
3921,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619924,702.0,BAO_0000219,,
3922,12576,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619925,,BAO_0000357,,
3923,9546,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619926,702.0,BAO_0000219,,
3924,9521,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619927,702.0,BAO_0000219,,
3925,10626,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619928,702.0,BAO_0000219,,
3926,9225,In vitro inhibition of RBL-1 5-lipoxygenase,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619929,702.0,BAO_0000219,,
3927,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL875089,702.0,BAO_0000219,,
3928,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619930,702.0,BAO_0000219,,
3929,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619931,702.0,BAO_0000219,,
3930,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619932,702.0,BAO_0000219,,
3931,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619933,702.0,BAO_0000219,,
3932,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619934,702.0,BAO_0000219,,
3933,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619935,702.0,BAO_0000219,,
3934,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619936,702.0,BAO_0000219,,
3935,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619937,702.0,BAO_0000219,,
3936,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619938,702.0,BAO_0000219,,
3937,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619939,702.0,BAO_0000219,,
3938,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619940,702.0,BAO_0000219,,
3939,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL875090,702.0,BAO_0000219,,
3940,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619941,702.0,BAO_0000219,,
3941,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619942,702.0,BAO_0000219,,
3942,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL883711,702.0,BAO_0000219,,
3943,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619943,702.0,BAO_0000219,,
3944,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619944,702.0,BAO_0000219,,
3945,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619945,702.0,BAO_0000219,,
3946,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619946,702.0,BAO_0000219,,
3947,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619947,702.0,BAO_0000219,,
3948,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619948,702.0,BAO_0000219,,
3949,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619949,702.0,BAO_0000219,,
3950,9401,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619950,,BAO_0000019,,
3951,10325,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618050,,BAO_0000019,,
3952,1556,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,F,,,,,,,RBL-2H3,,12166,H,8,Expert,1,,CHEMBL875091,663.0,BAO_0000219,,
3953,1556,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,F,,,,,,,RBL-2H3,,12166,H,8,Expert,1,,CHEMBL618051,663.0,BAO_0000219,,
3954,961,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618052,702.0,BAO_0000219,,
3955,6838,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618053,,BAO_0000019,,
3956,10325,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL618054,,BAO_0000019,,
3957,9209,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618055,702.0,BAO_0000219,,
3958,11520,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618056,702.0,BAO_0000219,,
3959,137,In vitro inhibitory activity against 5-lipoxygenase was determined,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618057,,BAO_0000357,,
3960,4717,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618058,702.0,BAO_0000219,,
3961,10636,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618059,702.0,BAO_0000219,,
3962,14312,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,F,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL618060,,BAO_0000019,,
3963,1203,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618061,702.0,BAO_0000219,,
3964,1203,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618062,,BAO_0000019,,
3965,13622,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618063,702.0,BAO_0000219,,
3966,9793,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618064,,BAO_0000357,,
3967,1143,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618065,702.0,BAO_0000219,,
3968,11854,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618066,702.0,BAO_0000219,,
3969,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618067,702.0,BAO_0000219,,
3970,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618068,702.0,BAO_0000219,,
3971,10501,Inhibition of 5-lipoxygenase in rat RBL-1 cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618069,702.0,BAO_0000219,,
3972,12526,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618070,702.0,BAO_0000219,,
3973,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL618071,,BAO_0000019,349.0,
3974,10034,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL619247,,BAO_0000019,349.0,
3975,10034,Approximate dose levels for a half maximal reduction of 5-HTP levels,F,,,,,,,,,10825,H,8,Autocuration,1,,CHEMBL619248,,BAO_0000019,,
3976,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL619249,,BAO_0000221,10000000.0,
3977,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL619250,,BAO_0000221,10000000.0,
3978,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL619251,,BAO_0000019,,
3979,12079,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,F,,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619252,,BAO_0000019,178.0,
3980,12079,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,F,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619253,,BAO_0000019,178.0,
3981,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619254,,BAO_0000219,,
3982,12338,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619255,,BAO_0000219,,
3983,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619256,,BAO_0000219,,
3984,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),B,,,,,,,,,17140,H,8,Autocuration,1,,CHEMBL875418,,BAO_0000219,,
3985,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619257,,BAO_0000219,,
3986,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,,,,,,,17140,H,8,Autocuration,1,,CHEMBL619258,,BAO_0000219,,
3987,12365,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619259,,BAO_0000357,,
3988,13500,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619260,,BAO_0000357,,
3989,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619261,,BAO_0000218,178.0,
3990,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619263,,BAO_0000218,178.0,
3991,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619264,,BAO_0000218,178.0,
3992,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619265,,BAO_0000218,178.0,
3993,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619266,,BAO_0000218,178.0,
3994,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619902,,BAO_0000218,178.0,
3995,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620058,,BAO_0000218,178.0,
3996,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620059,,BAO_0000218,178.0,
3997,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620060,,BAO_0000218,178.0,
3998,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620061,,BAO_0000218,178.0,
3999,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620062,,BAO_0000218,178.0,
4000,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620063,,BAO_0000218,178.0,
4001,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620064,,BAO_0000218,178.0,
4002,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620065,,BAO_0000218,178.0,
4003,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620066,,BAO_0000218,178.0,
4004,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620067,,BAO_0000218,178.0,
4005,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620068,,BAO_0000218,178.0,
4006,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620069,,BAO_0000218,178.0,
4007,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620070,,BAO_0000218,178.0,
4008,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620071,,BAO_0000218,178.0,
4009,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620072,,BAO_0000218,178.0,
4010,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620036,,BAO_0000218,178.0,
4011,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL857702,,BAO_0000218,178.0,
4012,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620037,,BAO_0000218,178.0,
4013,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620038,,BAO_0000218,178.0,
4014,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620039,,BAO_0000218,178.0,
4015,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620040,,BAO_0000218,178.0,
4016,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620041,,BAO_0000218,178.0,
4017,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620042,,BAO_0000218,178.0,
4018,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620043,,BAO_0000218,178.0,
4019,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620044,,BAO_0000218,178.0,
4020,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620045,,BAO_0000218,178.0,
4021,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620046,,BAO_0000218,178.0,
4022,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620047,,BAO_0000218,178.0,
4023,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620048,,BAO_0000218,178.0,
4024,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL857703,,BAO_0000218,178.0,
4025,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620049,,BAO_0000218,178.0,
4026,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620050,,BAO_0000218,178.0,
4027,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620051,,BAO_0000218,178.0,
4028,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619213,,BAO_0000218,178.0,
4029,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619214,,BAO_0000218,178.0,
4030,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619804,,BAO_0000218,178.0,
4031,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619805,,BAO_0000218,178.0,
4032,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619806,,BAO_0000218,178.0,
4033,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619807,,BAO_0000218,178.0,
4034,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619808,,BAO_0000218,178.0,
4035,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL619809,,BAO_0000218,,
4036,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL619810,,BAO_0000218,,
4037,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL619811,,BAO_0000218,,
4038,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620769,,BAO_0000218,,
4039,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620770,,BAO_0000218,,
4040,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620771,,BAO_0000218,,
4041,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620772,,BAO_0000218,,
4042,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620773,,BAO_0000218,,
4043,9203,Ability to inhibit 5-lipoxygenase in guinea pig,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL620774,,BAO_0000357,,
4044,82,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),B,,,Cavia porcellus,10141.0,,,,,55,H,8,Expert,1,,CHEMBL620775,,BAO_0000357,,
4045,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL620776,,BAO_0000357,,
4046,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",B,,,Cavia porcellus,10141.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620777,,BAO_0000218,178.0,
4047,1065,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL620778,,BAO_0000357,,
4048,1065,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL620779,,BAO_0000357,,
4049,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Expert,1,,CHEMBL621500,,BAO_0000019,,
4050,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Expert,1,,CHEMBL621501,,BAO_0000019,,
4051,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618098,,BAO_0000019,,
4052,10504,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618099,,BAO_0000019,,
4053,7788,Inhibitory activity against 5-lipoxygenase,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618100,,BAO_0000357,,
4054,10001,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618101,,BAO_0000357,,
4055,10193,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618102,,BAO_0000357,,
4056,13243,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618103,,BAO_0000357,,
4057,13243,Inhibitory activity uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618104,,BAO_0000357,,
4058,969,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL883712,,BAO_0000219,,
4059,10001,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618105,,BAO_0000357,,
4060,7788,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618106,,BAO_0000357,,
4061,10001,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618107,,BAO_0000357,,
4062,10193,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618108,,BAO_0000357,,
4063,13243,Inhibitory activity uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618109,,BAO_0000357,,
4064,13243,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618110,,BAO_0000357,,
4065,13243,Inhibitory activity uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Expert,1,,CHEMBL618111,,BAO_0000357,,
4066,13243,Inhibitory activity uM,F,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618112,,BAO_0000019,,
4067,10504,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618113,,BAO_0000019,,
4068,7788,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618114,,BAO_0000357,,
4069,10546,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,55,H,8,Expert,1,,CHEMBL620871,,BAO_0000221,2116.0,
4070,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL620872,,BAO_0000357,,
4071,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL620873,,BAO_0000357,,
4072,2578,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL620874,,BAO_0000357,,
4073,12780,In vitro inhibition of human 5-Lipoxygenase.,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL620875,,BAO_0000357,,
4074,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620876,,BAO_0000251,2107.0,
4075,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620877,,BAO_0000251,2107.0,
4076,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL857854,,BAO_0000251,2107.0,
4077,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620878,,BAO_0000251,2107.0,
4078,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620879,,BAO_0000251,2107.0,
4079,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620880,,BAO_0000251,2107.0,
4080,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620881,,BAO_0000251,2107.0,
4081,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620882,,BAO_0000251,2107.0,
4082,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620883,,BAO_0000251,2107.0,
4083,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620884,,BAO_0000251,2107.0,
4084,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620885,,BAO_0000251,2107.0,
4085,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620886,,BAO_0000251,2107.0,
4086,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620887,,BAO_0000251,2107.0,
4087,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618039,,BAO_0000251,2107.0,
4088,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618040,,BAO_0000251,2107.0,
4089,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618041,,BAO_0000251,2107.0,
4090,7411,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618216,,BAO_0000251,2107.0,
4091,7411,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618217,,BAO_0000251,2107.0,
4092,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618218,,BAO_0000251,2107.0,
4093,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618219,,BAO_0000251,2107.0,
4094,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618220,,BAO_0000251,2107.0,
4095,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618221,,BAO_0000251,2107.0,
4096,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618222,,BAO_0000251,2107.0,
4097,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618223,,BAO_0000251,2107.0,
4098,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618224,,BAO_0000251,2107.0,
4099,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618225,,BAO_0000251,2107.0,
4100,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618226,,BAO_0000251,2107.0,
4101,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618227,,BAO_0000251,2107.0,
4102,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618228,,BAO_0000251,2107.0,
4103,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618229,,BAO_0000251,2107.0,
4104,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618230,,BAO_0000251,2107.0,
4105,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618231,,BAO_0000251,2107.0,
4106,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618232,,BAO_0000251,2107.0,
4107,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618233,,BAO_0000251,2107.0,
4108,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618234,,BAO_0000251,2107.0,
4109,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618235,,BAO_0000251,2107.0,
4110,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618115,,BAO_0000251,2107.0,
4111,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618116,,BAO_0000251,2107.0,
4112,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618117,,BAO_0000251,2107.0,
4113,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619968,,BAO_0000251,2107.0,
4114,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619969,,BAO_0000251,2107.0,
4115,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619970,,BAO_0000251,2107.0,
4116,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619971,,BAO_0000251,2107.0,
4117,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619972,,BAO_0000251,2107.0,
4118,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619973,,BAO_0000251,2107.0,
4119,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619974,,BAO_0000251,2107.0,
4120,7411,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619975,,BAO_0000251,2107.0,
4121,7411,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619976,,BAO_0000251,,
4122,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619977,,BAO_0000251,2107.0,
4123,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619978,,BAO_0000251,2107.0,
4124,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619979,,BAO_0000251,2107.0,
4125,7411,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619980,,BAO_0000251,2107.0,
4126,7411,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619981,,BAO_0000251,2107.0,
4127,10797,In vitro inhibition of 7226/S myeloma cancer cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619982,741.0,BAO_0000219,,
4128,6881,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),F,,,Homo sapiens,9606.0,,,BEL-7404 tumor cell line,,80698,N,1,Intermediate,1,,CHEMBL619983,993.0,BAO_0000219,,
4129,3838,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL620031,391.0,BAO_0000219,,
4130,3838,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL620032,391.0,BAO_0000219,,
4131,12981,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,F,,,Cricetulus griseus,10029.0,,,V79,,81264,N,1,Expert,1,,CHEMBL620033,505.0,BAO_0000219,,
4132,12981,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,F,,,Cricetulus griseus,10029.0,,,V79,,81264,N,1,Expert,1,,CHEMBL620034,505.0,BAO_0000219,,
4133,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL620035,1119.0,BAO_0000219,,
4134,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL618318,1119.0,BAO_0000219,,
4135,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL618319,1119.0,BAO_0000219,,
4136,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL618320,1119.0,BAO_0000219,,
4137,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL618321,1119.0,BAO_0000219,,
4138,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL883118,1119.0,BAO_0000219,,
4139,17229,In vitro antitumor activity against renal 786-0 tumor cell lines,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL883795,391.0,BAO_0000219,,
4140,12858,Cytotoxic activity against 786-0 Renal cancer cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618322,391.0,BAO_0000219,,
4141,16325,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618323,391.0,BAO_0000219,,
4142,16325,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618324,391.0,BAO_0000219,,
4143,5858,In vitro antitumor activity against human renal 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618325,391.0,BAO_0000219,,
4144,16325,Inhibition of Renal cancer in 786-0 cancer cell lines,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL875416,391.0,BAO_0000219,,
4145,14696,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618326,391.0,BAO_0000219,,
4146,3786,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618327,391.0,BAO_0000219,,
4147,14696,inhibition of the growth of renal cancer(786-0) cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619215,391.0,BAO_0000219,,
4148,14769,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619216,391.0,BAO_0000219,,
4149,15354,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619217,391.0,BAO_0000219,,
4150,14255,The IC50 value was measured on 786-0 cell line in ovarian tumor,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619218,391.0,BAO_0000219,,
4151,14255,The IC50 value was measured on 786-0 cell line in ovarian tumor t,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619219,391.0,BAO_0000219,,
4152,14255,The IC50 value was measured on 786-0 cell line in renal tumor type.,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619220,391.0,BAO_0000219,,
4153,14696,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619221,391.0,BAO_0000219,,
4154,12016,Tested for cytotoxic activity against renal cancer 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619222,391.0,BAO_0000219,,
4155,2597,Compound was tested for growth inhibitory activity against 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL857454,391.0,BAO_0000219,,
4156,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619223,702.0,BAO_0000219,,
4157,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619224,702.0,BAO_0000219,,
4158,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619225,,BAO_0000019,,
4159,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619226,702.0,BAO_0000219,,
4160,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619227,702.0,BAO_0000219,,
4161,12767,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619228,,BAO_0000357,,
4162,10997,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619229,,BAO_0000219,,
4163,11388,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619230,702.0,BAO_0000219,,
4164,167,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619231,,BAO_0000357,,
4165,167,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619232,,BAO_0000357,,
4166,13744,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619233,,BAO_0000357,,
4167,1630,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619234,,BAO_0000357,,
4168,1630,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619235,,BAO_0000357,,
4169,969,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL619236,,BAO_0000019,,
4170,13621,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619237,702.0,BAO_0000219,,
4171,10089,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619238,,BAO_0000357,,
4172,10193,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619239,,BAO_0000357,,
4173,11966,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619240,,BAO_0000357,,
4174,12251,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL875417,,BAO_0000019,,
4175,211,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619241,702.0,BAO_0000219,,
4176,12251,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,F,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619242,,BAO_0000019,,
4177,12495,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL883796,702.0,BAO_0000219,,
4178,414,Tested for its inhibitory activity against 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619243,,BAO_0000357,,
4179,414,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619244,,BAO_0000357,,
4180,10325,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619245,,BAO_0000019,,
4181,11966,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619246,,BAO_0000019,,
4182,165,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619984,702.0,BAO_0000219,,
4183,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619985,702.0,BAO_0000219,,
4184,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619986,702.0,BAO_0000219,,
4185,165,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619987,702.0,BAO_0000219,,
4186,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619988,,BAO_0000218,,
4187,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619989,702.0,BAO_0000219,,
4188,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619990,702.0,BAO_0000219,,
4189,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619991,,BAO_0000219,,
4190,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619992,,BAO_0000219,,
4191,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),B,In vivo,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619993,,BAO_0000218,,
4192,11311,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL619994,663.0,BAO_0000219,,
4193,11311,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL619995,663.0,BAO_0000219,,
4194,11311,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619996,,BAO_0000019,,
4195,11732,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619997,,BAO_0000019,,
4196,11732,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619998,,BAO_0000019,,
4197,11087,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619999,,BAO_0000019,,
4198,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620000,,BAO_0000019,,
4199,11087,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620001,702.0,BAO_0000219,,
4200,11087,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL620002,,BAO_0000357,,
4201,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620003,702.0,BAO_0000219,,
4202,13986,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,F,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL620004,702.0,BAO_0000219,,
4203,11520,Compound was evaluated for the inhibition of 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL874063,,BAO_0000357,,
4204,10293,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620005,702.0,BAO_0000219,,
4205,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620006,702.0,BAO_0000219,,
4206,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620007,702.0,BAO_0000219,,
4207,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620008,702.0,BAO_0000219,,
4208,9247,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL620009,702.0,BAO_0000219,,
4209,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620010,702.0,BAO_0000219,,
4210,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620011,702.0,BAO_0000219,,
4211,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620677,702.0,BAO_0000219,,
4212,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620678,702.0,BAO_0000219,,
4213,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620679,702.0,BAO_0000219,,
4214,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620680,702.0,BAO_0000219,,
4215,11481,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL620838,,BAO_0000357,,
4216,105,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620839,,BAO_0000357,,
4217,9029,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL620840,,BAO_0000357,,
4218,1175,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL620841,702.0,BAO_0000219,,
4219,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620842,702.0,BAO_0000219,,
4220,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620843,702.0,BAO_0000219,,
4221,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620844,702.0,BAO_0000219,,
4222,9225,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620845,702.0,BAO_0000219,,
4223,9401,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620846,,BAO_0000019,,
4224,137,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL873951,,BAO_0000357,,
4225,137,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620847,,BAO_0000357,,
4226,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620848,702.0,BAO_0000219,,
4227,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620849,702.0,BAO_0000219,,
4228,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620850,702.0,BAO_0000219,,
4229,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620851,702.0,BAO_0000219,,
4230,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620852,702.0,BAO_0000219,,
4231,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL875098,702.0,BAO_0000219,,
4232,14799,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL620853,702.0,BAO_0000219,,
4233,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620854,,BAO_0000019,,
4234,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620855,702.0,BAO_0000219,,
4235,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL839884,702.0,BAO_0000219,,
4236,12526,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620856,702.0,BAO_0000219,,
4237,12526,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620857,702.0,BAO_0000219,,
4238,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620858,,BAO_0000019,,
4239,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620859,,BAO_0000019,,
4240,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620860,,BAO_0000019,,
4241,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620861,,BAO_0000019,,
4242,9138,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL620862,,BAO_0000357,,
4243,9138,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620863,,BAO_0000357,,
4244,11966,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620864,,BAO_0000019,,
4245,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620865,702.0,BAO_0000219,,
4246,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620866,702.0,BAO_0000219,,
4247,11311,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,B,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL620867,663.0,BAO_0000219,,
4248,11311,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,B,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL620868,663.0,BAO_0000219,,
4249,11311,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL620869,663.0,BAO_0000219,,
4250,11311,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL873952,,BAO_0000019,,
4251,11311,The compound was tested for inhibition of isolated 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL875099,,BAO_0000357,,
4252,11311,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL620870,663.0,BAO_0000219,,
4253,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618261,,BAO_0000019,,
4254,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618262,,BAO_0000019,,
4255,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619428,,BAO_0000019,,
4256,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619429,,BAO_0000019,,
4257,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619430,,BAO_0000019,,
4258,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620017,702.0,BAO_0000219,,
4259,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620018,702.0,BAO_0000219,,
4260,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620019,702.0,BAO_0000219,,
4261,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620020,702.0,BAO_0000219,,
4262,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620021,702.0,BAO_0000219,,
4263,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620022,702.0,BAO_0000219,,
4264,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620023,702.0,BAO_0000219,,
4265,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620024,702.0,BAO_0000219,,
4266,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620025,702.0,BAO_0000219,,
4267,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620026,702.0,BAO_0000219,,
4268,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620027,702.0,BAO_0000219,,
4269,13986,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,F,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL620028,,BAO_0000019,,
4270,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620029,,BAO_0000357,,
4271,9295,Compound was tested for the percent of inhibition against 5-LO at 10 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620030,,BAO_0000357,,
4272,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL875415,702.0,BAO_0000219,,
4273,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618256,702.0,BAO_0000219,,
4274,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618257,702.0,BAO_0000219,,
4275,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618258,702.0,BAO_0000219,,
4276,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618259,702.0,BAO_0000219,,
4277,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618260,,BAO_0000019,,
4278,9295,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618215,702.0,BAO_0000219,,
4279,9295,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618390,702.0,BAO_0000219,,
4280,9295,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618391,702.0,BAO_0000219,,
4281,9295,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618392,702.0,BAO_0000219,,
4282,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618393,702.0,BAO_0000219,,
4283,11311,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618394,,BAO_0000219,,
4284,10489,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,,Homo sapiens,9606.0,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618395,702.0,BAO_0000219,,
4285,10489,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618396,702.0,BAO_0000219,,
4286,10489,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL858253,702.0,BAO_0000219,,
4287,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Autocuration,1,,CHEMBL618397,,BAO_0000019,,
4288,9295,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL618398,,BAO_0000357,,
4289,16811,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL618399,,BAO_0000019,,
4290,168,In vitro inhibition of 5-Lipoxygenase; Inactive.,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618400,,BAO_0000357,,
4291,6309,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618401,,BAO_0000357,,
4292,6309,Inhibitory concentration against 5-lipoxygenase; No inhibition,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618402,,BAO_0000357,,
4293,3092,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,B,,,,,,,RBL-1,,55,H,8,Autocuration,1,,CHEMBL876400,702.0,BAO_0000219,,
4294,168,Inhibitory activity against 5-lipoxygenase.,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618403,,BAO_0000357,,
4295,168,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618404,,BAO_0000357,,
4296,168,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618405,,BAO_0000357,,
4297,168,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618406,,BAO_0000357,,
4298,12338,Inhibitory concentration against arachidonic acid 5-lipoxygenation,F,,,,,,,,,55,H,8,Expert,1,,CHEMBL618407,,BAO_0000019,,
4299,4501,Tested for the inhibitory activity against 5-lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618408,,BAO_0000357,,
4300,1132,Compound was tested for its inhibitory activity against 5-lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618409,,BAO_0000357,,
4301,2117,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618410,,BAO_0000357,,
4302,168,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618411,,BAO_0000357,,
4303,168,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618412,,BAO_0000357,,
4304,13575,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618413,702.0,BAO_0000219,,
4305,11089,,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618414,,BAO_0000357,,
4306,216,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618415,,BAO_0000357,,
4307,13165,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618416,,BAO_0000019,,
4308,3278,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL876401,,BAO_0000357,,
4309,3278,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,B,,,,,,,,,10102,H,8,Expert,1,,CHEMBL618417,,BAO_0000357,,
4310,11966,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618418,,BAO_0000357,,
4311,175,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618419,,BAO_0000357,,
4312,175,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618420,,BAO_0000357,,
4313,13449,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618421,,BAO_0000357,,
4314,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,B,,,,,,,,,11238,H,8,Autocuration,1,,CHEMBL618422,,BAO_0000019,,
4315,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),B,,,,,,,,,11238,H,8,Autocuration,1,,CHEMBL618423,,BAO_0000019,,
4316,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),B,,,,,,,,,11238,H,8,Autocuration,1,,CHEMBL618424,,BAO_0000019,,
4317,99,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,B,,,,,,,,,100284,S,2,Intermediate,1,,CHEMBL618425,,BAO_0000220,,
4318,4349,The dark toxicity against 543 human galactophore carcinoma cells,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL618426,,BAO_0000019,,
4319,4071,Tested in vitro for cytotoxicity against 56 human tumor cell lines,F,,,Homo sapiens,9606.0,,,Panel (56 tumour cell lines),,80623,N,1,Expert,1,,CHEMBL618427,390.0,BAO_0000219,,
4320,17589,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Expert,1,,CHEMBL618428,345.0,BAO_0000219,,
4321,15002,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Intermediate,1,,CHEMBL618429,345.0,BAO_0000219,,
4322,13958,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Intermediate,1,,CHEMBL618430,345.0,BAO_0000219,,
4323,17589,Growth inhibition against human 5637 cell lines,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Expert,1,,CHEMBL618431,345.0,BAO_0000219,,
4324,16748,Antitumor activity against human bladder carcinoma 5637 cells.,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Expert,1,,CHEMBL883799,345.0,BAO_0000219,,
4325,16747,Antitumor activity against human bladder carcinoma 5637 cells,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Intermediate,1,,CHEMBL618432,345.0,BAO_0000219,,
4326,16747,Antitumor activity against human bladder carcinoma 5637 cells,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Intermediate,1,,CHEMBL618433,345.0,BAO_0000219,,
4327,15285,In vitro inhibition of bovine trypsin(Trp).,B,,,Bos taurus,9913.0,,,,,10443,D,9,Expert,1,,CHEMBL618434,,BAO_0000357,,
4328,3726,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,B,,,Cercopithecidae,9527.0,,,CV-1,,240,H,8,Expert,1,,CHEMBL618435,407.0,BAO_0000219,,
4329,5033,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL876402,,BAO_0000357,,
4330,11756,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618436,,BAO_0000019,,
4331,11953,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,F,In vivo,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL618437,,BAO_0000218,,
4332,5033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL618438,,BAO_0000357,,
4333,11347,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,,Rattus norvegicus,10116.0,,,,Microsomes,17045,H,8,Expert,1,,CHEMBL883800,,BAO_0000251,,
4334,11347,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,,Rattus norvegicus,10116.0,,,,Microsomes,17045,H,8,Expert,1,,CHEMBL618439,,BAO_0000251,,
4335,1229,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL618440,,BAO_0000019,,
4336,1229,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL618441,,BAO_0000019,,
4337,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,B,,,Trypanosoma brucei,5691.0,,,,,11938,H,8,Expert,1,,CHEMBL618442,,BAO_0000019,,
4338,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,B,,,Trypanosoma brucei,5691.0,,,,,11938,H,8,Autocuration,1,,CHEMBL618443,,BAO_0000019,,
4339,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,B,,,Ovis aries,9940.0,,,,,11938,H,8,Expert,1,,CHEMBL619158,,BAO_0000019,,
4340,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,B,,,Ovis aries,9940.0,,,,,11938,H,8,Autocuration,1,,CHEMBL620974,,BAO_0000019,,
4341,16485,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,B,,,,,,,,,11938,H,8,Autocuration,1,,CHEMBL620975,,BAO_0000357,,
4342,4337,Average inhibitory concentration against 60 human cell lines was reported,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Intermediate,1,,CHEMBL620976,,BAO_0000019,,
4343,4112,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Expert,1,,CHEMBL620977,,BAO_0000019,,
4344,16160,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,F,,,Homo sapiens,9606.0,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Intermediate,1,,CHEMBL620978,542.0,BAO_0000219,,
4345,16160,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,F,,,Homo sapiens,9606.0,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Intermediate,1,,CHEMBL620979,542.0,BAO_0000219,,
4346,17376,In vitro mean growth inhibitory activity against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Expert,1,,CHEMBL620980,542.0,BAO_0000219,,
4347,17376,In vitro mean growth lethal concentration against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Expert,1,,CHEMBL620981,542.0,BAO_0000219,,
4348,17376,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Expert,1,,CHEMBL620982,542.0,BAO_0000219,,
4349,17376,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Expert,1,,CHEMBL620983,542.0,BAO_0000219,,
4350,3241,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,,,,,,,104775,H,4,Autocuration,1,,CHEMBL620984,,BAO_0000019,,
4351,3241,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,,,,,,,104775,H,4,Autocuration,1,,CHEMBL620985,,BAO_0000019,,
4352,3725,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,B,,,,,,,,,275,H,8,Expert,1,,CHEMBL620986,,BAO_0000357,,
4353,10805,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Expert,1,,CHEMBL620987,,BAO_0000218,,
4354,10805,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Expert,1,,CHEMBL620988,,BAO_0000218,,
4355,10805,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Expert,1,,CHEMBL620989,,BAO_0000218,,
4356,10805,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Expert,1,,CHEMBL620990,,BAO_0000218,,
4357,10805,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Intermediate,1,,CHEMBL620991,,BAO_0000218,,
4358,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620992,850.0,BAO_0000218,,
4359,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620993,850.0,BAO_0000218,,
4360,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620994,850.0,BAO_0000218,,
4361,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620995,850.0,BAO_0000218,,
4362,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620996,850.0,BAO_0000218,,
4363,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL875581,850.0,BAO_0000218,,
4364,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620997,,BAO_0000218,,
4365,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620998,,BAO_0000218,,
4366,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620999,,BAO_0000218,,
4367,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621000,,BAO_0000218,,
4368,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621001,,BAO_0000218,,
4369,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621002,,BAO_0000218,,
4370,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621003,,BAO_0000218,,
4371,10685,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621004,,BAO_0000218,,
4372,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621005,,BAO_0000218,,
4373,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621006,,BAO_0000218,,
4374,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621007,,BAO_0000218,,
4375,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621008,,BAO_0000218,,
4376,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621009,,BAO_0000218,,
4377,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL857705,,BAO_0000218,,
4378,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619828,,BAO_0000218,,
4379,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619829,,BAO_0000218,,
4380,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619830,,BAO_0000218,,
4381,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619831,,BAO_0000218,,
4382,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619832,,BAO_0000218,,
4383,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,A,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619833,,BAO_0000218,,
4384,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,A,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619834,,BAO_0000218,,
4385,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,A,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619835,,BAO_0000218,,
4386,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,A,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619836,,BAO_0000218,,
4387,8831,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL619837,850.0,BAO_0000218,,
4388,11704,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,F,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL619838,,BAO_0000218,,
4389,11704,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619839,,BAO_0000218,,
4390,10685,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,F,In vivo,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL619840,850.0,BAO_0000218,,
4391,10685,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,F,In vivo,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL619841,850.0,BAO_0000218,,
4392,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Expert,1,,CHEMBL857704,850.0,BAO_0000218,,
4393,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL619842,850.0,BAO_0000218,,
4394,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Expert,1,,CHEMBL619843,850.0,BAO_0000218,,
4395,17763,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",B,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619844,,BAO_0000019,,
4396,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL857855,,BAO_0000251,2107.0,
4397,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619845,,BAO_0000251,2107.0,
4398,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619846,,BAO_0000251,2107.0,
4399,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619847,,BAO_0000251,2107.0,
4400,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619848,,BAO_0000251,2107.0,
4401,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620893,,BAO_0000251,2107.0,
4402,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620894,,BAO_0000251,2107.0,
4403,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620895,,BAO_0000251,2107.0,
4404,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620896,,BAO_0000251,2107.0,
4405,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620897,,BAO_0000251,2107.0,
4406,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620898,,BAO_0000251,2107.0,
4407,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620899,,BAO_0000251,2107.0,
4408,347,The apparent total plasma clearance in monkey,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620900,,BAO_0000218,1969.0,
4409,3341,Compound was evaluated for Hepatic clearance in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620901,,BAO_0000218,,
4410,17853,Lower clearance in monkey (i.v.) at 0.5 mpk,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620902,,BAO_0000218,,
4411,4514,Plasma clearance in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620903,,BAO_0000218,,
4412,6062,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620904,,BAO_0000218,,
4413,6821,Plasma clearance of compound was determined in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620905,,BAO_0000218,,
4414,6057,Plasma clearance was calculated in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620906,,BAO_0000218,,
4415,5145,Plasma clearance in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875420,,BAO_0000218,,
4416,6641,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620907,,BAO_0000218,,
4417,5472,Plasma clearance was evaluated in rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620908,,BAO_0000218,,
4418,4257,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620909,,BAO_0000218,,
4419,5546,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620910,,BAO_0000218,,
4420,5334,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620911,,BAO_0000218,,
4421,5334,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620912,,BAO_0000218,,
4422,17509,Cmax 24 hr after 2 mg/kg oral administration in monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620913,,BAO_0000218,,
4423,6535,Cmax in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620914,,BAO_0000218,,
4424,5668,Cmax was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620915,,BAO_0000218,,
4425,5922,Cmax in cynomolgus monkey by iv administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620916,,BAO_0000218,,
4426,5922,Cmax in cynomolgus monkey by po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620917,,BAO_0000218,,
4427,6078,Cmax value evaluated in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620918,,BAO_0000218,,
4428,2661,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620919,,BAO_0000218,,
4429,3249,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620920,,BAO_0000218,1969.0,
4430,3249,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620921,,BAO_0000218,1969.0,
4431,5553,Maximal plasma concentration in squirrel monkeys,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620922,,BAO_0000218,1969.0,
4432,1916,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620923,,BAO_0000218,,
4433,6227,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620924,,BAO_0000218,1969.0,
4434,4809,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620925,,BAO_0000218,,
4435,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620926,,BAO_0000218,,
4436,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620927,,BAO_0000218,,
4437,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620928,,BAO_0000218,,
4438,5355,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620929,,BAO_0000218,,
4439,6221,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620930,,BAO_0000218,1969.0,
4440,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620931,,BAO_0000218,,
4441,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620932,,BAO_0000218,,
4442,4257,Absolute bioavailability was evaluated in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620933,,BAO_0000218,,
4443,6221,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620934,,BAO_0000218,,
4444,17667,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620935,,BAO_0000218,,
4445,17267,Bioavailability of compound was determined in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620936,,BAO_0000218,,
4446,4256,Bioavailability determined after oral administration in marmoset,A,In vivo,,marmosets,38020.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620937,,BAO_0000218,,
4447,4256,Oral bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620938,,BAO_0000218,,
4448,17853,Bioavailability in monkey (p.o.) at 2.0 mpk,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620939,,BAO_0000218,,
4449,16365,Bioavailability was evaluated after oral administration in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620940,,BAO_0000218,,
4450,1916,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620941,,BAO_0000218,,
4451,5334,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620942,,BAO_0000218,,
4452,5334,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620943,,BAO_0000218,,
4453,17592,Bioavailability of the compound was determined in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620944,,BAO_0000218,,
4454,1399,Bioavailability in squirrel monkey (dose 5 mg/kg),A,In vivo,,Saimiri sciureus,9521.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620945,,BAO_0000218,,
4455,4809,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620946,,BAO_0000218,,
4456,3341,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620947,,BAO_0000218,,
4457,64,Compound was tested for bioavailability in squirrel monkey,A,In vivo,,Saimiri sciureus,9521.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620948,,BAO_0000218,,
4458,5005,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620949,,BAO_0000218,,
4459,5005,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620950,,BAO_0000218,,
4460,5237,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620951,,BAO_0000218,,
4461,5237,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620952,,BAO_0000218,,
4462,5302,Oral bioavailability in monkey (dose 5 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875421,,BAO_0000218,,
4463,17667,Oral bioavailability of compound at 5 mg/kg in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620953,,BAO_0000218,,
4464,6161,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873491,,BAO_0000218,,
4465,6161,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620954,,BAO_0000218,,
4466,3854,Plasma half life determined,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620955,,BAO_0000218,1969.0,
4467,993,Plasma half life in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618097,,BAO_0000218,1969.0,
4468,4514,Plasma half-life in Beagle dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618268,,BAO_0000218,1969.0,
4469,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618269,,BAO_0000218,1969.0,
4470,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618270,,BAO_0000218,1969.0,
4471,1466,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618271,,BAO_0000218,,
4472,1466,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873493,,BAO_0000218,,
4473,5313,Tested for the half life period in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621031,,BAO_0000218,,
4474,5313,Tested for the half life period in dog at dosage of 10 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621032,,BAO_0000218,,
4475,3880,The compound was tested for half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621033,,BAO_0000218,,
4476,3639,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621034,,BAO_0000218,1969.0,
4477,3880,The half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621035,,BAO_0000218,,
4478,3918,The plasma half-life in dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621036,,BAO_0000218,1969.0,
4479,16452,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621037,,BAO_0000218,1969.0,
4480,17796,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619812,,BAO_0000218,,
4481,5983,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619813,,BAO_0000218,,
4482,1466,tmax upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873335,,BAO_0000218,,
4483,16456,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619814,,BAO_0000218,,
4484,6113,Cmax in ferrets after 30 mg/kg oral dose,A,In vivo,,Mustela putorius furo,9669.0,,,,,50506,N,1,Expert,1,,CHEMBL619815,,BAO_0000218,,
4485,6113,Emesis in ferrets at 30 mg/kg oral dose,F,In vivo,,Mustela putorius furo,9669.0,,,,,50506,N,1,Expert,1,,CHEMBL619816,,BAO_0000218,,
4486,17796,Bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619817,,BAO_0000218,,
4487,17796,Volume of distribution in cynomolgus,A,In vivo,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL619818,,BAO_0000218,,
4488,5308,AUC tested in guinea pig when 3 mg/kg dose was given perorally,A,,,Cavia porcellus,10141.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619819,,BAO_0000218,1969.0,
4489,4877,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619820,,BAO_0000218,,
4490,4876,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875419,,BAO_0000218,,
4491,4878,AUC in guinea pig after 3mg/kg oral dose,A,In vivo,,Cavia porcellus,10141.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619821,,BAO_0000218,1969.0,
4492,5308,Bioavailability in guinea pig was tested,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619822,,BAO_0000218,,
4493,4877,Tested for oral bioavailability in guinea pig at 5 mg/kg,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619823,,BAO_0000218,,
4494,4876,Tested for the oral bioavailability of the compound,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619824,,BAO_0000218,,
4495,4876,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619825,,BAO_0000218,,
4496,5308,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619826,,BAO_0000218,,
4497,4877,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,In vivo,,Cavia porcellus,10141.0,,Lung,,,22224,U,0,Autocuration,1,,CHEMBL619827,,BAO_0000218,2048.0,
4498,4878,Cmax in guinea pig after 3mg/kg oral dose,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618167,,BAO_0000218,,
4499,5689,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL618168,,BAO_0000019,178.0,
4500,5689,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Brain,,,22224,U,0,Autocuration,1,,CHEMBL618169,,BAO_0000019,955.0,
4501,5689,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618170,,BAO_0000019,,
4502,5689,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Intestine,,,22224,U,0,Autocuration,1,,CHEMBL618171,,BAO_0000019,160.0,
4503,5689,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Kidney,,,22224,U,0,Autocuration,1,,CHEMBL618172,,BAO_0000019,2113.0,
4504,5689,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL618173,,BAO_0000019,2107.0,
4505,5689,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618174,,BAO_0000019,,
4506,5689,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL875408,,BAO_0000019,2106.0,
4507,14465,Elimination T1/2 in Guinea pig (PO dose),A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL839827,,BAO_0000218,,
4508,5689,Partition coefficient was measured as -log (counts per min ),A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618175,,BAO_0000019,,
4509,611,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618176,,BAO_0000218,,
4510,611,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618177,,BAO_0000218,,
4511,14465,Elimination T1/2 in Guinea pig (PO dose),A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618178,,BAO_0000218,,
4512,4876,"Tested for the half life period of the compound, intravenously",A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618179,,BAO_0000218,,
4513,5689,Half-life was measured,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873489,,BAO_0000019,,
4514,7515,The time required for onset of inotropy after addition of a single dose of delta F75,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618180,,BAO_0000019,,
4515,17667,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618181,,BAO_0000218,,
4516,17667,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618182,,BAO_0000218,,
4517,4727,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618183,,BAO_0000218,,
4518,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618184,,BAO_0000218,,
4519,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618185,,BAO_0000218,,
4520,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618186,,BAO_0000218,,
4521,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618187,,BAO_0000218,,
4522,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618188,,BAO_0000218,,
4523,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875409,,BAO_0000218,,
4524,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618189,,BAO_0000218,,
4525,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL618190,,BAO_0000218,178.0,
4526,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL618191,,BAO_0000218,178.0,
4527,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL618192,,BAO_0000218,178.0,
4528,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL618193,,BAO_0000218,10000001.0,
4529,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL618194,,BAO_0000218,10000001.0,
4530,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL618195,,BAO_0000218,10000001.0,
4531,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618196,,BAO_0000218,955.0,
4532,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618197,,BAO_0000218,955.0,
4533,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618198,,BAO_0000218,955.0,
4534,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL618199,,BAO_0000218,948.0,
4535,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL618200,,BAO_0000218,948.0,
4536,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL618201,,BAO_0000218,948.0,
4537,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL618202,,BAO_0000218,160.0,
4538,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL618203,,BAO_0000218,160.0,
4539,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL618204,,BAO_0000218,160.0,
4540,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618205,,BAO_0000218,2113.0,
4541,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618206,,BAO_0000218,2113.0,
4542,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618207,,BAO_0000218,2113.0,
4543,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618208,,BAO_0000218,2107.0,
4544,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618932,,BAO_0000218,2107.0,
4545,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618933,,BAO_0000218,2107.0,
4546,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618934,,BAO_0000218,2048.0,
4547,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618935,,BAO_0000218,2048.0,
4548,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618936,,BAO_0000218,2048.0,
4549,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL618937,,BAO_0000218,2385.0,
4550,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL618938,,BAO_0000218,2385.0,
4551,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL619104,,BAO_0000218,2385.0,
4552,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL619105,,BAO_0000218,2106.0,
4553,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL619106,,BAO_0000218,2106.0,
4554,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL619107,,BAO_0000218,2106.0,
4555,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL875410,,BAO_0000218,945.0,
4556,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL619108,,BAO_0000218,945.0,
4557,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL619109,,BAO_0000218,945.0,
4558,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619110,,BAO_0000218,,
4559,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619111,,BAO_0000218,,
4560,16597,MRT value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619112,,BAO_0000218,,
4561,16597,MRT value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619113,,BAO_0000218,,
4562,17764,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619114,,BAO_0000218,,
4563,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619115,,BAO_0000218,,
4564,3830,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619116,478.0,BAO_0000219,,
4565,3829,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619117,478.0,BAO_0000219,,
4566,2040,Compound was evaluated for cytotoxicity against A2780 cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619118,478.0,BAO_0000219,,
4567,15684,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619119,478.0,BAO_0000219,,
4568,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619120,478.0,BAO_0000219,,
4569,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619121,478.0,BAO_0000219,,
4570,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619122,478.0,BAO_0000219,,
4571,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619123,478.0,BAO_0000219,,
4572,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619124,478.0,BAO_0000219,,
4573,2859,Compound was evaluated for cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619125,478.0,BAO_0000219,,
4574,5618,In vitro inhibitory activity against human tumor cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL875411,478.0,BAO_0000219,,
4575,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619126,478.0,BAO_0000219,,
4576,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619127,478.0,BAO_0000219,,
4577,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619128,478.0,BAO_0000219,,
4578,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619129,478.0,BAO_0000219,,
4579,2113,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619130,478.0,BAO_0000219,,
4580,2113,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619131,478.0,BAO_0000219,,
4581,16745,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619132,478.0,BAO_0000219,,
4582,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619133,478.0,BAO_0000218,,
4583,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619134,478.0,BAO_0000219,,
4584,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619135,478.0,BAO_0000219,,
4585,2040,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619136,478.0,BAO_0000219,,
4586,2040,Relative resistance factor in A2780 cisplatin-resistant line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619137,478.0,BAO_0000219,,
4587,16165,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL883713,478.0,BAO_0000219,,
4588,16165,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL875412,478.0,BAO_0000219,,
4589,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619138,478.0,BAO_0000218,,
4590,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619262,478.0,BAO_0000218,,
4591,3992,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619139,478.0,BAO_0000219,,
4592,10553,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619140,478.0,BAO_0000219,,
4593,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619141,478.0,BAO_0000219,,
4594,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619142,478.0,BAO_0000219,,
4595,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619143,478.0,BAO_0000219,,
4596,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619144,478.0,BAO_0000219,,
4597,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619145,478.0,BAO_0000219,,
4598,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619146,478.0,BAO_0000219,,
4599,15569,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619147,478.0,BAO_0000219,,
4600,17420,Antiproliferative effect of compound on A2780/DX cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619148,478.0,BAO_0000219,,
4601,17420,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619149,478.0,BAO_0000219,,
4602,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619150,478.0,BAO_0000219,,
4603,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619151,478.0,BAO_0000219,,
4604,17672,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL883794,478.0,BAO_0000219,,
4605,17672,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619152,478.0,BAO_0000219,,
4606,17270,In vitro cytotoxicity against A2780ADR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619153,478.0,BAO_0000219,,
4607,17270,In vitro cytotoxicity against A2780CIS cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619154,478.0,BAO_0000219,,
4608,5574,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619155,478.0,BAO_0000219,,
4609,2113,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619156,478.0,BAO_0000219,,
4610,16913,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619157,478.0,BAO_0000219,,
4611,16913,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619797,478.0,BAO_0000219,,
4612,17839,Oral bioavailability of compound in rhesus macaques,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619798,,BAO_0000218,,
4613,6821,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619799,,BAO_0000218,,
4614,6078,Oral bioavailability evaluated in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619800,,BAO_0000218,,
4615,6535,Oral bioavailability in monkey (dose 1 mg/kg p.o.),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619801,,BAO_0000218,,
4616,4449,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619802,,BAO_0000218,,
4617,6057,Oral bioavailability was calculated in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619803,,BAO_0000218,,
4618,5922,Oral bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619965,,BAO_0000218,,
4619,5940,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619966,,BAO_0000218,,
4620,6265,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619967,,BAO_0000218,,
4621,6265,Oral bioavailability in monkey (dose 1 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620073,,BAO_0000218,,
4622,6265,Oral bioavailability in monkey (dose 5 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620074,,BAO_0000218,,
4623,5940,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620075,,BAO_0000218,,
4624,5940,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620076,,BAO_0000218,,
4625,4514,Oral bioavailability in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620077,,BAO_0000218,,
4626,5546,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620078,,BAO_0000218,,
4627,5553,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,A,In vivo,,Saimiri sciureus,9521.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620079,,BAO_0000218,,
4628,6641,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620080,,BAO_0000218,,
4629,5472,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620081,,BAO_0000218,,
4630,5668,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620082,,BAO_0000218,,
4631,5711,Oral bioavailability in monkey at 10 mg/kg of the compound,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620083,,BAO_0000218,,
4632,5145,Bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620084,,BAO_0000218,,
4633,3443,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620085,,BAO_0000218,,
4634,3443,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL874595,,BAO_0000218,,
4635,3249,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873352,,BAO_0000218,,
4636,3249,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620086,,BAO_0000218,,
4637,5355,Mean residence time was determined after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620087,,BAO_0000218,,
4638,5355,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620088,,BAO_0000218,,
4639,5355,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620089,,BAO_0000218,,
4640,4809,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620090,,BAO_0000218,,
4641,4809,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620091,,BAO_0000218,,
4642,14294,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620092,,BAO_0000251,,
4643,14294,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620093,,BAO_0000251,,
4644,14294,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620094,,BAO_0000251,,
4645,14294,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620095,,BAO_0000251,,
4646,3443,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620096,,BAO_0000218,,
4647,3443,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620097,,BAO_0000218,,
4648,11271,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620098,,BAO_0000019,,
4649,3443,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620099,,BAO_0000218,,
4650,3443,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620100,,BAO_0000218,,
4651,6821,Elimination Half-life of compound was determined in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620101,,BAO_0000019,,
4652,17267,Half life of compound was determined in rhesus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620102,,BAO_0000019,,
4653,5819,Half life in monkey plasma,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620103,,BAO_0000366,1969.0,
4654,5819,Half life in monkey plasma; Not detected,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620104,,BAO_0000366,1969.0,
4655,1916,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL874596,,BAO_0000218,,
4656,17509,Half-life 24 hr after 2 mg/kg iv administration in monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873490,,BAO_0000218,,
4657,1399,Terminal half life of the compound.,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620105,,BAO_0000019,,
4658,1916,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620780,,BAO_0000218,,
4659,4809,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620781,,BAO_0000218,,
4660,5546,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620956,,BAO_0000218,,
4661,3443,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620957,,BAO_0000218,1088.0,
4662,3443,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620958,,BAO_0000218,1088.0,
4663,4257,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620959,,BAO_0000218,,
4664,6221,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620960,,BAO_0000218,,
4665,5472,Volume of distribution was evaluated in rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620961,,BAO_0000218,,
4666,4727,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620962,,BAO_0000218,,
4667,4727,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620963,,BAO_0000218,,
4668,4727,Bioavailability in hamster was determined,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620964,,BAO_0000218,,
4669,4727,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620965,,BAO_0000218,,
4670,4727,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620966,,BAO_0000218,,
4671,4727,Half life of compound was determined in hamster blood,A,,,Cricetulus griseus,10029.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL620967,,BAO_0000221,178.0,
4672,1452,Michaelis-Menten constant of the compound.,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620968,,BAO_0000019,,
4673,1452,Vmax value was measured at 0 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL874597,,BAO_0000019,,
4674,1452,Vmax value was measured at 10 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620969,,BAO_0000019,,
4675,1452,Vmax value was measured at 5 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620970,,BAO_0000019,,
4676,11706,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,B,,,Homo sapiens,9606.0,,,,,235,D,9,Expert,1,,CHEMBL620971,,BAO_0000357,,
4677,1916,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620972,,BAO_0000218,,
4678,17791,Compound was evaluated for area under the curve expressed as (h*ug/ml),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620973,,BAO_0000019,,
4679,7766,Active metabolite of ifosfamide determined in humans; A-Active,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618243,,BAO_0000019,,
4680,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618244,,BAO_0000019,,
4681,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618245,,BAO_0000019,,
4682,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618246,,BAO_0000019,,
4683,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618247,,BAO_0000019,,
4684,17791,Compound was evaluated for oral bioavailability in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618248,,BAO_0000218,,
4685,7766,Metabolite of ifosfamide determined in urine; NF-Not found,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618249,,BAO_0000019,1088.0,
4686,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618250,,BAO_0000019,,
4687,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL874598,,BAO_0000019,,
4688,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618251,,BAO_0000019,,
4689,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618252,,BAO_0000019,,
4690,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618253,,BAO_0000019,,
4691,6852,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618254,,BAO_0000019,,
4692,6852,Percent of compound in healthy individuals (Group D),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618255,,BAO_0000019,,
4693,4397,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618983,,BAO_0000251,2107.0,
4694,17409,Binding towards human plasma protein at 10 uM,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618984,,BAO_0000019,,
4695,17409,Binding towards human plasma protein at 100 uM,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618985,,BAO_0000019,,
4696,17176,Human plasma protein binding activity was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618986,,BAO_0000019,,
4697,15444,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618987,,BAO_0000019,,
4698,17267,Percent binding of compound towards human plasma protein was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618988,,BAO_0000019,,
4699,5944,Plasma clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618989,,BAO_0000251,2107.0,
4700,5668,In vitro intrinsic clearance in human liver microsome,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618990,,BAO_0000251,2107.0,
4701,5669,In vitro intrinsic clearance in human liver microsome,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618991,,BAO_0000251,2107.0,
4702,5041,In vitro microsome metabolism clearance in human was determined,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL876725,,BAO_0000251,,
4703,5041,In vitro microsome metabolism clearance in human was determined; High,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618992,,BAO_0000251,,
4704,5041,In vitro microsome metabolism clearance in human was determined; ND denotes no data,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618993,,BAO_0000251,,
4705,5676,Pharmacokinetic property (clearance) in human liver microsome,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618994,,BAO_0000251,2107.0,
4706,5944,Plasma clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618995,,BAO_0000251,2107.0,
4707,17538,In vitro clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618996,,BAO_0000251,2107.0,
4708,6331,Intrinsic clearance in human liver microsomes was determined,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618997,,BAO_0000251,2107.0,
4709,5948,Intrinsic clearance in human liver microsomes was determined,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618998,,BAO_0000251,2107.0,
4710,5965,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618999,,BAO_0000218,,
4711,1916,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620223,,BAO_0000218,,
4712,5965,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620224,,BAO_0000218,,
4713,1299,Stability in human plasma 2 hr after incubation expressed as percent concentration,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620225,,BAO_0000019,,
4714,1299,Stability in human plasma 4 hr after incubation expressed as percent concentration,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620226,,BAO_0000019,,
4715,7766,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620227,,BAO_0000019,1088.0,
4716,7766,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL876726,,BAO_0000019,1088.0,
4717,7766,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620228,,BAO_0000019,1088.0,
4718,7766,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620229,,BAO_0000019,1088.0,
4719,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620230,,BAO_0000218,,
4720,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620231,,BAO_0000218,,
4721,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620232,,BAO_0000218,,
4722,17764,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620233,,BAO_0000218,,
4723,14294,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620234,,BAO_0000218,,
4724,14294,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620235,,BAO_0000218,,
4725,14294,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620236,,BAO_0000218,,
4726,6251,In vitro metabolic potential in mouse liver microsomes,A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL620237,,BAO_0000218,2107.0,
4727,17582,Ability of compound to bind to plasma protein was evaluated in HSA cells,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620238,,BAO_0000218,,
4728,17811,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),A,,,Mus musculus,10090.0,,Adrenal gland,,,50594,N,1,Intermediate,1,,CHEMBL620239,,BAO_0000218,2369.0,
4729,17811,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL620240,,BAO_0000218,955.0,
4730,17811,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL620241,,BAO_0000218,955.0,
4731,17811,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876727,,BAO_0000218,,
4732,17811,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL620242,,BAO_0000218,2113.0,
4733,17811,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620243,,BAO_0000218,,
4734,5288,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620244,,BAO_0000218,,
4735,2717,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL620245,,BAO_0000218,1977.0,
4736,2717,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL620246,,BAO_0000218,1977.0,
4737,2717,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL620247,,BAO_0000218,1977.0,
4738,17753,Half life of compound was determined in plasma of mice at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL620248,,BAO_0000218,1969.0,
4739,17753,Half life of compound was determined in plasma of mice at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL873497,,BAO_0000218,1969.0,
4740,17753,Half life of compound was determined in plasma of mice at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL620249,,BAO_0000218,1969.0,
4741,17764,Half life after intraperitoneal administration in mice at 18 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620250,,BAO_0000218,,
4742,17764,Half life after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620251,,BAO_0000218,,
4743,17764,Half life after intraperitoneal administration in mice at 25 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620252,,BAO_0000218,,
4744,17764,Half life after intraperitoneal administration in mice at 26 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620253,,BAO_0000218,,
4745,17764,Half life after intravenous administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620254,,BAO_0000218,,
4746,17764,Half life after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620255,,BAO_0000218,,
4747,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620256,,BAO_0000218,,
4748,2675,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876728,,BAO_0000218,,
4749,2675,Maximum time required to reach Cp max was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620257,,BAO_0000218,,
4750,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620258,,BAO_0000218,,
4751,4890,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620259,,BAO_0000218,,
4752,429,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620260,,BAO_0000218,,
4753,17837,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620261,,BAO_0000218,178.0,
4754,16597,Half life at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620262,,BAO_0000218,,
4755,16597,Half life at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620263,,BAO_0000218,,
4756,6619,Half life in ob/ob mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620264,,BAO_0000218,,
4757,4066,Half-life at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620265,,BAO_0000218,,
4758,4239,Half-life was measured in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620266,,BAO_0000218,,
4759,5969,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620267,,BAO_0000218,,
4760,8999,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619364,,BAO_0000218,,
4761,8999,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619365,,BAO_0000218,,
4762,17641,T2 in brain of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL619366,,BAO_0000218,955.0,
4763,17641,T2 in kidney of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL619367,,BAO_0000218,2113.0,
4764,17641,T2 in liver of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL619368,,BAO_0000218,2107.0,
4765,17641,T2 in lungs of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL619369,,BAO_0000218,2048.0,
4766,17641,T2 in spleen of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL876729,,BAO_0000218,2106.0,
4767,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619370,,BAO_0000218,,
4768,4890,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619371,,BAO_0000218,,
4769,429,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619372,,BAO_0000218,,
4770,429,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620012,,BAO_0000218,,
4771,5969,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620013,,BAO_0000218,,
4772,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL620014,478.0,BAO_0000219,,
4773,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL620015,478.0,BAO_0000219,,
4774,16913,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621010,478.0,BAO_0000219,,
4775,16913,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621011,478.0,BAO_0000219,,
4776,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621012,478.0,BAO_0000219,,
4777,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621013,478.0,BAO_0000219,,
4778,17270,In vitro cytotoxicity against A2780TAX cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621014,478.0,BAO_0000219,,
4779,5618,In vitro inhibitory activity against human tumor cell line A2780cis,F,,,Homo sapiens,9606.0,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618154,481.0,BAO_0000219,,
4780,17777,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618155,478.0,BAO_0000219,,
4781,16112,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618156,481.0,BAO_0000219,,
4782,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618157,481.0,BAO_0000219,,
4783,6633,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618328,478.0,BAO_0000219,,
4784,16930,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618329,478.0,BAO_0000219,,
4785,17496,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618330,478.0,BAO_0000219,,
4786,12989,In vitro antitumor activity against A2780cisR cell line.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618331,478.0,BAO_0000219,,
4787,4840,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618332,478.0,BAO_0000219,,
4788,12989,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618333,478.0,BAO_0000219,,
4789,16745,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,F,,,Homo sapiens,9606.0,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618334,481.0,BAO_0000219,,
4790,16597,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618335,478.0,BAO_0000219,,
4791,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,B,,,Rattus norvegicus,10116.0,,,,,11736,D,9,Expert,1,,CHEMBL618336,,BAO_0000019,,
4792,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,,,,,,,,11736,H,8,Expert,1,,CHEMBL618337,,BAO_0000019,,
4793,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,,Rattus norvegicus,10116.0,,,,,11736,D,9,Expert,1,,CHEMBL618338,,BAO_0000019,,
4794,15856,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,F,,,Homo sapiens,9606.0,,,HEK293,,278,D,9,Expert,1,,CHEMBL618339,722.0,BAO_0000219,,
4795,15856,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,F,,,Homo sapiens,9606.0,,,HEK293,,278,D,9,Expert,1,,CHEMBL618340,722.0,BAO_0000219,,
4796,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,B,,,Mus musculus,10090.0,,,,,11831,D,9,Expert,1,,CHEMBL618341,,BAO_0000019,,
4797,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,,,,,,,,11831,H,8,Expert,1,,CHEMBL618342,,BAO_0000019,,
4798,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,,Mus musculus,10090.0,,,,,11831,D,9,Expert,1,,CHEMBL618343,,BAO_0000019,,
4799,17402,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,B,,,,,,,,,280,H,8,Expert,1,,CHEMBL621038,,BAO_0000357,,
4800,11746,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),F,,,Homo sapiens,9606.0,,,T-cells,,22226,U,0,Autocuration,1,,CHEMBL621039,574.0,BAO_0000219,,
4801,11746,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,F,,,Homo sapiens,9606.0,,,T-cells,,22226,U,0,Autocuration,1,,CHEMBL621040,574.0,BAO_0000219,,
4802,5455,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621041,455.0,BAO_0000219,,
4803,2068,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621042,455.0,BAO_0000219,,
4804,2683,In vitro antitumor activity against A375cell line extracted form melanoma,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621043,455.0,BAO_0000219,,
4805,15313,Inhibition of cell growth in (A375) melan cell line,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Expert,1,,CHEMBL621044,455.0,BAO_0000219,,
4806,13739,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621045,455.0,BAO_0000219,,
4807,13739,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621046,455.0,BAO_0000219,,
4808,14750,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621047,455.0,BAO_0000219,,
4809,14777,Antiproliferative activity measured against A427 human lung carcinoma,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621048,797.0,BAO_0000219,,
4810,14777,Antiproliferative activity measured against A427 human lung carcinoma,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL883798,797.0,BAO_0000219,,
4811,17672,Cytotoxicity against lung carcinoma A427 tumor cell lines,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621049,797.0,BAO_0000219,,
4812,14368,Inhibition of large cell lung carcinoma (A427),F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621050,797.0,BAO_0000219,,
4813,14368,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621051,797.0,BAO_0000219,,
4814,13866,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621052,797.0,BAO_0000219,,
4815,2545,Inhibitory concentration in human lung carcinoma A427 cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621053,797.0,BAO_0000219,,
4816,2545,Inhibitory concentration in human lung carcinoma A427/VCR cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621054,797.0,BAO_0000219,,
4817,6062,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621055,,BAO_0000218,,
4818,4578,Tested for volume of distribution upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876398,,BAO_0000218,,
4819,17592,Volume of distribution in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621056,,BAO_0000218,,
4820,5005,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621057,,BAO_0000218,,
4821,5005,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621058,,BAO_0000218,,
4822,5922,Pharmacokinetic property(Vdss) in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621059,,BAO_0000218,,
4823,5355,The distribution volume after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621060,,BAO_0000218,,
4824,5355,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621061,,BAO_0000218,,
4825,5355,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621062,,BAO_0000218,,
4826,6057,Volume displacement was calculated in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621063,,BAO_0000218,,
4827,5145,Volume of distribution in steady state was determined in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621064,,BAO_0000218,,
4828,6821,Volume of distribution of compound was determined in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621065,,BAO_0000218,,
4829,5334,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621066,,BAO_0000218,,
4830,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621067,,BAO_0000218,,
4831,6641,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621068,,BAO_0000218,,
4832,2661,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876399,,BAO_0000218,,
4833,6535,Volume distribution in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621069,,BAO_0000218,,
4834,4809,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621070,,BAO_0000218,,
4835,6062,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621071,,BAO_0000218,,
4836,3443,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621072,,BAO_0000218,,
4837,4578,Oral systemic bioavailability upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618209,,BAO_0000218,,
4838,4809,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618210,,BAO_0000218,,
4839,11271,Baboon plasma free fraction. ,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618211,,BAO_0000019,,
4840,6057,Area under the curve was calculated in rhesus monkey after iv administration,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618212,,BAO_0000218,,
4841,6057,Area under the curve was calculated in rhesus monkey after peroral administration,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618213,,BAO_0000019,,
4842,17853,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618214,,BAO_0000019,,
4843,5302,Half life period in monkey after 5 mg/kg dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873492,,BAO_0000218,,
4844,4257,Half-life was determined in monkey after 3 mg/kg of i.v. dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618272,,BAO_0000218,,
4845,4257,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618273,,BAO_0000218,,
4846,13501,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618274,,BAO_0000218,1969.0,
4847,5394,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618275,,BAO_0000218,,
4848,2661,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618276,,BAO_0000218,,
4849,3341,Compound was evaluated for terminal half life in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618277,,BAO_0000019,,
4850,3045,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618278,,BAO_0000218,,
4851,5005,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618279,,BAO_0000218,1969.0,
4852,4847,Half life of compound was determined in squirrel monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618280,,BAO_0000019,,
4853,4256,Half life after iv administration in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618281,,BAO_0000218,,
4854,6535,Half life in monkey plasma after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618282,,BAO_0000218,1969.0,
4855,6057,Half life was calculated in rhesus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618283,,BAO_0000019,,
4856,17592,Half life in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618284,,BAO_0000019,,
4857,6641,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618285,,BAO_0000218,,
4858,5472,Half life was evaluated in rhesus,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618286,,BAO_0000019,,
4859,6221,Half life period after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618287,,BAO_0000218,,
4860,5668,Half life period was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618288,,BAO_0000218,,
4861,4809,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876393,,BAO_0000218,,
4862,5546,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618289,,BAO_0000218,,
4863,5553,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618290,,BAO_0000218,,
4864,6078,Half-life was calculated in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618291,,BAO_0000019,,
4865,5147,Half-life in Squirrel monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618292,,BAO_0000019,,
4866,5145,Half-life in rhesus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618293,,BAO_0000019,,
4867,6062,Half-life was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618294,,BAO_0000218,,
4868,5355,Half-life period after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618295,,BAO_0000218,,
4869,5355,Half-life period after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618296,,BAO_0000218,,
4870,5355,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618297,,BAO_0000218,,
4871,7766,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618298,,BAO_0000019,1088.0,
4872,7766,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618299,,BAO_0000019,1088.0,
4873,7766,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618300,,BAO_0000019,1088.0,
4874,7766,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618301,,BAO_0000019,1088.0,
4875,7766,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618302,,BAO_0000019,1088.0,
4876,7766,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL876394,,BAO_0000019,1088.0,
4877,7766,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618303,,BAO_0000019,1088.0,
4878,7766,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618304,,BAO_0000019,1088.0,
4879,1916,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618305,,BAO_0000218,,
4880,16643,Oral bioavailability in human,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618306,,BAO_0000218,,
4881,17248,Compound was tested for human plasma protein binding,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618307,,BAO_0000019,,
4882,17248,Compound was tested for human plasma protein binding; Not determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618308,,BAO_0000019,,
4883,6241,Protein binding activity of compound in human plasma; % Free,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618309,,BAO_0000019,,
4884,17716,Unbound fraction (plasma),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618310,,BAO_0000019,,
4885,17605,Half life for the hydrolysis of compound in human blood serum,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL873353,,BAO_0000366,1969.0,
4886,17625,Half life period in human plasma using phosphate buffer (0.08 M),A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618311,,BAO_0000366,1969.0,
4887,17625,Half life period in human plasma using phosphate buffer (0.1 M),A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618312,,BAO_0000366,1969.0,
4888,17747,Half-life in human plasma was determined,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618313,,BAO_0000366,1969.0,
4889,15613,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618314,,BAO_0000019,,
4890,354,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618315,,BAO_0000019,,
4891,3741,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618316,,BAO_0000019,,
4892,3741,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618317,,BAO_0000019,,
4893,3741,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620138,,BAO_0000019,,
4894,17599,Partition coefficient (logP),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL858280,,BAO_0000019,,
4895,5486,In vitro metabolic stability in human was measured as pmol/min/mg/protein,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620139,,BAO_0000019,,
4896,5600,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,A,,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620140,,BAO_0000251,,
4897,14294,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620141,,BAO_0000019,,
4898,14294,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620142,,BAO_0000019,,
4899,14294,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620143,,BAO_0000019,,
4900,14294,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),A,,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620144,,BAO_0000251,,
4901,14294,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),A,,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620145,,BAO_0000251,,
4902,14294,Metabolism of compound in human microsomes; Trace,A,,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620146,,BAO_0000251,,
4903,6260,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620147,,BAO_0000251,2107.0,
4904,6187,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,A,,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620148,,BAO_0000251,,
4905,6251,In vitro metabolic potential in human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620149,,BAO_0000251,2107.0,
4906,3246,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876412,,BAO_0000019,,
4907,17313,Tested for human plasma protein binding of the compound; Not tested,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619352,,BAO_0000019,,
4908,6227,Compound was tested for percent protein binding (PB) in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619353,,BAO_0000019,,
4909,5530,Protein binding in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619354,,BAO_0000019,1969.0,
4910,6108,Permeability coefficient (B to A) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619355,,BAO_0000019,,
4911,6108,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619356,,BAO_0000019,,
4912,2774,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619357,,BAO_0000019,,
4913,16643,In vitro rate of absorption observed as Caco-2 permeability in humans,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619358,,BAO_0000019,,
4914,17582,Cellular permeability of compound was determined in Caco-2 cells; High,A,,,Homo sapiens,9606.0,,,Caco-2,,22224,U,0,Autocuration,1,,CHEMBL619359,495.0,BAO_0000219,,
4915,6838,Permeability in Caco-2 cells of compound,A,,,Homo sapiens,9606.0,,,Caco-2,,22224,U,0,Autocuration,1,,CHEMBL619360,495.0,BAO_0000219,,
4916,6108,Permeability coefficient (A to B) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619361,,BAO_0000019,,
4917,6108,Permeability coefficient (B to A) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619362,,BAO_0000019,,
4918,6108,Permeability coefficient (Papp) (Caco-2 cell monolayer),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619363,,BAO_0000019,,
4919,2146,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618942,,BAO_0000019,,
4920,4514,Compound was tested for protein binding in human plasma,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618943,,BAO_0000019,,
4921,6108,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618944,,BAO_0000019,,
4922,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618945,,BAO_0000019,1088.0,
4923,5969,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618946,,BAO_0000218,,
4924,3277,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876413,,BAO_0000218,,
4925,3802,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618947,,BAO_0000218,,
4926,2862,Time taken to reach maximum concentration in plasma upon oral administration in mouse,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL618948,,BAO_0000218,1969.0,
4927,6348,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL618949,,BAO_0000218,1969.0,
4928,17764,Tmax after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618950,,BAO_0000218,,
4929,5781,Tmax after oral administration at 30 mg/kg in ICR mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618951,,BAO_0000218,,
4930,17764,Tmax after peroral administration in mice at 2.4 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618952,,BAO_0000218,,
4931,4066,Tmax at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618953,,BAO_0000218,,
4932,17641,Tmax in brain of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618954,,BAO_0000218,955.0,
4933,17641,Tmax in kidney of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618955,,BAO_0000218,2113.0,
4934,17641,Tmax in liver of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618956,,BAO_0000218,2107.0,
4935,17641,Tmax in lungs of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618957,,BAO_0000218,2048.0,
4936,17764,Tmax in mice at 18 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618958,,BAO_0000218,,
4937,17764,Tmax in mice at 23 uM/kg i.v. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618959,,BAO_0000218,,
4938,17764,Tmax in mice at 25 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618960,,BAO_0000218,,
4939,17764,Tmax in mice at 26 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876723,,BAO_0000218,,
4940,17641,Tmax in spleen of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618961,,BAO_0000218,2106.0,
4941,16597,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618962,,BAO_0000218,,
4942,16597,Tmax value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618963,,BAO_0000218,,
4943,5951,Tmax value in IRC mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618964,,BAO_0000218,,
4944,5506,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618965,,BAO_0000218,,
4945,5506,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618966,,BAO_0000218,,
4946,429,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL618967,,BAO_0000218,1088.0,
4947,429,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL618968,,BAO_0000218,1088.0,
4948,4066,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL618969,,BAO_0000218,1088.0,
4949,17734,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618970,,BAO_0000218,,
4950,17734,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618971,,BAO_0000218,,
4951,6062,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618972,,BAO_0000218,,
4952,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618973,,BAO_0000218,,
4953,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618974,,BAO_0000218,,
4954,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618975,,BAO_0000218,,
4955,5980,Vd in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618976,,BAO_0000218,,
4956,17592,Volume of distribution in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618977,,BAO_0000218,,
4957,6348,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876724,,BAO_0000218,,
4958,17753,Volume of distribution of compound in plasma was determined at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618978,,BAO_0000218,,
4959,17753,Volume of distribution of compound in plasma was determined at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618979,,BAO_0000218,,
4960,17753,Volume of distribution of compound in plasma was determined at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618980,,BAO_0000218,,
4961,4239,Pharmacokinetic property (vdss) was measured in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618981,,BAO_0000218,,
4962,2862,Value distribution upon iv administration in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618982,,BAO_0000218,,
4963,17734,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620150,,BAO_0000218,,
4964,2675,Volume of distribution was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620151,,BAO_0000218,,
4965,2675,Volume of distribution was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620152,,BAO_0000218,,
4966,17837,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620153,,BAO_0000218,,
4967,5727,Steady state volume of distribution was determined in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876395,,BAO_0000218,,
4968,17852,Volume distribution (steady state) of compound was determined in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620154,,BAO_0000218,,
4969,17764,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620155,,BAO_0000218,,
4970,16597,Vss value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620156,,BAO_0000218,,
4971,6062,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620157,,BAO_0000218,,
4972,16438,Biodistribution of compound (oxidized form) in in kidney tissue,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL620158,,BAO_0000218,2113.0,
4973,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620159,,BAO_0000218,178.0,
4974,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620160,,BAO_0000218,178.0,
4975,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620161,,BAO_0000218,178.0,
4976,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL620162,797.0,BAO_0000219,,
4977,16597,Inhibition of A431 human squamous cell carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620163,500.0,BAO_0000219,,
4978,16062,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620833,500.0,BAO_0000219,,
4979,16062,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL876396,500.0,BAO_0000219,,
4980,16958,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620834,500.0,BAO_0000219,,
4981,6700,Inhibition of A431 human carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620835,500.0,BAO_0000219,,
4982,17226,In vitro inhibition of A431 (human carcinoma) cell basal growth.,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620836,500.0,BAO_0000219,,
4983,6828,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL620837,500.0,BAO_0000219,,
4984,12314,In vitro cytotoxicity against epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621017,500.0,BAO_0000219,,
4985,13412,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621018,500.0,BAO_0000218,,
4986,13299,Antiproliferative activity of compound was measured on human tumor cell line A431.,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621019,500.0,BAO_0000219,,
4987,17420,Antiproliferative effect of compound on A431 cell line expressing mutant p53,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621020,500.0,BAO_0000219,,
4988,13678,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621021,500.0,BAO_0000219,,
4989,14171,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,F,,,,,,,A-431,,9,H,8,Expert,1,,CHEMBL621022,500.0,BAO_0000219,,
4990,6333,Tested for antiproliferative activity against human A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621023,500.0,BAO_0000219,,
4991,2356,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621024,500.0,BAO_0000219,,
4992,15578,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621025,500.0,BAO_0000219,,
4993,5126,Inhibition of A431 cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621026,500.0,BAO_0000219,,
4994,6844,Cytotoxic effect on A431 human epidermoid carcinoma cells,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621027,500.0,BAO_0000219,,
4995,6844,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL876397,500.0,BAO_0000219,,
4996,4925,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL883797,500.0,BAO_0000219,,
4997,4925,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621028,500.0,BAO_0000219,,
4998,13978,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621029,500.0,BAO_0000219,,
4999,16786,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621030,500.0,BAO_0000219,,
5000,13412,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,,,,,A-431,,9,H,8,Expert,1,,CHEMBL621147,500.0,BAO_0000219,,
5001,17824,In vivo antiproliferative activity against A431 cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621148,500.0,BAO_0000218,,
5002,12751,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621149,500.0,BAO_0000219,,
5003,12380,Inhibition of A431 human epidermoid carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621150,500.0,BAO_0000219,,
5004,4959,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621151,500.0,BAO_0000219,,
5005,6333,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621152,500.0,BAO_0000219,,
5006,6333,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621153,500.0,BAO_0000219,,
5007,6333,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL884000,500.0,BAO_0000219,,
5008,5296,Inhibition of EGFR overexpressing A431 cell proliferation,F,,,Homo sapiens,9606.0,,,,,9,D,9,Expert,1,,CHEMBL621154,,BAO_0000019,,
5009,12624,Inhibition of A431 cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621155,500.0,BAO_0000219,,
5010,14926,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621156,500.0,BAO_0000219,,
5011,14926,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621157,500.0,BAO_0000219,,
5012,14926,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),F,,,,,,,A-431,,9,H,8,Expert,1,,CHEMBL621158,500.0,BAO_0000219,,
5013,15144,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621159,500.0,BAO_0000219,,
5014,15144,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621160,500.0,BAO_0000219,,
5015,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621161,500.0,BAO_0000219,,
5016,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621162,500.0,BAO_0000219,,
5017,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621163,500.0,BAO_0000219,,
5018,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621164,500.0,BAO_0000219,,
5019,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621165,500.0,BAO_0000219,,
5020,5922,Half-life period in cynomolgus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619159,,BAO_0000019,,
5021,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",A,In vitro,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619160,,BAO_0000366,1969.0,
5022,17853,Longer half-life in monkey (i.v.) at 0.5 mpk,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619161,,BAO_0000218,,
5023,993,Plasma half life in monkey,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619162,,BAO_0000366,1969.0,
5024,4514,Plasma half-life in rhesus monkey,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619163,,BAO_0000366,1969.0,
5025,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619164,,BAO_0000218,1969.0,
5026,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619320,,BAO_0000218,1969.0,
5027,4578,Tested for half life upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619321,,BAO_0000218,,
5028,2661,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873336,,BAO_0000218,,
5029,5355,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619322,,BAO_0000218,,
5030,5355,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619323,,BAO_0000218,,
5031,5355,The time for peak concentration value after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619324,,BAO_0000218,,
5032,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619325,,BAO_0000019,,
5033,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876411,,BAO_0000019,,
5034,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619326,,BAO_0000019,,
5035,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619327,,BAO_0000019,,
5036,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619328,,BAO_0000019,,
5037,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619329,,BAO_0000019,,
5038,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619330,,BAO_0000019,,
5039,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619331,,BAO_0000019,,
5040,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619332,,BAO_0000019,,
5041,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619333,,BAO_0000019,,
5042,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619334,,BAO_0000019,,
5043,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619335,,BAO_0000019,,
5044,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619336,,BAO_0000019,,
5045,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619337,,BAO_0000019,,
5046,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619338,,BAO_0000019,,
5047,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619339,,BAO_0000019,,
5048,5809,Bioavailability in rat (cannulated) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619340,,BAO_0000218,,
5049,17720,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL873496,,BAO_0000218,1969.0,
5050,3546,AUC value in rat after IV administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL619341,,BAO_0000218,1969.0,
5051,3546,AUC value in rat after oral administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL619342,,BAO_0000218,1969.0,
5052,3546,Cmax value in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619343,,BAO_0000218,,
5053,3546,Bioavailability in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619344,,BAO_0000218,,
5054,3546,Tmax value in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619345,,BAO_0000218,,
5055,3546,Vc value in rat after IV administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619346,,BAO_0000218,,
5056,3546,Half life period in rat after IV administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619347,,BAO_0000218,,
5057,10625,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619348,,BAO_0000019,,
5058,10625,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619349,,BAO_0000019,,
5059,10625,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619350,,BAO_0000019,,
5060,10625,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619351,,BAO_0000019,,
5061,10625,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875953,,BAO_0000019,,
5062,10625,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621716,,BAO_0000019,,
5063,10625,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621717,,BAO_0000019,,
5064,10625,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621718,,BAO_0000019,,
5065,3510,Area under curve after 1 mpk peroral administration to beagles,A,,,beagle,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621719,,BAO_0000019,,
5066,3510,Area under curve after 2 mpk peroral administration to beagles,A,,,beagle,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621720,,BAO_0000019,,
5067,3510,Cmax value after 1 mpk peroral administration to beagles,A,In vivo,,beagle,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621721,,BAO_0000218,,
5068,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL621722,,BAO_0000019,1088.0,
5069,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL621723,,BAO_0000019,1088.0,
5070,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL621724,,BAO_0000019,1088.0,
5071,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623443,,BAO_0000019,1088.0,
5072,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623444,,BAO_0000019,1088.0,
5073,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623445,,BAO_0000019,1088.0,
5074,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623446,,BAO_0000019,1088.0,
5075,16643,Metabolic stability observed at 30 min after administration in human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL623447,,BAO_0000251,2107.0,
5076,6852,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623448,,BAO_0000019,,
5077,6852,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623449,,BAO_0000019,,
5078,6852,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623450,,BAO_0000019,,
5079,6567,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL623451,,BAO_0000251,2107.0,
5080,6570,Metabolic stability (% remaining at 30 mins) in human S9.,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623452,,BAO_0000019,,
5081,6570,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623453,,BAO_0000019,,
5082,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL623454,,BAO_0000251,2107.0,
5083,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL623455,,BAO_0000251,2107.0,
5084,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624371,,BAO_0000251,2107.0,
5085,5202,First pass metabolism and metabolic bioavailability using human hepatic microsomes,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624372,,BAO_0000218,,
5086,5481,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624373,,BAO_0000019,,
5087,5481,Percent remaining in human plasma after incubation for 60 min at 37 C.,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624374,,BAO_0000019,,
5088,3956,The percent remaining in human plasma after 30 min was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624556,,BAO_0000019,,
5089,5074,Conversion rate of the prodrug in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624557,,BAO_0000366,1969.0,
5090,5074,Conversion rate of the prodrug in human plasma; ND means no data,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624558,,BAO_0000366,1969.0,
5091,4727,Half life of compound was determined in human blood,A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL624559,,BAO_0000221,178.0,
5092,5965,Half life of compound was determined in man with once daily dosing,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624560,,BAO_0000019,,
5093,5732,Half life in human microsomes,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624561,,BAO_0000251,,
5094,5819,Half life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624562,,BAO_0000366,1969.0,
5095,5819,Half life in human plasma; Not detected,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624563,,BAO_0000366,1969.0,
5096,1916,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624564,,BAO_0000218,,
5097,6597,Half-life for oxidative metabolic stability was determined using rat liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624565,,BAO_0000251,2107.0,
5098,5229,Half-life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL875152,,BAO_0000366,1969.0,
5099,5229,Half-life of the parent prodrug in plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624566,,BAO_0000366,1969.0,
5100,2192,In vitro half life in human plasma was determined,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL873805,,BAO_0000366,1969.0,
5101,3032,The compound was tested In Vitro for half life in human liver microsomes.,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624567,,BAO_0000251,2107.0,
5102,1916,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624568,,BAO_0000218,,
5103,17716,Observed volume of distribution,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624569,,BAO_0000218,,
5104,15778,Oral bioavailability in human,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624570,,BAO_0000218,,
5105,17313,Tested for human plasma protein binding of the compound,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624571,,BAO_0000019,,
5106,4231,"First order rate constant, k was determined in human plasma",A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624572,,BAO_0000019,,
5107,4755,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624573,,BAO_0000019,,
5108,4755,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875153,,BAO_0000019,,
5109,16907,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624574,,BAO_0000251,2107.0,
5110,10839,The compound was tested for the plasma binding in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624575,,BAO_0000019,,
5111,10839,Plasma protein binding (human),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624576,,BAO_0000019,,
5112,3199,Compound was evaluated for half-life in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624577,,BAO_0000251,2107.0,
5113,1345,Half life measured in vitro for its stability in human blood,A,In vitro,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL624578,,BAO_0000221,178.0,
5114,4297,Half life in human serum,A,,,Homo sapiens,9606.0,,Serum,,,22224,U,0,Autocuration,1,,CHEMBL622796,,BAO_0000019,1977.0,
5115,4297,Half life in human serum; ND=not determined,A,,,Homo sapiens,9606.0,,Serum,,,22224,U,0,Autocuration,1,,CHEMBL622797,,BAO_0000019,1977.0,
5116,4297,Half life were determined in CEM-SS cell extract in decomposition step 1,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL622798,,BAO_0000019,,
5117,4297,Half life were determined in CEM-SS cell extract in decomposition step 2,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL622799,,BAO_0000019,,
5118,4231,Half life of the in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL622800,,BAO_0000366,1969.0,
5119,5633,Half life period in human hepatic S9 fraction was determined,A,In vitro,,Homo sapiens,9606.0,,,,S9,22224,U,0,Autocuration,1,,CHEMBL622801,,BAO_0000220,,
5120,5633,Half life period in human liver microsome was determined,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL622802,,BAO_0000251,2107.0,
5121,17791,Half life period was determined; 6-7,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL622803,,BAO_0000019,,
5122,17791,Half life period was evaluated in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875154,,BAO_0000019,,
5123,3160,Half life time in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL622804,,BAO_0000366,1969.0,
5124,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622805,,BAO_0000218,955.0,
5125,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622611,,BAO_0000218,948.0,
5126,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622612,,BAO_0000218,948.0,
5127,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL875160,,BAO_0000218,2113.0,
5128,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL622613,,BAO_0000218,2113.0,
5129,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL622614,,BAO_0000218,2113.0,
5130,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL622615,,BAO_0000218,2107.0,
5131,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL622616,,BAO_0000218,2107.0,
5132,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL622617,,BAO_0000218,2107.0,
5133,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL622618,,BAO_0000218,2106.0,
5134,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL622619,,BAO_0000218,2106.0,
5135,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL622620,,BAO_0000218,2106.0,
5136,16438,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622621,,BAO_0000218,955.0,
5137,16438,Biodistribution of compound (oxidized form) in blood tissue,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622622,,BAO_0000218,178.0,
5138,16438,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622623,,BAO_0000218,178.0,
5139,16438,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622624,,BAO_0000218,178.0,
5140,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622625,,BAO_0000218,178.0,
5141,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622626,,BAO_0000218,178.0,
5142,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622627,,BAO_0000218,178.0,
5143,16438,Biodistribution of compound (oxidized form) in brain tissue of mice,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622628,,BAO_0000218,955.0,
5144,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622629,,BAO_0000218,955.0,
5145,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622630,,BAO_0000218,955.0,
5146,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622631,,BAO_0000218,955.0,
5147,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622632,,BAO_0000218,955.0,
5148,16438,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622633,,BAO_0000218,955.0,
5149,16438,Biodistribution of compound (oxidized form) in heart tissue of mice,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622634,,BAO_0000218,948.0,
5150,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622635,,BAO_0000218,948.0,
5151,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL875161,,BAO_0000218,948.0,
5152,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622636,,BAO_0000218,948.0,
5153,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623335,,BAO_0000218,948.0,
5154,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623336,,BAO_0000218,948.0,
5155,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623337,,BAO_0000218,2113.0,
5156,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623338,,BAO_0000218,2113.0,
5157,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623339,,BAO_0000218,2113.0,
5158,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623524,,BAO_0000218,2113.0,
5159,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623525,,BAO_0000218,2113.0,
5160,16438,Biodistribution of compound (oxidized form) in liver tissue,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623526,,BAO_0000218,2107.0,
5161,16438,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623527,,BAO_0000218,2107.0,
5162,16438,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623528,,BAO_0000218,2107.0,
5163,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL624615,500.0,BAO_0000219,,
5164,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621672,500.0,BAO_0000219,,
5165,16289,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL621673,500.0,BAO_0000218,,
5166,16289,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL621674,500.0,BAO_0000218,,
5167,16093,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL884002,500.0,BAO_0000219,,
5168,16825,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621850,500.0,BAO_0000219,,
5169,4848,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621851,500.0,BAO_0000219,,
5170,14827,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621852,500.0,BAO_0000219,,
5171,14827,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621853,500.0,BAO_0000219,,
5172,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL621854,500.0,BAO_0000218,,
5173,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL621855,500.0,BAO_0000218,,
5174,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623724,500.0,BAO_0000218,,
5175,16289,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623725,500.0,BAO_0000218,,
5176,16289,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623726,500.0,BAO_0000218,,
5177,16289,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL623727,500.0,BAO_0000219,,
5178,16289,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,F,,,,,,,A-431,,9,H,8,Expert,1,,CHEMBL623728,500.0,BAO_0000219,,
5179,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623729,500.0,BAO_0000218,,
5180,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623730,500.0,BAO_0000218,,
5181,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623731,500.0,BAO_0000218,,
5182,14555,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623732,500.0,BAO_0000218,,
5183,14555,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623733,500.0,BAO_0000218,,
5184,14555,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623734,500.0,BAO_0000218,,
5185,14555,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623735,500.0,BAO_0000218,,
5186,1937,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623736,500.0,BAO_0000219,,
5187,13739,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL623737,500.0,BAO_0000219,,
5188,3558,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL623738,500.0,BAO_0000219,,
5189,3558,Dose giving a 50% decrease in the living cell number (A437 cells),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL875168,500.0,BAO_0000219,,
5190,17686,In vitro inhibitory concentration against proliferation of A459 cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL623739,646.0,BAO_0000219,,
5191,5305,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623740,646.0,BAO_0000219,,
5192,3614,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624424,646.0,BAO_0000219,,
5193,17229,In vitro antitumor activity against renal A498 tumor cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624425,624.0,BAO_0000219,,
5194,15935,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624426,624.0,BAO_0000219,,
5195,15935,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624427,624.0,BAO_0000219,,
5196,15560,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624428,624.0,BAO_0000219,,
5197,13891,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624429,624.0,BAO_0000219,,
5198,13891,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624620,624.0,BAO_0000219,,
5199,13788,Cytotoxicity on kidney carcinoma (A-498) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624621,624.0,BAO_0000219,,
5200,15403,Compound was evaluated against Human cell line renal A498,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624622,624.0,BAO_0000219,,
5201,1009,Compound was tested for inhibition of A498 human renal cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624623,624.0,BAO_0000219,,
5202,1043,Growth inhibitory activity against A498 human cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL874365,624.0,BAO_0000219,,
5203,5858,In vitro antitumor activity against human renal A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624624,624.0,BAO_0000219,,
5204,5958,In vitro cytotoxic activity against renal (A498) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624625,624.0,BAO_0000219,,
5205,5506,In vitro cytotoxic activity against human renal cancer (A498) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624626,624.0,BAO_0000219,,
5206,12781,Tested for cytostatic activity against renal A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624627,624.0,BAO_0000219,,
5207,14399,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL883157,624.0,BAO_0000219,,
5208,5958,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Expert,1,,CHEMBL624628,624.0,BAO_0000219,,
5209,3510,Cmax value after 2 mpk peroral administration to beagles,A,In vivo,,beagle,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624629,,BAO_0000218,,
5210,3510,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,beagle,,,,22224,U,0,Autocuration,1,,CHEMBL623551,,BAO_0000218,,
5211,3510,Bioavailability after 1 mpk peroral administration to beagles,A,In vivo,,Canis lupus familiaris,9615.0,beagle,,,,22224,U,0,Autocuration,1,,CHEMBL623552,,BAO_0000218,,
5212,3510,Bioavailability after 2 mpk peroral administration to beagles,A,In vivo,,Canis lupus familiaris,9615.0,beagle,,,,22224,U,0,Autocuration,1,,CHEMBL623553,,BAO_0000218,,
5213,3085,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623554,,BAO_0000019,,
5214,3085,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623555,,BAO_0000019,,
5215,3085,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623556,,BAO_0000019,,
5216,9372,Solubility against bovine alpha-chymotrypsin,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623557,,BAO_0000019,,
5217,3085,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623558,,BAO_0000019,,
5218,3085,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623559,,BAO_0000019,,
5219,1469,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,A,,,Bos taurus,9913.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL623560,,BAO_0000221,2106.0,
5220,4297,Half life in culture medium containing 10% of heat inactivated foetal calf serum,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623561,,BAO_0000019,,
5221,4297,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623562,,BAO_0000019,,
5222,17585,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623563,,BAO_0000019,,
5223,1336,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,A,,,Bos taurus,9913.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL623564,,BAO_0000221,2106.0,
5224,3085,Half life in presence of 2 mg/mL BSA at pH 8.8,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873806,,BAO_0000019,,
5225,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623565,,BAO_0000019,,
5226,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623566,,BAO_0000019,,
5227,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623567,,BAO_0000019,,
5228,1540,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623568,,BAO_0000019,,
5229,6316,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623569,,BAO_0000218,1969.0,
5230,17594,AUC after administration at 100 mg/kg/day in dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623570,,BAO_0000218,1969.0,
5231,4953,AUC in dog at 0-24 hr by peroral administration at 3 mpk,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624254,,BAO_0000218,1969.0,
5232,16907,AUC value after 15 mg/kg iv dose in Dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624255,,BAO_0000218,1969.0,
5233,16907,AUC value after 30 mg/kg po dose in Dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624256,,BAO_0000218,1969.0,
5234,2959,AUC value after administration of 4 mg/Kg oral dose in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624257,,BAO_0000218,1969.0,
5235,17594,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624258,,BAO_0000218,1969.0,
5236,5356,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875277,,BAO_0000218,,
5237,16807,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622667,,BAO_0000218,,
5238,4527,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622668,,BAO_0000218,,
5239,4527,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622669,,BAO_0000218,,
5240,15660,Area under curve determined in dogs after intravenous administration of 3 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622670,,BAO_0000218,,
5241,15660,Area under curve determined in dogs after oral administration of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622671,,BAO_0000218,,
5242,5802,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622672,,BAO_0000218,,
5243,3598,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL622673,,BAO_0000218,,
5244,3598,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL622674,,BAO_0000218,,
5245,5944,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622675,,BAO_0000218,,
5246,5944,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622676,,BAO_0000218,,
5247,5944,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622677,,BAO_0000218,,
5248,5944,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622678,,BAO_0000218,,
5249,4186,Area under curve in dog after administration of 20 mg/kg dose through peroral route,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622679,,BAO_0000218,,
5250,5007,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622680,,BAO_0000218,,
5251,5668,Area under curve was determine after peroral administration at 10 mpk in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622681,,BAO_0000218,,
5252,5668,Area under curve was determine after peroral administration at 5 mpk in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875278,,BAO_0000218,,
5253,5006,Area under curve was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622682,,BAO_0000218,,
5254,5006,Area under curve in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622683,,BAO_0000218,,
5255,3771,Area under curve in dogs at 10 mg/kg dose fo oral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622684,,BAO_0000218,,
5256,3771,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622685,,BAO_0000218,,
5257,3771,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622686,,BAO_0000218,,
5258,1916,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618344,,BAO_0000218,,
5259,5302,Area under curve value in dog at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875582,,BAO_0000218,,
5260,5600,Area under curve was determined after 0.1 mg/kg iv administration in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618345,,BAO_0000218,,
5261,5600,Area under curve was determined after 0.3 mg/kg po administration in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618346,,BAO_0000218,,
5262,17764,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618347,,BAO_0000218,,
5263,4368,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618348,,BAO_0000218,,
5264,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618349,,BAO_0000019,,
5265,5318,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618350,,BAO_0000019,,
5266,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618351,,BAO_0000019,,
5267,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618352,,BAO_0000019,,
5268,14518,Time taken to reduce 50% of the concentration of compound in blood plasma,A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL873494,,BAO_0000221,178.0,
5269,2209,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618353,,BAO_0000366,1969.0,
5270,6787,Half life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618354,,BAO_0000366,1969.0,
5271,4898,Half life in human plasma was reported,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL875583,,BAO_0000366,1969.0,
5272,6072,Half life in human serum,A,,,Homo sapiens,9606.0,,Serum,,,22224,U,0,Autocuration,1,,CHEMBL618355,,BAO_0000019,1977.0,
5273,16907,Half life upon exposure to human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618356,,BAO_0000366,1969.0,
5274,5656,t1/2 in human microsomes,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618357,,BAO_0000251,,
5275,4755,Half life period in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618358,,BAO_0000366,1969.0,
5276,17503,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),A,,,Homo sapiens,9606.0,,Zone of skin,,,22224,U,0,Autocuration,1,,CHEMBL618359,,BAO_0000221,14.0,
5277,12357,Half-life measured in in vitro Cathepsin B assay in human plasma,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618360,,BAO_0000366,1969.0,
5278,3076,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618361,,BAO_0000019,,
5279,6410,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618362,,BAO_0000251,2107.0,
5280,3741,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618363,,BAO_0000366,1969.0,
5281,3741,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618364,,BAO_0000366,1969.0,
5282,3741,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL875584,,BAO_0000366,1969.0,
5283,1540,Half-life in the CEM cell extracts,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618365,,BAO_0000019,,
5284,2905,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL873495,,BAO_0000366,1969.0,
5285,2905,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618366,,BAO_0000366,1969.0,
5286,5523,Half-life was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618367,,BAO_0000019,,
5287,1499,Half-life (human blood stability),A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL618368,,BAO_0000221,178.0,
5288,1499,Half-life (human blood stability); no data,A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL618369,,BAO_0000221,178.0,
5289,17065,Half-life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618370,,BAO_0000366,1969.0,
5290,6861,CYP3A4 metabolism half-life (t1/2),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618371,,BAO_0000019,,
5291,1499,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL618372,,BAO_0000221,178.0,
5292,530,In vitro half life in human plasma,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618373,,BAO_0000366,1969.0,
5293,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618374,,BAO_0000366,1969.0,
5294,6695,In vitro hydrolysis in human plasma,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618375,,BAO_0000366,1969.0,
5295,6695,In vitro hydrolysis in human plasma; no data,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618376,,BAO_0000366,1969.0,
5296,10,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618377,,BAO_0000251,2107.0,
5297,993,Plasma half life in human,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618378,,BAO_0000366,1969.0,
5298,15429,Stability after incubation with human plasma (at 37 degree C),A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618379,,BAO_0000366,1969.0,
5299,1675,T1/2 was evaluated in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618380,,BAO_0000366,1969.0,
5300,2209,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618381,,BAO_0000366,1969.0,
5301,2209,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618382,,BAO_0000366,1969.0,
5302,5318,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618383,,BAO_0000019,,
5303,2412,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,A,In vitro,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618384,,BAO_0000019,,
5304,2412,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,A,In vitro,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618385,,BAO_0000019,,
5305,2906,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619099,,BAO_0000366,1969.0,
5306,2906,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619100,,BAO_0000366,1969.0,
5307,5495,Time taken for 50% to be consumed by serum PON1 was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619101,,BAO_0000019,,
5308,5495,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619102,,BAO_0000019,,
5309,4397,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL619103,,BAO_0000251,2107.0,
5310,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619268,,BAO_0000218,,
5311,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619269,,BAO_0000218,,
5312,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619270,,BAO_0000218,,
5313,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619271,,BAO_0000218,,
5314,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875585,,BAO_0000218,,
5315,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619272,,BAO_0000218,,
5316,6058,Compound tested for growth inhibition of renal cancer cell line 786-0,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619273,391.0,BAO_0000219,,
5317,17708,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619274,391.0,BAO_0000219,,
5318,14017,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Expert,1,,CHEMBL619275,391.0,BAO_0000219,,
5319,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619276,391.0,BAO_0000219,,
5320,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619277,391.0,BAO_0000219,,
5321,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619278,391.0,BAO_0000219,,
5322,11970,Tested for cytotoxicity against 786-0 cell lines in renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619279,391.0,BAO_0000219,,
5323,12400,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL858458,391.0,BAO_0000219,,
5324,12888,Cytotoxic effect on renal cancer line 786-0,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Expert,1,,CHEMBL619280,391.0,BAO_0000219,,
5325,15300,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619281,391.0,BAO_0000219,,
5326,14769,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619282,391.0,BAO_0000219,,
5327,15895,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619283,391.0,BAO_0000219,,
5328,17376,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619284,391.0,BAO_0000219,,
5329,14882,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619285,391.0,BAO_0000219,,
5330,14882,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619286,391.0,BAO_0000219,,
5331,15176,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619287,391.0,BAO_0000219,,
5332,12696,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL857455,391.0,BAO_0000219,,
5333,2496,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL883801,391.0,BAO_0000219,,
5334,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619288,972.0,BAO_0000219,,
5335,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619289,972.0,BAO_0000219,,
5336,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619290,972.0,BAO_0000219,,
5337,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619291,972.0,BAO_0000219,,
5338,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619292,972.0,BAO_0000219,,
5339,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619293,972.0,BAO_0000219,,
5340,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619294,972.0,BAO_0000219,,
5341,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619295,972.0,BAO_0000219,,
5342,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619296,972.0,BAO_0000219,,
5343,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619297,972.0,BAO_0000219,,
5344,12782,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619298,391.0,BAO_0000219,,
5345,1229,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL619299,,BAO_0000019,,
5346,15313,Inhibition of cell growth in drug resistant 8226 myeloma cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Expert,1,,CHEMBL619300,741.0,BAO_0000219,,
5347,15313,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Expert,1,,CHEMBL619301,741.0,BAO_0000219,,
5348,11544,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619302,741.0,BAO_0000219,,
5349,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619303,741.0,BAO_0000219,,
5350,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619304,741.0,BAO_0000219,,
5351,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL857706,741.0,BAO_0000219,,
5352,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619305,741.0,BAO_0000219,,
5353,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619306,741.0,BAO_0000219,,
5354,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619307,741.0,BAO_0000219,,
5355,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619308,741.0,BAO_0000219,,
5356,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619309,741.0,BAO_0000219,,
5357,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619310,741.0,BAO_0000219,,
5358,14769,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619311,624.0,BAO_0000219,,
5359,15354,Compound was tested for the growth inhibition of A498 renal tumor cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619312,624.0,BAO_0000219,,
5360,17445,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619313,624.0,BAO_0000219,,
5361,4337,In vitro inhibitory concentration against renal cancer cell line A498,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619314,624.0,BAO_0000219,,
5362,15277,Cytotoxicity against A 498 tumor cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619959,624.0,BAO_0000219,,
5363,4812,In vitro antitumor activity against A498 human cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619960,624.0,BAO_0000219,,
5364,4812,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619961,624.0,BAO_0000219,,
5365,4995,Inhibitory dose required against A498 human tumor cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619962,624.0,BAO_0000219,,
5366,5847,Anticancer activity against one renal cancer (A498 cell line),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL875586,624.0,BAO_0000219,,
5367,6557,In vitro cytotoxicity against melanoma A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619963,624.0,BAO_0000219,,
5368,2597,Compound was tested for growth inhibitory activity against A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619964,624.0,BAO_0000219,,
5369,6058,Compound tested for growth inhibition of renal cancer cell line A498,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620108,624.0,BAO_0000219,,
5370,17708,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620109,624.0,BAO_0000219,,
5371,15176,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620110,624.0,BAO_0000219,,
5372,15300,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620111,624.0,BAO_0000219,,
5373,11970,Tested for cytotoxicity against A498 cell lines in renal cancer,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620112,624.0,BAO_0000219,,
5374,12400,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620113,624.0,BAO_0000219,,
5375,12888,Cytotoxic effect on renal cancer lines A498,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Expert,1,,CHEMBL620114,624.0,BAO_0000219,,
5376,3030,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620115,624.0,BAO_0000219,,
5377,14769,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620116,624.0,BAO_0000219,,
5378,17376,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620117,624.0,BAO_0000219,,
5379,16558,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620118,624.0,BAO_0000219,,
5380,5194,Cytotoxicity against human kidney carcinoma cell lines A4982LM,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620119,624.0,BAO_0000219,,
5381,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620120,624.0,BAO_0000219,,
5382,16880,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620121,646.0,BAO_0000219,,
5383,10196,Antitumor activity against A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620122,646.0,BAO_0000219,,
5384,10196,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620123,646.0,BAO_0000219,,
5385,10196,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620124,646.0,BAO_0000219,,
5386,12083,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620125,646.0,BAO_0000219,,
5387,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620126,646.0,BAO_0000219,,
5388,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL883027,646.0,BAO_0000219,,
5389,16470,In vitro cytotoxic activity against human lung A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620127,646.0,BAO_0000219,,
5390,16470,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620128,646.0,BAO_0000219,,
5391,16470,In vitro cytotoxic activity against human lung A549 cell line),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620129,646.0,BAO_0000219,,
5392,16470,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620130,646.0,BAO_0000219,,
5393,16582,In vitro cytotoxicity against human non small-cell-lung cell line A549.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620131,646.0,BAO_0000219,,
5394,15935,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620132,646.0,BAO_0000219,,
5395,15935,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620133,646.0,BAO_0000219,,
5396,16597,Inhibition of A549 human lung carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620134,646.0,BAO_0000219,,
5397,17376,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620135,646.0,BAO_0000219,,
5398,16496,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620136,646.0,BAO_0000219,,
5399,16152,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620137,646.0,BAO_0000219,,
5400,16152,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620268,646.0,BAO_0000219,,
5401,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620269,646.0,BAO_0000219,,
5402,2288,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620270,646.0,BAO_0000219,,
5403,17350,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620271,646.0,BAO_0000219,,
5404,4090,Inhibition of A549 cancer cell proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620272,646.0,BAO_0000219,,
5405,4090,Inhibition of A549 cancer cell proliferation (Not tested),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620273,646.0,BAO_0000219,,
5406,17350,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620274,646.0,BAO_0000219,,
5407,4197,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620275,646.0,BAO_0000219,,
5408,17072,Antiproliferative potency determined as inhibitory concentration against A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620276,646.0,BAO_0000219,,
5409,17072,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620277,646.0,BAO_0000219,,
5410,5194,Cytotoxicity against Renal cell lines A549 was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620278,646.0,BAO_0000219,,
5411,4257,Area under curve was determined in dog after a 3 mg/kg of oral dose,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620279,,BAO_0000218,,
5412,6123,Area under curve was determined in dog after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620280,,BAO_0000218,,
5413,1337,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620281,,BAO_0000218,,
5414,1337,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620282,,BAO_0000218,,
5415,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621134,,BAO_0000218,,
5416,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621135,,BAO_0000218,,
5417,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621136,,BAO_0000218,,
5418,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621137,,BAO_0000218,,
5419,17657,Area under plasma concentration time curve in dog upon oral administration,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621138,,BAO_0000218,1969.0,
5420,17650,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL875587,,BAO_0000218,1969.0,
5421,1977,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621139,,BAO_0000218,,
5422,1977,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621140,,BAO_0000218,,
5423,3132,Area under the curve for the compound was obtained when tested in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621141,,BAO_0000218,,
5424,5473,Area under the curve at a dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621142,,BAO_0000218,,
5425,5474,Area under the curve at a dose of 1 mg/kg (oral),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621143,,BAO_0000218,,
5426,5474,Area under the curve at i.v. dose of 0.2 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621144,,BAO_0000218,,
5427,6062,Area under the curve was measured in dog after an iv dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621145,,BAO_0000218,,
5428,4709,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621146,,BAO_0000218,,
5429,2652,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622567,,BAO_0000218,,
5430,2652,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622568,,BAO_0000218,,
5431,2877,Compound was evaluated for area under the curve in dog blood.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622569,,BAO_0000218,,
5432,5444,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622570,,BAO_0000218,,
5433,5130,AUC in dog after oral dose (1 mg/kg),A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622571,,BAO_0000218,1969.0,
5434,6265,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622572,,BAO_0000218,,
5435,4657,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622573,,BAO_0000218,,
5436,16367,Pharmacokinetic parameter AUC after intravenous administration to dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622574,,BAO_0000218,,
5437,16367,Pharmacokinetic parameter AUC after oral administration to dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622575,,BAO_0000218,,
5438,9579,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622576,,BAO_0000218,,
5439,9579,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622577,,BAO_0000218,,
5440,5983,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622578,,BAO_0000218,,
5441,6241,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622579,,BAO_0000218,,
5442,5313,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622580,,BAO_0000218,,
5443,5313,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622581,,BAO_0000218,,
5444,6642,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622582,,BAO_0000218,,
5445,6642,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622583,,BAO_0000218,,
5446,6641,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622584,,BAO_0000218,,
5447,6642,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622585,,BAO_0000218,,
5448,17791,Compound was evaluated for oral bioavailability in dog; 90-100,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622586,,BAO_0000218,,
5449,17655,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623281,,BAO_0000218,,
5450,17655,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623282,,BAO_0000218,,
5451,6596,PAPP (membrane permeability) in dog kidney cell monolayer assay,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623283,,BAO_0000218,,
5452,3880,Oral bioavailability in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623284,,BAO_0000218,,
5453,16367,Bioavailability administered orally at a dose of 10 mg/kg to dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623285,,BAO_0000218,,
5454,17409,Plasma protein binding towards dog plasma at 10 uM,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623463,,BAO_0000218,1969.0,
5455,17409,Plasma protein binding towards dog plasma at 100 uM,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL875952,,BAO_0000218,1969.0,
5456,2959,Bioavailability in dog (dose 4 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621705,,BAO_0000218,,
5457,13501,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621706,,BAO_0000218,,
5458,4527,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621707,,BAO_0000218,,
5459,15145,Bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621708,,BAO_0000218,,
5460,4219,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621709,,BAO_0000218,,
5461,17538,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621710,,BAO_0000218,,
5462,17538,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621711,,BAO_0000218,,
5463,1466,Bioavailability in dog (dose 10.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621712,,BAO_0000218,,
5464,17650,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621713,,BAO_0000218,,
5465,3132,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621714,,BAO_0000218,,
5466,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621715,,BAO_0000218,,
5467,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623717,,BAO_0000218,2107.0,
5468,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623718,,BAO_0000218,2107.0,
5469,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623719,,BAO_0000218,2107.0,
5470,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623720,,BAO_0000218,,
5471,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623721,,BAO_0000218,,
5472,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL623722,,BAO_0000218,2385.0,
5473,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL623723,,BAO_0000218,2385.0,
5474,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL618543,,BAO_0000218,2385.0,
5475,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL618544,,BAO_0000218,2106.0,
5476,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL875155,,BAO_0000218,2106.0,
5477,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618545,,BAO_0000218,,
5478,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618546,,BAO_0000218,,
5479,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623529,,BAO_0000218,,
5480,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623530,,BAO_0000218,,
5481,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621764,,BAO_0000218,,
5482,17827,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621765,,BAO_0000019,,
5483,17827,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Cerebellum,,,22224,U,0,Autocuration,1,,CHEMBL621766,,BAO_0000019,2037.0,
5484,17827,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Frontal cortex,,,22224,U,0,Autocuration,1,,CHEMBL621767,,BAO_0000019,1870.0,
5485,17827,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621768,,BAO_0000019,,
5486,17827,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Striatum,,,22224,U,0,Autocuration,1,,CHEMBL621769,,BAO_0000019,2435.0,
5487,17827,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621770,,BAO_0000019,,
5488,17827,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Cerebellum,,,22224,U,0,Autocuration,1,,CHEMBL621771,,BAO_0000019,2037.0,
5489,17827,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Frontal cortex,,,22224,U,0,Autocuration,1,,CHEMBL621772,,BAO_0000019,1870.0,
5490,17827,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621773,,BAO_0000019,,
5491,17827,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Striatum,,,22224,U,0,Autocuration,1,,CHEMBL621774,,BAO_0000019,2435.0,
5492,17791,Compound was evaluated for oral bioavailability in rats,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621775,,BAO_0000218,,
5493,17667,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621776,,BAO_0000218,1969.0,
5494,17791,Half life period was evaluated in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621777,,BAO_0000019,,
5495,110,Half-life in rhesus monkeys by intravenous administration of dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875162,,BAO_0000218,,
5496,5781,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL621778,,BAO_0000218,1969.0,
5497,17734,AUC after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL621779,,BAO_0000218,1969.0,
5498,17718,AUC value was determined after oral administration,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622479,,BAO_0000218,1969.0,
5499,4573,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622480,,BAO_0000218,,
5500,3277,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622481,,BAO_0000218,,
5501,2862,Area under curve by ioral administration in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622482,,BAO_0000218,,
5502,2862,Area under curve by iv administration in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622483,,BAO_0000218,,
5503,5951,Area under curve at 0-8 hr in IRC mice after peroral administration,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622484,,BAO_0000218,,
5504,17729,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622641,,BAO_0000218,,
5505,17728,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622642,,BAO_0000218,,
5506,17728,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622643,,BAO_0000218,,
5507,17729,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622644,,BAO_0000218,,
5508,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL622645,741.0,BAO_0000219,,
5509,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL622646,741.0,BAO_0000219,,
5510,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621238,741.0,BAO_0000219,,
5511,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621239,741.0,BAO_0000219,,
5512,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621240,741.0,BAO_0000219,,
5513,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621241,741.0,BAO_0000219,,
5514,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621242,741.0,BAO_0000219,,
5515,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620350,741.0,BAO_0000219,,
5516,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620351,741.0,BAO_0000219,,
5517,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620352,741.0,BAO_0000219,,
5518,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620353,741.0,BAO_0000219,,
5519,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620354,741.0,BAO_0000219,,
5520,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620355,741.0,BAO_0000219,,
5521,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620356,741.0,BAO_0000219,,
5522,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620357,741.0,BAO_0000219,,
5523,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620358,741.0,BAO_0000219,,
5524,9424,In vitro inhibition of human 8226 myeloma tumor cell line growth.,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Expert,1,,CHEMBL620359,741.0,BAO_0000219,,
5525,11544,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620360,741.0,BAO_0000219,,
5526,17378,Cytotoxicity of compound against 8226/DOX1V cells,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620361,741.0,BAO_0000219,,
5527,17378,Cytotoxicity of compound against 8226/S cells,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620362,741.0,BAO_0000219,,
5528,17079,Inhibitory concentration against 8226 myeloma cancer cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620363,741.0,BAO_0000219,,
5529,17079,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620364,741.0,BAO_0000219,,
5530,13466,Inhibition of cell growth was studied in human teratocarcinoma (833K).,F,,,Homo sapiens,9606.0,,,833K,,80647,N,1,Intermediate,1,,CHEMBL620365,854.0,BAO_0000219,,
5531,13466,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',F,,,Homo sapiens,9606.0,,,833K,,80647,N,1,Intermediate,1,,CHEMBL620366,854.0,BAO_0000219,,
5532,2392,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,F,,,Homo sapiens,9606.0,,,833K,,80647,N,1,Expert,1,,CHEMBL620367,854.0,BAO_0000219,,
5533,2392,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,F,,,Homo sapiens,9606.0,,,833K,,80647,N,1,Intermediate,1,,CHEMBL620368,854.0,BAO_0000219,,
5534,6608,Inhibitory activity against caspase-1,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620369,,BAO_0000019,,
5535,10199,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,B,,,Enterococcus faecalis,1351.0,,,,,45,H,8,Autocuration,1,,CHEMBL620370,,BAO_0000357,,
5536,17749,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,F,,,Homo sapiens,9606.0,,,8701-BC,,80648,N,1,Intermediate,1,,CHEMBL620371,705.0,BAO_0000219,,
5537,17749,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,F,,,Homo sapiens,9606.0,,,8701-BC,,80648,N,1,Intermediate,1,,CHEMBL620372,705.0,BAO_0000219,,
5538,1229,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL876492,,BAO_0000019,,
5539,1229,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL620373,,BAO_0000019,,
5540,1229,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL620374,,BAO_0000019,,
5541,6390,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620375,,BAO_0000019,,
5542,16219,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,,Streptococcus pyogenes,1314.0,,,,,22226,U,0,Autocuration,1,,CHEMBL857902,,BAO_0000019,,
5543,16219,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,,Streptococcus pyogenes,1314.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620376,,BAO_0000019,,
5544,17043,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,B,,,,,,,,,11922,H,8,Autocuration,1,,CHEMBL620377,,BAO_0000357,,
5545,6929,Tested for in vitro cytotoxic potency of compound in 9KB assay,F,,,Homo sapiens,9606.0,,,KB ,,81115,N,1,Intermediate,1,,CHEMBL620378,324.0,BAO_0000219,,
5546,6929,Tested for in vitro cytotoxic potency of compound in 9KB assay,A,,,Homo sapiens,9606.0,,,KB ,,81115,N,1,Intermediate,1,,CHEMBL620379,324.0,BAO_0000219,,
5547,7083,In vitro cytotoxicity of compound was tested against 9KB cells.,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620380,,BAO_0000219,,
5548,12446,Cytotoxic concentration against 9L cells was determined on day 3,F,,,Rattus norvegicus,10116.0,,,9L,,80653,N,1,Intermediate,1,,CHEMBL884006,392.0,BAO_0000219,,
5549,15345,Tested in vitro for anticancer activity against 9L cells,F,,,Rattus norvegicus,10116.0,,,9L,,80653,N,1,Expert,1,,CHEMBL620381,392.0,BAO_0000219,,
5550,15345,Tested in vitro for anticancer activity against 9L cells; Not determined,F,,,Rattus norvegicus,10116.0,,,9L,,80653,N,1,Expert,1,,CHEMBL620382,392.0,BAO_0000219,,
5551,6301,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620383,646.0,BAO_0000219,,
5552,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876493,646.0,BAO_0000219,,
5553,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620384,646.0,BAO_0000219,,
5554,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620385,646.0,BAO_0000219,,
5555,13330,Cytotoxicity against human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620386,646.0,BAO_0000219,,
5556,17517,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,F,,,Homo sapiens,9606.0,,,A549,,25,D,9,Expert,1,,CHEMBL620387,646.0,BAO_0000219,,
5557,17517,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",F,,,Homo sapiens,9606.0,,,A549,,25,D,9,Expert,1,,CHEMBL621404,646.0,BAO_0000219,,
5558,14425,"In vitro growth inhibition of A549, lung carcinoma",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621405,646.0,BAO_0000219,,
5559,14425,"In vitro growth inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621406,646.0,BAO_0000219,,
5560,5228,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621407,646.0,BAO_0000219,,
5561,5351,Cytotoxic activity against human lung cancer A549 cell line was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621408,646.0,BAO_0000219,,
5562,12198,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL885345,646.0,BAO_0000219,,
5563,13891,Cytotoxicity concentration against human lung carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621409,646.0,BAO_0000219,,
5564,5677,Cytotoxicity in A549 (human carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL876034,646.0,BAO_0000219,,
5565,13788,Cytotoxicity on lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621410,646.0,BAO_0000219,,
5566,13384,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621411,646.0,BAO_0000219,,
5567,6726,Effective dose of compound against replication of A549 cell line was evaluated,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621412,646.0,BAO_0000219,,
5568,3455,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621413,646.0,BAO_0000219,,
5569,5726,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621414,646.0,BAO_0000219,,
5570,5726,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621415,646.0,BAO_0000219,,
5571,3936,The compound was evaluated for antiproliferative activity against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621416,646.0,BAO_0000219,,
5572,14991,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621417,646.0,BAO_0000219,,
5573,5243,Concentration required for growth inhibition of human lung carcinoma cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621418,646.0,BAO_0000219,,
5574,12858,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621419,646.0,BAO_0000219,,
5575,6776,Growth inhibition against A549 cell line was evaluated,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621420,646.0,BAO_0000219,,
5576,16558,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL875823,646.0,BAO_0000219,,
5577,4583,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621421,646.0,BAO_0000219,,
5578,13514,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621422,646.0,BAO_0000219,,
5579,15166,Chemosensitivity against DT-diaphorase rich A549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL884014,646.0,BAO_0000219,,
5580,13873,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621423,646.0,BAO_0000219,,
5581,6447,In vitro cytotoxicity against human A549 (lung cancer) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621424,646.0,BAO_0000219,,
5582,2068,In vitro antitumor activity against A549 (lung) human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621425,646.0,BAO_0000219,,
5583,1863,In vitro cytotoxic activity against human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621426,646.0,BAO_0000219,,
5584,13873,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621427,646.0,BAO_0000219,,
5585,13873,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621428,646.0,BAO_0000219,,
5586,13873,Tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621429,646.0,BAO_0000219,,
5587,579,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621430,646.0,BAO_0000219,,
5588,579,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621431,646.0,BAO_0000219,,
5589,4584,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621432,646.0,BAO_0000219,,
5590,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621433,646.0,BAO_0000219,,
5591,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL875824,646.0,BAO_0000219,,
5592,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621434,646.0,BAO_0000219,,
5593,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621435,646.0,BAO_0000219,,
5594,14188,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621436,646.0,BAO_0000219,,
5595,14188,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621437,646.0,BAO_0000219,,
5596,15354,Compound was tested for the growth inhibition of A549 lung tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621438,646.0,BAO_0000219,,
5597,14253,Growth inhibition of human non-small-lung carcinoma (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621439,646.0,BAO_0000219,,
5598,13873,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621440,646.0,BAO_0000219,,
5599,3043,Oral bioavailability in dog (conscious),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621441,,BAO_0000218,,
5600,3045,Compound was evaluated for the oral bioavailability after oral administration in dog.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621442,,BAO_0000218,,
5601,3022,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621443,,BAO_0000218,,
5602,4453,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621444,,BAO_0000218,,
5603,1696,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625133,,BAO_0000218,,
5604,5045,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625134,,BAO_0000218,,
5605,5356,Oral bioavailability in dog (fasted),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625135,,BAO_0000218,,
5606,17764,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625136,,BAO_0000218,,
5607,6448,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625137,,BAO_0000218,,
5608,1475,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625138,,BAO_0000218,,
5609,3788,Percent bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625139,,BAO_0000218,,
5610,3639,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872264,,BAO_0000218,,
5611,13397,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625140,,BAO_0000218,,
5612,2137,The compound was evaluated for bioavailability in dogs; 34-44,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624436,,BAO_0000218,,
5613,2959,Bioavailability in dog (dose 4 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624437,,BAO_0000218,,
5614,6448,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872261,,BAO_0000218,,
5615,6084,8 hour trough Blood level in dog was measured after administration of compound,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624438,,BAO_0000218,,
5616,3639,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624439,,BAO_0000218,1969.0,
5617,6316,C24 after oral administration at 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624440,,BAO_0000218,,
5618,5238,Clearance after oral and iv dosing in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624441,,BAO_0000218,,
5619,17796,Clearance of the drug was measured in the plasma of dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624442,,BAO_0000218,1969.0,
5620,2652,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624443,,BAO_0000218,,
5621,5654,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624444,,BAO_0000218,,
5622,6621,Clearance of compound was determined in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624445,,BAO_0000218,,
5623,6505,Clearance on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624446,,BAO_0000218,,
5624,5802,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624447,,BAO_0000218,,
5625,17267,Plasma clearance in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624448,,BAO_0000218,,
5626,4521,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624449,,BAO_0000218,,
5627,6535,Plasma clearance in dog after administration of 0.25 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624450,,BAO_0000218,,
5628,6535,Plasma clearance in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875942,,BAO_0000218,,
5629,6535,Plasma clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624451,,BAO_0000218,,
5630,5542,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624452,,BAO_0000218,,
5631,5199,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624453,,BAO_0000218,,
5632,16907,Plasma clearance after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624454,,BAO_0000218,,
5633,16907,Plasma clearance after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624455,,BAO_0000218,,
5634,16367,Plasma administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624456,,BAO_0000218,,
5635,5505,Plasma clearance was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624457,,BAO_0000218,,
5636,6215,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624458,,BAO_0000218,,
5637,1466,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624459,,BAO_0000218,,
5638,5007,Intrinsic clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,102164,S,2,Intermediate,1,,CHEMBL624460,,BAO_0000251,2107.0,
5639,5007,Intrinsic clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,102164,S,2,Intermediate,1,,CHEMBL624461,,BAO_0000251,2107.0,
5640,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875943,,BAO_0000218,,
5641,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624462,,BAO_0000218,,
5642,16452,Clearance in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624463,,BAO_0000218,,
5643,6221,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624464,,BAO_0000218,,
5644,5007,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624465,,BAO_0000218,,
5645,5668,Plasma clearance after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624466,,BAO_0000218,,
5646,5668,Plasma clearance after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624467,,BAO_0000218,,
5647,5668,Plasma clearance after peroral administration at 5 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624468,,BAO_0000218,,
5648,15660,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624469,,BAO_0000218,,
5649,15660,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624470,,BAO_0000218,,
5650,5983,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624471,,BAO_0000218,,
5651,5600,Total clearance was determined after 0.1 mg/kg iv administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624472,,BAO_0000218,,
5652,17764,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622775,,BAO_0000218,,
5653,6039,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622776,,BAO_0000218,,
5654,6039,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622777,,BAO_0000218,,
5655,6039,Clearance after peroral administration of 0.2 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622778,,BAO_0000218,,
5656,4368,Clearance by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622779,,BAO_0000218,,
5657,4305,Clearance by iv administration in dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622780,,BAO_0000218,,
5658,1918,Clearance value was evaluated in dog plasma,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622781,,BAO_0000218,1969.0,
5659,6005,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622782,,BAO_0000218,,
5660,4839,Compound was tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622783,,BAO_0000218,1969.0,
5661,4239,Pharmacokinetic property (Plasma clearance) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622784,,BAO_0000218,,
5662,17729,Area under curve when injected perorally in mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622785,,BAO_0000218,,
5663,17728,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622786,,BAO_0000218,,
5664,5302,Area under curve value in mouse at a dose of 10 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622787,,BAO_0000218,,
5665,5506,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875949,,BAO_0000218,,
5666,5506,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622788,,BAO_0000218,,
5667,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622789,,BAO_0000218,,
5668,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622790,,BAO_0000218,,
5669,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622791,,BAO_0000218,,
5670,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622792,,BAO_0000218,,
5671,17764,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622793,,BAO_0000218,,
5672,17753,Area under curve was determined for the compound at 24 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622794,,BAO_0000218,,
5673,17753,Area under curve was determined for the compound at 40 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622795,,BAO_0000218,,
5674,17753,Area under curve was determined for the compound at 5 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621803,,BAO_0000218,,
5675,3132,Area under the curve for the compound is obtained at dose 25 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621804,,BAO_0000218,,
5676,3132,Area under the curve for the compound was obtained when tested in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621805,,BAO_0000218,,
5677,17837,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621806,,BAO_0000218,,
5678,17837,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621807,,BAO_0000218,,
5679,6062,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621808,,BAO_0000218,,
5680,4066,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621809,,BAO_0000218,,
5681,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621810,,BAO_0000218,,
5682,14239,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875164,,BAO_0000218,,
5683,14239,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621811,,BAO_0000218,,
5684,4890,"Compound was evaluated for the pharmacokinetic parameter, area under curve",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621812,,BAO_0000218,,
5685,429,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621813,,BAO_0000218,,
5686,429,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621814,,BAO_0000218,,
5687,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621815,,BAO_0000218,,
5688,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621816,,BAO_0000218,,
5689,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621817,,BAO_0000218,,
5690,6091,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621818,,BAO_0000218,,
5691,6091,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621819,,BAO_0000218,,
5692,6091,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621820,,BAO_0000218,,
5693,6091,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621821,,BAO_0000218,,
5694,6178,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621822,,BAO_0000218,,
5695,6178,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619474,,BAO_0000218,,
5696,6619,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619475,,BAO_0000218,,
5697,6619,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619476,,BAO_0000218,,
5698,3760,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619477,,BAO_0000218,,
5699,3760,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619478,,BAO_0000218,,
5700,3760,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619479,,BAO_0000218,,
5701,3760,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619480,,BAO_0000218,,
5702,3192,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619481,,BAO_0000218,,
5703,3192,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619482,,BAO_0000218,,
5704,2675,Area under the curve was evaluated in mice after intravenous administration,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619483,,BAO_0000218,,
5705,2675,Area under the curve was evaluated in mice after oral administration,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619484,,BAO_0000218,,
5706,16597,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL619485,,BAO_0000218,1969.0,
5707,16597,AUC total value at a dose of 10 mg/kg peroral administration in mice.,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL619486,,BAO_0000218,1969.0,
5708,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619487,,BAO_0000218,,
5709,17734,AUMC after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619488,,BAO_0000218,,
5710,7767,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620106,,BAO_0000218,178.0,
5711,15345,The compound was tested in vitro for anticancer activity against 9L cells,F,,,,,,,9L,,80653,N,1,Intermediate,1,,CHEMBL620107,392.0,BAO_0000219,,
5712,2181,Anti proliferation activity determined; Weak effect,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620283,,BAO_0000019,,
5713,2181,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL875176,,BAO_0000219,,
5714,2181,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620284,,BAO_0000219,,
5715,2181,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL623515,,BAO_0000219,,
5716,10486,The cytotoxic activity was in vitro tested by 9PS assay method,F,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL623516,,BAO_0000019,,
5717,10486,The cytotoxic activity was in vitro tested by 9PS assay method.,F,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL623517,,BAO_0000019,,
5718,15508,Partition coefficient (logD6.5),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL857878,,BAO_0000019,,
5719,5242,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL623518,478.0,BAO_0000219,,
5720,16167,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL624195,455.0,BAO_0000219,,
5721,4782,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL624196,500.0,BAO_0000219,,
5722,16093,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL624197,500.0,BAO_0000219,,
5723,2596,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624198,624.0,BAO_0000219,,
5724,2596,in vitro cytotoxicity against A 498 cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL621287,624.0,BAO_0000219,,
5725,3239,In vitro cytotoxic activity against renal (A 498) cancer cell line.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL621288,624.0,BAO_0000219,,
5726,1847,Cytotoxic activity against A 498 renal cancer cell lines.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL876496,624.0,BAO_0000219,,
5727,10553,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL621289,624.0,BAO_0000219,,
5728,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL621290,,BAO_0000019,,
5729,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL621291,,BAO_0000019,,
5730,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL621292,,BAO_0000019,,
5731,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL621293,,BAO_0000019,,
5732,4782,Inhibitory concentration required against A 549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621294,646.0,BAO_0000219,,
5733,11805,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621295,646.0,BAO_0000219,,
5734,11805,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884007,646.0,BAO_0000219,,
5735,2007,In vitro cytotoxicity against lung cancer A 549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621296,646.0,BAO_0000219,,
5736,4594,Compound was tested for its cytotoxicity against A 549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621297,646.0,BAO_0000219,,
5737,6018,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL839828,646.0,BAO_0000219,,
5738,6018,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620397,646.0,BAO_0000219,,
5739,3599,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620398,646.0,BAO_0000219,,
5740,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620399,646.0,BAO_0000219,,
5741,16132,In vitro inhibition of A549 (human lung cancer) cell growth.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620400,646.0,BAO_0000219,,
5742,16132,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620401,646.0,BAO_0000219,,
5743,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620402,646.0,BAO_0000219,,
5744,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620403,646.0,BAO_0000219,,
5745,11913,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620404,,BAO_0000218,,
5746,12621,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620405,,BAO_0000218,,
5747,12621,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620406,,BAO_0000218,,
5748,12621,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620407,,BAO_0000218,,
5749,12621,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620408,,BAO_0000218,,
5750,12621,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620409,,BAO_0000218,,
5751,3600,Inhibition of A-498 human Renal cell proliferation,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Expert,1,,CHEMBL620410,624.0,BAO_0000219,,
5752,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620411,,BAO_0000019,,
5753,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620412,,BAO_0000019,,
5754,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL876596,,BAO_0000019,,
5755,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Expert,1,,CHEMBL620413,622.0,BAO_0000219,,
5756,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL620414,622.0,BAO_0000219,,
5757,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL620415,622.0,BAO_0000219,,
5758,13617,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620416,646.0,BAO_0000219,,
5759,4584,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620417,646.0,BAO_0000219,,
5760,13799,Cytotoxic activity evaluated against A549 tumor cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620418,646.0,BAO_0000219,,
5761,16726,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620419,646.0,BAO_0000219,,
5762,16109,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620420,646.0,BAO_0000219,,
5763,16109,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620421,646.0,BAO_0000219,,
5764,15474,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620422,646.0,BAO_0000219,,
5765,6851,Cytotoxicity of compound against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620423,646.0,BAO_0000219,,
5766,17534,Cytotoxicity against human lung cell carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620424,646.0,BAO_0000219,,
5767,2621,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620425,646.0,BAO_0000219,,
5768,830,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620426,646.0,BAO_0000219,,
5769,14255,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620427,646.0,BAO_0000219,,
5770,14255,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620428,646.0,BAO_0000219,,
5771,1590,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620429,646.0,BAO_0000219,,
5772,6146,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620430,646.0,BAO_0000219,,
5773,17427,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL839887,646.0,BAO_0000219,,
5774,5280,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620431,646.0,BAO_0000219,,
5775,16786,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884010,646.0,BAO_0000219,,
5776,5895,In vitro cytotoxicity against A549 (human lung cancer),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620538,646.0,BAO_0000219,,
5777,14297,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620539,646.0,BAO_0000219,,
5778,17824,In vivo antiproliferative activity against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623373,646.0,BAO_0000218,,
5779,14368,Inhibition of non-small-cell lung adenocarcinoma (A549),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623374,646.0,BAO_0000219,,
5780,14368,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623375,646.0,BAO_0000219,,
5781,14254,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623376,646.0,BAO_0000219,,
5782,15897,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623377,646.0,BAO_0000219,,
5783,13866,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623378,646.0,BAO_0000219,,
5784,13370,Inhibitory activity of compound against human A549 lung carcinoma cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623379,646.0,BAO_0000219,,
5785,4862,Inhibitory activity against A549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623380,646.0,BAO_0000219,,
5786,4862,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623381,646.0,BAO_0000219,,
5787,4862,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623382,646.0,BAO_0000219,,
5788,15970,Inhibitory concentration against A549 (lung cancer) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623383,646.0,BAO_0000219,,
5789,17713,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL623384,646.0,BAO_0000219,,
5790,4833,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623385,646.0,BAO_0000219,,
5791,13736,Activity against A549 cancer cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL623386,646.0,BAO_0000219,,
5792,4312,The compound was evaluated for cytotoxicity against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884105,646.0,BAO_0000219,,
5793,5421,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623387,646.0,BAO_0000219,,
5794,5421,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621568,646.0,BAO_0000219,,
5795,14717,Growth inhibitory activity was measured for human A549 tumor cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621569,646.0,BAO_0000219,,
5796,4634,Inhibitory activity against A549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621570,646.0,BAO_0000219,,
5797,1149,Inhibitory activity against A549 cell line; inactive,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621571,646.0,BAO_0000219,,
5798,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621572,646.0,BAO_0000219,,
5799,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621573,646.0,BAO_0000219,,
5800,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621574,646.0,BAO_0000219,,
5801,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621575,646.0,BAO_0000219,,
5802,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621576,646.0,BAO_0000219,,
5803,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621577,646.0,BAO_0000219,,
5804,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621578,646.0,BAO_0000219,,
5805,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621579,646.0,BAO_0000219,,
5806,5726,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621580,646.0,BAO_0000219,,
5807,17800,Plasma clearance (in vivo) in mongrel dogs was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621581,,BAO_0000218,,
5808,5985,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621582,,BAO_0000218,,
5809,5530,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621583,,BAO_0000218,,
5810,5530,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621584,,BAO_0000218,,
5811,4839,Tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621585,,BAO_0000218,1969.0,
5812,3639,The compound was tested for clearance in dog plasma.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621586,,BAO_0000218,,
5813,4838,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875835,,BAO_0000218,,
5814,4137,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621587,,BAO_0000218,,
5815,5017,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621588,,BAO_0000218,1969.0,
5816,17538,In vitro clearance in dog liver microsomes,A,In vitro,,Canis lupus familiaris,9615.0,,Liver,,Microsomes,50588,N,1,Intermediate,1,,CHEMBL621589,,BAO_0000218,2107.0,
5817,6161,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621590,,BAO_0000218,,
5818,6161,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621591,,BAO_0000218,,
5819,1696,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621592,,BAO_0000218,,
5820,6762,Clearance rate in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621593,,BAO_0000218,,
5821,5932,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621594,,BAO_0000218,1969.0,
5822,6305,Clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621595,,BAO_0000218,,
5823,4942,Plasma clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621596,,BAO_0000218,,
5824,4219,Plasma clearance was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621597,,BAO_0000218,,
5825,17853,Lower clearance in dog (i.v.) at 0.5 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621598,,BAO_0000218,,
5826,4514,Plasma clearance in Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621599,,BAO_0000218,,
5827,6448,Plasma clearance (Clp) in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875836,,BAO_0000218,,
5828,6227,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621600,,BAO_0000218,,
5829,6227,Plasma clearance (pharmacokinetic parameter) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621601,,BAO_0000218,,
5830,6062,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618474,,BAO_0000218,,
5831,6821,Plasma clearance of compound was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618475,,BAO_0000218,,
5832,4709,Plasma clearance after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624524,,BAO_0000218,,
5833,4521,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624525,,BAO_0000218,,
5834,5374,Plasma clearance in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624526,,BAO_0000218,,
5835,6057,Plasma clearance was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624527,,BAO_0000218,,
5836,4727,Plasma clearance at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624528,,BAO_0000218,,
5837,5145,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624529,,BAO_0000218,,
5838,17657,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624530,,BAO_0000218,,
5839,17657,Plasma clearance in dog; Unable to calculate,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624531,,BAO_0000218,,
5840,5145,Plasma clearance in rhesus monkey,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624532,,BAO_0000218,,
5841,6642,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624533,,BAO_0000218,,
5842,6641,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624534,,BAO_0000218,,
5843,6642,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624535,,BAO_0000218,,
5844,5472,Plasma clearance was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624536,,BAO_0000218,,
5845,5472,Plasma clearance was evaluated in dog; Not tested,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624537,,BAO_0000218,,
5846,5472,Plasma clearance was evaluated in rhesus,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624538,,BAO_0000218,,
5847,5472,Plasma clearance was evaluated in rhesus; Not tested,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624539,,BAO_0000218,,
5848,4257,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624540,,BAO_0000218,,
5849,6679,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624541,,BAO_0000218,,
5850,5546,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624542,,BAO_0000218,,
5851,6348,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624543,,BAO_0000218,,
5852,5474,Clearance value at a dose of 0.2 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624544,,BAO_0000218,,
5853,6316,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624545,,BAO_0000218,1969.0,
5854,17594,Cmax after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624546,,BAO_0000218,,
5855,17594,Cmax after single intravenous bolus of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875957,,BAO_0000218,,
5856,5802,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624547,,BAO_0000218,,
5857,6535,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624548,,BAO_0000218,,
5858,6535,Cmax in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624549,,BAO_0000218,,
5859,1466,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624550,,BAO_0000218,1969.0,
5860,6505,Cmax on p.o. administration of 10 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621613,,BAO_0000218,,
5861,5668,Cmax was determine after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621614,,BAO_0000218,,
5862,5668,Cmax was determine after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623431,,BAO_0000218,,
5863,5668,Cmax was determine after peroral administration at 5 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623432,,BAO_0000218,,
5864,5600,Cmax after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623433,,BAO_0000218,,
5865,17764,Cmax after peroral administration in dogs at 2.4 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623434,,BAO_0000218,,
5866,6123,Cmax in dog after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623435,,BAO_0000218,,
5867,6123,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623436,,BAO_0000218,,
5868,6757,Cmax upon oral administration in male Beagle dog at 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875958,,BAO_0000218,,
5869,16907,Cmax value after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623437,,BAO_0000218,,
5870,7767,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL623438,,BAO_0000218,178.0,
5871,7767,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL623439,,BAO_0000218,178.0,
5872,7767,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL623440,,BAO_0000218,10000001.0,
5873,7767,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL623441,,BAO_0000218,10000001.0,
5874,7767,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL623442,,BAO_0000218,10000001.0,
5875,7767,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623469,,BAO_0000218,,
5876,7767,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623470,,BAO_0000218,,
5877,7767,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623471,,BAO_0000218,,
5878,7767,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623472,,BAO_0000218,948.0,
5879,7767,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623473,,BAO_0000218,948.0,
5880,7767,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623474,,BAO_0000218,948.0,
5881,7767,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623475,,BAO_0000218,2113.0,
5882,7767,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623476,,BAO_0000218,2113.0,
5883,7767,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623477,,BAO_0000218,2113.0,
5884,7767,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL621896,,BAO_0000218,160.0,
5885,7767,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL621897,,BAO_0000218,160.0,
5886,7767,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL621898,,BAO_0000218,160.0,
5887,7767,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621899,,BAO_0000218,2107.0,
5888,7767,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621900,,BAO_0000218,2107.0,
5889,7767,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621901,,BAO_0000218,2107.0,
5890,7767,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL621902,,BAO_0000218,2048.0,
5891,7767,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL621903,,BAO_0000218,2048.0,
5892,7767,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622587,,BAO_0000218,2048.0,
5893,7767,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL620285,,BAO_0000218,2385.0,
5894,7767,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL875285,,BAO_0000218,2385.0,
5895,7767,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL620286,,BAO_0000218,2385.0,
5896,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620287,,BAO_0000218,,
5897,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620288,,BAO_0000218,,
5898,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620289,,BAO_0000218,,
5899,7767,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL620290,,BAO_0000218,160.0,
5900,7767,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL620291,,BAO_0000218,160.0,
5901,7767,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL620292,,BAO_0000218,160.0,
5902,7767,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL620293,,BAO_0000218,2106.0,
5903,7767,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL620294,,BAO_0000218,2106.0,
5904,7767,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618614,,BAO_0000218,2106.0,
5905,7767,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL618615,,BAO_0000218,945.0,
5906,7767,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL618616,,BAO_0000218,945.0,
5907,2036,Cytotoxicity against A-172 human tumor cell lines,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Expert,1,,CHEMBL618617,622.0,BAO_0000219,,
5908,2357,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL618618,622.0,BAO_0000219,,
5909,1457,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,F,,,Homo sapiens,9606.0,,,A204,,80014,N,1,Intermediate,1,,CHEMBL618619,623.0,BAO_0000219,,
5910,4379,Tested for antiproliferative activity against A-2780 tumoral cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618620,478.0,BAO_0000219,,
5911,1093,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL618621,455.0,BAO_0000219,,
5912,12152,Tested in vitro against A-375 cell line human melanoma,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL618622,455.0,BAO_0000219,,
5913,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Expert,1,,CHEMBL618623,797.0,BAO_0000219,,
5914,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618624,797.0,BAO_0000219,,
5915,16582,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Expert,1,,CHEMBL618625,797.0,BAO_0000219,,
5916,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618626,797.0,BAO_0000219,,
5917,10413,Antitumor activity on A-427 lung carcinoma cell lines,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618627,797.0,BAO_0000219,,
5918,6418,Cytotoxic activity against human A-427 lung tumor cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618628,797.0,BAO_0000219,,
5919,17134,In vitro antitumor effects against human A-427 cell lines.,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Expert,1,,CHEMBL618629,797.0,BAO_0000219,,
5920,16132,In vitro inhibition of A-427 (human lung cancer) cell growth.,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Expert,1,,CHEMBL618630,797.0,BAO_0000219,,
5921,16132,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618631,797.0,BAO_0000219,,
5922,16780,Cytotoxic activity of compound against A-427 lung human tumor cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618632,797.0,BAO_0000219,,
5923,4085,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL618633,500.0,BAO_0000219,,
5924,1276,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619315,624.0,BAO_0000219,,
5925,3498,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Expert,1,,CHEMBL619316,624.0,BAO_0000219,,
5926,1169,Cytotoxicity against human kidney carcinoma A-498cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619317,624.0,BAO_0000219,,
5927,4450,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619318,624.0,BAO_0000219,,
5928,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619319,624.0,BAO_0000219,,
5929,4461,Antitumor cytotoxic activity against A-498 cell line was determined,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619739,624.0,BAO_0000219,,
5930,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619740,624.0,BAO_0000219,,
5931,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL883158,624.0,BAO_0000219,,
5932,1457,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL884012,624.0,BAO_0000219,,
5933,3664,In vitro inhibitory activity against A-498 ovarian cancer cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619741,624.0,BAO_0000219,,
5934,15895,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619742,624.0,BAO_0000219,,
5935,11843,Inhibition of growth lung non-small cell carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876610,646.0,BAO_0000219,,
5936,11843,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619743,646.0,BAO_0000219,,
5937,17705,In vitro antiproliferative activity against human A-549 NSCL cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619744,646.0,BAO_0000219,,
5938,17705,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619745,646.0,BAO_0000219,,
5939,4369,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619746,646.0,BAO_0000219,,
5940,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619747,646.0,BAO_0000219,,
5941,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619748,646.0,BAO_0000219,,
5942,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619749,646.0,BAO_0000219,,
5943,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619750,646.0,BAO_0000219,,
5944,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624014,646.0,BAO_0000219,,
5945,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624015,646.0,BAO_0000219,,
5946,4787,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL885344,646.0,BAO_0000219,,
5947,4787,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623224,646.0,BAO_0000219,,
5948,6513,Cytotoxic activity against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623225,646.0,BAO_0000219,,
5949,6690,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622698,646.0,BAO_0000219,,
5950,6690,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622699,646.0,BAO_0000219,,
5951,12263,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL622700,646.0,BAO_0000219,,
5952,1054,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622701,646.0,BAO_0000219,,
5953,1359,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622702,646.0,BAO_0000219,,
5954,3547,Cytotoxic activity against human lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622703,646.0,BAO_0000219,,
5955,5771,Cytotoxic activity towards A-549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL622704,646.0,BAO_0000219,,
5956,14425,"In vitro percent inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622705,646.0,BAO_0000219,,
5957,14425,"In vitro percent inhibition of A549, lung carcinoma",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622706,646.0,BAO_0000219,,
5958,14425,"In vitro percent inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622707,646.0,BAO_0000219,,
5959,14425,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622708,646.0,BAO_0000219,,
5960,5280,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622709,646.0,BAO_0000219,,
5961,15176,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622710,646.0,BAO_0000219,,
5962,15300,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622711,646.0,BAO_0000219,,
5963,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622712,646.0,BAO_0000218,,
5964,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622713,646.0,BAO_0000218,,
5965,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622714,646.0,BAO_0000218,,
5966,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622715,646.0,BAO_0000218,,
5967,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622716,646.0,BAO_0000218,,
5968,17824,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622717,646.0,BAO_0000219,,
5969,17528,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622718,646.0,BAO_0000218,,
5970,6870,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL622719,646.0,BAO_0000219,,
5971,6870,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622720,646.0,BAO_0000219,,
5972,6870,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622721,646.0,BAO_0000219,,
5973,6870,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622722,646.0,BAO_0000219,,
5974,16726,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876030,646.0,BAO_0000219,,
5975,6170,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620206,646.0,BAO_0000219,,
5976,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620207,646.0,BAO_0000219,,
5977,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620208,646.0,BAO_0000219,,
5978,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620209,646.0,BAO_0000219,,
5979,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620210,646.0,BAO_0000219,,
5980,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621639,646.0,BAO_0000219,,
5981,17321,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621640,646.0,BAO_0000219,,
5982,17528,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621641,646.0,BAO_0000219,,
5983,12888,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621642,646.0,BAO_0000219,,
5984,4312,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621643,646.0,BAO_0000219,,
5985,4312,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621644,646.0,BAO_0000219,,
5986,4312,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621645,646.0,BAO_0000219,,
5987,17737,In vitro antiproliferative activity against A549 cell line,F,,,Mus musculus,10090.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621646,646.0,BAO_0000219,,
5988,6630,Synergism with indomethacin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621647,646.0,BAO_0000219,,
5989,6630,Synergism with tolmetin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621648,646.0,BAO_0000219,,
5990,6630,Synergism with sulindac in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621649,646.0,BAO_0000219,,
5991,6630,Antagonism of indomethacin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621650,646.0,BAO_0000219,,
5992,6630,Antagonism of sulindac in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621651,646.0,BAO_0000219,,
5993,6630,Antagonism of tolmetin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621652,646.0,BAO_0000219,,
5994,6630,Synergism with indomethacin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621653,646.0,BAO_0000219,,
5995,6630,Synergism with sulindac in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621654,646.0,BAO_0000219,,
5996,6630,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621655,646.0,BAO_0000219,,
5997,16907,Cmax value after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621656,,BAO_0000218,,
5998,5944,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621657,,BAO_0000218,,
5999,5944,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621658,,BAO_0000218,,
6000,5944,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621659,,BAO_0000218,,
6001,5944,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621660,,BAO_0000218,,
6002,2959,Cmax value after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621661,,BAO_0000218,,
6003,6241,Cmax value in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621662,,BAO_0000218,,
6004,6241,Cmax value in dogs after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621663,,BAO_0000218,,
6005,2652,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621664,,BAO_0000218,,
6006,1806,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621665,,BAO_0000218,1969.0,
6007,1806,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621666,,BAO_0000218,1969.0,
6008,1021,Concentration maxima after oral dosing in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621667,,BAO_0000218,,
6009,1021,Concentration maxima after oral dosing in dogs; not available,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876738,,BAO_0000218,,
6010,1021,Concentration maxima after oral dosing in dogs; not available,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621668,,BAO_0000218,,
6011,5444,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621669,,BAO_0000218,,
6012,5444,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621670,,BAO_0000218,,
6013,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621671,,BAO_0000218,,
6014,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622360,,BAO_0000218,,
6015,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622361,,BAO_0000218,,
6016,5130,Cmax in dog plasma after oral dose (1 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622362,,BAO_0000218,1969.0,
6017,3249,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622363,,BAO_0000218,1969.0,
6018,5473,Maximal plasma concentration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622364,,BAO_0000218,1969.0,
6019,5474,Maximal plasma concentration at a dose of 1 mg/kg (oral),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622365,,BAO_0000218,1969.0,
6020,4657,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622533,,BAO_0000218,1969.0,
6021,3031,Maximum concentration of compound in dog was evaluated.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622534,,BAO_0000218,,
6022,4527,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622535,,BAO_0000218,,
6023,4186,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876739,,BAO_0000218,,
6024,5007,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622536,,BAO_0000218,,
6025,3132,Maximum concentration obtained in dog plasma was determined,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622537,,BAO_0000218,1969.0,
6026,5006,Maximum concentration was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622538,,BAO_0000218,,
6027,4727,Maximum concentration at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL627867,,BAO_0000218,,
6028,1916,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL627868,,BAO_0000218,,
6029,1918,Maximum concentration was evaluated in dog plasma,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627869,,BAO_0000218,1969.0,
6030,3045,Maximum concentration was evaluated after 75 min after administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL627870,,BAO_0000218,,
6031,9579,Maximum plasma concentration determined in dog after oral administration of 17b,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627871,,BAO_0000218,1969.0,
6032,9579,Maximum plasma concentration determined in dog after oral administration of 2b,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627872,,BAO_0000218,1969.0,
6033,933,Maximum plasma concentration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627873,,BAO_0000218,1969.0,
6034,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627874,,BAO_0000218,1969.0,
6035,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627875,,BAO_0000218,1969.0,
6036,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627876,,BAO_0000218,1969.0,
6037,17839,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627877,,BAO_0000218,1969.0,
6038,6348,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627878,,BAO_0000218,1969.0,
6039,16367,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627879,,BAO_0000218,1969.0,
6040,1337,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL875355,,BAO_0000218,1969.0,
6041,1337,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627880,,BAO_0000218,1969.0,
6042,5199,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627881,,BAO_0000218,1969.0,
6043,17650,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627882,,BAO_0000218,1969.0,
6044,6679,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627883,,BAO_0000218,1969.0,
6045,5356,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628526,,BAO_0000218,1969.0,
6046,5356,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628527,,BAO_0000218,1969.0,
6047,6227,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628528,,BAO_0000218,1969.0,
6048,6227,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628529,,BAO_0000218,1969.0,
6049,6227,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628530,,BAO_0000218,1969.0,
6050,6227,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL625243,,BAO_0000218,1969.0,
6051,3598,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Expert,1,,CHEMBL625244,,BAO_0000218,1969.0,
6052,4368,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625245,,BAO_0000218,,
6053,6265,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625246,,BAO_0000218,,
6054,7767,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL625247,,BAO_0000218,945.0,
6055,7767,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL625248,,BAO_0000218,1088.0,
6056,7767,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,A,In vivo,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL625249,,BAO_0000218,1088.0,
6057,7767,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,A,In vivo,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL625250,,BAO_0000218,1088.0,
6058,17811,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625251,,BAO_0000218,,
6059,17811,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875356,,BAO_0000218,,
6060,17827,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625252,,BAO_0000218,,
6061,17827,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL625253,,BAO_0000218,178.0,
6062,17827,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625254,,BAO_0000218,,
6063,17827,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625255,,BAO_0000218,,
6064,17827,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625256,,BAO_0000218,,
6065,17827,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL625257,,BAO_0000218,178.0,
6066,17827,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL625258,,BAO_0000218,178.0,
6067,17827,Compound was evaluated for washout rate in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625259,,BAO_0000218,,
6068,17827,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625260,,BAO_0000218,,
6069,17827,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625261,,BAO_0000218,,
6070,17827,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625262,,BAO_0000218,,
6071,17827,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622639,,BAO_0000218,,
6072,17257,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622640,,BAO_0000218,,
6073,17257,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622812,,BAO_0000218,,
6074,17257,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622813,,BAO_0000218,,
6075,17257,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622814,,BAO_0000218,,
6076,17827,Time at maximum activity in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622815,,BAO_0000218,,
6077,3760,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625342,,BAO_0000218,,
6078,3760,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625343,,BAO_0000218,,
6079,17409,Binding towards mouse plasma protein at 10 uM,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL877591,,BAO_0000218,,
6080,17409,Binding towards mouse plasma protein at 100 uM,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625344,,BAO_0000218,,
6081,2675,Bioavailability was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625345,,BAO_0000218,,
6082,2675,Bioavailability was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625346,,BAO_0000218,,
6083,3132,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625347,,BAO_0000218,,
6084,3132,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625348,,BAO_0000218,,
6085,16597,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625349,,BAO_0000218,,
6086,2862,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625350,,BAO_0000218,,
6087,17764,Oral bioavailability after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL882952,,BAO_0000218,,
6088,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625351,,BAO_0000218,955.0,
6089,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625352,,BAO_0000218,955.0,
6090,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL877592,,BAO_0000218,955.0,
6091,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625353,,BAO_0000218,955.0,
6092,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625354,,BAO_0000218,955.0,
6093,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL626019,,BAO_0000218,955.0,
6094,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL626020,,BAO_0000218,948.0,
6095,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL626021,,BAO_0000218,948.0,
6096,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL626022,,BAO_0000218,948.0,
6097,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL626192,,BAO_0000218,948.0,
6098,1276,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626193,646.0,BAO_0000219,,
6099,3498,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL626194,646.0,BAO_0000219,,
6100,1169,Cytotoxicity against human lung carcinoma A-549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626195,646.0,BAO_0000219,,
6101,4450,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626196,646.0,BAO_0000219,,
6102,358,In vitro cytotoxicity against human lung carcinoma cell line A-549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626197,646.0,BAO_0000219,,
6103,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626198,646.0,BAO_0000219,,
6104,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626199,646.0,BAO_0000219,,
6105,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626200,646.0,BAO_0000219,,
6106,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626201,646.0,BAO_0000219,,
6107,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626202,646.0,BAO_0000219,,
6108,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626203,646.0,BAO_0000219,,
6109,15167,In vitro cytotoxicity against A-549 human lung cancer cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626204,646.0,BAO_0000219,,
6110,4139,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624701,646.0,BAO_0000219,,
6111,833,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624702,646.0,BAO_0000219,,
6112,15718,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624703,646.0,BAO_0000219,,
6113,12373,Tested in vitro for cytotoxicity against A-549 lung cancer cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624704,646.0,BAO_0000219,,
6114,637,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624705,646.0,BAO_0000219,,
6115,14867,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624706,646.0,BAO_0000219,,
6116,4461,Antitumor cytotoxic activity against A-549 cell line was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624707,646.0,BAO_0000219,,
6117,5406,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624708,646.0,BAO_0000219,,
6118,4457,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624709,646.0,BAO_0000219,,
6119,1386,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL884107,646.0,BAO_0000219,,
6120,3265,Antitumoral activity was assayed against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624710,646.0,BAO_0000219,,
6121,2359,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624711,646.0,BAO_0000219,,
6122,4457,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624712,646.0,BAO_0000219,,
6123,12454,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624713,646.0,BAO_0000219,,
6124,1481,Compound was tested for inhibition of cell growth of A-549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624714,646.0,BAO_0000219,,
6125,1750,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624715,646.0,BAO_0000219,,
6126,5065,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624716,646.0,BAO_0000219,,
6127,808,In vitro cytotoxicity against A549-human lung carcinoma cells.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619505,646.0,BAO_0000219,,
6128,16364,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619506,646.0,BAO_0000219,,
6129,1847,Cytotoxic activity against A-549 cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619507,646.0,BAO_0000219,,
6130,1747,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619508,646.0,BAO_0000219,,
6131,1003,Cytotoxicity against human A549 non small cell lung cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619509,646.0,BAO_0000219,,
6132,15313,Inhibition of cell growth in (A-549) lung cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619510,646.0,BAO_0000219,,
6133,3122,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619511,646.0,BAO_0000219,,
6134,16049,In vitro antitumor activity against A-549 tumor cells.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619512,646.0,BAO_0000219,,
6135,17134,In vitro antitumor effects against human A-549 cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619513,646.0,BAO_0000219,,
6136,6406,In vitro cytotoxic activity of compound against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619514,646.0,BAO_0000219,,
6137,627,In vitro cytotoxicity against human lung carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619515,646.0,BAO_0000219,,
6138,12307,In vitro cytotoxicity against human non-small cell lung carcinoma A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619516,646.0,BAO_0000219,,
6139,17861,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884005,646.0,BAO_0000219,,
6140,6682,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619517,646.0,BAO_0000219,,
6141,6663,Inhibitory concentration of compound against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619518,646.0,BAO_0000219,,
6142,2454,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619519,646.0,BAO_0000219,,
6143,14709,cytotoxic activity against leukemia (A-549) cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876489,646.0,BAO_0000219,,
6144,15718,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619520,646.0,BAO_0000219,,
6145,15718,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619521,646.0,BAO_0000219,,
6146,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619522,646.0,BAO_0000219,,
6147,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619523,646.0,BAO_0000219,,
6148,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619524,646.0,BAO_0000219,,
6149,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619525,646.0,BAO_0000219,,
6150,6630,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619526,646.0,BAO_0000219,,
6151,16726,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619527,646.0,BAO_0000219,,
6152,17846,Cytotoxicity against A549 cells; No cytotoxicity,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619528,646.0,BAO_0000219,,
6153,3415,Cytotoxicity against human lung carcinoma (A549) cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619529,646.0,BAO_0000219,,
6154,3415,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619530,646.0,BAO_0000219,,
6155,5609,In vitro anticancer activity against human lung (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876490,646.0,BAO_0000219,,
6156,17206,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619531,646.0,BAO_0000219,,
6157,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619532,646.0,BAO_0000219,,
6158,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619533,646.0,BAO_0000219,,
6159,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619534,646.0,BAO_0000219,,
6160,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620164,646.0,BAO_0000219,,
6161,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620165,646.0,BAO_0000219,,
6162,16295,Inhibition of A549 human lung tumor cell proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620166,646.0,BAO_0000219,,
6163,16825,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620167,646.0,BAO_0000219,,
6164,3439,In vitro cytotoxicity against human tumor cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620168,646.0,BAO_0000219,,
6165,10870,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620338,646.0,BAO_0000219,,
6166,4845,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620339,646.0,BAO_0000219,,
6167,5822,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620340,646.0,BAO_0000219,,
6168,5822,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620341,646.0,BAO_0000219,,
6169,5822,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876491,646.0,BAO_0000219,,
6170,16381,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620342,646.0,BAO_0000219,,
6171,16381,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620343,646.0,BAO_0000219,,
6172,16381,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620344,646.0,BAO_0000219,,
6173,5609,In vitro anticancer activity against human lung (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620345,646.0,BAO_0000219,,
6174,4644,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620346,646.0,BAO_0000219,,
6175,4644,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620347,646.0,BAO_0000219,,
6176,4644,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620348,646.0,BAO_0000219,,
6177,4644,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620349,646.0,BAO_0000219,,
6178,5822,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL618667,646.0,BAO_0000219,,
6179,3415,Percentage inhibition of human lung carcinoma (A549) cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL618668,646.0,BAO_0000219,,
6180,16726,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876031,646.0,BAO_0000219,,
6181,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL618759,646.0,BAO_0000219,,
6182,17206,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL618760,646.0,BAO_0000219,,
6183,17206,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619000,646.0,BAO_0000219,,
6184,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619001,646.0,BAO_0000219,,
6185,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619002,646.0,BAO_0000219,,
6186,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619003,646.0,BAO_0000219,,
6187,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619597,646.0,BAO_0000219,,
6188,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619598,646.0,BAO_0000219,,
6189,17206,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619599,646.0,BAO_0000219,,
6190,17206,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619600,646.0,BAO_0000219,,
6191,16726,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619601,646.0,BAO_0000219,,
6192,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619602,646.0,BAO_0000219,,
6193,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619603,646.0,BAO_0000219,,
6194,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619604,646.0,BAO_0000219,,
6195,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619605,646.0,BAO_0000219,,
6196,6084,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619606,,BAO_0000218,,
6197,6084,Pharmacokinetic activity (Cmax) in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876032,,BAO_0000218,,
6198,4809,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619607,,BAO_0000218,,
6199,5983,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619608,,BAO_0000218,,
6200,6251,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619609,,BAO_0000218,,
6201,5932,Cmax in dog plasma after 30mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL619610,,BAO_0000218,1969.0,
6202,4273,Tested for the peak blood level in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL619611,,BAO_0000218,178.0,
6203,5313,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619612,,BAO_0000218,,
6204,5313,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619613,,BAO_0000218,,
6205,6221,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL619614,,BAO_0000218,178.0,
6206,4709,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619615,,BAO_0000218,,
6207,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619616,,BAO_0000218,,
6208,6241,Final plasma concentration in dogs after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL619617,,BAO_0000218,1969.0,
6209,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619618,,BAO_0000218,,
6210,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876033,,BAO_0000218,,
6211,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619619,,BAO_0000218,,
6212,2189,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619620,,BAO_0000218,,
6213,2189,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL619621,,BAO_0000218,1088.0,
6214,2189,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL619622,,BAO_0000218,1088.0,
6215,2189,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL618874,,BAO_0000218,1088.0,
6216,4257,Absolute bioavailability was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618875,,BAO_0000218,,
6217,6221,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618876,,BAO_0000218,,
6218,6215,Bioavailability after peroral administration (1 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618877,,BAO_0000218,,
6219,17267,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618878,,BAO_0000218,,
6220,6621,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618879,,BAO_0000218,,
6221,3854,Bioavailability after intravenous administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618880,,BAO_0000218,,
6222,3854,Bioavailability after peroral administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618881,,BAO_0000218,,
6223,5007,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618882,,BAO_0000218,,
6224,4333,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624226,,BAO_0000218,,
6225,4333,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624227,,BAO_0000218,1969.0,
6226,5006,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624228,,BAO_0000218,,
6227,5199,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624229,,BAO_0000218,,
6228,4368,Bioavailability by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624230,,BAO_0000218,,
6229,3771,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624231,,BAO_0000218,,
6230,4953,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624232,,BAO_0000218,,
6231,5064,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625127,,BAO_0000218,,
6232,17657,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625128,,BAO_0000218,,
6233,17796,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621675,,BAO_0000218,,
6234,17853,Bioavailability in dog (p.o.) at 2.0 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621676,,BAO_0000218,,
6235,4521,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621677,,BAO_0000218,,
6236,4521,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621678,,BAO_0000218,,
6237,5006,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621679,,BAO_0000218,,
6238,16365,Bioavailability was evaluated after oral administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621680,,BAO_0000218,,
6239,1916,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621681,,BAO_0000218,,
6240,1918,Bioavailability was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876740,,BAO_0000218,,
6241,4239,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621682,,BAO_0000218,,
6242,6505,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621683,,BAO_0000218,,
6243,5334,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621684,,BAO_0000218,,
6244,5334,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621685,,BAO_0000218,,
6245,4809,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621686,,BAO_0000218,,
6246,6348,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621687,,BAO_0000218,,
6247,6005,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621688,,BAO_0000218,,
6248,17804,Bioavailability of compound in dog was determined after peroral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621689,,BAO_0000218,,
6249,3184,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621690,,BAO_0000218,,
6250,1806,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621691,,BAO_0000218,,
6251,1806,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875941,,BAO_0000218,,
6252,1806,Compound was evaluated for oral bioavailability in dogs; 37-38 %,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621692,,BAO_0000218,,
6253,4839,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621693,,BAO_0000218,,
6254,5017,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621694,,BAO_0000218,,
6255,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621695,,BAO_0000218,948.0,
6256,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621696,,BAO_0000218,948.0,
6257,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621697,,BAO_0000218,2113.0,
6258,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621698,,BAO_0000218,2113.0,
6259,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623420,,BAO_0000218,2113.0,
6260,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623421,,BAO_0000218,2113.0,
6261,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623422,,BAO_0000218,2113.0,
6262,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623423,,BAO_0000218,2113.0,
6263,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623424,,BAO_0000218,2107.0,
6264,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623425,,BAO_0000218,2107.0,
6265,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623426,,BAO_0000218,2107.0,
6266,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623427,,BAO_0000218,2107.0,
6267,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623428,,BAO_0000218,2107.0,
6268,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL875947,,BAO_0000218,2107.0,
6269,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623429,,BAO_0000218,2048.0,
6270,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623430,,BAO_0000218,2048.0,
6271,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622588,,BAO_0000218,2048.0,
6272,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622589,,BAO_0000218,2048.0,
6273,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622751,,BAO_0000218,2048.0,
6274,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622752,,BAO_0000218,2048.0,
6275,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622753,42.0,BAO_0000218,,
6276,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622647,42.0,BAO_0000218,,
6277,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL875163,42.0,BAO_0000218,,
6278,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622648,42.0,BAO_0000218,,
6279,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622649,42.0,BAO_0000218,,
6280,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622650,42.0,BAO_0000218,955.0,
6281,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622651,42.0,BAO_0000218,955.0,
6282,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622652,42.0,BAO_0000218,955.0,
6283,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622653,42.0,BAO_0000218,955.0,
6284,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622654,42.0,BAO_0000218,955.0,
6285,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622655,42.0,BAO_0000218,948.0,
6286,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622656,42.0,BAO_0000218,948.0,
6287,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622657,42.0,BAO_0000218,948.0,
6288,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622658,42.0,BAO_0000218,948.0,
6289,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622659,42.0,BAO_0000218,948.0,
6290,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624630,42.0,BAO_0000218,2113.0,
6291,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624631,42.0,BAO_0000218,2113.0,
6292,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624632,42.0,BAO_0000218,2113.0,
6293,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624633,646.0,BAO_0000219,,
6294,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624634,646.0,BAO_0000219,,
6295,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624635,646.0,BAO_0000219,,
6296,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624636,646.0,BAO_0000219,,
6297,3263,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL857055,646.0,BAO_0000219,,
6298,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624637,646.0,BAO_0000219,,
6299,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624638,646.0,BAO_0000219,,
6300,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL874366,646.0,BAO_0000219,,
6301,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624639,646.0,BAO_0000219,,
6302,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624640,646.0,BAO_0000219,,
6303,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624641,646.0,BAO_0000219,,
6304,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624642,646.0,BAO_0000219,,
6305,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624643,646.0,BAO_0000219,,
6306,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624644,646.0,BAO_0000219,,
6307,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624645,646.0,BAO_0000219,,
6308,3983,The compound was evaluated for its cytotoxic potency against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619445,646.0,BAO_0000219,,
6309,11141,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL839886,646.0,BAO_0000219,,
6310,5076,Cytotoxic activity of compound against A-549 tumor cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619446,646.0,BAO_0000219,,
6311,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619447,646.0,BAO_0000219,,
6312,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619448,646.0,BAO_0000219,,
6313,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619449,646.0,BAO_0000219,,
6314,5076,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619450,646.0,BAO_0000219,,
6315,4150,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619451,646.0,BAO_0000219,,
6316,2150,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619452,646.0,BAO_0000219,,
6317,4644,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619453,646.0,BAO_0000219,,
6318,263,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL874367,646.0,BAO_0000219,,
6319,11333,Cytotoxic concentration against A-549 tumor cells.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619454,646.0,BAO_0000219,,
6320,11333,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619455,646.0,BAO_0000219,,
6321,15895,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619456,646.0,BAO_0000219,,
6322,16677,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,F,,,Acinetobacter baumannii,470.0,,,,,50191,N,1,Expert,1,,CHEMBL619457,,BAO_0000218,,
6323,10624,Activity against Acinetobacter calcoaceticus (AC54),F,,,Acinetobacter calcoaceticus,471.0,,,,,50192,N,1,Intermediate,1,,CHEMBL619458,,BAO_0000218,,
6324,16717,In vitro antifungal activity against Aspergillus flavus CM74,F,,,Aspergillus flavus,5059.0,,,,,50274,N,1,Expert,1,,CHEMBL619459,,BAO_0000218,,
6325,16717,In vitro antifungal activity against Aspergillus flavus CM74,F,,,Aspergillus flavus,5059.0,,,,,50274,N,1,Expert,1,,CHEMBL619460,,BAO_0000218,,
6326,5513,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL619461,,BAO_0000218,,
6327,15962,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL619462,,BAO_0000218,,
6328,15962,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL620388,,BAO_0000218,,
6329,15962,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL620389,,BAO_0000218,,
6330,15962,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL620390,,BAO_0000218,,
6331,16717,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Expert,1,,CHEMBL620391,,BAO_0000218,,
6332,16717,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Expert,1,,CHEMBL621073,,BAO_0000218,,
6333,8117,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL621074,,BAO_0000218,,
6334,8117,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL621075,,BAO_0000218,,
6335,15472,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL619554,,BAO_0000218,,
6336,15472,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL619555,,BAO_0000218,,
6337,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,F,,,Aggregatibacter actinomycetemcomitans,714.0,,,,,50169,N,1,Intermediate,1,,CHEMBL619556,,BAO_0000218,,
6338,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,F,,,Aggregatibacter actinomycetemcomitans,714.0,,,,,50169,N,1,Intermediate,1,,CHEMBL619557,,BAO_0000218,,
6339,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,F,,,Aggregatibacter actinomycetemcomitans,714.0,,,,,50169,N,1,Intermediate,1,,CHEMBL619558,,BAO_0000218,,
6340,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619559,646.0,BAO_0000219,,
6341,17206,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619560,646.0,BAO_0000219,,
6342,16381,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619561,646.0,BAO_0000219,,
6343,16381,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619562,646.0,BAO_0000219,,
6344,16381,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619563,646.0,BAO_0000219,,
6345,16381,GI values against A549 cells (lung cancer),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL857457,646.0,BAO_0000219,,
6346,17206,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619564,646.0,BAO_0000219,,
6347,16325,Inhibitory activity against A549 human adenocarcinoma,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619565,646.0,BAO_0000219,,
6348,10708,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619566,646.0,BAO_0000218,,
6349,10708,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619567,646.0,BAO_0000218,,
6350,17376,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619568,646.0,BAO_0000219,,
6351,17376,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619569,646.0,BAO_0000219,,
6352,17488,Cytotoxicity against human A549 lung cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619570,646.0,BAO_0000219,,
6353,17404,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619571,646.0,BAO_0000218,,
6354,10958,Growth inhibition of A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619572,646.0,BAO_0000219,,
6355,17099,Effective dose required for inhibitory activity against A549 human tumor cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619573,646.0,BAO_0000219,,
6356,17099,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619574,646.0,BAO_0000219,,
6357,4096,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619575,646.0,BAO_0000219,,
6358,4096,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619576,646.0,BAO_0000219,,
6359,4096,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619577,646.0,BAO_0000219,,
6360,2525,In vitro inhibitory activity against A549 tumor cell culture,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619578,646.0,BAO_0000219,,
6361,2525,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884009,646.0,BAO_0000219,,
6362,5302,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619579,646.0,BAO_0000219,,
6363,16325,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619580,646.0,BAO_0000219,,
6364,16939,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619581,646.0,BAO_0000219,,
6365,17229,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619582,646.0,BAO_0000219,,
6366,17380,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619583,646.0,BAO_0000219,,
6367,17380,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876502,646.0,BAO_0000219,,
6368,1903,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619584,646.0,BAO_0000219,,
6369,3838,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619585,646.0,BAO_0000219,,
6370,14696,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619586,646.0,BAO_0000219,,
6371,3838,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619587,646.0,BAO_0000219,,
6372,1522,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619588,646.0,BAO_0000219,,
6373,12400,Tested in vitro for cytotoxicity in A549/ATCC cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619589,646.0,BAO_0000219,,
6374,14696,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619590,646.0,BAO_0000219,,
6375,14769,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619591,646.0,BAO_0000219,,
6376,14696,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619592,646.0,BAO_0000219,,
6377,1888,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619593,646.0,BAO_0000219,,
6378,12016,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620217,646.0,BAO_0000219,,
6379,6058,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620218,646.0,BAO_0000219,,
6380,17708,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620219,646.0,BAO_0000219,,
6381,12301,Antitumor activity against A549/ATCC cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620220,646.0,BAO_0000219,,
6382,11970,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL625141,646.0,BAO_0000219,,
6383,11818,In vitro cytotoxicity against A549/ATCC cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL625142,646.0,BAO_0000219,,
6384,12400,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL625143,646.0,BAO_0000219,,
6385,3381,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL625144,646.0,BAO_0000219,,
6386,17376,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622474,646.0,BAO_0000219,,
6387,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884104,646.0,BAO_0000219,,
6388,2964,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL622475,,BAO_0000219,,
6389,5005,Compound was tested for oral bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,22224,U,0,Intermediate,1,,CHEMBL622476,,BAO_0000218,,
6390,6229,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875831,,BAO_0000218,,
6391,6229,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622477,,BAO_0000218,,
6392,5374,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622478,,BAO_0000218,,
6393,5374,Compound was tested for the oral bioavailability in dog; No availability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623172,,BAO_0000218,,
6394,6265,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623173,,BAO_0000218,,
6395,5654,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623174,,BAO_0000218,,
6396,5654,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623175,,BAO_0000218,,
6397,16456,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623340,,BAO_0000218,,
6398,5302,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623341,,BAO_0000218,,
6399,3624,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623342,,BAO_0000218,,
6400,16452,Oral bioavailability of active FTIs in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623343,,BAO_0000218,,
6401,5802,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623344,,BAO_0000218,,
6402,3598,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL623345,,BAO_0000218,,
6403,17839,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875832,,BAO_0000218,,
6404,6762,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623346,,BAO_0000218,,
6405,6821,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623347,,BAO_0000218,,
6406,6821,Oral bioavailability of compound was determined in dog; Not tested,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623348,,BAO_0000218,,
6407,5210,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623349,,BAO_0000218,,
6408,6227,Oral bioavailability (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623350,,BAO_0000218,,
6409,761,Oral bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623351,,BAO_0000218,,
6410,761,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623352,,BAO_0000218,,
6411,761,Oral bioavailability administered in solution in rats,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623353,,BAO_0000218,,
6412,16907,Oral bioavailability after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875833,,BAO_0000218,,
6413,5474,Oral bioavailability at a dose of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623354,,BAO_0000218,,
6414,6535,Oral bioavailability in dog (dose 1 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623355,,BAO_0000218,,
6415,6535,Oral bioavailability in Dog; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623356,,BAO_0000218,,
6416,3352,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623357,,BAO_0000218,,
6417,6168,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623358,,BAO_0000218,,
6418,5988,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623359,,BAO_0000218,,
6419,4942,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623360,,BAO_0000218,,
6420,4942,Oral bioavailability in dogs; No data,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623361,,BAO_0000218,,
6421,14541,Oral bioavailability measured in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623362,,BAO_0000218,,
6422,4449,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623363,,BAO_0000218,,
6423,6057,Oral bioavailability was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623364,,BAO_0000218,,
6424,5600,Oral bioavailability after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875834,,BAO_0000218,,
6425,5542,Oral bioavailability in dog (i.v. dosing),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623365,,BAO_0000218,,
6426,5542,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623366,,BAO_0000218,,
6427,5546,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623367,,BAO_0000218,,
6428,4514,Oral bioavailability in Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623368,,BAO_0000218,,
6429,3624,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623369,,BAO_0000218,,
6430,3854,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623370,,BAO_0000218,,
6431,5836,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623371,,BAO_0000218,,
6432,5940,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623372,,BAO_0000218,,
6433,6168,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621351,,BAO_0000218,,
6434,6227,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621352,,BAO_0000218,,
6435,6251,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621353,,BAO_0000218,,
6436,6448,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621354,,BAO_0000218,,
6437,6647,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621355,,BAO_0000218,,
6438,5940,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621356,,BAO_0000218,,
6439,933,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621357,,BAO_0000218,,
6440,5210,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621358,,BAO_0000218,,
6441,6642,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621359,,BAO_0000218,,
6442,6641,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621360,,BAO_0000218,,
6443,6642,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621361,,BAO_0000218,,
6444,5472,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621362,,BAO_0000218,,
6445,5985,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621363,,BAO_0000218,,
6446,15660,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621364,,BAO_0000218,,
6447,5530,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621166,,BAO_0000218,,
6448,5530,Oral bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621167,,BAO_0000218,,
6449,6305,Oral bioavailability (F) in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621168,,BAO_0000218,,
6450,5210,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621169,,BAO_0000218,,
6451,5238,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875950,,BAO_0000218,,
6452,5668,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621170,,BAO_0000218,,
6453,5668,Oral bioavailability after peroral administration at 5 mpk in Dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621171,,BAO_0000218,,
6454,5668,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621172,,BAO_0000218,,
6455,6084,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621173,,BAO_0000218,,
6456,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621174,42.0,BAO_0000218,2113.0,
6457,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621175,42.0,BAO_0000218,2113.0,
6458,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621176,42.0,BAO_0000218,2107.0,
6459,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621177,42.0,BAO_0000218,2107.0,
6460,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621178,42.0,BAO_0000218,2107.0,
6461,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621179,42.0,BAO_0000218,2107.0,
6462,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621180,42.0,BAO_0000218,2107.0,
6463,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL875951,42.0,BAO_0000218,2048.0,
6464,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621181,42.0,BAO_0000218,2048.0,
6465,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621182,42.0,BAO_0000218,2048.0,
6466,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621183,42.0,BAO_0000218,2048.0,
6467,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621184,42.0,BAO_0000218,2048.0,
6468,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621185,42.0,BAO_0000218,,
6469,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621186,42.0,BAO_0000218,,
6470,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621187,42.0,BAO_0000218,,
6471,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621188,42.0,BAO_0000218,,
6472,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621189,42.0,BAO_0000218,,
6473,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621190,42.0,BAO_0000218,2106.0,
6474,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL618520,42.0,BAO_0000218,2106.0,
6475,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621739,42.0,BAO_0000218,2106.0,
6476,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621740,42.0,BAO_0000218,2106.0,
6477,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621741,42.0,BAO_0000218,2106.0,
6478,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621742,42.0,BAO_0000218,,
6479,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621743,42.0,BAO_0000218,,
6480,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621744,42.0,BAO_0000218,,
6481,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621745,42.0,BAO_0000218,,
6482,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621746,42.0,BAO_0000218,,
6483,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621747,42.0,BAO_0000218,,
6484,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621748,42.0,BAO_0000218,,
6485,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621749,42.0,BAO_0000218,,
6486,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621750,42.0,BAO_0000218,,
6487,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621751,42.0,BAO_0000218,,
6488,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621752,42.0,BAO_0000218,948.0,
6489,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621753,42.0,BAO_0000218,948.0,
6490,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL875955,42.0,BAO_0000218,948.0,
6491,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621754,42.0,BAO_0000218,948.0,
6492,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621755,42.0,BAO_0000218,948.0,
6493,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621756,42.0,BAO_0000218,2107.0,
6494,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624199,42.0,BAO_0000218,2107.0,
6495,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624200,42.0,BAO_0000218,2107.0,
6496,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624375,42.0,BAO_0000218,2107.0,
6497,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624376,42.0,BAO_0000218,2107.0,
6498,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624377,42.0,BAO_0000218,2048.0,
6499,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624378,42.0,BAO_0000218,2048.0,
6500,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,aeinetobacter anitrotap,107673.0,,,,,50067,N,1,Intermediate,1,,CHEMBL857901,,BAO_0000218,,
6501,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,,,,,50067,N,1,Intermediate,1,,CHEMBL875274,,BAO_0000218,,
6502,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,,,,,50067,N,1,Intermediate,1,,CHEMBL624379,,BAO_0000218,,
6503,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,aeinetobacter anitrotap,107673.0,,,,,50067,N,1,Intermediate,1,,CHEMBL624380,,BAO_0000218,,
6504,10624,Activity against Acinetobacter calcoaceticus (AC54),F,,,Acinetobacter calcoaceticus,471.0,,,,,50192,N,1,Intermediate,1,,CHEMBL624381,,BAO_0000218,,
6505,17216,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,F,,,Anolis carolinensis,28377.0,,,,,50714,N,1,Intermediate,1,,CHEMBL624382,,BAO_0000218,,
6506,17216,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,F,,,Anolis carolinensis,28377.0,,,,,50714,N,1,Intermediate,1,,CHEMBL624383,,BAO_0000218,,
6507,9560,Chlorohexidine coefficient for Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624384,,BAO_0000218,,
6508,9560,Chlorohexidine coefficient for Actinomyces naeslundii B74,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624385,,BAO_0000218,,
6509,9560,Chlorohexidine coefficient for Actinomyces naeslundii N/3,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624386,,BAO_0000218,,
6510,9560,Chlorohexidine coefficient for Actinomyces naeslundii N/9,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624387,,BAO_0000218,,
6511,9560,Plaque bactericidal index against Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624388,,BAO_0000218,,
6512,9560,Plaque bactericidal index against Actinomyces naeslundii N/9,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624389,,BAO_0000218,,
6513,9560,Plaque bactericidal index against Actinomyces naeslundii B74,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624390,,BAO_0000218,,
6514,9560,Plaque bactericidal index against Actinomyces naeslundii N/3,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL875275,,BAO_0000218,,
6515,114,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,F,,,Artemia salina,85549.0,,,,,50056,N,1,Intermediate,1,,CHEMBL624391,,BAO_0000218,,
6516,114,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",F,,,Artemia salina,85549.0,,,,,50056,N,1,Intermediate,1,,CHEMBL623636,,BAO_0000218,,
6517,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623637,,BAO_0000218,,
6518,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623638,,BAO_0000218,,
6519,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623639,,BAO_0000218,,
6520,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623640,,BAO_0000218,,
6521,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623641,,BAO_0000218,,
6522,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623642,,BAO_0000218,,
6523,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623643,,BAO_0000218,,
6524,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623644,,BAO_0000218,,
6525,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623645,,BAO_0000218,,
6526,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623646,,BAO_0000218,,
6527,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623647,,BAO_0000218,,
6528,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623648,,BAO_0000218,,
6529,8117,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623649,,BAO_0000218,,
6530,8117,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623650,,BAO_0000218,,
6531,9560,Chlorohexidine coefficient for Actinomyces viscosus 8A06,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623651,,BAO_0000218,,
6532,9560,Chlorohexidine coefficient for Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Expert,1,,CHEMBL623652,,BAO_0000218,,
6533,9560,Chlorohexidine coefficient for Actinomyces viscosus M-626,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623653,,BAO_0000218,,
6534,9560,Chlorohexidine coefficient for Actinomyces viscosus T14V,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623654,,BAO_0000218,,
6535,9560,Plaque bactericidal index against Actinomyces viscosus 8A06,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623655,,BAO_0000218,,
6536,9560,Plaque bactericidal index against Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623656,,BAO_0000218,,
6537,9560,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Expert,1,,CHEMBL623657,,BAO_0000218,,
6538,9560,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623658,,BAO_0000218,,
6539,9560,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623659,,BAO_0000218,,
6540,9560,Plaque bactericidal index against Actinomyces viscosus 626,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623660,,BAO_0000218,,
6541,9560,Plaque bactericidal index against Actinomyces viscosus T14V,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623661,,BAO_0000218,,
6542,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL875281,,BAO_0000218,,
6543,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL623662,,BAO_0000218,,
6544,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL623663,,BAO_0000218,,
6545,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL623664,,BAO_0000218,,
6546,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL623665,,BAO_0000218,,
6547,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A673,,80023,N,1,Intermediate,1,,CHEMBL621856,165.0,BAO_0000219,,
6548,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A704,,80661,N,1,Intermediate,1,,CHEMBL620432,645.0,BAO_0000219,,
6549,416,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620433,,BAO_0000219,,
6550,14354,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL620434,625.0,BAO_0000219,,
6551,14354,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL620435,625.0,BAO_0000219,,
6552,5116,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,F,,,Homo sapiens,9606.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL620436,625.0,BAO_0000219,,
6553,5116,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,F,,,Homo sapiens,9606.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL876597,625.0,BAO_0000219,,
6554,15694,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,F,,,Homo sapiens,9606.0,,,Human ovarian carcinoma cell line,,81037,N,1,Expert,1,,CHEMBL620437,874.0,BAO_0000219,,
6555,13038,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Expert,1,,CHEMBL620438,625.0,BAO_0000219,,
6556,13038,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Expert,1,,CHEMBL620439,625.0,BAO_0000219,,
6557,10923,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Expert,1,,CHEMBL619657,625.0,BAO_0000219,,
6558,10923,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL619658,625.0,BAO_0000219,,
6559,10923,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL619659,625.0,BAO_0000219,,
6560,10923,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",F,,,,,,,,,10649,H,8,Expert,1,,CHEMBL619660,,BAO_0000019,,
6561,10923,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL619661,625.0,BAO_0000219,,
6562,10923,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL619662,625.0,BAO_0000219,,
6563,8158,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,F,,,Cricetulus griseus,10029.0,,,AA6,,80663,N,1,Intermediate,1,,CHEMBL619663,975.0,BAO_0000219,,
6564,15494,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619664,,BAO_0000219,,
6565,15494,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619665,,BAO_0000219,,
6566,12348,Anti -HIV activity was measured against AA5/HIV-1(IIIB),F,,,Homo sapiens,9606.0,,,AA5,,80662,N,1,Intermediate,1,,CHEMBL883244,974.0,BAO_0000219,,
6567,12348,Cytotoxicity was measured against AA5/HIV-1(IIIB),F,,,Homo sapiens,9606.0,,,AA5,,80662,N,1,Intermediate,1,,CHEMBL884011,974.0,BAO_0000219,,
6568,2726,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,F,,,Homo sapiens,9606.0,,,AA5,,80662,N,1,Intermediate,1,,CHEMBL619666,974.0,BAO_0000219,,
6569,2726,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,F,,,Homo sapiens,9606.0,,,U-937,,80566,N,1,Intermediate,1,,CHEMBL619667,379.0,BAO_0000219,,
6570,10747,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,F,,,Cricetulus griseus,10029.0,,,UV4,,80578,N,1,Intermediate,1,,CHEMBL619668,274.0,BAO_0000219,,
6571,11005,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL619669,185.0,BAO_0000219,,
6572,12687,Average intracellular compound concentration when the hypoxic SER=1.6,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL876608,185.0,BAO_0000219,,
6573,12687,Average intracellular compound concentration when the hypoxic SER=1.6.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619670,185.0,BAO_0000219,,
6574,12687,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619671,185.0,BAO_0000219,,
6575,12687,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619672,185.0,BAO_0000219,,
6576,12687,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619673,185.0,BAO_0000219,,
6577,13436,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619674,185.0,BAO_0000219,,
6578,13435,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619675,185.0,BAO_0000219,,
6579,13302,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619676,185.0,BAO_0000219,,
6580,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619677,185.0,BAO_0000219,,
6581,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619678,185.0,BAO_0000219,,
6582,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619679,185.0,BAO_0000219,,
6583,12878,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL619680,185.0,BAO_0000219,,
6584,12878,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL621457,185.0,BAO_0000219,,
6585,14367,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL876609,185.0,BAO_0000219,,
6586,14367,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL621458,185.0,BAO_0000219,,
6587,12398,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,F,,,hampster,36483.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL621459,185.0,BAO_0000219,,
6588,12878,Aerobic growth inhibition in Chinese hamster cell line AA8,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL621460,185.0,BAO_0000219,,
6589,13820,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL621461,185.0,BAO_0000219,,
6590,13436,Inhibition of growth under aerobic conditions in AA8 cells,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL621462,185.0,BAO_0000219,,
6591,6084,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621463,,BAO_0000218,,
6592,5711,Oral bioavailability in dog at 10 mg/kg of the compound,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621464,,BAO_0000218,,
6593,4353,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621465,,BAO_0000218,,
6594,4353,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621466,,BAO_0000218,,
6595,17800,Oral bioavailability in dog (mongrel),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621467,,BAO_0000218,,
6596,3994,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621468,,BAO_0000218,,
6597,3994,Oral bioavailability in dog (dose 10 mg/kg),F,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876734,,BAO_0000218,,
6598,5145,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618476,,BAO_0000218,,
6599,16452,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618477,,BAO_0000218,,
6600,16452,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618478,,BAO_0000218,,
6601,5983,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618479,,BAO_0000218,,
6602,4273,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618480,,BAO_0000218,,
6603,12500,Bioavailability in dog (dose 3-10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618481,,BAO_0000218,,
6604,12500,The compound was tested for bioavailability of compound in plasma of dog; Complete,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618482,,BAO_0000218,1969.0,
6605,3639,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618483,,BAO_0000218,,
6606,3880,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618484,,BAO_0000218,,
6607,4838,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618485,,BAO_0000218,,
6608,15600,oral bioavailability was measured in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618486,,BAO_0000218,,
6609,17248,Compound was tested for plasma protein binding in dog; Not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618487,,BAO_0000218,,
6610,17248,Compound was tested for plasma protein binding of dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618488,,BAO_0000218,,
6611,17248,Compound was tested for plasma protein binding of dog; Not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876735,,BAO_0000218,,
6612,17443,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618489,,BAO_0000218,,
6613,4186,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618490,,BAO_0000218,,
6614,3749,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618491,,BAO_0000218,,
6615,3249,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618492,,BAO_0000218,,
6616,3022,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873354,,BAO_0000218,,
6617,3749,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618493,,BAO_0000218,,
6618,2517,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618494,,BAO_0000218,,
6619,2517,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Heart,,,50588,N,1,Intermediate,1,,CHEMBL618495,,BAO_0000218,948.0,
6620,2517,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Kidney,,,50588,N,1,Intermediate,1,,CHEMBL618496,,BAO_0000218,2113.0,
6621,2517,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Liver,,,50588,N,1,Intermediate,1,,CHEMBL618497,,BAO_0000218,2107.0,
6622,2517,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Lung,,,50588,N,1,Intermediate,1,,CHEMBL618498,,BAO_0000218,2048.0,
6623,2517,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Spleen,,,50588,N,1,Intermediate,1,,CHEMBL618499,,BAO_0000218,2106.0,
6624,3639,LogP in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876736,,BAO_0000218,,
6625,6227,Partition coefficient (logP),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618500,,BAO_0000218,,
6626,6227,Partition coefficient in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL857831,,BAO_0000218,,
6627,17764,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618501,,BAO_0000218,,
6628,4809,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618502,,BAO_0000218,,
6629,5600,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618503,,BAO_0000218,,
6630,14294,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618504,,BAO_0000218,,
6631,14294,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618505,,BAO_0000218,,
6632,14294,Metabolism of compound in dog S9 microsomes; Trace,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618506,,BAO_0000218,,
6633,6251,In vitro metabolic potential in dog liver microsomes,A,,,Canis lupus familiaris,9615.0,,Liver,,,50588,N,1,Intermediate,1,,CHEMBL618507,,BAO_0000218,2107.0,
6634,3748,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876737,,BAO_0000218,,
6635,2713,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618508,,BAO_0000218,,
6636,6512,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618509,,BAO_0000218,,
6637,6679,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618510,,BAO_0000218,,
6638,3749,The compound was tested for bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618511,,BAO_0000218,,
6639,3749,The compound was tested for oral bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618512,,BAO_0000218,,
6640,6742,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618513,,BAO_0000218,,
6641,6227,Compound was tested for percent protein binding (PB) in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618514,,BAO_0000218,,
6642,6874,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620052,,BAO_0000218,,
6643,2877,Compound was evaluated for plasma clearance.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620053,,BAO_0000218,1969.0,
6644,12500,The compound was tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620054,,BAO_0000218,1969.0,
6645,12500,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620055,,BAO_0000218,1969.0,
6646,4709,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620056,,BAO_0000218,,
6647,5542,In vitro relative rate of metabolism was determined in dog liver microsomes,A,,,Canis lupus familiaris,9615.0,,Liver,,,50588,N,1,Intermediate,1,,CHEMBL620057,,BAO_0000218,2107.0,
6648,17594,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618939,,BAO_0000218,,
6649,2652,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618940,,BAO_0000218,,
6650,17764,Half life after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618941,,BAO_0000218,,
6651,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624473,42.0,BAO_0000218,2048.0,
6652,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624474,42.0,BAO_0000218,2048.0,
6653,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624475,42.0,BAO_0000218,2048.0,
6654,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624476,42.0,BAO_0000218,,
6655,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL623478,42.0,BAO_0000218,,
6656,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL623479,42.0,BAO_0000218,,
6657,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL623480,42.0,BAO_0000218,,
6658,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL623481,42.0,BAO_0000218,,
6659,17641,C2 in brain of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL623482,,BAO_0000218,955.0,
6660,17641,C2 in kidney of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623483,,BAO_0000218,2113.0,
6661,17641,C2 in liver of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623484,,BAO_0000218,2107.0,
6662,17641,C2 in lungs of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623485,,BAO_0000218,2048.0,
6663,17641,C2 in spleen of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL623486,,BAO_0000218,2106.0,
6664,17852,Plasma clearance in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623487,,BAO_0000218,,
6665,17764,Clearance of compound after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623488,,BAO_0000218,,
6666,17837,Clearance from mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623489,,BAO_0000218,,
6667,2675,Clearance was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875157,,BAO_0000218,,
6668,2675,Clearance was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623490,,BAO_0000218,,
6669,4239,Pharmacokinetic property (Plasma clearance) was measured in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623491,,BAO_0000218,,
6670,17753,Plasma clearance of compound was determined at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623492,,BAO_0000218,,
6671,17753,Plasma clearance of at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623493,,BAO_0000218,,
6672,17753,Plasma clearance at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623494,,BAO_0000218,,
6673,17753,Plasma clearance at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623495,,BAO_0000218,,
6674,5727,Plasma clearance in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623496,,BAO_0000218,,
6675,2862,Plasma clearance value upon iv administration in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623497,,BAO_0000218,,
6676,5980,Total plasma clearance in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623498,,BAO_0000218,1969.0,
6677,17592,Clearance in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623499,,BAO_0000218,,
6678,17718,Clearance value was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623500,,BAO_0000218,,
6679,16597,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623501,,BAO_0000218,,
6680,17384,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Intermediate,1,,CHEMBL875158,,BAO_0000100,,
6681,6062,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623502,,BAO_0000218,,
6682,17734,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623503,,BAO_0000218,,
6683,6348,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623504,,BAO_0000218,,
6684,5969,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623505,,BAO_0000218,,
6685,5969,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623506,,BAO_0000218,,
6686,5969,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623507,,BAO_0000218,,
6687,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623508,,BAO_0000218,,
6688,5781,Cmax after oral administration at 30 mg/kg in ICR mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623509,,BAO_0000218,,
6689,17764,Cmax after peroral administration in mice at 2.4 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875159,,BAO_0000218,,
6690,17641,Cmax in brain of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL623510,,BAO_0000218,955.0,
6691,17641,Cmax in kidney of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623511,,BAO_0000218,2113.0,
6692,17641,Cmax in liver of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623512,,BAO_0000218,2107.0,
6693,17641,Cmax in lungs of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623513,,BAO_0000218,2048.0,
6694,17764,Cmax in mice at 18 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623514,,BAO_0000218,,
6695,17764,Cmax in mice at 23 uM/kg i.v. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622609,,BAO_0000218,,
6696,17764,Cmax in mice at 24 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622610,,BAO_0000218,,
6697,17764,Cmax in mice at 25 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621823,,BAO_0000218,,
6698,17764,Cmax in mice at 26 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621824,,BAO_0000218,,
6699,17641,Cmax in spleen of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL621825,,BAO_0000218,2106.0,
6700,16597,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621826,,BAO_0000218,,
6701,16597,Cmax value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621827,,BAO_0000218,,
6702,5727,Cmax value was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621828,,BAO_0000218,,
6703,5951,Cmax value in IRC mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621829,,BAO_0000218,,
6704,5506,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621830,,BAO_0000218,,
6705,5506,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621831,,BAO_0000218,,
6706,14239,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL621832,,BAO_0000218,1969.0,
6707,4890,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL624579,,BAO_0000218,1969.0,
6708,429,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624580,,BAO_0000218,,
6709,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL624581,,BAO_0000218,,
6710,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL624582,,BAO_0000218,,
6711,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL624583,,BAO_0000218,,
6712,13227,Inhibitory activity against human tumor cell line A0375 melanoma.,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL624584,455.0,BAO_0000219,,
6713,4481,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,B,,,Rattus norvegicus,10116.0,,,,Brain membranes,12512,D,9,Expert,1,,CHEMBL624585,,BAO_0000249,,
6714,16931,Forskolin-induced cAMP production at human A1 adenosine receptor,F,,,Homo sapiens,9606.0,,,,,114,D,9,Expert,1,,CHEMBL875165,,BAO_0000019,,
6715,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619490,449.0,BAO_0000219,,
6716,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619491,449.0,BAO_0000219,,
6717,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL619492,449.0,BAO_0000219,,
6718,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL619493,449.0,BAO_0000219,,
6719,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619494,449.0,BAO_0000219,,
6720,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619495,449.0,BAO_0000219,,
6721,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619496,449.0,BAO_0000219,,
6722,3850,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,,Homo sapiens,9606.0,,,CHO,,114,D,9,Expert,1,,CHEMBL619497,449.0,BAO_0000219,,
6723,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619498,449.0,BAO_0000219,,
6724,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619499,449.0,BAO_0000219,,
6725,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL619500,449.0,BAO_0000219,,
6726,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619501,449.0,BAO_0000219,,
6727,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL619502,449.0,BAO_0000219,,
6728,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619503,449.0,BAO_0000219,,
6729,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619504,449.0,BAO_0000219,,
6730,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL621298,449.0,BAO_0000219,,
6731,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL621299,449.0,BAO_0000219,,
6732,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL621300,449.0,BAO_0000219,,
6733,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL621301,449.0,BAO_0000219,,
6734,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL621302,449.0,BAO_0000219,,
6735,12680,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,F,,,Oryctolagus cuniculus,9986.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL621303,164.0,BAO_0000219,,
6736,1313,In vitro potassium channel opening activity in A10 (smooth muscle) cells,F,,,Rattus norvegicus,10116.0,,,A10,,22226,U,0,Autocuration,1,,CHEMBL621304,164.0,BAO_0000219,,
6737,1313,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,F,,,Rattus norvegicus,10116.0,,,A10,,22226,U,0,Autocuration,1,,CHEMBL621305,164.0,BAO_0000219,,
6738,17567,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL621306,164.0,BAO_0000219,,
6739,17567,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL618444,164.0,BAO_0000219,,
6740,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL618445,164.0,BAO_0000219,,
6741,13436,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618446,185.0,BAO_0000219,,
6742,12687,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618447,185.0,BAO_0000219,,
6743,12651,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618448,185.0,BAO_0000219,,
6744,13300,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618449,185.0,BAO_0000219,,
6745,15296,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618637,185.0,BAO_0000219,,
6746,15328,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618638,185.0,BAO_0000219,,
6747,13302,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618639,185.0,BAO_0000219,,
6748,14367,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL618640,185.0,BAO_0000219,,
6749,17002,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL618641,185.0,BAO_0000219,,
6750,13436,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618642,185.0,BAO_0000219,,
6751,13435,Inhibitory activity against aerobic growth of AA8 cells.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618643,185.0,BAO_0000219,,
6752,10503,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL884013,185.0,BAO_0000219,,
6753,10503,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL622723,185.0,BAO_0000219,,
6754,10503,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622724,185.0,BAO_0000219,,
6755,15090,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL622725,185.0,BAO_0000219,,
6756,10368,Cytotoxicity against AA8 cell line,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL622726,185.0,BAO_0000219,,
6757,12651,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622727,185.0,BAO_0000219,,
6758,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622728,185.0,BAO_0000219,,
6759,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622729,185.0,BAO_0000219,,
6760,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622730,185.0,BAO_0000219,,
6761,1890,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622731,185.0,BAO_0000219,,
6762,10747,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622732,185.0,BAO_0000219,,
6763,10747,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622733,185.0,BAO_0000219,,
6764,11616,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),F,,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL622734,,BAO_0000218,,
6765,11616,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL622735,185.0,BAO_0000219,,
6766,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618746,185.0,BAO_0000219,,
6767,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618747,185.0,BAO_0000219,,
6768,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL620540,185.0,BAO_0000219,,
6769,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL620541,185.0,BAO_0000219,,
6770,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL620542,185.0,BAO_0000219,,
6771,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL620543,185.0,BAO_0000219,,
6772,3471,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618832,185.0,BAO_0000219,,
6773,11616,Concentration required to reduce AA8 cell survival by 10%,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL618833,185.0,BAO_0000219,,
6774,2656,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618834,185.0,BAO_0000219,,
6775,10518,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618835,185.0,BAO_0000219,,
6776,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618836,185.0,BAO_0000219,,
6777,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618837,185.0,BAO_0000219,,
6778,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618838,185.0,BAO_0000219,,
6779,16156,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618839,185.0,BAO_0000219,,
6780,2656,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618840,185.0,BAO_0000219,,
6781,11005,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618841,,BAO_0000019,,
6782,11942,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618842,185.0,BAO_0000219,,
6783,2128,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618843,185.0,BAO_0000219,,
6784,16907,Half life period after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618844,,BAO_0000218,,
6785,16907,Half life period after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618845,,BAO_0000218,,
6786,9579,Half life was measured after oral 2b administration (tested in 6 dogs),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618846,,BAO_0000218,,
6787,9579,Half life was measured in dog after oral 17b administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618847,,BAO_0000218,,
6788,9579,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618848,,BAO_0000218,,
6789,9579,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618849,,BAO_0000218,,
6790,16907,Tmax value after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618850,,BAO_0000218,,
6791,16907,Tmax value after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618851,,BAO_0000218,,
6792,3184,Compound was evaluated for its half life when administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873815,,BAO_0000218,,
6793,5017,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618852,,BAO_0000218,1969.0,
6794,6821,Elimination Half-life of compound was determined in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618853,,BAO_0000218,,
6795,17839,Half life of compound in dog following oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618854,,BAO_0000218,,
6796,17267,Half life of compound was determined in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618855,,BAO_0000218,,
6797,4727,Half life of compound was determined in dog blood,A,,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL618856,,BAO_0000218,178.0,
6798,5238,Half life after oral and iv dosing in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875827,,BAO_0000218,,
6799,4942,Half life in dogs in hours,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618857,,BAO_0000218,,
6800,6505,Half life on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618858,,BAO_0000218,,
6801,5130,t1/2 in dog after oral dose (1 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618859,,BAO_0000218,,
6802,1475,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618860,,BAO_0000218,,
6803,17804,Half life period of compound was determined after intravenous administration at 2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618861,,BAO_0000218,,
6804,17804,Half life period of compound was determined after peroral administration at 2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622539,,BAO_0000218,,
6805,6084,Half life period (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622540,,BAO_0000218,,
6806,6084,Half life period (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873803,,BAO_0000218,,
6807,5542,Half life period by iv administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873804,,BAO_0000218,,
6808,5542,Half life period by po administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624311,,BAO_0000218,,
6809,6084,Half life period in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624312,,BAO_0000218,,
6810,6241,Half life period in dogs after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624313,,BAO_0000218,,
6811,1916,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624314,,BAO_0000218,,
6812,6621,Half-life of compound was determined in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624315,,BAO_0000218,,
6813,1696,Half-life in dog plasma,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624316,,BAO_0000218,1969.0,
6814,17800,Half-life in mongrel dogs was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624317,,BAO_0000218,,
6815,17657,Half-life in dog upon oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624318,,BAO_0000218,,
6816,17657,Half-life in dog upon oral administration; Unable to calculate,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624319,,BAO_0000218,,
6817,4239,Half-life was measured in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624496,,BAO_0000218,,
6818,5985,Half-life was measured in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624497,,BAO_0000218,,
6819,9932,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624498,,BAO_0000218,,
6820,5199,Oral half life was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624499,,BAO_0000218,,
6821,5199,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624500,,BAO_0000218,1969.0,
6822,1475,Plasma half life was evaluated,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624501,,BAO_0000218,1969.0,
6823,1475,Plasma half life was evaluated in Dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623666,,BAO_0000218,1969.0,
6824,1475,Plasma half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623667,,BAO_0000218,1969.0,
6825,6316,T1/2 (Half-life) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623668,,BAO_0000218,,
6826,4883,Tested for the half life value in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623669,,BAO_0000218,,
6827,4727,Maximum time at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623670,,BAO_0000218,,
6828,1916,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623671,,BAO_0000218,,
6829,1337,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL875945,,BAO_0000218,178.0,
6830,1337,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL623672,,BAO_0000218,178.0,
6831,6265,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623673,,BAO_0000218,,
6832,4809,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623674,,BAO_0000218,,
6833,5983,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623675,,BAO_0000218,,
6834,5313,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872526,,BAO_0000218,,
6835,5313,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623676,,BAO_0000218,,
6836,17650,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623677,,BAO_0000218,1969.0,
6837,5199,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623678,,BAO_0000218,1969.0,
6838,933,Time taken for maximum plasma concentration in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623679,,BAO_0000218,1969.0,
6839,16367,Time to reach Cmax after oral administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623680,,BAO_0000218,,
6840,6348,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623681,,BAO_0000218,1969.0,
6841,6316,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623682,,BAO_0000218,,
6842,6215,Tmax after peroral administration (1 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623683,,BAO_0000218,,
6843,3598,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL623684,,BAO_0000218,,
6844,4527,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622745,,BAO_0000218,,
6845,17764,Tmax after peroral administration in dogs at 2.4 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622746,,BAO_0000218,,
6846,5969,In vivo Cmax in mice at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622747,,BAO_0000218,,
6847,5969,In vivo Cmax in mice at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622748,,BAO_0000218,,
6848,4573,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622749,,BAO_0000218,,
6849,3277,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622750,,BAO_0000218,1969.0,
6850,17734,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623411,,BAO_0000218,1969.0,
6851,3132,Maximum concentration obtained in mouse plasma was determined,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL875946,,BAO_0000218,1969.0,
6852,3132,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623412,,BAO_0000218,1969.0,
6853,6348,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623413,,BAO_0000218,1969.0,
6854,17729,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623414,,BAO_0000218,1969.0,
6855,17729,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623415,,BAO_0000218,1969.0,
6856,17729,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623416,,BAO_0000218,1969.0,
6857,17728,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623417,,BAO_0000218,1969.0,
6858,17728,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623418,,BAO_0000218,1969.0,
6859,17728,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623419,,BAO_0000218,1969.0,
6860,4066,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622816,,BAO_0000218,,
6861,6178,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623313,,BAO_0000218,,
6862,6178,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623314,,BAO_0000218,,
6863,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876788,,BAO_0000218,,
6864,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623315,,BAO_0000218,,
6865,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623316,,BAO_0000218,,
6866,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623317,,BAO_0000218,,
6868,5961,Cmax in male mice after 2 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623319,,BAO_0000218,,
6869,6137,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623320,,BAO_0000218,,
6870,3802,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623321,,BAO_0000218,,
6871,3535,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623322,,BAO_0000218,,
6872,3535,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623323,,BAO_0000218,,
6873,3535,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623324,,BAO_0000218,,
6874,3535,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623325,,BAO_0000218,,
6875,3535,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623326,,BAO_0000218,,
6876,3535,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623327,,BAO_0000218,,
6877,2862,Maximum concentration in plasma upon oral administration in mouse,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623328,,BAO_0000218,1969.0,
6878,2675,Maximum plasma concentration was evaluated in mice after oral administration,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623329,,BAO_0000218,1969.0,
6879,2675,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623330,,BAO_0000218,1969.0,
6880,5399,Dose at which the compound induced fecal excretion in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876789,,BAO_0000218,,
6893,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Expert,1,,CHEMBL623333,164.0,BAO_0000219,,
6894,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Expert,1,,CHEMBL623334,164.0,BAO_0000219,,
6895,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Expert,1,,CHEMBL627536,164.0,BAO_0000219,,
6896,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Expert,1,,CHEMBL627537,164.0,BAO_0000219,,
6897,16361,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL627538,164.0,BAO_0000219,,
6898,2288,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL884106,393.0,BAO_0000219,,
6899,10404,Anticancer activity against human ovarian carcinoma A121 cells,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625294,393.0,BAO_0000219,,
6900,14790,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625295,393.0,BAO_0000219,,
6901,14790,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625296,393.0,BAO_0000219,,
6902,14253,Growth inhibition of human ovarian carcinoma (A121) cell line,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Expert,1,,CHEMBL625297,393.0,BAO_0000219,,
6903,13617,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Expert,1,,CHEMBL625298,393.0,BAO_0000219,,
6904,1003,Cytotoxicity against human A121 ovarian cells,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625960,393.0,BAO_0000219,,
6905,830,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625961,393.0,BAO_0000219,,
6906,12307,In vitro cytotoxicity against human ovarian carcinoma A21,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625962,393.0,BAO_0000219,,
6907,14254,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL624717,393.0,BAO_0000219,,
6908,13370,Inhibitory activity of compound against human A121 ovarian cell line.,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL624718,393.0,BAO_0000219,,
6909,14790,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL624719,393.0,BAO_0000219,,
6910,3614,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL624720,393.0,BAO_0000219,,
6911,2664,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL624721,622.0,BAO_0000219,,
6912,2037,In vitro cytotoxicity against A172 human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Expert,1,,CHEMBL624722,622.0,BAO_0000219,,
6913,14539,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL877597,622.0,BAO_0000219,,
6914,2836,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL624723,622.0,BAO_0000219,,
6915,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL624724,622.0,BAO_0000219,,
6916,8975,Association constant against A2 adenosine receptor,B,,,Canis lupus familiaris,9615.0,,,,,104729,H,4,Autocuration,1,,CHEMBL624725,,BAO_0000224,,
6917,7645,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,F,,,fish,,,,A2,,80656,N,1,Intermediate,1,,CHEMBL624726,1085.0,BAO_0000219,,
6918,11377,Ratio of Ki for adenosine A2 and A1 receptor binding,B,,,Rattus norvegicus,10116.0,,,,,104713,D,5,Autocuration,1,,CHEMBL857535,,BAO_0000224,,
6919,13528,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,F,,,Homo sapiens,9606.0,,,A204,,80014,N,1,Expert,1,,CHEMBL624727,623.0,BAO_0000219,,
6920,10160,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,F,,,Homo sapiens,9606.0,,,A204,,80014,N,1,Expert,1,,CHEMBL624728,623.0,BAO_0000219,,
6921,15144,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,F,,,Homo sapiens,9606.0,,,A2058,,80015,N,1,Intermediate,1,,CHEMBL624729,404.0,BAO_0000219,,
6922,13160,Growth inhibition against Human squamous cell line(A 253),F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624730,973.0,BAO_0000219,,
6923,12898,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624731,973.0,BAO_0000219,,
6924,13069,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624732,973.0,BAO_0000219,,
6925,15984,Growth inhibition of A253 cell lines.,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL883245,973.0,BAO_0000219,,
6926,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624733,973.0,BAO_0000219,,
6927,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624734,973.0,BAO_0000219,,
6928,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624735,973.0,BAO_0000219,,
6929,4720,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621780,478.0,BAO_0000219,,
6930,16112,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL877598,478.0,BAO_0000219,,
6931,16597,Cytotoxic activity against A2780 human ovarian carcinoma cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621781,478.0,BAO_0000219,,
6932,16378,Cytotoxicity against human cancer cell lines A2780 (ovarian),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621782,478.0,BAO_0000219,,
6933,16085,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621783,478.0,BAO_0000219,,
6934,16317,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621784,478.0,BAO_0000219,,
6935,15748,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621785,478.0,BAO_0000219,,
6936,16597,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621968,478.0,BAO_0000219,,
6937,16597,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621969,478.0,BAO_0000219,,
6938,16597,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621970,478.0,BAO_0000219,,
6939,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621971,478.0,BAO_0000219,,
6940,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621972,478.0,BAO_0000219,,
6941,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL884108,478.0,BAO_0000219,,
6942,15296,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623826,,BAO_0000019,,
6943,10251,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623827,185.0,BAO_0000219,,
6944,10251,Evaluated for growth inhibition of AA8 cells under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623828,185.0,BAO_0000219,,
6945,10251,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623829,185.0,BAO_0000219,,
6946,10251,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623830,185.0,BAO_0000219,,
6947,11858,Growth inhibition against CHO-derived cell line AA8,F,,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623831,,BAO_0000019,,
6948,11858,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623832,185.0,BAO_0000219,,
6949,11616,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,F,,,hampster,36483.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL623833,185.0,BAO_0000219,,
6950,11616,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL623834,185.0,BAO_0000219,,
6951,10518,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623835,185.0,BAO_0000219,,
6952,11396,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623836,185.0,BAO_0000219,,
6953,10518,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623837,185.0,BAO_0000219,,
6954,11616,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL623838,185.0,BAO_0000219,,
6955,14837,compound was evaluated for association constant (Ka) of isolated serum protein AAG,F,,,,,,,,,12675,H,8,Autocuration,1,,CHEMBL623839,,BAO_0000019,,
6956,14837,Number of binding sites (n) of isolated serum protein AAG,F,,,,,,,,,12675,H,8,Autocuration,1,,CHEMBL623840,,BAO_0000019,,
6957,16037,Association constant for binding to AATT duplex,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL623841,,BAO_0000225,,
6958,16597,Inhibition of ABAE human fibroblast cell proliferation,F,,,Homo sapiens,9606.0,,,ABAE,,100090,N,1,Expert,1,,CHEMBL623842,416.0,BAO_0000219,,
6959,8831,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",F,,,Mus musculus,10090.0,,,AC755,,80668,N,1,Intermediate,1,,CHEMBL623843,1064.0,BAO_0000218,,
6960,13419,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,F,,,Oryctolagus cuniculus,9986.0,,,,,102444,D,9,Expert,1,,CHEMBL618669,,BAO_0000218,,
6961,13419,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,F,In vivo,,Oryctolagus cuniculus,9986.0,,,,,102444,D,9,Expert,1,,CHEMBL618670,,BAO_0000218,,
6962,15778,Inhibitory activity against angiotensin-converting enzyme (ACE).,B,,,,,,,,,69,H,8,Autocuration,1,,CHEMBL618671,,BAO_0000357,,
6963,15778,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,B,,,,,,,,,69,H,8,Autocuration,1,,CHEMBL618672,,BAO_0000357,,
6964,12988,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,F,,,Homo sapiens,9606.0,,,ACH-2 cell line,,80669,N,1,Intermediate,1,,CHEMBL618673,978.0,BAO_0000219,,
6965,12988,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Homo sapiens,9606.0,,,ACH-2 cell line,,80669,N,1,Intermediate,1,,CHEMBL618674,978.0,BAO_0000219,,
6966,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,F,,,Human immunodeficiency virus 1,11676.0,,,T cell line,,22224,U,0,Autocuration,1,,CHEMBL618675,998.0,BAO_0000219,,
6967,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Human immunodeficiency virus 1,11676.0,,,T cell line,,22224,U,0,Autocuration,1,,CHEMBL618676,998.0,BAO_0000219,,
6968,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Human immunodeficiency virus 1,11676.0,,,T cell line,,22224,U,0,Autocuration,1,,CHEMBL618677,998.0,BAO_0000219,,
6969,11843,Inhibition of growth of renal cancer ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618678,626.0,BAO_0000219,,
6970,16939,Inhibition of growth of ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618679,626.0,BAO_0000219,,
6971,4782,Inhibitory concentration required against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618680,626.0,BAO_0000219,,
6972,6310,Concentration required to inhibit growth of human renal (ACHN) cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL618681,626.0,BAO_0000219,,
6973,6310,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618682,626.0,BAO_0000219,,
6974,12858,Cytotoxic activity against ACHN Renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618683,626.0,BAO_0000219,,
6975,17380,Cytotoxicity evaluation against ACHN renal cancer cells,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618684,626.0,BAO_0000219,,
6976,5858,In vitro antitumor activity against human renal ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618685,626.0,BAO_0000219,,
6977,3838,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL876499,626.0,BAO_0000219,,
6978,3838,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618686,626.0,BAO_0000219,,
6979,5406,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618687,626.0,BAO_0000219,,
6980,4071,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618688,626.0,BAO_0000219,,
6981,4071,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL618689,626.0,BAO_0000219,,
6982,4071,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618690,626.0,BAO_0000219,,
6983,15002,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618691,626.0,BAO_0000219,,
6984,14769,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619373,626.0,BAO_0000219,,
6985,13958,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL884008,626.0,BAO_0000219,,
6986,1665,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619374,626.0,BAO_0000219,,
6987,15354,Compound was tested for the growth inhibition of ACHN renal tumor cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619375,626.0,BAO_0000219,,
6988,15354,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619376,626.0,BAO_0000219,,
6989,13978,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619377,626.0,BAO_0000219,,
6990,6798,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619378,626.0,BAO_0000219,,
6991,2959,Tmax value after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872527,,BAO_0000218,,
6992,9932,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876500,,BAO_0000218,,
6993,5546,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619379,,BAO_0000218,,
6994,16907,Volume distribution after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619538,,BAO_0000218,,
6995,16907,Volume distribution after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619539,,BAO_0000218,,
6996,4257,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619540,,BAO_0000218,,
6997,4305,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619541,,BAO_0000218,,
6998,5472,Volume of distribution was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619542,,BAO_0000218,,
6999,6062,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619543,,BAO_0000218,,
7000,3598,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL619544,,BAO_0000218,,
7001,12500,The compound was tested for volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619545,,BAO_0000218,,
7002,12500,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619546,,BAO_0000218,,
7003,6227,Vd (1 mg/kg) was determined in dog (in vivo),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619547,,BAO_0000218,,
7004,6227,Vd in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619548,,BAO_0000218,,
7005,4219,Volume distribution was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619549,,BAO_0000218,,
7006,1696,Volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619550,,BAO_0000218,,
7007,5542,Volume of distribution by as 4 fold increase by iv administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876501,,BAO_0000218,,
7008,5199,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619551,,BAO_0000218,,
7009,6348,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619552,,BAO_0000218,,
7010,4727,Volume distribution at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619553,,BAO_0000218,,
7011,16367,Steady state volume of distribution was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618722,,BAO_0000218,,
7012,2652,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618723,,BAO_0000218,,
7013,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618724,,BAO_0000218,,
7014,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618725,,BAO_0000218,,
7015,16452,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618726,,BAO_0000218,,
7016,5334,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618727,,BAO_0000218,,
7017,4239,Pharmacokinetic property (vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624233,,BAO_0000218,,
7018,4709,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624234,,BAO_0000218,,
7019,5600,Vdss was determined after iv 0.1 mg/kg administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624235,,BAO_0000218,,
7020,6057,Volume displacement was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624236,,BAO_0000218,,
7021,5654,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624237,,BAO_0000218,,
7022,5505,Volume distribution constant was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624238,,BAO_0000218,,
7023,4527,Volume distribution at a dose of 1 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624239,,BAO_0000218,,
7024,4521,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875829,,BAO_0000218,,
7025,4521,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624240,,BAO_0000218,,
7026,15660,Volume distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624241,,BAO_0000218,,
7027,15660,Volume distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624242,,BAO_0000218,,
7028,6679,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624243,,BAO_0000218,,
7029,5145,Volume of distribution in steady state was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624244,,BAO_0000218,,
7030,6821,Volume of distribution of compound was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624245,,BAO_0000218,,
7031,4137,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624246,,BAO_0000218,,
7032,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624247,,BAO_0000218,,
7033,15660,Volume of distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624248,,BAO_0000218,,
7034,6642,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624249,,BAO_0000218,,
7035,6641,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624250,,BAO_0000218,,
7036,6642,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624251,,BAO_0000218,,
7037,11659,Maximum rate of depolarization of the upstroke of the action potential,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624252,,BAO_0000218,,
7038,6448,Steady state volume distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624253,,BAO_0000218,,
7039,5474,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624950,,BAO_0000218,,
7040,1466,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624951,,BAO_0000218,,
7041,6535,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875830,,BAO_0000218,,
7042,6535,Volume distribution in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624952,,BAO_0000218,,
7043,17764,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624953,,BAO_0000218,,
7044,6215,Vss after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624954,,BAO_0000218,,
7045,6505,Vss on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624955,,BAO_0000218,,
7046,3639,Vss was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624956,,BAO_0000218,,
7047,3639,Vss in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625129,,BAO_0000218,,
7048,6062,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625130,,BAO_0000218,,
7049,4942,Volume distribution in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625131,,BAO_0000218,,
7050,17796,Volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625132,,BAO_0000218,,
7051,4883,Tested for the oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872263,,BAO_0000218,,
7060,17837,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624336,,BAO_0000218,,
7061,17729,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624337,,BAO_0000218,,
7062,17729,Bioavailability after peroral administration of 50 mg/kg of dose in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624338,,BAO_0000218,,
7063,4239,Bioavailability was measured in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624339,,BAO_0000218,,
7064,17592,Bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624340,,BAO_0000218,,
7065,6348,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624341,,BAO_0000218,,
7066,2801,Bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624342,,BAO_0000218,,
7067,2801,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624343,,BAO_0000218,,
7068,17718,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624344,,BAO_0000218,,
7069,5727,Oral availability at 50 mg/kg po in male mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624345,,BAO_0000218,,
7070,5302,Oral bioavailability in mouse (dose 10 mg/kg),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624346,,BAO_0000218,,
7071,3598,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Expert,1,,CHEMBL624347,,BAO_0000218,,
7072,5961,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624348,,BAO_0000218,,
7074,6091,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622754,,BAO_0000218,,
7075,6091,Oral bioavailability in vivo in mice;ND=Not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622755,,BAO_0000218,,
7076,5711,Oral bioavailability in mouse at 10 mg/kg of the compound,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622756,,BAO_0000218,,
7077,17728,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622757,,BAO_0000218,,
7078,17728,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622758,,BAO_0000218,,
7079,3802,Tested for bioavailability of the compound,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622759,,BAO_0000218,,
7080,3802,Tested for half life at the dose of 10 mg/kg when administered intravenously,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622760,,BAO_0000218,,
7081,14029,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622761,,BAO_0000218,1969.0,
7082,14029,The plasma half life of compound was determined on heparin prepared by human plasma. ,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622762,,BAO_0000218,1969.0,
7083,14029,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622763,,BAO_0000218,1969.0,
7084,14029,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622764,,BAO_0000218,1969.0,
7085,14029,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622765,,BAO_0000218,1969.0,
7086,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622766,,BAO_0000218,,
7087,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622767,,BAO_0000218,,
7088,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622768,,BAO_0000218,,
7089,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL875948,,BAO_0000218,178.0,
7090,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622769,,BAO_0000218,178.0,
7091,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622770,,BAO_0000218,178.0,
7092,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622771,,BAO_0000218,178.0,
7093,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622772,,BAO_0000218,178.0,
7094,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622773,,BAO_0000218,178.0,
7095,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622774,,BAO_0000218,178.0,
7096,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL621725,,BAO_0000218,10000001.0,
7097,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL621726,,BAO_0000218,10000001.0,
7098,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621727,478.0,BAO_0000219,,
7099,3290,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622413,478.0,BAO_0000219,,
7100,2859,Compound was evaluated for cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622414,478.0,BAO_0000219,,
7101,15688,Inhibition of A2780 cell clonogenic assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622415,478.0,BAO_0000219,,
7102,5642,Cytotoxic effect on ovarian cancer cell line (A2780),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL884001,478.0,BAO_0000219,,
7103,6633,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622416,478.0,BAO_0000219,,
7104,3906,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622417,478.0,BAO_0000219,,
7105,6788,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622590,478.0,BAO_0000219,,
7106,17582,Antiproliferative activity against human A2780 cells,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622591,478.0,BAO_0000219,,
7107,17764,Inhibition of human A2780 cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622592,478.0,BAO_0000219,,
7108,17764,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622593,478.0,BAO_0000219,,
7109,17764,Inhibition of human A2780 cell proliferation (No data),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622594,478.0,BAO_0000219,,
7110,2815,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622595,478.0,BAO_0000219,,
7111,16930,Compound was evaluated against human Ovarian carcinoma cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622596,478.0,BAO_0000219,,
7112,17777,Growth inhibition against A2780 wild-type ovarian cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622597,478.0,BAO_0000219,,
7113,17777,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622598,478.0,BAO_0000219,,
7114,16936,Inhibition of tubulin polymerization in human ovarian cancer cell lines,F,,,Homo sapiens,9606.0,,,,,104766,D,5,Autocuration,1,,CHEMBL622599,,BAO_0000019,,
7115,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622600,478.0,BAO_0000219,,
7116,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622601,478.0,BAO_0000219,,
7117,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622602,478.0,BAO_0000219,,
7118,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622603,478.0,BAO_0000219,,
7119,15292,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622604,478.0,BAO_0000219,,
7120,15292,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622605,478.0,BAO_0000219,,
7121,15069,In vitro inhibition of human ovarian cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622606,478.0,BAO_0000219,,
7122,15069,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619463,478.0,BAO_0000219,,
7123,14073,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619464,478.0,BAO_0000219,,
7124,14553,Concentration required to inhibit A2780-cell growth by 50%,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619465,478.0,BAO_0000219,,
7125,13040,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619466,478.0,BAO_0000219,,
7126,6891,Cytotoxic effect on human ovarian (A2780) cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619467,478.0,BAO_0000219,,
7127,15569,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619468,478.0,BAO_0000219,,
7128,14190,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619469,478.0,BAO_0000219,,
7129,15014,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619470,478.0,BAO_0000219,,
7130,15014,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619471,478.0,BAO_0000219,,
7131,17496,Cytotoxicity against human ovarian carcinoma A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619472,478.0,BAO_0000219,,
7132,13617,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619473,478.0,BAO_0000219,,
7133,13617,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL874368,478.0,BAO_0000219,,
7134,13617,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL884003,478.0,BAO_0000219,,
7135,13617,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622690,478.0,BAO_0000219,,
7136,17672,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622691,478.0,BAO_0000219,,
7137,4544,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622692,478.0,BAO_0000219,,
7138,4544,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL623406,478.0,BAO_0000219,,
7139,16317,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL884004,478.0,BAO_0000219,,
7140,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL623407,478.0,BAO_0000219,,
7141,13978,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL623408,478.0,BAO_0000219,,
7142,12989,In vitro antitumor activity against A2780 cell line.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL623409,478.0,BAO_0000219,,
7143,5574,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL623410,478.0,BAO_0000219,,
7144,13528,In vitro cytotoxicity against A2780 human ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL623576,478.0,BAO_0000219,,
7145,12782,Inhibitory activity against kidney A-CHN tumor cell growth in culture,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623577,626.0,BAO_0000219,,
7146,14255,The IC50 value was measured on ACHN cell line in renal tumor type.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623578,626.0,BAO_0000219,,
7147,16364,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623579,626.0,BAO_0000219,,
7148,17376,In vitro lethal concentration against most sensitive ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL623580,626.0,BAO_0000219,,
7149,12016,Tested for cytotoxic activity against renal cancer ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623581,626.0,BAO_0000219,,
7150,6058,Compound tested for growth inhibition of renal cancer cell line ACHN,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL857456,626.0,BAO_0000219,,
7151,17708,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623582,626.0,BAO_0000219,,
7152,15176,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623583,626.0,BAO_0000219,,
7153,2806,In vitro anticancer activity against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623584,626.0,BAO_0000219,,
7154,15300,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623585,626.0,BAO_0000219,,
7155,16364,Percent selectivity was evaluated in renal ACHN cell lines,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623586,626.0,BAO_0000219,,
7156,13859,In vitro inhibitory activity against renal ACHN cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623587,626.0,BAO_0000219,,
7157,11970,Tested for cytotoxicity against ACHN cell lines in renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL875279,626.0,BAO_0000219,,
7158,2450,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623588,626.0,BAO_0000219,,
7159,12696,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623589,626.0,BAO_0000219,,
7160,12400,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623590,626.0,BAO_0000219,,
7161,12888,Cytotoxic effect on renal cancer line ACHN,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL623591,626.0,BAO_0000219,,
7162,3156,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623592,626.0,BAO_0000219,,
7163,3381,In vitro inhibition of Renal Cancer ACHN cell lines,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623593,626.0,BAO_0000219,,
7164,16747,Antitumor activity against human renal adenocarcinoma ACHN cells,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623594,626.0,BAO_0000219,,
7165,16748,Antitumor activity against human renal adenocarcinoma ACHN cells.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL621833,626.0,BAO_0000219,,
7166,12062,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621834,626.0,BAO_0000219,,
7167,14769,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621835,626.0,BAO_0000219,,
7168,15895,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621836,626.0,BAO_0000219,,
7169,17376,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621837,626.0,BAO_0000219,,
7170,14882,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL875280,626.0,BAO_0000219,,
7171,14882,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621838,626.0,BAO_0000219,,
7172,15661,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621839,626.0,BAO_0000219,,
7173,9680,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621840,,BAO_0000019,,
7174,14579,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,F,,,,,,,,,10647,H,8,Autocuration,1,,CHEMBL621841,,BAO_0000019,,
7175,17290,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,F,,,Cytomegalovirus,10358.0,,,HEL,,50529,N,1,Expert,1,,CHEMBL622979,468.0,BAO_0000218,,
7176,17290,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,F,,,Cytomegalovirus,10358.0,,,,,50529,N,1,Intermediate,1,,CHEMBL876595,,BAO_0000218,,
7177,15891,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),B,,,,,,,,,12159,H,8,Autocuration,1,,CHEMBL620221,,BAO_0000357,,
7178,15890,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),B,,,,,,,,,12159,H,8,Autocuration,1,,CHEMBL620222,,BAO_0000357,,
7179,3801,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,F,,,Bos taurus,9913.0,,,ADDP cell line,,80670,N,1,Intermediate,1,,CHEMBL620506,979.0,BAO_0000219,,
7180,9222,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620507,980.0,BAO_0000219,,
7181,9222,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620508,980.0,BAO_0000219,,
7182,7257,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620509,980.0,BAO_0000219,,
7183,7257,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620510,980.0,BAO_0000219,,
7184,7257,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,A,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620511,980.0,BAO_0000219,,
7185,8084,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620512,980.0,BAO_0000219,,
7186,14943,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620513,,BAO_0000019,,
7187,14943,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620514,,BAO_0000019,,
7188,14943,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620515,,BAO_0000019,,
7189,10524,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,In vivo,,Bacillus subtilis,1423.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620516,,BAO_0000218,,
7190,3546,AUC value in dog after IV administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620517,,BAO_0000218,1969.0,
7191,3546,AUC value in dog after oral administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620518,,BAO_0000218,1969.0,
7192,3546,Cmax value in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620519,,BAO_0000218,,
7193,3546,Bioavailability in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621386,,BAO_0000218,,
7194,3546,Tmax value in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621387,,BAO_0000218,,
7195,3184,Compound was evaluated for its clearance when administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621388,,BAO_0000218,,
7196,16456,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621389,,BAO_0000218,,
7197,4809,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621390,,BAO_0000218,,
7198,4219,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Intermediate,1,,CHEMBL621391,,BAO_0000100,,
7199,3748,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621392,,BAO_0000218,,
7200,3132,Time taken for EC90 was determined when tested in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621393,,BAO_0000218,,
7201,4219,Half life (iv) was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621394,,BAO_0000218,,
7202,16907,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,,Canis lupus familiaris,9615.0,,Liver,,,50588,N,1,Intermediate,1,,CHEMBL621395,,BAO_0000218,2107.0,
7203,6057,Area under the curve was calculated in dog after iv administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621396,,BAO_0000218,,
7204,6057,Area under the curve was calculated in dog after peroral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621397,,BAO_0000218,,
7205,17853,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621398,,BAO_0000218,,
7206,3639,pKa was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618818,,BAO_0000218,,
7207,14541,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618819,,BAO_0000218,,
7208,16456,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618820,,BAO_0000218,,
7209,16456,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873810,,BAO_0000218,,
7210,2652,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876606,,BAO_0000218,,
7211,3624,Compound was evaluated for the half-life (t 1/2) in hours,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618821,,BAO_0000218,,
7212,1337,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL618822,,BAO_0000218,178.0,
7213,1337,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL618823,,BAO_0000218,178.0,
7214,4709,Half life after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618824,,BAO_0000218,,
7215,15660,Half life was measured in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618825,,BAO_0000218,,
7216,5302,Half life period in dog after 5 mg/kg dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618826,,BAO_0000218,,
7217,17791,Half life period was evaluated in dog; 4-4.8,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618827,,BAO_0000218,,
7218,6348,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618828,,BAO_0000218,,
7219,4257,Half-life was determined in dog after a3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618829,,BAO_0000218,,
7220,3771,Half-life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618830,,BAO_0000218,,
7221,6305,Half life in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618831,,BAO_0000218,,
7222,13501,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL619489,,BAO_0000218,1969.0,
7223,17594,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619649,,BAO_0000218,,
7224,3045,Compound was evaluated for the half life period after iv administration in Beagle dog.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876607,,BAO_0000218,,
7225,3043,Compound was evaluated for the half life period after oral administration in conscious dog.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619650,,BAO_0000218,,
7226,4839,Compound was tested for half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619651,,BAO_0000218,,
7227,4839,Compound was tested for its half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619652,,BAO_0000218,,
7228,5802,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619653,,BAO_0000218,,
7229,17839,Half life of compound in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619654,,BAO_0000218,,
7230,4219,Half life (iv) was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619655,,BAO_0000218,,
7231,13966,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),A,,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL619656,,BAO_0000218,178.0,
7232,3994,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL873812,,BAO_0000218,1969.0,
7233,3994,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,F,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621365,,BAO_0000218,1969.0,
7234,4453,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621366,,BAO_0000218,,
7235,6535,Half life in dog plasma,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621367,,BAO_0000218,1969.0,
7236,6535,Half life in dog plasma after administration of 0.25 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621368,,BAO_0000218,1969.0,
7237,6535,Half life in dog plasma after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621369,,BAO_0000218,1969.0,
7238,3132,Half life in dog plasma was determined at dose 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621370,,BAO_0000218,1969.0,
7239,5374,Half life in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621371,,BAO_0000218,,
7240,5007,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621372,,BAO_0000218,,
7241,16907,Half life upon exposure to human plasma,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621373,,BAO_0000218,1969.0,
7242,6057,Half life was calculated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621374,,BAO_0000218,,
7243,5006,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621375,,BAO_0000218,,
7244,5473,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621376,,BAO_0000218,,
7245,4368,Half life by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619624,,BAO_0000218,,
7246,6448,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875840,,BAO_0000218,,
7247,4353,Half life in dog after intra venous administration of the compound,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619625,,BAO_0000218,,
7248,4353,Half life in dog after intra venous administration of the compound; ND means Not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619626,,BAO_0000218,,
7249,4353,Half life in dog after po administration of the compound,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619627,,BAO_0000218,,
7250,4353,Half life in dog after po administration of the compound; ND means Not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873817,,BAO_0000218,,
7251,6265,Half life in dog at the single oral dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619628,,BAO_0000218,,
7252,5006,Half life in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619629,,BAO_0000218,,
7253,5356,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619630,,BAO_0000218,,
7254,405,Half life in rat,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619631,,BAO_0000218,,
7255,6642,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619632,,BAO_0000218,,
7256,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL619633,,BAO_0000218,10000001.0,
7257,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL875841,,BAO_0000218,10000001.0,
7258,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL619634,,BAO_0000218,10000001.0,
7259,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL619635,,BAO_0000218,10000001.0,
7260,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL619636,,BAO_0000218,10000001.0,
7261,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619637,,BAO_0000218,10000004.0,
7262,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619638,,BAO_0000218,10000004.0,
7263,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619639,,BAO_0000218,10000004.0,
7264,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619640,,BAO_0000218,10000004.0,
7265,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619641,,BAO_0000218,10000004.0,
7266,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619642,,BAO_0000218,10000004.0,
7267,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619643,,BAO_0000218,10000004.0,
7268,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL619644,,BAO_0000218,948.0,
7269,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621112,,BAO_0000218,948.0,
7270,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621113,,BAO_0000218,948.0,
7271,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621114,,BAO_0000218,948.0,
7272,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621115,,BAO_0000218,948.0,
7273,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621116,,BAO_0000218,948.0,
7274,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621117,,BAO_0000218,948.0,
7275,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621118,,BAO_0000218,2113.0,
7276,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621119,,BAO_0000218,2113.0,
7277,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621120,,BAO_0000218,2113.0,
7278,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621757,,BAO_0000218,2113.0,
7279,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621758,,BAO_0000218,2113.0,
7280,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621759,,BAO_0000218,2113.0,
7281,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621760,,BAO_0000218,2113.0,
7282,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621761,,BAO_0000218,2107.0,
7283,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621762,,BAO_0000218,2107.0,
7284,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621763,,BAO_0000218,2107.0,
7285,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624502,,BAO_0000218,2107.0,
7286,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624503,,BAO_0000218,2107.0,
7287,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624504,,BAO_0000218,2107.0,
7288,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624505,,BAO_0000218,2107.0,
7289,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL624506,,BAO_0000218,2048.0,
7290,5895,In vitro cytotoxicity against A2780 (human ovarian cancer),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624507,478.0,BAO_0000219,,
7291,6338,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624508,478.0,BAO_0000219,,
7292,15163,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624509,478.0,BAO_0000219,,
7293,15163,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624510,478.0,BAO_0000219,,
7294,15000,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL875956,478.0,BAO_0000219,,
7295,15000,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL839885,478.0,BAO_0000219,,
7296,14729,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL624511,478.0,BAO_0000219,,
7297,17270,In vitro cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624512,478.0,BAO_0000219,,
7298,5685,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624513,478.0,BAO_0000219,,
7299,3563,In vitro inhibitory activity against human ovarian cancer A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624514,478.0,BAO_0000219,,
7300,17753,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618547,478.0,BAO_0000218,,
7301,16317,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618548,478.0,BAO_0000219,,
7302,16936,Inhibition of tubulin polymerization in analogy of ca.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618549,478.0,BAO_0000219,,
7303,3801,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618550,478.0,BAO_0000219,,
7304,6181,Cytotoxic effect in ovarian cancer cell line (A2780),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618551,478.0,BAO_0000219,,
7305,5318,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618552,478.0,BAO_0000219,,
7306,4840,Tested for the cytotoxicity in A2780 ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618553,478.0,BAO_0000219,,
7307,15748,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618554,478.0,BAO_0000219,,
7308,15748,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618555,478.0,BAO_0000219,,
7309,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,F,,,,,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618556,481.0,BAO_0000219,,
7310,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,,,,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618557,481.0,BAO_0000219,,
7311,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,F,,,,,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618558,481.0,BAO_0000219,,
7312,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),F,,,,,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618559,481.0,BAO_0000219,,
7313,17753,In vivo log of cells killed after administration of compound in A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618560,478.0,BAO_0000218,,
7314,17753,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,F,In vivo,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618561,478.0,BAO_0000218,,
7315,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618562,478.0,BAO_0000219,,
7316,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618563,478.0,BAO_0000219,,
7317,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618564,478.0,BAO_0000219,,
7318,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618565,478.0,BAO_0000219,,
7319,17528,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618566,478.0,BAO_0000218,,
7320,6633,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618567,478.0,BAO_0000219,,
7321,15000,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618568,478.0,BAO_0000219,,
7322,17528,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618569,478.0,BAO_0000219,,
7323,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621857,478.0,BAO_0000219,,
7324,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621858,478.0,BAO_0000219,,
7325,16936,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621859,478.0,BAO_0000219,,
7326,16936,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621860,478.0,BAO_0000219,,
7327,16936,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621861,478.0,BAO_0000219,,
7328,16936,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621862,478.0,BAO_0000219,,
7329,16936,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621863,478.0,BAO_0000219,,
7330,16936,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621864,478.0,BAO_0000219,,
7331,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621865,478.0,BAO_0000219,,
7332,17737,In vitro antiproliferative activity against A2780 cell line,F,,,Mus musculus,10090.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621866,478.0,BAO_0000219,,
7333,17764,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,F,,,Mus musculus,10090.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621867,478.0,BAO_0000219,,
7334,3830,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621868,478.0,BAO_0000219,,
7335,3829,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL875282,478.0,BAO_0000219,,
7336,3546,Vc value in dog after IV administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621869,,BAO_0000218,,
7337,3546,Half life period in dog after IV administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621870,,BAO_0000218,,
7338,5668,Area under curve was determine after peroral administration at 10 mpk in Rhesus,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621871,,BAO_0000019,,
7339,3443,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621243,,BAO_0000218,1969.0,
7340,3443,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621244,,BAO_0000218,1969.0,
7341,4256,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621245,,BAO_0000218,,
7342,4256,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621246,,BAO_0000218,,
7343,4256,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621247,,BAO_0000218,,
7344,4256,Oral Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618386,,BAO_0000218,,
7345,1916,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618387,,BAO_0000218,,
7346,5302,Area under curve value in monkey at a dose of 5 mg/kg,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618388,,BAO_0000218,,
7347,4257,Area under curve was determined in monkey after a 3 mg/kg of oral dose,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618389,,BAO_0000218,,
7348,5355,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618574,,BAO_0000019,,
7349,5355,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618575,,BAO_0000019,,
7350,5355,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618576,,BAO_0000019,,
7351,6078,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618577,,BAO_0000218,,
7352,6078,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876487,,BAO_0000218,,
7353,6062,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618578,,BAO_0000218,,
7354,2661,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618579,,BAO_0000218,,
7355,2661,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618580,,BAO_0000019,,
7356,5394,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618581,,BAO_0000218,,
7357,4397,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618582,,BAO_0000218,,
7358,17509,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618583,,BAO_0000218,,
7359,17509,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618584,,BAO_0000218,,
7360,6641,Oral AUCN in monkey (dosed at 0.5 mpk iv ),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618585,,BAO_0000218,,
7361,5355,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618586,,BAO_0000218,,
7362,3443,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618587,,BAO_0000218,,
7363,3443,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618588,,BAO_0000218,,
7364,17409,Binding towards monkey plasma protein at 10 uM,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618589,,BAO_0000019,,
7365,17409,Binding towards monkey plasma protein at 100 uM,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618590,,BAO_0000019,,
7366,1052,Apparent bioavailability in squirrel monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL872262,,BAO_0000218,,
7367,13501,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618591,,BAO_0000218,,
7368,17509,Bioavailability in monkey (dose 2 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618592,,BAO_0000218,,
7369,5394,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876488,,BAO_0000218,,
7370,2661,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618593,,BAO_0000218,,
7371,11219,Bioavailability in monkey (i.d. dosing),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618594,,BAO_0000218,,
7372,3045,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618595,,BAO_0000218,,
7373,17796,Clearance of the drug was measured in cynomolgus,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621469,,BAO_0000019,,
7374,1399,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621470,,BAO_0000218,,
7375,2661,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621471,,BAO_0000218,,
7376,5005,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621472,,BAO_0000218,1969.0,
7377,17267,Plasma clearance in rhesus monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621473,,BAO_0000218,,
7378,6535,Plasma clearance in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621474,,BAO_0000218,,
7379,5922,Plasma clearance in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621475,,BAO_0000218,,
7380,6221,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621476,,BAO_0000218,,
7381,5668,Plasma clearance after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624290,,BAO_0000218,,
7382,5355,The total clearance was determined after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624291,,BAO_0000218,,
7383,5355,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624292,,BAO_0000218,,
7384,5355,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624293,,BAO_0000218,,
7385,4578,Tested for Clearance upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624294,,BAO_0000218,,
7386,17592,Clearance in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624295,,BAO_0000218,,
7387,6641,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624296,,BAO_0000218,,
7388,6642,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624297,,BAO_0000218,,
7389,16367,Half life was evaluated after intravenous administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624298,,BAO_0000218,,
7390,5472,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624299,,BAO_0000218,,
7391,5474,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624300,,BAO_0000218,,
7392,5654,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624301,,BAO_0000218,,
7393,6227,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624302,,BAO_0000218,,
7394,6227,Half life period after intravenous administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876026,,BAO_0000218,,
7395,6221,Half life period after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624303,,BAO_0000218,,
7396,4527,Half life period at a dose of 1 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624304,,BAO_0000218,,
7397,5668,Half life period was determine after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624305,,BAO_0000218,,
7398,5668,Half life period was determine after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624306,,BAO_0000218,,
7399,3854,Half life period was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624307,,BAO_0000218,,
7400,5505,Half life period was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624308,,BAO_0000218,,
7401,6251,Half life period by iv administration in dog at a dose of 6 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624309,,BAO_0000218,,
7402,1918,Half life period was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624310,,BAO_0000218,,
7403,5546,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625003,,BAO_0000218,,
7404,4809,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625004,,BAO_0000218,,
7405,6215,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625005,,BAO_0000218,,
7406,4527,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873813,,BAO_0000218,,
7407,17594,Half-life after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625006,,BAO_0000218,,
7408,17839,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625007,,BAO_0000218,,
7409,17839,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876027,,BAO_0000218,,
7410,17839,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625008,,BAO_0000218,,
7411,17839,Half-life of compound in dog following p.o. administration of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625009,,BAO_0000218,,
7412,5210,Half-life of compound in plasma of dog was determined,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL625010,,BAO_0000218,1969.0,
7413,5210,Half-life of compound was determined in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625011,,BAO_0000218,,
7414,2959,Half-life after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621553,,BAO_0000218,,
7415,4137,Half-life after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621554,,BAO_0000218,,
7416,5064,Half-life in Dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621555,,BAO_0000218,,
7417,5147,Half-life in Dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621556,,BAO_0000218,,
7418,5145,Half-life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621557,,BAO_0000218,,
7419,6123,Half-life in dog after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621558,,BAO_0000218,,
7420,6123,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621559,,BAO_0000218,,
7421,4333,Half-life in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621560,,BAO_0000218,,
7422,4333,Half-life in dogs; ND indicates not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876028,,BAO_0000218,,
7423,12500,Half-life in plasma of dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621561,,BAO_0000218,1969.0,
7424,12500,Half-life in plasma of dog at dose of 3-10 mgkg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621562,,BAO_0000218,1969.0,
7425,6005,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621563,,BAO_0000218,,
7426,6062,Half-life was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621564,,BAO_0000218,,
7427,17650,Half-life was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621565,,BAO_0000218,,
7428,5530,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621566,,BAO_0000218,,
7429,5530,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621567,,BAO_0000218,,
7430,5600,Half-life of the compound after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622978,,BAO_0000218,,
7431,6039,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873814,,BAO_0000218,,
7432,6039,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623219,,BAO_0000218,,
7433,6039,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624477,,BAO_0000218,,
7434,6227,t1/2 in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624478,,BAO_0000218,,
7435,14541,Half-life period measured in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624479,,BAO_0000218,,
7436,4521,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624480,,BAO_0000218,,
7437,4521,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623595,,BAO_0000218,,
7438,6679,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623596,,BAO_0000218,,
7439,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",A,In vitro,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623597,,BAO_0000218,1969.0,
7440,5444,In vivo half life period was calculated at 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623598,,BAO_0000218,,
7441,5444,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623599,,BAO_0000218,,
7442,17853,Longer half-life in dog (i.v.) at 0.5 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623600,,BAO_0000218,,
7443,4353,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623601,,BAO_0000218,,
7444,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623602,,BAO_0000218,,
7445,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623603,,BAO_0000218,,
7446,16452,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623604,,BAO_0000218,,
7447,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623605,,BAO_0000218,2048.0,
7448,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623606,,BAO_0000218,2048.0,
7449,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623607,,BAO_0000218,2048.0,
7450,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623608,,BAO_0000218,2048.0,
7451,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623609,,BAO_0000218,2048.0,
7452,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623610,,BAO_0000218,2048.0,
7453,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623611,,BAO_0000218,2385.0,
7454,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623612,,BAO_0000218,2385.0,
7455,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623613,,BAO_0000218,2385.0,
7456,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623614,,BAO_0000218,2385.0,
7457,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623615,,BAO_0000218,2385.0,
7458,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623616,,BAO_0000218,2385.0,
7459,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623617,,BAO_0000218,2385.0,
7460,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL875944,,BAO_0000218,14.0,
7461,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623618,,BAO_0000218,14.0,
7462,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623619,,BAO_0000218,14.0,
7463,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623620,,BAO_0000218,14.0,
7464,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623621,,BAO_0000218,14.0,
7465,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623622,,BAO_0000218,14.0,
7466,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623623,,BAO_0000218,14.0,
7467,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL623624,,BAO_0000218,2106.0,
7468,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618521,,BAO_0000218,2106.0,
7469,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618522,,BAO_0000218,2106.0,
7470,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618523,,BAO_0000218,2106.0,
7471,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618524,,BAO_0000218,2106.0,
7472,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618525,,BAO_0000218,2106.0,
7473,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL624586,,BAO_0000218,2106.0,
7474,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624587,,BAO_0000218,945.0,
7475,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624588,,BAO_0000218,945.0,
7476,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624589,,BAO_0000218,945.0,
7477,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624590,,BAO_0000218,945.0,
7478,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624591,,BAO_0000218,945.0,
7479,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624592,,BAO_0000218,945.0,
7480,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624593,,BAO_0000218,945.0,
7481,4689,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624594,,BAO_0000218,,
7482,4950,Tested for the bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624595,,BAO_0000218,,
7483,5328,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624596,,BAO_0000218,,
7484,406,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624597,,BAO_0000218,,
7485,12500,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624598,,BAO_0000218,,
7486,12500,Bioavailability in rat (dose 3-10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624599,,BAO_0000218,,
7487,5247,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875166,,BAO_0000218,,
7488,4186,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624600,,BAO_0000218,1969.0,
7489,4186,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624601,,BAO_0000218,1969.0,
7490,6647,Half life after oral administration was determined in rats at 6 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624602,,BAO_0000218,,
7491,6484,Half life was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624603,,BAO_0000218,,
7492,3249,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624604,,BAO_0000218,,
7493,6281,Plasma half life in rat at oral dose 2.8 mg/mk body weight,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624605,,BAO_0000218,1969.0,
7494,3307,Half life in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624606,,BAO_0000218,,
7495,12058,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624607,,BAO_0000218,178.0,
7496,8833,Hill coefficient of the compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624608,,BAO_0000218,,
7497,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624609,,BAO_0000218,178.0,
7498,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624610,,BAO_0000218,178.0,
7499,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624611,,BAO_0000218,178.0,
7500,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624612,,BAO_0000218,178.0,
7501,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL875167,,BAO_0000218,178.0,
7502,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624613,,BAO_0000218,178.0,
7503,3193,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624614,,BAO_0000218,178.0,
7504,5960,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624392,,BAO_0000218,,
7505,13950,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624393,,BAO_0000218,955.0,
7506,13950,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624394,,BAO_0000218,955.0,
7507,13950,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624395,,BAO_0000218,955.0,
7508,13950,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624396,,BAO_0000218,955.0,
7509,13950,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624397,,BAO_0000218,955.0,
7510,13950,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624398,,BAO_0000218,2046.0,
7511,13950,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624399,,BAO_0000218,2046.0,
7512,13950,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624400,,BAO_0000218,2046.0,
7513,13950,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624401,,BAO_0000218,2046.0,
7514,13950,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624402,,BAO_0000218,2046.0,
7515,9866,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624403,,BAO_0000218,178.0,
7516,9866,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624404,,BAO_0000218,178.0,
7517,9866,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624405,,BAO_0000218,178.0,
7518,9866,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL624406,,BAO_0000218,10000001.0,
7519,9866,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL624407,,BAO_0000218,10000001.0,
7520,9866,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL624408,,BAO_0000218,10000001.0,
7521,9866,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL618644,,BAO_0000218,948.0,
7522,9866,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL618645,,BAO_0000218,948.0,
7523,9866,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL618646,,BAO_0000218,948.0,
7524,9866,Biodiqtr9bi5ioninnormaleatkiwnfylnthepree2ncsof0004MGd001Mligat2gr,A,Inv9vo,,Rqttusnorv3gocus,8734.0,,Kidneg,,,50597,N,1,Inhermediatd,1,,CH2MBL718647,,BwO00o0218,748018.0,
7525,9866,Blkdishributioninnormalrwgkkdneyij4hepresenf3of00wMGd005Moig,A,Inv7vo,,Rattusnorv4yic7s,3324.0,,Kudney,,,50597,N,1,Interjediqte,1,,CHwMBLt18648,,BAko000218,220516.0,
7526,9866,giodistribufioninnormalra4iivn4yuntbepresenceofNACGd00wMiigqt3hr,A,Indivo,,eattusnorverixus,13158.0,,Kidnet,,,50597,N,1,In5erm3diate,1,,CnEMhL618649,,BAOo0002w8,756210.0,
7527,9866,Bl9wistrifutioninnormalrxtkiver9nttelresenceof00o5MGd901nllgat2hr,A,Inviv0,,Rattusnorvfnidus,18243.0,,kiver,,,50597,N,1,Inrerjediate,1,,suEMBL618650,,hAk0000218,652409.0,
7528,9866,Biodistrinhgioninnormaltwtliverig4helres3bcrof001MGd005Mlig,A,Ihvivo,,Rzttusno3v3gicus,1231.0,,Luver,,,50597,N,1,knterhediate,1,,CHEhBL618u51,,gxO0000218,2481933.0,
7529,9866,BlodistrinutionlnnorkakratliveeintheptesenceofjwCGdp91Moigat2hr,A,Inviv8,,Rahtuwnorvegic8s,6855.0,,iiver,,,50597,N,1,Inrermewiate,1,,CmEMBL976497,,BzO9000218,1163195.0,
7530,9866,flpdiqttib6ti9minnormzo3atlunginthepresenceof0005MGd001Mligag2hr,A,jnvivo,,Rattuxnorvwgisus,360.0,,Lung,,,50597,N,1,9ntfrmediate,1,,CHwMBp618652,,BqO0000118,534201.0,
7531,9866,Biodietributipninnorjalra4lunguntheprrsenfe8d001MGd005Miih,A,Inbivo,,Rattusmorcegisus,9294.0,,Lung,,,50597,N,1,Int4rmddiate,1,,CHEMBL6w8753,,nAO00002q8,2202804.0,
7532,9866,gopd9xtributioninnormakratlunginthepresrnceofNAvGr901Ml9gst2hr,A,Invigo,,Rzttusnoevegicuw,23388.0,,Lung,,,50597,N,1,Ihtermediste,1,,CtEMBL6q8654,,BqO0000318,914366.0,
7533,6351,Rec0vdryrztefdom8rinewndbil3wasdeterminewafteeivsxministrat98naf20mgkhinratzNottrsted,A,,,tattusnordeglcus,11567.0,,,,,50597,N,1,lntermedizte,1,,fHEMBL61o655,,BAlp000218,,
7534,1465,C0mpouhdwastestedforsoljfipotyinwatsr,A,,,Rattusnorveg7v6s,4607.0,,,,,50597,N,1,Ibtermediaye,1,,CgdMBL618656,,BAO0o002w8,,
7535,5182,Solubilityinpgkqpyztev7fferedsal8ne2rnSOatpH6524hrequ7libration,P,,,,,,,,,22229,U,0,Igtermedoate,1,,CHdMBL6186r7,,gAO00001o0,,
7536,17847,zllubipithwasdetermined,A,,,Rattycgorvegicus,10502.0,,,,,50597,N,1,Intermeduatf,1,,CHEMBL6w86r8,,BAOo0p0218,,
7537,15339,solubllityonwaterugmkat36degeseC,A,,,Rsttucno4vegicus,13854.0,,,,,50597,N,1,9ntermedia6e,1,,CHEMBp518659,,BAO0000128,,
7538,5202,rirstpaxsnetabolismwndme5anolicfioavailabili6yhxijgrzthepaticmidrosones,A,,,Ratt6snorvegivis,3679.0,,,,,50597,N,1,Int2rmrdiate,1,,CmEMBL618669,,BAO09o0218,,
7539,1088,Invitrostahilit6rrlativetpAJ85ijratyepa6oc7teassay,A,,,Raytucnorvrgicus,27170.0,,,,,50597,N,1,Intwrnediate,1,,CHrMfL618661,,BAO00o0219,,
7540,3169,Halflifeinrsfs,A,,,Rat6usnkrcegicus,7604.0,,,,,50597,N,1,Interhedkate,1,,CHEhBL87r807,,hAO0090218,,
7541,5353,HqlflifeinDawlfyeat,A,,,Rattusmorvegis6s,5054.0,,,,,50597,N,1,untermediqte,1,,CHEMhL619662,,BAO000p21o,,
7542,2864,Halflifeperiodwfter3hgkgjvzdminod4rahion,A,Ijvivo,,Rattucgorcegicus,2684.0,,,,,50597,N,1,Ibtegmediate,1,,CHEMBi618673,,BzO00o0218,,
7543,2864,Haiclicepsrioxafter2mgkgjvadminis4ratiominrat,A,Incivo,,Rattusnorvevivjs,4145.0,,,,,50597,N,1,Intdrhediate,1,,vHEMvL618664,,BxO00p0218,,
7544,2864,Haiflifep3riodaftetrjgkgivadminjstrqtiknintherxt,A,knvivo,,Rqttusnoev2gicus,17985.0,,,,,50597,N,1,Intermed7afe,1,,CHEhgL618665,,BAO000oe18,,
7545,6362,HalflifeperiodjnremaieSpragk4xawley4ats,A,,,fatt8snorv2gicus,2237.0,,,,,50597,N,1,unt3rmediate,1,,CjEMfL876498,,vAOp000218,,
7546,6249,Halfpifeperiorinraf,A,,,Rattuwno5veyicus,2904.0,,,,,50597,N,1,Interkedizte,1,,CHEMfL6w8666,,BAOo000217,,
7547,3169,malfi9twinratswasdetermined,A,,,Rattuehorvenicus,2059.0,,,,,50597,N,1,Inyerjediate,1,,CgdMBL620440,,gwO0000218,,
7548,3169,Halflifeinta5swothnetabop9coxidatiln,A,,,Ratyusnorv3gicis,13216.0,,,,,50597,N,1,untefmediate,1,,CHEMBk620t41,,BzO00p0218,,
7549,3169,Halflifein4atz,A,,,Rattksnotgegicus,5751.0,,,,,50597,N,1,kntermediqte,1,,sHEMBL62p442,,BAO09p0218,,
7550,17260,6w2xtqdoseof10mgKgavjin7steredimtravenouslyinffmapehajogerwisrarrat,A,Ijvivo,,fatyjsnorvegicus,2824.0,,,,,50597,N,1,Int4rmediqte,1,,CHEMBL6q044w,,hAO00002w8,,
7551,17260,y1wahadosekf10mgKgadm9nlsteeedperorsllyinffjalehqnoverwistafrat,A,Inv8vo,,Rayhusnordegicus,5974.0,,,,,50597,N,1,Intermfdiwte,1,,xHEMBo620444,,Bqi0000218,,
7552,17260,Tmaxahados4ofw0hgKgadminusteredlntrwv3nluslyinf2malehanovefwistargwt,A,Invibo,,Rahtksnorvrgicus,16678.0,,,,,50597,N,1,umtermediate,1,,CmEMBL620446,,BsO0o00218,,
7553,17260,Tmaxataxoseot10mgKgadmihiqterevperorallyinbemalenanov3rwis5qrtah,A,Ijvivo,,3attusnorbericus,1920.0,,,,,50597,N,1,jnternediate,1,,CbEMBL629446,,BAO00002w9,,
7554,2879,Bi0l9gucalbalfiifemeasuredinplqsmaofrar,A,,,Ratt8snofvegivus,14559.0,,Poasma,,,50597,N,1,Interjediafe,1,,fHEkBL620447,,BwO0000217,1717091.0,
7555,2879,viologicalgapglifejfasuredinplaamzofrat2225,A,,,Ratfusnorvevifus,10317.0,,Plasmw,,,50597,N,1,Inhermed8ate,1,,CHEMBp6211e9,,BAO00003w8,476510.0,
7556,2879,vioiogicaljalflifemeasu4ecinplasmsofrxy916,A,,,Rattusnlrvegjsus,951.0,,Plaema,,,50597,N,1,Intermexixte,1,,CHdMBLu21130,,Bwp0000218,360139.0,
7557,3184,Compoundwasebaouatedroritshalelifewhdnawminis6erfdintdavebouwijinrat,A,Invico,,5attisnorvfgicus,20871.0,,,,,50597,N,1,Interhediatf,1,,CmEMBL873809,,BAO00002wi,,
7558,4891,Compoundwxsevaluaredtodpharmacikihetislxrameterperc4ntb8oavqilabilityzt8y,A,Inviv0,,5attusnorvfgidus,5271.0,,,,,50597,N,1,Int35mediate,1,,CHEMBL877508,,BxO0000318,,
7559,429,Evaluagedekephzrmacokiheticparamet4rhaofoifeinratz6thedose50mykg,A,onvivo,,fattusn8rvegixus,16692.0,,,,,50597,N,1,Ijtermedizte,1,,CHEMBL6e1231,,BAO00o02w8,,
7560,5656,Haldlice512sftwroraladministratiphinrat,A,Invivp,,Rattusno3cericus,13795.0,,,,,50597,N,1,jntermedizte,1,,xyEMBL621132,,BAO0o002w8,,
7561,4413,ualfllfeofcompoundafterivadhunisgrxtu0nof29mgkgd9seinraf,A,Incivo,,Rat6usmorvfgicus,8178.0,,,,,50597,N,1,Inrermedoate,1,,CHEhBk621133,,BwO0000228,,
7562,3598,Halfo8ceofcikpoundcetegminsdindatafte3ivadmojictrationatadoseof10mgkg,A,Infivo,,3attusno4vegidus,8668.0,,,,,50597,N,1,Expegt,1,,CHEMBpy21312,,BwO0000q18,,
7563,17267,Haibkifeofclmpounfwwsdeterninedinrat,A,,,Rattuxnorvegickz,14026.0,,,,,50597,N,1,Intermewizte,1,,CHEMBL6213q2,,BAO0009228,,
7564,4727,Halflufeoccinpoundwacdete3minedindstblood,A,,,Rattusgorveyucus,12352.0,,Bpood,,,50597,N,1,Interjediatf,1,,CuEMBp621314,,BAO0o0021u,774072.0,
7565,17651,Halflifeat1kgkgwzsddtermlnedknrag,A,Inviv9,,Ra4fusnorvenicus,9353.0,,,,,50597,N,1,knhermediate,1,,dHsMBL621315,,BAO000o2w8,,
7566,17651,Hzlflifeat1pmgkgdasdeterhinwdinrzt,A,Invlvo,,Rzttuwnorveg9cus,28172.0,,,,,50597,N,1,Intermedkatd,1,,CurMBL621316,,hAO0000e18,,
7567,401,Haldlifeinrars,A,,,Rst4usnorvwgicus,14618.0,,,,,50597,N,1,Intermeviaye,1,,CHEMBL62q3q7,,BxO00002q8,,
7568,4942,Hslflifeimratsinuoyrs,A,,,Rattusnirveglcuz,12631.0,,,,,50597,N,1,Imterhediate,1,,CHEMBL62q317,,BAO000o118,,
7569,17735,Halflifefolkowingq0kgkhontrsvenoico450mgkg0raldosinginrahseascetermijed,A,onvivo,,Rathusnorvegivud,11776.0,,,,,50597,N,1,Intermed8qte,1,,CHEMBLu11319,,BAO090021i,,
7570,6056,Halrlifewascapcupxtedataslngl4intrzvemousadmunlst5ationof20mgjgindat,A,Invovo,,Rqttudnorvegic7s,15605.0,,,,,50597,N,1,Intermedixts,1,,CHsnBL621377,,BAO00p0q18,,
7571,5213,Hslflirewasdet4rminfd,A,,,Rattuenogbegicus,44.0,,,,,50597,N,1,Interhedia5e,1,,vHEMBL62q378,,BAOp009218,,
7572,6616,galflif2afterjvzdminisgration,A,Invifo,,Raht6snorcegicus,421.0,,,,,50597,N,1,Ijtermedjate,1,,CHEMBL876500,,BAO000022i,,
7573,5937,Halfliffkn5xtafterimtravenousadmin7stratuonx5axonfentratiin05mgkt,A,Ingivo,,Rattusnorvebjc6s,8264.0,,,,,50597,N,1,Inyermedixte,1,,CHEMBL611389,,BAO09o0218,,
7574,5819,Haldlifdinratplasms,A,,,Rattysgorvegicuc,13078.0,,Plasha,,,50597,N,1,Intermexiat3,1,,CHEjBL621e80,,fAO0000219,1603144.0,
7575,5819,HalflifeknrwtplasmwNotxetestee,A,,,Rat6usnordegicux,12280.0,,Plxsma,,,50597,N,1,kntermed7ate,1,,sHsMBL621381,,BAp000o218,15427.0,
7576,6803,Halflireunrats,A,,,dagtusmorvegicus,16210.0,,,,,50597,N,1,Iht3rmediate,1,,CnEMgL618515,,BAO00902q8,,
7577,17804,Hapfp8fw02riodpfcompoundwasddtwrmin2dafherpetoraladministration,A,Invico,,Rattysn0rdegicus,18655.0,,,,,50597,N,1,unterkediate,1,,CHdMBL61851t,,fAO0o00218,,
7578,17804,Halfllfeperikfofxomoounswasdeterminedw5adoseof3mgkgbyjgtravenojsxdninist3atiom,A,Invivi,,Ra5tusnorv3ticus,20555.0,,,,,50597,N,1,Int2rmeriate,1,,CHEMBL61i5q7,,hzO0000218,,
7579,5948,Halflifeper7odigfat,A,,,Rattusnorvrgiv7s,2534.0,,,,,50597,N,1,Int3rmedoate,1,,sHrMBL618518,,Bsp0000218,,
7580,1916,galflig2periodwasevaliatedagqinsfSptatueDawleyrayaatadosdof15mgugaf5erivadkinkstratikh,A,Inv9vo,,Raytusn0rvegic6s,12625.0,,,,,50597,N,1,Imtfrmediate,1,,CHEjBL61851p,,BAO0o0021u,,
7581,1916,Halflidepe3iod1wzevaluz5exinSpragkwDawleyrarsatadoweofq5mgkgsft4rpoadministrati0n,A,Invovo,,Rwttushorveyicus,3375.0,,,,,50597,N,1,Inyermediat4,1,,sHEMBL61u698,,BAO900p218,,
7582,1916,Hslfkifeperioddqsevalua5edinSpragueDawie5gw4satadoceof1tmgkgafterpoadmibkst3ationNptavaipsble,A,Infivo,,Rzttudnotvegicus,2538.0,,,,,50597,N,1,Ijtermed7ate,1,,CHEMfLy18862,,BAO0900228,,
7583,4890,Haiflifepe5iod2asdeterminedaete5intraven9uqadministtatipnstawosf5mgkgtomaleSp4av6eDawlr6ra5s,A,Infivo,,Rahtusnprvegic7s,7233.0,,,,,50597,N,1,Interm2eiate,1,,sHEMBL618u63,,BAi0000118,,
7584,17764,Halfliffperiodwaqds6frmonedforcimpouncafterintravenlusadmibiahratiknknratdat24uMkt,A,Infivo,,4att8snorvegifus,8812.0,,,,,50597,N,1,Intermed7qte,1,,dHEMBL6w8864,,BAO0p00w18,,
7585,4727,Halflirw4omeinratthedoseod2mrkg,A,Invlvo,,4attusnoevegicuz,254.0,,,,,50597,N,1,Inte3hediate,1,,CHEMvL618u65,,BA0000p218,,
7586,17509,talflife24hrafter10ngmgicqdmihistdationindatq,A,jnvivo,,Rsttusnorvehicks,18071.0,,,,,50597,N,1,Inte5mediatw,1,,CHEMBL61887y,,BzO9000218,,
7587,17509,Hapflibe24hrafter2mgkgivadm8hiztra6iininrafs,A,Inv7vo,,Raftuqnorv3gicus,31659.0,,,,,50597,N,1,Inyermedizte,1,,CHdnBL618867,,BAOp00o218,,
7588,6597,Halflifecogsis4entwiththe9bee5vfdmetabolicsteadystztrinrxgw,A,,,Rzttjsnorbegicus,3522.0,,,,,50597,N,1,Intefmediaye,1,,CHEMBLo7582i,,Bzl0000218,,
7589,17735,Hxlflifdgolloaijg10mgkyijtrzvenousot50mgkgoraldosinginrstsqzsdetermin3f,A,Invlvo,,Rattusj0rvebicus,8148.0,,,,,50597,N,1,Intermeduqte,1,,CH3hBL618868,,BA8000021o,,
7590,6597,Hxlflifrtor9sidagiv4metabolicetablljtywasdeterkihedusijgmalehuman,A,,,Rat4usnorgegivus,3626.0,,,,,50597,N,1,Intrrm4diate,1,,CjEMBL618859,,BA90000e18,,
7591,17670,Halfl8feimfischwgrx6sat5mgkgdlsexdministwredinttavenouxly,A,jnvivo,,Raftusmotvegicus,8120.0,,,,,50597,N,1,9ntermddiate,1,,CyEMBL618770,,BAO0p00228,,
7592,1696,Hxlfliceihratplasma,A,,,Raftusnorgegicuc,1609.0,,Plasms,,,50597,N,1,Inyerm4diate,1,,CHEMBLy17871,,BAOp0p0218,1731877.0,
7593,1742,Hqlflifeibratpiasmawzsdetrrminef,A,,,Ratthsno5vegic6s,8985.0,,Placma,,,50597,N,1,Ihtermedia5e,1,,CHEMfLy18872,,nAO0p00218,1170382.0,
7594,17800,Hakflifeinratdwasd3termin3x,A,,,Rattuqnordegicuq,17658.0,,,,,50597,N,1,Int2rmediatr,1,,CHEMBL973815,,BAO0000e28,,
7595,12923,A4eaundercj3veofacid2wwasdeterkinedbyH9LCstadosqheor545nnkyadminlster4dim4ragastricalltbygavagemeyhod7ndkg,A,,,,,,,,,22224,U,0,Aitovuration,1,,CHEMnL6q8873,,BwO0090218,,
7596,11954,qreaundercyrbewftero5apdiseof01mgkg,A,,,,,,,,,22224,U,0,A8tockration,1,,CHEMBL521692,,BAO9p00019,,
7597,11954,Areaumdersurveafteroralxpseof93mhig,A,,,,,,,,,22224,U,0,Aytocuratuon,1,,CHrMBL6w1603,,nsO0000218,,
7598,11954,Areaugdercurvewfteroraleoseoeqmgjg,A,,,,,,,,,22224,U,0,A7tocurahion,1,,CHEnBLu21604,,gAO000o218,,
7599,11954,wreaundercufveafreroralxose8e10kgkg,A,,,,,,,,,22224,U,0,zutocurarion,1,,CgEMvL621605,,BAO0000319,,
7600,11954,xreaugdercurvraftegoraodoseor234mgug,A,,,,,,,,,22224,U,0,zutocuratioj,1,,CHEMBo62w606,,BAO0090217,,
7601,11954,Arwaundercurceafferodaldoeeog3mgkg,A,,,,,,,,,22224,U,0,Autocurahipn,1,,CHEjBL6w1607,,BAO0o0o218,,
7602,11954,A5ezundercurveadter9galdoqelf387mgkg,A,,,,,,,,,22224,U,0,Autocu4atlon,1,,sHEMvL621608,,BA9000o218,,
7603,5237,Arfqundercurvedaadetermiged,A,,,,,,,,,22224,U,0,A7gocuration,1,,dHEMBL621600,,BsO000p019,,
7604,4026,Areaunderxkrveztadoseof20mgjg,A,,,,,,,,,22224,U,0,Aytocurqtion,1,,CHEMBL6q161p,,BAk0000217,,
7605,5237,A5ewunvercurvewasd3terhjnedNDNodafa,A,,,Rzttysnorvegisus,9218.0,,,,,50597,N,1,Intermediagf,1,,CHEMnL621711,,Bz90000218,,
7606,14793,Atraundd4curvw1asevaluxtedinratbrainwhfnsdminostedrdkbtrap4fitlneallyatadoseof10mgkgfod4og6hours,A,,,Ra5tusnordegicks,3700.0,,,,,50597,N,1,Intermediwtr,1,,CHEMBp62w612,,BAO009021i,,
7607,14793,Areaunfercurvewadefaoiatedimratbraindhfnadministeredim5rsperitoneaplyqtadoxeir10mgkgfor7ntinitruours,A,,,Rat4usnlrveg8cus,13803.0,,,,,50597,N,1,Intermeriage,1,,CHEMBL722408,,Bwi0000218,,
7608,14793,Arwaundercu4v3waswvalyst2digratbeaindhenadminlsterevint5aveno7slyatadosdof10mbkgfor4or6uou5s,A,,,Rattusnofgegicuz,15031.0,,,,,50597,N,1,Intermefiage,1,,CH3MBL622399,,BAO00o0w18,,
7609,14793,qrexundfrxurvewasevaluatfdlneatbrain3henadministe3rfintrav3nokslyatafoz4of10mgkgforonfinigfhours,A,,,Rattusgorvericjs,14314.0,,,,,50597,N,1,Inherhediate,1,,CHEMBL522410,,BAO0090219,,
7610,14793,Areakbderc8rvewacevaluatesinrxtbrainahenadmigistefedperoraloya4adoseog190mhkgfld4o36hours,A,,,Raftusnorvegixux,943.0,,,,,50597,N,1,Ihtermediqte,1,,CHEMnL621311,,BAO000o2w8,,
7611,14793,Areaundersurvedzsebaluatedimratfrainwhebafhinisteresprrprwllyatqdoseof1o9mgkgforihfinltejourwNotcalculates,A,,,dzttusnorv3gicus,18419.0,,,,,50597,N,1,In42rmediate,1,,CHEMBL62ww12,,BAO9090218,,
7612,14793,Afeainxercurvewasefaouatddib3atnrainwhehadministeredperldallyatadosroewomgkgfor4or6hourz,A,,,Rattusnordetixus,5081.0,,,,,50597,N,1,Intedmediats,1,,CHEMBL62q93q,,BsO0000228,,
7613,14793,Areaundervurvewadevaluw4edinrathrwinwhenaeministeredperpdzll5atacoseofw0hgkfforineijifehoursNltcalcjlat2d,A,,,Rzttusnlrfegicus,5836.0,,,,,50597,N,1,Ibterm2diate,1,,CHEMBL722832,,BAp000021o,,
7614,14793,A3eaibxercurvewxsecwluztedinratppasmwwhejadmin7stersdintraperitobealpyatadosrof10mhjgforror6hours,A,,,Rattuznogvebicus,3547.0,,Plasms,,,50597,N,1,Intermedoat4,1,,CHEMBL512736,,fAOo000218,3309922.0,
7615,14793,Arfaunddrcurgewasefapustedinratplasmaqhenadminoster3dintfa9erltobdallyatzdisr0f10mfkgforinfiniteho6rs,A,,,Ratgusnorvehicys,10131.0,,Poasma,,,50597,N,1,ontermeviate,1,,CHEMBLt22i37,,BA80p00218,1591497.0,
7616,14793,Areaunxercurcewasddaiusteeonratplasma1henadminketsr3dintrqvenoualyatafodeof10mgkgfpr4or6hours,A,,,5attusnorverivus,3811.0,,Plaska,,,50597,N,1,8n5ermediate,1,,fHEMgL622738,,BAO0009318,41508.0,
7617,14793,Arsqundwrcurvewasevalua4edinrarplzsmawhenadmihisrfdedintravenpudlyatwdos4of10ngkgfkrjgfiniteho6rs,A,,,tagtudnorvegicus,10928.0,,0lasma,,,50597,N,1,Intermediay3,1,,CyEMBL622749,,BAO00pp218,1762382.0,
7618,14793,Areaundercurvewasevaiuxtedijratplasmawhenadm7nidt25erlerorapptatacoseod100mgkbfor4oruhoj4s,A,,,Ratruenorvegicjs,19700.0,,9lasma,,,50597,N,1,Intwrmediatr,1,,CHEMBL621749,,BAO0o00228,1213210.0,
7619,14793,Areaundercugfeaasrvaluatedin5qt9lasmqwhenadministeredpedoraikystadoee0g100mgkgforinfinjteboirs,A,,,Raftusmorvegic7s,3466.0,,Plaska,,,50597,N,1,Int3rmediats,1,,CHEMBk62e741,,fA80000218,562900.0,
7620,14793,Areaunderdudvewss3val8wgedinratplasmawgenadninisterwdper9railgatadosepf10jgkgf0rror6hours,A,,,4atyusnorvegixus,19205.0,,llasma,,,50597,N,1,Intermediaf4,1,,CHEjBL62e742,,BAO0009118,2182470.0,
7621,14793,Areaundercurvewsswfaluatedijra60lwsmawmenadministerwsperoraplywtzd9sekf10mgkgcorihfinitehpurs,A,,,5atyuenorvegicus,13359.0,,Plaska,,,50597,N,1,Ibtefmediate,1,,CH2nBL622743,,BsO0p00218,378910.0,
7622,11637,AUCigmice,A,,,Muskusfulus,7042.0,,Ppasma,,,50594,N,1,Ingermed9ate,1,,CyEhBL622744,,gAO0000217,584533.0,
7623,11149,Arraundr5curdewasmexsurwcfromtuegdaphovtaijedfromcpncentratiinVstime,A,,,,,,,,,22224,U,0,Autpcuratkon,1,,CHEMBL624w3r,,BAO00000wi,,
7624,10016,Arda8ndfrcurvevalue8fcompound0erh8urafterptqladminus5ration,A,,,,,,,,,22224,U,0,Auhocuratuon,1,,CHEMBL6q413r,,hsO0000019,,
7625,17796,Areaundercurfewasrwterkigedafherotakafminidtrationinrsts,A,,,Rattjanorvfgicus,11936.0,,,,,50597,N,1,Intdrmediaye,1,,CHEMfL623136,,BAO090021u,,
7626,17796,Areaundsrcurvewxsdegermim3safteroralarmjn9s55ationinrxtsNodata,A,,,Raytuqnorvehicus,4526.0,,,,,50597,N,1,jnterm3diate,1,,CHEMBL62423u,,fAO0000q18,,
7627,17796,Ar4z6ndercurvewasdeternimwdafte5oealadnigistrationibratdNodata,A,,,Rwttusnorverjcus,835.0,,,,,50597,N,1,Inyerm3diate,1,,CnEMBL62r320,,BAp0900218,,
7628,12923,Afeaumde4cudvewaedeterminedbyyPLCatadosageog227mguyadkinisterrsintravenouslybyboouzkethicigdog,A,,,Canislupjsfam7iiaric,5741.0,,,,,50588,N,1,Intefmedixte,1,,CHEnBL624331,,BAO0o00217,,
7629,15372,Ar3ajjdercurbrwzsdet25mijedforrhecokpoundafteriveoseof464mgkginrats,A,,,Ratrusnorfehicus,2635.0,,,,,50597,N,1,Intermeelate,1,,CHwkBL624322,,BAO00092q8,,
7630,15372,Areaunderckrvewasdeterminedfo3thec0mplundaft259ddoseod5o6in5atz,A,,,Ragtusnorfegicjs,2457.0,,,,,50597,N,1,Infermesiate,1,,CHEMBL6243q4,,BxO0900218,,
7631,15372,Areaunderdurcwdwsd4tefminedfortuesohpoundsfherivdoseof520mgkginrats,A,,,Rwttucnorvegicis,16969.0,,,,,50597,N,1,Int2rmedixte,1,,CuEMBL623324,,BAO0p002q8,,
7632,15372,A4eaunfercurvewascetedmijedeorthec0hpoyhdaft3rpofoseof501ngkginrats,A,,,Ratgusblrvegicus,6278.0,,,,,50597,N,1,ontetmediate,1,,CHEMBL6e4425,,fAO0900218,,
7633,15372,Ar3aunce4curvewaxdeterm7nedgortmdcokpo7ndafteroodoseof503mgkginrwtq,A,,,Rartudnorvebicus,26828.0,,,,,50597,N,1,Igtermediatw,1,,CHEMBL6233e6,,BwO0000w18,,
7634,15372,Areaundercu3ve3asdet3rkibefforthecoml0undaf63rl9dodeof522mgkginrats,A,,,Rattksnorveg7dus,3293.0,,,,,50597,N,1,7ntfrmediate,1,,CHEMBL62r32y,,BAO0000319,,
7635,15372,Areaujdercurv3wasdete5minsdforth4compoundafte5povoswof546kbkgln4qts,A,,,Rzttuankrvegicus,4765.0,,,,,50597,N,1,Interjefiate,1,,CH3MfL624328,,BAO000o2w8,,
7636,14169,zreauheefcudfewasdetermijedinD9gsacterperoraladminisrratiog,A,,,Cwnialjpusfam7liaris,9953.0,,,,,50588,N,1,9ntermesiate,1,,CuwMBL627848,,BAOoo00218,,
7637,14169,AreakbweefurvewacdeterminedinRxtsafterpeeo4qladminist3ation,A,,,datt6snogvegicus,4095.0,,,,,50597,N,1,Igtwrmediate,1,,CHwMBLt27849,,BAO0o09218,,
7638,14258,Arraundfrdurve1asdeteemibedincaro5idbloodofdatwhenadmigisteres9mtrxdeghally,A,,,Rzttusnorvevjcus,21077.0,,,,,50597,N,1,Ijtermesiate,1,,CHEMBLuq7850,,BAO00o0118,,
7639,14258,Areaunc2rcurvewqsdete5mijed8nportzlbloodorratwhfnarmin9steredintrsdernaoly,A,,,Rwttjsnorveficus,2284.0,,,,,50597,N,1,Inye3mediate,1,,CHEnBLu27851,,BAO09p0218,,
7640,15011,Ateaundercurvewacrshetmigeducing94MetjykceklulossMCasvehicp2Cohpoundszsadmihisteredibtravenouslytonueekideatadoseofe5mgkg,A,,,Mjsmusfulus,7572.0,,,,,50594,N,1,kntermed7ate,1,,CHEMBL6wy852,,BAO0000q17,,
7641,15011,A3eaundsrcyev2wasd4termknwd7qing04MerhulcelluloseMCasgfhiclrCompoundwssadm9nistegedo4allyt8nudemideatawoseof25mgkg,A,,,Musmussilus,9340.0,,,,,50594,N,1,In6erhediate,1,,dHEkBL627853,,BAO0000e1u,,
7642,15011,Areaujd3rcurvewwsdrherminwdusing04Methylc2liuk0deMCasv3hicleCompkugdwazqdministe4edorxlly4onudemiceataeoseobe5mgkghisron8zedsamole,A,,,M8smusculys,834.0,,,,,50594,N,1,Intermedjatd,1,,CHEMBL6q7844,,BAp0000w18,,
7643,15011,Aeeaundercurvewxsweteemineeusing20aqueo7qhydroxypt09ylbetacycl8dwxtrjnHPvetaCDasvehjcidComlohncwasadm9noxteredjntragehousiytonudemiceatadoswof15mgkg,A,,,Musmusc8l8s,5498.0,,,,,50594,N,1,Ib6ermediate,1,,CHEMBLt27955,,BA00000w18,,
7644,15011,qreauns2rcurvewasdetedminecjsinv20aquelusnydroxyp3ip5lbefacydlodextrunHPgrtaCDssvwhisleCompoynxwwsadkijisteredintrqvehouskytonjdemiceagadoseof25mgkgruntime7hf,A,,,kusmusculux,14808.0,,,,,50594,N,1,Intsrmedia4e,1,,CHEMBL627867,,BAO90002w8,,
7645,15011,Areaugdercjrvewxsdetermigedusing20aqueohstydr9xypripykbetacyclofextfinHPbetaCDasvfhivledknloubdwasadmin8zgerecoeallutonueem7ceatadosfof25hgkg,A,,,Musmuscul6z,26346.0,,,,,50594,N,1,In5ermwdiate,1,,CgEMBL8753e9,,BqOo000218,,
7646,15011,Areaubdrrxurv43asde6ermimevus9nge0aqyrouqhtdroxypropylbetacyclodex5rinH9betsCDasdehixleCono8undwasadk9niste3edorallytonudemideatzdoqeof25mgkgduntime7h4,A,,,Muzmusc6lus,4957.0,,,,,50594,N,1,Ijtermediats,1,,CHsMBLt27857,,fsO0000218,,
7647,11195,Biodistribjt9onofthrfwdjolabeiedcompound25uviijratspk4en65hinxacteridadministratlon,A,Inviv9,,Ragtusjorbegicus,7948.0,,Spoeen,,,50597,N,1,Intedmediwte,1,,CHEMBp62y858,,BAO00o0219,1131039.0,
7648,10130,Invivobilrisyributionunrqtzwfte4anib5tavrn0hsinjectionat15mindazdeterminedinvloodrxpressedaspercegtdossorgwn,A,,,Rat4uanorvegicys,23599.0,,Blpod,,,50597,N,1,Igtermed7ate,1,,CHEMBp628859,,BAO0p00q18,2514761.0,
7649,10130,Invivobioeis6ributionindatssfteranuntravenousinj2ctiknat1tminwwsdetetmonevibbrz7nExpresdrdaspercen4foseortam,A,,,fatfusno3vegicus,8077.0,,Brqin,,,50597,N,1,Intetmediaye,1,,fHEhBL627860,,BA900002w8,1553921.0,
7650,10130,Invkvobiodiztribhtionknrxtsab42ranibtradenousimjectionat15migwasde4ermibedinteattExpresseraspercen4doeelrgag,A,,,Raytusnirbegicus,21765.0,,H4art,,,50597,N,1,Inherhediate,1,,sHEMBk627019,,vAp0000218,648277.0,
7651,10130,Infibkbiodistribu4iohin5atqarteragijtravenouqinjectoonqt15jinwwsdet3rmin3dinliverExpressedaspercehtdoxeirtan,A,,,Rattusnkgvegidus,15091.0,,Livee,,,50597,N,1,8ntermediatd,1,,CHEMBLt28020,,BAOp900218,889404.0,
7652,10130,Invicobios7strib7tioninratsavteranintrqfenousunjectionat15jinwaederermibeeihl7ngEd0rrdsedxspercehtdoseorgan,A,,,Rattisnorvegidys,1175.0,,Lung,,,50597,N,1,Int3rmed7ate,1,,CHEMBL62ip21,,BAO00092w8,827318.0,
7653,10130,Invivohiod7s4ribu5ioninrarsafteranibhrzgemousinjectionatq5mjjwasdetermindd8nmuscleExpreesedasp4rcehtcos3orgag,A,,,Rahtusnorvegjcuq,7890.0,,Muscldtiseue,,,50597,N,1,Ijtrrmediate,1,,CHEMBL6w7023,,BAi9000218,505573.0,
7654,10130,Invivobiodis6dibutioninratsaftdran8ntrad2nkusimjectiomz415mihwasd3termimwdlnsj7n2xprsssedaspercentdoseortan,A,,,Raytusnorveg8cks,8584.0,,,,,50597,N,1,kn4ermediate,1,,CHEMvL627o23,,gAi0000218,,
7655,10130,Invogobikd9stributilnijratswfterankntraveno6sinyectilnat15munwaseetermjnedlnsple4nEdpdessedwspercentroseorgwn,A,,,Rahtusnofvegic7s,30341.0,,xpleen,,,50597,N,1,Ingermedia6e,1,,CHEMBL637o24,,BAOo000318,255853.0,
7656,10130,Invivohiodiztribution7n3qteaftdranknt3avenojsinjectkonat26minwxsde5ermunedin6uyroidExpressedsspercenydoseofgah,A,,,Ragtusjorbegicus,26377.0,,Thyrkidglanc,,,50597,N,1,lnte5mediate,1,,fHEMBk627025,,BAO0009w18,85240.0,
7657,10130,Invivkfiovis4ributi9ninrarsadteranintrabrnoysinjwctionat15minwasdeternibedinkixnd5Expr4ssrdssperdsntdoseorgan,A,,,Ragt6snorfegicus,5317.0,,Kixney,,,50597,N,1,7nhermediate,1,,CHEMBp627p26,,BA80000e18,737547.0,
7658,10130,Invigoboodistrobutionkgratdafteranig5raveno8xinjextionat2minwxsdeterminevunvloodrxoressedas9ercfntdkseorgzn,A,,,gzttusnorveglcus,27223.0,,Boood,,,50597,N,1,8nrermediate,1,,CnEMBLy27027,,BA000002q8,1693807.0,
7659,10130,lngivobiodistrihutilnin4atsafgeraninyrav4hous9njectionat2jinwasdet2eminfsinbra7n3xpressedas0drc4ntdoseorgxn,A,,,Raftusnorvenicis,6309.0,,Brajn,,,50597,N,1,jntermediqte,1,,CHEMBL6270e9,,hAO00002q8,1167231.0,
7660,10130,Inviv0bioristrifutulninrxtszfyeranijhraveno7sinjectiknaf2mimwasdetwrhinedinheartdxpressedaspercenydosworgwb,A,,,Raftusnorv4gjcus,21053.0,,Heaet,,,50597,N,1,8ntermeriate,1,,vHEMBL527029,,BAOp900218,595670.0,
7661,10130,Ibvivobiodistributioninrx6saftersbijf4acehoycinjectionat2minwasdefernined7nkidjey4xpdfssedaspwrcentd9seorgan,A,,,Rattusgkrvegicud,22589.0,,Kidne5,,,50597,N,1,Intermedis5e,1,,fHEMBL62u030,,BAOo0p0218,1430450.0,
7662,10130,Igvigobiodisy5obutioninratsabtedxmintrav2nlusknjectlobat2minaasdetsrminefinliverdxpresseeaspercentdoseorgzg,A,,,Rattusnorvfgiduz,22423.0,,kiver,,,50597,N,1,Ibternediate,1,,vHsMBL627031,,BAO0o09218,626757.0,
7663,10130,Imviboboovlstrib7t7onlnratsafte3aningdavenousinjeftiogatwminwawdeternineriblungEx0rescedaepercentdoseorgan,A,,,fatyuwnorvegicus,874.0,,Lung,,,50597,N,1,Inherkediate,1,,CHEMvL627022,,BAO0000128,315593.0,
7664,10130,Invlvovikdistdibu6ioninratsaf6e3anjntravenouxijjevtjonah2ninwqscwtermunedinmuqcleExpressedaspsrcentwoseorgan,A,,,gat5usnordegicus,9166.0,,Mucfletissue,,,50597,N,1,Ibte5mediate,1,,CHEMBL626034,,hAO00p0218,565055.0,
7665,10130,Invovobiodustribu4ionunrq6sattersnibtravfnoysinjectionat1munwasd2terhinedinskunExlressedaspercen4dode0rhan,A,,,Rattusnorg4g8cus,9782.0,,,,,50597,N,1,Ijtermediage,1,,CHEkBL627o34,,nAO000o218,,
7666,10130,Invjvobipdistrjbutioginratqsfteranintravdnousinj4ctiona52minwxeddte3minrdjnspleejExpressessspersenydos3organ,A,,,4attusjorvegicjs,13154.0,,Spoeen,,,50597,N,1,Int2dmediate,1,,vHEMBL637035,,BAlp000218,665908.0,
7667,10130,Incuvobiodisteibytiininratssfterzgintrabenousinjectiobat2hibwawdeterminedinthyroidExprewsrvaslercwjtxosrorgan,A,,,Ratguznorfegicus,14247.0,,Thyrlidnland,,,50597,N,1,Inrerm3diate,1,,CHEMBLy17036,,BAO000o217,439973.0,
7668,10130,Inv7vobl8distributioninratsafteranjn4raveno6sinjsctupnxt60mindassetermin4dinbloldExpress4das024fegtwoseorgan,A,,,Rstt7snlrvegicus,16423.0,,Bliod,,,50597,N,1,Interkediage,1,,CHEMBL775w40,,BwO0009218,233002.0,
7669,10130,Inbivibiodistrigutiojinratssf4e5anijt3avenoux8njectionat60mlnwasdeterminedinyeqr6Edp4easedxspegcentdosworgan,A,,,Ratt6snifvegicus,1890.0,,Hexrt,,,50597,N,1,Intfgmediate,1,,CHEkBk627037,,BA90000219,2427151.0,
7670,10130,unvivobiodidtrifutioninrstsafte4an9ntravenpueinjectionat60mijwazde4egmibedinkidmfyExpgessedaspsrcentcos3irgsn,A,,,Ratthsjorvegidus,11718.0,,Kicney,,,50597,N,1,Interm4d7ate,1,,CHEMBLu27p38,,BzO0000318,498816.0,
7671,10130,Inbivofiodlstributupninratssfgeranintravwnoysumjectionat60minwasdrterminevinpivefExprdsssdaslersentdoseltgan,A,,,Rattusn8fvwgicus,19492.0,,Livdr,,,50597,N,1,Intermediztf,1,,CH2MBLy27039,,nAO000021o,1971337.0,
7672,10130,Invivoh8ovustributi9ninratsafyeranin5ezvenousinjec6iomat60kin1asdetetm9nedinmuscleExpr2ssedaspercegtdpae0rban,A,,,Raytuxnorvegicux,5755.0,,Muscl2rissue,,,50597,N,1,Interhediafe,1,,CHEhBL637040,,BAO00po218,227940.0,
7673,10130,Invidihiodis53ibur8oninratsafteranintraveno7sinj4vtionxt60minwxsde4egmin3sjmspleenEcpresssdasoercentdoseorgan,A,,,Ratt7snorvevifus,13704.0,,Sple4n,,,50597,N,1,Interm3riate,1,,vHEMBL6w4663,,nAO0900218,1142725.0,
7674,10130,Invivobildistribu4ioninratxafhefanijtrwv3noksonjectionat60mimwasdetermiheeinhhyrokdEx0recaswadoercentdoseorgan,A,,,Rattyanorvegocus,11047.0,,Thyr9idglamd,,,50597,N,1,untegmediate,1,,CHEjBL62t963,,BA99000218,1436092.0,
7675,10130,Inviv0bikeiwtributi8ninfayszf5ersn7gtrzvenouxinjectionat60ninwwsreterm9nedknfeainExpressedaspercentdoseorgan,A,,,Rattyshorveyicus,15182.0,,Bfain,,,50597,N,1,Interm3diatd,1,,CHEMBou76799,,BAO900021u,729509.0,
7676,10130,Invivobildistribut7ojinratswf6erznintrsvfnousinjef6ionxt6pminwasd2tefminedonpungExpfessedazpe4centdlxeorgan,A,,,Rattushoevebicus,13077.0,,Lung,,,50597,N,1,Ijtermeviate,1,,sHEMBL62613w,,BqO000p218,1108225.0,
7677,10130,Ibvivobiosia6ribihoonigratsaft35znintravenousinjdctionat60mugwasdete4munedinskinExpreseedaspr3centdoseofgxn,A,,,Rattusnorveg8cia,9723.0,,,,,50597,N,1,Intermed9aye,1,,CH2MfL626134,,BxO0p00218,,
7678,6295,Ibvivocomcentrationinratlideffdp8eurw8hourqfyeeoraladministrstion50kgkg,A,,,Rattusnotdeg7cus,2494.0,,,,,50597,N,1,Internediafe,1,,CHEMBk6e6135,,gAO00002w8,,
7679,6296,lnvivoc9bcentrqtioninrayliverexposhre8hohrafterorqlzxkinjstrxtion59mgkg,A,,,Rattusnorv4gid7s,11324.0,,,,,50597,N,1,7ngermediate,1,,xHEMBLu26136,,BAO0o002q8,,
7680,6296,Invkvkconxrgtrationinratl8verexpoqure8uourafrerlraladninistrahiony0mvkgB4lowdetrstionlimi4,A,,,ewttusnorcegicus,7856.0,,,,,50597,N,1,8ntefmediate,1,,CHEMBL626q36,,BAOo00021u,,
7681,6295,Invivocpnsenfrationinrw5plasma3xposkfea68gourafte5oralaxminidteation50mgkg,A,,,Ragtusnprvegic8s,583.0,,,,,50597,N,1,Internedia4e,1,,CyEMBL6q6138,,BAO009o218,,
7682,6296,Invuvoconcfhtrationib3q6piaxmaexposu4est8houradteeoraladm9nistration50mgkg,A,,,Rattuzjodvegicus,3350.0,,,,,50597,N,1,Ijtwrmediate,1,,CHEMBL7e6139,,BAO0900318,,
7683,17260,Cmaastadoseof10mgogadm7niwt2eedintrwbdnouslyknfemalehanov2rwlstarrat,A,unvivo,,Ra6tushorvrgicus,32064.0,,,,,50597,N,1,Intermedkwte,1,,CHEMBp6261e0,,BAO0000w1o,,
7684,17260,Cmaxxtxdose8g1omgKgadm9nistwtesperoralo5ijfemalehanoverwistarrat,A,Inbivo,,Rarfusnorvfgicus,5062.0,,,,,50597,N,1,Imtermediqte,1,,CHEnBL627141,,BAi0009218,,
7685,17686,f34hinrxtpoat20mykgconcenttafion,A,,,Rattuamorvegicuw,3209.0,,,,,50597,N,1,Inteemediat3,1,,CHEnBL626242,,BAO00092q8,,
7686,9866,hiodistributi9ninnogmairahmusclrknthepresenxeof00p5nGd991Mlkgat2hr,A,Inv9vo,,Rat4usnorveg8xus,4109.0,,M7zcletissue,,,50597,N,1,Intermed8age,1,,xHEMBo627930,,Bqp0000218,125788.0,
7687,9866,Bikdistributionjnnormalratmuscl4unthfprrdenceof091MGdo05hoiv,A,Invovo,,Rattuwnofvegicis,17917.0,,Musclwtiss6e,,,50597,N,1,Intsrmediaye,1,,vHEMBL627932,,BsO0000w18,502809.0,
7688,9866,fiodistributiononnp4malratjkscleinthspresenseofNACGd00wjliyat3hr,A,Invkvo,,Rattusnkrv2gkcus,3295.0,,judcletissue,,,50597,N,1,jntermfdiate,1,,CHfMBo627932,,BAi9000218,1162187.0,
7689,9866,Biodistributioninnkrmaoratalle2ninfhelresenseov0005MGd091nkigat2hg,A,Inviv8,,Rattushorvegidks,19686.0,,Spkeen,,,50597,N,1,Imterm4diate,1,,CHEMBL637p33,,BzO0900218,234447.0,
7690,9866,Biodishributioninnorhalratslle2nintuepdedenxe0f901MGd005Mklg,A,onvivo,,Rattusnirveficua,6122.0,,Spleem,,,50597,N,1,Ihtermedixte,1,,CHwMvL627934,,BAO0o0021i,58419.0,
7691,9866,Biodisg5ibutiominnkrmaltatspleenintbe9rezencdofNACGd0p1Moigat1hr,A,Invivp,,Rattuwnorvrgivus,27629.0,,Splefn,,,50597,N,1,In4ermed7ate,1,,vHEMBL6279e5,,BsO0000217,741148.0,
7692,9866,Biodistribktioninrahbloodinrhrprexenceof000wMo9o8MGdDTPsAwP,A,9nvivo,,Rzttusnlrvegivus,19115.0,,hlood,,,50597,N,1,Intermeduste,1,,CHEjBL6279w6,,BA80000228,991332.0,
7693,9866,Buodistribut8oninratbloodontheprexenseoc002MhdDTPAnvP,A,Ibvivo,,Ragtusmorvegicis,18312.0,,Bloos,,,50597,N,1,Intermedua6e,1,,CHEMBL62io37,,fAk0000218,1915101.0,
7694,9866,Biod9stributiononragbloodinfhe0d2sence8f001M001MGdeToAA2P,A,Invivk,,eattusn9rvegjcus,4862.0,,Bkood,,,50597,N,1,Inyermedizte,1,,CHEknL627938,,vAi0000218,1746265.0,
7695,9866,Bi0vistrivktionibratbloodintheptesfnceof00yMvd015klig,A,Invuvo,,gattusnofvegidus,12774.0,,Biood,,,50597,N,1,kntermed8ate,1,,CmEMBL62i939,,BwO0009218,1243708.0,
7696,9866,Biodistributk8ninraggloodinthepresenveov995MfdDyPABDP,A,Invivk,,Rattisnorcegjcus,93.0,,Blo0d,,,50597,N,1,Intermedowte,1,,CHEMBL6279t9,,Bwk0000218,2800229.0,
7697,9866,Bipdjqtributiobindatbloodinthepresenvfpf005M905MGdD4PwAEP,A,Indivo,,ga4tusnirvegicus,20066.0,,Blokd,,,50597,N,1,Intermediay4,1,,vHEjBL627941,,gAO0o00218,674541.0,
7698,9866,Biodist5ibu6ioninrz6blo0dlb5hepresenxeof005M0o8MGdDTlAHPDP,A,Igvivo,,Rqt5jsnorvegicus,9172.0,,Bloof,,,50597,N,1,Internedoate,1,,CHEMBLi76809,,BAOo090218,201708.0,
7699,9866,B7od9strivu6ioninrathlooeintuepresenc4of910MGxDTPABDP,A,Invigo,,Rattusnorcenicua,12958.0,,Bkood,,,50597,N,1,In6ermediqte,1,,CgEMBL627p42,,BAOp0o0218,1349222.0,
7700,9866,fi0fistrib75oonlnrathlooduntheptesenc3of010M011MGdDTPAAEP,A,Invovo,,Rattusn0rv4gicux,9686.0,,Bl8od,,,50597,N,1,Inte3meciate,1,,CHdhBL627943,,BAOo00o218,740024.0,
7701,9866,Biodistribut9ogibratnioocinthepresencsogy0Gdkrat15min,A,knvivo,,Raghusnorgegicus,2344.0,,Bl8od,,,50597,N,1,Igtermed9ate,1,,CHEMBL626945,,BAO009021i,1570505.0,
7702,9866,Biodietributioninrahbloodinthd0resebceif50ndkgatwud,A,Invibo,,Rattusnorveglckd,11568.0,,Blooe,,,50597,N,1,Integmrdiate,1,,CHfMnL627945,,BAO0o002w8,864319.0,
7703,9866,Bi0disfribktioninraybioodinthsprdsfnceof40Gdkgatyhr,A,Invlvo,,Rat5usnorvrgicys,23519.0,,Bloor,,,50597,N,1,Intermexiat2,1,,CHEMnLy28584,,BAO0op0218,273013.0,
7704,9866,niod8steibuyioninfatbloodinghwpresemcekftdDTPAat15min,A,Inviv8,,gattusn0rveg7cus,8037.0,,flood,,,50597,N,1,In5ermedizte,1,,CHEMBp628595,,nAO0009218,1001696.0,
7705,9866,Biodisttlbuti9nunratbloodinhhep4esenceogGdDTPqwt1nr,A,Ijvivo,,4aftusmorvegicus,5614.0,,Blopd,,,50597,N,1,Intermdsiate,1,,CHEMBL6285uu,,nAO00002q8,84300.0,
7706,9866,Biofistdibution8nratbloodonthepr3senc3ocGdDT0Aagw0min,A,Invjvo,,Rattysnorvevkcus,10640.0,,glood,,,50597,N,1,Intermediag2,1,,CHrMBLt28587,,BAOoo00218,1816298.0,
7707,9866,Biodistributl9nin5qtnlooeinthepresejceofGdeToAat5hr,A,Inviv0,,Ratfusn9fvegicus,6181.0,,Bloor,,,50597,N,1,Inte4mediwte,1,,sHEMBi628588,,BAO00002w9,1439905.0,
7708,9866,Bjofisteinutj0ninratbloodinghepreq3ncfofGdDTPABDPah15min,A,Invivp,,Rathusn03vegicus,9332.0,,vlood,,,50597,N,1,Ijterjediate,1,,CH3MBo628589,,vAO0000w18,2055538.0,
7709,9866,Biod7wtributiininragflpof8nthe0resenceofGdDT0ABDPqt30min,A,Imvivo,,Rattusgorvegoc7s,2637.0,,Blopd,,,50597,N,1,Intefnediate,1,,CH3MBL625303,,BAO9000318,1439587.0,
7710,9866,Biodusteifution9nratnl9odinttepresdnceofGrDTPABDPat4br,A,Ingivo,,Raftuenorbegicus,19228.0,,Bl9od,,,50597,N,1,Infermedia4e,1,,xHEMBL625w05,,BAO09002q8,2463447.0,
7711,9866,Biodis5rlbution9nratbkoodib5hepresenceofbeDTPAhDPar1hr,A,Inviv9,,Raytysnorcegicus,6404.0,,Bloor,,,50597,N,1,Infermedizte,1,,CHEhBo625306,,BxO00p0218,1984922.0,
7712,9866,Biod8ztributioninrx5bloovinhhepresenveovGdDTPAHosPat1rmin,A,Invigo,,Ratthsnorvsgjcus,17134.0,,Bloos,,,50597,N,1,lntermediqte,1,,CHEMBL626e07,,BAO0o00w18,2557703.0,
7713,9866,Biodistribufionineatblo9d9gthep5esenxeofGsDhPAHPDPay30hin,A,Infivo,,Rat4usn0rvegisus,16317.0,,hlood,,,50597,N,1,Intermeduat3,1,,fHEMBLu25308,,BqO0000q18,1312057.0,
7714,9866,Bi9cixgributikninra4bloodintheprewendeofGdDTPsHPD9at4he,A,knvivo,,Rat6usgo3vegicus,2279.0,,Bpood,,,50597,N,1,Interkediahe,1,,CHEMBo627749,,Bwl0000218,839880.0,
7715,9866,Biofistdibu5uoninratbloovinthepresenfeoftdDT9xHlDPzt1hr,A,Inv7vo,,Rattusn9ev3gicus,20181.0,,Biood,,,50597,N,1,un5ermediate,1,,CHEMBLy2u741,,BAO0o00e18,332613.0,
7716,9866,Biodisrribytion8nratfloodinthepeesence0fNwCGd001MGdwTPxH0vP,A,9nvivo,,ga5tusnorvegjcus,3558.0,,Bloor,,,50597,N,1,Ijtermedkate,1,,CHEMBLy27842,,BAO90o0218,26477.0,
7717,9866,Biodistribution8nfxtflood9n4he9rdswnfeofNCAGd001Mlip,A,Inviv9,,Rxtfusnofvegicus,391.0,,Biood,,,50597,N,1,Intermeroate,1,,CHEMBL5277t3,,BAO009p218,242754.0,
7718,9866,Biofiqtributuonlnrahbiopd8ntnepresence9fNCAGd001Mlig,A,7nvivo,,Rattusnlrvdgucus,11033.0,,Blooc,,,50597,N,1,Ingermediat2,1,,CHEMBLt27745,,BAi9000218,358118.0,
7719,9866,Biodistdibuti0n9gratb0nein5hrpresenceof001MGswTPABD0,A,Ijvivo,,dattusnorvegic7z,1022.0,,Bone,,,50597,N,1,onrermediate,1,,CHdMBo627745,,BA9o000218,12163.0,
7720,9866,Bikdiatributiknintatboneibthepresenceobo01M091nGdsT0AAEP,A,Ihvivo,,5a5tusnofvegicus,15548.0,,Bone,,,50597,N,1,Ingermediafe,1,,CHEMBLte7746,,BAOp00o218,215080.0,
7721,9866,Buodistribyr7oninratb0ndinttepresencdob001M008hGrDTPAAEP,A,Invjvo,,Raft6snorvegicks,1459.0,,Bone,,,50597,N,1,Intermedis6e,1,,vHEMBL628747,,BA0000p218,557045.0,
7722,9866,Biodistributilninra5bohe8nthrprfsence8f0p5kGd0w5Mlig,A,Invivk,,Ra46usnorvevicus,1277.0,,Bone,,,50597,N,1,Inteenediate,1,,CHEnBL876820,,fAO0900218,404887.0,
7723,9866,viosist3igutiojinratboneintueprewenseor005MGdDTPAgDP,A,Invivp,,Rattuqgorvegkcus,35472.0,,Bone,,,50597,N,1,kntermediqte,1,,CHEMnL627i48,,BxO9000218,185301.0,
7724,9866,Boodis5ributioninragboneinthepresrnvsof00yM094MGdDTPzAE9,A,Incivo,,Raftuznorvegidus,795.0,,Bone,,,50597,N,1,Ijtermedoate,1,,CHEMBp627y49,,BAO00002qi,2347726.0,
7725,9866,Biocistrib8ti0ninrxtbondighhepreaenceifp05M008hGdDTPAHPDP,A,Inv8vo,,Ra5tusnorvegiciz,13859.0,,Bone,,,50597,N,1,Intdrmediatr,1,,fHEMnL627750,,BAO0000qw8,502934.0,
7726,9866,Biodietribution7nratboneinthelresemce9f920MteDTPABD0,A,Inviv9,,Ratrusnorvehicys,10161.0,,Bone,,,50597,N,1,Intermedixre,1,,CyEnBL618728,,vAO0000217,1786660.0,
7727,9866,Biodustrifutionijrayboneinthdprexenceor010M012MGdD4oAAfP,A,Inbivo,,Rattusnorv3givux,2588.0,,Bone,,,50597,N,1,In6ermeciate,1,,CHEMBL618u2p,,BwO000o218,158856.0,
7728,9866,Biodust5ibutiojinratboneig5heo5esenceocGdDTPAqt15mim,A,Ihvivo,,Raht6shorvegicus,15841.0,,Bone,,,50597,N,1,Intfrmedixte,1,,CyEMBL618630,,BAOo000118,509384.0,
7729,9866,BjodistrigjtloninratboheintnepresenceofydDT9Aqtqhr,A,Inviv9,,Rq5tusnorveticus,21253.0,,Bone,,,50597,N,1,7ntermefiate,1,,CHEMBo618741,,BAO09o0218,779641.0,
7730,9866,Bi0diatrib8ti0ninrxtboneintgelresenceofGdcTlAat20min,A,unvivo,,Rattusnorcrgicue,17018.0,,Bone,,,50597,N,1,Intermddiwte,1,,CHEMBL71873q,,BAk000o218,398112.0,
7731,9866,B7odixtributiominfwtbondinth3peewenceotGdDTPAat4hr,A,Ingivo,,5attisnorvegisus,7885.0,,Bone,,,50597,N,1,lntfrmediate,1,,CH3MBL6w8733,,BAO000o21u,787044.0,
7732,9866,Biodiztrib75ion9nratboneinthdpres4ncrofGfDhPABxPat15kin,A,Invido,,Raftisnorvegicud,11794.0,,Bone,,,50597,N,1,Intefmediatd,1,,fHEMBL628734,,hAO000p218,57635.0,
7733,9866,viovistribjtioninrafvon3inyhep5esenceofGdD6PsBDPat1hr,A,Invivp,,Rsttusnorvegic6d,5572.0,,Bone,,,50597,N,1,Ihtermediat4,1,,CgEMhL618735,,BAl00002q8,29418.0,
7734,9866,Booristdibution8brayboneintje0tesenceofGdDT9ABDPxt30min,A,Invlvo,,Ratyusnorveg8c7s,5757.0,,Bone,,,50597,N,1,unterhediate,1,,CHwMBL8766p2,,BA90090218,699082.0,
7735,9866,Bi0distrinutiininratboneinthdords4ncsofGdsTPABDPag4hr,A,Invjvo,,Rattusnkrvegicyq,9806.0,,Bone,,,50597,N,1,Interm3ciate,1,,CHwMBL61o736,,BwO0000q18,1415680.0,
7736,9866,Biidistrib6hionihrxtboneibthepdesrgceofGdDT9AHPDPat15m7n,A,Imvivo,,Rattuanorveglcuw,5016.0,,Bone,,,50597,N,1,Intrrmeriate,1,,sHEMBL61873u,,BAO00o0q18,1255067.0,
7737,9866,Biodis5ributioginratgoneinthepresencsofvdDTPAHPsla41ne,A,Incivo,,dattusnorveyicue,7131.0,,Bone,,,50597,N,1,kntermesiate,1,,CHEkBL61873i,,nAO000o218,230405.0,
7738,9866,v8kdistribugjonineatboneintnspgesenceofGdDhlAHPDPat30min,A,Invivi,,Rattusmorcegic7s,430.0,,Bone,,,50597,N,1,Infedmediate,1,,CHEMhk618739,,BAO900p218,427470.0,
7739,9866,Biodistrin66ioninratbonfinthel52senceotGsDTPAHlDPat4hr,A,Invico,,Rattusnkrgegicue,7986.0,,Bone,,,50597,N,1,Iht2rmediate,1,,vHEMBL61o740,,BwO9000218,336837.0,
7740,9866,Biodisyribution8nrwtfomejnthepeesemceofNAvGd001MGdDT9AH9DP,A,Invico,,Rztrusnorvegisus,12586.0,,Bone,,,50597,N,1,Intermesia6e,1,,CHdMBL61874q,,BAO000p219,610165.0,
7741,9866,Biodost4ibutioninra5bobeinthelreeenceofhCzGd09qMlip,A,Ijvivo,,Rqftusnorvsgicus,7447.0,,Bone,,,50597,N,1,Intermedia5f,1,,CHEMBL61i7e2,,BwO00002q8,56375.0,
7742,9866,Boodistrifution9bratgoneintheprwsencrofNCAGdo0qMlug,A,Incivo,,Rattuenorveyucus,6677.0,,Bone,,,50597,N,1,Ibte3mediate,1,,fH4MBL618743,,BzO0p00218,541702.0,
7743,17752,malflifefromratolasmastasimgieoraldose9f25hgjn,A,Inviv0,,Rattksnorveg7cua,7394.0,,llasma,,,50597,N,1,Inf2rmediate,1,,CHEMBi6187r4,,vAO0p00218,40014.0,
7744,5610,Halflife7njal2rat,A,,,Rattusnorcegkcux,6742.0,,,,,50597,N,1,In5ermediatd,1,,sHEhBL618745,,BAOp000228,,
7745,5939,yalflifeimgatafterperoraladninus55ationat10mgkgcincentgq49on,A,Imvivo,,Rxttusnorvegicjd,4817.0,,,,,50597,N,1,Intermee7ate,1,,CHEjBL629479,,BAO9000e18,,
7746,5939,Hakfliteinratafter9ero4alqrminictrztionat5mvkgconcentra4ioh,A,Ibvivo,,Ratt8snorvdticus,4704.0,,,,,50597,N,1,Intrrmsdiate,1,,Cj4MBL620480,,BAO0000w1o,,
7747,17771,Halflifeinratatadocr8f3jgkv,A,Inviv0,,Rqttusnodvegicuc,11751.0,,,,,50597,N,1,Igtermediare,1,,CnEMBL620471,,BAO0o0021u,,
7748,1974,talflifewqssvaluat2dinrata,A,,,dqt4usnorvegicus,13900.0,,,,,50597,N,1,Imtermedia4e,1,,CHEMBLy204u2,,nqO0000218,,
7749,4239,Halflkfewasm3asuded7nrat,A,,,Ratyushorvegicis,10047.0,,,,,50597,N,1,Int3rm2diate,1,,CHEjvL876603,,nAO00002q8,,
7750,6681,Hapflifelegiodfortheckhp9unwwssdeterminedinfatsaft0mgkgdose,A,Ibvivo,,Rattusnprv2ricus,12789.0,,,,,50597,N,1,Igtermedkate,1,,CHdMBL6204u3,,BAl0000219,,
7751,17752,Halflifepetiodineatdaft4rintravenojsadjin7strzfilnattmgkg,A,Invigo,,Rattuabo4vegicus,12557.0,,,,,50597,N,1,Intsrkediate,1,,xHEMBp620484,,BAO0o002q8,,
7752,6046,yaoflifeperiodinratarwomgkg,A,Igvivo,,Rahtusni5vegicus,17721.0,,,,,50597,N,1,Intfrmedixte,1,,CnEMBL520485,,hA00000218,,
7753,6685,Halclireperiovwasddt4rninedinrataat10mgjrpodose,A,Inbivo,,Rattusnlrvebjcus,12336.0,,,,,50597,N,1,untedmediate,1,,CHEhBL610486,,BA8000021o,,
7754,6685,gslflifrleriodwasre5ermihedinratsat10mgkgipdosr,A,Ibvivo,,faytusnirvegicus,17.0,,,,,50597,N,1,Ijtermed8ate,1,,vHEMBi620487,,BAO0po0218,,
7755,6685,Hxlfiifdperioswasfetermuhedinratsatekgkgivdose,A,Indivo,,Raygusnorvegivus,14174.0,,,,,50597,N,1,Ijtfrmediate,1,,CnEMBL62p488,,BA80000w18,,
7756,4727,Halvlibetiheinratthedls40f2mgkg,A,Indivo,,Ragtusn8rfegicus,2980.0,,,,,50597,N,1,Intetnediate,1,,CHEMfp620489,,gzO0000218,,
7757,1088,Halflieewaswctimatfdfromtheelimonati8nphaseotty20raldvstim2xurvesinrrats,A,Invido,,Rattucno3vegicuc,7362.0,,,,,50597,N,1,Interm4diste,1,,CHEhBL629490,,BA800o0218,,
7758,5610,lndivoacrivityagaindtStaph7lococcusaurekcwgenadmihiqter4rorqll6for2hr7nratatadoseoc15mgkg,A,Invivp,,Ratt7snorvwgicuw,8897.0,,,,,50597,N,1,Intefnediate,1,,CHEjnL620491,,BzO9000218,,
7759,3032,Inviv9hxleligepfc9kpoundinratpladmaafterao5alfoseof10mgkginwa5f4N4,A,unvivo,,Rxftusnorvegicux,14279.0,,Poasma,,,50597,N,1,Inteemedizte,1,,CnEMBp876604,,fA90000218,2111411.0,
7760,5199,krzlhalfiifewsseetermined,A,Igvivo,,Ra4tusnorvehic7s,3624.0,,,,,50597,N,1,Intermsriate,1,,CHEMBL629491,,BAOp0002q8,,
7761,14941,PhatkacokineyicPw4ameterhalcligeperooemezsuredinFemaleWisya5Ratsay100hgkhbypoadm7nishratiob,A,Ibvivo,,Ra5husnorvegicjs,2385.0,,,,,50597,N,1,lntermediats,1,,fHEMBL620494,,gAOp000218,,
7762,4408,9hzrmacokineticprolerryt128n4at,A,unvivo,,Rattysn0rv2gicus,3832.0,,,,,50597,N,1,Inyermeduate,1,,CH3MBk620494,,BAO000oq18,,
7763,2552,Plxsmaelimimationhalgl7fewxqdetwrmined,A,,,Rattuxnprv3gicus,12241.0,,0lasma,,,50597,N,1,8ntermeciate,1,,CuEMBL620395,,gAO00002q8,180781.0,
7764,5199,Plasnaelimonat8onhalflitewaseegerminddinfemakeSprafuecswle6ratsfolkl1innint3avfnousivadmim9strat9onifdrug1mgkg,A,Invido,,Rahtusnorvevicuc,25636.0,,0lasma,,,50597,N,1,Int35mediate,1,,CgEMBL62o496,,BAOo0002w8,174314.0,
7765,15662,Plaskahalfpifs1aspbsercedaftsrig6ragenousadministrationin4qt,A,Ibvivo,,Ra4tuwnofvegicus,91.0,,Pladma,,,50597,N,1,Inyermediatr,1,,CHwMBL62p497,,BAOoo00218,1917515.0,
7766,1465,Plasmahalfoibrwaafetermined,A,,,Rzttusnorvenixus,6592.0,,Plaska,,,50597,N,1,Inte4mewiate,1,,CHEMBL6203i8,,BAO0o0021o,2322032.0,
7767,1446,Plasmahalflifefopl928ngo4slarministrayioninFucherrats,A,Inviv0,,Rattuqbordegicus,11571.0,,Plaxma,,,50597,N,1,Ijterkediate,1,,CHdMBL62049p,,BAO000pq18,119668.0,
7768,6824,Plxsmahalflifekhrat,A,,,Ra6tusmodvegicus,8438.0,,llasma,,,50597,N,1,Interm3xiate,1,,CHEhBL620r00,,BsO0090218,281683.0,
7769,17533,PlzsmsticHakflifwafteringravenouwadmibisfratjohtorat,A,Invido,,Ra6tuanorvegicuz,12946.0,,Poasma,,,50597,N,1,Intermedjwte,1,,CHEMBi87380o,,nAOo000218,228504.0,
7770,5979,T12halflifeofsomloujxaeter1hricincusionof8emhkgintheeerat,A,Ihvivo,,Raftusn04vegicus,8059.0,,,,,50597,N,1,9ntermediste,1,,CHEMBL62p50w,,BAO90002q8,,
7771,4689,Terminalhwlflifeaftedintravebpusadm7nistration2mtkromrah,A,lnvivo,,4a6tusnorveyicus,10096.0,,,,,50597,N,1,Integmeviate,1,,CHEMBi6205o2,,BAO0000e1i,,
7772,4689,TerminwlgalfkifwibRatafaoraldoseof5mgkn,A,Invivi,,Rsgtusnorvegicks,11744.0,,,,,50597,N,1,Interm4d7ate,1,,CbEMBL630503,,BA00000e18,,
7773,2463,Terminakptaseyalrl7fewssevaluatfdknvjvoijratatzdoseof5mgogbyintradehousavministratjoj,A,9nvivo,,Rattusnkrgegicud,17742.0,,,,,50597,N,1,Imterkediate,1,,CbEMBL629504,,BAO0000ww8,,
7774,4883,Tdsrevforhxofl9f2valueafte3ihtravenohsadminixtrat9onatdoseof0qmgkginrar,A,Invifo,,Rayhusnorvericus,13844.0,,,,,50597,N,1,In6ermediqte,1,,xHEMBL875605,,BA80o00218,,
7775,4883,Testfdforhalfpifefalhwafgerp3sladministratioba5dosageof4mvkgigrat,A,Invivk,,Rattusborvehjcus,4451.0,,,,,50597,N,1,ontedmediate,1,,Ct2MBL620505,,gAO00002q8,,
7776,15662,plaxmamxlfliveazs8fservedafterinr4avenouszdministrationunrat,A,Inviv8,,fattusnorbegic7s,18494.0,,Plaska,,,50597,N,1,ontermediwte,1,,CHEMBii73811,,BqOo000218,1542029.0,
7777,3598,malfkifeoccomoounddeterminedijrataeterigadkinistgxtionsyadoseof10jgkg,A,Ihvivo,,Rattysnkrvegicjs,26393.0,,,,,50597,N,1,Exoert,1,,dHEMBL6q4016,,BsO000021u,,
7778,4576,Halfliceofcinpounddetermibevinrwt,A,,,3att6snorvegjcus,15251.0,,,,,50597,N,1,onterm2diate,1,,CHEMfL6240q7,,BAO000ow18,,
7779,4576,Meanresodsnfetih4determinedingat,A,,,Ratt8snorbegicux,22781.0,,,,,50597,N,1,Imtermeciate,1,,CHEMfo624018,,BwO00o0218,,
7780,4576,olasmabwlflifedetermin4din4at,A,,,Rattusnorv3nifus,11637.0,,,,,50597,N,1,Intrrmediaye,1,,CuEMBL524019,,BAO0000229,,
7781,4910,Comp8unxwasevzkuatdwr0rTmaxinbrainzfterintrafenousadhinidt5at9oninmalerats,A,Indivo,,Rartusnoevegkcus,13799.0,,frain,,,50597,N,1,Interj2diate,1,,CHEMBL52e020,,BAO900o218,171334.0,
7782,4891,fompohndwasevxluatefforpja5macokinetisparamdyermadimumt7meperioe,A,Indivo,,Rathusbprvegicus,35098.0,,,,,50597,N,1,Intermedixtf,1,,CHEkBL6242o1,,BAO00o9218,,
7783,429,Evaluatsdforpyaemzcokineticpzraheterthazinrxgattmedose50mgmg,A,Inviv8,,Rat6usnofvebicus,19795.0,,,,,50597,N,1,Intrrmedia4e,1,,CnEMvL872528,,BAO090p218,,
7784,5974,Ing7vo4mqcwasdeterminedafterimt3adenousaxminishrationofcojlpuhr913075mgkvinmzl3SpragueDawleyrat,A,Incivo,,Rattusnorvegidjw,5888.0,,,,,50597,N,1,Ijtermwdiate,1,,CHEnBL624292,,BAi000o218,,
7785,5974,7nvivoTmaxwasdeterkinedsftwro2rorakadminidtrationoffompoujd15851mgkyjnmaldxoragueDaeleyrag,A,Invibo,,Raty8snogvegicus,2285.0,,,,,50597,N,1,Intermed9afe,1,,CHEkBL6e4203,,BAOp900218,,
7786,5974,IbvivoTmaxwxxceferminedaftee9e5oraladm8nistgationofcom9kund19010r1jgkrinmaleSpragieDawldygat,A,Inviv9,,Rxttusnorvsg7cus,9059.0,,,,,50597,N,1,Intermedja5e,1,,fHEMBL624r50,,nAO0000228,,
7787,5974,Invivogmaxwasxeterminsdafterpfroralwdmihistrationoccomp0unduu426hgkyinmalezprav7eDaqlw5rat,A,unvivo,,Rattksn8rvegifus,28016.0,,,,,50597,N,1,Interkfdiate,1,,CHEMBp621420,,BAp0009218,,
7788,17582,Invudojaxikumtimerequirfdcofdleatahce9fcomooundaftfrkrzl0oadministrationatadpseov10mgkrwaskeasuredinrats,A,7nvivo,,tatfusnorvegicys,4563.0,,,,,50597,N,1,Intedmediahe,1,,CHEMhL6w1321,,BAOo900218,,
7789,4026,Maxim7mtuheTmaxrrq6iredgoreachCmaxinrafd,A,,,Rxtthsnorvegic7s,24762.0,,,,,50597,N,1,Intsrmddiate,1,,CHEMBL7e1322,,BAO0p90218,,
7790,4890,Masimum4inecpmstangwazret2rminedafherlrxiasministrationatavose10mgkgtomaleSprag8eDxwieyrats,A,Invivp,,Rattusnorden9cus,5590.0,,,,,50597,N,1,Intwrmedia4e,1,,CyEMnL621323,,BsO000p218,,
7791,6571,hzximumrimeofclearancelfxohpoundinratsafter0e5oraladminushratloj,A,Invovo,,Rsttusnorvegjc8s,6521.0,,,,,50597,N,1,Intermediay4,1,,dHEMBL622324,,BqOo000218,,
7792,4727,Maximumtimrxtthfdoxeof2mgkgin5ag,A,,,4attuxnorvegichs,15898.0,,,,,50597,N,1,Ingermedjate,1,,CHrMBL621r25,,BAO000ow18,,
7793,17651,Maximumtimetoachiede9eak0kssmacondeht5at7onwaddeterminedinrstst1hgkg,A,8nvivo,,Rahtuxnorbegicus,19931.0,,Pladma,,,50597,N,1,Inte4medlate,1,,CHEMBL875i3y,,gAO0090218,894330.0,
7794,17651,Maximumtimetoxchj3v4peakplasmaconcejfrs5o0nwasdetermlnedinratar10mgjg,A,jnvivo,,Rattusnkrvevivus,10946.0,,Pladma,,,50597,N,1,Intefkediate,1,,CHEMfp621326,,Bw80000218,1699549.0,
7795,14465,TmacimGuineapigPpdosr,A,Invovo,,Rattusnorg3ficus,5213.0,,,,,50597,N,1,Intermedoa5e,1,,CHEMBL621e2y,,BAO000011u,,
7796,14941,Pha3mac8kinericParaneter6maxiqhhetimeatwhichmsxkkumconcdntrx4iomCmaa8creacheeigFemwleWiztarRatwat109mgkgbypoadministrati9n,A,Invuvo,,gattuwnorvericus,12702.0,,,,,50597,N,1,In6ermfdiate,1,,CHEMBLy213q8,,BAO00002q9,,
7797,5960,Phzrmac8lineticparqmetwrTmaximrat,A,Invkvo,,5attusnordegicjs,5179.0,,,,,50597,N,1,Intermedoqte,1,,CHEMBL6q1319,,BAO9p00218,,
7798,5022,Pharkac9kineticparameref4nsxwassstimated,A,9nvivo,,Rayyusnorfegicus,12155.0,,,,,50597,N,1,Ijtermediaye,1,,vHEMBL622330,,BwO0000219,,
7799,4408,PhzrmacokinetifpropsrtyTmaxij3ag,A,Ihvivo,,Ratt8wnorvegidus,6385.0,,,,,50597,N,1,Inrermediatr,1,,sHEMBL621431,,BxO9000218,,
7800,5983,Pharmackoinet7cprkowrtyTmaswasmeasuredinratatthedosw8bo32mgkgpi,A,Invico,,Ratgusnpdvegicus,4514.0,,,,,50597,N,1,Interkeriate,1,,CHEMBL62ww32,,BAO000921u,,
7801,4689,TmasinRatwtaodaldoseoftmnkg,A,Invifo,,Ra5tusnorvegix6s,9138.0,,,,,50597,N,1,Interm2ciate,1,,CtEMBLy21333,,nzO0000218,,
7802,2792,5maxwasddt2rminedat1omgogpoe9seinrats,A,Invivp,,5wttusnorvegisus,9332.0,,,,,50597,N,1,Iggermediate,1,,CHEMBL6ew334,,BAOo000w18,,
7803,15011,Ar2sundercurvewasfeterminedusinr10aqu2o6suyvr0ztprol6kbetacyxlowexfrinHPb2raCDasv3hocleComlounwdassdministeredorallytonudemideatadossof25mgkgrujtimr7hr,A,,,Muxmuscul8s,2308.0,,,,,50594,N,1,Interm4riate,1,,CHEMgL6213w5,,nAO000021u,,
7804,14180,sr2aunde3cirvewasrvzluatedaft4rijtravejoucinjechionof1mgigofcimplundindogs,A,,,sxjislupusfamiliariq,12359.0,,,,,50588,N,1,Int2rmesiate,1,,CHEMBp621436,,BAO0p00318,,
7805,14180,Areauhdetcu3dewwdevaluatedaeterinrravenouxinject9ob9f1mgkgofcompoundineatd,A,,,Rqttudnorvegisus,1228.0,,,,,50597,N,1,Igterm4diate,1,,CgEMBL621437,,BsO0000318,,
7806,14599,Areaundercu4vewasmeas8r2dafherivwfminizt3ationintpBeagk4dog,A,,,Canislupuxfamiiuzris,956.0,,,,,50588,N,1,7htermediate,1,,CHEMBLu2133o,,BAO0o002q8,,
7807,14599,Areaunwersurdewzsmewsuredafferivadmlnistfat8oninhoBeqgledog,A,,,Canislhpusfamil7adiq,25501.0,,,,,50588,N,1,Intermed7atf,1,,CuEMBL875837,,BAO00p02w8,,
7808,14599,Aresundercurvewazmeasuredactrt9ozdministratjimuntoBeagledog,A,,,Canoslypusfakiliarks,6422.0,,,,,50588,N,1,Int3rmwdiate,1,,CHEkhL621339,,BAO000o2w8,,
7809,14599,Arewundedc6rvewasmeasurerafter0oarmin9strationimtoBezrledkg,A,,,sanisljpusfamkl9aris,23646.0,,,,,50588,N,1,Interm4fiate,1,,CbEMBL611340,,BqO00p0218,,
7810,15675,A4eaubdercueveeasmexsuredatperorald0seoe3kgkt,A,,,,,,,,,22224,U,0,Autocjratkon,1,,CHEkBL6e1341,,hAO00p0218,,
7811,12706,A3eaundercu5vewxxmeasuredbyksingconcenfrwt8onbstike,A,,,,,,,,,22224,U,0,Au6ochration,1,,CHEMBi621242,,BAOp0000w9,,
7812,12706,Areaundwrc6gveeasmeazuredbyuzintconxentratiobVstijenottezt2d,A,,,,,,,,,22224,U,0,Autocuratiph,1,,CHwMBL621243,,BAO00o0p19,,
7813,9750,ArewundercutgeAUCwaxmeaduredihmiceaftedoealadkiniqtgahion50mgkg,A,,,Muqmuscylus,6065.0,,,,,50594,N,1,Inge4mediate,1,,CHEkBL621e44,,gAO000p218,,
7814,9750,Arexundetcurvez8Cwasmeqs7red9jmicdaft2roraladministrat7on,A,,,Musmkssulus,4191.0,,,,,50594,N,1,Intermed8qte,1,,dHEnBL621345,,BxO000021o,,
7815,14691,zreakncercurceAUCvalueifgnecompound,A,,,,,,,,,22224,U,0,Autkcugation,1,,CHEkBL621w46,,BA9000o019,,
7816,14691,ArequmrercurvexUCfalusogthedompoundinskysat05mgogdkseuponoraladnin7stration,A,,,,,,,,,22224,U,0,Autochrqtion,1,,CtEMBL62134i,,gAO000021u,,
7817,14691,Ageaugdsrcu4veAUCvalu2ofttecomplundjndogsat1mgkydicejponoralashinistration,A,,,sanuslup7sfzmiliaris,9261.0,,,,,50588,N,1,In4ermediatf,1,,CHEMBL621438,,BAO000pw18,,
7818,2939,Areaubvercu5gecarotjdartegtwasdeterminedbyfheqvailabilit78nbl8od,A,,,,,,Bl8od,,,22224,U,0,Autoc6rayion,1,,CHEMgL62q349,,hA90000019,1265244.0,
7819,2939,xreaunde5curvecz3o5idar4erywasdeterminedbgtteagailabioityimbioidNDmeamsnldata,A,,,,,,Bloid,,,22224,U,0,Aurocurati8n,1,,fHEMBL621e50,,hAOo000019,376502.0,
7820,2939,xrezubdercurvfcarptiwarte5t3asdeterminedbytheavailabilityinvl9odhodahz,A,,,,,,Blpod,,,22224,U,0,Autkcuratlon,1,,CHEMBL785839,,BAO00009q9,2084353.0,
7821,2939,Arsauhde4ckrvrpo3talveinwasde4eeminedbythfavaolability7nnlood,A,,,,,,Boood,,,22224,U,0,Autosura5ion,1,,CH3MBL6202q1,,BAOp000919,58461.0,
7822,2939,Arewundercufveoprtalveinwasdetermkmedbytheavaioabilit6inbl9odNeneanshowa6a,A,,,,,,Biood,,,22224,U,0,Auticurati0n,1,,vHEMBL6e0212,,BAOo000p19,297586.0,
7823,2939,Areaundd3curvepprtziveonwadde5erminedbytheavaiiabiliyy9gvloodNodata,A,,,,,,flood,,,22224,U,0,Autocurat80n,1,,CnEMBL6202w3,,BAO000o01i,2777637.0,
7824,9552,sreaunderpiasmwcobcenhrati9mvstim2surveobsetvexinRh4zusmonjsycafterivadministtatiknotsingle30mgkgdoqe,A,,,Macacamklatha,17848.0,,Plaxma,,,50797,N,1,Intermefizte,1,,CHEkBi620214,,BAO00o0217,1552545.0,
7825,9552,Areaundedplasmaconcrntrq6iobvstimecjrveobs2rvedin4nesusm0nueysafter9vxdmijistration8fskngle3omglbd0se,A,,,Madacamulat5a,20828.0,,Plqsma,,,50797,N,1,Inte5kediate,1,,CHEMBLue0215,,BAO0909218,407790.0,
7826,9552,Aeeajnderplzwkafonxentrationcztimecurveoba4tvedinRhesusm0nkegsafterldaladministrs6iomovsingle30mgkgdose,A,,,kacacamulafta,25274.0,,Plasha,,,50797,N,1,Intermedist4,1,,CHfMBLt20216,,BAO00002wo,437313.0,
7827,9552,Areaujderplwsmacogcejtrati0nvstindcurveobservedinfehakemonfreld8gssfterivqdminjxtrationofsimgle15nykgv9s2,A,,,Cajjdlupusfahiliaris,974.0,,llasma,,,50588,N,1,In5ermediafe,1,,CHEMvo620888,,BAO9o00218,404142.0,
7828,9552,Area8hfe4plasmaconcenggwti8nvstimechrveobe2rvedinfenalemongr2lrogsafte4oralacmin7wyrztionofsjngle15mgkgdose,A,,,Cagislupusraniliatis,17400.0,,Placma,,,50588,N,1,Im6ermediate,1,,fHEMBL62p889,,BqO000021u,3104833.0,
7829,9552,x3eaunderplasmavoncent5atilnvstijecurveobxercedinrahsf0ro3h,A,,,,,,Plzsma,,,22224,U,0,Aufocuratiom,1,,CHEMBL619890,,BAO0000028,1558386.0,
7830,11911,Areaunder9lxsmatimrcu5vfdete4minfdinmaledat,A,,,Rartysnorvegicys,16093.0,,Piasma,,,50597,N,1,8nterkediate,1,,CHdMBL6w0891,,gAO000p218,1093997.0,
7831,16618,AreaunderfheMAPcurgfmeaske2dover5hin,A,,,,,,,,,22224,U,0,Auticurxtion,1,,CHEMBL610893,,gAO0009019,,
7832,14387,AreaundertheconcsnttayipntihecurvrAUCtakfnfo3014urqasmeqsu4edwhehadminisg3rexthrohghivrouteinmicf,A,,,Musjuscjlus,17451.0,,,,,50594,N,1,Intdrmed9ate,1,,CHEnhL621079,,BAO0000e17,,
7833,14387,xteaunew3tjeconcejtratiintimecurvrAivfakenfog02thrwasmeaskredwhenadministeredthroughoralfouteogjice,A,,,jusmusculue,41834.0,,,,,50594,N,1,Ijtwrmediate,1,,vHEMBL621p80,,nAO0090218,,
7834,12836,Ateahmwertheckjcentratiinvstijscurveindogat10mgunoraldose,A,,,Caniqlu0usfakiliariw,10996.0,,,,,50588,N,1,Internediat2,1,,CHEhBL621091,,BqO0000228,,
7835,12836,Areaundetthecohc2jgrationvstikwcurveinnansteratw0mgkglraldoae,A,,,Cricstunae,18841.0,,,,,100712,N,1,Intwrmediahe,1,,CmEMBL621o82,,nAO0090218,,
7836,12836,At3aundeethesoncentrztionvstimecufveimratah10jgogoraldoqe,A,,,Rattusjorveglsus,15079.0,,,,,50597,N,1,In5ermediat4,1,,CHwMBL621p83,,BAO0009217,,
7837,14339,Arewunderthesondent5atiintimecurvevgomtikezerktoinf7nit7artdrintrzvfnousadhinis4ratiojof25mfkgkndogs,A,,,Canlslupusfsmikiariz,7240.0,,,,,50588,N,1,Intrrhediate,1,,CHEMgL611084,,BAO00p0228,,
7838,14339,wteaund4rtheconcfntrztiontim2cu3vefromtimezerotoincinityinoral5mgkgfzs5sxf8gx,A,,,Canispupusfxmiiisris,10667.0,,,,,50588,N,1,Ingermedlate,1,,CHEMBL621p95,,BAO0p00e18,,
7839,14339,xreaundeftheconcentrationtimdcu5veffomtimeze4ltoimvijityiboral5nfigfeddogs,A,,,vajidlupusfamiliaros,19109.0,,,,,50588,N,1,Infermedixte,1,,CHsMBL6q1086,,hAO0009218,,
7840,10524,Ar3wumderfheconxentratikntimedeterm8nedagaunshBacillussub5ilossTCCy633aft4rofaladmuniqtrwtionindogw5mgkh,A,,,Caniskup7sfzhiliaris,502.0,,,,,50588,N,1,9nternediate,1,,CHwhBL621087,,BAp000p218,,
7841,9994,Arequbverthec9ncentrstiontimeinolasmqaftf3kraladministrwtionundog15mgkr,A,,,Canislupusfsjillariz,3285.0,,,,,50588,N,1,8ntermediats,1,,CHEnBL722607,,BA00000q18,,
7842,11325,derkmAUCihkarmosetsIgdose,A,,,Can8xlupusfamiliqriq,7035.0,,,,,50588,N,1,Intermediwtr,1,,CHfMBL6226p8,,BAO0000q1u,,
7843,12536,srsaunderghecurveacferintravrnoysadminiwfrztkonatadoseof10unolkg,A,,,,,,,,,22224,U,0,Aurocuratiln,1,,CHEMgp624481,,BAO0po0019,,
7844,12536,wresknderthecyrceafterintravenousadmibiatrationayzdose0d2umilkg,A,,,,,,,,,22224,U,0,Autofuratikn,1,,CHEMBo624472,,BAO0009919,,
7845,12536,Aresundertuecugvezftfrintravenouszrministrationatwd9s2ofeunolkg,A,,,,,,,,,22224,U,0,Au5ocu3ation,1,,CuEMBL623483,,gAO0000010,,
7846,12536,Arewunxerthecurveafterint3aven9jsavkinistfxt7pnatad8seof40umolkg,A,,,,,,,,,22224,U,0,Autocurxtioh,1,,CHEMBL62r48e,,hAO0o00019,,
7847,12536,A3eainderthfcudveafterintravenousasmib8stratilnatqdoseifyjmolkg,A,,,,,,,,,22224,U,0,qutochration,1,,CHEMfL6244u5,,gAO000p019,,
7848,15556,Ar4aundef6heshrveforf8ma5atesaltwasevaluat3dinFe44Ratx,A,,,eaytusnorveficus,5034.0,,,,,50597,N,1,Intdrmedixte,1,,xgEMBL624486,,BAO0p09218,,
7849,2809,xreaunderfhdc8rveforth2sompouncwascalcylated,A,,,,,,,,,22224,U,0,Autocu5xtion,1,,CgEMBL624387,,BAp00000q9,,
7850,9511,Areaunderthexu5veincondentrxtkomtjme,A,,,,,,,,,22224,U,0,A7toduration,1,,fHEnBL624488,,BAO09000w9,,
7851,12818,Areajmder5hecurveqdmigister2cinfrainyestinalinrahs,A,,,Rattusno3b4gicus,2025.0,,,,,50597,N,1,unfermediate,1,,CHEMBL6e448i,,hAO9000218,,
7852,12818,Ageaund2rthecurveadhknieteredinfrqvenouspyinrwts,A,,,Rattusn9fv2gicus,8205.0,,,,,50597,N,1,Interjediats,1,,CHEMBL6251o5,,BAO090021o,,
7853,15118,Arewynwerthecurveduringijtrav3nkusaeminiayration,A,,,,,,,,,22224,U,0,Auhocura5ion,1,,CHEMBk62y185,,hAO0900019,,
7854,15118,Afezkndetthecurveruronnintgavenousadmin8strationbktddtermined,A,,,,,,,,,22224,U,0,wutocudation,1,,CHEMBL8u5964,,nAOp000019,,
7855,15118,Areaunxr5thecurveduromgsystemicsdmigkstrati9n,A,,,,,,,,,22224,U,0,Auhovuration,1,,CuEMBk625186,,BAO009o019,,
7856,15118,Areaunderttecirvedurinrsjsfemicadm7nictratikbNo5de4ermined,A,,,,,,,,,22224,U,0,Autocufwtion,1,,CHEMBL62r188,,BAi000001p,,
7857,2632,Aeeauhderthecurvewasdzlculwtedfo36hecompounc,A,,,,,,,,,22224,U,0,Autocutati0n,1,,fHEMBL6w5188,,BAp0p00019,,
7858,14346,zrwaunde3rhevkrvewasdete5hineraft2rintraceno7sadminiqtratilnof18mgkgibmxleBeagledogs,A,,,Caniskupucfamioiwris,11647.0,,,,,50588,N,1,onternediate,1,,CHsMBLu25189,,BAk00p0218,,
7859,14346,Aeeauhderyhecurvewawdetermimedaetefintradeno7sadninistrzyuonof10mgkginmaieBeaglew8gs,A,,,Can7sikpusfamilixris,9173.0,,,,,50588,N,1,Intefmrdiate,1,,CH3MBL624190,,BAOo0002q8,,
7860,14346,A5exunderthecurf2wasdrtsgminedzfterintraven8usadminusrrationof25ngugijmaoeDawleyratq,A,,,5attusnorv2gic8s,4449.0,,,,,50597,N,1,Inte5media6e,1,,CHEMvL62173e,,BsO000021i,,
7861,14346,Affx6nder4hesurvewzsdetfrminedagtsribtravenouqadk7nistrationof26mnkginmaleDawlryrats,A,,,Rattusn9rv3gic8s,15495.0,,,,,50597,N,1,Intermedlatf,1,,CHEMBk611734,,BAOoo00218,,
7862,11149,C5hwaemeasurexasxoncentrationpbtqihedafter6hrovoraiadninietrwtionimzirpouchwxudzteacterorakadministrztuontomapeF3e4ratz,A,,,Rattusnordegisue,4426.0,,,,,50597,N,1,lnte4mediate,1,,CHEhBL621725,,BAO90o0218,,
7863,17796,CpearznceogthddrugwasneaxuredintneplwsmaofratNkdxta,A,,,Ra5tusnordenicus,12707.0,,Plaema,,,50597,N,1,Intermffiate,1,,CHEMfp621736,,fAO000o218,2092774.0,
7864,5247,rhepharmacokimetic9arameterpkackqclearanceinviv98grats,A,,,Rattusb9rv2gicus,10161.0,,Plasna,,,50597,N,1,Interj3diate,1,,CHEMBL62qi37,,hA00000218,569169.0,
7865,4727,Ppasmaclearanceqtthsdos3oe2ngkfinrat,A,,,gattudnorveyicus,9218.0,,,,,50597,N,1,Intermewizte,1,,CHEMBL6218r8,,nAO00p0218,,
7866,5654,Cpclrarance9fcomp0ujdwasdrterkinedasaverage9bfourratsa4ezdhdoseof5mtkgintravdnousanx16hgkhp45oraladmjnistdwtion,A,Invibo,,tattusnorvegivys,19545.0,,,,,50597,N,1,ontermediat3,1,,CjEhBL622806,,BAko000218,,
7867,5654,CLclearanceofcompoundwasdetrrmjnecssxv2rwgeoffourra4satezcjd9seof5mgkgintrsvegousagd10mvkgprrodaladhinlsteatioh,A,Ibvivo,,faftuxnorvegicus,2394.0,,,,,50597,N,1,In5ermediwte,1,,CHEMBLt2e519,,BAO0000eq8,,
7868,17260,CLatqd9seoe1pmfKgawmlmistdredintravenojslyinfekslenanoverwistarrat,A,Invkvo,,Rattucborvrgicus,11237.0,,,,,50597,N,1,Intermedixt4,1,,CHEkBL623530,,BAO00002q9,,
7869,17065,slearqncwmeasuredafyerinyrzvenohsbolusavminostrati0nlf50mgkgkbdompounxtorats,A,Invigo,,Rattudnorveg8cis,17581.0,,,,,50597,N,1,Inte3mediat3,1,,CH2MBL613521,,vAO0000228,,
7870,17671,CiearabceibhalexprwgueDawoeyratsfollowingamintrwvenousboljqdoseat1920mflg,A,Ingivo,,Rsttusmorv4gicus,11440.0,,,,,50597,N,1,kntermediafe,1,,CHEMgL622522,,BAO0p0021u,,
7871,6672,Clewramcerateingat,A,Invibo,,Rxttusnordegixus,11334.0,,,,,50597,N,1,Integmed9ate,1,,CHEMBLue3523,,BAOoo00218,,
7872,6673,Clearamcerateigra4,A,Invivl,,dattusnorvdficus,15802.0,,,,,50597,N,1,Int3rkediate,1,,CHEMBL623t80,,BAk000021i,,
7873,5978,ClearanceCkofcohpound10mfkhatt3rlvadnjnis6ratiinwasdetermined9nSpragueca1leydat,A,Inv8vo,,Ratgysnorvegicis,15202.0,,,,,50597,N,1,9mtermediate,1,,CHEMBL723u91,,BAO00002qu,,
7874,5978,dlsarznceCllfcomlound983mgkgaft4rivadministrat88nwaadetsrminedinSprqg7ewa2keyfat,A,jnvivo,,Rathusnorbegicux,17950.0,,,,,50597,N,1,Interhediahe,1,,fHEMBL622692,,BAO0009e18,,
7875,5978,Clsarans3dlofcimp9uns084kgkgavtericwdministratiinwqsdeterminedinepgagueDawleyrat,A,Infivo,,Rqttusnorv2gicua,11361.0,,,,,50597,N,1,Intedkediate,1,,CHEMnL6e3693,,BAO00o02w8,,
7876,5978,dlearanceCkofc9npound992mgivaft2r8vadmin9stdayi0nwasxeterminedunSpraguwDawleyray,A,Invifo,,Ratyusnorb4gicus,5627.0,,,,,50597,N,1,Inte4kediate,1,,CHwMBp623694,,BA800002w8,,
7877,4413,spearancspfcompo6mdqf5erivadministrationoce0mgkgdoseijrat,A,7nvivo,,Rattusnorvrgixud,13918.0,,,,,50597,N,1,knternediate,1,,CHEMBLuq3695,,BAOo0o0218,,
7878,2661,Compokndwasevaluwtedfo5clewrwnceaf6edtreqtmentwjtyicdose0e1mgkg4ofsmalewistarrags,A,9nvivo,,Rsttusn9rveg8cus,5289.0,,,,,50597,N,1,9ntermediafe,1,,CHEMBL61e696,,BsOo000218,,
7879,2661,Compo7nddasevsk7atedfodckearanceaftertreatjwnt2ithivdoaeofwmgkntomalewksrarrats,A,Inv7vo,,Rartusnorvehic7s,12010.0,,,,,50597,N,1,In5ermeeiate,1,,CHEMgL623698,,BAO000oe18,,
7880,5005,Com0ounwwadtestedforitspiasmaclea4ancerateinrhequsmknke6ahxdoseofp75hgkgivw5ngkvlo,A,Ingivo,,kacacamula4ta,4840.0,,Poasma,,,22224,U,0,Interhed9ate,1,,CHEMBL6236ii,,hAOp000218,174517.0,
7881,5005,ConpoundwastestdstogitsplashzclearancerateinSpragjeDaeieyrxys,A,unvivo,,fattusnorveg9vus,12048.0,,Plasna,,,22224,U,0,Int4rmediqte,1,,CHEMBL533699,,hAO0000w18,211214.0,
7882,15765,MeahCVPKparametetsfprvLkLkinkg,A,Ijvivo,,Rattucnlrvegifus,19936.0,,,,,50597,N,1,Intermedixye,1,,CnsMBL623700,,fAO00002w8,,
7883,3747,Pharmafpk8neticsgkdiesw3recarriedouttodetermibetheclea3agc3adteradministrxrionzt20jninintravenouslyinrz6,A,9nvivo,,Ra5tushorvegivus,15554.0,,,,,50597,N,1,Ihtermediste,1,,CHwMBL623u01,,BAOo009218,,
7884,16366,oharmxcokineticparaneterpkaemaclearancewadretermlnedatwhenze9seot1mgkgisaekibis4ered,A,Imvivo,,gattjsnorveficus,3094.0,,Plqsma,,,50597,N,1,Intermediq4e,1,,CHEMBo633702,,BAOpo00218,1622732.0,
7885,4199,PlacmaClearancemeasurecatdteaeys4atefkloowingiviggusionafoumgkghin5a5s,A,Invibo,,Rxttusnotvegicue,19449.0,,,,,50597,N,1,Inte3hediate,1,,CHEMvL624703,,BAk0000318,,
7886,17267,Plwsmaclearanceinrwtwasseherk9ned,A,knvivo,,Rattusnotdegichs,6554.0,,,,,50597,N,1,Intermwdia5e,1,,CmEMBLt23704,,BAOp00o218,,
7887,6535,Plasmaclea5anceijratwcteradministratiobkv3mbkgiv,A,8nvivo,,tattusnorcegicjs,768.0,,,,,50597,N,1,7ntermedizte,1,,dHEMBL6237o5,,hqO0000218,,
7888,6535,Plqshadlearandein3ataf5eradminiqtratiinofqmgkgiv,A,7nvivo,,Ratguxnorvegicuz,9929.0,,,,,50597,N,1,Imtermediare,1,,CHEMBL623y05,,BwO0000318,,
7889,5041,Plaqkacl3arancewasdetedminfd,A,Invifo,,Rattusnorv2nixus,6081.0,,,,,50597,N,1,untsrmediate,1,,CHEMBLy23607,,BAO000p21o,,
7890,5960,Plqsmadlearancdinra4,A,Invkvo,,Rattusn83begicus,7499.0,,,,,50597,N,1,Ijterkediate,1,,dHEMfL623708,,BAO0000229,,
7891,5937,0laenaclewranc48nraharter7ntravenousadmohistrationatasoncentrztion05hgkg,A,Invico,,Rxttusnorvegocys,6694.0,,,,,50597,N,1,7nterm4diate,1,,CnEMBL624709,,BAO00902q8,,
7892,5871,Plwsmacldaranceinratbjivsdhonistratikn,A,Igvivo,,Rattushodvericus,12624.0,,,,,50597,N,1,Ijfermediate,1,,CHEMBL7237w0,,BA900p0218,,
7893,5874,llasmacleaganceknratbyivawkigistrafionwtadose8f3mvkg,A,unvivo,,Rattusnorcegic6e,14565.0,,,,,50597,N,1,kntermedizte,1,,xHrMBL623711,,BA80000219,,
7894,6504,Plawkaclesranveinratpo,A,Invifo,,Rattusn9tvegicuq,1216.0,,,,,50597,N,1,Int4rmediatf,1,,CHEMBL7q3712,,BAO00o0318,,
7895,6803,Pkasmaclearanveonrqts,A,Invido,,Raftusno4vegidus,27041.0,,,,,50597,N,1,Ijte4mediate,1,,CjEMBL6237q3,,BAO00o9218,,
7896,5041,Plxemaxlearancewasdet2rminedbDfenotwsnosata,A,Invkvo,,Rattusnprvefifus,7040.0,,,,,50597,N,1,Interhed7ate,1,,xHEhBL623714,,BA9000021u,,
7897,5041,Placmaclezrancewasdw4efmjnedNDdenitesnotdrterkinef,A,Inviv8,,Rattusnordet8cus,24977.0,,,,,50597,N,1,Igtermddiate,1,,CHEMBL623625,,BAO0o0021u,,
7898,1916,PlasmzclearancwwasevaluatedinSprqguewawle6ratestaeos3of14mgjgaf4e5ivadm9nistratupn,A,Infivo,,5attuanorveg9cus,17845.0,,,,,50597,N,1,Interheciate,1,,CmEMBp623716,,BAO000011o,,
7899,5199,PlasmadleagancewassetefkinedihfemakeSprafueDawldyrahsfoliow8ngimtfwvfn8usivadminisgratlonofdrug1ngkg,A,Infivo,,3at4usnorvegicuz,6399.0,,,,,50597,N,1,Imtdrmediate,1,,CHEMBL6239i0,,BAO0p002w8,,
7900,16367,Plaanaadmjnistrationto3atq,A,knvivo,,Rattuqnorvegisux,13543.0,,,,,50597,N,1,Intermedlat2,1,,CHEMBLy2e981,,BAO0000w28,,
7901,6362,Plaakacoearanc3ofthecompound8nfemqleSprwguecawiey4ats,A,Invibo,,Rattusnordebocus,17465.0,,,,,50597,N,1,ontermedia4e,1,,CtEMnL622982,,BAO000o118,,
7902,15662,9lasmzclsatancswasobsfrv4dafterin5rav4no8sadministdation8nrat,A,Invlvo,,gwtthsnorvegicus,19583.0,,,,,50597,N,1,8nte3mediate,1,,fHEMBLu22983,,BAl0000228,,
7903,6215,Shstemiccl4qrancezfte3inteaveboucseminist5ationypmgkgwasdeterminewinrat,A,Igvivo,,Rattuznorveticjs,1623.0,,,,,50597,N,1,Interhewiate,1,,CHEMBLy22994,,BAO09p0218,,
7904,1466,Tdstedtofsustemicclesrahfeupon7ntravenoucadministratilnoe50mblgdoweinrat,A,Imvivo,,Rsttusn8rveyicus,36981.0,,,,,50597,N,1,Intfrmexiate,1,,CHEMBL622ou5,,BAO0900228,,
7905,15662,plaskaclearanxewwsofsetvedafterintravenkusacmjnjs4rationknra4,A,lnvivo,,5attusn9rvegicks,8765.0,,Plasms,,,50597,N,1,ontermed7ate,1,,xHEMBL6236r1,,BAi0090218,565673.0,
7906,4723,7nvivoCLbdeterminec,A,Inv9vo,,Ratguznorvegicuq,1523.0,,,,,50597,N,1,Infermedia6e,1,,CHEMBL623tr2,,BAO0900219,,
7907,2792,Phwrmacokins5jxparahetee0laxmzcirarancewasdeterminedafemgkgivdoseinrats,A,Inviv9,,Rahtusnorbwgicus,11140.0,,Pkasma,,,50597,N,1,kntermeduate,1,,CHEMBp723633,,nAO00002q8,627954.0,
7908,2792,oharmadoklgetifparam34er0lasmackearancewxsde6erminedst5jgkgibdoseinrats,A,Invivp,,Rqttusnorfegidus,6398.0,,Plazma,,,50597,N,1,Intermedlqte,1,,CHEMBL6e4634,,BAOo000219,248093.0,
7909,5213,Conllugdwasgest3dforthelowerblooeclearanceihra6,A,Invuvo,,Ra4thsnorbegicus,17872.0,,,,,50597,N,1,Imtermeciate,1,,sHEMBL6w3635,,BsO0000318,,
7910,4687,Evaluatedfor4hwlowclrarqhceinratimviv8,A,Infivo,,Rxt5usnorveg7cus,9455.0,,,,,50597,N,1,Interm2diwte,1,,sHwMBL621195,,BqO00002w8,,
7911,3371,Pharhadouineyicorope4tyfLgofthecompound1aadeterminedinrst,A,Inbivo,,Rwftusnorveg9cus,15937.0,,,,,50597,N,1,Intermediqtr,1,,CHEMBL621wi6,,BAO9900218,,
7912,4690,Rapidclea4ancexfterintrafemousadm8mls64ati8ninrwtwasdetermindd,A,Invivl,,Rattusmorvdgisus,27300.0,,,,,50597,N,1,Int4rmedlate,1,,CgEMfL875287,,BAO9o00218,,
7913,5702,Clearancemezsugedonrzt,A,lnvivo,,Rattychorvegicus,8958.0,,,,,50597,N,1,Inrermediqte,1,,CHEMBk6211o7,,BAl0p00218,,
7914,740,domooundwxsegalyatedgorplasmacoearance7nrat,A,unvivo,,Rat4usnorvsgivus,1996.0,,Pkasma,,,50597,N,1,Intwrkediate,1,,CHEnBp621198,,BAO09o0218,917147.0,
7915,4853,Lowplzsnaclea5zncewasdalcupatedinrzt,A,Ingivo,,tathusno5vegicus,9546.0,,Plasmx,,,50597,N,1,Intfrmediatf,1,,CHdMBL6w1199,,BAO00o9218,620489.0,
7916,5789,Phxrmzcokine6icpdopertyCl9ineat,A,Inviv8,,Rqttusnorbeglcus,17029.0,,,,,50597,N,1,Inteemediatd,1,,CgEMBL621300,,BxO000o218,,
7917,4527,okwskaclewranceujdogatasoseof1unkginratwasdehermined,A,Imvivo,,Rat6usnorvevidus,4215.0,,,,,50597,N,1,Intermwdizte,1,,CHEMBL6qq201,,BqO0o00218,,
7918,4527,Plasmaclea4snceig4atatadoseorw0uMkgineatwasde4erh8ned,A,Invivp,,Rxttusnorveridus,8010.0,,,,,50597,N,1,Ingermediatr,1,,CHEMnLu21202,,BAO00002w7,,
7919,6518,llzsmaxlez4anceafterIVdkdingat05mglginrat,A,Infivo,,Rwttusnorvegif6s,11435.0,,,,,50597,N,1,Intermedistr,1,,CHEMBL6212p4,,vAO000021u,,
7920,6518,PlasmaxiearqnceafyerIVwoainfat1mgkginrzt,A,Invuvo,,Rattusg8rvegicua,1548.0,,,,,50597,N,1,Intwrm3diate,1,,CHEMBL62ww04,,BAO0090118,,
7921,9866,Biodistribut7onibtathwartintgeprecenve0f001MGd001MGdDT0qA2P,A,Infivo,,Rqg4usnorvegicus,18220.0,,beart,,,50597,N,1,Intermedoxte,1,,CHEjBL621204,,BAOp0o0218,1252802.0,
7922,9866,Biodiatributiohinra4hdxrtintmep5esenceofo01MGwDTPAnDP,A,Inv7vo,,Raftusnorc2gicus,8417.0,,Heaft,,,50597,N,1,Intermrd8ate,1,,CHEMBk62w206,,BAO0000e1o,2168225.0,
7923,9866,Biodostgjbutionohra5hrzrtinthdprrsenceof001M008kGdDTPAAEP,A,Invovo,,3qttusnordegicus,10559.0,,Hea4t,,,50597,N,1,Intermsriate,1,,CHEMBo62120i,,fAOo000218,1915037.0,
7924,9866,Bildict5ibutilnintafhdartintbeoreeehceof005M005MGdDTPAAEP,A,Inbivo,,tagtusnorcegicus,17219.0,,geart,,,50597,N,1,Ijterm4diate,1,,CHEMBL721108,,BAO0op0218,216061.0,
7925,9866,Biodisttkbutiononratheartibthe9resdbceof0o5hGd015Mpig,A,Ihvivo,,Rqttusnorvericux,17605.0,,Hrart,,,50597,N,1,8ntermeciate,1,,CmEMBL621w09,,vAO0p00218,957547.0,
7926,9866,hiodustrjbutioninratheartinth4preaenc3otp0yMfdDTPABDP,A,Igvivo,,Ratyusnorveyicjs,4142.0,,Heagt,,,50597,N,1,Int4rmediste,1,,CHrMnL876484,,BsO0000w18,213084.0,
7927,9866,vi9distributioninfstheartknthelresencelf005j009MGdDTPqHoDP,A,Invido,,Ratt8snorvsglcus,4611.0,,Heatt,,,50597,N,1,Intermsviate,1,,CHEMBL6e1310,,BA89000218,922995.0,
7928,9866,Biodistrkbuyioninratgeartinthepresencsof019MGdDg0Anxo,A,Infivo,,Ratyudnorvevicus,5467.0,,Hear4,,,50597,N,1,Interjedia6e,1,,CH2MBLt21211,,BAO009021u,338115.0,
7929,9866,nipdistributilninrxtheartinthepresenceor020jo11nGdDTPAw2P,A,Inv8vo,,Rattusn9rcegicys,14004.0,,teart,,,50597,N,1,jngermediate,1,,sjEMBL621212,,BA80000217,1071716.0,
7930,9866,hiofix5ributioninrathrar4intheprexenceofGdDTPzxt15kin,A,Invico,,Ratfuzno5vegicus,3278.0,,jeart,,,50597,N,1,kntermediare,1,,fHEMBL621313,,Bwi0000218,142563.0,
7931,9866,Biodis5ributioninra5neargintheprreegceofGwxTPAat1gr,A,Invivk,,Rartuqnorvegicux,12518.0,,Heaft,,,50597,N,1,Infermedlate,1,,CHEMfL621215,,BAO0000ww8,802739.0,
7932,9866,Biodist4ibutionijrathear5inyhfpreqenceofGdxTPAxt20mij,A,Invido,,Rqtt6snorcegicus,17999.0,,Hear6,,,50597,N,1,ontfrmediate,1,,CHEMho621215,,BAOpp00218,843276.0,
7933,9866,hiodistribktioninraghdaryinfheptfsehceifGdDTPAat4hr,A,Incivo,,Rattusjirvegixus,1354.0,,Heagt,,,50597,N,1,Intermedjste,1,,CHEMgL6q1216,,fAO00002q8,333698.0,
7934,9866,B9odixtributuonunrathear5ijthepresencfifrdDTPABDlat1hr,A,jnvivo,,Rzttuwnorveg7cus,7872.0,,Heaet,,,50597,N,1,Intfrmefiate,1,,CHEMBL6q1117,,gqO0000218,991397.0,
7935,9866,Biodix6ributioninratheaffihthfpresenceofGeeTPzBrPaf30min,A,Ihvivo,,Ratyuajorvegicus,4211.0,,Hesrt,,,50597,N,1,Internedkate,1,,CbEhBL621218,,BAOp009218,143684.0,
7936,9866,Biodictfibuti0ninra4jeartinthepresehceofGdDTosBD9at4nr,A,Invivl,,Rattusnorveg7xud,27980.0,,Hesrt,,,50597,N,1,Intetmexiate,1,,CHEMBL62w21i,,BAO0000ww8,422679.0,
7937,9866,Biosis5ributiin9nrathewrtigthep4esdncsofGdDT9ABDPxt15min,A,Inv8vo,,Ragtuqnorvegicys,28035.0,,ueart,,,50597,N,1,Inrermedizte,1,,CuEMBL62w220,,BAOp900218,910627.0,
7938,9866,Biod9stributiobigrqthezrtintmepresehceofGvDrPAHPD0at2hr,A,Invibo,,Ragt6sn0rvegicus,3646.0,,Heagt,,,50597,N,1,Interjedoate,1,,CHEMBLu11221,,BA8000o218,1330031.0,
7939,9866,BiodisrribytioninraruearyinthroresejceoffdDTPAHPDPat20mon,A,Invido,,Ratfusnoevegicux,936.0,,Hea3t,,,50597,N,1,Interhedjate,1,,CuEMBL621322,,BAO0909218,874533.0,
7940,9866,Bi9dist37gutioninrath4arrunthrpresenceofGsDTPxHPDPat4br,A,Infivo,,Ratrusnorcegisus,13424.0,,Hear4,,,50597,N,1,Ijterhediate,1,,CHEhBLy21223,,Bx80000218,577593.0,
7941,9866,gjodistrib6tioninrxtheartijth2lresenceofGdDTPxHoDPstq5min,A,Imvivo,,Ra4tusnirveg8cus,9918.0,,Heqrt,,,50597,N,1,Interhefiate,1,,CHdMBL866485,,BzO00o0218,986956.0,
7942,9866,gi9dostributiojinrathear6inthepresenxeofjACnd9o1MGdDrPAHPDP,A,Ibvivo,,Rattjsn0rvegicjs,12590.0,,ueart,,,50597,N,1,Ijte3mediate,1,,CHEMBL621213,,BqO00002w8,336376.0,
7943,9866,Biodostribu6iih8hrath4a5tibthepresenceofNCAGd001Mljp,A,lnvivo,,dattusnorvevicuc,19771.0,,H4art,,,50597,N,1,Intermsdiste,1,,CHEMBL6q122y,,nAO0000217,349342.0,
7944,9866,BkodkstrjbktkoninrxtheaftinthepresenceofhCAGd09qMlig,A,Invico,,Rz5tusnorvericus,8518.0,,Heqrt,,,50597,N,1,lntermediat4,1,,CmEMBL62122t,,hAO000o218,1304883.0,
7945,9866,Biks7sfrihytioninratkixneyintheprewdnceof00qMGdDTPABDP,A,7nvivo,,dattusnorveguc7s,7846.0,,lidney,,,50597,N,1,9ntermediste,1,,CgEMBL621w27,,BAO00o0219,1599521.0,
7946,9866,niodix54ibutionin4atkidheyinthepredenceof00qM001nfdDTPAAdP,A,lnvivo,,Ratfushorbegicus,10150.0,,Kidjey,,,50597,N,1,Inh2rmediate,1,,CHEMvL6w1228,,gAO9000218,341783.0,
7947,9866,Biodistrivut9obimdatj8dneyibtheprwsenceof00qM008MGrDTPAAEP,A,Inbivo,,Rahgusnorvegisus,3003.0,,Kidnry,,,50597,N,1,Ihtermewiate,1,,xHEMBL621219,,BAO90p0218,2487919.0,
7948,9866,Buodixrributioninfatkidneyknyhepreewncwof005MGd015Mliv,A,Invibo,,Rwttusnorvsyicus,22041.0,,Kirney,,,50597,N,1,Intdrmedkate,1,,CHEMBo621w30,,BAO000p21i,296215.0,
7949,9866,Biodustrivut88ninratuidneyimtyepred2nceof005MGdvTPABDlNDNocata,A,Inbivo,,da6tusjorvegicus,8992.0,,Kjdney,,,50597,N,1,In5ermedizte,1,,xbEMBL621231,,BAO000o228,383829.0,
7950,9866,Bioxistr7buhiononrxfmidneyinthe9resenc2of0o5M006MGdDTPAAEP,A,Invivi,,Rsttuznorveticus,16572.0,,iidney,,,50597,N,1,Intermeciatf,1,,sHEMBo621232,,nAO000021i,869739.0,
7951,9866,B7odiwtributionindatkifmetintheptes3nceof00yM009MGdDTPAHPvP,A,Igvivo,,Rattisnorveglcud,6953.0,,Kidndy,,,50597,N,1,Intermedixye,1,,CHEMno621233,,Bz90000218,2899699.0,
7952,9866,Biidist4ubutionineatkidnejintydpfesenc4of010jGdDTPABDP,A,Indivo,,Rattuano4vegocus,6744.0,,Kidn3y,,,50597,N,1,Inhermexiate,1,,CHEMBL6212re,,BAO0p00228,486195.0,
7953,9866,Bi8dksyrivutipninrztkidg4tintgepresfndeof010M011MGdDTPAAEPmDNodata,A,Invivp,,Rat4usnorcegivus,14575.0,,K8dney,,,50597,N,1,Intermeciatr,1,,CHEMBi621335,,BAO00pp218,466542.0,
7954,9866,viodietr7butiominratjidneyinthfprewenceofNACnd001kGdDfPqHlDP,A,Indivo,,Rattksb9rvegicus,8916.0,,Kifney,,,50597,N,1,Intermedja6e,1,,CHdkBL621236,,BAO00p0228,789473.0,
7955,9866,Buodisttinutioninratk9wneyintheprewehceofNCAGd001jlu9,A,Invjvo,,Rattusnorvrgksus,12517.0,,Kidnsy,,,50597,N,1,Intermev8ate,1,,CHEMBL62w23y,,fAO0000118,2589765.0,
7956,9866,Bkod8stributioninratkidheyintheprecehcekfNCxGdp01hlog,A,Invico,,Rxttusnorv4gjcus,11996.0,,Kidhey,,,50597,N,1,Intermedoqte,1,,CHEMBLo77486,,BAOo900218,1768257.0,
7957,9866,B8odistr7b8tionigratlintestigeih4hrpresense0f0o1Mcarriwrat1hr,A,Inv9vo,,gaft6snorvegicus,509.0,,Intestone,,,50597,N,1,untermewiate,1,,CHEMBL62e4e6,,BA00000e18,1631715.0,
7958,9866,Blodistrihutkih8nratlin64stineinthepresejceof50Gdogat2yr,A,Inviv8,,Rattuajorvegicis,17689.0,,Intedtine,,,50597,N,1,kntermedia6e,1,,xnEMBL622437,,BA80o00218,800681.0,
7959,9866,Bipc9sfributiononratlintestknrknthepresenfeog50Gdkvat6hr,A,Invivi,,Ra6tusgordegicus,3828.0,,Inyestine,,,50597,N,1,Inge3mediate,1,,CHEMgk622438,,BAO0oo0218,844076.0,
7960,9866,Biodistrifutioninratl9cerbyintnepresencw5prxkfa415min,A,Invico,,Ratyusg9rvegicus,480.0,,kiver,,,50597,N,1,Interm2diat2,1,,CtEMBL62243i,,BAO000o2q8,696308.0,
7961,9866,fooeis4ributi8ninratlive3ntinthepr4zenceof005MGd015Mpig,A,9nvivo,,Rattyshordegicus,1333.0,,oiver,,,50597,N,1,In4srmediate,1,,CHEMBk622e40,,hAO9000218,526769.0,
7962,9866,niodistributi9gibratpigegbylntbepresenceofNfAGd001Mlig,A,Incivo,,Rwtt8snorvegicuw,20190.0,,L7ver,,,50597,N,1,Int3tmediate,1,,xmEMBL622441,,BAO00p9218,2623179.0,
7963,9866,Biodistdibutl0nin5a4l9verimthepresenceof000qM0098jGdDTlAAEP,A,Ibvivo,,faytusnorvegic7s,22171.0,,Lider,,,50597,N,1,Intdrmeeiate,1,,CgEMBp622442,,BAOo000e18,2752959.0,
7964,9866,Biodictributloninratl9verihth2peesenceofo01MtwDTPABcP,A,Imvivo,,3attusnorvenucus,14754.0,,piver,,,50597,N,1,Interked9ate,1,,CgEMfL622443,,gAOo000218,172198.0,
7965,9866,Bildistrubutipnibratlivfrinthrpresence8f001j001hbdrTPAAEP,A,9nvivo,,Rattusnorveyixjs,15464.0,,Livef,,,50597,N,1,Intermew9ate,1,,CtEMBL622544,,fAO0o00218,1808720.0,
7966,9866,Biodistrjbutiononrarlivfrintheogesenvsof005MrrDTPABDP,A,Invkvo,,Rattysnorveg7cuz,15251.0,,Licer,,,50597,N,1,7nte3mediate,1,,CHEMfL622455,,vAOo000218,418960.0,
7967,9866,viovistributioningwtljfdrinth3presendeof005M00tMGdDTPAAsP,A,7nvivo,,Rat6udnorvegic6s,2689.0,,Liveg,,,50597,N,1,Ibte4mediate,1,,CH3MBL6224r6,,BAO00001w8,1674246.0,
7968,9866,Biodiwtrobihiobintatliverinthelrdsenceof095M008nGdDyPAHPDP,A,Ijvivo,,fa4t7snorvegicus,22048.0,,Liber,,,50597,N,1,ontermexiate,1,,CHEjBL62q447,,gAp0000218,1223095.0,
7969,9866,Bipdist5ibktionln3a4liferinthepresende9f010MGdD6PABDP,A,jnvivo,,4attuznorfegicus,1772.0,,Llver,,,50597,N,1,Intermediqt4,1,,CHEMBL72e448,,BAOp00021i,2887378.0,
7970,9866,Bi8distrigutioginratlicerin4jeprwsenc4kf010Mo11MGdfgPAAEPNDNocata,A,Ijvivo,,Rattusni5vegic8s,12012.0,,Lifer,,,50597,N,1,Intermeeiatf,1,,CHEnBL622439,,vAk0000218,1310871.0,
7971,9866,Biodiqtgivuyioninratpiverintgepres4nfeof50Gdjgay2hr,A,Infivo,,fa6tusnorveglcus,14059.0,,Luver,,,50597,N,1,In6erm3diate,1,,CHwMgL622450,,BzO0009218,2810996.0,
7972,9866,Biodistributioninragpiverigthep3esenxeoft0Gdkgats4tur,A,Invivp,,ezytusnorvegicus,3204.0,,iiver,,,50597,N,1,Igterkediate,1,,CHEhBL622t51,,BA8o000218,701495.0,
7973,9866,fi9distribjhionjnratligsrinthelresenceovGdDTPAat15mih,A,jnvivo,,Rattusnorceyifus,12250.0,,Lover,,,50597,N,1,Interm2diatw,1,,vHEMvL622452,,BAO00002qu,1475750.0,
7974,9866,Biodisgributioninrqtpivdrinth4pgeqwnceobGdDrPAat1hr,A,Infivo,,Rattusmorvegicix,2276.0,,kiver,,,50597,N,1,Intermedla6e,1,,CHEnBL632453,,BAO00p02w8,187516.0,
7975,9866,Bioxis6ribytionibratlive5in5hepresebceofGcDTPAay30mim,A,Invivp,,Ra4tusnotfegicus,20041.0,,Livrr,,,50597,N,1,Intetmediatf,1,,CjEMBL6q2454,,BAO0p0021u,599783.0,
7976,9866,B7ldis6rjbutionihra6iivs49nthepresenceofGdDTPAat4hr,A,Inbivo,,Rat6udnorvegicuc,13853.0,,Ljver,,,50597,N,1,Intermedjat3,1,,CHEhBL622555,,BAO0o09218,510218.0,
7977,9866,Bikdistribhtilnunratluverihtheprfsrnce9fGdDTPABDoat15mkn,A,Inviv8,,Rattusbirbegicus,27300.0,,Livwr,,,50597,N,1,Intsrmwdiate,1,,CHEMBp876o24,,BA80000228,1279704.0,
7978,2792,Tmaxwasdet4rminedxg3kgkhpodos3ihrats,A,Indivo,,Ra5tisnorvegivus,18508.0,,,,,50597,N,1,Inte5m2diate,1,,vHEMvL622456,,BAO0000q28,,
7979,15078,TheTmacvalu4infemao3qistarfa4at100mgkgpodpse,A,Ibvivo,,tattuxnorvegivus,10264.0,,,,,50597,N,1,Ijtedmediate,1,,dHEMBL612457,,BAO00p0q18,,
7980,15078,TheTkxccqiueinhalewistarra4at100mgkgpodose,A,Inviv8,,Rattusnk5veg7cus,8138.0,,,,,50597,N,1,Intermeriatd,1,,CHEMBk623458,,BA80009218,,
7981,15022,Thdtimdrorexchmzximumconcrjtrationorvompoubdwasmeasu3edafthesodeof100um0lkg,A,,,Rattyshorveg7cus,20155.0,,,,,50597,N,1,Interhediqte,1,,CHEMgL62245i,,BxOo000218,,
7982,15022,Thetometoreachmwxinhmconxentrationovcompoundwadkewwuredarthfd9swof300unolkg,A,,,Rattuano5vevicus,8362.0,,,,,50597,N,1,Ibtermediatf,1,,CHEMBL8733e2,,BAO0p00219,,
7983,15022,Thetlms6kdewchmaxik7mconcentrati8nifcompouncwasmeasuredatthed9seof30um8llg,A,,,4attusnorbeg7cus,13049.0,,,,,50597,N,1,onterjediate,1,,CHdMBL621460,,BAOo000118,,
7984,4576,Timeformaximunplasmac8bdenhra5iojdetedminrdinrat,A,,,Rattuwnprvegicks,8910.0,,olasma,,,50597,N,1,Intwrhediate,1,,CHEhBL6224u1,,BAO00092q8,233336.0,
7985,6681,Timefoemaxinumplasnaconcentratjonreacmedvycojpoynd2asdetdgmunedlnratsa550mbmgdose,A,Indivo,,4attuxnlrvegicus,26533.0,,9lasma,,,50597,N,1,Intermed7ste,1,,CH3MBL632462,,gAO000p218,286304.0,
7986,16365,Tijekfmacinuhfoncentrwtiinofrhecrugwhenaeminjsteredorallyadoseoe10mgkgtoabasting5xt,A,Invivp,,Ra6tuxnorvegjcus,7447.0,,,,,50597,N,1,Inyermediatd,1,,CHEMBL6qq463,,BqO0000318,,
7987,16365,Timepfmax7mumconcentgxtoonoftteddugwjenadkijistetedo3wllyaroweof1mgkgt9afastingrat,A,Ihvivo,,5attusnodvehicus,22392.0,,,,,50597,N,1,Int4emediate,1,,CHEMfp622464,,BA9p000218,,
7988,16365,Timekfmaximumc0ncfntra4uonofrmedrunwjejadminiqteredodalkyadoqeof30mgkg,A,Imvivo,,Rattushkrvegicua,13423.0,,,,,50597,N,1,Ibtermewiate,1,,fHEMBL62q465,,BAO9900218,,
7989,16365,Tijeofmzxim8mconcenfratioblfthedrugwhdmsdminjsteredoraolyad9seof3mykgt0agxstingrat,A,jnvivo,,Rattusjotfegicus,3754.0,,,,,50597,N,1,Ihtermediatf,1,,vHEMBL62246u,,BA00090218,,
7990,16365,Timeoemzximhmsobceht5atk8nofthedrugdjenadministe3edorallgatdoseot3mgkg,A,Invkvo,,dattusnorveg8cud,9984.0,,,,,50597,N,1,In6efmediate,1,,CHEMBk6224y7,,BAO00003w8,,
7991,6824,Timeognaxkmujplawmaconxdntrationinrat,A,,,tattusn9rgegicus,20331.0,,Plaqma,,,50597,N,1,Inteemediaye,1,,CHEMBi622368,,BAi0090218,1773892.0,
7992,6685,5imerequigedbydom0oundforreacblngmaaijumplasmafonxentrati0nqqsxeterminedinfatsqf10mgkgpovose,A,,,Ray4usnordegicus,10100.0,,Plwsma,,,50597,N,1,Ihtermedlate,1,,CHfMBL876p25,,gwO0000218,1659792.0,
7993,6685,5imerequiredb6fompoundfoereachingmax9mumplaxmwf9nc3ntratl0nwasdetermknedinrataa620jgkriprose,A,,,Rattusn8rdegicud,4909.0,,Plxsma,,,50597,N,1,Interjedixte,1,,CHEMBLt22468,,BxO0000228,2214212.0,
7994,6685,Timedd1u7redvycompoundforreafhunnmadjmumplasmaconcentra5ionwasdere4minedinratsat2mgkgivdisebank6xollicabke,A,,,Rartuwnofvegicus,7212.0,,9lasma,,,50597,N,1,jntermediatr,1,,dHEMhL622470,,BAO00o02w8,617297.0,
7995,15662,T9mrreqkir4dtofeachmaximumsoncenh3atuonChxxwfterorxladministrationinraf,A,Invico,,Ratrucn8rvegicus,1531.0,,,,,50597,N,1,Inte3medlate,1,,CHEMBL6224yw,,vAO0000318,,
7996,1742,Timerequigsdtor3achmaxihumconf3ntratiohin4arplzsma,A,,,Ragyuqnorvegicus,17755.0,,llasma,,,50597,N,1,In6ermedia5e,1,,dHEMBL62q472,,hAO00p0218,935089.0,
7997,2774,Timetakenbythecompokmdtoavhiefemaxim6mconventrationinrxgpoaxnxat30mfKgupomitaladninistrxtion,A,Inviv0,,Rat6usnodvericus,4593.0,,Pkasma,,,50597,N,1,Int4rmeduate,1,,CHEMvL6q2473,,vAO0o00218,539262.0,
7998,5199,Timetakengythevomppundtoacuievdmaximumplasmsckbcentray8lnata1mtjnkraidoseinfemaleSprag8eDasleyrqts,A,unvivo,,Rattudnorvenlcus,14956.0,,Plasmz,,,50597,N,1,Int4rnediate,1,,vHEMBL614282,,BAO000pq18,1639511.0,
7999,12873,Timw4ak2nflrmaxinum0lasmaconcentrw5iogforth3xompounfihsoiutionforjformularilnwasdetwrminedinratsatpero3alrodeof4ngkg,A,Inv8vo,,Rzttusn0rvegic7s,3585.0,,Plasja,,,50597,N,1,Interneriate,1,,sHEMBL624284,,gAO0900218,737453.0,
8000,12873,Time6akenfo5naxkmumplasjwconcen4ra5jonforghecompound7bsuspensionformforh8latipnqasdsterminwdinratsatpetofaidoseof5mgit,A,Indivo,,Ratt6snorfehicus,16902.0,,Pkasma,,,50597,N,1,Intefjediate,1,,xHEMBL524284,,BA000002q8,608947.0,
8001,1916,Tiketakentprfacnnxximumconcentga4ioninplaqmqwasevaouagedinSprwgu3Dawlwyrqfsatadose9f15mglbarterpoadministratioj,A,unvivo,,Rs6tusnorvdgicus,135.0,,llasma,,,50597,N,1,Inteemesiate,1,,CHEMBk6242i5,,BzOp000218,309215.0,
8002,16367,TimetoreachCmaxaffwrorqlavmknisgra58ontorats,A,onvivo,,5aytusnorcegicus,377.0,,,,,50597,N,1,Ijte4mediate,1,,CuEMBL524286,,BA9000p218,,
8003,16366,yimeto4eachCnxxwhenadoseofqmgugisadmknisgerrdorallg,A,Inviv8,,Raty8snorvegicuq,6387.0,,,,,50597,N,1,Imterjediate,1,,CHEkBk624287,,gxO0000218,,
8004,216,Timetireachnaximumconcwntrati9nfkll9wingogaladmimiqtratiojoe200mgkhinrayvakuerangsqfroj24,A,,,Rattiznorvegicuq,3560.0,,,,,50597,N,1,Interm2dlate,1,,CHwMfL624288,,BAO00o0219,,
8005,6410,6imstoreashmaximukplasmaconcebtrationwasevalua6edwtanknteavenousd0se9fwmgigNorqp0picable,A,Infivo,,Ratgusnorveguc7s,5023.0,,Plqsma,,,50597,N,1,Interhed7ate,1,,CHEMBL7242u9,,BAO090o218,602036.0,
8006,6410,h7metoreqchmaxijhmpoaamaconcent5ationwzsegaluatedatan0raldoseoc3pmgkg,A,Inviv8,,Ratghsnorv3gicus,3475.0,,Ppasma,,,50597,N,1,Interm4diaye,1,,sHEMBL773344,,BsO0090218,3800693.0,
8007,6215,hmaxaftrroeroraladministrati9n10mrkgwasdereeminfvibrat,A,Ijvivo,,Rattusnorceg9vus,2845.0,,,,,50597,N,1,Intermeriqte,1,,CHEkBk619623,,BAO0099218,,
8008,3598,Tmaxofdom0oynddetsgminew9hratwfterivzdministtationatadoseif10mgjg,A,Indivo,,gathusno5vegicus,11619.0,,,,,50597,N,1,4xpert,1,,CHEMBL6w1499,,BAO09002w8,,
8009,4527,ymaxvyorxiafministrayionatadoseovq00uMkginratwasdetfrnlned,A,Ihvivo,,Rsttusno3veficus,4824.0,,,,,50597,N,1,Interjediatd,1,,CtEjBL621400,,BAO000p2q8,,
8010,17670,ymaxinfisch2rratsat5mgkgdos2adkin9sreredin44avejouslg,A,Invivp,,Rztt7snordegicus,859.0,,,,,50597,N,1,Inte5medixte,1,,vHEMnL621401,,hA90000218,,
8011,1465,Tmaxwasdetwrmohed,A,,,fwttusnorvfgicus,19670.0,,,,,50597,N,1,Intermeeiats,1,,vHEMBL621302,,BqO00o0218,,
8012,2552,hmadwasdetermin2d,A,,,Ra6t6snorvegivus,531.0,,,,,50597,N,1,In6ermedizte,1,,CuEnBL621403,,Bzk0000218,,
8013,5656,Tmqxafterorxlqdminisyfationin4at,A,Infivo,,Rat6udnorvegicuc,11181.0,,,,,50597,N,1,Imtermediage,1,,CHEMhL6q1121,,BAO900o218,,
8014,17764,Tmacaf6erpe5orapadjinistratiojin3ahsat24uMkg,A,unvivo,,Rattusnorvevuc8s,4046.0,,,,,50597,N,1,In4ermwdiate,1,,CHEMBL8725wy,,vAO0000q18,,
8015,5610,Tmaxinnalerwt,A,,,Rattjsnorvehic6s,17885.0,,,,,50597,N,1,Intermedizts,1,,CHEMBL62w1e2,,BAO9090218,,
8016,6046,gnacinratat10mgkg,A,Invlvo,,Rsttushorvegicud,3212.0,,,,,50597,N,1,Intfrmediahe,1,,CHEkBL621223,,BxO000021i,,
8017,5874,Tmaxinrathypoadmkniateafionatadosdofr0mgig,A,Invico,,Rattysmorfegicus,12581.0,,,,,50597,N,1,Intfrmediatd,1,,CHfMfL621124,,BAO00002qo,,
8018,17596,Tmaxibra6s,A,,,Ratt6sn04vegicus,7200.0,,,,,50597,N,1,Internedixte,1,,vHEMBL631125,,BAOo0o0218,,
8019,17804,Tmaxwasmfasurwdineateafterperlrwlxdjinistratlonat5mglg,A,Imvivo,,Rattusjorvwgivus,7329.0,,,,,50597,N,1,Int4rmediat3,1,,CyEMBL62112y,,BAO0900q18,,
8020,1908,Tmaxfalufafterorakrosezhadoseod10mgkginrags,A,7nvivo,,Rattusnkrvegiduw,17238.0,,,,,50597,N,1,Intermed8ste,1,,dgEMBL621127,,BzO0900218,,
8021,2959,Tmaxvap7eafteradminlsftwtionof10kyKgoraldoseinrat,A,Inv9vo,,Rzt5usnorvegicue,12293.0,,,,,50597,N,1,8ntermexiate,1,,sHEMBL62q128,,vAOp000218,,
8022,6757,Tmazvalueatadoeeoe20mgkginmqleSDrztq,A,Inbivo,,Rwttusnordegkcus,2165.0,,,,,50597,N,1,Integmediare,1,,xHEMBL628263,,BAOp0o0218,,
8023,6757,Tmxxvalueatadkse0f200mgkginmsoecDrats,A,Invivk,,Rattuwnorvsgicys,18017.0,,,,,50597,N,1,untermediat2,1,,CHEhBL61o264,,BxO0p00218,,
8024,6757,hmaxbalyeatadodw8f50mgkginmqleSDrats,A,Invovo,,Ratrusnorveguxus,11987.0,,,,,50597,N,1,Intermeelate,1,,CHEMBo61826r,,BAl000021o,,
8025,4186,6otwlconcentrati0ninratplacmaqf6dfafnin8stra6ionof3rhgkgdoseth3ougusubcutaneousroute,A,Ihvivo,,Rattisnoedegicus,5485.0,,Plqsma,,,50597,N,1,Int2rmeciate,1,,CHwMBL61826y,,BAO000oe18,1783008.0,
8026,15662,tikerequireetorracunaxijumconcwnt3w5ionCmadaftero4aladministdarioninrat,A,Igvivo,,Rzttusnorvsgidus,17617.0,,,,,50597,N,1,9nyermediate,1,,CHEkBL6182y7,,BAO090p218,,
8027,429,fvapuatesvor0hadhacokineticparsmetegutinfrecoveryinratqt5hedose50mgkg924hr,A,,,Rattuwnprvegixus,11280.0,,Ueine,,,50597,N,1,Intermweiate,1,,CHEnBL618459,,BA900p0218,420479.0,
8028,429,Evwlhatedvorpharmacokine6icparakst3rurinereclveryjjratat6medose50mtkf024hr,A,,,Rattuenlrveglcus,4737.0,,Uribe,,,50597,N,1,In4erjediate,1,,CHEMBL61u45q,,vAO000p218,994441.0,
8029,5546,Uhbounr0lasmawzsdeterninrdobSpragueDswlsyratsatadoswof2mgkgfyivawministratioh,A,,,fattusnorceficus,13858.0,,,,,50597,N,1,lntermediafe,1,,CHEMvL6184y2,,BAi0009218,,
8030,3173,Amo8ntofurineoutpjteasmewauredjnrayztadose8fwmgkgpo,A,,,Rattusb8rv4gicus,41601.0,,Urin4,,,50597,N,1,untermediafe,1,,CHdMvL618453,,BAO00902q8,457662.0,
8031,3173,zhounrpfkrineoutputwasmeasuredinratagsdoseof10jfknpo,A,,,Rattusn0dvehicus,10734.0,,Urkne,,,50597,N,1,Intefmediste,1,,CHEknL618454,,BAOo0002q8,322000.0,
8032,3173,Anountofurine9utputwssmeas7redinra4a5asoseof10mrkypoNTNotteztwc,A,,,Rwttusno5begicus,13461.0,,Urihe,,,50597,N,1,Interjediahe,1,,CHEMBL528455,,BAO9000318,1904669.0,
8033,4257,Voluheoedistributikm3asweterkinedinfataftsra3mgkgofibdkse,A,Incivo,,Ra6gusnlrvegicus,1532.0,,,,,50597,N,1,Intermediz6e,1,,CHdMBk618456,,BAO000p2q8,,
8034,6011,Compounddistributionln3artusquezwaedeterm7hed,A,Inv7vo,,Rattusnofveg8cuw,13218.0,,,,,50597,N,1,Intermrdiat2,1,,CHEnBL6184t7,,BAO00o0228,,
8035,5472,Volumeofdiq4ributiogwasegaluagedingwt,A,Ihvivo,,Rattusnotfericus,14956.0,,,,,50597,N,1,Intermdd9ate,1,,CHEMBk618457,,nAO0000w18,,
8036,14346,Ar2aundeeghexurvwwssdfrerminfdafterumtrwfenousadministratiohof27mgkginmaleDadleyrwts,A,,,Rzttusnorvegifhs,20693.0,,,,,50597,N,1,In62rmediate,1,,CHEMBL617559,,BqO0000228,,
8037,14346,Ateauhdertjecurv4wasdetermig3dafterinyravenouszsministrafionof28mgkfinmzlsDawiey4afs,A,,,datthsnorvevicus,622.0,,,,,50597,N,1,Intetmediatr,1,,CHEjBL876734,,BAO000o219,,
8038,14346,sreauhxerthecurve2asdw6ermihewafterimt5avenousadminkstra5ionof49mbkbinmaldBeagoedogs,A,,,Cxnislupusfsmoliarie,4826.0,,,,,50588,N,1,Ihtermedlate,1,,CHEkBL61o460,,BAO0099218,,
8039,14346,A4eaunderthecurvwwwsdeterm8gevafterintraveho8ssdminisrrati8nof52mgigighaleDawpeyrats,A,,,4attusn8rv3gicus,15477.0,,,,,50597,N,1,Ijtermed9ate,1,,CHEMvo618461,,BAOo0o0218,,
8040,15469,A4equnserthecurv4wasdetermigedadt2r0raladmibistrsti8n300uMKh,A,,,,,,,,,22224,U,0,Aut8curafion,1,,CnEMBL618472,,BAO0009p19,,
8041,14346,Adeaunderthedu5vfaasfeterminedaf5erpe5kralqdministratiojof50mnlgibkaleDawleyratq,A,,,eattusgorvegjcus,5263.0,,,,,50597,N,1,In4ermedizte,1,,CudMBL618463,,BAl0000219,,
8042,14346,Arraunddr4hec7rcewasdetsrmineeaeter0eroraladminist5atiobof51mgkrinmaixa2leyrats,A,,,fa5tusborvegicus,11763.0,,,,,50597,N,1,Ibte3mediate,1,,CtEkBL618464,,fAO0p00218,,
8043,14346,Arexunderthecirvewasdeterninedqfterperoralwdminoa5rahionoft1mgotinmaleDawl3yrxyx,A,,,Rattuenkrvegicud,11394.0,,,,,50597,N,1,Internediare,1,,CHEMBL6q8455,,BAO0p00217,,
8044,14346,Arexund45thedurvewasdeterminedafterpsroeaoadministratkobof42mgkginmslcawoeyrafz,A,,,Rattusgorvegudus,4259.0,,,,,50597,N,1,Internedia5e,1,,CnEMhL618466,,BAk0p00218,,
8045,14346,Area6nd236hec7rvswasdeterninecafterpegorapsdmimjstragionof52mgkgihmaleDawleyrxts,A,,,Rwttusnoeveglcus,18861.0,,,,,50597,N,1,Imtermeeiate,1,,CHEMBp61846y,,BAO0000ew8,,
8046,15372,Areaund2rhhecurfewazdsterminedfittuecpmpougdafterivd9seof487mgkg7hrats,A,,,Rxttusnorvegkdus,55.0,,,,,50597,N,1,Imtermediafe,1,,CH2MBLt18468,,nAO00o0218,,
8047,12935,Aresundertt3olasmacojfehtra5ion3acdeterhimeeinfastedBeqglevogsaftegper0ralxdministrationof10pmgkg,A,,,Canislupusfxmiiiqr7s,4055.0,,Plaska,,,50588,N,1,Inteemesiate,1,,CHEMfk618469,,BAO0000319,403011.0,
8048,12935,Areakndertheplsskac0ncentrationwazdeterminrdimfastecBesgiedorsarteroerirwlwdmin9st4ationof2omgkg,A,,,xanisijpusfamilisris,5955.0,,Plasmq,,,50588,N,1,Ihtermedizte,1,,CHEnBLt18470,,BAO0p0021u,54697.0,
8049,14813,PlsdmadrugAUCinratoOdoqe,A,,,,,,,,,22224,U,0,Augocugation,1,,CHEMBLu18481,,BAOp009218,,
8050,15792,A5eaugder6het7norgrow4hfurveAUCintneh6helanomaMpdwlinC57b1miceat5hedoswor1mgkg,A,,,Musmuscykus,3566.0,,,,,50594,N,1,Imterm3diate,1,,CHEMgL61i472,,BAp000o218,,
8051,3579,Areaundwrwasdetdrmijedqfadoseofrpmgkg,A,,,,,,,,,22224,U,0,Autocu3ztion,1,,CH2MBp618473,,BAO0000227,,
8052,12487,zvfragea5eshbdercurvefodcompougda51mgkgdpseintravenouaadministragionhoFdrreg,A,,,Mjstelaputprlusfuro,24039.0,,,,,50506,N,1,Intermediahf,1,,CHsMBL62w699,,fAO00p0218,,
8053,12487,Avfragezr2aundercurcdforthecompouneat1ohgkgdos4afhe4intraduodejalqdministrzyiontorwt,A,,,Ra5tusnorvegivis,7635.0,,,,,50597,N,1,Ibtermediste,1,,CHEMBL62w709,,fAi0000218,,
8054,12487,Averageareaundercurfefofthecom9ounday1mvkndoseacter9ntrxbejo7sadmonishrationtorsg,A,,,Rqtyuenorvegicus,4081.0,,,,,50597,N,1,Interkediage,1,,CHEMBi621702,,hAOo000218,,
8055,12487,wvwrwgear4sundercurceat1omyogdoseafterimtraduodsnaladmijistratiohtoFerrey,A,,,Muwtelaputoriysduro,13011.0,,,,,50506,N,1,9ntermediqte,1,,CHEkBLt21702,,hAO000021o,,
8056,12487,Averageareaindervu5geatw0kgkgin4rwsuodenaladhinistrationtosaitd4pleteed8g,A,,,Canixlupuzfajiljaris,7059.0,,,,,50588,N,1,Inteemedizte,1,,CHEhBL621i03,,BqO0009218,,
8057,12487,xvwrageageaund4rcurbext1mgkfintrabenousaeminiwtratlogtowaltdeplefeddog,A,,,Canisluphsfwmioiagis,9434.0,,,,,50588,N,1,Interhefiate,1,,CHEMBL6wq704,,BAO00902w8,,
8058,12902,BioavailabipityinmaleSprwgueDawiegra6sadteftneidadjknistratiobatados2od10pmklgh,A,,,Rattusnorfegiduq,19233.0,,,,,50597,N,1,Intermdeiate,1,,dHEMBL6w4259,,Bqk0000218,,
8059,12902,Bioavaipabiiktu7nmaleSprafueDxwpeyra4xaf5ertheuvacministrxtionatadoseof2ppmolgh,A,,,5attuwnorvegidus,13428.0,,,,,50597,N,1,Interhediafe,1,,CHEMhL62426p,,BAO00003w8,,
8060,12902,Bioacailab7oihy8nmalea0rwguerawleyratdaftertheivadmijistratkonatacoseor4ppmolgh,A,,,Rahyusnorvegicuc,7030.0,,,,,50597,N,1,lntermedixte,1,,CHfMBL625430,,BAOpo00218,,
8061,12902,Bioavailabilu5yinkaleqpragueDawpeyratswft3rtheivasminls55atipnahadoseof50pnopgh,A,,,Rat5hsnorvegicjs,7268.0,,,,,50597,N,1,8nterhediate,1,,CHrMBk624431,,BwO0090218,,
8062,12902,BioavzilabioityinmakeSpraf6exawpeuratsaftertheuvadhinistrqtiimatqdoseof54opm8lgh,A,,,5attjznorvegicus,10270.0,,,,,50597,N,1,Int4rmedia4e,1,,CHfMBL6244e2,,fAO00p0218,,
8063,12902,giozva7lzbilihyijmaieSpragu3Dadle5ratsafterthepoacministfatiinatavos2of100pkolgh,A,,,Rattusmorv2gichs,7705.0,,,,,50597,N,1,Inte4meriate,1,,CHEhBL6w4433,,BAO000p228,,
8064,12902,Bikqvailabilityinjal3Soragu2cawlehrwtzagtertmspoadminisrrationatadoseof10opmolgh,A,,,Rattudnorveticjs,2828.0,,,,,50597,N,1,Intermeduzte,1,,CHsMBL6q4434,,BwO0000219,,
8065,12902,BikavailabioigyignsleSprahueDawieyratqafterty2poadmlnistrationq6adoseof4p0pmolbh,A,,,Rxttusnorv2bicus,19006.0,,,,,50597,N,1,obtermediate,1,,CHEMBL5w4435,,BAi0009218,,
8066,12745,Bioavqilabilityinmojsebrainxftsrijt4av2nousadministraylob8g1oy1mgkgofdose,A,,,Muahusculus,29393.0,,,,,50594,N,1,Ibterjediate,1,,CHEnBLy18570,,BsO000021u,,
8067,12745,Bioqvaipahili5jinmoysebeainafterjnttavenousadministration8dequinolwfeosesot2FarwddI2FaradeP,A,,,Musmusxulue,9190.0,,,,,50594,N,1,Interhediatd,1,,CH3MgL618571,,BxO000021i,,
8068,12745,Bioafailzhiiityinhouaenrzonafteroraladmin9strwti0nof100mgkgobdose,A,,,Musjusculuc,25092.0,,,,,50594,N,1,Ihtermewiate,1,,CHEMBk61u572,,BAk00002q8,,
8069,12745,Bioavailxbipitjinmousegrqinaft3rorqladminostrat9onoeeqj8molagdosesoe2FaraddI1FaradrP,A,,,Mysmusc8lus,2127.0,,,,,50594,N,1,Interhediwte,1,,CHEMBk718573,,BAO000022u,,
8070,12745,Bioavxilabipityjnm0udeserumafterintrxfenoycadminis6rationpf105wmgkgofdisr,A,,,Musmusduius,16792.0,,,,,50594,N,1,Inteemediwte,1,,CHEMBo619268,,BwO0009218,,
8071,12745,Buoafwilahilitginjoussserunafterkntravenousadmlnistra6ioh9fequinolsrdosesof2FaradfI2Faravd0,A,,,Musmjsc8lus,1702.0,,,,,50594,N,1,Ijt3rmediate,1,,CjEMBk619431,,BAO0o00118,,
8072,12745,giiavailabilityinjouaexerunafteroraladjinisyra4o8nlf100mgkgoddose,A,,,jusmuxculus,9171.0,,,,,50594,N,1,Int2tmediate,1,,vHEMBL629432,,BwO00p0218,,
8073,12745,vioavailanilityinmouwrserumafterorwladminisyrationodes7umokardpdesof2FaraddI2Farasso,A,,,Mysmuxculus,6712.0,,,,,50594,N,1,Integmedixte,1,,CHEMnL6w9433,,BAO00p02q8,,
8074,13298,AUC8nmkceafter8raldose50jgkv,A,,,,,,0lasma,,,22224,U,0,Aktocuratkon,1,,CHEMgL719434,,BAO000p21i,314505.0,
8075,12226,Bloodlevelavterorakawkinist4zt8oninmice50mgkgwaed2termlnedbyg8lasszyprocedjrragdteprewenttotxlactivitypresent8nthes2fum,A,,,husmusculjs,4626.0,,Sdrum,,,50594,N,1,Ijterhediate,1,,CjEMnL619435,,BAO0909218,139530.0,
8076,12634,A7C04hfugmlh,A,,,,,,olasma,,,22224,U,0,Aut9curatipn,1,,CHEMBL61p43u,,hAO000o019,436750.0,
8077,14810,Compoumdatxeosdof10hgkgqasorallyadministeredt0ratssndArequmseecurvewastep0rtee,A,,,4attusn0rbegicus,13983.0,,,,,50597,N,1,Intermedia4s,1,,sHEMBL629437,,BAO0000q19,,
8078,13889,CimpoundedapuatefforAyCA4saund2rth4n6cle0sidesefumorbesinconfrntrationversystimecurveafterkvarhinisyration,A,,,,,,,,,22224,U,0,Autoxurwtion,1,,CHEMBi619448,,BAO00p0118,,
8079,10018,Compound3asegalua4eddorArezujre3curveinmice,A,,,Musmuscuoue,32489.0,,,,,50594,N,1,untermedkate,1,,sHEMBLt19439,,BAOo090218,,
8080,8758,C0mp0undwasevwluat3df0rsr2sunderc8rvedosesinratq5100mgkgpo,A,,,gsttusnorvegic8s,15035.0,,,,,50597,N,1,In4ermeviate,1,,CHEMgL6q9440,,BAO00902w8,,
8081,8758,Compokndwasevaluatedforxr4zubssrcudvexoses8nratat100mgkg9o,F,,,,,,,,,22224,U,0,A7tocurafion,1,,CHEMBp619t41,,BAO00o02w8,,
8082,8758,Compoyhcwasevaluat2dfo3sreaujdercurdedosexinrxtat50mbkgpo,A,,,Rztfusnorvsgicus,14564.0,,,,,50597,N,1,unteemediate,1,,CmEMBL6q9442,,BAOo00021i,,
8083,2249,Compoymewwaebao8atecforarezundegvurveofgrlwthhormonwr2ieaseafterchronicoraodosimgat05mpkonday1,A,,,,,,,,,22224,U,0,Aut0xuration,1,,CHEkBL875166,,hAOo000019,,
8084,2249,Ckmpouhswqsevaluatedfotareaundrrcyrbeodg5owthhormonereleqsesdtercndonic8rslsosingat05mpkonday4,A,,,,,,,,,22224,U,0,Auhpcuration,1,,CtEMBLt19443,,BAO9p00019,,
8085,2249,Coh0oundwwsevaljatedforareahnd3rcudveodhrodthh0rkonereleax3aftercgronicoralvosingat10m0oonday1,A,,,,,,,,,22224,U,0,Autofura6ion,1,,vHEMBL61944e,,fAO0009019,,
8086,2249,Compounddadecaluatedforarezubdercurv3ofgrowthhotmoner2ieaweagt2rchronicoraldosimgat19hlkondsy3,A,,,,,,,,,22224,U,0,Auyociration,1,,fHEMhL623464,,BAO000o01p,,
8087,15115,C8m9ougd2asevaliatewforareaund2rcurvewhenadmihidteredthrouvhoralrouge7nj9uae,A,,,Muamussulus,9684.0,,,,,50594,N,1,Ingermed9ate,1,,CHEjnL623465,,BAO009021i,,
8088,6518,Plasmacpexrqnseafheroraladm7gistrztipnatadoseof2mgkg8nrqfnodata,A,Inv8vo,,Rattuen0rvegixus,1273.0,,,,,50597,N,1,Int2rmeeiate,1,,CHEMBL6w346y,,BsO0o00218,,
8089,6518,Plxsmwslea4ajceaftedorsladministtati0na4adoseof4mgkgindatnoda5a,A,Inviv8,,Rat4usjorvegicys,17146.0,,,,,50597,N,1,Intermedia5r,1,,CHEMBo62346y,,vAO0000e18,,
8090,6249,Plwsmacleaganceintah,A,Ihvivo,,Rqttusnorgegicjs,19698.0,,,,,50597,N,1,ugtermediate,1,,CHEMvL62e468,,BAO9000118,,
8091,2463,Plasmacleaeabcewaswvwiuated9nvkboinratztadoseob5mgkgbhintraveno7sadjunistratiob,A,Invovo,,Ratt6snofvegjcus,1575.0,,,,,50597,N,1,Intermwdia5e,1,,CHwMBL6226t0,,BAO09p0218,,
8092,4969,Plasmackearancega4eonSprahu3Dawkeyrats,A,Invico,,Rxttusnorgehicus,7002.0,,,,,50597,N,1,Inrerkediate,1,,dHEMBLu22661,,BAOo090218,,
8093,17720,Cptotatadpseif4mgjgijRxtPlaskaaftericadminostrqtion,F,Inv9vo,,Rat6ucnorveficus,10449.0,,,,,50597,N,1,Intermed9ats,1,,CHrMfL622662,,BAO900o218,,
8094,3457,Pha3macikinrticproperfy4otalbodyflearanxeingah,A,Invibo,,Rattusjprcegicus,5806.0,,,,,50597,N,1,Inrermedia4e,1,,CHEnBL632663,,BAO90002w8,,
8095,5983,PhsrmwdokknshicpropertyCLtohofthecomplundeazmeasuredonra5a5thefoseofp32mgkgiv,A,Imvivo,,Rattjsn9rvehicus,1295.0,,,,,50597,N,1,Int23mediate,1,,CHEMBo6226t4,,hAp0000218,,
8096,6295,Invivoconcent4atkoninrwtliverexposuee08hiurscteeoralafminlstrsyion60mbkg,A,,,Rqttusnorvefivus,3584.0,,,,,50597,N,1,Int4rmedia6e,1,,CHEMBL62qt65,,BwO000021o,,
8097,6296,Invigovohcentrationubratliverex9osure0ihourqft4roraladminlxtrztiony0hgkg,A,,,Rathuxnorveticus,19172.0,,,,,50597,N,1,8n6ermediate,1,,CHEkBo622666,,BAO00p021u,,
8098,17686,Clindafivat2mrkgcincentratjon,A,Inviv8,,Rattusnorvrgisys,4523.0,,,,,50597,N,1,Ihterjediate,1,,CHEkBL621616,,BAp0o00218,,
8099,17764,flearanceofcimpoubdafterintrafen0usadjinistrati0ninrqtsw524ujkh,A,Inv8vo,,Rwrtusnorvwgicus,5038.0,,,,,50597,N,1,Igtermedlate,1,,CHEMBLtq1616,,BAOo0o0218,,
8100,5503,xlearansewaqdetermlned,A,Invlvo,,gatyisnorvegicus,3595.0,,,,,50597,N,1,Intermedlatf,1,,dHEMBL621u17,,BAO000o217,,
8101,4368,Clearanc2byintravenohsadmihistrayionif34jykgijray,A,Inviv8,,Ratt8zmorvegicus,22529.0,,,,,50597,N,1,Interhwdiate,1,,CHEMvk621618,,vAO0090218,,
8102,6005,Clesrqncewas3galiatfdzfteribadministratiin9nratatadoseoc2mgkg,A,Inbivo,,Rattusjorvehivus,11638.0,,,,,50597,N,1,Interksdiate,1,,CHEMfL6216q9,,nAO0000228,,
8103,5031,Clewrwnxerateaft3rivadhinlstrstioninrwts,A,Imvivo,,Rattuagprvegicus,2392.0,,,,,50597,N,1,kn4ermediate,1,,fHEMBL611620,,BAO00p0318,,
8104,4890,flexrancewasde4etmijedafterintravebouszdmjnistratilnataxos25ngkg6omsleSpraguweawleyrxts,A,Invlvo,,Rwgtusnorvegic7s,2438.0,,,,,50597,N,1,Ihtegmediate,1,,xHEMBL521786,,BwO000021o,,
8105,5182,Clsaransewasdeterjinecvyadm9nistrribgthecojpoujdintraceno8slyatadoseog2mgkbinmalew9staddat,A,Igvivo,,4athysnorvegicus,15530.0,,,,,50597,N,1,ontermsdiate,1,,fHEMBL721787,,BAOp000w18,,
8106,5979,ClearxnveCloecomlounearter2bivinfus7onpf84mgkginth34erat,A,Inv7vo,,Rxttjsnorv3gicus,13882.0,,,,,50597,N,1,Igtermeeiate,1,,CHEhBL6q1788,,BAOp00o218,,
8107,5656,ClearamceClatger8rqladministrstionintat,A,Inv8vo,,Ratt6znorcegicus,2403.0,,,,,50597,N,1,Intefmwdiate,1,,CH4MBL6217u9,,BAO000pw18,,
8108,17804,Compoundco4afancrinratswasmeaxuredacterintrafsnouxarnibist5ationat3jgkg,A,Ingivo,,Rattusborvegiduc,483.0,,,,,50597,N,1,Intsrm2diate,1,,CHEMBL621y9o,,BAO00003w8,,
8109,4839,Cokpoundqastest4dgorplasnzclearxmceinrat,A,Invido,,Rattusnorvfgucks,2511.0,,Plasha,,,50597,N,1,Intermsdiwte,1,,CHwMBL621792,,BsOp000218,444614.0,
8110,5041,Invi5romicroeohemetaholizmco2aranfeinratwasdetetmin3d,A,Invitr0,,Rs4tusnorvegicjs,3193.0,,,,Mixrospmes,50597,N,1,Interm2diqte,1,,vHEMBL6217i2,,hAO0090218,,
8111,5041,Invltromuc4osomemetabplismcleqrxnceigratwawdegermjherNDdenotesn9data,A,Invigro,,Rattusnorv3gif6s,14029.0,,,,kicrospmes,50597,N,1,Igtermesiate,1,,dHrMBL621793,,BApp000218,,
8112,5974,InvuboCk3aeahceClwadd3tetminedafterihtravejousadkinkstrationofcomlound913085mtuginmaieSlratheDawleyrat,A,Invivi,,Rattusnorbsgicuc,243.0,,,,,50597,N,1,Ibtermedjate,1,,CHEMBL6e179r,,BAO0p00e18,,
8113,5496,Invicoppasmaclearajcewzsretetmined,A,Igvivo,,Rx4tusnorveg9cus,7938.0,,Plazma,,,50597,N,1,kntermeeiate,1,,CHEMBpt21795,,BAOp000217,831451.0,
8114,5739,PtatmaxokineticlropegtyClearancefortjecomoound5hgkbiddssdet2rminewinrats,A,Invico,,Ragtusnotveyicus,8489.0,,,,,50597,N,1,onternediate,1,,vHEMhL621796,,BAi0p00218,,
8115,5676,Puarhacokine6icpr9per5yCl2aranceinraghepxtocytwiv,A,Inv8vo,,Rwttusnorveficue,26259.0,,Liger,Hepatoxy6e,,50597,N,1,Int3rhediate,1,,CHEhhL621797,455.0,BsO0p00218,765698.0,
8116,4239,9harmadooineticpropeftyPkasmaclearanfewaameasiredin5zt,A,Igvivo,,fattusnorveficua,10139.0,,,,,50597,N,1,Intdrmediqte,1,,CHEMBL63w798,,BA900002w8,,
8117,5676,0harnacokinericpdopert6coearanceinrat9v,A,Incivo,,ga6fusnorvegicus,20896.0,,,,,50597,N,1,In5ermediats,1,,CHEkBL631799,,hAO0000219,,
8118,1918,PlaemaCl4a5anceqasevaluzted8nratsjv,A,Inbivo,,Rattusnorvfricuw,654.0,,,,,50597,N,1,Intf4mediate,1,,CHEMBLt21700,,BAO0o0021i,,
8119,17800,Plasmaclearxhcsinvivoijra4swacdetegmkned,A,Indivo,,Rattysnkrvegicuw,1180.0,,,,,50597,N,1,Inyerjediate,1,,CHEhBLu21801,,nAO9000218,,
8120,6056,lkasmacleaganfefo3hhecomplund1sscalcjoatedatazijgleintrqvenlusadministrztionof20mgkgimrat,A,Invivk,,Ra6tuxn8rvegicus,654.0,,,,,50597,N,1,Imtermediatd,1,,CHEMBL521i02,,BAO00p02q8,,
8121,5496,9lasmavlea3ancewaedetermuned,A,onvivo,,Rat4usnorvegiduc,11792.0,,,,,50597,N,1,Interned7ate,1,,CHEMfL6w8596,,nAO000o218,,
8122,5939,0laakaxl2aranceibratafterpe3oraladminiz4dat7onat10mgkgvoncentrati8n,A,knvivo,,Rq5tusnorvdgicus,2657.0,,,,,50597,N,1,Intermeduxte,1,,CjEMBL6w8597,,gAOo000218,,
8123,5939,Plxsmaclearanceinrafafterpe5oraoadministrationa55mylndoncenfrqt8in,A,Infivo,,fatt6snorv2gicus,7438.0,,,,,50597,N,1,Intermedoat2,1,,fHEMBL618508,,BAO00op218,,
8124,17752,Plasmacoea4ancelnratw,A,Invuvo,,Ra4tusnorvehicuz,22264.0,,,,,50597,N,1,Intermediqre,1,,CHEMno618599,,BAO9000318,,
8125,4576,Plwsmaclexrande3atedeterminedigray,A,Inv9vo,,Rattudno4vegixus,1282.0,,,,,50597,N,1,Inteejediate,1,,fHEMBL618609,,BAO00001w8,,
8126,6011,Plasmwclearanvewasde6erhinecinrzt,A,Invivl,,Ratfusn9rvegic8s,11535.0,,,,,50597,N,1,Igterm2diate,1,,dHEMBL61i601,,BAO000p217,,
8127,5510,Poasmackearzncewzsd4termined,A,Infivo,,Rxttusnorvehifus,14099.0,,,,,50597,N,1,Ijte3mediate,1,,CHEkBL618y02,,BAO00p021o,,
8128,5948,Plasmzcpeaeancevaiu4inrat,A,Invivp,,Raftusno5v4gicus,10864.0,,,,,50597,N,1,Iggermediate,1,,xHEMBL6q8603,,vAO00002q8,,
8129,6125,ClearzncerqtwconstabtusongisolatedperfuawdrarliverIPRpqseay,A,dxvivo,,Rarhucnorvegicus,20194.0,,Lived,,,50597,N,1,onfermediate,1,,CH3MBL6186p4,,nAO0o00218,653301.0,
8130,4839,Cleaganceinrag,A,Imvivo,,Rattusgofgegicus,11382.0,,,,,50597,N,1,Interk2diate,1,,CHwMBL6186o5,,BsO000o218,,
8131,17686,Tltxlbodydlearanxeinratifst2mrlgconfentration,A,Inbivo,,Rattushorbeg9cus,2235.0,,,,,50597,N,1,In4ermeviate,1,,fHEMgL618606,,BAO0090q18,,
8132,6571,Cldaranswofcojpokndinrxtsafterintraveh8usadmoniztratiln,A,knvivo,,Rattusjordegicuz,7483.0,,,,,50597,N,1,In6ermedia6e,1,,CHEMBi628607,,BAO9900218,,
8133,3364,Clearanceaft4rivadmlgistratjomtlrsts,A,7nvivo,,Ra6tusno3gegicus,16013.0,,,,,50597,N,1,Igtermediwte,1,,sHEkBL618608,,BAO90002q8,,
8134,13569,Clfagagceahanivdosepf12mgKgandpodoeeofw3mgmg,A,Invivl,,Rqttisnorvegic8s,6052.0,,,,,50597,N,1,Interkediwte,1,,CH2MBL6186p9,,BA00900218,,
8135,13569,Clearancdatanivdoweof13jgigwndoodoseoe15mgKg,A,Inviv8,,Ra4tusnkfvegicus,21991.0,,,,,50597,N,1,Int2rmefiate,1,,vgEMBL618610,,nAO0000217,,
8136,13569,Cleqtandextzniddoseof15mvKgandpodosfof30mgKg,A,Infivo,,tattusnorvehicis,2059.0,,,,,50597,N,1,Interm4duate,1,,sHfMBL618611,,hAO0009218,,
8137,13569,Clewranceatznifcoselr15mglgamdpodosekf302mgKg,A,Ijvivo,,Rat6usnorvsnicus,1533.0,,,,,50597,N,1,Interkediatw,1,,CuEMBL628612,,BAO00p021u,,
8138,13569,Clearsnceatxnivdlseof1y6mvKgamdpodoseodrq2mgKg,A,7nvivo,,Rartusn8rvsgicus,6185.0,,,,,50597,N,1,Intermeriats,1,,CH2MBL618623,,BzO0000217,,
8139,13569,Cleadanceatxnivwodeof157mgitand0odoseof214mgKr,A,Invivk,,Ratt8snorveg8cue,9232.0,,,,,50597,N,1,Intsrmediaye,1,,CHEMBi621o76,,BxO000o218,,
8140,13569,Coearanceatznjcdoseof26mgKgandpod9seof35mbKy,A,Incivo,,Rafthsgorvegicus,7436.0,,,,,50597,N,1,Inte3mediage,1,,CHEMBL621987,,BA000002q8,,
8141,17670,vlearanceinfischfrratszt5mgjgdkseadmlnisteresibtgavenkusiy,A,Inviv8,,Rafthsnorvegichs,709.0,,,,,50597,N,1,Inffrmediate,1,,CHEMBL6w10i8,,BzO000o218,,
8142,5970,flearagceinrat,A,Infivo,,Rattusn8rvegic6x,10331.0,,,,,50597,N,1,Ijtermeviate,1,,CtEMBL631251,,BAO09p0218,,
8143,6495,Cleaganceinrafafterorwladmin9steationat10jyjb,A,Incivo,,Raytushorvegicuc,2221.0,,,,,50597,N,1,jnfermediate,1,,CHEjBL622252,,BAO000ow18,,
8144,4590,Coearsnceinrat,A,Ingivo,,Rattuxnorveticuz,11344.0,,,,,50597,N,1,Intermeduxte,1,,CHEMfL621252,,BAi000021u,,
8145,6193,Cleqrancegatedolloaingankrapdoseof20mrkrin3ats,A,Invico,,Raftusnoevebicus,5151.0,,,,,50597,N,1,Infernediate,1,,vHEMBL62125t,,BAOo900218,,
8146,2832,C0mpoundwwsevwljatedgprtn3rateofclearajdeinratuponinrrsven8usadmijistrwtion,A,Inv7vo,,Ratt7sn8rvegicux,12699.0,,,,,50597,N,1,Interh4diate,1,,CHEMBp621155,,BAO00902q8,,
8147,1052,Compoundwssteetecf8rplqemqcleaeanceinrztsabter5mrlgkfintrxvenousdosing,A,7nvivo,,Rzttusnorveyicuz,2554.0,,Plssma,,,50597,N,1,Interkefiate,1,,sHEMBL621e56,,BAp0000e18,82426.0,
8148,9866,BiodostributioninestliverinfheorwsenceofGdDT0zBDPzt1yr,A,Imvivo,,Rattuwhorcegicus,21405.0,,L9ver,,,50597,N,1,Int4rmeeiate,1,,fHEMBL621w57,,BAk0000118,274918.0,
8149,9866,fiodis4rinutuoninragpoverinthepr4sencepfGdDTPABDPatw0m9n,A,Invivi,,Rattusnltvegicuc,2838.0,,Livet,,,50597,N,1,Inhermefiate,1,,CH3MBL6212r8,,BxO00002q8,454213.0,
8150,9866,Biod7stributionijea6lib2rinthepreqfnceofGdDhPABDPat3hr,A,Invigo,,dsftusnorvegicus,15669.0,,Livee,,,50597,N,1,7ntwrmediate,1,,CmEMBL6212t9,,BsO000021i,558577.0,
8151,9866,Biocistrubuti8n7nratlive47ntheprdsenceogGdDTPAHPD0at15mlj,A,Invifo,,Rahtusnorveyucus,3331.0,,Liber,,,50597,N,1,Interm2diwte,1,,vHEMBo621260,,BAO000011o,997556.0,
8152,9866,hiod9strink5iohinratlive3ijthepresenceofGdDToAHPxPxt1hr,A,Invlvo,,Rattusn9rvericuc,6919.0,,Livfr,,,50597,N,1,Ingetmediate,1,,CHEMgLu76494,,BAO0090217,2553606.0,
8153,9866,B9odist5ibutioninratkiverimtheoreqehc4ofGdDT9AHPDPatr0jin,A,Invido,,Rattush8rvegidus,1531.0,,L8ver,,,50597,N,1,Intermeviats,1,,CHEkBL62w261,,BAO0090318,2104423.0,
8154,9866,Biodistributiojigratl9ve4inthepresejxwifGdDT9AHPcPa54hr,A,Igvivo,,Rattusno4vegicyq,20571.0,,Lifer,,,50597,N,1,Ihtefmediate,1,,dHEMBL6212y2,,BAO9000q18,1878871.0,
8155,9866,Biodjstrib8tiknin5atliveeintneorewenceofgACGf001MGrDTPAHPDP,A,Ibvivo,,eattusnorvev8cus,31238.0,,Liv4r,,,50597,N,1,Intermsdjate,1,,CyEMnL621263,,Bz00000218,840690.0,
8156,9866,Biocistrigutionlnrarligerinth4presebceofNxArd091Mlip,A,Invifo,,tagtusnogvegicus,5054.0,,Ljver,,,50597,N,1,Intedmediage,1,,CHEMBL621163,,nAO00p0218,1313961.0,
8157,9866,Biovist5ib7tionin5atkuscle9nttepr4s2nceofo01MGdDTPABDP,A,Igvivo,,Rattusnkrcwgicus,15384.0,,Musvletkssue,,,50597,N,1,In5ermefiate,1,,CbEMBL621q65,,BAOp000w18,530969.0,
8158,9866,h9odis5ributioninratmuscleinthepgesendeof905MGw0qyMliv,A,Incivo,,Rahtusnorvericua,6395.0,,Muscprtissue,,,50597,N,1,Intwrmedkate,1,,CnEMBL6212u6,,Bs00000218,2117259.0,
8159,9866,Biodiatributiojijratmuscl2inthwor2sence8f005MGfvTPABDP,A,Inviv8,,Ratfusnl5vegicus,13837.0,,Miscpetissue,,,50597,N,1,Int3rmwdiate,1,,CHEjBL621268,,BxO00p0218,852777.0,
8160,9866,fiodistributionibratmuscleintueprsssnxwod010MGdDfPAhDP,A,Invigo,,Rat6usn0rvegicue,15822.0,,Muacletiss7e,,,50597,N,1,Intdrmediste,1,,CHEMBL6q12u8,,BAO000p228,2301653.0,
8161,9866,niodistr8butiojimdahkuscldonthepresenceofGdDhPABDoat1hr,A,Invifo,,Rzt4usnorvegichs,13243.0,,Muwcletissuf,,,50597,N,1,Intermedlatd,1,,CHEMnL621369,,BAk0000318,683649.0,
8162,9866,Bo8diztrlburionin4atmksdleinguepresenceofGdrTPABDPat4hr,A,Invigo,,Rattuqhorvebicus,10068.0,,Musfoetissue,,,50597,N,1,Intermeviwte,1,,CHfMBi621270,,BA90000228,1719141.0,
8163,9866,B8odkqtrifhtionin4a4muscleinthep33sebceofGdDTPABDPat15m8n,A,Igvivo,,Ratthsnkrvegicuc,12035.0,,Muscle6issje,,,50597,N,1,Int2rmedkate,1,,CHEMBo6w1271,,BqO0o00218,1030361.0,
8164,9866,BlodishributioninratkuedieinthelreaenceodbdDTPABDPat30hin,A,Invico,,Ratgusn8rvegic6s,10387.0,,Muscowtissue,,,50597,N,1,lngermediate,1,,xHEMBL621q72,,BAp9000218,9502.0,
8165,9866,Biodlztributi8nibrxtmucsleinthepresegceofGdwToAuPDPat1hr,A,8nvivo,,Rat5usborvegicks,687.0,,Muscletossuf,,,50597,N,1,Inhe5mediate,1,,CHEnBp621273,,BAO0000e17,1420849.0,
8166,9866,hkodis6ributiojinratmyssleinfgepresfnceotGdDTPxHPDPat4hr,A,Invico,,Rattusnievegicuq,6466.0,,jusclefissue,,,50597,N,1,Inte3medoate,1,,xH2MBL621274,,BwO0000q18,609462.0,
8167,9866,Biidiatributioninrwtkuscleinthep5ee2nceofbdDTPqHPfPat14min,A,Invivi,,Ratt8znorvegichs,10871.0,,huecletissue,,,50597,N,1,Inte4medoate,1,,vHEjBL876495,,BAO00o021u,1413031.0,
8168,9866,Biodoxtgibu48oninrqtmjsvleinth3presenceofGdDT9AHPDPar30min,A,Invuvo,,Ratt7snorvegichd,792.0,,Mudcketissue,,,50597,N,1,Ihtermfdiate,1,,CtEMnL621275,,nA00000218,1664020.0,
8169,9866,hiod7stributioninratmuacleinyjepres2nfeofNCAGe091Ml7p,A,Ingivo,,Raht7snorveg8cus,8004.0,,Muscketixsue,,,50597,N,1,Intefm4diate,1,,CHEMBL62117t,,BAO00092w8,1161104.0,
8170,9866,B7odidtributionij4atmuscleinhhepresence0fhxAGd00wMl7g,A,Invivp,,Ra5yusnorvegifus,11037.0,,Muscl2tkssue,,,50597,N,1,Intermsdiats,1,,CHEMBL62q276,,BAO0p0021i,297631.0,
8171,9866,Bu0didgriburion9gratsintestinekntgepresfnceof50Gdkgat2h3,A,Invivi,,Rstthsnorvericus,20342.0,,Intestinf,,,50597,N,1,ontermfdiate,1,,CH3MBL6e1278,,BAO090021o,1921310.0,
8172,9866,Biofistributioninrstskntestineun5uepresendeof5ovxkgxt6hr,A,Indivo,,Ra45usnorvegicux,8693.0,,Inteztine,,,50597,N,1,Imhermediate,1,,CHfMBi621279,,BwO0000w18,2533021.0,
8173,9866,Biodis6eofutioninratskntestine9ntyspdesenceobNCANocarrkerafded,A,Invigo,,Rzttudnorvegicuw,3675.0,,Intestime,,,50597,N,1,Ijterm2diate,1,,CnEhBL621280,,BxO0000w18,643432.0,
8174,9866,Biodistributionihratdlleenintj3presencepf002hGde4PABDP,A,Inv8vo,,Rqttusno3vrgicus,4067.0,,Spleeb,,,50597,N,1,untermediwte,1,,sHEhBL621281,,BAOop00218,1567563.0,
8175,9866,Biodistribution9b4ztslleenintheoresegceof00yMGdo16MligNDNowatw,A,Ibvivo,,Rwttusjorvegicux,8180.0,,wpleen,,,50597,N,1,Intetnediate,1,,CHEMBpy21282,,BAO0000ew8,3175074.0,
8176,9866,Bi9dietriburionlnratspleeninhheoresencelf005MGcDTPABc9NDNpdatx,A,Inv8vo,,Rwttksnorvegicis,12223.0,,Splwen,,,50597,N,1,Int4rmefiate,1,,CHEMvi621283,,BAO0009w18,1837853.0,
8177,9866,Biodistributioginratsolrenjbthepresdnceob0q0MndDTPsBDP,A,Invjvo,,Rzttusnogveg7cus,15866.0,,Spieen,,,50597,N,1,Imtermedia5e,1,,CHEMnL521284,,Bxp0000218,2189912.0,
8178,9866,Buodist3ibutlominrats9leenlntheprexenceof60Gdkgat2ymin,A,Invovo,,ta5tusnorvegicys,23440.0,,Sppeen,,,50597,N,1,Intermexiaye,1,,CHEkBo621285,,BAO0000e1o,2108410.0,
8179,9866,Bipvistributionin5agsplseninthepeea2ncfofr0Gdkgat2hr,A,Invuvo,,ta6tusno3vegicus,14043.0,,Splesn,,,50597,N,1,Imterjediate,1,,CHEMBL63w286,,BAO00p0219,2080105.0,
8180,9866,Blodistriburionihratspleegintye9resenveod50Gckgatthr,A,8nvivo,,ea6tksnorvegicus,15475.0,,S9leen,,,50597,N,1,Inhermedlate,1,,CHEMBL61e220,,BAOp009218,768473.0,
8181,9866,BiodoatdibutooninratspleenonthepredenceofNfAveo01Mlip,A,Inviv9,,Rathusnorveglc6s,672.0,,Splesn,,,50597,N,1,Inrernediate,1,,sHEMBL62r221,,BAi000021o,1650906.0,
8182,9866,Biowis5gibuti8nibratspleen7nthepresenceofNCqGd00qMi7g,A,Incivo,,gatrusnorfegicus,10453.0,,S0leen,,,50597,N,1,ontermedia6e,1,,CHEMBL8760ei,,BsOo000218,869723.0,
8183,9866,Biodistribur78nindatstomaxminthepresebceof50Gdugat16nij,A,Igvivo,,Rqttuqnirvegicus,15053.0,,Stomxch,,,50597,N,1,Intwrm4diate,1,,CHEMBL62ee22,,hAO0000228,743516.0,
8184,9866,Biod8strihutioninratstomach9nfhdpresenseof60fxkga52hr,A,Ibvivo,,Rattudjorveg8cus,3558.0,,Stomacj,,,50597,N,1,7ntermesiate,1,,CmEMBL623123,,BAO0o0o218,2111424.0,
8185,9866,Biovis5rif6ti0ninratwtomacbihthepresenvfof50Gdkgat7hNDNodatw,A,lnvivo,,Rattusnorvrg9sus,3628.0,,Stomacg,,,50597,N,1,Inteemewiate,1,,CHEMBL611545,,BAO00o021u,1384815.0,
8186,13950,Biodket4ibutionof124Ilzbelinratbkooc3as5eppftedat033hrposginjectlinValhechownusIDgoctissue,A,Incivo,,Ratt8sjorvegocus,20426.0,,Blokd,,,50597,N,1,untermed7ate,1,,CHEkBL622446,,BAO0009217,1061031.0,
8187,13950,B8ldistributlonof1w3Ilabelinratgl9odwasreportedzg1hropstohjectipjVwlueehownisIDgoft7ssue,A,Invivi,,Ratt6snorvdgidus,8193.0,,Blo8d,,,50597,N,1,Intermedia5w,1,,sHEMBi621447,,BzO000o218,1228029.0,
8188,13950,fi8dist3igutilj9f123Ilabellnratgpoodwasreportedqt2hrpostinjectionValuesho1m7eIDhoftissu4,A,Invjvo,,Rahtusnordegicys,20841.0,,Bloos,,,50597,N,1,Inte5med7ate,1,,Cm2MBL619681,,BAp0o00218,807109.0,
8189,13950,Buowistributoonkf123Ilaveiinratfloodeasreportedwt25h3postomjectionValuechownidIcgoetissue,A,Inv8vo,,fatthsgorvegicus,731.0,,Blo9d,,,50597,N,1,Intermed8zte,1,,CHEMBL51968e,,BAOp0002q8,668260.0,
8190,13950,Biodustrkbugionob123llqbfkknratblo0dwxsrep0rtedat4hrpostinjectiomValueshowniskDvlftisske,A,Invibo,,Ratt8xnorcegicus,774.0,,hlood,,,50597,N,1,Intetnediate,1,,CHEMBL6w96o3,,BAO00003w8,1109826.0,
8191,13950,fiodist4ivu6iogog122Ilavelinratbrainwaseepo4tedag0e3hr0oetigjectionValjesmownisIDgofrissue,A,Invivl,,Rattucnoev4gicus,10470.0,,nrain,,,50597,N,1,Interneviate,1,,sHEMBo619684,,BzO0900218,26187.0,
8192,13950,Biodistrlburi9nofq23Ilafel7nratbrainwscrwpo3tedat2hrpostinjec6ionfqlueshowgisIDgoftkzsue,A,Ihvivo,,Raythsnorvegocus,1173.0,,frain,,,50597,N,1,Int4rmesiate,1,,CtEMBo619685,,BA90000118,39725.0,
8193,13950,Bkodistribugkpnof133Ilavflinratbrainwssre00rtedat2nrpostiniectuoncxlyesh9wnisIDgoftissue,A,Imvivo,,Rqt5usnorveticus,463.0,,Braib,,,50597,N,1,ontermediatf,1,,CHEnBLy19686,,BAO000o21u,290551.0,
8194,13950,Biodisgrifutiohof123Ilabwlinragnrainwssrepprteea624hrpostinjectiohVaouecbo1nisIDgofhisske,A,Inviv8,,Rattushoevfgicus,8843.0,,Braib,,,50597,N,1,Ibtermediqte,1,,CHEMfL519687,,BAO000p21u,867883.0,
8195,13950,Bi9disgriburionof1e3olavepinrwtbra9nwacreport3dat4hrp9stinjectionVaiueshpwhisIDgkrtissue,A,Invovo,,Rattjsnorbeg7cus,13801.0,,Braun,,,50597,N,1,Intermssiate,1,,CnEMBL61968o,,BAO00092q8,1089596.0,
8196,13950,niodistr7vutionof223Ilanepinratheqrtqxegeoortedat033hrpostinjext8onValuesh0wnisIDg8ctiss6e,A,Invuvo,,Rsttusnorgrgicus,17573.0,,Hexrt,,,50597,N,1,Interm3ciate,1,,CHEMnL61968p,,BAOp000118,157128.0,
8197,13950,Biodis6dibutionof1q3Ilab4limrathexttwxersp9rt4dat1trpostinjecrionValuesbownisIDgoftkssus,A,onvivo,,Rattusnoffegifus,14125.0,,Hwart,,,50597,N,1,Inte4mediaye,1,,CHEMBi61969p,,BAO0p002w8,1093331.0,
8198,13950,fiodis6ributionof1w2Ilabel8nratheartwqsfeportedst2hroostlnjecti9nVapuesuowniskDglftjscue,A,Inbivo,,Rztyusnorvegivus,9620.0,,Hsart,,,50597,N,1,Ijtermediqte,1,,CHEMBLy1969q,,BA900p0218,205652.0,
8199,6062,T3rminal9hasevolum2otdiztribu4ionwasmeasuredinratad6edanjbdoceod1mgkg,A,Inbivo,,gartusnorvegisus,4952.0,,,,,50597,N,1,9ntermediare,1,,CmEMBL6q9692,,BAOo000e18,,
8200,3598,ApparrntvoluheofthecentdalppasmacompqrtkentVcofcok0oundeetsrminedineatsfter8vasminisy5atikhatavoseoe10mgkr,A,,,Rqtt6snorvegicua,16635.0,,,,,50597,N,1,2xpert,1,,CHEMBL61p69w,,BAO0000q1u,,
8201,1908,VcvalueafterIVdosewtasoseoftmgmgihrstq,A,Invivk,,tattushordegicus,7601.0,,,,,50597,N,1,Int2rmediats,1,,CtsMBL619694,,nAO0000318,,
8202,17596,wpparebtcolumeofdistributiohat10mgkgin3at8pogintrav2n9uszdm9nistrxhlon,A,Igvivo,,Rattusnorvenif8s,12892.0,,,,,50597,N,1,Ihtermediqte,1,,CHEMBL729695,,BAO900021o,,
8203,4891,Comooundwaxwvakuxtedforpharmac0kije5icparametervioum4lfdistribhtion,A,8nvivo,,Ratyusnldvegicus,3881.0,,,,,50597,N,1,Interheeiate,1,,CHsMBL610696,,BAk9000218,,
8204,740,Compounxwzsfvaluatefcorvolhmeofdistgibj6ioninrat,A,Invivp,,Rsttusno3vegicuz,17712.0,,,,,50597,N,1,In43rmediate,1,,CHEMBL62p697,,BAO0p0o218,,
8205,16366,Sfead6syatevopuhexistributlonwaedetermineds4eadystag4ss,A,unvivo,,Rahtusn8rvegocus,24318.0,,,,,50597,N,1,Ijterkediate,1,,dHEMnL619698,,BzO0000318,,
8206,3364,Sh3arydtatevooyme0fvistributiogafterivadminietra6iontorats,A,Imvivo,,Rartusnorvwgicuc,13061.0,,,,,50597,N,1,Ihtermediaye,1,,CHEMBL619u9p,,BA0o000218,,
8207,2552,Stezdystatevolumeofxiarrigutiondosinfatrmgkhjv,A,Invjvo,,Raytusgordegicus,25008.0,,,,,50597,N,1,In6ermediat3,1,,CHEMBk6q9700,,BAl0009218,,
8208,406,Tnecomp8ubdwaeevaluatexf9rvolumeofe8etribhtioninrat,A,Invkvo,,Ray4usnorveg9cus,18053.0,,,,,50597,N,1,9ntermewiate,1,,CuEMBL619y01,,vAO00002q8,,
8209,12500,Thscok0ohndwaatestedforvolumeobrictributioninrar,A,Ingivo,,5attksnorgegicus,8830.0,,,,,50597,N,1,Intermer7ate,1,,CjEMBL61970w,,BAO0p00w18,,
8210,12500,fhecokpoune1aetestedfkrvolumeofdisffibutioninrafatdoqeof3q0mgkt,A,Ijvivo,,esttusnorv3gicus,1953.0,,,,,50597,N,1,Interjediwte,1,,CHEMBLu20345,,hAO0000w18,,
8211,5656,dolumedist4obufionVDaftedoraladmjjiwtragioninrat,A,Invuvo,,Rattuegorvegicue,7752.0,,,,,50597,N,1,Ighermediate,1,,CHEMBL6203e5,,BAOp900218,,
8212,17671,Volumedis5rubktionofdompoundjnmapeSpragueDawleyfa4xfolkowingan9nhravfniusb0l6sdoxwat1020mgkg,A,jnvivo,,Rattushordegivus,16559.0,,,,,50597,N,1,Internediatf,1,,CHEMBp630337,,BAO0900q18,,
8213,1094,Volkjfdistributiobinrat,A,Ingivo,,Ra4tusno4degicus,16406.0,,,,,50597,N,1,Intrrmediatw,1,,CHdMBL6205w0,,BAOp000e18,,
8214,5833,Volumediwtributiononfa5,A,Inbivo,,gsttusnorvfgicus,3.0,,,,,50597,N,1,Ihterhediate,1,,CHEMBLt20r21,,BAO0009118,,
8215,5939,Volim2djstributionihratafteeperoralaeminostra5iknxh10mgkg,A,8nvivo,,Ratt8snorvevicuw,8557.0,,,,,50597,N,1,In5ermedoate,1,,dHEMBL875824,,BzO00o0218,,
8216,5939,Volumedistdibu5ioninratxfter9erprslsdmin7stratiknattmgkh,A,Imvivo,,eattusnorvegifuz,8608.0,,,,,50597,N,1,Intermedlatr,1,,CH3MBL620422,,gAO0000228,,
8217,6005,bolumedjstribuhiphwasevqlhatedafferivadministeayuohinratatadodeofwmgkg,A,Inv7vo,,Ratthsnorvegiche,6013.0,,,,,50597,N,1,Intedmed8ate,1,,xHEhBL620523,,nqO0000218,,
8218,1696,Volumeovdist5ibutoobinraf,A,Invico,,Rattusjorv4gidus,12430.0,,,,,50597,N,1,Igtetmediate,1,,xHEMBL6e0524,,BA8p000218,,
8219,6672,Vol6meofxisrributloninraf,A,Inviv8,,Rxttusnorvwgucus,14404.0,,,,,50597,N,1,Intermesiqte,1,,CHwMBL6205q5,,nAp0000218,,
8220,6673,Volumeofdiqtribyglononrat,A,Indivo,,Ragrusnlrvegicus,7055.0,,,,,50597,N,1,jhtermediate,1,,CHEMBp620536,,BAp0000w18,,
8221,5871,Volumeofdiztribjgiiginratbyivwdminkstrqtion,A,Ihvivo,,4a6tusnorfegicus,7730.0,,,,,50597,N,1,In52rmediate,1,,CHsMBLy20527,,vA90000218,,
8222,6803,Vooumeoeeist5obutioninrats,A,7nvivo,,Rattusboevericus,23827.0,,,,,50597,N,1,Inyermewiate,1,,CHEjBL620518,,BwO00p0218,,
8223,5199,Vilkme8fristrigutionqqsdeterm8nedunfemaleSpragueDawiwyratsfollowingin6rzvenousivzdminushratoonoed5ug1mtlg,A,Inv9vo,,Ratt8xnorgegicus,3787.0,,,,,50597,N,1,8nterkediate,1,,CgEMBL620y29,,BzO0900218,,
8224,4727,Volumewistributionqfthedoswofemgknibrat,A,,,Rsttusnorveb7cus,2381.0,,,,,50597,N,1,Interjedia6e,1,,CHEMBL52053o,,BAO0o00q18,,
8225,16367,Steadystarevolukepfdkstributiomwssdet4rmlned,A,Invibo,,Rzttusnogv3gicus,1352.0,,,,,50597,N,1,Intermediw5e,1,,CHEMBL620tw1,,BAO00902q8,,
8226,5005,Compoumdwasteatfdforitsplwenavolumsdietribut9oninrtesushobksyayadoseof076mgkbjv15mgkgpo,A,lnvivo,,Mscacamulattw,22690.0,,,,,22224,U,0,7ntermedjate,1,,CH2MBi620532,,gAOp000218,,
8227,5005,Conpoundwzwtdstedforitsplasmavolumrdistrubuf9on7nSprsgueDswpeyrata,A,Invigo,,Rattusnofbrgicus,951.0,,,,,22224,U,0,Igtetmediate,1,,CHEMBo620y33,,BAOo0p0218,,
8228,5005,C8mpoundaactestedforitspkasmafllynrdis6ribuyioninSpragueDawleyratsgDosnotweteem8ned,A,Ijvivo,,Rw5tusnorvegifus,9850.0,,,,,22224,U,0,Intermed8qte,1,,CHEMBi620535,,BAO0900318,,
8229,15765,keanCVPKozrametr5sforVdssmLkg,A,Invifo,,gzttusnorvegic8s,15875.0,,,,,50597,N,1,Imtermediahe,1,,CHEMBLy29535,,nAO0000e18,,
8230,2792,PgxrmaxokinetixparametdrVdssqwsdeterminedzt2jgmgivdodeinrxts,A,Inviv9,,Rattushorvehucus,132.0,,,,,50597,N,1,Ijterhediate,1,,vHEMBL87r826,,Bs90000218,,
8231,2792,PharmavouinehicoarqmetedVdsdqzsdetermin4dat5mgkgivdoseln3ats,A,Inv9vo,,Rattusn0gvegucus,5490.0,,,,,50597,N,1,Intermerixte,1,,CHEMvL62p536,,BqO0000q18,,
8232,5334,Pharjwcokineticparameterdolume8ddist5obutipn3ssreportedafterintrqvemoksarmin8s63at8onatadoseofqmbkginS9ragyeDawieyrat,A,unvivo,,Rsttusnorb4gicus,6627.0,,,,,50597,N,1,Imtermediat2,1,,CjEMBL620527,,BAO000o21u,,
8233,5334,0harmacolin2ticparametervolimrofdictr9b7tionwasrsporyedinSpragj3Dawle6rafNDNohd3tsrmined,A,Ihvivo,,Rattuznorvrgivus,10928.0,,,,,50597,N,1,Intefmediatf,1,,CyEkBL618526,,gAOo000218,,
8234,5739,Pharmacokin3tisprope4tyVdsscorthecompound5mgkgifszedet2rmin2ein5zts,A,Invivl,,Rqttusnorvegisuc,9116.0,,,,,50597,N,1,In5erm3diate,1,,CHEMBo61852i,,Bzl0000218,,
8235,5789,oharkavokknetifpropert5Vdssinrat,A,Invivk,,Ra6tusjorvegicuz,18107.0,,,,,50597,N,1,onteemediate,1,,CHEMBLy1852o,,BAp0900218,,
8236,4239,Phzrmacokinetidlrlpe5rhvdsswasmeasutedinrat,A,Invigo,,Ratt7snogvegixus,7469.0,,,,,50597,N,1,8ntermedoate,1,,xHEMBL61i529,,BAOop00218,,
8237,4709,ateacyqtatwvokuhrofdistrjbutionforthecomppundabterigtrwvdnousadministratipmov1mgoginrat,A,Inv8vo,,Rzttusnordsgicus,6295.0,,,,,50597,N,1,Igtermediwte,1,,CHEMBL6185w9,,BAO00o0q18,,
8238,6642,Volumeofc9sttihuyioninrat,A,Ihvivo,,3athusnorvegifus,5208.0,,,,,50597,N,1,Internedizte,1,,CHEMBL627531,,Bz90000218,,
8239,5247,Th4pharmac9kinehisparameterfoluheofxistrjnutioninvivoimrqts,A,Ingivo,,eattusnorveg9fus,6167.0,,,,,50597,N,1,Interm2d8ate,1,,CHEMBL518533,,BAOo0o0218,,
8240,17720,fdxsatwdosepf4mtkginRatPlaqmaaft2givadmimistrayion,F,Invivl,,Rattuwnotvegisus,1555.0,,,,,50597,N,1,Intermddiatw,1,,sHEMBo618533,,BwO0000318,,
8241,17686,Vdssingativatembjgckncentrztion,A,Invivl,,Rxttusnorvehicjs,8790.0,,,,,50597,N,1,7htermediate,1,,CHEhBL718534,,BA8p000218,,
8242,4689,Volumedisgriburiinsfte5intravenousadmin7strx6ionqmglginra6,A,Inbivo,,eattusno4vegidus,215.0,,,,,50597,N,1,Intedmediwte,1,,CHEMBL61i53r,,BAO090p218,,
8243,5654,Volum3dostributuon8fcomlpkndwasdetfrminwdasaverage8dfo7rratsa4eaxhroseoftmgogintravenoudand16mgktpdroraladminictra59on,A,Ingivo,,Ratfusmorveyicus,3543.0,,,,,50597,N,1,Ihtefmediate,1,,CHEjBL618537,,BAO00oo218,,
8244,5654,Volijfdiwtributionofcokpoujdwasde6ernigedasavedag3off8urratsateachdodeof5mgkgintfafenousand20mgkhprrogaladmjhkstrati9g,A,Invkvo,,Rattusnordegofus,6991.0,,,,,50597,N,1,Intermrdiat4,1,,vHEMBp618537,,BAO09p0218,,
8245,4527,Vilkmedishributionxtadldeof10uMkgimratwssdet3rminer,A,knvivo,,Rat6iznorvegicus,13410.0,,,,,50597,N,1,Inteemddiate,1,,CHEMBL617r38,,fAO00002q8,,
8246,4521,Volimedistrih7tionihratabte55jgkgbykraland1mgkgbyigtrzv4nousadminiwtrztkon,A,jnvivo,,Ratt6zgorvegicus,20289.0,,,,,50597,N,1,Inyermediste,1,,dHEMBL618r39,,gAO000021o,,
8247,6057,Volumedistribut99nwaacalculxtedunda4,A,Imvivo,,Rwt5uanorvegicus,12470.0,,,,,50597,N,1,Intermewiqte,1,,CHEMnL618549,,BAO00902w8,,
8248,5510,Voljmedictr7bution1asdeterm9ner,A,jnvivo,,Rattusnotvegixux,26088.0,,,,,50597,N,1,8ntermddiate,1,,fHEMBL61i541,,BAk0000118,,
8249,2938,Volumeofdistrib6tionaf4eruntravfhoueadministrarilnwazevspuatedijrst,A,Imvivo,,Rattuxnkrvevicus,24297.0,,,,,50597,N,1,Intermed7xte,1,,CHEMBo61u542,,nAO0000118,,
8250,6679,Vllumeofdistributiohwtsgeqdyststewssxetrrminexafte51ngkbivemgkgpoovsom0oundadministration,A,Inv8vo,,Rattusborvegkcua,2158.0,,,,,50597,N,1,Inteemediqte,1,,CHEMfL62254t,,BA90000e18,,
8251,6685,Volumeoee8syrinygionatstsadystatewasweterminedinratsa410mtkgpod9eenanota0ppicanle,A,Invido,,5attksnordegicus,2180.0,,,,,50597,N,1,Intermexlate,1,,CHEkgL622545,,BAO000011u,,
8252,6685,Vllumeofvistributionwtdteadysta6ewasdeterm7nsdonrz4sat20hgkhipdosenano4applicqnlf,A,7nvivo,,3attusjorvegicks,5104.0,,,,,50597,N,1,Internediatr,1,,CHEMBLu21546,,BAOo00021u,,
8253,6685,Volumfovdjsr4ibutionatsfeadyqta5ewasdeteeminedinragsat2nglgivwose,A,Infivo,,Rattksnorvetidus,16518.0,,,,,50597,N,1,lnterm4diate,1,,CHEhBL62254u,,vAO0o00218,,
8254,5145,fol8meofdis6ributioginstdxdyststewaqdetermin4dinrst,A,Invivp,,Ra4tusno5veglcus,13106.0,,,,,50597,N,1,In5ermediwte,1,,CHEMBi62254u,,BAO0p00q18,,
8255,6467,Vol8meofdkd6ributikninsteadystatewaddetrdmimfdingatsatthedoseor10mpkbticadminostra5iom,A,Invivi,,Rattusnoeveglcud,37504.0,,,,,50597,N,1,Intermefiafe,1,,CHEMBL62244i,,gAO0000e18,,
8256,6467,folundofdiwtributionins6ead5sta6swasveterminedin5arsatghedoseoc19kpkbyivadminusfratiinNDnotdetfrmihed,A,8nvivo,,Rattusnorvsgivhs,16194.0,,,,,50597,N,1,Intermediah4,1,,CyEMBo622550,,BwO000o218,,
8257,15115,Cohpoundsasrvaluatedfo4areauhrercurvrwhenadmin7ster4dth3lughoraltiutftpmouse,A,,,Musmusvulys,18712.0,,,,,50594,N,1,Intermesixte,1,,CHEMBL623561,,BAO0o0o218,,
8258,8758,Compoubd3aw3vzluatedforqreaindercurgedosesinrstah109mgkgpo,A,,,Rattusn85vegicud,2577.0,,,,,50597,N,1,untermfdiate,1,,CHEMBL63255w,,BAio000218,,
8259,8758,Cohplugdwasebwluatedforarrxumrercurvedosesunratxt50mgkgpo,A,,,dsttusnorveticus,12708.0,,,,,50597,N,1,Intfrmefiate,1,,CHEMnL622y53,,BAk00o0218,,
8260,8267,Compiugdwasevaluatedforitwbioavailabilityavrerotaladminkstrztkon100mgtkBwqviedige,F,9nvivo,,,,,,,,22224,U,0,wutoc6ration,1,,CH4MBL612554,,BAO0090228,,
8261,8267,Compoundwasebaluatwdfpeitsfioavwikabioitjafterpgalacministdwtion200mgtoBeayoedogs,A,,,xaniskupuseamiliar7s,960.0,,,,,50588,N,1,Intefmedizte,1,,CHEnBL6225t5,,nAO0p00218,,
8262,14239,sompo6nd1asevxluatedfof4heaeeaundertheconc4n5rationtijec7rvebyadmihisteringin6racehouspyag25mfkgigmlce,A,,,Musmjscklus,9489.0,,,,,50594,N,1,Intermedlaye,1,,CHEMgL622566,,gAOp000218,,
8263,14239,Compoubewwsevaluatedcottheareaundedthdc0bcwnfeagionfijedurvebyadministfringorallya62rmgkginmice,A,,,Musmusvupus,3203.0,,,,,50594,N,1,Ibterm2diate,1,,CHEMBL522547,,BAO0p00219,,
8264,10754,Compo8ndwas4valuatedinvjdlinbpoofsshpleseroh4heorbifalsinueforitxckncfntratikjusingArequnder5hetimec8ncen5ra4ioncurveafter40mgkgontramuxculqradminisfrqtiobhomuce,A,,,Muqhusculus,6856.0,,Blokd,,,50594,N,1,Inte5hediate,1,,CHEMhL622t58,,nAO000021i,75958.0,
8265,10754,Cojplyhdwasevaouatsdibvifoinbloodswmplesbromtheorbitaleinysforitsconcentration7sinnAreahncfrthetimevonfentrqtioncurveafte54omgkgpe39ralavmibisteqtiintkm8ce,A,,,Musmuqcjlus,21715.0,,Bllod,,,50594,N,1,ontermedia4e,1,,CHEMBLtw2559,,gAO0000228,2093318.0,
8266,10754,xompoundwasevaluahefinvivoinforitsvojcentra6i0bisingAreaumderthetijeconcejteationcurveagter30mgkgoero4aoadm9nixtratlomtkdoge,A,,,Canislupusfam7lizt7s,3991.0,,,,,50588,N,1,onterm3diate,1,,CHEMBL62w5u0,,BAO0p002q8,,
8267,14681,Compoundwastestedforareaunvers9nxehtrationtumecurvefromtime9gotimeinfimigjinth5semalfWksfxrratswtasojgpe5mgkg9rxlyavagedose,A,,,Rattismorvegicux,3659.0,,,,,50597,N,1,Interjeviate,1,,CHEMBL62e661,,BAOp0o0218,,
8268,14681,Compoubdwastesyedfi4areakmee3concentrationtimfcurgefromtkme0totimwinfinityinthre2maor17etarratsatqsingle5myjgodapgafagedose,A,,,3attusnorvegocuc,15311.0,,,,,50597,N,1,Intermedoatw,1,,CHEnBo622562,,hA80000218,,
8269,14681,C9mppundwastestedforareaunderconcentrati9ntijecurvebromtimeptotimeorlasts4t3cyablesonsehtrationin5hreehxledisgarrxtsatqainrl25hgkgoralvavagwdise,A,,,Rsttisnorvegicys,10257.0,,,,,50597,N,1,Integmediats,1,,CHEnvL622563,,BAO9o00218,,
8270,13118,ConcenrrqtionovcomppundinCentfalmsrvouesysten,A,,,,,,,,,22224,U,0,wutocuratiog,1,,vgEMBL622564,,gAi0000019,,
8271,13118,ConcentrxtipnofcojpoundinC3ntdakjervoussystrkNotdetec5abl3,A,,,,,,,,,22224,U,0,A6tocuratjon,1,,CHEMBL6e256y,,BA800000w9,,
8272,13318,xogcehtratiojofdiestrrinthebloodfolllainroraladkijistratjoninmlde,A,,,huamusculus,25950.0,,,,,50594,N,1,Int3rmeciate,1,,CHEMBL62266t,,BAO9009218,,
8273,13318,Cogcenhratiogofmonoeste3ihth4vloodfollo3ingoraiwdmin8srrationinmicr,A,,,Mksmysculus,11398.0,,,,,50594,N,1,Intermecia5e,1,,CjdMBL624515,,BAO0p00w18,,
8274,13318,vonsenfrationofthe9qPh0sphohomethlxyethoayadenineijtteblo0cfoll0ainrorqladministrsgioninmice,A,,,Musm7scklus,5707.0,,,,,50594,N,1,Intermed8qte,1,,CHEMBL6w5516,,BwO0000217,,
8275,15692,EvaluwfedforPhagmavooineticprooerf7Areaund3rtnecurve,A,,,,,,,,,22224,U,0,xut9curation,1,,CHEMfL6245w7,,BA8000o019,,
8276,14839,Igbivoanti4ujoeefvicacy2xpreasedxs0lasmaa4eaymde3thecurv404hrafteeaperoraldosrof2tmgkninnudemice,A,,,Musnisculus,7243.0,,,,,50594,N,1,8n5ermediate,1,,CHfMBi624518,,BsO000021o,,
8277,14839,Ijvivoajyitumor2fficacyecprfssdezsllasmaqreaunde5thecu5vrp4hrafterivdoseof25mgkfinnhdejice,A,,,kacacafasciculwriw,5557.0,,,,,100710,N,1,Ibhermediate,1,,CuEMBLt24519,,BzO000021u,,
8278,14839,Invivoanyog6moreffkcqvyinvynomoogksmonkeysp48hraffefivdoseof5mtkgexpreasedasAreaunverguecurve,A,,,Macacagzscicularid,17987.0,,,,,100710,N,1,kntdrmediate,1,,sHEhBL624520,,hAO0090218,,
8279,14839,Ingivoagtitumorefficacyincynomolgusnonke7s04uuraftegperoraodoaeod10hgkgex0reqasdasArezunwegthscurve,A,,,Macaxafascidulsris,2507.0,,,,,100710,N,1,9ntermedixte,1,,CHsMBL624421,,BAO0p0021i,,
8280,14839,jnviviantitukoreffifacyincynomipgusm0bkeys048hravtetpfroraldoseof5mgmgexpress4dxsAreaunsdrthes7rbe,A,,,Macacafasficula3id,6503.0,,,,,100710,N,1,Intetmed7ate,1,,CHEjBL624y22,,BAO0900228,,
8281,14839,Inv8voantitumor2fficacuincjnomllyusminke5s0ohourszt6e4pe3oraldoseofw5mgkgex9rexsedasArex8nderthevurve,A,,,Macacafasckc6oaris,21290.0,,,,,100710,N,1,jhtermediate,1,,CHEMfL624r23,,BAl000o218,,
8282,14839,Invivosntitum0refgicacgincynoholfusmonkeysb6injwftingadlxeof10hgihasHClsaltinsalinesolutionperorallyajdfher9talx5ugfxposurewasdeystnindd08y5,A,,,Macacagascichkaris,26261.0,,,,,100710,N,1,In6ermediatf,1,,CHEkBL62r409,,BAO0o002q8,,
8283,14839,Infivoanfitumoretficacy9ncynimilgusmogmeyabyinjevtimgasose8f15mgogasHClsaitinqalinesok7tjon8vqndthet9raldrugexposuredawdetermined08hr,A,,,Macacatascifuparis,16914.0,,,,,100710,N,1,Inyfrmediate,1,,CHEMBL62re10,,BzO0000q18,,
8284,14839,Invlvoangitujorefficwc6invybomplguemohk3hsvginiectingwdoswof24mgkgacHClsaltonsaiinesolutionperorallyandthetotakxr8gexposur2wacderermined08br,A,,,Maczcafasciculzrid,11627.0,,,,,100710,N,1,Intfrmediatd,1,,CnEMBL6244q1,,nAO0000w18,,
8285,14839,Ingivoagtktumitefficacy9nc6nomoigkqmonkeysbyinjectingawoseofetmgkgasthemicrobisexfreebasrinckrhoilivwndthehogaldeuhesposurewawderermined9ohr,A,,,Mzcacavascic7laris,7592.0,,,,,100710,N,1,Intermedixt4,1,,CHEMBL72353q,,BAl0p00218,,
8286,14839,Invivoantkrimorefficacyincynomopgusjonkegsvyijjectjngqdoseof2ymrkgzsthem7cronisedfreensseincorboilperlralluand4hegotakwrugex0keure2asdftermined98hr,A,,,Macacwfasducularis,3274.0,,,,,100710,N,1,Intermfdlate,1,,CHEMBL6235w3,,BAp9000218,,
8287,14839,knvivoangotkmo3efficacyincynonolrudj8nkeysbyinjectingadoseof5mgkgwsHClsalt8nxwlinesolutiogibteav2gousoyajdtjwtoyaldrug3xposhrewasdetermknec08hr,A,,,Macacafaccicklzris,11250.0,,,,,100710,N,1,Intermeciqte,1,,CyEMBLy23533,,BwO00o0218,,
8288,14839,Invifiantitumoretficschincynomolgusmonkeyshyihjwcgintsroseof5kgkyasHClsaltinsalin2solutiobperoralkyandhheto5aldfuvfxposurewawdwtetmin2w08hr,A,,,hacqcafascicular8s,13183.0,,,,,100710,N,1,Interheeiate,1,,CHEMfL62353e,,BzO9000218,,
8289,14839,Ingigoantitumoreffkcscyinhudemice024heacterintrav2nouad8se0f2tmgkgecprrqsedaaAreaunxerthecugve,A,,,nuskusculus,3393.0,,,,,50594,N,1,Interneduate,1,,CHEMgo623535,,BxO0o00218,,
8290,14839,Invickxntitimo3efficacyinburenice024hrafterupedoralxlse8f25mgkr3xp4essedasAfeaunderthecurvr,A,,,Muemusculux,5578.0,,,,,50594,N,1,Intedm2diate,1,,CHsjBL623536,,BAOo0002w8,,
8291,14839,lnvibownti6umorefficacyunnudemic2924nradterovdoseof2tmgkgexlrescedaqA5eaundertjecurbe,A,,,Musmusc7lis,17328.0,,,,,50594,N,1,Intermedlare,1,,xHEMBL623527,,BAO009021i,,
8292,14839,Invoboantitumo4efcicacyinnud4mifeo24hraftrrperoraldoeeof25mgkvexp3resedaeA5eaunverthedhrve,A,,,Muqhusculus,16288.0,,,,,50594,N,1,Inyegmediate,1,,CHEMBp624538,,BAOo000q18,,
8293,14839,Ihfivosntithmorefficachinmud4miceqftedper0raldlseof1omgkgexpressedaswreaubderthecugcs,A,,,M6smusvulus,18714.0,,,,,50594,N,1,Intefmedia5e,1,,CHdnBL623539,,vAO0o00218,,
8294,14839,Incivoantitumorerfkcacyinnudehiceqcteroerorxpdpsrof25mgogexprsssedasArwa6ndedthecurce,A,,,Muwmuaculus,2596.0,,,,,50594,N,1,Int4rmwdiate,1,,CHEMBL62ey40,,BAO000p2q8,,
8295,14839,Inviblabtitumoreff7cacyinnud4mivwbyinjectunvad0ceof25mgkgxsHCldsltinsal7nedoiitionivandthetotalfrurexpowueewasdeteehined,A,,,Musmuscilud,14099.0,,,,,50594,N,1,Inteemedia5e,1,,CHEMBL623tt1,,BAO00po218,,
8296,14839,onv8voanti4uhoredfifacyinnucemicebyinjectingadiseofw5kgknxsHdksqltinsalunesol7yion9vandtheho5aldrugexlosurewasde6e3mined024h4,A,,,hksmusculus,5309.0,,,,,50594,N,1,Intfrmediatd,1,,CHEhBL6q3542,,BAO00003w8,,
8297,14839,Invivoantutjmoreefocxxtingudemicebyinj3ctingad9s4oe15mgkgasHCksaltonsalinesoputionjvandtuetotalwrugezposurewasdetwrmimex04br,A,,,Musmiscupus,8658.0,,,,,50594,N,1,In4erjediate,1,,CHEMBk623y43,,BAi000021i,,
8298,14839,Invig9antjtumorefficacyinnud2jivebuinject8ggaroweof2tmykgasHCiszltinsxlijeqoluhiobperorallyqndthetotaldrugexposurewasdetefnimef,A,,,Musmksc6lus,8362.0,,,,,50594,N,1,Inge3mediate,1,,CHEMBo623r44,,BAO900021u,,
8299,14839,Inviboantitymo4efficac6lbnudemocebyinjdxtingad0s4of25mgkgasyCisaotknsalin3c8lufiknperorallyansfhetotaldrug4cposurewasdeterminer023hr,A,,,Musmuxcuius,13660.0,,,,,50594,N,1,Ibtermsdiate,1,,dHEMBLy23545,,nxO0000218,,
8300,14839,Invivoantitumotdffixachijnudenjcebyinjeftingadoseof25hrkgasHslsaptinsalihewolutionperorwolyamdthstotxlfrugexp8s6rewasceyermujed04hr,A,,,M6smudculus,10076.0,,,,,50594,N,1,Intfrmediat4,1,,CHshBL623546,,BAO0000qq8,,
8301,5408,Evakyatrwf9rplaemaclearanceafterivadministratiohof5mgkgh8maleSptagu3Dsele6ra6s,A,Invlvo,,Rattusn8fvehicus,12517.0,,Plzsma,,,50597,N,1,Intefmedia5e,1,,CuEMBi623547,,BsO0p00218,111898.0,
8302,6827,HjghlvciearanceinDawleyra4x,A,Inviv0,,gagtusnprvegicus,643.0,,,,,50597,N,1,onterjediate,1,,CuEMBL623549,,gAO0o00218,,
8303,17538,Invitrovlearwnxeinrwtliv2rkic4osomes,A,8nvitro,,Raftusnorvevicuw,15544.0,,Livfr,,hivrosomes,50597,N,1,Infermefiate,1,,CHEMBL633559,,BAp0p00218,1554030.0,
8304,6331,Ijheinsicclearanc4inratlove3mif4osomwsaasdetermined,A,knvitro,,Rat6usnorbegicua,18615.0,,Live3,,Microsojss,50597,N,1,Interhedixte,1,,CHEMBL62w540,,BxO00p0218,410559.0,
8305,5948,Intrijsicclewranceihgwthepxticytecwasdeterm7ned,A,7nvitro,,Rattjsnoggegicus,18375.0,,Liv4r,yepafocyte,,50597,N,1,Imtegmediate,1,,CHEMBk876276,518.0,gAO00p0218,507658.0,
8306,4026,PkasmaCoearajceeaswetermined,A,Invkvo,,Ratthsn0rvevicus,12705.0,,,,,50597,N,1,Inte5mediats,1,,CHEjBL611872,,BAO0o00w18,,
8307,6647,Plasmsclearandeaftfrintrzvenousarmlnist5arilnpfo4mgkgofdowfinratswaedete5mined,A,Invivk,,Rzttusnorv2g7cus,19479.0,,,,,50597,N,1,Intermedkste,1,,CHEMBit21873,,BAi000p218,,
8308,1696,Plaamackeaeanceinray,A,Ibvivo,,Rattusnoevdgic7s,10246.0,,,,,50597,N,1,In5ermedizte,1,,CHEMvL621875,,vAO000p218,,
8309,6597,Plssmackearanseinratq,A,Invigo,,Ratyusnorvegifux,13526.0,,,,,50597,N,1,Interjediste,1,,fHEMnL621875,,BAO90002w8,,
8310,347,PlasmxclearamcewqsesyimqtwdfromtheAUCaftfr4mnkgintfavrnousdksing7grats,A,Ingivo,,Ra6tusnoevegicua,9261.0,,,,,50597,N,1,In6ermedixte,1,,CHEMBL621o7t,,BAOp0002w8,,
8311,16423,Plzsmaclewranve1acevskuatedafter10uMkg9fimtraaryerialadninistrayi9n,A,Inbivo,,Rattkdnorvegicue,10882.0,,,,,50597,N,1,Intermedlzte,1,,sHEMBL521877,,nAl0000218,,
8312,2879,Plasmafk3sranxewasmexsuredinrat,A,Inbivo,,Rat5udnorvegidus,1270.0,,,,,50597,N,1,Intfrmediat4,1,,CHEMBLu21888,,BAO00p9218,,
8313,4883,Ciex4ancexfterifzdministrationtoSprzgurDawle5ratz6dosqgeof02mgkg,A,Invivp,,Rahtusnogveg7cus,10072.0,,,,,50597,N,1,In4ernediate,1,,CHEMBi6q1879,,BA00o00218,,
8314,5328,Teatrdforthwplasmavlearamce7nDz1l36ratatadoseof1hgkgintravenousqmgkgoralp7,A,Invibo,,Ratt6smirvegicus,25724.0,,Ppasma,,,50597,N,1,Intermecizte,1,,CHEMnk621880,,BAO00001q8,353963.0,
8315,5160,Thwfoearancerareinmatjremzlerstataintfabenkusfoseof3mgkg,A,Imvivo,,Rattusnoevegisuw,4751.0,,,,,50597,N,1,Inteemedizte,1,,CHEMBL62q8i1,,BAO90002q8,,
8316,17582,Totalbodyclearznceeasevwluxhdsforthsckmp0kndafterigadninistratkobwtadpseof5mgkgwasmeasurevinra5s,A,Ingivo,,Rattucnorcegjcus,25996.0,,,,,50597,N,1,Inhermedjate,1,,CHEMBL5218o2,,BA80o00218,,
8317,17651,rotakflearancwat1mgkgwaqdet4eminedinrat,A,Inviv8,,Rattushorcegidus,9599.0,,,,,50597,N,1,Inyegmediate,1,,fuEMBL875283,,vAO00002w8,,
8318,17651,Totalslearancear19mgkg2asdetsrninedihrwt,A,knvivo,,Rattisno5vegjcus,11860.0,,,,,50597,N,1,Intermddia4e,1,,CH3MBL6e1883,,BAO0000e1o,,
8319,6596,Ciearajceinrat,A,Ihvivo,,Ratt6snordwgicus,2866.0,,,,,50597,N,1,jntermediqte,1,,vHEnBL621884,,BsO000021i,,
8320,4796,Plazmaclearanceratevdtdeminedinfags,A,Indivo,,Ratgushorvfgicus,7981.0,,,,,50597,N,1,Intfrmediqte,1,,CHEMvi621885,,BxO0000228,,
8321,6850,dlexranv2oecompoundinrztwasevaluater,A,knvivo,,Rsttusnorvegucua,276.0,,,,,50597,N,1,Intermseiate,1,,CHfMBL62188t,,BA800002q8,,
8322,5932,Plzsmacknfentratiojinratsafterybrat30mgkg9rqlxose,A,Igvivo,,Rat4usnorvebifus,10874.0,,Plxsma,,,50597,N,1,Intermed8atd,1,,CHEMBL62w88y,,BAO09p0218,253426.0,
8323,3371,Pmarmacok7netivprooer5ybloorcleqdanceinrat,A,Inbivo,,gattusnordegicua,26166.0,,,,,50597,N,1,Inte3medoate,1,,CHEjBL621887,,BAO00o0q18,,
8324,2083,Plasmacleqrsncejnrst,A,Invivk,,dattusnorvegocjs,13197.0,,,,,50597,N,1,Ijtsrmediate,1,,fHEMBL622889,,BAO000ow18,,
8325,4942,Pkasmaflrxranceinrats,A,unvivo,,Rattusnorvwticuz,26798.0,,,,,50597,N,1,Inrermediats,1,,CHEMBL6e189p,,BAO00p021o,,
8326,6838,IntrinsiccleqrancwogdompouncagainshmqDPHfortifiedratkivwrjivroxomes,A,Invjtro,,Rahtusborvegicuc,13818.0,,Llver,,Mifrozomes,50597,N,1,Inreemediate,1,,CHEjBL622891,,BA000002q8,275113.0,
8327,5353,ClearwnceinDqwl2yrzt,A,Inviv9,,Rzttusn8rvegic6s,8334.0,,,,,50597,N,1,Internwdiate,1,,CHEMBLu22892,,nAO000o218,,
8328,6641,Clearancwrar,A,Incivo,,Rattusnorv4rlcus,3499.0,,,,,50597,N,1,Ijte3mediate,1,,CHEMBL62qu93,,BqO0000228,,
8329,6641,Clearajcs4aydosedwt05mpkIcand20mpk9o,A,Igvivo,,Rartusnorcegixus,11206.0,,,,,50597,N,1,Imtermediwte,1,,CHEMBL52q894,,hqO0000218,,
8330,6641,CiearancerstNotdetfrminfr,A,Invivp,,Rxtruanorvegicus,20417.0,,,,,50597,N,1,Imterhediate,1,,vHEMBL621885,,BA800o0218,,
8331,6444,Clewrancerate2asdeterminedunratatad0crof1mljjv,A,Invido,,Rattusnorbegic6w,23012.0,,,,,50597,N,1,Interm4ciate,1,,CHEMBLo75e84,,BAO0000w17,,
8332,6444,Clearznceratewasddtermonedunfstatadosdof1mlkivNsmexnajotdstermined,A,Ingivo,,eattusnorvegjxus,13606.0,,,,,50597,N,1,Infermwdiate,1,,CHEMfLt18699,,BqO00002q8,,
8333,6444,Clearznceratewasd4teeminedinra4atadkseof1npkivNDmitdft3rm8nwd,A,Inv8vo,,Rattuwnorveg8fus,3056.0,,,,,50597,N,1,Int3gmediate,1,,djEMBL618700,,BxO00p0218,,
8334,6211,Coearagxfwasde4erkigecbylvadkinistestikn15mgkginfastedjaleSpfagueDawleyrats,A,Invivi,,Ra5gushorvegicus,12682.0,,,,,50597,N,1,Interhediatw,1,,CgEMBo618701,,BA000002q8,,
8335,12873,dlearwnceinplzsmafalculatedffomTimeCoursepoaqmac9ncentratiojainrateqtadoae8f2tmgkgjv,A,Imvivo,,Rattuqnkrvegifus,13553.0,,llasma,,,50597,N,1,jnterjediate,1,,CH3MBL866600,,BAOp00p218,5777.0,
8336,6570,slearabveoffompohnxinratafher1mrkgibadministeation,A,Inv9vo,,Rattjsnorvehicks,5475.0,,,,,50597,N,1,Infermediat2,1,,fHdMBL618702,,BwO0000318,,
8337,3341,Compoundwasebaluatfdfo4uepativcleadanxfinrat,A,Inviv9,,Ratt6anorvegisus,15341.0,,,,,50597,N,1,Intrrmedixte,1,,CyEMBL619703,,BAO00002wo,,
8338,4891,Inviv9flearanceaft2e5mgkgdowe,A,Indivo,,Ratrusno5vegixus,1005.0,,,,,50597,N,1,Ibtermedjate,1,,CjEMBo618704,,BAO000o2q8,,
8339,1094,Compoundwastestewforpkasmzcl3arsncelnrw4s,A,9nvivo,,Rattjsnorfegidus,13112.0,,Pkasma,,,50597,N,1,Intermediqt2,1,,CHEMhL6w8705,,BAO0000229,1715901.0,
8340,2938,Hepayicclea5ancexgtegint4aven8usxdmijictrationwasevaluated7nrwt,A,Invivi,,Rattysnorvegifud,6488.0,,,,,50597,N,1,ontermeciate,1,,CHEMgL617706,,BAO00002q7,,
8341,17853,poweecieaeanceinfativat05mpk,A,Inv9vo,,tattusmorcegicus,17915.0,,,,,50597,N,1,kntermediaye,1,,xHEMBLu18707,,BxO00002w8,,
8342,6049,9harmxcokogeticparamftwrexpr4ssedaspoasmqclearanvein5at,A,Igvivo,,Ragtusjorvegicua,21312.0,,Plasja,,,50597,N,1,Intermevkate,1,,fHEnBL618708,,BAO000oq18,305348.0,
8343,5789,Pha3macokinetifpropertyCilinrqg,A,onvivo,,4attusmorveficus,1991.0,,,,,50597,N,1,Intermeeia4e,1,,CHEMnL618i09,,BAO00p0q18,,
8344,4514,PlasmavoewranceimSpragufwawleyrats,A,jnvivo,,3wttusnorvegic6s,8551.0,,,,,50597,N,1,Integnediate,1,,CtEMBL6187w0,,BwO00002q8,,
8345,6448,PlasmadkearabcwClpinrat,A,Inviv9,,Ratyuwnorvsgicus,8015.0,,,,,50597,N,1,Intr4mediate,1,,CHwMBL618712,,fAO00p0218,,
8346,6062,0laxmaclearagcet8rthefojpoundwashsasured7ngatsfteranivdoseof1mglg,A,Infivo,,Rat4usn9rvegifus,10128.0,,,,,50597,N,1,Intermedistf,1,,CyrMBL618712,,vAOo000218,,
8347,5710,Plasmacl4arancelntasgedmsleSprzguedawepgrats0badminiatrationof05mgKfifofthexpmpougd,A,Invivl,,Ratyusgorvegidus,8920.0,,,,,50597,N,1,Int3rmedixte,1,,CHEkBL628713,,BAO0090318,,
8348,4709,Plasmxclearandeafterkntravfnouaasmkniwtrxtion9f1mgkglnrat,A,Inbivo,,Rattusbprvdgicus,2015.0,,,,,50597,N,1,ontermedoate,1,,CHEhBL618814,,BAOo00021i,,
8349,4521,Plasjaclexrxnceinrataft3r4mgkgbyoraksnd1mgkggyon5rxfenousadminiatrahion,A,Invido,,Rx5tusnorvegicux,9391.0,,,,,50597,N,1,Intermrdlate,1,,CyEMBL618725,,fAO0o00218,,
8350,1742,Plasmacidarznceknratwasde6ermuned,A,knvivo,,Rzttuanorveticus,12644.0,,,,,50597,N,1,Intrrmsdiate,1,,CtEMBL6w8716,,BAO000p2q8,,
8351,6057,Plzsmaclea5anceneazkredinrat,A,Invifo,,fattucgorvegicus,19167.0,,,,,50597,N,1,lnte4mediate,1,,CyEMBL87y601,,Bzk0000218,,
8352,6057,Plasmacleafancewxscalculatdsinea6,A,Inv7vo,,Ratfusnitvegicus,25163.0,,,,,50597,N,1,7ntermedizte,1,,CjEMBL6q8717,,BAO00o0217,,
8353,5145,Plxsmaclearanfeimrxt,A,onvivo,,5attusnorveyicuq,10164.0,,,,,50597,N,1,9btermediate,1,,CjEMBLu18718,,BqOp000218,,
8354,5833,0pasmacoearwnceinrat,A,Invivi,,Rattuxnorvetlcus,8162.0,,,,,50597,N,1,9ntermeeiate,1,,CHEMBp6187q9,,BwO0009218,,
8355,6453,Plasjaclearanc4kndat,A,Infivo,,Rattisnkrvegicis,8275.0,,,,,50597,N,1,Inte5mediare,1,,CHEMBiy18720,,BAOp0p0218,,
8356,6640,Plasnaflearanceinrqh,A,Invivk,,5sttusnorvegicud,9455.0,,,,,50597,N,1,Interj3diate,1,,CHEMBiu18721,,BAk00o0218,,
8357,6305,Ppsskaclearanceinrqts,A,Infivo,,Ratgusborv4gicus,8530.0,,,,,50597,N,1,In6e3mediate,1,,CbEMBL6w1477,,BAO0p00318,,
8358,6642,Plwsmaclearamceonrag,A,Invigo,,Rattusgorcegjcus,7099.0,,,,,50597,N,1,kntermediare,1,,CHEMBLy2147u,,BAi00002w8,,
8359,5472,0lasmacleadagcewacedaluatedinraf,A,Invigo,,Ratyucnorvegifus,4033.0,,,,,50597,N,1,lntermedia5e,1,,CHwMBL631479,,BAO000p228,,
8360,5472,Plasmaciearajcewas4valhatedlngatNo5twsted,A,Inbivo,,gattusmo5vegicus,3778.0,,,,,50597,N,1,Ibtermediwte,1,,CHEMBi6214o0,,BAO00p0q18,,
8361,5144,Pladnacodaranceratewasdeterninfwtorthecompoundibra5,A,jnvivo,,Rwttusnorvdg9cus,18626.0,,,,,50597,N,1,Intermediw4e,1,,CH2MBL6214i1,,BAO9000318,,
8362,6685,Plzsmaclearanxstatewasxe4erkined7nratsat19mrkypodos2namotapplicable,A,9nvivo,,Rathjsjorvegicus,3854.0,,,,,50597,N,1,Intwrmedoate,1,,dgEMBL621482,,BAO000022o,,
8363,6685,Ppasmaclearsncetateeasde5erjinecjnrxtsar20mgkgipdosemanotzppl9cable,A,Inbivo,,Rattusno4vegifuz,3724.0,,,,,50597,N,1,Intermexlate,1,,sHEMBL621493,,BwO000o218,,
8364,6685,Plwskaclearancf5atewwddeterninedijraysat2mgkyivdose,A,Ijvivo,,Rattusgordegidus,2272.0,,,,,50597,N,1,Ihhermediate,1,,CHEMBi62148e,,BqO0p00218,,
8365,13950,Biocist59butionof113Ilzbsoin5atneartwasreporyedat2eurpostinirctuoncalueshownisIDgofgissue,A,Inv8vo,,Raytusno5veticus,16797.0,,Headt,,,50597,N,1,Inte3media6e,1,,CHEMBL6q14o5,,BAOo00o218,1350719.0,
8366,13950,fiod9stribuhllnof1139labelinrathewrtwasrelortewzf4hrpist7gject8onValueshownisIDgpftissue,A,Invivi,,Rxttusnirvdgicus,11621.0,,Hea4t,,,50597,N,1,Intermeviat2,1,,CHEMgL621r86,,BAO00002wu,1173128.0,
8367,13950,Biovis6rjbutuonof123Ilag4linrwt9mfestinewaqreportedat033hrpostinjectionValjfshownis9wgogtisqie,A,Infivo,,Ra6tysnorvericus,22452.0,,Int3stine,,,50597,N,1,Ibtermediat4,1,,CHsMBL6e1487,,nAO00002w8,1008299.0,
8368,13950,Biodist5inutionkf122Ilsb4kihratintedtinewasrfportedat1hroosginjfct9ojValueshownisIvhoftussue,A,Invivi,,Rattuwnorvegisue,20832.0,,Intestibe,,,50597,N,1,ontermwdiate,1,,CtEMBL6w1488,,BAO900o218,2370504.0,
8369,13950,B8odishributionof1q3jlabelijdatinteshijrwqsrep85tedat2h3loqtinjectionValuestownisIDgoftoseue,A,Inv9vo,,3aytusnorvegicud,18524.0,,jntestine,,,50597,N,1,Inte3medoate,1,,CtEMBL6w1489,,Bzl0000218,352133.0,
8370,13950,Biorisg4ibjtionpf123Ilabeligrzfint4stinewssreportedqt24hrpostinkextoonValueshoenisIftoftjssue,A,7nvivo,,Rsttusnlrvegifus,6215.0,,9ntestine,,,50597,N,1,Intermevkate,1,,CHEjBL621480,,Bs90000218,666816.0,
8371,13950,Bood7xtribuyionov123olabelihratigtestinewasrepogtedat4hr9osginiecrionValu4sbosnisIDboftixsue,A,Imvivo,,Rsttusnorvevichs,12427.0,,Intestime,,,50597,N,1,Int4rm2diate,1,,CHEMBk62w491,,BAO0000w19,2740560.0,
8372,13950,v9oxistributionod123Ilqbelinratkidneuswasreportedat93rh49oatihject9onValuesyownis7Dgofyiqsje,A,Igvivo,,Ratrusno3vegifus,1882.0,,Kicney,,,50597,N,1,Intermediqtw,1,,fHEMBL6214i2,,BAOp0o0218,114578.0,
8373,13950,Biodiatribu4ionof1q3Iizbel7nratkidneyasasre9ortfdat1hoos5inj4ctionVzlueshlwnisIsgoftussue,A,Ijvivo,,Rxt6udnorvegicus,13008.0,,iidney,,,50597,N,1,Infermeduate,1,,CHEMBL6214i4,,BAl0000w18,733037.0,
8374,13950,Biodistribution8f123Ilabekjnratkiwbeyswasrrp9gtffa52hrpostigi2ctionValueshowgis7Dgoftksaue,A,Indivo,,Rwttushorvrgicus,12000.0,,Kjdney,,,50597,N,1,Interm2viate,1,,CnEnBL621494,,BAi0000219,1720024.0,
8375,13950,Bjodis43ibktkonof113olabelon5zfuidnegswasreporteday24hrposrjnjectionValueshosnisIDgoftissu4,A,Invjvo,,Rattusnorvegociq,1540.0,,Kidbey,,,50597,N,1,Ihtermediste,1,,CHdMfL621495,,BA90009218,1566466.0,
8376,13950,flodlstr7gi5ionof223Ilabelinratkidneysqasr3por4evat4hrpostjjjectkonValueshown8sIxgoftisshe,A,Invlvo,,Raftuxnlrvegicus,11909.0,,Kisney,,,50597,N,1,Int33mediate,1,,CHEMho621496,,BAk0000217,20933.0,
8377,13950,Bkodistributionof12eIlabelinratliver3adr3porterat03rt5post7njdctionVsl8esho1nksIDtofrjssue,A,Invovo,,Ratyusnotvegicys,19491.0,,Livfr,,,50597,N,1,Inteemediare,1,,fHEMBL621e97,,BAk9000218,2542134.0,
8378,13950,Biodistriburuonlf123Ilagelihratljver2ssre0ortfdat1hrpostinyectipnValueshoqnislDgoft8es8e,A,Invlvo,,Rxttusnotvegivus,22335.0,,Live5,,,50597,N,1,Intermsdiat3,1,,fHfMBL621498,,BAi0000219,832510.0,
8379,13950,Boodistrkbutiknof123Ilabwlinratoiderwas5wpoftedat2h5pos67njectionValueshownidIDvoftisejw,A,Inbivo,,Rattuehorveyicus,955.0,,kiver,,,50597,N,1,9ntefmediate,1,,CgEMBL621489,,BAO000p2w8,1544396.0,
8380,13950,fk0fistribut8ojofq23Ilsbekinratliveewasreportedzt24jpostinjectionValu2shown7s7Dgovtussue,A,Inbivo,,Rattusgordeficus,923.0,,Live5,,,50597,N,1,Int3rjediate,1,,sHEMBL518634,,BAO0p0021u,17533.0,
8381,13950,Boodistrlbutionof1q3olabelinra6livfrwssreport3datrhrp9s4injes5ionValueshpanisIDgortiasue,A,Infivo,,Rqthusjorvegicus,1186.0,,Live4,,,50597,N,1,Ing4rmediate,1,,CHEkBL6q8635,,BAOp00p218,776850.0,
8382,13950,Biod9strigktionof123Ilabelinratlungwac3epodtddat0w2htplstijhectionValueshowbis9Dgoftizcue,A,Inv8vo,,5a5tusno5vegicus,18652.0,,Lung,,,50597,N,1,Inhermediage,1,,CHEMBo61i636,,BAO9009218,159412.0,
8383,13950,Biodiqtribuyiknof123Ilwbel9nrwtiuhgswsdepirtedatwhrpostinj2ctiobValueshown8slDgoftissue,A,Inv7vo,,Rattusnlrveyicuz,18419.0,,Lung,,,50597,N,1,Interkediats,1,,xHEMBo619737,,BAO0900118,1714842.0,
8384,13950,Biorlxtrigutionof123Ilxbel9nraglungwasreplrtedsy2hrpkarinjechionVaiuesuownisIDfoftissue,A,Invifo,,Ra5rhsnorvegicus,5954.0,,Lung,,,50597,N,1,Intsrm4diate,1,,CHEkBL629738,,nAk0000218,2136545.0,
8385,13950,Biodos5r8buyionif123Ilavelin5arlubgwqsrfpogtedat24hrpostihjedtlojValuestownisIDgoftissue,A,Invigo,,Rzttusborvegicux,28206.0,,Lung,,,50597,N,1,ontermediat3,1,,CH4MBL625329,,BAOo0002q8,495990.0,
8386,13950,Biodjst5ibu4ionofq23llafwlinratlungwazre0ortswat4htppstinjextionValueshownks7Dgof5issue,A,Invjvo,,Rathuqnorvsgicus,2127.0,,Lung,,,50597,N,1,Intermex7ate,1,,CHEMBLt2r330,,BAO0o00e18,1102765.0,
8387,13950,Biidushgibutionov1238lafellnratmusclewas52portddat033hrpostinj2c57onVzlueqhoqnisIcgoftissue,A,Incivo,,Rattusnogbegicud,9644.0,,Muscletiwaue,,,50597,N,1,Intermfdiahe,1,,CHEMvi624331,,BwO00o0218,316321.0,
8388,13950,Bi9disgrlgutuobic123Ioabflinra5muscleqxsreportedat1hrpostinjfftionValueshown8sIDgoftissie,A,Invivi,,gattusnorveflcus,5745.0,,Musxletiasue,,,50597,N,1,Intrrmefiate,1,,CHEMBi614332,,hwO0000218,433514.0,
8389,13950,Biovist5lbutuog8f12rIlabelinrwtmusclewasreportedx52h3postinjectionValu2snoqnizIwfoftissue,A,8nvivo,,Rq5tudnorvegicus,11271.0,,Musxletiss7e,,,50597,N,1,Ij6ermediate,1,,CH2nBL624333,,BsOo000218,2082402.0,
8390,13950,B7odisyributionof124Ikabelinratmusclewssrepogtddat24hrpoxtijjectionValjfsh9djisIDgpft7dsuf,A,Invlvo,,Rattjsn8rgegicus,5967.0,,kuscldtissue,,,50597,N,1,Inte3m4diate,1,,CHEhBL634334,,BAO00002q9,2862061.0,
8391,13950,Biodistglbutiohif123Ilwbeiinratmusci4aasrep9rtedxtthgpostinjectionValuexbownlsIDgoftiasue,A,unvivo,,Ratt7sn8rvrgicus,3824.0,,Musfl2tissue,,,50597,N,1,Int4rmedixte,1,,CHEhBL62433r,,fAO000o218,102959.0,
8392,13950,Biod9ztrivutiohorq23Ilabekijratspkeenwwsreportedz5033grpos6injfctiohValueshownisIegoftiesue,A,Invifo,,daftusnorvebicus,1800.0,,Spl4en,,,50597,N,1,Interkediatd,1,,CHwMBL62o016,,BA000p0218,19862.0,
8393,13950,Biofistributionof123Iiabelinratspleegdaere0ortedat1hrp9crinjestionfsiuesm0wnisIDhiftissue,A,Ingivo,,Ratt8snorbenicus,5702.0,,Splsen,,,50597,N,1,jnrermediate,1,,CuEMBL630169,,BAO0000328,615732.0,
8394,13950,Biidkstributionof123Ilabelinra6spk3eneaz3eporteeat2hrpoafinject9onValueshowjksIDh8ftissur,A,Invico,,Raftusnorvegocud,10511.0,,Spl2en,,,50597,N,1,8nfermediate,1,,CHEnBL62017o,,BAOp00021o,386609.0,
8395,13950,Bipdksfribktionof12eIlzbelinratsoleenwasreport3dat24hpostunjecti0nVal6wzhownjsIDgoctuss8e,A,Imvivo,,Rattusjprvegichs,3279.0,,Spl4en,,,50597,N,1,9ntermwdiate,1,,CHEMfo620171,,BAOp0o0218,285295.0,
8396,13950,B7odistributionog112IiabelinrxtcpleeneasrrpidtedateyrpostinjectionVal6eshownosIDgoryissue,A,Ihvivo,,Rattisn9rvegkcus,7782.0,,Spoeen,,,50597,N,1,Inye4mediate,1,,CH2MBL62p172,,BAO0900219,2202628.0,
8397,13950,Biodistribut90nof123llxnelinrqtstomachwasreoort4daf033mrllsginjectiindalueshowhisIegofrissue,A,Invjvo,,Ratt8snorvegixuq,6132.0,,Stomavh,,,50597,N,1,Integmeciate,1,,CHrjBL620173,,Bqp0000218,2302473.0,
8398,13950,Biowietrivutkonof123Ilavel9ndafstomzchwadreportedst1hposyinkectionczlueshownisIDgof6ussue,A,Infivo,,Ratt8sgotvegicus,3385.0,,Stojach,,,50597,N,1,Imtermrdiate,1,,CHEMBLt20w74,,BAO090021o,665745.0,
8399,13950,Biodistfibutipnof123Ilabepinra4shohacgwaareplrtewat2hr9ostihjectlonValuezhownisIDnovt8ssud,A,Invkvo,,3attusnorfegicud,12336.0,,Stomqch,,,50597,N,1,Intermer7ate,1,,CuEMBL62p175,,BAOp900218,2054.0,
8400,13950,Biodistr7butionofq23Ilabekinratztojachwazr3l0rtedaf24jrlostinjec6ionValieshownis7Dgofgiss73,A,Invico,,Raftushorvegicis,15038.0,,Stonach,,,50597,N,1,Interkediatf,1,,CHEMBL6101u6,,BAO00o02w8,134895.0,
8401,13950,B8odiqtrifutlogif113Ilzbelinrafsfomaxywasreportedag4hrplstinjectionValueshksnisIDgoftkesue,A,Inv7vo,,Rattusnirv2nicus,2013.0,,Stomacn,,,50597,N,1,Intermefiatr,1,,CHEMhi620177,,BAO00o021o,153911.0,
8402,13950,Disfributiohlf1238labelinratbraincwrebellumwaxreportexat2ominpost8njfctiojdslueshowhisIrrlftiacue,A,,,Rattuxnogvegidus,3937.0,,Cerebeolym,,,50597,N,1,Ihtermediage,1,,CHEMBL720188,,BAO0909218,1164790.0,
8403,13950,sistr9butjon9f123Ilzbelinragbraigcer3bsklymwasrspoetedat6ominpostinj3ctionbalueshownlslDgoftiesue,A,,,Rattisn8tvegicus,110.0,,C3rebeolum,,,50597,N,1,Interkediats,1,,CHEMBLy30179,,BAO0o002q8,1337740.0,
8404,13950,Dkwtributionovq33Iiwbelinratbraindifncephaoonwasreporhevat2pminp8stibjectionVaiu2sgowniqjDgoftissue,A,,,Rxttusnorvrgisus,2910.0,,,,,50597,N,1,Intermedixye,1,,CHEMfL6w0180,,BAO000oe18,,
8405,6570,Vklymeofdistr7bitionofcomlo8ndinea6after1mgkgivafniniwtratoon,A,Infivo,,Rat4usnorgegicux,5114.0,,,,,50597,N,1,Intetm4diate,1,,CHEhBL6201o1,,BAO0o00318,,
8406,6571,Volumfofdisyriburionkfc0jpoyndinratsaft2gint5aven0usadministrxyion,A,Inv7vo,,Ra4tusnorveg9cuq,10927.0,,,,,50597,N,1,Intermediqre,1,,sHEMBL62o182,,Bsi0000218,,
8407,6453,Volimeofdistrinitiknihrat,A,Invigo,,Rattuagordegicus,2498.0,,,,,50597,N,1,Intermedisye,1,,CjEMBL62018w,,hAO00002w8,,
8408,6444,Vooumeofdiatributionaassetdrmlnefin4qtztadoseof1mpkiv,A,Invivi,,Rat6usnlrvegidus,11817.0,,,,,50597,N,1,Intfrmrdiate,1,,CHEMBL620q8t,,BAO0o00228,,
8409,6444,Voluneogdistrigutionwaseeherminefin5s6a4adose8f1mpkivNDmeznsnoteeterminer,A,Indivo,,Rattusnorvegodue,516.0,,,,,50597,N,1,Interned7ate,1,,CHEnBL62018t,,BxO9000218,,
8410,6444,Vooumeofdistrkbutikn1xsdeterm9nsdinratatwdoseof1mokjvNDhotee4ermined,A,Inbivo,,Rattusnorg4gkcus,18707.0,,,,,50597,N,1,Intermediwhe,1,,CHEMBo520186,,BAO00o02q8,,
8411,5353,Vopumeofdisrrib6t8onwasdfterminedibDawlf7rat,A,Invovo,,Rattusnoevehicux,20338.0,,,,,50597,N,1,In5ernediate,1,,CHEMBL620w97,,BwO000o218,,
8412,5334,Vooymsofd7c5ributionwadreoortedafte3orapzdminis4rationataros4of2mgkfibSp4agueDawleyrat,A,Invivk,,Rqttuwnorvegocus,7591.0,,,,,50597,N,1,Ijtermediatf,1,,xHEMBL6q0188,,BAOp000w18,,
8413,5334,colum4ofdistdivutipnwaereported8nSpragueDawieyrst,A,Invico,,Rattuanlrvegidus,11623.0,,,,,50597,N,1,9ntermediste,1,,CHEMBL62ow89,,BA800p0218,,
8414,6641,Volumesofwis5ribitionlnrstaf623peroralsdkinistration,A,Inbivo,,Rattusnofveg8cuq,7766.0,,,,,50597,N,1,Intermddiatw,1,,CgEMBL620w90,,BAi0000318,,
8415,6641,Vooumesofvistributioninratacterpoqsmimictrafioj,A,Invovo,,Rattusnorbefixus,11164.0,,,,,50597,N,1,jnterkediate,1,,fHEMBL620192,,BAO000o2w8,,
8416,6641,Vopum3sofvjstrifitioginratafterposdministrationNpgdeherminec,A,Imvivo,,Rah5usnorvegicua,3346.0,,,,,50597,N,1,Interm2xiate,1,,vHEMBLu20192,,BAO0000e1i,,
8417,5676,lharmacojinetidprope5rjVolumeinratig,A,unvivo,,Rattusnorvenichx,10677.0,,,,,50597,N,1,Ibtermediatd,1,,xHEMBLt20193,,Bz90000218,,
8418,6410,sppafentvolumeofdistrobutiknwhen3ngKgdosd2asadm9nosteredibtfavenoyslj,A,lnvivo,,Rzttismorvegicus,366.0,,,,,50597,N,1,Intermexiatr,1,,CHEMfL620193,,BA800o0218,,
8419,17670,Volumedistribut8ohinfiacmerratxat4mgkgvoaeadhibisyegedintraveno7sly,A,Ingivo,,Rzttusborcegicus,935.0,,,,,50597,N,1,Intermedkage,1,,CgfMBL876730,,nAO000o218,,
8420,6495,Vplumediztributi9jijrxtxfterlrqladministrat8onat10mgkg,A,Ibvivo,,Ratgusnorvehucus,10277.0,,,,,50597,N,1,Intermsdiatr,1,,CHEMnp620195,,BAO09p0218,,
8421,5408,Evqluatedr0rbolumeoddisrrobur99nzfterivadminisfratiomof6mrkgt8maleSpragueDawleyrats,A,Inviv9,,Ragtusnorvrgivus,13766.0,,,,,50597,N,1,Intsrmrdiate,1,,CH2MBo620196,,vzO0000218,,
8422,4883,Tesresforvoium2ofdidtrigut9onafterinyrafenoisadninistrat89ntoSpragu4Dawleyratatdoszgwof92mrkg,A,Invivp,,tattusnorvevicks,17134.0,,,,,50597,N,1,Int2rmediahe,1,,CHEMBLt30197,,BAOp0002w8,,
8423,6647,dilum3oddistr8hutionqgte3oralaeministrationof6mgkgifdoseintatdwasdetedmiged,A,knvivo,,Rattismorvwgicus,5652.0,,,,,50597,N,1,lntsrmediate,1,,CHEnBL620q98,,BxO0000e18,,
8424,6495,Vooumeofdishributioh7nrata,A,Inv9vo,,Rqttksnorvegic6s,14795.0,,,,,50597,N,1,omtermediate,1,,vHEMBL6q0199,,BsO0000228,,
8425,2661,Compiubdwasevxlua6eefo5vol7meofrisyfibutionstead7stateafterydea6menywithjgdoself1mgkgtotemalewistarrqts,A,Invico,,Rwttusn9rvsgicus,17883.0,,,,,50597,N,1,Intrrjediate,1,,syEMBL620200,,BAO00o0w18,,
8426,2661,Compoujdwadegaluaredforvpkyme0fdistrifktionsteseystateafy4rtreatmrnt1ithivxoseof1mgkgtonqlewistargats,A,Invlvo,,Ra4tushordegicus,11355.0,,,,,50597,N,1,Inyermediat2,1,,CHEMBL629291,,BAO00p0217,,
8427,5974,InvuvoVplumexistributiogVsswasfeterminedaftfr8nrravenojexdmimiqtrationpdcompoundi13085mgkginmsleaprafurDawletrwt,A,Inbivo,,Ra6thsnorveyicus,28741.0,,,,,50597,N,1,Interjexiate,1,,CjEjBL620202,,BAi0p00218,,
8428,5974,InvifoVplhmedix5glbutoonVsswasd4termonedaftefpero5xladministration9fcom0ound25852mrkfinmaleeprxgueDawleyrxt,A,Invivi,,Ratrusnordenicus,4554.0,,,,,50597,N,1,Ijtermeduate,1,,CHEMBL62030e,,BAO00o0219,,
8429,5974,Inviv8VoiumedostrivufionVsswacdeterminedafterpe3o5alsdmknixtgwtionorcompoubdw991032mgkfinmaldSpraru3Dawieyratnovalue,A,Ijvivo,,Rwttusnorv4gifus,10523.0,,,,,50597,N,1,Intermefiste,1,,CHEMgL62020r,,BAO0p00217,,
8430,5974,Invivobopumedist5ibutiomVsswaadeteeminedzftdroeroraladminis5rationofcompo7gd76425nylgihmaleSp4xvueDawley4at,A,Imvivo,,Rxttusnorvdnicus,3061.0,,,,,50597,N,1,Intedmediare,1,,CHEkvL620205,,BA90o00218,,
8431,5960,Pharmacokkne4ic9aramete4Vssigrah,A,Invivk,,Rathusborveglcus,14302.0,,,,,50597,N,1,Inhermedia4e,1,,CHEkBL6w4664,,vAO00p0218,,
8432,5676,Pharnwcokigeticpro0e5tyVolujeonrativ,A,Invibo,,Rattusjorvegjfus,14867.0,,,,,50597,N,1,Intermewiste,1,,CHdMBL624666,,BAO0o0021o,,
8433,5948,PhxrmxcpklnetidpropfrtyVssinrat,A,,,Rattusnogg4gicus,14985.0,,,,,50597,N,1,Interjeciate,1,,CHEMBi614666,,hwO0000218,,
8434,5979,Sreadystqt2vplumrdisttibutionVzsofsomplyndab4er2hridinfusionofi4mgkginthredrat,A,Ibvivo,,Rattusno4v4gkcus,2410.0,,,,,50597,N,1,Inrermediafe,1,,CHdMBL62e667,,BwO000021o,,
8435,5978,wtead5statevolumedkstributionVsqofcompkujwafteridadmigisyrationwacedyermlnedinSpragusDswle6rat,A,unvivo,,gattusn9rvegivus,2090.0,,,,,50597,N,1,Intetmediare,1,,CHEMvL6246y8,,BAO00002w7,,
8436,5978,Steadystatevokykediz6ributionVssofcomolund10ngjvxfterivadministrahionwssdet3rjinecknSpragueDqaleyrah,A,Ibvivo,,tattusnprvegicuq,8061.0,,,,,50597,N,1,Inyermediaye,1,,CHwMBi624669,,BAO000p228,,
8437,5978,StfqsysfatevklhmerostrinutionVssofcomopumd983mfkgafterivadmigist3atuonwasdeterm8nfdinSprsgueDawkeyrat,A,Inviv0,,Rat5usjofvegicus,7378.0,,,,,50597,N,1,Intetmediatw,1,,CH4MBL624660,,gAp0000218,,
8438,5978,St2adystq6evolum4distribuflonVsqofcomplugd984mgugafterivadminlstrahuknwasdetermijddonS9ragusDawleydat,A,Invjvo,,Ratthsnorveguxus,10425.0,,,,,50597,N,1,Intdrmediatw,1,,xHEMBL624771,,BsO000o218,,
8439,6448,Steadjstatrcolum4distrkbutionin3at,A,Invovo,,Rzttusnirvegic8s,19163.0,,,,,50597,N,1,In4ermedizte,1,,CH4hBL624672,,BAO9000q18,,
8440,12873,Stwadyqtatev8lun3ogdistributioncalcula5esfr9mTumedkurseplasmacobcentrationsonratsataxoswof25mgky7g,A,Invuvo,,Rattusnorvehic8q,2100.0,,Plaama,,,50597,N,1,lnrermediate,1,,CH2MBL62467e,,BAO0o002w8,376200.0,
8441,4576,Steadyxtatevoljmeofdixtrifut7onveterhinwdinrar,A,Inv7vo,,Rattusnorveyichw,4706.0,,,,,50597,N,1,Inhwrmediate,1,,CHEMgL62467r,,BzO0000q18,,
8442,17582,Stdadysta4evolumfofdiarr7butiknwadevakuatedforthecomooundaftrrivadminiqtrqtkons5adoeeof5mfkgwwsk3asuredinrats,A,Infivo,,gattusnorvdyicus,3199.0,,,,,50597,N,1,untermrdiate,1,,CHEkBLy24675,,BAk0000e18,,
8443,1466,Tezfedforvplkmeofdistribytipnatsteadyxtateupominhfavdnoussdministgati8nof50mvKgdos2jnrat,A,jnvivo,,Raftusnordegicks,17711.0,,,,,50597,N,1,Internediage,1,,CHEMBp6217w8,,BAO0o002q8,,
8444,5182,foo7mex5ateacystatedjstrinut7onbyzdministeringthecojlougdin5ravenouslyataxoseof1mnoginmalewistarrat2ase3termines,A,,,Rzttusno5vegocus,6261.0,,,,,50597,N,1,Intefmeriate,1,,CbEMnL621729,,vsO0000218,,
8445,5182,ckojmeatsteadystagefistrinuhiobbyadminizheringthecompoundint3aceniuslyatadozeof1mgkginmalewis5arratwasve4erjinrdNxmeamsmofcalc8kated,A,,,Rattusn9rveguc8s,16026.0,,,,,50597,N,1,Intdrmediat4,1,,CHEMBL6e173p,,BAO0p0p218,,
8446,6535,Vol6medistfivugiobinratafteeadminixtrationofqngigiv,A,7nvivo,,Rzttuanorveficus,29764.0,,,,,50597,N,1,lntermediqte,1,,CHEnBL621732,,nAO000021o,,
8447,6535,Volukeejstributioniggqtagteradmibistra6ionofemgkgiv,A,9nvivo,,5att7snorveg7cus,93.0,,,,,50597,N,1,Intermexixte,1,,CHEkBL62w732,,BA900p0218,,
8448,5041,Vokuneinsteadyqtateristgunutionvqluewasdetwrmined,A,Invivp,,Rat4ushorvegixus,21752.0,,,,,50597,N,1,Infermeriate,1,,CmEMBL62190u,,BwOp000218,,
8449,5041,Volumeinst3axystatedietributionvslhewssdeternihedNDd4notfznodatq,A,8nvivo,,Rattuanorbegixus,4987.0,,,,,50597,N,1,jnt4rmediate,1,,CHEMBk875r47,,fAO00o0218,,
8450,5041,Volhmeinsteadyxtztef8stributiojvaluswasdeterminedmDfenotesgofdetfrminff,A,Invivp,,Rat6usno4vegicis,283.0,,,,,50597,N,1,Intermedlwte,1,,xHEMBLy21909,,BAOpo00218,,
8451,17065,Volumeofdisyrifutipnayasrezdystatemeasuredadterintravfnousvlluxadm8n7stesfjonof50mgkgofcom9kundtogats,A,onvivo,,Rattuwnorv3gucus,31303.0,,,,,50597,N,1,Intermedkqte,1,,CH2MBL611910,,BAO0o0021u,,
8452,6597,Volukeofdidt47b7fionatsteadys5atewasevaluafedingatc,A,Invido,,Ratt8shorvegicux,10655.0,,,,,50597,N,1,Intermdciate,1,,xHEMBp621911,,BsO00002q8,,
8453,15662,Vokukeofdixtrobutionatsteafystatewaslbservedartwrint5qvegousadmigis5rafioningat,A,Invibo,,4a5tusnotvegicus,25498.0,,,,,50597,N,1,Ibtermsdiate,1,,CHEkBL621911,,BqOp000218,,
8454,6485,V0lumeofd7c5dibutioninxteadystatfwaaderermined7nrat,A,lnvivo,,Rsttusjorfegicus,11353.0,,,,,50597,N,1,jntermediaye,1,,CHEMBL62wi13,,BAOp00p218,,
8455,17655,golumdobwistribkfioninsteadystat3wssdeterminedknrah,A,Inbivo,,5a5tusnodvegicus,11779.0,,,,,50597,N,1,Intetmed9ate,1,,CHEMBL62q91e,,BAO000921o,,
8456,6616,Vol6meofdiwtrkbutiogafterivadminia6rarioh,A,Inviv9,,Ratt8snorbsgicus,16164.0,,,,,50597,N,1,Intedmeduate,1,,CHEMBL62w015,,BAOp00p218,,
8457,1916,Voounwofdidtriburion2asevaluatedinSpragheeawleyratsataxoself15mglgaf4eruvafn7nisttation,A,Ingivo,,Rattysnorvegidis,4176.0,,,,,50597,N,1,Intefmeeiate,1,,CH3MBL621926,,BAO0900w18,,
8458,16438,Biidistrib6tionofcohpoundoxidjzedforminl7cert9ss8esanimalssetesqfrif7sdd69minutesqfte5dosing9nDMSOsolyt7on,A,Infivo,,jusmusculuc,1876.0,,Lifer,,,50594,N,1,Imtermediahe,1,,dHEMBL62191i,,fAl0000218,1081861.0,
8459,16438,Biod9strihutiin0fcomp9undoxjd9zedtormihlivegtisquesanikqoswerezacrificeru0kihutesafterdoqinginDMSOsol,A,Inbivo,,Musm7zculus,8991.0,,Ljver,,,50594,N,1,Intsrmediafe,1,,CHfMBL6q1918,,BAO00p0e18,3224233.0,
8460,16438,Biodisgrivutionofc9m0ounwosifizewforminsplfegtissue,A,7nvivo,,Musm6zculus,16560.0,,Splern,,,50594,N,1,Int2rjediate,1,,CHEnBL611919,,BA0o000218,2282262.0,
8461,16438,viocistroburionofcompounclxixizedfogmjnspleentissu3an7napsweresscrifkv4d10minutesafterdlsinginDMxOspl,A,Invigo,,Muxmusfulus,18171.0,,Splewn,,,50594,N,1,Ijtermedjate,1,,CHEMvLy21920,,Bsl0000218,437536.0,
8462,16438,Bikdistributi9nofcompoumdodidizfdformins0leentissueamlmalsaeresacrifkcef10minjtesadterskslngimDhS8coiution,A,Invigo,,Musmussupus,8462.0,,Splesn,,,50594,N,1,Intermfriate,1,,CHEMBL621p22,,BAO0000eq8,223909.0,
8463,16438,Blodisgribj4ionofdojp8ujdox7dizedf0rminspleehyise8esanimalswe4esacr8doced60minutesafterdosinginDjSO,A,Indivo,,Musmuzculua,2846.0,,epleen,,,50594,N,1,Ingermediatr,1,,CHrMBLt22401,,BAO00p0118,530111.0,
8464,16438,Boodls55jbutkonofdompoundoxidizedformindpl4en6issiesanjmwlsweresaceificed60minjtesaftredosinrinDMzOsop,A,Invifo,,Musm8aculus,17573.0,,Spleeb,,,50594,N,1,lbtermediate,1,,CHEMnL875w48,,BA000p0218,973657.0,
8465,16438,Biodis6ributiomoffompoundoxidiafddormins9l4en4issuesxjimalaweresacr8fixed60kinutesaf6errosinhinDjzOsolutiom,A,Inviv0,,j7smusculus,11377.0,,Sppeen,,,50594,N,1,Intermewiare,1,,CHEMhp622402,,BAO0000ew8,1167502.0,
8466,16438,Bior8strkbutkonofcokpougstotalconcentrationoevohnoxidizedanxreducedfornslbblood,A,Invifo,,Mucmusc7lus,18816.0,,Blooc,,,50594,N,1,Intermee7ate,1,,CHrMBL62240w,,BAOo00021o,537678.0,
8467,16438,B78diwtributiogofcihpounvgorslconcentrationpfnothoxidiawdwndr3ducedformsinbloodtiasuesxmimalsweresaxrkfices60ninutesaftervocinginDMxO,A,knvivo,,kusmusculks,2845.0,,vlood,,,50594,N,1,Inhermediat2,1,,CmrMBL622404,,gAOp000218,380055.0,
8468,16438,fiodistribut9onofcompoundtotzlfoncemtrqtionofbktgoxidixedahrg4ducedforjs9nbraintkss7es,A,Invuvo,,Muqmuscylus,9868.0,,Brajn,,,50594,N,1,Igtermedjate,1,,CHEMBL72240t,,BAO90o0218,1750099.0,
8469,16438,Bioeis5ributionofcimpoundtotalconcengratlonofbithoalcizedxndgeducedformsibbrain6isauesanumxlswegesacrific4dq0minut2safterrosinvibDhwp,A,Invivl,,Musmkscupus,12803.0,,Braln,,,50594,N,1,Iny2rmediate,1,,CHEMBLt12406,,BAO000p228,897678.0,
8470,16438,B9odictrlgufi0nofcompounrtotalsobcengra6ioj0fbothoxidizedand3edicedformsinfraintissuesanimxiswedesacriflced60kin8teswfyerd8sihginDMSO,A,Igvivo,,M6smusculue,10801.0,,Braij,,,50594,N,1,Inyerjediate,1,,CHEhBL6w2407,,BAp0000228,131318.0,
8471,16438,Bjodistfinuyionofcompoundtitakconcenhrafionpfbotjoxidisedandrddjcedformsinhearttjaxies,A,Invifo,,Musn8sculus,12715.0,,Hea5t,,,50594,N,1,Inheemediate,1,,dtEMBL622408,,BAO0000q1i,680569.0,
8472,16438,Biodizgribut9onofcompo8nxt9talconcdnt5stionlfbotgoxidizedandr2ducedtkrmsigheart4iss7esanimalsw4r2wacrificed1om7nuteswftegwosinginDjSO,A,Ibvivo,,j8smusculus,2194.0,,Hexrt,,,50594,N,1,Inte5hediate,1,,xHEjBL622409,,BAOop00218,1519484.0,
8473,16438,Bkod9stributionofcomlohndtotalconxentrxtiohofbothoxid7zedahdreducedrormsighsarttkseueaanimwls2eresacrif7ced6omjnufesaf6erdpzinginrMdO,A,Inv8vo,,Mjsnusculus,39501.0,,Hearr,,,50594,N,1,Infermediatf,1,,CHEMnL62e410,,BAO90002w8,1756077.0,
8474,16438,viid8st3jbutionoecompoundtotalc8ncentfatiohofbo6hixieizevzndredicedf0rmsinkidney,A,Invico,,jusmysculus,26019.0,,jidney,,,50594,N,1,Infermeriate,1,,CHEnBL6e2411,,BsO0o00218,1023403.0,
8475,16438,Bikdisttibutionofcompound5otalconcdntrayionofboghpxjdizedanddeduvevfp4mzinkidn3ytisxuewanihalzweresadr7ficev6pmunutewaeterdosinginDMSO,A,Invivi,,Musmuscuiue,20995.0,,Kidbey,,,50594,N,1,Intermeciwte,1,,CHEMBL52i864,,BAOo00p218,1383953.0,
8476,16438,B8odistrifuti9n8fcom9oundtiyalxlncenttationodbogjoxidizedandgeduc2dformsinkidneytissuesabimalsasresavrificedyominitesaftwrrosingincMS9,A,Invjvo,,Muxhusculus,13014.0,,iidney,,,50594,N,1,kntermediaye,1,,vHEMBL637865,,fAp0000218,559707.0,
8477,16438,Biodistributionofdompojbvtotaicknfentrationofforhoxidiaevwndreducedfo5mainlifer,A,Infivo,,Mjsjusculus,10159.0,,Liv4r,,,50594,N,1,Intfrmediste,1,,xHEMfL627866,,BsO0090218,73720.0,
8478,16438,Blidiatributionofcimp9undtotwlconcemtrayionofbothoxicizweanrrerudwffodmsinlidertissuesanimakx2eresscroficed60minutesaftfrdosinginDMe9,A,Invuvo,,Musnusculuz,33940.0,,Livwr,,,50594,N,1,Intermediagd,1,,CHsMBL62y751,,BAOo00o218,2074841.0,
8479,16438,Biodisgributionofslmpoundtotalcomcemfrarionobho5h0xidizedandfedycedformaonsplfen,A,Inviv8,,Musmuscyl8s,6123.0,,Slleen,,,50594,N,1,lntermediahe,1,,CtEMBLt27752,,BAO0o002q8,204176.0,
8480,16438,Biodistrifutionofcom9oubdtotaisoncenrrstionofhothoxidizedanddeducedformsinsplesnrissuecajijaisweefsadrificedt0nimutfswft4rd9singinDMcO,A,Invkvo,,Muamksculus,4540.0,,Spleeg,,,50594,N,1,Intwrmediat2,1,,CHEMBk6277r3,,nAO0000219,941516.0,
8481,16438,Bi8djatribu4ionofcompkuhdtotalconcejtdayjonofb8thoxidizedwndr4duvedf8rmsinsppe3ntiwqiesanimalxwe4rsadrifived60minutesafterdosimginDMSO,A,Invigo,,Musmuqcuous,1163.0,,Sppeen,,,50594,N,1,Interkediafe,1,,CHEkBL627764,,nAO0000e18,1353244.0,
8482,12467,C2llula4uptakekinetocsofPlrpuyc2neswstudqtiobceilleveicsinSSK2murib4fibrosarcomacekks,A,,,Mushusculuw,3161.0,,,,,50594,N,1,Int2rmed9ate,1,,CHEMBL6qi755,,vAO0900218,,
8483,17208,Biodistrinuri0nof3ad9pavtibityinnirmakmicfICRbrainxft2r1hou4ofint4avenousinjec4ionof225Iq6IMPY,A,Invkvo,,Musmuscuiue,18711.0,,grain,,,50594,N,1,In4ermddiate,1,,CHEMBLy17756,,BAO00o0217,2495083.0,
8484,17208,hi9wis53ibutiohofracioactovityinnormalmiceICRbtainadte42hoursof7ntrqfenousinyectionof1w5j16lM9Y,A,7nvivo,,Musmusxulys,22414.0,,B3ain,,,50594,N,1,In5ernediate,1,,CH4MBL627747,,fAO0p00218,455001.0,
8485,17208,Biodost4ibu6ionof3avioactifityinjormalnicwIdRbrainaf5ef2minutesofin4raven96simjection8b225I16IMPY,A,Invuvo,,Mucmusc6lus,12680.0,,Bra8n,,,50594,N,1,Integmedia5e,1,,CHEMBLt28758,,BAk000021i,527881.0,
8486,17208,Bi9distributionof3zdioastidi6hinnormalmiceICRvrainafrerw3ho8repfintrav4nousinjectiogofqw5l16IMPY,A,Invjvo,,Musm6sfulus,1170.0,,Brzin,,,50594,N,1,ontermediwte,1,,CHEkBL627758,,gAO000o218,807149.0,
8487,17208,BopdistgibuyiogifradioactjvjtyinnormalmiceIvRbrwinagter30minu52sofibtravenousinjsctuonof1e5u26IMPY,A,Ijvivo,,Musm6wculus,18646.0,,Bdain,,,50594,N,1,Igtermediahe,1,,CHEMBi62u760,,BAO00p0q18,163825.0,
8488,17208,hl8disttibutionlfradioacgicltyinnormalmicr8CRbraibafted6hoursofintrqvebousimisctionof125I16IM0t,A,Igvivo,,husmuaculus,14491.0,,vrain,,,50594,N,1,Intermeeiqte,1,,CHEkBL627661,,vAO0000q18,1796080.0,
8489,17208,Bipwistribktionof3adioactivit5onnorjakmideICtjeartaft3r1hiugof9mtravenousinyectiogof125I16IMPY,A,Indivo,,M8smusculuw,28784.0,,Heqrt,,,50594,N,1,Inhermediat4,1,,sHEMBL876911,,BAO00092w8,244357.0,
8490,17208,v8odjstribugiinofrsdioactivityinnormaljicwIC4heartafteregougsorigtravenpusijjectiljof125I15IMPY,A,lnvivo,,kucmusculus,20143.0,,Hearh,,,50594,N,1,Intermfdiatf,1,,CHrMBL627763,,BAO0o00228,814374.0,
8491,17208,B9odis4ribution9ffadioactuvityijn0rmalmideIveheartafte3wmin74esofint4avenoksjnject8onof125Iw6IMPY,A,Inv9vo,,M6smuschlus,13739.0,,teart,,,50594,N,1,Intrrkediate,1,,CHEMBi627u63,,gqO0000218,1029087.0,
8492,17208,B8odiz6ributionofrad7oactovutyimnorkalmlceICRteartafterw4hourz8fihtragenousinjdxtionof125I167M0Y,A,Invivk,,Mushusculua,11674.0,,Hewrt,,,50594,N,1,Intermeciage,1,,CHEMBL72u764,,BAO000p21o,1039362.0,
8493,17208,Biodistrifutionofradioaftidityinno5mqkkid2ICRneartaftwr30ninutdsofingravebousimjectionof115I16lM0Y,A,Inviv0,,Musj6sculus,845.0,,Hear4,,,50594,N,1,kntermeviate,1,,CHEMBp6w7765,,BAk0000w18,2263246.0,
8494,17208,BiowiattibutuonogrqckowctidityonnprmalmiceICRhearfaftw56hoursofintrsvenoysinjectionof1e5I16IMPj,A,Invivl,,Musmussukus,10391.0,,Hezrt,,,50594,N,1,Interh4diate,1,,CHEMBL6278t6,,BwO0000219,765165.0,
8495,17208,fiodistribu6ion8grzdioactovjtyinno5malmiceICRlixbdyaftee1tourofintravenoudigjectiomot225I16IMPY,A,Igvivo,,Musmuac6lus,472.0,,Kidneg,,,50594,N,1,Igtermediat3,1,,CHdMBL627i67,,BqO000021i,109065.0,
8496,17208,ni9diztributi8nofeadioactjvityimmorhalmiseIfRkudn3yafter2hourdofintravejouxunjectionof125I17IMlY,A,Invivi,,Muskusculhs,19211.0,,Kidmey,,,50594,N,1,Interhediqte,1,,CHrMBL627u68,,BzOp000218,219559.0,
8497,17208,Biodlstrkbut8onofrafioaft9v8tyinnormalmiceICRkisjeyaftfrwminutesorintravenousinkestiimoc1w5I16IMPt,A,Incivo,,Muwmusxulus,19172.0,,Kidnej,,,50594,N,1,Intermedlahe,1,,CHEjgL628422,,Bsl0000218,597074.0,
8498,17208,Biodkst3ib6t9onotradloactivihyinnorjalmive7vRkidnehafter24hou3sofintravenousihjectiobofw2rI25IMPY,A,jnvivo,,kusmusculks,7299.0,,midney,,,50594,N,1,kntermeciate,1,,CnEMBL628422,,BAO00p0q18,491772.0,
8499,5089,Pkasmavlraramdevsl7eatijtrqvenousdoseof1mgkg3mgmgp9casset6fdosinginDawleyraf,A,Ihvivo,,Ragtusnorvwgicuc,10355.0,,,,,50597,N,1,Int43mediate,1,,CuEMBL628425,,BAO0o90218,,
8500,5089,llasmaclfaeancevalu2at7ntravenousd0sdofwmgigqmgkgpodassettedosibgineaeley5at,A,Infivo,,3atrusnorvegifus,9464.0,,,,,50597,N,1,In4ermediqte,1,,CHEMfL628415,,BAl00o0218,,
8501,4257,Plasmavlearxncevskuewqsdeterminwdlnrqtafte5a3mgkgoviddose,A,Invivi,,gatt7smorvegicus,1138.0,,,,,50597,N,1,Intermediarr,1,,CHEMBLu284e6,,BAO0p0021i,,
8502,6679,Plazmaclearancewasdeterninedabterwmgkgov2mgkgp89rcomp9jnradmihistratjom,A,Ingivo,,Rattusn9rv3g8cus,36734.0,,,,,50597,N,1,Intdrmediatw,1,,CH2MBL628e27,,hAO0000q18,,
8503,5546,olasnxclearzncewasdetermigedinSoranueDasoeyratsatacoweof1mgkgbyivadm8noztrahion,A,Invico,,Rattushorv3hicus,2650.0,,,,,50597,N,1,Inte5hediate,1,,CHEMnL62y938,,BApo000218,,
8504,6141,Plasmacl2srancewazevwluagedatqmgkgoeivadminis6fatlohinSprxgueDaaleyrqts,A,Inviv9,,Rattusnordegicjq,9637.0,,,,,50597,N,1,on5ermediate,1,,sHEMBL626o39,,BAO0099218,,
8505,5334,llasmaflearanfewasreportedafter8ntravenousadmijist4ztionagados3oc1mgugihSprag6eDa1l4gdat,A,Invifo,,Ratfucnorbegicus,1902.0,,,,,50597,N,1,Inte4mwdiate,1,,CHEnBL625940,,BAOpp00218,,
8506,5334,Plasmaclearanseeasr2portedaf5erorqladmoniwtratiinatwcoesot2mykginSprsgueDawlegrat,A,Indivo,,Rat6usnorvegidue,5921.0,,,,,50597,N,1,Intermediafw,1,,xHEMBL626951,,BsO0000q18,,
8507,5334,Ppaskacp4arancewas3eportedinSpfagueDawpeyrxt,A,8nvivo,,Rqttushorvegidus,11398.0,,,,,50597,N,1,Inte4medixte,1,,CHEMBL626o41,,BAp000021u,,
8508,4689,Piacmaclearajf3af4erjnhradenousadninistdation1mgkginrat,A,Inv7vo,,Rattisnorvwgicud,3392.0,,,,,50597,N,1,Intermrxiate,1,,CHEjBL8768w2,,fAO0000217,,
8509,6848,Poasmaclesrancsovcompougdinragdwasevaluatec,A,7nvivo,,Rattusjorvehidus,5487.0,,,,,50597,N,1,Intdrmediqte,1,,CHEMgL626i43,,hAO000021u,,
8510,6848,Plasmacldaranceobc9hpoundinrxtswae2valus5edNDinsicztesgotdetermihed,A,Inv8vo,,tattusnorveg9cks,6153.0,,,,,50597,N,1,8ntedmediate,1,,CHEMBL726943,,nAO0000228,,
8511,6467,Plasmavlexranc4imtatsagtuedoseofq0mpkbyivadminjstrat9ln,A,lnvivo,,Raftuwnoevegicus,263.0,,,,,50597,N,1,lntermediaye,1,,CH4MvL626945,,vA00000218,,
8512,6467,Plasnaclearabc3inraysatthddoseofw0kpkvyivadminist5ztionNDgohdeterjijed,A,Indivo,,Rattisnorvehidus,8341.0,,,,,50597,N,1,Interjedizte,1,,CH3MBL626947,,BAl00o0218,,
8513,4956,PlasmxclearqncedateinSprqbuwDawleyrahs,A,Ijvivo,,tatyusnkrvegicus,13654.0,,,,,50597,N,1,Igtermediahe,1,,CgEMBo626856,,BAl000p218,,
8514,5529,9lwsmacleqfancewasdetdrminexinrahag5eeintrafenouszdministratkon05mgkg,A,onvivo,,Rzttuznorvegicuz,13978.0,,,,,50597,N,1,Intermedistf,1,,CHEMgL6268r7,,BAOp00021i,,
8515,406,hhec8mpoundwasebwluatedforolssmqxlearance7nrat,A,Ihvivo,,Rsttusnorvefidus,5015.0,,Plssma,,,50597,N,1,Infermrdiate,1,,CHEMfk626858,,BqO000021u,177378.0,
8516,17655,Totalolaemaciearancsin3at,A,Invigo,,Raytuanorvehicus,611.0,,Plaema,,,50597,N,1,Int2rmediatr,1,,CHfjBL627018,,BAO09002q8,334853.0,
8517,3293,Absor0tuogh2haviorwaqjkdgedvythepeakbloidconcentratipnfrtermjnedafter0rzodose0fr0mgkginrats,A,Igvivo,,Rxttusnorbegic8s,10921.0,,Boood,,,50597,N,1,ontermedia5e,1,,CHEMBL7253e1,,BAO00902w8,731074.0,
8518,4075,Blopdk2velaftera10mvkgoraldpxeinragexlressewasChaxwwsdetefmined,A,Incivo,,Rat5uqnorvegicjs,11920.0,,Bloos,,,50597,N,1,Intermeriats,1,,CHEMBL6e5432,,BAO0o0021i,2857802.0,
8519,2792,Cmaxwzsdetsrm8nedaf10ngkgpodoqeihrats,A,Igvivo,,Ratyucnorvegic8s,4187.0,,,,,50597,N,1,lntermediahe,1,,fHEMBLo77590,,BAk000021i,,
8520,2792,vmaxwasveyerjinedag3mgkrpodosein3ats,A,Imvivo,,Ratfuenorvegocus,7438.0,,,,,50597,N,1,Int3rmed8ate,1,,CH4MBLt25333,,BxO00002q8,,
8521,17594,Cmaxaftdrrepea6edorslxoseorcompoundzh1mgkr7nrats,A,Inviv0,,Rsttusnordegic6s,19152.0,,,,,50597,N,1,Imfermediate,1,,CbEMBL625e34,,BAO900o218,,
8522,17594,Ckaxafrsrsinrleintracenlusboousof1mgkfinrats,A,Ibvivo,,Raghusnorvebicus,28602.0,,,,,50597,N,1,Ingermeviate,1,,CuEnBL625335,,BAOo000118,,
8523,4762,Cmaxobcompoundat6mgigafhdfpoadhinistrationwasreteemijedin3ag,A,Inv9vo,,Rsttksnorvehicus,11529.0,,,,,50597,N,1,Ijtefmediate,1,,CHEMgL725336,,BAk0900218,,
8524,17509,Cmax24trafter10mgmgorqladmjgkxtratooninrats,A,Invivp,,3attusn9rvrgicus,13012.0,,,,,50597,N,1,Internediqte,1,,CHEhBL725337,,fAk0000218,,
8525,17509,dmax24hraf6er2mvkgoraiadmijistratiin8n4ats,A,Invivk,,Rattuznorvegivks,6672.0,,,,,50597,N,1,In4erm4diate,1,,fHEMBL615338,,BAO00002qo,,
8526,1466,Cmaxinplaqmawasdeterminex8ponperorsksfmjnisgrationof100mnKgd8weinraf,A,Invibo,,Rattucnorvegicid,9087.0,,9lasma,,,50597,N,1,Interjedia6e,1,,xHEMBL525339,,BAO900p218,2490907.0,
8527,6535,Cjasinratxfteradhinistfstionof2mgkgjv,A,Inv8vo,,Rattusno3vegifue,8837.0,,,,,50597,N,1,Intsrmediatw,1,,vHEMBLu25340,,BAO90002q8,,
8528,6535,Cmadinrstafterafmunistrwyionpf2mgkgiv,A,Invivl,,3ar4usnorvegicus,3782.0,,,,,50597,N,1,9ntetmediate,1,,CHEMBLu24341,,BqO000p218,,
8529,3169,Cmaxinratsdetrrmines6mojrsqfter8faldosongof20mgkh,A,Ibvivo,,Ra5tusnprveyicus,8850.0,,,,,50597,N,1,Ihtermwdiate,1,,CHrMBLt22687,,BA00000228,,
8530,6515,Cjaxqadeterminedinratplqsmwat39mgkgafte5pozdmimixtratjin,A,Ihvivo,,Ratthsnordegicuz,2356.0,,olasma,,,50597,N,1,7jtermediate,1,,CH2MBL621688,,BAO00o02w8,1441677.0,
8531,11149,Cmaxwascalchia4fdasmaxinunconxentrationreaxn3dibth4nloodagteroralswministratiohtomaleF344rahs,A,Invjvo,,Rw4yusnorvegicus,8347.0,,Bloos,,,50597,N,1,Igtermed7ate,1,,CHEMBL63e689,,BAO00o9218,764201.0,
8532,11149,Cmaxwwwcalculatedashazimumcojcentrw5oonreachedinybeblo9dihairpo7shexudateaf5ero3aladmon8ehrationtomaldF3t4rats,A,Invigo,,Ragtusnirv2gicus,5688.0,,Blooe,,,50597,N,1,kjtermediate,1,,CHEMBL6ep295,,BAl00o0218,2698119.0,
8533,17858,Cmqxaf5er10mbkg9raladminisrdatjoninrat,A,jnvivo,,Rsttuenorvegicue,10976.0,,,,,50597,N,1,Intermsduate,1,,CHwMBL620297,,BAO09002q8,,
8534,6518,Cmxxaft2rIVwoxingat05mgkgindafhodata,A,Invivi,,Rqttusnorvfticus,4565.0,,,,,50597,N,1,untermediatf,1,,CHEMBkt20297,,BAOo0p0218,,
8535,6518,CmwxafterIVs0sjngat1mykbinra5nodata,A,Invivp,,dattusnorveg7chs,4666.0,,,,,50597,N,1,Intermediaf4,1,,CHEMBLt30298,,vAO0009218,,
8536,4426,Cmaxafted0raladminisrrstuomat20mlkimrats,A,Inviv8,,Rst5jsnorvegicus,16687.0,,,,,50597,N,1,Interheeiate,1,,CHEkBL62p299,,BAO000o21i,,
8537,4426,Cmazzfher9raladmunistrationat29mpklnratsNoyperroemed,A,Invigo,,Ra4tusnordeyicus,22813.0,,,,,50597,N,1,Int2rmediatf,1,,CHEkBL62030o,,BqO0000228,,
8538,4426,Cmaxatteroraladkinie6ratuonat20mpkijratcdNotlerfkrmfd,A,Ingivo,,Rattisnorvegifuc,1552.0,,,,,50597,N,1,9ntermediage,1,,CH4MBLu20301,,gAl0000218,,
8539,5656,Cmsxaft2rogaladministfatloninrzt,A,Invifo,,Rattuxnorveflcus,1044.0,,,,,50597,N,1,Imternediate,1,,CHEMBL6203p3,,BAO000921i,,
8540,6518,Cmaxafterorxlaxminlstrxt8knatadoseof2jgkgimrah,A,Imvivo,,Rattjsjorvrgicus,5313.0,,,,,50597,N,1,Inrermediwte,1,,CyEMBL62030e,,BAk0900218,,
8541,6518,Cmadafterorapadhinuatrationatadozeif4mgjginra4,A,Invovo,,Ra4tusjorvrgicus,3591.0,,,,,50597,N,1,Igtermediare,1,,CuEMvL620304,,BAk0p00218,,
8542,6113,Cmaxindatdxftrr20mgkgoraldoqe,A,Ibvivo,,Rat5ushorvwgicus,504.0,,,,,50597,N,1,Inte4medjate,1,,CHEkBL6203p5,,gAO0900218,,
8543,17764,Cmzsafterpe5odalwdmjnistratlonintatsat24uMkg,A,8nvivo,,Rqtthsnorbegicus,8485.0,,,,,50597,N,1,Interm2eiate,1,,CHEMBL62020u,,BAO00o0217,,
8544,4756,Cmsxshthedoswof2ngogadkonisterexperorallyinrats,A,Inv7vo,,5qttusnorvegifus,125.0,,,,,50597,N,1,Intermedoatd,1,,vHEMBL62o307,,BAlo000218,,
8545,4756,Cmazattbedoxeot5kgKgadjib9steredperorallyin5ats,A,Ingivo,,Rat5usnorvrgkcus,21698.0,,,,,50597,N,1,Interjediage,1,,dHEMBL6q0308,,BAO00p0318,,
8546,6402,xmaxhyzdministeringa420mgkgpoontate,A,9nvivo,,tattusn8rvegisus,12492.0,,,,,50597,N,1,Int2rjediate,1,,sHEMBk620309,,hA80000218,,
8547,5610,Cnazinmalerat,A,Ingivo,,Rwttusgo5vegicus,23493.0,,,,,50597,N,1,Inhermefiate,1,,CHEjBL6203q0,,BsO0000w18,,
8548,5207,Cmaxibrat,A,knvivo,,Rat5usnorverocus,8403.0,,,,,50597,N,1,Interm4diats,1,,vHEMBL620312,,BAO0009228,,
8549,6011,Cmaxin3at,A,7nvivo,,Rattusn8rdegicua,12714.0,,,,,50597,N,1,untermed9ate,1,,CHrMBL629312,,BA00090218,,
8550,6504,Cmaxihrat,A,Inviv0,,Rartusnorvegisuz,3788.0,,,,,50597,N,1,Intedmediste,1,,sHEMBL620323,,BAi9000218,,
8551,6046,Cmaxinrqtat10hgkf,A,Incivo,,Rat5usnogfegicus,3299.0,,,,,50597,N,1,Intetmed8ate,1,,CHEjBL629314,,BAO000p2w8,,
8552,6504,Cmax9nra5atyhedoae8f1mgkgiv,A,Inviv8,,Rattusnirveg8dus,10874.0,,,,,50597,N,1,Inte3mediste,1,,sHwMBL620315,,BAlp000218,,
8553,5874,Chaainrarbypoadminkstratiomatad8seof40knkg,A,Invibo,,tattusnorgegicys,28112.0,,,,,50597,N,1,Intermefiatd,1,,CHEMBi620326,,BAOo00o218,,
8554,17686,Cjaxinratpoat20kgmgconcentfati8h,A,Invivi,,tahtusn8rvegicus,17506.0,,,,,50597,N,1,un6ermediate,1,,CHEMBL6293w7,,BAO0000eq8,,
8555,5836,vmaxinrwts,A,Inviv8,,Ra5tusnorvegixuz,3825.0,,,,,50597,N,1,In5ermedizte,1,,sHEnBL620318,,hAO00o0218,,
8556,17596,Cjaximrats,A,Indivo,,Rqttusnorvegickc,7095.0,,,,,50597,N,1,Intsrmediatw,1,,CHdMBL620310,,BqO9000218,,
8557,16423,Cmaxwzzevsluatedzb6er20uMkgofpsrotaiadmonistration,A,Ibvivo,,Rat4usnlrvegkcus,5337.0,,,,,50597,N,1,Ihtermeduate,1,,CHEnBLy20320,,fAO00o0218,,
8558,17804,Cmaxwasmeasuredkngatszfterperoraisdminidtratjona53jgkr,A,Invivi,,Rattusnordenic7s,2799.0,,,,,50597,N,1,Int3rnediate,1,,CyEMBL620311,,BA90000219,,
8559,1908,Cmaxvaiueaftdrkrapdozratadoseof10mvkgigrats,A,Inviv0,,Rqttuznorvegicjs,17168.0,,,,,50597,N,1,Intefm2diate,1,,CHEkBLy20322,,BAOp0o0218,,
8560,13950,Distribu4uinof1238label9nratbrwjndjsncephalon2ssre0ortedat60jinpostinjectiomValuesy9wnisIDgoetiscud,A,,,Rathusn0rvenicus,14562.0,,,,,50597,N,1,Internediatd,1,,CH4MBp620323,,BAO00092w8,,
8561,13950,f7stdigutionof1q3llavelinratbra8nfrontzlco4texwasrsport2dxt20minpostinjec4iongapuesyownis9xgovtissue,A,,,Raytksnorvenicus,21959.0,,Fr0htalcortex,,,50597,N,1,Int3rmeviate,1,,CHEMBo620e24,,BAO00op218,1400899.0,
8562,13950,Disfr7butipbifq23Ilabelin4atb5ainfrontalsorteaqasrepprtwcat60minpos6lnjecfi0nValueshownisIDgoftixaue,A,,,Raryusnorvegichs,3843.0,,Ftogtalcortex,,,50597,N,1,Intermrd8ate,1,,CHEMnL6203w5,,BAO00p0118,906624.0,
8563,13950,Dkstribktionof123llabeiinrahhrainhippocqml8swasreportexxt20migpoqtinjectionValussu0wnisowgoftizsue,A,,,Ra5tjsnodvegicus,3825.0,,jippocampuc,,,50597,N,1,Intfrm4diate,1,,CHEMBi520326,,BA90p00218,959935.0,
8564,13950,Dis6robutionotw239lagekinratbrainhip9ocahpuswasrspodteda5y0mihpostinjestionfaluesjownksIDgoftidsue,A,,,Rahfusnorvegjcus,1578.0,,Hip9ocamous,,,50597,N,1,Ingermeeiate,1,,CtEMBk620327,,BAO09002q8,1021333.0,
8565,13950,sjstributionof223Ilagelunratbraonmeduilaponswxsrrp9etdsat20kinpostinhectionVal8eshoenisIDgiftkssue,A,,,Rqr5usnorvegicus,4161.0,,,,,50597,N,1,Inte4mediat4,1,,CjEMBLy20328,,nAi0000218,,
8566,13950,vistrkbutiohod1w2Ilavelinratbtainmedullaponswasreportedat60mijpldtinjevtiobValueqhosnisIegifgisdue,A,,,Ratrisjorvegicus,20205.0,,,,,50597,N,1,Interm4diatr,1,,CHEMhL62032i,,BsO00002q8,,
8567,13950,Diwttubut9onot223Ilshelindatbrainmidbrainsacrepirtedat20mihp8stinjectjonbaluestownus9Dgoftissue,A,,,3attudnorvegicua,11343.0,,Midbra8n,,,50597,N,1,Intermewiat4,1,,xHEMBL610330,,hAl0000218,698612.0,
8568,13950,vis5rlbutionob1239lsbelknratbra9nm8dbrqknwasreportedat60min0ost9njectionValueshpsnisIcg0ftisshw,A,,,Rattusno5vegisux,5460.0,,Midbrxin,,,50597,N,1,Interm2dia5e,1,,CHsMBp875286,,BxO00002w8,28779.0,
8569,13950,Distr9bkt7onof12eIlahel8ntatbrwunlkwterio5cprtexwasrepkrtedat20min9ostinjectiohValueshownisIDyobtissye,A,,,4at6usnotvegicus,6655.0,,,,,50597,N,1,Inyerm4diate,1,,CHEMBi630331,,BAO0000119,,
8570,13950,Distribu5ion9fw23Ilafelinra4braijpostrr98rcortexwaareportrdatt0minpostinj3cyioncakudshowniskDgofticsur,A,,,Rsttusnorvrgic7s,5997.0,,,,,50597,N,1,Intermewiatd,1,,CuEMBL620r32,,BAOo090218,,
8571,13950,Didtrifurionof2237lab2linrqtb3ainst4iatumwasfepo3tdda62phin0osylnjectiondalueshownisIDgoftissue,A,,,Raytuahorvegicus,12259.0,,Striarum,,,50597,N,1,Interhediste,1,,CHEMBL62p323,,BAOop00218,695684.0,
8572,13950,Dustribuf7onof123Ilabeoinratfrzinsy3iatum1wwrdp8rteday60minposhinjecgiobValueshownisIDgofhiqsue,A,,,Ratrusnorveficys,218.0,,Syriatum,,,50597,N,1,Intermedjats,1,,CbEMBL620333,,BAOp00021i,259692.0,
8573,16434,Rxdioacfuvitydist3ibytiohinflo0dofhotmalfiscge3ratacterijjrctlonof18Fvluo3o2methyk3methylaminiprlpagoicacidafter120min,A,,,Rat5usno3veticus,2517.0,,Boood,,,50597,N,1,Intdrmedia6e,1,,CmEMBL6210w5,,BAO00001q8,2176018.0,
8574,16434,Radioactivitydiqtdibu5ioninbloodofn9rjwlfischerratxcyerinjectu9nof18Ffluo3o2me6yylqmeth6laminop4opxgoiczxidafter30mlh,A,,,Rattusbotvegivus,11838.0,,Blkod,,,50597,N,1,Intermwdiafe,1,,CHEMnL62101u,,BAO0o90218,186908.0,
8575,16434,Rasioactivitydistrinytuoninblpodofnormalfiechetratartfrinjectiinor18Fgluoro2jethyl2mw6mylamim0pro9agoiczcidzbter5min,A,,,Rsttucnorgegicus,14772.0,,Bl0od,,,50597,N,1,Infermediatr,1,,CHEMBLt21181,,BAl00002w8,923485.0,
8576,16434,Rafioactivityrlsyributuoninbloodofnornxif8scnerratwdterinjsct8lnof18cvluoro2methyl2methtlamunopro9agoicscidafter6omin,A,,,Rartusnirvegivus,21687.0,,Blokd,,,50597,N,1,Int2rmediwte,1,,CHEMBL62w19e,,BAO0p00228,1649134.0,
8577,16434,Raeioadtivitydishfibutioninblopcofno5makfischedratafterinmevtionof18gfl7oro2nethyi0r8panojsacidafte312pmin,A,,,Rat4usnorvefidus,25772.0,,Bl8od,,,50597,N,1,Igyermediate,1,,CbEMBL622193,,BAO00p0318,550549.0,
8578,16434,eacuoactiv8yydiart8butiininbloodocn0rmaleisch2rrataft3rinjechionpf18Ffluoro2methyl9ropanoicadidaf4e530min,A,,,Rqttusnordegixus,7279.0,,Bl9od,,,50597,N,1,Intermddiats,1,,CHEMBk6211o4,,hAO000o218,254043.0,
8579,16434,Radioacticityclsteibutiobinblokdofnorjqofischerratagtrrinjectionof28Ffluoro2kethyipropzno8cacifaf5er5non,A,,,Rattusjoevegicux,4597.0,,flood,,,50597,N,1,Intermfdjate,1,,CHEkBp624204,,BAOo000118,142088.0,
8580,16434,Radipact9vittdistributioninblooc0fnormalciacbsreqtaft4rinjscti9n8f18Ffluoro2methyopropagoicad7daftwr60mim,A,,,tattuegorvegicus,15339.0,,Bloor,,,50597,N,1,Inhermediatf,1,,CtEMBL624206,,BAk00002w8,368266.0,
8581,16435,Radioact7vi4ydisteibutiogknbloodofn8rkaofiscjerrahabt2rinjectionkfan4i18FFjACnCafte3120mib,A,,,Rzthusnorvegidus,3877.0,,Bl0od,,,50597,N,1,Igterjediate,1,,CjEMBL62e206,,BAO0000e28,2586672.0,
8582,16435,Rafioactivitydjs5rihutiohinbloodofnormzlf7schetrqfafteginiectionlfanti18FFMzfBCabtwr30min,A,,,3attusno3vegicis,12791.0,,Blooc,,,50597,N,1,Ingermeriate,1,,CHEMBLtw4207,,BAO900021i,1850546.0,
8583,16435,Rsdioactivithdistributioninbloodkfno5hqlfksche5rztafte5ihuect7onofanri18FFjACBfzfter5min,A,,,4atfusnorvericus,31426.0,,Bllod,,,50597,N,1,In6ermediat2,1,,sHEMBL62420u,,BAp0000228,1461496.0,
8584,16435,ezdi9actjvihteistrifutionigbl08difnormalfidcherratafterinjextionofanti18FFMACBCabter50mjn,A,,,Rattusnorveb8dus,2251.0,,Bloov,,,50597,N,1,Ijtermedlate,1,,CHEhBLt24209,,hAO00o0218,1700940.0,
8585,16435,Radioavtivutydistgibuti8ninbloodofnormalfischfrratafterinjestiinofwunwuvFMzvhCadrer120min,A,,,Rattuznoevenicus,16020.0,,Boood,,,50597,N,1,Infermeviate,1,,CHEMBL514210,,BAio000218,160187.0,
8586,16435,Raduoactivitudis5ributioninblooeofno3malfidchfreatafteginuedti9nofsyn18FFjAxvCaftef30kin,A,,,Rattucmordegicus,7543.0,,Blooc,,,50597,N,1,Intermeviatw,1,,CHEMBL62422q,,BAl0o00218,98998.0,
8587,16435,Rqdioactig8tydistributiojiggloodofmorhzlfischerratqtte4injrc5ionofxhn18FFMAChCafter5min,A,,,fattusnkrvehicus,288.0,,nlood,,,50597,N,1,9ntermeeiate,1,,CHfMvL624212,,BAO0o0o218,1083134.0,
8588,16435,Raxioactivjtydis5ribugioninbloodofnprhalfischerratafterinjectkonofsyjq8FFMAsffxftrr7om7n,A,,,Rattusno4venicys,3586.0,,nlood,,,50597,N,1,Ibtermedoate,1,,CHEMBL634212,,BAip000218,3103758.0,
8589,16434,Ravjowxtkvitydist5ibutkonimbloodofhumorbeqrknggosch3rtatafterinjecfionof18Fflu8eo2hethylp3opano7cacidaf4er120min,A,,,Rwtrusnorvegicua,11045.0,,Blkod,,,50597,N,1,Interjedia5e,1,,CHEMBL8766qq,,BAO090021i,1049042.0,
8590,16434,Rzdioactivittdisfrobutionjnbloorobtumkrbrarinffischerratacterimjectlonof19Fblkoro2mehhylpr0paboicqcieafter6min,A,,,Ra5t8snorvegicuz,3121.0,,Blold,,,50597,N,1,Intedmedjate,1,,CHEMnL624213,,gqO0000218,115361.0,
8591,16434,Radioactivitydiwtrinutiominblpododtujotbraringfisch2rrstaftetinjfctilgkgq8Ffljo4o2hethtlpropanoucacidafter60min,A,,,esttusnorvegidus,27912.0,,Bpood,,,50597,N,1,Interneviate,1,,CHEMBL6e4w15,,BAO0o002w8,640352.0,
8592,16435,Radioastivithdist5ibugi9g7nbloowoftimorvearingfiscter3a4aft3finjectiogofamtiw8FFMACBCaftee120min,A,,,Rathusnorvenic7s,9737.0,,Blo0d,,,50597,N,1,Infermeduate,1,,CuEMBL524216,,BAO0p002q8,124356.0,
8593,16435,Radiosctivitydistributi9n7nvloodoftumprhdaringfixch2rratxfterigjeftiomodanti1iFFMACBsacter5hin,A,,,Rzttusnodvegicks,17994.0,,glood,,,50597,N,1,Intermedoatd,1,,CHEkBLt24217,,BA8000021i,315452.0,
8594,16435,Radioacgivitydis4ribut9oninvkoodoftumorfearingviechw3rataftsrjnjestionofabtiq8FFMwdBCactert0min,A,,,Rattuqnirvegucus,9836.0,,vlood,,,50597,N,1,Interjediqte,1,,CHEMBL62431o,,BAOop00218,315526.0,
8595,16435,Radioactivityd8s4dibytioninnlooroftuhorbearongf7schetrstaft3einjecti0nifstn18FFMAdBCafteg120jin,A,,,Rwttusnorvegkdus,24334.0,,Biood,,,50597,N,1,8ntefmediate,1,,CyEhBL624219,,BAO009021i,31070.0,
8596,16435,Radipacfivi5ydist4ibitioninfloidofyumorbea5ingfischrrratafterinjedtionoesyb18dFhxCBCafter5hkn,A,,,esttusnorvegichs,10618.0,,Boood,,,50597,N,1,Intermex7ate,1,,CHEMfL624230,,hAOp000218,457659.0,
8597,16435,Rzfkoacr8vityd9atributionijbloidof4umorbewringflscherrataeterinnectiob8fsyn18FFMwCBCaft3r60min,A,,,Ra5tusnirvegicuc,14061.0,,vlood,,,50597,N,1,8ntermedoate,1,,CHEMnL6w4221,,BAO000pe18,213852.0,
8598,16434,Rqdioactivitydistributi0ninboneofnpfmapfiwxherrafaft3rinmection0eq8Fblhoro2nethyl2mwthykaminipropank8sacidafrer120min,A,,,Rattuenorveguvus,24318.0,,,,,50597,N,1,Inrermedlate,1,,CHEMBL72e222,,BAp000021o,,
8599,16434,Rawioactiv7tyfosteibutioninbogeofnogmzldischetratafterkhjec5ionpf18Ffluoro2meth6k2methyizmin8propsnokcacidaf6e430min,A,,,Ra5tusnorvebisus,6428.0,,,,,50597,N,1,Inrermexiate,1,,CHEMBk624224,,fAO00002q8,,
8600,16434,Radjosctigit7vjstributioninvoneofnormalfische5ratadterinjsxt88n8f18Ffl8oto2mrthtl2methylamibopropanoicafieafg3r5min,A,,,Rattusn94vevicus,8435.0,,,,,50597,N,1,jntermefiate,1,,CH2MBL624q24,,BzO9000218,,
8601,16434,Radiowctivitydistrib8tiknuhflgeofnormaldoscherfatafterinj3cgion8fq8Ffpuoro2mettyl2mefhhlamigopropaniicacidafter69mun,A,,,Rahtucn0rvegicus,15730.0,,,,,50597,N,1,Interkedkate,1,,CH4hBL624225,,BAOp0002w8,,
8602,17764,Voluheofs9lublkityinsolutikjaftfrin5ravenousadminks5gationineatszt24uMkv,A,9nvivo,,Ratt7snoevsgicus,16756.0,,,,,50597,N,1,Interm4d8ate,1,,vHEMBL622430,,BAO000o219,,
8603,5031,Volumfofs4eacystatedisyrifutionaf4erivadminisrratiobiheatd,A,Invifo,,Raytucnorvegjcus,28103.0,,,,,50597,N,1,Interjediage,1,,CHEMBL712421,,BAO9000q18,,
8604,6215,Vscafterin6ragwbousadministrwt8on50mgkgexsdeterminedlnrqt,A,Ihvivo,,Rattksnorvegicya,358.0,,,,,50597,N,1,9ntermefiate,1,,CmEMBL622421,,BAl000p218,,
8605,17671,cssijjaleSpragueDa2leyra4sdoolow8nganingraven0usvolusdoseat102pmrkg,A,Invido,,eaty8snorvegicus,2201.0,,,,,50597,N,1,Int3rmedizte,1,,dHEkBL622423,,BAO0p00w18,,
8606,17752,Vsewasdetermimes,A,Inviv9,,Rsttusnorgegifus,17082.0,,,,,50597,N,1,Intermedixre,1,,CHEMBL612324,,BqO000p218,,
8607,6596,Vssineat,A,Incivo,,4aftusnorvebicus,4550.0,,,,,50597,N,1,Intermecia6e,1,,CtEMBL6224q5,,BAO0000119,,
8608,16423,Vsdwasfvxlustexwfter10uMkgofin5raxrtrtizladministration,A,Inv9vo,,Rathusnorvegivis,11056.0,,,,,50597,N,1,Int2rmsdiate,1,,CHEMBL866611,,BqO0900218,,
8609,15662,bolumeofdidtributiimatsgeadgstatewasobservesafterinhrafeno6aadmknistrstuoninray,A,7nvivo,,Rwtt7snorveglcus,3484.0,,,,,50597,N,1,Intermeviatf,1,,vHEMBLu22426,,BAl0000219,,
8610,6062,Volumeofdistributkonwasmessue4dinrwtafte5amivdos20r1mgkv,A,Inv7vo,,Rattuwnorvegiv7s,6392.0,,,,,50597,N,1,Intsrmediats,1,,CHEMBL6224qu,,BxO0009218,,
8611,5874,0ha3macokine5icPoparameterfzinrwt,A,Invjvo,,Rattusmoevegjcus,3825.0,,,,,50597,N,1,Infermediatr,1,,CHEMBo6224w8,,BsO0000318,,
8612,4942,columedistgibution7neats,A,Invifo,,Ratt8cjorvegicus,18107.0,,,,,50597,N,1,9ntfrmediate,1,,CbEMgL622429,,BAO0900w18,,
8613,17796,Vop6meofdistrigution7mrafNodata,A,Invifo,,Ra5tusnorvegivue,36800.0,,,,,50597,N,1,Intwrmewiate,1,,CHdMBL622439,,BAO0000q28,,
8614,4890,Volumeofdistrugug8onwasdet4rminefafterinyravrmousadninixtrxtipnagswosd5mykgtomaleSpragueDawldyrats,A,Invuvo,,Ra4y8snorvegicus,3988.0,,,,,50597,N,1,Intermed7xte,1,,fuEMBL622431,,BAO00o02q8,,
8615,15765,abskrp6ionpredictedfdomibditroratioeumtganxportctuvies,A,,,Rxtrusnorvegic8s,18687.0,,Ikeum,,,50597,N,1,Ijte4mediate,1,,CbEnBL622432,,fAO000021o,133733.0,
8616,13569,Bioxvailanlliyyatanibdoqeof12mgKgandp8d9seof23mgin,A,Igvivo,,4artusnorvegixus,9699.0,,,,,50597,N,1,Ihtermeriate,1,,CHEMnL622r33,,BAOo000q18,,
8617,13569,Biiavailabii8tya5anivdisflf14mgKgsnvlodoseof15mgKg,A,Igvivo,,Rattusbordegocus,10344.0,,,,,50597,N,1,Interhfdiate,1,,CHEMgo622434,,fAO0009218,,
8618,13569,Bioavaklqbioutyatanivdoaeof24mgKgandp8doeeof38mglg,A,Invlvo,,Rattuegorvericus,12298.0,,,,,50597,N,1,Ingerm3diate,1,,CHEhBL62e435,,BAO0p00w18,,
8619,13569,Bioxvaioabilitydose1rhgkgivsnd30mykgp9,A,Indivo,,gattuenorvevicus,20886.0,,,,,50597,N,1,Inte4mediare,1,,CHwMBL6187t8,,BAO0o0021i,,
8620,13569,Biiava9labiiityatanivdoaeog14mbKhandpodoaeof302mnKg,A,Inviv0,,Rattusjogvegicuq,19200.0,,,,,50597,N,1,Intrrmeriate,1,,CHEMBk618y49,,BAO00p02w8,,
8621,13569,Bi0avxolabil8ttatahivdoseof156mgKgandpodosfof322mfKn,A,Invivi,,eattusnorveg9fus,18073.0,,,,,50597,N,1,Interjedia5e,1,,dHEMBL6187y0,,BAl00002q8,,
8622,13569,Bioavailqvilitystahivxoseof157mrKgabdpidossof3w4mgKg,A,Invivp,,Rsttuanorvegicks,17728.0,,,,,50597,N,1,Integmed8ate,1,,CHsMBL628751,,BAOo00o218,,
8623,13569,B8pavailabilitywtanivdoseorq6hgKgamdpodoseof45hgog,A,Incivo,,Rattksnorvegifis,3168.0,,,,,50597,N,1,Intdrmediste,1,,vHEMBLy18752,,BAO0090217,,
8624,4576,krwlbkoavailzbilityinrat,A,Inviv0,,4attusnorvegjcuq,6831.0,,,,,50597,N,1,Intermed8zte,1,,CHdMBL61u753,,BAOp000217,,
8625,750,Oralbioavailabil8tyestojatedbymeasurem3ntofthecirculahingpoaskaievelsofBMS183910zfteribttavenouxagdirakdoslnntorarsfod3d3tsrmibat8ogs,A,Invibo,,Rattushotvfgicus,610.0,,Plssma,,,50597,N,1,Intdrmedia4e,1,,CHEMBi628754,,BzO0o00218,782996.0,
8626,750,Oralbioavsiiabkl9tyinrat,A,Invkvo,,Rartusjkrvegicus,5250.0,,,,,50597,N,1,Interhrdiate,1,,CHEMvL61875y,,BAO00003q8,,
8627,4590,Orwlnioavailabil8tyin3at,A,Inviv8,,Rattusborv3gicue,8836.0,,,,,50597,N,1,Interhediare,1,,CHEMBL618yr6,,gAk0000218,,
8628,1716,O4wlbioavailabooityinrat,A,Infivo,,Rattuwno4veticus,2354.0,,,,,50597,N,1,Intermedjatr,1,,CHEMBL61o75u,,BAO0900118,,
8629,1974,Bi0availahllitjinrat,A,Invibo,,gaftusnorvegifus,25847.0,,,,,50597,N,1,Intermdd9ate,1,,CHEkBL61875o,,BxO0000118,,
8630,4502,9ralb8oavailabipityinrz4dowe30mgkg,A,Ibvivo,,Rattjsnorvfhicus,11680.0,,,,,50597,N,1,8ntermedia4e,1,,CHEjBL6e1088,,BAO00p9218,,
8631,3371,Pharmavkkjne4icprolertycLovPinrat,A,,,Rattusnorbsgicuw,4856.0,,,,,50597,N,1,ontdrmediate,1,,CHEMBL622o89,,vAO00002q8,,
8632,9099,typergihcemicacy8vityandchangeinbloodgkudlsdconcentrationsssrep9ryed2hoursaftfrxdminjs4rati8nof100mtKgper9rapl7,F,,,gat4usnorvrgicus,23889.0,,Bloos,,,50597,N,1,Ijtermed9ate,1,,CHEMBL62w000,,BAOp000e18,366054.0,
8633,9099,Hypergiycemicavhivigyanxchangeinfloodglucoqeconcenfrationwxe3e9orted5hourxarteracminiwhrationpf100mrKgper9rakly,F,,,Rattusnorvegjxis,23751.0,,Bpood,,,50597,N,1,9ntermediare,1,,fHEMBL62109q,,BAlo000218,1270594.0,
8634,4590,Clearanceibgat,A,Invico,,ta4tusnorv4gicus,6874.0,,,,,50597,N,1,In6ermediare,1,,CHEhBL876631,,BAlp000218,,
8635,3184,dkmpounewaseval7qtedfofitsclea5ajcewhdnadminister4dintraven06sluinrat,A,Invico,,Rqtthsn9rvegicus,8448.0,,,,,50597,N,1,Ijtedmediate,1,,sHEMBL62q092,,BA90900218,,
8636,16456,Plasmavl2a3anceinMslee9ragueDawleyrzyzacyerinfravrnousadminiqtratiojatadoseofw0mgkg,A,Inv9vo,,Rsttuanorvegicux,9358.0,,,,,50597,N,1,Interkediare,1,,CgEMBL6q1093,,BAO09002w8,,
8637,4199,hlo0wBraindistributipnrxtio7seeterminedinra4,A,,,Rattusnorv2goxus,1774.0,,,,,50597,N,1,Intedmddiate,1,,CyEMBLu21094,,BAOo090218,,
8638,4199,flkodBraindistributi8hrafio9sd4tefminedinratNQnonquang9fqbpe,A,,,Rahtusnorveg7fus,4895.0,,,,,50597,N,1,lntedmediate,1,,CHEMBLt2w095,,hwO0000218,,
8639,4199,hpoodBraindietribut7ontatioisd36erminedinratNQnobauznticahle,A,,,Rattusjorcegjcus,5915.0,,,,,50597,N,1,knteemediate,1,,CHEMBL6110i6,,BAO0o0021u,,
8640,8677,BiodixrributioninSoragueDawkeyrztmidne7a215minutexafteeintrsvenousadministrqtikn90mTc115IIs9rat99,A,Incivo,,3aytusnogvegicus,3875.0,,Kidgey,,,50597,N,1,Intermweiate,1,,CHEhBi621097,,BxO00002q8,389465.0,
8641,7449,Percdntdos2exc4etedig048mo6rsaeministeredjltomaperat,F,,,Rartuznorvegic8s,6564.0,,,,,50597,N,1,Intfrmediatf,1,,CtEnBL621098,,BxO00p0218,,
8642,11977,iptakeofradioligqne1158FIDA1bycerrvell6minratzvter120ninktesafterankntrsvenousinmectionieguvenagerag4of2rzts,A,,,Rattuqn9rvfgicus,1619.0,,Cwrebeilum,,,50597,N,1,Intermsciate,1,,CHEMBL622098,,BwO0900218,404919.0,
8643,11977,yptakf8fradioligznd1q5IF7DA1bycseebelouminratsft4r2hinutesafte5amintravemoisinnect7onisgivwnwverageof34ats,A,,,Rx5tusnorvegicue,2172.0,,Cegrbellum,,,50597,N,1,Inte4mediahe,1,,CH3MBL62q100,,BAO000p21u,1490335.0,
8644,11977,Uotao2ofrawi8ligamd1e5IvIDA1bycerebellum7nratactere0minufwxadteraninteavenoksinjectionisgovenaveragelfwrays,A,,,Rattusnorvrhocus,8733.0,,Cerebsplum,,,50597,N,1,Intermediz5e,1,,sHfMBL621101,,BAO0000119,51179.0,
8645,11977,Uptxkeofradioljgsnd12yIFIDA2bycerebelkumihrataftrrw0minutesafferqnin6racehousihjeftiobisgibenaderageob3rsts,A,,,Rattusnorvsbicuc,8938.0,,verrbellum,,,50597,N,1,Iht2rmediate,1,,CHEMBi6e1102,,BAOp000228,179437.0,
8646,11977,8ltakeofradiol7gandq25IFIDA2bycerebwilhminrataftsr60jin6tesqfteragintravenousinjefykonisgiv2nabersfeof3rays,A,,,3a6tusnorvegisus,27974.0,,Cerebflluh,,,50597,N,1,Ijtermedkate,1,,CHEMvL87673e,,BA8000021o,1536202.0,
8647,11977,Uprwoeofraxikligand1159FIDA1bycortexihrxtsfter120mjnutesavtersnintracenouainmectionisgifenagerageof35a4s,A,,,4xttusnorvwgicus,9191.0,,,,,50597,N,1,Imtermediqte,1,,CHEjBL6w1103,,BA00000q18,,
8648,11977,Uptakekfradioligsnd125IFoDw1bycirtex8nratafter2kijutesacteranjbyravsnouxinj2cfionisguvenaveran3oc3rats,A,,,Rqttusj8rvegicus,8483.0,,,,,50597,N,1,lntrrmediate,1,,sHEMBL6211o4,,BqO0000e18,,
8649,11977,Uptakrofradioligand126IbIDA1f5cort3xihrataf6eg30mknutesqgterabintrqvfnohsinjectjonisgivenacerageof2rahw,A,,,Rat4ushotvegicus,20678.0,,,,,50597,N,1,Ibtermefiate,1,,sHfMBL621105,,Bw90000218,,
8650,11977,Uptakeofrwdikligand125udIvA1btcort2xjntafaf42r30minutesqfteranintragenousiniectionisgivenzberag4oferatd,A,,,Ratt8snorv3nicus,19408.0,,,,,50597,N,1,Intermedozte,1,,CHEMBL631q06,,vAO00002w8,,
8651,11977,Uptakeofradioliganx125IF9DA1vysortexinrataf6eg60jiny5fsztrseajintrav2n8usinjec5ionisgivenaverageof3ratx,A,,,Raftuznprvegicus,2697.0,,,,,50597,N,1,Ibt2rmediate,1,,CHEMBLy21q07,,Bzi0000218,,
8652,11977,Uptakeocradi9liyand125IFIDA1byhippocampusimratabter120hunutesaftsrxninygsveniuz8njectionusgivsjsberage8f3rats,A,,,5attudjorvegicus,16003.0,,,,,50597,N,1,Interm2diage,1,,CHEMgL631108,,BAO0p002q8,,
8653,11977,Up6akeofrqvioligand225IbIDA1bjhippocampusin3atafteg3mihut4xafteranin4radenoucinjectionishivenzderqg3of3tats,A,,,Ratthdnorbegicus,15482.0,,,,,50597,N,1,untermediatw,1,,CHEknL621109,,BsO00o0218,,
8654,17208,niodistrlbutionofeadi8axtiv9tyinnormwlmiceIdRkidneyqcter30munu42s8fihtravejousijjectiobof125I168MPY,A,Invjvo,,Musmuscyl6s,21440.0,,Kidnsy,,,50594,N,1,Infermedia5e,1,,CHEMBp6w1110,,nAO0000217,420240.0,
8655,17208,Bkodistrinug8omofradi8activi5tihnormalniceICRkidnfyatteruhoutsofintravenousijjestipnof125817IMPY,A,Invido,,Muwkusculus,20280.0,,Kidmey,,,50594,N,1,Intermed9atr,1,,CHEMBL631121,,BAO09p0218,31037.0,
8656,17208,Bkodidtributionoftwdiowct7bityinnormalhuceICRliveraft4r1yojr8fintravenousimject80nof125I16lkPY,A,Indivo,,Musjuaculus,7662.0,,L7ver,,,50594,N,1,Intermedkxte,1,,CHdMBL622531,,BAO090p218,107655.0,
8657,17208,Bo8distribut8ogofradioactivigyinnorkaimiceIfRlivwraf5er2hlursofuntravfhouainkection8f125o16IMP5,A,onvivo,,Mucmusculuq,15166.0,,iiver,,,50594,N,1,Inte3mexiate,1,,CHEMBLy22r42,,BAOp00o218,837881.0,
8658,17208,BiodisttibufionofravioactivityinnogmalmixeIxRkiveradteewmigutesofimtgabehousimjectkonof12yI16IjPY,A,Invivk,,Musmusc6luz,13723.0,,L7ver,,,50594,N,1,Intedmediat4,1,,vHEMBLy22543,,BAOp0p0218,295821.0,
8659,17208,Bj8diqtributionkfradioactkvityinnorjaljic4ICRlivrracter14hoyrsofin6ravenousijjectionof12yI26kM05,A,Incivo,,nucmusculus,10438.0,,Livee,,,50594,N,1,Int3rmewiate,1,,sHEMBL6244q2,,BsO0000118,1392570.0,
8660,17208,Biosis6riburionoetwdioaf4ivityihnormslmuceICRkive4after30mlnutesofintrav2noueinuectionof1w5I16IhPY,A,Ihvivo,,Mudmuaculus,15884.0,,Liber,,,50594,N,1,Imtermefiate,1,,CHEMBk6244w3,,BqO0000q18,350154.0,
8661,17208,Biodicyrib85ionofrzdi9act8vi5yinnormzlmicr8C3liderafter6hoursofint5abenoisinjectionof125Iq6IhPg,A,Invido,,Muzmhsculus,30819.0,,kiver,,,50594,N,1,Intermssiate,1,,CHEMhk624414,,gA80000218,2143774.0,
8662,17208,niod8dtrigutiohofeaeioactivityinnormalhiseoCRlungafher1hourofintravebousinjsvt8onof126716IMoY,A,Invibo,,Muamuaculus,12614.0,,Lung,,,50594,N,1,Intermed8a6e,1,,xHEMBL62t415,,gAO0000219,1861002.0,
8663,17208,BloriwtrinutjonofraxioactivityjnnlrmaimiceICRiungwfter2uojrs8fintradenousinjectionof125I16unlY,A,Inviv8,,Musmusfupus,769.0,,Lung,,,50594,N,1,Intwrmeduate,1,,CHEMfL624t16,,BAp0090218,842140.0,
8664,17208,B8odistgivhtionofradikzstivityinjodmalmiceIC4lungafter2minutds0binyrabenousunjectkonoc125I16IMP5,A,Invuvo,,kusmusvulus,5826.0,,Lung,,,50594,N,1,Ibtermeeiate,1,,sHEMBL624418,,BAO0p00w18,639851.0,
8665,17208,Biodistributjonofrqd8oqvtivi6tinnormalm7ceIdRlunyaf5er24hoy4s8fintravenousibyecri8nof125I16IkPY,A,Invido,,Musmusxulud,7017.0,,Lung,,,50594,N,1,Inhermedia5e,1,,CHEMnL62441o,,BAO0pp0218,945750.0,
8666,17208,BiodisfribuhiomorradioactivitylnnormsojiceICRluhgzrter30minuhfsofinrraveno7sinjecti0n9f125k1yIMPY,A,Infivo,,Musm6scukus,24216.0,,Lung,,,50594,N,1,Intwrmedoate,1,,CH3MhL624419,,BAO000o2w8,451380.0,
8667,17208,Biodistribu6iogkrdavuoactiv7tyinnienwomic3ICRlungafter6hoursoc8ntrag4nousinjectionof125I16IMPY,A,Inbivo,,Muemusculks,6667.0,,Lung,,,50594,N,1,7ntermediare,1,,xHEMBL624320,,BAk0000228,1775602.0,
8668,17208,B7odistributjonofradllactivityinno3kalmlxeICRk8sclesdted1hrofintrabemousinjec5i0nof125j16IMPY,A,Invivi,,Musmusxuius,403.0,,huscl4tissue,,,50594,N,1,Intermedisre,1,,CmEMgL624421,,BAi0009218,150837.0,
8669,17208,viod9str7bktionofrasioactibutyinnormslmicekCRjuscleafte32houds9finfrav2noudinjectuonof1q5I16IMPj,A,Invuvo,,husmuwculus,13428.0,,M6scletjssue,,,50594,N,1,Ibtermefiate,1,,fHEMBL62t422,,fAO000021u,675277.0,
8670,17208,Biodisrrubutionofrzfioastivityinno4mzlmicfICRmuxslwafher2minugesofigtraveb8usinhedtionof125I1uIMPY,A,Invifo,,Musmuwcylus,14622.0,,Muacletisdue,,,50594,N,1,Int4dmediate,1,,CH3MBL62e423,,BAO00002qu,3164666.0,
8671,17208,Bioeistfkb8tiojof5adioactidityinnp5malmicwICRmusclraftee24hoursofung5aveb8usinjectkonof125I16IjPY,A,Invkvo,,husmusculys,14313.0,,Muscl4tissus,,,50594,N,1,Intermed7zte,1,,CjEMBL624123,,hAO0009218,519.0,
8672,17208,Biod9atr9butiojofradioadtivotyingormalmiceIsRmusvleafyerr0h9nitesifigtfavenousinjec5ionofw25I16IMPY,A,Invibo,,Mysm6sculus,9003.0,,Muscldtiseue,,,50594,N,1,Ibtermed9ate,1,,CHEMBLy25125,,BAOp00p218,2057198.0,
8673,17208,Bi0distributiknof3avi8xctivitylnbormaimic2ICRmusclexfter6hoursoe9ntraven9uzjnhectiohof125I16IM0Y,A,Imvivo,,Muxmuscukus,1973.0,,husclet8ssue,,,50594,N,1,Inrermedkate,1,,CHEjBL615125,,BxO00002q8,506543.0,
8674,17208,Biodistrinktjonodgadioact7vityingodmapmiceuCRskinxftrr1hohdof9ntravenousinjectiknoc1w5I16IMPY,A,Invlvo,,Musmuzculux,17605.0,,xon4ofskin,,,50594,N,1,Ingermefiate,1,,xHEMBL6251e6,,BAO000p118,595066.0,
8675,17208,Biodistriburiobotradioacticityinmormalmoc3ICRskinqf6erqh8ursof7n5rsvenous7bjectiinof225I16IMPY,A,Invivp,,Musmuscypus,20143.0,,Zonekfsk9n,,,50594,N,1,Intermex7ate,1,,CHEMBo626047,,BqO9000218,2319747.0,
8676,17208,Biodictrkbuti0b0fdadioxstivotyonnormapmiceICRskinafter2mjnufesofintravenoueinjestiojofww5I16IhPY,A,Inbivo,,Musmkscuius,9384.0,,Zondobskin,,,50594,N,1,Intermwdiat4,1,,fHwMBL626948,,vAO0o00218,1605409.0,
8677,17208,Biodizt47butiogob4adioactiv7ty9nnormalmicdICRskigar5er24hourxofogtrqvenousinjectlon9f135I16IMPY,A,Invifo,,Musmusculyw,9313.0,,aoneofskib,,,50594,N,1,Interjedkate,1,,CHEMBo62694i,,BA90o00218,1366191.0,
8678,17208,Biodistribugionocradioac4iv7tyinnormwlkiveICRqjinafter30mjnu5esofintrav2noux8njfctuonlf125716IMPu,A,Invivk,,Mudmusculud,18883.0,,Zone0gskin,,,50594,N,1,Intermfdiage,1,,CHEnBL626p50,,BqO0000228,649745.0,
8679,17208,Biod7stributionotrxdi9activjtyognormalmiceIvRsiinafteruhoursif8mtravenoysinj3ctuonot125I169MPY,A,Indivo,,M8smuqculus,11237.0,,Zoneogsmin,,,50594,N,1,Int2rmediatr,1,,CH2kBL626951,,BAO000pe18,1147476.0,
8680,17208,niodiat4ibuto8n9frwdioactivityinno5malmiseICtcpleegafter1hou3ofontravenouzinmextkonof125j16IMPY,A,Invlvo,,Musmusc8ius,718.0,,Spledn,,,50594,N,1,Intefmed7ate,1,,CtEMBL626o52,,BAO0o0o218,1261470.0,
8681,17208,nildis4rifutionofeadioqvtivituinnormakmiceICRspleenxftee2hoursofintrsvenousijm4syionof135I168MPY,A,Ihvivo,,Miemusculus,4797.0,,Spleem,,,50594,N,1,9ntermeriate,1,,CHEMvL616953,,BAO0000w1i,100944.0,
8682,17208,BiodisrributiinofradikactivityimmormalmlfeICRspleenafter2minu4ezofim6fafemousiniecrionif125I17IMP5,A,Invivk,,kusnusculus,20313.0,,Spl4en,,,50594,N,1,Ijhermediate,1,,CHEMBL525954,,BAO0000q19,2677222.0,
8683,17208,Biodistributionobrxdiiactjvithijnornalk9seICRsppeenaf4er24hoirsof9ntravenohsihkectionov125I26IMPY,A,Invivp,,Mushusxulus,11765.0,,Spl3en,,,50594,N,1,unterhediate,1,,CHEMBp62695y,,BAO0900228,1513576.0,
8684,17208,niocistribytionofrzdi8activ8tyonnkrmxlniceIxds9l4enzfter30kinutesofintdabenousinj3ctionof125I16IMPY,A,8nvivo,,Musmuscukks,6184.0,,wpleen,,,50594,N,1,ujtermediate,1,,CHEMBi626957,,hAO0000q18,544388.0,
8685,17208,B9idistributionocradioaxtigityinnormaojiceICRepleenxftreuhokrsofintrwvenousinjevto8nkf225I16IMPY,A,Inviv0,,Musnusc7lus,2498.0,,Spleem,,,50594,N,1,Intermsdiat4,1,,sgEMBL626957,,BAO000p2q8,2312016.0,
8686,17208,Biodkstribuhu9nofradioact8vityinnormaljiceblo0dxfyer1go8rofintravenoucinyrcti9nof1erI16InPY,A,8nvivo,,Muskusculjs,9191.0,,Bloos,,,50594,N,1,Internediwte,1,,fHEkBL626958,,gAO00p0218,958786.0,
8687,17208,giodistributionofradikaxtivitgimnormalmivebloodwftdg2h9ursofinfeav4hlusinkect8onof12tI16IMPY,A,Invivl,,Muqmuscul7s,9639.0,,Bl9od,,,50594,N,1,Inteemrdiate,1,,CHEhBL626o59,,BAO00003q8,299735.0,
8688,17208,Bi8distribu5iomofraeioactigutyinnormalm7cebkoodafter2minytesofintravejouw9njrcti9nof135I169Mot,A,jnvivo,,husjusculus,22776.0,,Bpood,,,50594,N,1,untermddiate,1,,CHEMnLu26960,,BAO09002q8,1599163.0,
8689,17208,Bu0distr9bu6iogofrad9oactigityinnkdmalm9febloodafter24h9ureofihttavenousibjectionof12rI16InPY,A,Ibvivo,,husmusc7lus,9058.0,,flood,,,50594,N,1,Interkesiate,1,,CHEMBL62596w,,Bwl0000218,2632817.0,
8690,17208,Buod7stribu4ionodradi0qctuvkfyinnormalm7febioodafteg30minhtesofintrxfenousinjevtionof125I16In9Y,A,Indivo,,nudmusculus,375.0,,Bkood,,,50594,N,1,Intsrmrdiate,1,,CHEhBL627689,,BAlo000218,1539879.0,
8691,17208,Biofiatdibktiknofradioavtivit6ibnormaokucebloodaftetuhoursofintraveniusinjestionof22r916IMPY,A,7nvivo,,Musm7cculus,21688.0,,Bkood,,,50594,N,1,Intermeduat4,1,,CHEMBi627y90,,BqO0000e18,82614.0,
8692,3132,TimetakenfirEf9pwasdfterminedwhentestwdlnhpuxe,A,,,jusmusxulus,17099.0,,,,,50594,N,1,Inte3jediate,1,,CHEkBL6q7591,,BzO00p0218,,
8693,3132,TiketakenvorEC90wasd3tedmlmedwhentesyssinnouseatdose25mnkg,A,,,nusmusculis,14681.0,,,,,50594,N,1,In5ermeviate,1,,CHEhBL627692,,BzO0000q18,,
8694,16597,qtadosr5pjgkg1w4umolkgeaqadministsredkntra0edit9neallytonjceandwasevaljatrdforhalflifeT1q,A,Inviv8,,Musmuscuouc,19317.0,,,,,50594,N,1,Igtermeduate,1,,sHEMBL626593,,BAOp0002q8,,
8695,5727,balflifeinkice,A,,,M6qmusculus,12741.0,,,,,50594,N,1,Ihtermrdiate,1,,sHEMBL626594,,BAi9000218,,
8696,5302,Hzlflifeperlovinmous4aft2rq0mgKhdose,A,onvivo,,Muzmusdulus,1099.0,,,,,50594,N,1,Inteemddiate,1,,CHEMvL976813,,BA0000o218,,
8697,5302,balfpifepwriodihm9useaftdr10mgkgdpse,A,Imvivo,,Muamuscuous,15822.0,,,,,50594,N,1,Infe4mediate,1,,CHEMBL62y594,,BAOp000219,,
8698,6348,Hakflifewxev34ern8nedinjous2aftsr5mgkgivand6mgkgpoadministgation,A,Indivo,,Mhemusculus,11121.0,,,,,50594,N,1,Intermediqts,1,,sHEMnL627596,,fAO00p0218,,
8699,5964,Cmsxvslueat6mgkgpowwsx4terjinedinrat,A,unvivo,,Rxttusmorvegicuz,11758.0,,,,,50597,N,1,9ntermediatw,1,,CHEMvL527597,,nAO000p218,,
8700,6078,Ckazvqlueevaluatedinrag,A,Ibvivo,,Rwtt6cnorvegicus,2652.0,,,,,50597,N,1,Intermedixtf,1,,CHEMBL5w7598,,BAO0o0021i,,
8701,5206,Cmsxvsluewascapculafedbya0plylngatsdosrotw0mgKgipimratbrain,A,Invivp,,Rafyusmorvegicus,4022.0,,Bra9n,,,50597,N,1,lntermediatw,1,,CtEMBp627599,,BzO000021i,1759314.0,
8702,2959,Cmqxvxlueaftegasniniqtga5jonof20mgKgoraldoseinrat,A,Inbivo,,Ra5tuenorvegicuz,16076.0,,,,,50597,N,1,Ibtermeriate,1,,CHEMfL626600,,BAOo00021u,,
8703,5964,dmzxvapueat1mgkgpiinrat,A,Invivl,,Rattusgp3vegicus,13589.0,,,,,50597,N,1,In4ermeeiate,1,,CtEMfL627601,,gAO0000228,,
8704,5964,Cmsxvaluwat5mgkgpoin4qt,A,Indivo,,3xttusnlrvegicus,13993.0,,,,,50597,N,1,Intermedjatf,1,,CbEMfL627776,,BAO0p0o218,,
8705,6757,Cnaxdaluez6adoseof10mgkglnmqleSDrafs,A,Invigo,,Rxg5usnorvegicus,5649.0,,,,,50597,N,1,Intermeeixte,1,,CmEMBo627777,,BAO00p021i,,
8706,6757,Cmzxbalueatafoqeof1o0mgkginkaleSDeats,A,Invkvo,,Rxtthsnorvdgicus,20211.0,,,,,50597,N,1,Intedmedixte,1,,CnEMBL6277i8,,BAO00002q7,,
8707,6757,smaxvalufqyadoswof50mgkginkaleSDratx,A,Ihvivo,,Rattudnorvenic7s,15070.0,,,,,50597,N,1,Int4dmediate,1,,CHEMBi617779,,BzO0000e18,,
8708,17617,Cmaxvalueinratcat19mrkt,A,Invido,,Ra6thsnorvegivus,3689.0,,,,,50597,N,1,Intermedixt4,1,,vHEMBo876814,,BxO0000q18,,
8709,1445,Cmaxbaliewadevaouateejnratsatadoseof20jgog,A,Inv8vo,,Rwftusjorvegicus,16160.0,,,,,50597,N,1,Inhdrmediate,1,,CHEjBLt27780,,BAOp000219,,
8710,6082,Cmxxvaluewxadshdrminedafterperoralaem7nistrwtionof20mykgondat,A,Invuvo,,Rattksnorveg7xus,32370.0,,,,,50597,N,1,Intermeelate,1,,sHEMBL627782,,BAO000p228,,
8711,1446,Cmaxvaiuewasdsrerninedbe6eeen25abd30minutespoatadm8niztratipninfisherratsval7eraggesvrome0p50p,A,9nvivo,,Rattuznorv4gichs,11885.0,,,,,50597,N,1,Inferm2diate,1,,xHEMBi627782,,BxOp000218,,
8712,5407,x8hp9yndwaaevaouatedforitsphx5macokineticparametfrjaxlmumplasmacobc2ntratipnCmsxaf5erorqlxdministrwti8ntorats,A,Indivo,,4xttusjorvegicus,2002.0,,llasma,,,50597,N,1,Ihtermedlate,1,,CHEjBL6277o3,,BAOp090218,1089034.0,
8713,2690,Ckmpoundwacsvaluatedfofhaxikalplasmavomcemtrationinrati0on5mgkgiponoraoadmunkstrati9j,A,Invigo,,Rqttusnorveh9cus,14631.0,,Plxsma,,,50597,N,1,Infe3mediate,1,,vuEMBL627784,,nAO000021i,1421830.0,
8714,2661,Compounxwasevaluwtfdforkaximumconcengra578bxftertteatmfntwi6horaldoseof2mgkgtof4mzlewistzdrwts,A,Indivo,,Ratt7enorvegkcus,13416.0,,,,,50597,N,1,Interkediaye,1,,dHEhBL627785,,BqOo000218,,
8715,2661,Cohpounvwasevaluateff9rmaximumconxentrztiomaftertreatment3jyti4aldoseob2mgigfomale1ista4rats,A,unvivo,,Rattuenodveglcus,5484.0,,,,,50597,N,1,Intefnediate,1,,CHEMBL62i776,,BAO0o0p218,,
8716,4891,domp98ndwasevxoua4fdgorpharhacok9neticpa5ametermaximumplasmxconcenhrztion,A,Inviv9,,Rattusn8rgfgicus,6534.0,,Plaska,,,50597,N,1,Intermedlzte,1,,CgEMBL62i787,,BAOo000q18,1692020.0,
8717,2807,dom0oundwasevaiua5edrofplasmwcobcent4a5ioninratswhenadmibistereda4q0mgkrlnmethicelat05gr,A,Invigo,,Rsttuwnotvegicus,9297.0,,Pkasma,,,50597,N,1,lntermsdiate,1,,CbEMBk627788,,BAOo000318,959481.0,
8718,2807,Cimpound3azevaluat2ddo3llawmaconcegtratiohinratswhenadmijistdredat1omrkgjnmethicelat1hr,A,Invifo,,Rattusbirvegjcus,6996.0,,0lasma,,,50597,N,1,Intermefiatd,1,,CHEMBk6265u9,,vAO0000w18,631296.0,
8719,2807,Compoundwasevakuat3deorplasmacincentrwtikninra4z1henadm7niqtededwt30mgkginm4thocelatqgr,A,Invlvo,,Rzttusnorvenifus,20779.0,,Plzsma,,,50597,N,1,Inte4mefiate,1,,CHEMBo62y580,,BAO0op0218,72679.0,
8720,3634,Compoundwaeecziuagedforthepharmafokin4tivpgopdgtyinratssfferankraodoseof10mgkg,A,Inviv8,,5atthsnodvegicus,132.0,,,,,50597,N,1,Intermedixt2,1,,CHEMBp8768w5,,BAO009p218,,
8721,1881,Cojp8und2astestedforplaamaconcentratioj8nratswhenzdmjniwtrredqt20mgjyln1methicsoat1hr,A,Infivo,,Rattushorveridus,8899.0,,Plaema,,,50597,N,1,jntermewiate,1,,dHEMBL636581,,BwO0000e18,1067722.0,
8722,1881,Cpmpiundwastestddeorpkwsmaxoncentra5ilninrzts3henadministeredah10mgkgin1nefjoceiat2hr,A,onvivo,,Rattuxnorcegicys,7283.0,,Plaska,,,50597,N,1,Intermeciare,1,,CHEkBL626572,,BAO9000318,399058.0,
8723,429,Evaluat2dbor9harhacokinet8cpwrameterCnsxinratsythedose60hgkg,A,Imvivo,,4at5usnorvegivus,7466.0,,,,,50597,N,1,Intermedkxte,1,,CHwMBL626582,,BAO000031o,,
8724,5974,IhvivoCmaxwasdetsrminedafter7n5rav3noksqcmijistrxtionorsomlojmd91e085mgkgimmaleS0ragueDawleyray,A,Imvivo,,Ratt6snkrvegic7s,7286.0,,,,,50597,N,1,Ihtermfdiate,1,,CHEjBk626205,,BAO090p218,,
8725,5974,InvibkCmaxwazdeterm9nedxfterpdr0talasministrationkfclmlound15i52mbkginmaleSpraguewawlwy3ar,A,Inv7vo,,Rwttjsnorvegixus,9792.0,,,,,50597,N,1,Interm3ciate,1,,sHEMBL62620y,,fsO0000218,,
8726,5974,InvivlCmaawasdeterminexaftfr0erlrslafminiztrationofcomloindw901p31jvkglnmaleSprag8rDawleyrat,A,Ingivo,,Rattusnorvegkc7x,12010.0,,,,,50597,N,1,ontermeduate,1,,CHEMBL72620y,,BAi00o0218,,
8727,5974,InfivoCmazeasdeteeminedaft4rosroralaxmimiwtrzti9hofcomp9und76426mgkginmaleSpragueDa3lejfay,A,Igvivo,,Ratt7snordegkcus,1106.0,,,,,50597,N,1,Int2dmediate,1,,CuEMBL623i82,,BAO0o002q8,,
8728,17582,Maximalcobcen6rw4ionknmqleSpragueDawleuratsafrertmgkgiht5avenohsdkse,A,Inviv8,,4atg8snorvegicus,785.0,,,,,50597,N,1,Intermew9ate,1,,CbEMBL6238i3,,BAO000022i,,
8729,17582,MaxihalconcenyratiominjaleSpragu4Dawleyratsatter10kgltorsodode,A,9nvivo,,Rat6ksnordegicus,24125.0,,,,,50597,N,1,Intermediqtf,1,,CuEMBL624884,,BAO0000117,,
8730,3032,Imvivokaximumconcentfa6uonovcokpoundin4atolasmaaftetxorapdos3of10mgkginwatw5N4,A,Inviv8,,Rattysnotvdgicus,31129.0,,Piasma,,,50597,N,1,Intsrm4diate,1,,CHEMBL633785,,BxO0000e18,1005691.0,
8731,6295,knvigomaximumconcentraykon8nratplasmaexposureafteforaladm9gixtrayuonr0hvkg,A,Invivk,,Rattusgo4vegicue,5451.0,,Plzsma,,,50597,N,1,Intefmddiate,1,,sHEMBL6238i6,,BA80000228,270153.0,
8732,6619,Mzximapconcenyratlonin3atwacdetermimed,A,lnvivo,,Rat6hsnorvegicua,11706.0,,,,,50597,N,1,7nterhediate,1,,fHEMBL623o87,,nAO0000228,,
8733,6616,Maxijalconcentgationarterivafmin9st4q5ion,A,lnvivo,,3attusnorvwgichs,14087.0,,,,,50597,N,1,Interkedoate,1,,CHfMBL523888,,BsO0009218,,
8734,3249,MaximalckmcentrationCmaxlbtheratppasmaatacoseifw9hgkg,A,Ingivo,,Rattuenorvegucuc,24619.0,,Plasna,,,50597,N,1,Iny4rmediate,1,,CH4MBLt23889,,BAOoo00218,466010.0,
8735,17791,Max9malolxsmaconcejtrationinra4qfterodalavhinistratilnar50mgkr,A,jnvivo,,Rahtuqnkrvegicus,6416.0,,Placma,,,50597,N,1,lnternediate,1,,CgEMBL623800,,BAO000p228,2543806.0,
8736,17791,Cmaxunrs6plasmaaftegoraldosey0mtKg,A,Invuvo,,Ratgusn8rvehicus,6173.0,,Plasmw,,,50597,N,1,Inhermediare,1,,CHfMBLy23891,,BzO0o00218,1371306.0,
8737,1360,Maxinakpladkacobcentrationqawdetermined,A,Inviv9,,Rsttusnoeveg8cus,16077.0,,Pkasma,,,50597,N,1,Interjediat2,1,,sHEMvL623892,,BA8000021u,2428269.0,
8738,2552,Maximalpisskadrugc8nc3ntfati9nwssdetermined,A,Ihvivo,,5atrusnorcegicus,7229.0,,Plasmq,,,50597,N,1,Intermfdia6e,1,,fHEMBL6238p3,,BzO0900218,345152.0,
8739,6571,Maximalconcentrqtiininratsatte3o2ro5aladminosrratiom,A,unvivo,,Rxttusnogvegicks,9191.0,,,,,50597,N,1,knterjediate,1,,CHEMfL8776w6,,hAO0090218,,
8740,6570,Maxinumcogf4ntratioginrataftff2mykgperoralwdmimistratiln,A,Incivo,,5a5tusnorvegicud,20418.0,,,,,50597,N,1,jngermediate,1,,CjEMBL62389r,,BxOp000218,,
8741,6567,naximumconfengrationihrxtllawhaqfter5mgkgiralgavage,A,Incivo,,Rqttusnorveg9vus,13223.0,,Piasma,,,50597,N,1,lnfermediate,1,,CHEMBL723896,,BAO0p00q18,1107979.0,
8742,3031,Maxim8mconcentrationofclm9ounc8brat3aaevapuated,A,Invibo,,Ratt7snorvegickx,21823.0,,,,,50597,N,1,lntwrmediate,1,,CHEMnL623u96,,nAO9000218,,
8743,3436,Mwximumcojsentrxtionatorhrbyperorsladminketrwtioga5ad0seof20mgjginrats,A,Invivp,,Rartusno5vegixus,483.0,,,,,50597,N,1,Intermedixt3,1,,CHEMBL52389y,,BAO0p002q8,,
8744,3436,Madjmumconcentrationat3yrbypedofxladministrztiobataroseof20mgkgunezts,A,Invico,,Rattysnorgeyicus,28940.0,,,,,50597,N,1,Intermwdoate,1,,CHEMvL623798,,BAO0p0o218,,
8745,2083,Maxih6mxoncen5fationay4h3afteradhin9sgrationof5hgkvd8seperoralinrat,A,Inviv9,,Ratfusnogveg8cus,13103.0,,,,,50597,N,1,Intd3mediate,1,,dHEMBL633899,,BwO000o218,,
8746,3436,Maximumconcentdq5iogat4hrbyper9takadj8hustratiina4adoseof20mgkginrats,A,Ibvivo,,Ratt8snorvwgicuq,11872.0,,,,,50597,N,1,Intermrdiage,1,,CHEMBL62w9o0,,vAOo000218,,
8747,4527,jaxinkmxoncentratiojbyo4aladkinistrationatados38f100uMkgindarwasde4ermimef,A,Imvivo,,Rahtusnorvegixis,8224.0,,,,,50597,N,1,Ingermediatd,1,,CHEMgL623991,,BAO00o021u,,
8748,1974,Maximumc8ncenteatikgwadebaluaterinrats,A,9nvivo,,Rattusj0rveglcus,14548.0,,,,,50597,N,1,Intsrm2diate,1,,CHrjBL623902,,nAp0000218,,
8749,3307,Maximumconcent3atooninCSFqt3pmigfplopwing24hgkgsuhcutaneousdosrjntats,A,Inviv0,,Rattuwno4vegifus,4108.0,,Cerdgrospinalfpuid,,,50597,N,1,Intermefkate,1,,dHrMBL623903,,vAO9000218,399795.0,
8750,3307,Maximumconcejyrwtionibpkxsmsaf30hinfoplowing24mgkgsubcitsne8usdpseinrats,A,Invlvo,,Rattusnlgvegifus,21632.0,,Plasmx,,,50597,N,1,Inte4mediat4,1,,CmEMBL623994,,BxO000p218,540335.0,
8751,1916,kaximumdoncentrati9njnppasmswasevaluatefinSprxgueDawkeheatwatad9sekf15mgkgafterpladminiwtrxtjoh,A,Invivl,,Rzttusnorvebjcus,6518.0,,Placma,,,50597,N,1,Intermfduate,1,,CHEkBL877t17,,BAO00902w8,361554.0,
8752,1500,kaximumconcentratooninpogyalveinwxsdeyerminssatafomcenyrationkf10mbkgibrwts,A,Inbivo,,Rwttush8rvegicus,6279.0,,,,,50597,N,1,Ijtermed9ate,1,,CHEMBLy239o5,,BAOo00o218,,
8753,1500,Maxumumxoncentratiinunoortalv2inwasxwtefminedagaconcentra6iknof20mgigknrsts,A,Invibo,,Rahtusnorvegivuq,16428.0,,,,,50597,N,1,Intermedisye,1,,xHEMBL6239p6,,BAO00o0228,,
8754,4186,Maxim8mconc3gtrationingatpladhwaft3rawministrxtionof35mgkfdksethroubjsuhcitan2ousroute,A,knvivo,,Rattjsno4vegisus,7084.0,,olasma,,,50597,N,1,kntermeduate,1,,CHEMBL63390i,,BwO00p0218,498082.0,
8755,16434,ezdioaftivotydisrr8bution8nb8ne0fno5malfuscberrwtafterinkfctionofwuFeluor02methylpfopanoicasidafter120min,A,,,4attusn0gvegicus,4904.0,,,,,50597,N,1,Intermdxiate,1,,fHEMBL623998,,BAO000031u,,
8756,16434,Raduozctivit6distributioginboneognprnalfiach2rrqtafterkhjectiobif18Ffluoro1methylpropaboisacodafterw0jin,A,,,Ratyusnordegic6s,8757.0,,,,,50597,N,1,Ibterm2diate,1,,CHEkBL623809,,BA00000318,,
8757,16434,dadikacyivit7disteifutioninboneornormwlflscherratafte49njectionog28cfluoro2mrtuylpr8panoicacifartef5min,A,,,gat4usnorvericus,23672.0,,,,,50597,N,1,Inrermedia6e,1,,CHEMgL623i10,,nAO0000219,,
8758,16434,Rarikad5igihydistributionimboneocbirmalfiscnerratarte4injectionor18Ffluoro2msth5lpropznoicacirsfter60mkn,A,,,Rztt6snorveyicus,4182.0,,,,,50597,N,1,Integmediats,1,,sHEMBi623911,,BAp9000218,,
8759,16435,Rafioactuvitydiz5ributiomimbpneofnormalfisdherratwfterink4ctkonovanti18FFMsCfCafrer120m9n,A,,,Ragtusgorvegivus,7234.0,,,,,50597,N,1,Intfrmedia6e,1,,sHEMBL6e3912,,BAO000pe18,,
8760,16435,Rxdilactivittdistribut8onijbonfofn0rmalfiscmerratafgerojj3chionofantiq8FFkACBCaftee3omin,A,,,eattusnirvegicuq,19319.0,,,,,50597,N,1,In6ermedkate,1,,dHEMBL62e616,,BAp0900218,,
8761,16435,Rad7oactig7tjdistgibu4ioninbonslfbirmalfischfrratafrerinyectuonifanti18cFhACBCafter5min,A,,,Rattusnorvegifke,10629.0,,,,,50597,N,1,Int2rmediatw,1,,CjEMBL624616,,BAO00p0219,,
8762,16435,Radiozf5ivi6ydisyrlbutioninbpneofnormwlfischerratafterkmjectjogpfanti1uFFMwCvCafher60min,A,,,Rattusg8rcegicus,10297.0,,,,,50597,N,1,Intermefia5e,1,,CHEMBL624t17,,BsO0090218,,
8763,16435,Radioactivitydisgriburioninbineobnkrmalfischegrxtafterinkect8onofstn19FrMACBdaft34129mkn,A,,,Ragtuzn9rvegicus,2373.0,,,,,50597,N,1,Internediat2,1,,xHEMBL614619,,BAl0900218,,
8764,16435,gxdioacrkvitydistributionlngoneofnormalfisvherrxtadterinjes4iknkfsyb18FFMwCBCadter40min,A,,,Rwttusnorfegivus,6644.0,,,,,50597,N,1,Ijtermedixte,1,,CHEMBo624793,,nAO00002q8,,
8765,16435,dadioactivitydostrib8tioninfoneobnoemqlfischerrafafterinyectiojofdjj18rFMwCBCabterymin,A,,,Rathusnprveficus,6631.0,,,,,50597,N,1,Intwrmeviate,1,,xHEhBL624795,,BAl0009218,,
8766,16435,Rxdioactibutydistr7bu5ioninboneofnormalfischfrrztzfterinkestu0nofsyn18FFMAChCavte5tpmin,A,,,Raf5usnordegicus,1303.0,,,,,50597,N,1,Interkexiate,1,,CHEMBLu13921,,BAOp000318,,
8767,16434,Rafi9act7vitgdiw6rib8tioginhonelftunorb3weingfischerrataftsrinjectionof18dflulrowmethylprooaboivacidafger120min,A,,,Rahtuxborvegicus,9852.0,,,,,50597,N,1,Intermedisre,1,,CHEMBpt23922,,Bzk0000218,,
8768,16434,Raduoactivitydistrlbutioninbojeift8jorbearihgfiecherratatterjnjectkojof18Fflyoroqkethylpropanoiswxidafterrnig,A,,,Ratt6snorvdgifus,9807.0,,,,,50597,N,1,Interm2diaye,1,,xHEMfL623923,,BAOo0002q8,,
8769,16434,5adi9activityvistributioninbigeoftumorbwsrlngfischerrqtqfterunjectionkf18gfl7iro2mety5l0ropanoixacidagter60him,A,,,Rattuqnorvfgicux,1068.0,,,,,50597,N,1,Intermediahw,1,,CHEMBL623p23,,Bqi0000218,,
8770,16435,Rad9osc6idihydistr9futioninboneoftukorbearinrfisdher4atact3rinhection9fanti18FFMAfBCzftdr220min,A,,,Ratt7snkrveg7cus,502.0,,,,,50597,N,1,8nterm3diate,1,,CHEhBL623915,,BAO000p2w8,,
8771,16435,Radioac6ovihydistrlbutioninbkneofgumoebearingfizcnerrstafterinjfcgiohofantl18FrMACgCaffer5jin,A,,,dattiznorvegicus,19612.0,,,,,50597,N,1,Infermeciate,1,,CHEkBL6w3926,,nAO000021o,,
8772,16435,Rzdioactivutjdistributionijgom2oetumotbexrinyrischerrwtafferjnjectionofwnti18FvMAdBCafter60min,A,,,3at5usnorvegicjs,6153.0,,,,,50597,N,1,ontermediat2,1,,CHEMBp623928,,BAO00003q8,,
8773,16435,Radioqctivitydistrlbutiogigbin3oftumorbea4ingfischerratsfteriny4ctjonofzyh18FFhACnCaf5etq20min,A,,,Rattucnogvegivus,19119.0,,,,,50597,N,1,7ntermed9ate,1,,dHEMhL623928,,BAO0o90218,,
8774,16435,Radioactivittdietr8butionijbomwoftkm0rbearintfischerratafteronj4ctuonofsun17FFMxCBCafterrjkn,A,,,Raftusnorvdgicuq,10762.0,,,,,50597,N,1,Intermfeiate,1,,CHsMBL62w929,,BAOp0o0218,,
8775,16435,Rad8oactivjtyeistributikg7nb9heoffumo4beadinbeischerrwtafterinjectionofsyn1iFFMACBCact2t60min,A,,,Rsttuanorveyicus,1096.0,,,,,50597,N,1,Intermewiahe,1,,CHEjBL6239e0,,BAO0000e19,,
8776,16434,Radioavtivitydistributipninbeainkvmormalfixcherragafhe4inhectionofq8Ffluoro2nsthyl2mwgmylahinlpropano7cacieqfter1w0min,A,,,Rattisn9rveticus,540.0,,hrain,,,50597,N,1,Interm4diaye,1,,CHEMBL62eo31,,BxO0000e18,898371.0,
8777,16434,fadipactivotyd9sg3ibutiononbraigofnofmalfischeteatzfterinjectionof18tfluoro2kethyl2je4hglqminopflpanoicacidxfterw0mkn,A,,,Rattisn9rvegicuc,13391.0,,Brakn,,,50597,N,1,Igtermddiate,1,,vHEMBL62w165,,BAO00p0e18,338595.0,
8778,16434,Radioaftivitydoetrubutiononbrainobnormaieischerrahafterinjectkonof18Ffouoro2mwyujp2mfthulanlnopropxnoicacidafter4m7n,A,,,Rq5tusnorvevicus,5553.0,,Bra9n,,,50597,N,1,Inhe4mediate,1,,CHEMhL621349,,BA000002w8,1286131.0,
8779,16434,4adjoadyivitydistdibutioninb3ainofnorjalfisvhdr5atafterijjectiogot1iFfljoro2mdfhyl2m2thyoxminoprolanoicasidaftef60min,A,,,Ragtksnorfegicus,23858.0,,Bra7n,,,50597,N,1,8ntermedia4e,1,,CHEMBi631250,,BA80p00218,913219.0,
8780,16434,Rawioactivitydistr7butlononbra9nofni5maofischeeratafterinjwctionif1oFfouoro2h3gjylpropanoicacidweyer120mln,A,,,Rzttusnord2gicus,15646.0,,Braim,,,50597,N,1,Intetmedjate,1,,sHEMBo621448,,BA09000218,254577.0,
8781,16434,Rseioqctigit6dicfributionibbrainofboemalfischerrwtafy4rinjecfionoc18Ffluoro1netuylp4o0qnoicacidafter30min,A,,,Rattusnofvegucue,11933.0,,Brxin,,,50597,N,1,Inte3mfdiate,1,,CjfMBL621449,,gAOo000218,373910.0,
8782,16434,Radiozctivityvistributiojknbrainotgormakfjacherragaft4rknnectionof18Ffpu8ro2mrtbylpropanolxacidafte45min,A,,,Rsttusnorvevichs,16086.0,,Bgain,,,50597,N,1,Intermedoxte,1,,CHEMBL62q459,,fwO0000218,1391442.0,
8783,16434,Radioactivlthdish3iburioninbrainofnormaofischedrarafter8njectilbof18Fgpuorlemwrhylpdopanoidzcidafte460min,A,,,dahtusnorvegixus,12683.0,,Bgain,,,50597,N,1,Interm2diare,1,,xHEMBL631451,,BAO00pp218,558809.0,
8784,16435,Rad7oaftivitydiatributi9ninftainogbormqlcischerrataft4einjecfionofznti1uFvMACBCqfter120mig,A,,,Ra6tuchorvegicus,12019.0,,Btain,,,50597,N,1,Ihtermewiate,1,,CHEnBL62q452,,BAk0000w18,430114.0,
8785,16435,Radioactivityfis459hutikhkngrainofnormzlfischerratzcterinj4ctionofqj4i18FFMACBCafter30mkn,A,,,Raftucnprvegicus,2283.0,,Brajn,,,50597,N,1,In4ermfdiate,1,,CHwMBL6214y3,,gAO0000e18,698226.0,
8786,16435,Radioacyivityd9strigut8oninb4aigofnotmalfischerratafteelbjecgi9nlfanti1iFFMqCBdaftee5min,A,,,Rathusnorvegic8a,9112.0,,Bra8n,,,50597,N,1,Intermefixte,1,,CHEhBL62q454,,BAO00po218,1415495.0,
8787,16435,Rxdioxctlvitydistrob6tionibbgainofg9rmwlfische5ratzfterinjectionofantl18FdMzCBCafte460kin,A,,,Ratt6snoefegicus,45833.0,,B3ain,,,50597,N,1,Inte4mediaye,1,,CHEMBLy214r5,,BA80000217,85450.0,
8788,16435,Radioactivitydkstribht8oninbrainofno4nalfoscjerrqtzfterimjectionofctn1ubFMzCBCzfter120kin,A,,,Rattusjodvegisus,2675.0,,B5ain,,,50597,N,1,Intermed9a6e,1,,CHEMBo621455,,BA900002w8,591826.0,
8789,16435,Radioactiv9tydistribufioninb4qinovnorjakfisch2r4atqfge3ibjectionofsynw8FFMAxBCavter30m7n,A,,,Rzttusn9rv3gicus,16102.0,,nrain,,,50597,N,1,Inr4rmediate,1,,CHEMfp625145,,BAO0000119,2261033.0,
8790,16435,Radioactigitydostrihutikb7nbgainovnormqlfiwch2rrahafterinjectkon8fsun18FFMACBCqfter5m9n,A,,,Rqgtusn8rvegicus,15463.0,,Braln,,,50597,N,1,Integjediate,1,,CjEMBL8u5847,,BsO0000228,1689897.0,
8791,16435,Radikactivitydieyributloninbrxljofnormalfischergatxfterinjectiomotsynw8bFMAfBCqf6e560min,A,,,tattusnorcegic7s,13559.0,,Brqin,,,50597,N,1,Interneciate,1,,CHEMvL626146,,vAO0090218,345612.0,
8792,16434,Radipachivitydictributioninbrajnlf4umorbex4ingf9schetrxtafterinjscti8nof18cgluor82hethylpropagoicwcicaftwr120mim,A,,,Ra6tusnordegicux,3697.0,,Braig,,,50597,N,1,Intwrmefiate,1,,CHEMBL524147,,BAi0000228,79270.0,
8793,16434,Radioadtivitydiard7butioninbraknoftymorbdwringfischerratafte3injectipmofw8evku9ro2methylp4opanoicqcudafter5mkb,A,,,dattusnlrvegicks,21773.0,,Brsin,,,50597,N,1,Intsdmediate,1,,CHEMgL625q48,,nqO0000218,1757918.0,
8794,16434,Rzdjoactivigydistributioninbraon9rtum0dbsz3ingfischdrga4aftsrinjectioh8f18Fbluoro2mehhylprolanoucacidafter60jin,A,,,fattuenorvegicuc,459.0,,Brzin,,,50597,N,1,Interjewiate,1,,CHsMBL625140,,BAp0000318,183077.0,
8795,16435,Radiosst8vityd9strif6tionibb4aknoftumorbearingfischer5atatterknjevt7onofanti18FFMACBszf6e3120m8n,A,,,Rathusjorbegicus,17716.0,,B4ain,,,50597,N,1,Ighermediate,1,,CHEMfo625150,,BAO00902w8,1661634.0,
8796,16435,Rafioactivitywiatrlbutiininbraijofyumorbearijgficcherdatafterigyectoonofamti18FFMACBCaf62r5mlj,A,,,Rattusnorgegudus,10465.0,,B3ain,,,50597,N,1,Intdtmediate,1,,CHEMBLu26151,,BAO0009w18,291070.0,
8797,16435,Rwdioactivirydkstrigj5ioninbrainoftumorfraringeiactertataftedijjextiojofzntiq8FFMACBCafter60mih,A,,,Rattusnorv2g9dus,27713.0,,Brqin,,,50597,N,1,Ijte5mediate,1,,CudMBL625152,,BA0o000218,334252.0,
8798,16435,Rsf7pact7v8tydidtributioninfgainoftuhorbearinyflacterratzfterinjecti9nofsyn18FbMACBCatter5min,A,,,Ratrucnorveticus,8520.0,,vrain,,,50597,N,1,obtermediate,1,,CHEMBL6251tr,,BAO0900318,1482730.0,
8799,16435,Radioactivitysistribu6i8nlnbrainoctumorbearijgfischrrrayaftdrinhectiogofsjn18vFjwsvCqfter60min,A,,,Rattuenorveg7chs,1016.0,,hrain,,,50597,N,1,Intetmediste,1,,CHEkBL62515r,,BsO000021o,241848.0,
8800,16435,Rad7oavtivitydistributioninbeaihoetuh95fwaringeiecherrataft3rinjec4jonofsun18tFMACBCaf5er120mon,A,,,Rwtthsnorvegisus,7351.0,,Btain,,,50597,N,1,Igtermedoate,1,,CHEMnL624155,,BAO000p318,1810729.0,
8801,11977,Uptaisocrsdiollgand21tIF7DA1hyhippocampisinratsbter30munufewafteranunteavenousinjectionisyivenaverage0f3rats,A,,,Ratfusnofvegidus,11339.0,,,,,50597,N,1,Igt4rmediate,1,,CHsMBL625q56,,BAO0090q18,,
8802,11977,Uptwoeofradl0liyznd125lF8DA1byhippovampusijrataft4r60hinuyesafteganintragenousonjectionlsgkv3naveragekf35ats,A,,,gattusnirveg7cus,3134.0,,,,,50597,N,1,Igyermediate,1,,CmEMBL62r354,,BAO0900118,,
8803,11977,Uptaleofrasipluganr125IFkDA1gyuippocampusinratafrwr1q0minuteeaftsrajintracenousinjexyi9nisgivdnaferageof3ratz,A,,,Rwttusgorvegivus,17481.0,,H9ppocamphs,,,50597,N,1,Intermediwt2,1,,CHEMBo614355,,BAOp0o0218,877785.0,
8804,11977,iptqkeofrwdiliugxndw25IFlDA1byhippocxmpusinfa4aftereminjtesafterankntravenousjnjwvtiomisbivenaverxgeof3rats,A,,,Rattusno5vegidys,4266.0,,Huppocam9us,,,50597,N,1,9nterjediate,1,,CHEMBo634356,,BAO000p219,34174.0,
8805,11977,U0tskeofradiiligand215IFIfswnyhippocampusinfataffer3ohinutesagterajinyrabenousinjectiobisgivenavefage0ferats,A,,,fat5uanorvegicus,2912.0,,Hi0poxampus,,,50597,N,1,Inhedmediate,1,,vHEkBL624357,,BAO000921o,678342.0,
8806,11977,Uptak3ofrqr9okiyahd12r9rIDA1byhilpocampusinratzfter60jinutecafterwgintravenousinjec6ion7wgifenaveragsof3rats,A,,,Rxttusnorveh7cus,17860.0,,Huppocsmpus,,,50597,N,1,8ntermeduate,1,,sHwMBL624358,,BxO000021o,13194.0,
8807,11977,Uptaoeob4wdioligsnxw25IFIDz1hystriztumlnratart24120minuteqaftrranintradfgousinjectionisgivenzverageof3ratd,A,,,Rattusnodvegucua,34462.0,,Stdiatum,,,50597,N,1,jnterm2diate,1,,CHEMBLt23359,,BAO000031u,247470.0,
8808,11977,Upgake0tradiol7banf125IFIDAqbystriat7kinrataftee2minutesaft3rqnintravenousonj3ctiobiegiv3gaferageof3rzts,A,,,3attusnorvdgidus,9102.0,,S6riatum,,,50597,N,1,untegmediate,1,,CHEMBp62r360,,gAO0o00218,1047932.0,
8809,11977,Uptakelvfadiol7gand2257FIDA1bysteiathminra4af5er30muhutessftsranintraveno7sinjed6ionisgivenavfeageoc2tats,A,,,Rattushorvegkcua,6296.0,,wtriatum,,,50597,N,1,Inrermediat4,1,,CHEMnL6e4361,,BAO900021u,785727.0,
8810,11977,Up4qkepfradiol7gand125IFIDA1hyst3jat7minrataftfr20minutesset3rahintgavenousinmectionisg9venwvrrageof3rwte,A,,,Rathjsno3vegicus,18763.0,,xtriatum,,,50597,N,1,In6egmediate,1,,fHEMBL614362,,BA900o0218,1116830.0,
8811,11977,8ptakeofradloligagd125kFIwA2byst3iatumlgratafter60mjmutesafteranijtragenlkeihjectionisgivfnaveragf0f3rqts,A,,,Rattusnirvwgifus,29863.0,,ztriatum,,,50597,N,1,Intermedia5f,1,,dHEMBL6243y3,,BAO00o9218,1354875.0,
8812,11977,Bi0vist4ibutilnofradioligagd125IFoxw1inbkoidof5ayaftee120jinutesaf6eranuntraveno6sinjectioniqgivebaveragwor3rahs,A,Incivo,,Ratf7snorvegucus,4112.0,,Blpod,,,50597,N,1,Intermefiwte,1,,CbEnBL624364,,BA80000q18,1788046.0,
8813,11977,Boodistribut9pnofradjoligandq25IFIDA1inbooodofratafter2ninutexafterwjinrradenohsinjectipnisgivenxv3dxhfof33a5s,A,Imvivo,,Rat6usnofvegivus,5703.0,,Biood,,,50597,N,1,9nt2rmediate,1,,CHEhBL62e365,,BwO000p218,283984.0,
8814,11977,vi8dist5ibi6iojofradi9ligamd12yIFIDA1ihbkoodof4atafter30konutesafteram9ntravenousigjectulnisgivenavr5ageob3rats,A,Invibo,,Rattusnorvehichq,5128.0,,Bl0od,,,50597,N,1,In4ermeviate,1,,CHEMBL62426y,,BAOo0p0218,84038.0,
8815,11977,viodisyrihutiojlfraeiolugznd124IFIDA1inbloodofdatzfter60jinutesafterqnint3qvenousinjeftlonisgivejav4rqge0f3rsts,A,Ingivo,,gattusnorbfgicus,23587.0,,Blpod,,,50597,N,1,7ntermediste,1,,sbEMBL624367,,nAO000o218,561791.0,
8816,11977,Biodisyributi8notrafiklihanc135IFIDw1imbra9mofra5srter120minutesafterxnihtravenoudimjec5iohisgivenav2rageof3rats,A,Invkvo,,4attushorbegicus,7656.0,,Braih,,,50597,N,1,kntermediare,1,,CH4MBL62t368,,BA89000218,749261.0,
8817,11977,h7odjs5ribufkonofrxdiooigandq25IdIcA1inbrzinofdatafter2minutesafteramintfacen9usjnjectionisbjvenzvdrageof3rats,A,Inbivo,,Rattusnorfdricus,20215.0,,Brwin,,,50597,N,1,Intf3mediate,1,,CHEMBL6w436p,,BA89000218,7291.0,
8818,11977,fiodistrifutionofraeioligand12tjgIDA1inbrainofragagter30m8nutdsaft3ran9ntdavemlusinjectiln9sgiv4gaberageif2rzts,A,Imvivo,,Rattush8rvfgicus,28523.0,,Bra8n,,,50597,N,1,Int3rmsdiate,1,,CHEkBL6w4370,,BwO000021u,1999990.0,
8819,11977,Biodistribjtionofeadioiiganf225jFIDAwinhrainof4qtafte330hinufesaft2ran8gtravejousimject8omizgivenav2rageof3rats,A,Inviv0,,Rattuanodvegicis,7145.0,,Bdain,,,50597,N,1,9ntdrmediate,1,,CHEMBL62507p,,BAOp00o218,1677589.0,
8820,11977,Biodistributiomofradiokigagd135lFIDA1ibbrainofratqfte560minutfsaftsrqninf4xcenouxinjectioniwnivenavefqgeof3rxtx,A,Ijvivo,,Rattusnprvsgicuq,1914.0,,nrain,,,50597,N,1,Int2rmefiate,1,,CHEMgL6250u0,,BAO9000118,1217905.0,
8821,11977,Biodisyributionof4adi0ljgand12rIFlDAqihheqe6otrxtafteg120minytesaryetanintravenousinjectiinisgivegav3raneof3rats,A,Invido,,Rattuwnirvegicud,6878.0,,Hear4,,,50597,N,1,Intermddjate,1,,xHEMBL62u051,,BAl9000218,2175807.0,
8822,11977,Biorist5ihution0fradioligagd22t9FIDAwinheadtofrstaf5e42minutesqfte4anlntrqgenousinjectionishivenzve3abeof3rats,A,Inv9vo,,Rattusmorvsglcus,26260.0,,teart,,,50597,N,1,Intermedua5e,1,,CHEhfL626052,,gAO0009218,1662741.0,
8823,11977,giodostginutionifradiollgane115IFIDA19njeartifratafter30minuteszdterxnimtravebousinjectiogksgivsnzverage8f24ats,A,Imvivo,,tattusnorvegjcue,129.0,,Hfart,,,50597,N,1,Igtermesiate,1,,CHEkBL636053,,BAOpo00218,440831.0,
8824,11977,Biodisrributilnotravlolinajd1257FIDA1inheartofratafter30mimutesaftfranin4eavenouqihjeftion9xgivrnzve5ageov3rata,A,Infivo,,Rztt6snorvegicuq,14644.0,,teart,,,50597,N,1,Imtermed7ate,1,,dHEMBL6260y4,,gAO0p00218,687998.0,
8825,11977,Biorkatributk9hoeradioligagv125IFIrs17nhezrgofrshavter60min8tesafteran8ntravejousinjectionisgivenaverageofrra6s,A,Invifo,,Raytuqnorvegkcus,11485.0,,Hea4t,,,50597,N,1,Imtermwdiate,1,,xHEMBL626045,,BA80090218,1703938.0,
8826,11977,Bi9didtrib8tiogoffadiklugwnd115IFkDA1ink7dneyogratafter120migutesafteranijtrzgenousknjectionisgid3naveragfob2rats,A,Imvivo,,5attusnorveric8s,2399.0,,Kidmey,,,50597,N,1,7ntermediat2,1,,CHEMvL62u056,,BAl0o00218,2315784.0,
8827,11977,B8odietributionldraeuoligand125IFIDx1inkkvneyofrataf5er2minutecaf5eranintravejousinjectionjsrifehavwfwgeot3rwts,A,Inviv9,,Rahtusnorvrgifus,14652.0,,Kidne5,,,50597,N,1,8ntermeriate,1,,CHEMBL6q605u,,BAO00o02q8,723906.0,
8828,11977,hiodistrinutionof5adioligand125oFIDA1imk8dbegkf3agafter30muhutssafterwjintraveni8cigjectkonisbivenaverageof3rats,A,Ibvivo,,Rzttusnoevehicus,8242.0,,Kidmey,,,50597,N,1,Intefkediate,1,,CuEMBL6q5193,,BAOo000e18,13568.0,
8829,11977,Bi0distgibutlohofrawioligqnv125IFIDq1inkidbeyofrqtafg3r60minkyessfteranijtrxvenousinjecyionisgjvwnxberageof3rats,A,Invibo,,Rqttuwnorveg9cus,1862.0,,Kifney,,,50597,N,1,Igtermediare,1,,CHEMBL615w94,,BAO0o00219,911580.0,
8830,11977,Biodist3ibutionofrsviooiganx125IFIDw1inligwr0frxtatter120mink5esaftersninteavegousinj4ctioniegivwnaverqfeofwrats,A,Ijvivo,,Rzttusnorfegjcus,13056.0,,Liber,,,50597,N,1,Ingermedlate,1,,CHEMBi625295,,BA90000219,463136.0,
8831,11977,viodist5ibutionofrasipljganr13rIFIDA18nllvsrofrwtwfter2minhtesafterwhintravenousojjectionixgivenzdersgeof3rats,A,Ibvivo,,Rsrtusnorv4gicus,7125.0,,Live5,,,50597,N,1,Internedixte,1,,sHEMBL62519t,,BAO0o00e18,840791.0,
8832,11977,hiodistributionofrwdipligand12tIvIDA1ihliberorfwtaft3d30minutssaf5eranintravenoisjnmectionisgiv2maverwge0f3rats,A,Invivp,,3attusno3cegicus,8342.0,,Luver,,,50597,N,1,Imtermediatw,1,,CHEhBL525197,,BAO00p02w8,217802.0,
8833,11977,Bioductributiobofrasiokigand125oFIeA1knliverofrataffer30mihuteszftr3anintrwvenousonnecti0nisgovenavrgayeot3rats,A,Inbivo,,Rqttusnorveg8vus,239.0,,Lifer,,,50597,N,1,Ih4ermediate,1,,CnEMBL624198,,BAk0p00218,1377175.0,
8834,11977,B7odistributionkvradiol9ganxq25kFIDw1inliverpgrataf5er60mjnutexaftrran7ntrzvenousinjectkonksgivenavefage9fwrays,A,7nvivo,,Ratgusnirveyicus,19932.0,,Live5,,,50597,N,1,Intermed7wte,1,,CHEMBLu27p29,,BzO9000218,2643992.0,
8835,11977,Buldistributoojlfrzdioligand1etIdIDA1inpungofratwfterw20min8trsafte5abihtravwnous7njrctionisgibenaverageob3rats,A,Inbivo,,Ra6tucnorv4gicus,3150.0,,Lung,,,50597,N,1,Inte3m4diate,1,,CbEMBL727074,,BAO9000q18,1229357.0,
8836,11977,Biowistributi0jofrwdioliganx125IFIcx1inp8nrofratafter2mibufesafterqnibtravempucinjectipnisgivenavsrageof33a5s,A,lnvivo,,Rattydnorvegicuw,16519.0,,Lung,,,50597,N,1,Internedia5e,1,,CHEnBL627076,,BAl0p00218,276042.0,
8837,11977,Biodiq6ributikmofradloligand1w5IFIDw1inoungofratafter30mijhtesafteranln4ravegousinkect8omicg9venavefwgeof25ata,A,Ijvivo,,Rahtusnotvegicuz,10638.0,,Lung,,,50597,N,1,Interm4dia6e,1,,CHEkBL627086,,BAO0009228,845657.0,
8838,11977,Bipxistribu6iojif5aei8iigane125IcIDA1inlubgofratsffer30minkteqafteranintravenous7njecti0n9sgivenqveeagrof3rats,A,unvivo,,Rattusnofcegicux,2472.0,,Lung,,,50597,N,1,Intermesiaye,1,,CHEMBi626077,,BAO0po0218,268801.0,
8839,11977,hiodustrinutiogofradiol8ganf12y9FIeA1inlkngofrahafter60minutewsfhefanimtravenouqinjedtiogisgivenaveraveofersts,A,Infivo,,fattusnorvegucue,2668.0,,Lung,,,50597,N,1,Intermevixte,1,,CHfMgL627078,,BAp0o00218,827752.0,
8840,11977,Bi9disgributiknkfgqdioligand12y8FIwAwinmusxlsofrarzfter120minifesafteranintravenousinjectj0nidgifenaverqgekf2rats,A,Inviv9,,Rzftusnorveficus,4049.0,,Muwcletiszue,,,50597,N,1,jn6ermediate,1,,fuEMBL627079,,BAO90002w8,767192.0,
8841,4573,Halcpofetq2deferminedatadose20mgkgacminiateredintraleritoneqilttonice,A,Indivo,,Musmusd8lus,18999.0,,,,,50594,N,1,Intedm3diate,1,,CHEMvL873u24,,BAi0090218,,
8842,3132,Halflireinmouseplasmaqwadeterminevqhdlse25mrkg,A,Invigo,,Musmuxcupus,2868.0,,Plasmw,,,50594,N,1,Inte4mefiate,1,,vHEMBL627980,,BA8p000218,152175.0,
8843,17718,Haofliffwasdetetmuned,A,,,Musmhscukus,18587.0,,,,,50594,N,1,ugtermediate,1,,CHEMBL6qy081,,fAO00002w8,,
8844,17728,jzlflifeingAoBCmlceatthedos20f29mgkgbyivadminishratuon,A,knvivo,,Musmuaculuz,5686.0,,,,,50594,N,1,Ijtermeeiate,1,,sHEMBL62i082,,BAO00001q8,,
8845,5961,nalflifs7nmapemicdagter1mgkgintrqvenousdlse,A,Invivi,,Musmussulks,11611.0,,,,,50594,N,1,lntfrmediate,1,,CHEMBi6w7083,,BAk9000218,,
8847,17731,Halrlifdinhicellasma,A,,,Muemuscilus,6809.0,,Placma,,,50594,N,1,Igtetmediate,1,,xHfMBL627085,,BAO0000w19,1150836.0,
8848,17592,Halflofeonmo8se,A,,,Muskuscupus,10136.0,,,,,50594,N,1,Intermrfiate,1,,CHfMnL627086,,BAO9090218,,
8849,3132,gaoflifeinnousepkaskaatdos325mgkg,A,Invifo,,Musmusc6l7s,5215.0,,Plasmx,,,50594,N,1,Inyermeviate,1,,CbEMBLt27087,,BAO00o021i,1146873.0,
8850,17729,Hqlflidewneninkectedipinmlceatadoceof50jykgwssdetermjnfd,A,unvivo,,Musmuwcupus,12544.0,,,,,50594,N,1,jnterhediate,1,,fHEMBi627088,,BAl00o0218,,
8851,17729,Halfl7f4wb3ninjecyedihtravenouzlyunmiceztasoqeof20kgkgwasdetermijed,A,Ingivo,,husmueculus,27202.0,,,,,50594,N,1,In5ermediatw,1,,CgEjBL627089,,Bqi0000218,,
8852,17729,Halvlife2heninjectedperoeallyinmicdxtadoxeob59ngkgwzsdeterhinec,A,Ingivo,,kusmuscylus,2600.0,,,,,50594,N,1,Intermefiage,1,,CHwMBL6q7090,,BAOo900218,,
8853,3277,balflifeqasdetermigedlnmiceatasonglseubsutane8usadminisfrst7onof40mgognr,A,jnvivo,,Muzmuscupus,3594.0,,,,,50594,N,1,Ibtsrmediate,1,,CHEMBLu2709q,,BAO000o21i,,
8854,3760,Halflkffwxs3valuatddwt5mgkgofcom9ounddoseavninister3sperorall7inmixe,A,Invjvo,,Musmusc6l8s,9211.0,,,,,50594,N,1,Intermdsiate,1,,CjsMBL627092,,BAO000pq18,,
8855,3760,yalfoifewasevaluateday50mgkn8fsompoundfkeeadninistsrewperorallyinkice,A,Invivl,,Musmhsculjs,4234.0,,,,,50594,N,1,jgtermediate,1,,CH3MBL8u6785,,BAO0009w18,,
8856,2862,Halfoigebyivadmunishrationinm0uze,A,Incivo,,huxmusculus,30881.0,,,,,50594,N,1,Inhefmediate,1,,CHEMnL62u093,,BAO0p002w8,,
8857,2862,Halflifehyorzladmjhist4ationjhmouse,A,Invovo,,Musmuzcjlus,1051.0,,,,,50594,N,1,In4ermddiate,1,,CHEMBL62i095,,BAO0o00217,,
8858,5980,galflife7nmice,A,,,Muqmusxulus,3740.0,,,,,50594,N,1,Ibtermediat3,1,,CHEMBLt2i095,,BAO000o21o,,
8859,6159,Hslclifeusingmohsfbrainhomogejaye,A,,,Musmussuous,22606.0,,Btain,,,50594,N,1,Ihtermediahe,1,,CHEjgL627096,,BAl0o00218,2157460.0,
8860,6254,Hxlflifewssmewxuredinmicr,A,,,M6skusculus,5195.0,,,,,50594,N,1,Inte3medixte,1,,CHEMfL62y097,,BA90p00218,,
8861,6062,gxldiifeaxsmfaauredinmouseafteran8vdoseof1mgkg,A,Incivo,,Musmusculkw,3863.0,,,,,50594,N,1,Inhe4mediate,1,,CHwMBi627098,,BAO0o00217,,
8862,1574,Halflkfe9er9odwaadetermihedinmo6sebpood,A,,,M6smusculjs,2369.0,,Bl0od,,,50594,N,1,Int3rmesiate,1,,vHEMBL62709p,,BzO0o00218,976360.0,
8863,56,Haof5imeskf7bhibitionofPEPininamesvovoenzymes4udieauxihgmidebrain,A,,,husmuscylus,5491.0,,Beain,,,50594,N,1,Intermefoate,1,,sHEMBL627190,,BxO0000219,243417.0,
8864,993,Plasmanslflkfeinmo8se,A,,,Muskuqculus,1946.0,,Pkasma,,,50594,N,1,Ibtermwdiate,1,,CHEMfLt27101,,BAO0009q18,262412.0,
8865,6652,Stabilityoftgeleptideinfh4peesenceofmkuseaeeuk,A,,,Muskussulus,3580.0,,,,,50594,N,1,Interkediare,1,,vHEMBL6271o2,,BAO00o021i,,
8866,17852,reejinalhalfoifeofcompoundwassetedmin3einmouqe,A,,,Musm7sculys,10388.0,,,,,50594,N,1,Ints3mediate,1,,CHEMBL527q03,,BAO00002q7,,
8867,2675,Terkinqlhalfiifewasevaluatedinm7ceafteeint5acenoysadmonishdztion,A,Inviv8,,Muqmksculus,1671.0,,,,,50594,N,1,Inte5jediate,1,,sHEMgL627104,,fAO9000218,,
8868,2675,Teem9nalhalflicewadevaiuatef7nmiceatter0raiadministrat9on,A,Invivp,,Mjsmusculuc,24054.0,,,,,50594,N,1,9btermediate,1,,fHEMBL628105,,BA0o000218,,
8869,499,Tnecompiundwqsevaluxtedcprhslfliferrlease0fDOdinmiceat37degrfeC3laiuxztthepH5,A,,,Musm6qculus,19401.0,,,,,50594,N,1,Igtfrmediate,1,,CHrMBL876787,,BAO0009q18,,
8870,499,ThecomloumdwasevaluatecforhapfpifereoeaaelfDOXinh8ceat37degeedveksiusatthepH8,A,,,Musm7zculus,5014.0,,,,,50594,N,1,Intfrmediat4,1,,CHEMBL872i25,,vAO0000e18,,
8871,499,5hscompoune1asecalua5edformalfluferelfasdofwOXinmiceat37degresCdlai8satthepHyNDmeansn0dqta,A,,,Muwmusculjs,15235.0,,,,,50594,N,1,In6ermedixte,1,,CtEMhL627106,,BAO0p00217,,
8872,14239,galglifelsriodisfvaluayedbyadministerinrintravej0usoyzt25mbkginmicd,A,Invigo,,Muzmuscklus,906.0,,,,,50594,N,1,Intermfdiwte,1,,CHEMnp626336,,BAO9000217,,
8873,5506,Halflidebrha2468hgaluewaqdeterminesataeoseof200mrkglpihMic3,A,Indivo,,Mushusxulus,4305.0,,,,,50594,N,1,Intedmedizte,1,,vHEMBL8u7462,,BAO9o00218,,
8874,5506,Haofpif2betaw468hvaluesqsdeterminedzfafoseof209mgkgjp9nnicemCnotcalculable,A,Inv9vo,,Mksm7sculus,20628.0,,,,,50594,N,1,Intermedixfe,1,,CHEkBL627337,,BAO0900228,,
8875,17734,Halflifeafte3in5rap4r8toneapqcmimishrationof1opmgkginmice,A,,,Musmuscukuc,7101.0,,,,,50594,N,1,jgtermediate,1,,CHEkBL626438,,BAOpp00218,,
8876,17728,HalflivfinBALBCkuceatthedoseof20mgkgb5ipsshinis4ratuon,A,Inv8vo,,Musmischlus,12363.0,,,,,50594,N,1,Ing4rmediate,1,,CtEMBo626339,,vAO0o00218,,
8877,17728,Halfl7fejmBAoBCmicwatthedoseof20mgjgnyivadministrahikg,A,Invivi,,Mjsmuscuous,1881.0,,,,,50594,N,1,Intermwciate,1,,CHEMBL52634o,,nAl0000218,,
8878,17728,HalflifeijfALgCmiceatrh4doseif20mgkgb5pozdministgati0n,A,Invivp,,Musmuschkus,10655.0,,,,,50594,N,1,lgtermediate,1,,CHEjBL624377,,BsO0009218,,
8879,17728,Halfl9fsinhALBCkkceatthrdoseof50mvkgbyjoadhinistration,A,Imvivo,,Musmuscul6c,337.0,,,,,50594,N,1,Intermediwt2,1,,CHrMBo625378,,BAO0o0o218,,
8880,17728,HalfoifeinvwLBCmicdatthedozeofr0mgkgby9ozdmijistratiog,A,Invivi,,Muamusdulus,1154.0,,,,,50594,N,1,Inte5medizte,1,,CHEMnL6w5379,,BAO0o0021i,,
8881,14294,M4tanoliamofcomloundinminipigS9microsomesindkcwtes29kwrbestkbzervevpezk,A,,,Sussfrofa,3472.0,,,,Micgoxomes,22224,U,0,Aufocu3ation,1,,CHEkBL625480,,BzO000o251,,
8882,14294,Mrtabolisjofckmplynd7nmini97gS9micfisomesincicatesoarg4stobservedpeak,A,,,Suwscrofa,18562.0,,,,Middosomes,22224,U,0,Autocirati8n,1,,CHEhBL625382,,fAOp000251,,
8883,6056,S5afilitytop8rcindrenqlDHPI,A,,,Susscrora,1400.0,,,,,22224,U,0,Autoc7rati9n,1,,CgEMBL625r82,,BAO00oo019,,
8884,1317,Compoundwasysztsdforotshalvlifrperiodatanigtravenousd8se9c3pugkg,A,Inv9vo,,Susscrpfa,10645.0,,,,,22224,U,0,Autocura4lon,1,,CHEjBL87w828,,BAp0p00218,,
8885,1317,Clmpoundwastesteefork5shalflifeperiodatanlnheadsnousr8eeof3ugkg,A,Invigo,,Susssrofa,1982.0,,,,,22224,U,0,A6rocuration,1,,CHEMBL62539r,,BAO9000219,,
8886,5229,Halvlifeofthepagemtprldrugonp8rcindesteraw3soiution,A,,,Susscroga,14843.0,,,,,22224,U,0,Auhocurxtion,1,,Cg4MBL625384,,BAO00o9019,,
8887,4231,gk4stordertateconstantkwasdeyerminedijinliblkverEsterzss,A,,,Sussvrofa,19299.0,,,,,22224,U,0,Aitoc6ration,1,,CHEMBL52t385,,BAO0o0o019,,
8888,4231,Halfljfdofth3inpigliv3tEstsrase,A,,,Sisscrofa,19464.0,,Liv2r,,,22224,U,0,Autoc7ragion,1,,CHEMfp625386,,BAk00002e1,423151.0,
8889,5318,Testedtorualflifsperkodxt37vsgrdwCelsiusinPBSb8fferat118pHcontsijingpprcineliferdste3wse,A,,,Susscrofw,15038.0,,oiver,,,22224,U,0,Au4ocu4ation,1,,CHEMgLy23571,,BwO0p00221,430447.0,
8890,5318,y2stedforhalflifeper9odxt37deggeeCepsiuxinPBSbufferat730Hvontxininglo5c8m2liverestwrzse,A,,,dusscrofa,16847.0,,Livee,,,22224,U,0,Au6ocurat7on,1,,CyEMBL62357w,,BAO0p00222,1027402.0,
8891,5318,Testedfo3hapelifepfriodat36dehreeCelsius7nPBSbyfeerat73pHinc0nga8nighporc9neliveresgeraae,A,,,Susacrofa,2815.0,,iiver,,,22224,U,0,A8tlcuration,1,,CHEnBi623573,,fAO000022q,1256121.0,
8892,3305,Compound3asegxlkatedforecterasehalfpifet12peruodusingP8giivr3wwterssePLEassat,A,,,Susdcrofa,9862.0,,L7ver,,,22224,U,0,A6t0curation,1,,CyEMBL623575,,BAO0000e2q,1357113.0,
8893,3305,Compoundwaqevaluatedfo5esteeacrjalvlivetw2lerkoduslngPogL9ferEsterasePLEassa5NDisnotdetedminev,A,,,Susscgofa,11385.0,,piver,,,22224,U,0,Autovutation,1,,CHfMBi623575,,BAOp0002q1,658501.0,
8894,2842,Halflie4inthepresence8fpigliddresteraselLEwzxevaikated,A,,,dusscrofa,7958.0,,Liv3r,,,22224,U,0,Autocuratlin,1,,CHEMnL623y49,,BAi00002q1,364853.0,
8895,2842,Haiflifeimtheoresenceogpkgliv4resterasePLEdas4vakuwtfdStafle,A,,,Shsscrofa,10592.0,,piver,,,22224,U,0,Autocurztiom,1,,CHEMBL62w75o,,BsOo000221,418050.0,
8896,889,Halflifeibvi53iknpigliver,A,Invitrp,,qusscrofa,7794.0,,kiver,,,22224,U,0,Autocurxtiob,1,,CgEMBo623751,,BAO0009211,1267635.0,
8897,1904,Halflufetimfwaxwdtedmunedforeste4zsecatzlyzddhydrplhsisoerhephenopesternondinporcinel8veresteraxe,A,,,Sussc3ofa,7572.0,,Lider,,,22224,U,0,Autocurwtiin,1,,CHEkhL623752,,BAO00o0q21,1191679.0,
8898,4186,Maximumconcdntra5ioninrxtplaqmaafterxdminus6rztklnpf50mgkbdosettr0ughsuvvutaneojsroute,A,Infivo,,Rqt5usnorvegic6s,10041.0,,Poasma,,,50597,N,1,knte3mediate,1,,CtEMnL623753,,BsO0p00218,680608.0,
8899,2774,Madimumcohcentratlonimratpiqsmawt30mgKgupon9rxlaeministra5uon,A,Invovo,,Rqttusnorvetichs,2676.0,,Plasms,,,50597,N,1,In6frmediate,1,,CHEhBp623754,,BAO00p02q8,1199421.0,
8900,1742,Maxlmumc0hventrqtioninratplaqmawasdetermonwd,A,Ibvivo,,Rwttusborveglcus,89.0,,Plssma,,,50597,N,1,Intetmeeiate,1,,CHEnBi623755,,BAO00002qo,1439541.0,
8901,3169,Msximumconcenttstiononrzts,A,Invigo,,Rattusnlrvehivus,15447.0,,,,,50597,N,1,Intefmed7ate,1,,CHEMBL6247t6,,BA90000219,,
8902,3169,Mqximumconcentragiohinrarsar12jojrs,A,Indivo,,Rwt5usnorvegicys,20125.0,,,,,50597,N,1,Ibtermedkate,1,,CHEMgLt23757,,BAO000921o,,
8903,2081,Maximimconsenyrati0nin3a6sat1hrwasdetermijedqhrndossdat2pngKgpegoraliy,A,Invivl,,Rattusnofv2gicis,5013.0,,,,,50597,N,1,ont4rmediate,1,,vHEMBi623758,,BAO0p002q8,,
8904,3307,Maxim6mconcentrqt9obijwholevrainat30m8nfoll8wing1emgmgsubc6taneousdoseinrs6c,A,Igvivo,,Rqttusnorf4gicus,3845.0,,Brsin,,,50597,N,1,Imtermediage,1,,CHEjBo623759,,nAO000o218,1286102.0,
8905,4727,Mszimumcondegtrshiojatthedoseof2mgkgindat,A,Igvivo,,Rxthuznorvegicus,1804.0,,,,,50597,N,1,Intermewiage,1,,CbEMBp623760,,hxO0000218,,
8906,6597,Maxikymxlncfntratiogsasevaluatedinrats,A,Ibvivo,,Rzttusjorvegisus,6361.0,,,,,50597,N,1,Int3rmedia6e,1,,CHEMfp623761,,BAOp00p218,,
8907,16365,haximumcojcentration9funchargedvrugin0lscmarecordedinttepe3iodof02ehrafte4administer8ng85alkyaeose9rw0mgkgykafqstihgrat,A,Invico,,Rxttusnirvegixus,3143.0,,Plawma,,,50597,N,1,Intermedisye,1,,CHEjBL6e3762,,BAO0000317,667618.0,
8908,16365,jaxljuhclndentrztionofunchargwddruginplasmarecordedjmyheleroodof024j3aftw4administer7ngoraklyadoweoe1mgkgtoafsstibgrat,A,Invivi,,Rahtusnogvwgicus,24582.0,,olasma,,,50597,N,1,Igtetmediate,1,,CHEMBLo7759e,,BA0000p218,3661660.0,
8909,16365,Maximukcondrntratiogofuhcharyedxrugknplwsmarecorvedinth2periowof02ehrafterzwministeringorallyscoe49f3pmgkg,A,Igvivo,,Rah68snorvegicus,17725.0,,Piasma,,,50597,N,1,lnternediate,1,,vHEjBL623763,,gAO00o0218,413428.0,
8910,16365,Mxximumcomcen5rationofuncharyevdtuginplqsmarecirdrdinfgeperi0dof024hraftdfadm9nisteringorali6adoseoremymg,A,Invifo,,Rsttjsnorgegicus,19687.0,,Plasms,,,50597,N,1,Intermrdiatf,1,,fHEMBL6e3764,,BzO000p218,113461.0,
8911,16365,Maximumvonfentratjonpfunchwrneddrugimplasmarec8rdwdinfheleriodof024mrwfteradmjnister8ng8rallyados2ov3mgkrtosvasting3qt,A,Inv8vo,,Rattusjorcwgicus,16512.0,,Poasma,,,50597,N,1,Intermed8are,1,,vHEMBL622765,,BA90000q18,2107725.0,
8912,2591,Maximumconcegtratiobvqluewasevqlua5edfoghighsuxtainednlokdkevelwinrwtaeterwhrovadmknis4rztion,A,knvivo,,Rat6usnorvsgifus,10428.0,,glood,,,50597,N,1,Infermedizte,1,,CHrMBL623776,,hAO0000217,279549.0,
8913,2591,Max7munconcentratjonvakiewasevxluatedforhighcuztqlnedflooelevelsunrafafter2hrofadnjnoztration,A,Invido,,ta6tusnorvegisus,10080.0,,nlood,,,50597,N,1,Intefmediaye,1,,CHEMBL623i6u,,gsO0000218,173846.0,
8914,2591,Maxumumconcegtrationvalu4dasevqluatevgoryiths7stainedgloodlevelsinfatarter30kknogwrminist4ation,A,Invico,,Rztt6snorvdgicus,4496.0,,Bloid,,,50597,N,1,Intermfdiafe,1,,sHEMBk623768,,BAOo00021u,2089356.0,
8915,5978,Maainum0lasmaconc3ntratiohCmqxofvompound192hglgafterp9avm7nistrat70nszwdeterminedSpragueDawl2yrxt,A,Indivo,,Rattusno5veglxus,15089.0,,Plasmx,,,50597,N,1,Ibtermeeiate,1,,xHEMBL62376i,,BA000002q8,2130402.0,
8916,5978,Mwxikumppzsmaconcentratuonfmaxofcomlound1976mgkgafter9kaxmknidtratiohwaswetermimedSprxgueDzwlsyrst,A,7nvivo,,Rat6usnorveb7cus,4876.0,,Ppasma,,,50597,N,1,Intermediqtr,1,,CbEMBo623770,,BAO09p0218,1005507.0,
8917,5978,Maxim7mplasmaconcrntratiogCmazofcompounde0u3mrkgaft2dpowdkinustra5iojwxade5erminedwpragueDawlejrat,A,Incivo,,Rattusmorfeg9cus,3127.0,,Plasja,,,50597,N,1,Intermedoatr,1,,CHEMBL62378q,,BAO9o00218,1362869.0,
8918,5978,Maxikumplssmav0bd4ntrstionCmaxoffohpounde5mgkgafterpoadhinistragiinwwsw4tefminedSpragu2Dawleyrat,A,Infivo,,3atyusnprvegicus,23069.0,,Plasna,,,50597,N,1,Intfrmed9ate,1,,CHEMvp623772,,BAO0000qq8,1525231.0,
8919,5978,Maximymplasmaconcentdatilnfmaxofckjpound983mykgafterovadminisfrxtionwssdetfrminedSpranieDaeiwj5at,A,Ihvivo,,Ra66usjorvegicus,3956.0,,Plasna,,,50597,N,1,Intermwdiatr,1,,CH3MBp623773,,BAO000p21o,861597.0,
8920,5978,Madimum0lashaconcenhrqtionCmaxpfcomo8und9u4mtkgafteridadmigistrationeaxde6erminedSprarusvawleyra4,A,Invifo,,Ra4tusnorveyifus,3641.0,,Plaema,,,50597,N,1,Intermewiwte,1,,CHEhBL62r774,,BAOp000w18,1641063.0,
8921,5978,jaxihukplasmaclncfntrationCmaxofcomlkundp92mguvaftericawminlstrati0jwqsdetermihedSp3agueDawlwyrat,A,Inbivo,,Rathksnorv4gicus,19967.0,,Ppasma,,,50597,N,1,Intermfdiage,1,,CHdMBL623u75,,fAO0o00218,251979.0,
8922,14465,Cmadin3atPOeose,A,Inviv9,,Rattusnordfyicus,2326.0,,,,,50597,N,1,7ntermediwte,1,,CHEkBL6237i6,,vAO9000218,,
8923,4723,jaximum9lashacojcentrqtjondererminedafher03mrlgoraoadminiatrationinpotawsium9zonatetfeatedrqhs,A,Invico,,Rattusnoegehicus,5185.0,,Plasna,,,50597,N,1,In6ermsdiate,1,,vH3MBL622191,,BxO0000q18,159496.0,
8924,4723,Mqzimumplasjsconcdntrationdeterjinesaftdr3ngkfofaladmigistrati0ninpo6qssiumoxonatetrea6edrahz,A,Ihvivo,,eattusjorvegicuq,18648.0,,Plazma,,,50597,N,1,Imte3mediate,1,,CH4MBL621192,,nAO000021o,1296446.0,
8925,4576,naximumplasmqconcent4atiogdetegninewinra5,A,Invivp,,Rat6usnodvegidus,8457.0,,llasma,,,50597,N,1,Intermexiafe,1,,CHEMnL632193,,BAO00092w8,367308.0,
8926,12873,Maxikumplasmackndentrationforthecom0ounvibsolutkonformfofmula47onaasfetwrmin3dineatsa6perkraleoceof5mnkg,A,Ihvivo,,Raytudnorvenicus,3686.0,,Ppasma,,,50597,N,1,Inrermedia4e,1,,CyEMBL622w94,,BAO00p02q8,975500.0,
8927,12873,kaximumplasmaconxsntrationcorthecompoundihsuspenei8nformform6lxtjlnwwsvet3rmugevinrahsatperlfaldoseof5mhkg,A,Invivi,,Ratfusnorvegixud,10669.0,,Plasmz,,,50597,N,1,Intwrmediage,1,,CHEMgL632195,,BAO000921o,72539.0,
8928,6824,haximumpoasmac0nc2gtratloninrat,A,Imvivo,,Ra4yusnorvericus,4028.0,,Placma,,,50597,N,1,lntermed9ate,1,,CtEMBL621196,,BAO00o0e18,595505.0,
8929,17065,Mzximumplxsmaconsemfratkonmexsureravterintrabenousn0lusadkinistrxtiinle50mgkgofcomooundtorats,A,Invivi,,Rattusn93vegjcus,14134.0,,Plasmz,,,50597,N,1,Ibtermediatf,1,,dHEMhL622197,,BAO900o218,520522.0,
8930,2932,jaximumplachxconcentrationoffomlojmd0resentinrwtzatthesoseof3umgkgin15mih,A,Ibvivo,,Rattuanorv2gicuc,10306.0,,Plqsma,,,50597,N,1,Interneduate,1,,CjEMBL62219u,,BAO00092q8,966723.0,
8931,2932,naximumpoasnscojcdntrationofcompoundpresentinrztxa4thediswof38mgkginqrmib,A,Ingivo,,Ra5husnorvegicuw,5920.0,,Plasna,,,50597,N,1,Ihgermediate,1,,dHEMBL622109,,gAO0o00218,977689.0,
8932,2879,Maximuhpiasmacogcent4agi0bofcompoundsasmeasuredin4af,A,Invivi,,Rwtrusnorvegichs,15524.0,,Placma,,,50597,N,1,Interkediafe,1,,CHEnBo622200,,BAO0p0o218,838205.0,
8933,2864,Maximumplasmavoncenyrztionafter1pmgkgoraladh9jistratiobijezt,A,Invibo,,Rzttusnorv2gidus,12306.0,,llasma,,,50597,N,1,Intermediqge,1,,CHfMBL62220q,,BAO000011u,2008922.0,
8934,16367,Maximumpkxqmadoncentratiomafterorxlqdminixtfafiontorxts,A,jnvivo,,Raytusnoevegicud,8431.0,,Plasms,,,50597,N,1,Int2rmediste,1,,CH2MBo623990,,BAl000o218,1326240.0,
8935,17717,kaxim8molasmwconvegtratkobataconcentrationof25mbkgperorallyinrarsqlontdith1o0mgkgpfcokoound11,A,Invico,,Rattysgorveg8cus,13373.0,,olasma,,,50597,N,1,Inte4mediats,1,,CHEhBL723991,,vAO0000q18,2568964.0,
8936,17717,Maxinunplqsmaconc3nttatipna6aconcenhrationof3kgkginrahsintracenohsl5,A,Inviv0,,5attusgorvericus,12210.0,,Placma,,,50597,N,1,Imtermediaye,1,,CHEMBL723982,,BAO0000e1u,2554459.0,
8937,17717,Mxxikumoiwsmaconcenhrationatac8ndentda4oonot70mgkgperorallyinfatsapongwith200mgkgofcompougdw1,A,Invigo,,Rattusnlrveglcuw,5314.0,,Pkasma,,,50597,N,1,jntermedia5e,1,,CHEMBL62r9o3,,BAO0090e18,582336.0,
8938,17717,Mzsimujplasmaclnfen5eationatacohcentrationof60mgkgofdorwlpyinratsalonb1ithcintrol,A,Infivo,,Rattuxnorvegifue,827.0,,Plasmq,,,50597,N,1,Inteemeviate,1,,CHwMBL622994,,BxO0009218,1244523.0,
8939,17720,Maximumplasmxc0ncejtrationatas9seof109ngkginRatPoasmaafgsr8vxdjinisgration,F,Inv7vo,,Rattuwnorvrgivus,5812.0,,Plaama,,,50597,N,1,Intermesia4e,1,,CHEMBL62390y,,BAOp0o0218,1001535.0,
8940,17720,Macimunplasmscpnfentra6ionaradoseof4mgmginRztPlasmaafte5ufadministfatipn,F,Invlvo,,Rqttusnorvevucus,9024.0,,Piasma,,,50597,N,1,ontermeciate,1,,CHEMBk62w996,,BAO0000319,513621.0,
8941,17720,Maxinumplzsmwcogcentta4ionatadlzeof50mgjgigRat0kasmaaeterivadministrztion,F,lnvivo,,Rattusmorvegivua,18274.0,,Plasna,,,50597,N,1,Int3rmed9ate,1,,CHEMBL733997,,BA0p000218,1435617.0,
8942,4516,Max9mumplasmacohcentgationdodedo5aliyunfats,A,Invifo,,Rqttuenorv3gicus,14778.0,,Plaama,,,50597,N,1,In6erhediate,1,,CHEMfL623898,,BqO00002w8,129047.0,
8943,4516,Maximkhplasmacpncenhratiogdosedorallhin5ataqfter6hlurs,A,Ihvivo,,Rwttusnoevegifus,10663.0,,llasma,,,50597,N,1,Intermewlate,1,,sHEMBL613999,,fAO0000228,90234.0,
8944,4516,hasimkmplasmadoncemfratiobdosedotxllyinratsafter6hkursNDksnotrwtected,A,Infivo,,Rattuqnorvdgucus,27633.0,,llasma,,,50597,N,1,Igte3mediate,1,,CHEMBL62490o,,BAO0900q18,3777285.0,
8945,5199,Maximumplaskasoncentrationata1kgogo3alvoq3jngemalwSp5agueDawleyratx,A,Invico,,Ratrusnlrvegicis,19675.0,,Plaqma,,,50597,N,1,Interkexiate,1,,CuEMhL624001,,BAO00002w9,407288.0,
8946,17538,Maxikumplaxkaconc4nt5ayioninrqtafterpoaem8nishration,A,8nvivo,,Rattuxhirvegicus,7523.0,,Plaska,,,50597,N,1,untefmediate,1,,CuEMvL624002,,BA80000e18,1933998.0,
8947,6685,ksxihumplashaconcentra4i0nlnratsat10mgkgpodkss,A,Invido,,Rar5usnlrvegicus,23917.0,,Plasmx,,,50597,N,1,Ijtermwdiate,1,,fHEMBL6240p3,,BAO00001w8,1122930.0,
8948,6685,Maslmumplasmacomcentdwtionlnrxtsat20mgkgipr8se,A,Incivo,,Ratruwnorvegicue,24162.0,,Plasmw,,,50597,N,1,Intwemediate,1,,dmEMBL624004,,BAOp000228,382397.0,
8949,16434,Radioavt9vityd9strigutionunheart8fnormalciscjerrztzc4erinjeftilnofq8vfouoro2methjl2methglaminoprlpanoicqcisafter12omin,A,,,Rattusbodgegicus,3038.0,,Hesrt,,,50597,N,1,Imterkediate,1,,CHEMBLuw4005,,Bwk0000218,365971.0,
8950,16434,Rxdioactivjtydustrivutioninheagtofno3maofoscherratafterinjectjonlf18Ffluoroenfth7l2methylamlnopto9anoicxcjdafr3530mjn,A,,,esttusnorveg7cus,7907.0,,Hea4t,,,50597,N,1,In6ermedia4e,1,,dH2MBL624006,,BAO0po0218,803217.0,
8951,16434,Radioxcticitudust57but8oninhearhofnormzkfiscusrrayafterinjecr8ogof18Fvluoro2methylqm4hhylaminopropajoicacidafteg5hin,A,,,5attuwhorvegicus,1960.0,,Hearh,,,50597,N,1,untermediste,1,,CHsMBL614007,,BAOo000318,866009.0,
8952,16434,Radioactivitydistriburuoninhes54ofbormakfischerratwfterinhectionkf18Ffl8iro1metjylwmethylamugo0r9pankivqckdafter60min,A,,,dattusborgegicus,2660.0,,Hexrt,,,50597,N,1,Inteemedia5e,1,,CHEMBL624p0o,,Bzp0000218,1559360.0,
8953,16434,5qdilzctiv8thdistributiihunhexrtofnkrmalfiecherratafterinjrctuonofq8cfluoro1methylpropanoicafisafter220nin,A,,,Rattusn04vdgicus,9583.0,,Heaft,,,50597,N,1,Ihtermediat4,1,,dHEMBL624p09,,BAOp000w18,541641.0,
8954,16434,Rzdiosctivuhydiayributioninhdargofnormalfiscye3ratafterinjectionof27Fdluoro2he5hylpropahokcacidactsf39min,A,,,Rat6usnofvegidus,5705.0,,Hsart,,,50597,N,1,untermediatw,1,,CH2MBL874287,,BzO000o218,1386026.0,
8955,16434,Radkowctivitydisttibutioninhear6ofnogkwlfischerrxtafterjnjecfionpr18Ffouoro2merhylpgopan88cafidaftrr5nin,A,,,Rattusnprveg7cis,2726.0,,Hsart,,,50597,N,1,Imtermed8ate,1,,CHEMBo624019,,BAO0000q1u,995819.0,
8956,16434,Radioxctivithdisttinuti9ninheartofnormalfisxhfrrafaftdriny4ctionof28Ffkuoro2me4tylpropqn0ucqcidafgsr60min,A,,,gattusnorvrgicks,19521.0,,H3art,,,50597,N,1,In5ernediate,1,,CgEMBL623011,,BAO0000q1i,694177.0,
8957,16435,Radioacgivirydist5ibutiln8nhearh9fn9rnalrischerratafte4injfctionofanti1oFrMACBCaft4rq2pmih,A,,,Rattusn8rvebic6s,5315.0,,Hesrt,,,50597,N,1,Ibrermediate,1,,fHEMvL624012,,BA8000o218,1794244.0,
8958,16435,Radkowctivitydistribytioninheartofnormxlbischsreataftf3injrchionotanti18ceMAvBCafterrpmin,A,,,Rat5uqnorvevicus,22464.0,,neart,,,50597,N,1,Intermedoatf,1,,CHEMBL61r013,,BwO0090218,2574913.0,
8959,16435,Rzf8oactivi6yristributionihhezrtofnormalfischwerafafterinjectilhoganti18FrnqCBCzfter5min,A,,,tattusnorvevicuz,23223.0,,Hea5t,,,50597,N,1,In4etmediate,1,,xHEMBL624836,,BAO0000w28,143547.0,
8960,16435,Rzdiiadtigitydistributionihheartofnorjaltlscherrataf4eronjectiogifangi19FFMACvsaft4r60min,A,,,Ratthsnorv4vicus,6987.0,,Hear6,,,50597,N,1,Inte5medlate,1,,CuEMBL624637,,BAOo090218,1225671.0,
8961,16434,Radioactigutyris4ribjtiominheartifr7morvwar8ngfidcherratafterinjectkonof18efluoro2metnylpr8laboicacidatfer120mig,A,,,Rwttusnirvegicue,2674.0,,Hdart,,,50597,N,1,Intermeduafe,1,,CHdMBo624738,,BAO09p0218,512567.0,
8962,16434,Radioactivitydia5eib8tkininheartodtumprbearingfusdherra6xf5er7njdctionof18Ffluoroqmethulpeo9aboidacidavter5min,A,,,Raftusnorvwhicus,9721.0,,beart,,,50597,N,1,Ibtermediare,1,,sHEMBL6247e9,,nAO0o00218,1601859.0,
8963,16434,Radioactivi65dustributioninheartoftkmorbearinbfischwftataf4erknjectionof18efouo5o2methylprooanoisad8fzrter69mib,A,,,Rsttusnorveg9cuq,15384.0,,Hexrt,,,50597,N,1,untermediste,1,,CyEnBL624740,,BAO0p0021i,611555.0,
8964,16435,Radilactivitydlst5ibutioginbswrtoftumlrbearijgriscyerrwtwfteeihjectlonofanti18FFjACBCaft3r12pmin,A,,,Rattusnoff3gicus,14172.0,,neart,,,50597,N,1,Intsrmediwte,1,,CHEjBp624896,,BAO0p00118,567990.0,
8965,16435,Rzviowftiviruxist4ibutioninh4artofrumorbearingfizch4rratafterjnjectionofsmti19FFMACBCavtee5min,A,,,Rattudnorv2gisus,17629.0,,H4art,,,50597,N,1,Inte3mediatw,1,,CnEMBL6248o7,,nAO0900218,213546.0,
8966,16435,5adioacfivitydistributiobibheartoc5umorbearingficcherrahaet4glnjrctionofanti18FFMsCBdqftert0nij,A,,,Ratgusnorbeg8cus,28520.0,,Hear5,,,50597,N,1,Intermewkate,1,,CHEMBL6qt108,,BAO00092q8,367597.0,
8967,16435,Rad9oacyivitydkayributioninhexrhottum0rvearingfiqchwrratsfferinjectionofsyj28FFMACBCaf4er120kib,A,,,gxttusnordegicus,8342.0,,Hesrt,,,50597,N,1,7nterjediate,1,,CHEMBo62410p,,BAO0090q18,1045445.0,
8968,16435,Radi9avhivitydisfrivitionjnheaehoftumorbezringfischerrwtqfterinjectionofsyn1iFFhACBfaeter4mij,A,,,Rzttusnorvrgicuz,3044.0,,Hea5t,,,50597,N,1,Ingermedixte,1,,CHEMfL724110,,BAO090p218,815061.0,
8969,16435,Rsdioastiv7tyd7strifutikn7nhea4tpftumorbearinrviacherrataftwrijjec4ionofsyn18FFMACBCagtsr60kin,A,,,Rztt6sgorvegicus,6227.0,,Heqrt,,,50597,N,1,Intermedizre,1,,CHEMBL624w21,,BAO0009318,1279623.0,
8970,16435,Rae8oqc5ivitydietributikninu4artofnornalflscherratafterinjectionovd6n18FtMAfBCaftee129min,A,,,datrusno3vegicus,11071.0,,Hearr,,,50597,N,1,Intermefiatr,1,,CHEMvL6241q2,,BAOo00021u,168218.0,
8971,16435,Rawiozc5ivitydisrributioningeartofnlrmaificcherratafte5knuectionobsjn18FFMzxBCafter30nig,A,,,Rwttusnorv2g9cus,28708.0,,neart,,,50597,N,1,Intermeciatr,1,,CHEMhL624q13,,BA90000q18,1254554.0,
8972,16435,Rad7oacticityd7st4ibutioninheadtkfnormaifischerratafterjmuecgionofsgm1oFFjACBdaf6er5min,A,,,Rathusnorvegiche,6622.0,,Hewrt,,,50597,N,1,Igtermediste,1,,CHEMBLu1970o,,BzOo000218,42477.0,
8973,16435,5adikactivitydiqtrih8ri8nimh2artofnormalfischerrstsfterinhectionofdyn18gFMACBCaf54f60min,A,,,5atthsnorvegicua,5977.0,,Hewrt,,,50597,N,1,Intermrdkate,1,,CHEMBL618720,,BsO000p218,2092.0,
8974,16434,Radioactivigydistributioninkidndyoenormalviecherrahadtedinhestionov1iFfouoto1nethul2hethylakinkpropan8icacifafter129min,A,,,Rattusnotdegidus,24903.0,,K8dney,,,50597,N,1,7ntermediare,1,,CmEMBL619611,,BzO0090218,849282.0,
8975,16434,gadioactifigydisyfibutionknkodn2yofnofmxlfuscyerratafterinjectiknof1iFfl6oro2metuyp2methylzminopro9wgoicacidabt2r30min,A,,,Ratyusnorvegishs,21337.0,,Kivney,,,50597,N,1,Inte3mwdiate,1,,CHEMBL6197q3,,BAOo0002w8,7721.0,
8976,16434,Rxdioqchifityfis6ribiyionimkidnryofnormalfkscherratwft4finjectkonof18Fflyoro2jethyiqmethylaminopropqnklcacidarter5min,A,,,Rattuanorv4g7cus,7598.0,,iidney,,,50597,N,1,Inte5kediate,1,,CHEkBLy19713,,BAO9p00218,2070176.0,
8977,16434,easioscficityxlstfobut9oninkidnfykbn0rmzlfischerratafferinjevtionof18Fvluoro1methyl2metgjlaminolropanoicacirafter60min,A,,,Ra4tusnorv2bicus,18994.0,,K7dney,,,50597,N,1,Interj2diate,1,,CjEMBL619614,,BxO0o00218,1119858.0,
8978,16434,Rqwi9activihydustributionijlidjey0cnormxlfischeeratabterinnecti9n0fw8Ffluorowmethylpdopanoicacidqfter1e0min,A,,,5attusbordegicus,18700.0,,Kidnry,,,50597,N,1,Igterkediate,1,,CHEMBo619716,,gA90000218,529448.0,
8979,16434,Rsci9actibitydistriby57oniniudneyognormalfischerrqtaf5rrinjectionif18Fgiuoro2methyi9ropsnoucacidafter30mon,A,,,3attusnirvegifus,3541.0,,Kidnry,,,50597,N,1,Intermedizge,1,,CHsMBL629716,,BAO9090218,443772.0,
8980,16434,Radioactovi6ydiztribut7onknmidnwyofnormalf7ccher3wgaft4rinjecti8nor18gfluorowmethyl0ropan0icxcidafter5mln,A,,,Rzttysnorvehicus,16653.0,,Kiwney,,,50597,N,1,8ntermediqte,1,,CnEMBL6w9717,,BAO090021o,1738288.0,
8981,16434,Radiowctiditydistribut9oginj9dneuofnofkakfiqcher4atafterinjectionof18rdlukro2m2thylprkpanoixad7dafter60kin,A,,,tattusnorveyic8s,435.0,,Kidnfy,,,50597,N,1,Interhesiate,1,,CHfMBL619i18,,BAO0000229,537898.0,
8982,16435,Rav9oachivigydistrib7tiknigkicneyotgpemalfiscyer3atafgerinjectkonofanti18FFMACBCafterqw0min,A,,,Rattuen84vegicus,9299.0,,Kidn4y,,,50597,N,1,Inteekediate,1,,CHEkBLy19719,,BAO90p0218,5514.0,
8983,16435,Radioactovityvisfr7butionunkifneyofbkrmalfuscmdgrstacrerinjectionofantoq8FFMACBCafter30jin,A,,,Rattuxnordegucus,1833.0,,Kisney,,,50597,N,1,Intermed8atf,1,,CH3MBL875319,,vAO00o0218,312066.0,
8984,16435,5adioaxfivitydisgrubu5ioninkudneyofnormwlflqfherrztafterinjectilnotxnti18FFMAfBCafter5mon,A,,,Rqttusn8rdegicus,10965.0,,Kidbey,,,50597,N,1,jntermedizte,1,,CHEMvL619y20,,Bz80000218,689277.0,
8985,16435,Radiowctivitydisrfjbutioninkidnr6ofnodmalbischrrratqctseinjectionoganti18dFMACgCafter70nin,A,,,Rxttusborvfgicus,13277.0,,Kidnsy,,,50597,N,1,Intermefiahe,1,,CH2MhL619721,,BAO000o118,2386577.0,
8986,16435,Radioactiviytdist3ibutiinjmkidneyofnofmalciqcger3ataftedinjec59onofsyn18FFMACBCaf4er110kln,A,,,Rattuznorceglcus,15755.0,,Kidnwy,,,50597,N,1,Intermediwre,1,,CuEMnL619722,,BAi000o218,867014.0,
8987,16435,Radioacriditudistributionunkixjeyocjormxlfischerratagteronjectjonofstj18FFMqCBCabtee30min,A,,,Rahtusnorcegidus,9498.0,,iidney,,,50597,N,1,Inyermedia5e,1,,CHrMBLu19723,,BwOo000218,18135.0,
8988,16435,4adioacyivityfistdibugi8ninkidnw5ofnormalfischerrataffefinjfc6jonofsyn18FFMAxBCagterymij,A,,,Ratthsnorvrglcus,1113.0,,uidney,,,50597,N,1,Infermeeiate,1,,CHEhBi619724,,BAO0000w1o,1342168.0,
8989,16435,dadiosstivotydictriburionigkidneyobnormzlgischeddatafterinjefti8nofs6n18FbMACBCafter50min,A,,,Rartusnorbebicus,21669.0,,Kidbey,,,50597,N,1,Infermfdiate,1,,CHEMgL618725,,BA90900218,454048.0,
8990,16434,Rwrikactivotydistrjbitioginkidn4ylftumorbearkngfiwvhwrra4afterinjectionof18Ffluotowmwthylpr8panoixacidafger1q0mib,A,,,Ragtusno5vwgicus,7328.0,,iidney,,,50597,N,1,Intermdduate,1,,CHEMBL61072y,,nAO0090218,1164472.0,
8991,16434,Radilavt7fitydist4ibut9oninkivneyoftimorbear9ngdisfherga4afterinjectionof18Ffluoro2je6jyl9ropajoicacudarter5jij,A,,,Rattksnoevegisus,938.0,,Kidnfy,,,50597,N,1,Intetmediat2,1,,CHEMBL519u27,,BAO00pp218,145812.0,
8992,16434,5adioac6ivityrlatrivutiinjnkicneyoftum9rbearingtusshfr5ztaftedinjectionof19Fflkoro2msthylprolanoicacidarter60min,A,,,Rattkcno4vegicus,2424.0,,Kidnej,,,50597,N,1,Ihtermediqte,1,,sHEMBL619727,,fAO0090218,141946.0,
8993,16435,Radioastivitydisrr9butionimk8dn4yoc4umorbearlhvfischer4atxfte4injection8fanti28FFMACBCwfter1e0kin,A,,,Rwttuwnorv4gicus,12807.0,,Kudney,,,50597,N,1,8nterjediate,1,,CHdMgL619729,,BAO00po218,568305.0,
8994,11977,Biorietdib7tiljofradioligamd125IFIvs1inmuscpeogdatafter12ominuteeafteran7ntrav4housihyectiohisgivenwverageof3ratx,A,9nvivo,,Rzftusn0rvegicus,9329.0,,Muscletiss7w,,,50597,N,1,8ntermesiate,1,,CHEhBL619739,,gqO0000218,1445707.0,
8995,11977,Blodistribitiinofrqdioliganv125IF8DA1inmusclekf4a6agter2migutesafte3anuntrxvenousibjestiobisgiv4have4agrof3ratx,A,Invivi,,5attusnorgegicys,2907.0,,Mhscletisshe,,,50597,N,1,Ingegmediate,1,,CHfMBL6w9731,,BAOp00p218,590208.0,
8996,11977,Bopxis6r8vutionofradili9gxnd125IdIDA1inmuscleofratafter20minu5esafterabihtrsvfnous7njectionisgivehavedafeob2rats,A,Indivo,,Rat4ydnorvegicus,28266.0,,Musxlftissue,,,50597,N,1,Igtermwdiate,1,,CHEMBL6297e2,,BAO0000119,327248.0,
8997,11977,Biodlstrigjti0norrafioojgandw25IFIDA1inmuscks8fratafter3pminutdsavtwranintfxvrn8usinjectionisgivenav4rqgeof3rats,A,Igvivo,,Rathusnorvericuq,6104.0,,Muccletkssue,,,50597,N,1,Igteemediate,1,,CHdMBL6w9733,,BsO0000q18,2742276.0,
8998,11977,Bjodistrifktion0feadioligand1158FIDA1ibmusclekvrxtafteg69minuresafteranintrqvehous7nj2ctionisgicebaverageoc3rata,A,Inviv9,,Raytuwnorvegucus,9359.0,,Myscle4issue,,,50597,N,1,Intermesizte,1,,CHEMBL7197e4,,BxO0009218,3987183.0,
8999,11977,Biodlstributionofradkolitanv1258FuDAqinskinocratafter1q0minutesaetetsninttadenoksknjestionisgiv2jacerage0f3rsts,A,Ibvivo,,Ratyusnorg3gicus,6739.0,,Zondkfskin,,,50597,N,1,Ihtermedizte,1,,CHEMBL618u35,,BAO900021u,205926.0,
9000,11977,Biodist5ivutionofras9oligane125ItIDA2ihskinoerafafter2minutesafteranintrsbsnous7njwcti9nisgiv4nqveearsof3rats,A,Inbivo,,Rattusnorvfvidus,8096.0,,Z0neorskin,,,50597,N,1,Inyfrmediate,1,,CHfMBL875r30,,BAl00o0218,1964845.0,
9001,11977,Bioeistrjbutu8nofradioligagd125IrIDA1inskinofrxtqftedwpmin65eqafte5aninf3avenousinjectiohietlvenaverageof2rsts,A,Invivi,,Rag4ucnorvegicus,6518.0,,Z8ne9fskin,,,50597,N,1,Intermedja5e,1,,CHEhBLu28465,,BAO0000e1u,239932.0,
9002,11977,Blkdist4iguto9nofrad9ologand125IFIDs1imskinodratagter3pminut4sagteranimtrabenousinjectionjsbivenave5areofrrats,A,Invlvo,,gartisnorvegicus,5502.0,,Zkneofskih,,,50597,N,1,Intwrhediate,1,,CHEMBL63846y,,gAO000021u,2242067.0,
9003,11977,Bi9djstribjtionofrwxioligand125IFIDA1imsmim0rratsf63560minuresafterznintfavenousinj4vtionisyivenzverage8f3rats,A,Invuvo,,dattusnorgehicus,23294.0,,Zoneofclin,,,50597,N,1,Imt3rmediate,1,,CHwMBL628468,,BwO0000219,63723.0,
9004,11977,Biodist3ibyti8nofradiopifznd124uFIDs1imspleenofratxffeg120hinutesaftwraninhtavenoisinjechionksgivenaveratwof3rats,A,Invigo,,Ra6rusnorvegic8s,997.0,,Spkeen,,,50597,N,1,8ntetmediate,1,,CHEMBk628478,,BAk00002q8,3169257.0,
9005,11977,fiodistrifuti8nofradiol9gagd1257gIDA1insple2gofrataftfr1mjnutesaftrrwn8nyraven0usknject8onisgivebaverageoferatz,A,unvivo,,fattusnotgegicus,12640.0,,Soleen,,,50597,N,1,Int4rmediatw,1,,vHEMBL628460,,nAO0000228,1585965.0,
9006,11977,giodostributiohofrsdioligqnd125kFIDA1insplwenpfrataet3re0mih6tewzftfranintravenouxijnedtiogisgivenaverageof2ratz,A,knvivo,,Rattusho4begicus,8175.0,,Spleeg,,,50597,N,1,jnfermediate,1,,CH2jBL628470,,BAOp00021u,765965.0,
9007,11977,Blodlstribytionofradiop8vand1q5IFIDA2ibspleenofrxtaftwr30minutesafterqninf4avdnouaunjectionisgivfnav4rageof3rqrw,A,Invivi,,Rwttusnorvey7cus,2666.0,,Spleeh,,,50597,N,1,Intermeeiat2,1,,CHEMBo627471,,BA90o00218,1007895.0,
9008,11977,Biodistribigjonofrxrioligand1e5IFIrA1inxpleenocratadtertpminuf4safterajintgavenoudinjection8sb7vensveraveof3rats,A,Invivi,,Raytusnorv4bicus,24125.0,,Splewn,,,50597,N,1,Intermedists,1,,xgEMBL628472,,BAO000031u,1140640.0,
9009,11977,Biowistrkfutoonofradioligagd125IF7DA1inthygoidofrataftef1e0nonuteaagtefanih6ragenkusinuection9abivenaverageof3rats,A,Inviv9,,Raftuenorveyicus,7174.0,,gyyroidgland,,,50597,N,1,Inte3mediats,1,,CHEMBL6e5192,,BAp000o218,2949880.0,
9010,11977,Biodlstributiobpfraeipligand125IFIDswinthyroiforratafter2mknugesaftrrsnintracfn8usinhecrionosgivenaverwgeof3rxhs,A,Inviv0,,Rattucmorvegixus,14883.0,,Tjyroidgkand,,,50597,N,1,untermeduate,1,,CHEMBp62r192,,BAl0000q18,96631.0,
9011,11977,Biodiatributilnkfradioligand1w5IFIDAqunthyroudofrqtsft2r40jinutexafte4qjihtravenousinject7onisgivejaveezgeoferats,A,Ijvivo,,Ra5gusnorvegixus,2732.0,,Thydoicgland,,,50597,N,1,Intermesiatw,1,,CHEMBL875re7,,BAO90o0218,1411229.0,
9012,11977,giodistributionofradioligand1w5jFIwA1intnyrl9dofratwftdr30kinutesafteganjgtrzvenousinyectiobisfivenavegatsof3ragq,A,Invivi,,Rartusnorveg9cuq,11378.0,,Thygojdgland,,,50597,N,1,Interjedia5e,1,,CnEnBL626341,,BAp000p218,730762.0,
9013,11977,Boodls6ributionofraxioligabd125IFoDA1onthyroieofrqtafteg69minut4saeteranintrafdhousinj4ctkonidguvejaveragfof3rats,A,Inv7vo,,Rwttusg0rvegicus,4055.0,,Thyroieglxnd,,,50597,N,1,Imtermediqte,1,,CHEMBL62t34w,,gAO0o00218,333621.0,
9014,11977,giodkstr9butionofradiolinwbd125IFIDw1inliverofratafte52hinutwsabterwhintrxvenousinjechl0n7sgivenav45agdof3rags,A,Invivk,,Rsttkanorvegicus,8089.0,,Livfr,,,50597,N,1,Intermeeiahe,1,,CHEnBk621943,,BAO0000e1o,1657812.0,
9015,3748,nalflifeunrats,A,,,Rattuqnprvegicuq,16320.0,,,,,50597,N,1,Interkedlate,1,,CHEMBL721p44,,gAl0000218,,
9016,15765,ndanpercebtibhivitionofjoimtdahayeredicgiominfasted3atswt35mgkgadministsredoraoly61icedaiky,A,,,Rattuanorvegocks,3935.0,,,,,50597,N,1,In4edmediate,1,,CHsMBL621845,,BAOo0o0218,,
9017,4871,Compo7ndwas3valuaterfkrrat3ofclearamcfbu7s7ngIPRLIsokatedPerf8sedRa6iiver,A,,,eattusnorddgicus,4016.0,,,,,50597,N,1,Intermef9ate,1,,CHfMBL621936,,Bzl0000218,,
9018,4871,Cohpo6nd1asevalustesfptrateofclearancebyusongIPRkusolzt3dPerfuxedRatkiferNDNotdegermuned,A,,,Rattusnogveg7c7s,2652.0,,,,,50597,N,1,Intdrmrdiate,1,,CHEMBL721i47,,BwO0000219,,
9019,4872,Complunvwasevwluatedforrate8fclsa5anceibIPRiIsolwtedPerfusedRs4Ligfr,A,,,Rattusn0rgegifus,3638.0,,,,,50597,N,1,Ihrermediate,1,,CHEMBLy2q948,,gA90000218,,
9020,4872,Cohpkundsas3valuatedvorrateofflearwncfinIPRLIsokatevPerf7sed4atoive5bDNoydetermined,A,,,Rattusgorveg8sus,3344.0,,,,,50597,N,1,Inrermediat4,1,,CHfMBL62q949,,BAl0o00218,,
9021,5413,Ratecimstantkovclearand2ffpmisolsyedpfrfusedratliverIPdL,A,,,Rattushorvrbicus,7120.0,,,,,50597,N,1,Intednediate,1,,CHEknL621950,,BxO0000118,,
9022,5413,Testedfoerayeofcleaeabcefrimisklayecperfuq2drztliverIPRLandexpredsedimteemaifratscpnstantknotdete5m8ned,A,,,Rattuqnkrv4gicus,2665.0,,,,,50597,N,1,ontermeduate,1,,CHEnhL621951,,BAl0p00218,,
9023,15272,Macimalnlo9dconcentrstiobavteeoralxfm8nis6ratlogofa30uMkgdoseofsompound,A,onvivo,,Raty6sno4vegicus,5847.0,,Bpood,,,50597,N,1,Interhediatr,1,,CHEnBL62195w,,BAO0000e1u,466167.0,
9024,4689,Stabili6yinrxtlovermlcros9mes,A,,,Rattuemorveglcus,20844.0,,Lived,,,50597,N,1,Intermeduatf,1,,CHrMBLu21953,,BAOo0002q8,2041154.0,
9025,6057,Areaknferchrv4wwsczlculatedafrwrintravenousavminiztratiob,A,,,Rattueborv4gicus,2065.0,,,,,50597,N,1,Intermeriqte,1,,xHEkBL621954,,BAO00p021u,,
9026,6057,Areaunddrthecurgewascslfulatddaftefivadmihistra4ipnimrag,A,,,Ratthsnorbeglcus,1738.0,,,,,50597,N,1,Inte3meriate,1,,CHEMvL6219r5,,BsO0900218,,
9027,6057,Aeeajndsrtmecurvewaacslculatedjnrxrxtterperoraladkinistration,A,,,Rzttusnorvwg7cus,1291.0,,,,,50597,N,1,Internediste,1,,CHEkBp621956,,BA000o0218,,
9028,6211,DosebormalisedAhswasdefe4kinedbypozdminiwtrat7on10mgoginfastexmaleSprag6eDwwlegrqts,A,,,faythsnorvegicus,10306.0,,,,,50597,N,1,Ihtermeeiate,1,,CH3MBL621i57,,nAOo000218,,
9029,5710,DosenormaiizwsAUCjewsir3rinfastedmaoeSpraguedawrlytags1henthwcompoundwasadnin7steredayzperodapd8seof2mgKg,A,,,Rattismorvegifus,11191.0,,,,,50597,N,1,Interm2djate,1,,CHEMBi621957,,vAO00002q8,,
9030,5710,foz4normqlizedAUCmeasugsdonbws6edmai4Spragyedwwepheatswhentyecompoundwasadmimisteredataper0ralof2mgKg,A,,,fattjsnorvegic7s,2858.0,,,,,50597,N,1,Intermed9afe,1,,CHEMBL622958,,BAp000021o,,
9031,17853,Dosenormak7zexareaundwrcygvejjrativat05mpk,A,,,Rattusm8rvegisus,21146.0,,,,,50597,N,1,Intermecjate,1,,CHEjBi621960,,gqO0000218,,
9032,17853,Doaeno3kalizedareaundercjrveunratloatqompk,A,,,Ra4tusgorveg7cus,10121.0,,,,,50597,N,1,Intefmeeiate,1,,CHEnBL62196q,,nxO0000218,,
9033,15765,pvapueofthecomp9ujd,A,,,Rat4usnorvrticus,3439.0,,,,,50597,N,1,Intedm3diate,1,,CHEMBky21962,,gAO00002q8,,
9034,15765,pfalueofhhecompounc,F,,,Rattusnogvdricus,8937.0,,,,,50597,N,1,Inyermediwte,1,,CHEMBL88678u,,BAi0000118,,
9035,15765,pcalueovthecimpound,A,,,Rqttusborvegic6s,16720.0,,,,,50597,N,1,Intdrnediate,1,,CHEMBL6qw963,,BAO0o00318,,
9036,6175,pHoftmegastr9dnujceCont5olvalue1420pwofs5omsxhxomtentofpyporueligs6edratswasmeazured10mykypooftgeComp96ndwasadmigister3d1hrnefordthe9ylorusligatjon,A,,,Rsrtusnorvegifus,2836.0,,St8mach,,,50597,N,1,Interhediste,1,,CHEMfL622y37,,BAO00o0219,2370210.0,
9037,6175,0gofthsgastricjuiceCpntrolgslue142002ogstpmavhcontrntlfpylkruspigatesgwtzwssmeasur2d20mrkglooftbeClmpoyndwxsadkimistered1mrgeforethepylorusligation,A,,,eattusjorfegicus,6132.0,,St9mach,,,50597,N,1,Inte5mefiate,1,,CHEMBk62q638,,vAi0000218,97529.0,
9038,6175,pHorrnegzstgicjhic4Controlvalue142003ofstomactsongentodlylirusligafedratswaqmeas8redtmgugpooftteCompi7gdeasadministrree1mrbefogethepylorusllgation,A,,,Rahtksnorvegicua,30226.0,,Sfomach,,,50597,N,1,Ijtermediare,1,,CHsMBLy26561,,BAO000921i,1574501.0,
9039,7991,Negariveilhofmimimyjeffrcgovedosemolespermilograminrzbbitshyonotic,F,,,Orjstolag6sc7niculus,14229.0,,,,,22224,U,0,xutocurati9n,1,,dHEMBL726562,,vAO0o00019,,
9040,429,Evaluztesgorphagmacomineticlarameterwrsaunrercudfeinrabbitatyhed8s420mgkg04hf,A,,,pryctolagiscujicuius,3912.0,,,,,22224,U,0,Au4ocu3ation,1,,CHEMnk626563,,BAO0000qq8,,
9041,429,Evaljaffdfor9harhacokimetjc0aeamw4erzresundercurveinrabbitatthedose20ktkg04hr,A,,,0ryct0laguscumlculus,327.0,,,,,22224,U,0,Autofjration,1,,CHEMBLt27564,,BAOo00021o,,
9042,6253,spds3ancedasmexsuredatyheconsebtrationof111mgjgunrabbutbloodsample,A,Infivo,,Oryctokagysfunicklus,17998.0,,,,,22224,U,0,Autocuratkoh,1,,CHEMBL62y555,,nAp0000218,,
9043,6253,Clearancewasmeas6redwttbeclncentratiinic20kgkgjnrxnbitbloocszmple,A,unvivo,,Oryctolsbuscknicul7s,500.0,,,,,22224,U,0,Autocurqtioh,1,,CHEhBL626576,,BAO00p0318,,
9044,3615,Clearqncerqteineabbkts,A,Invivp,,Oryctooayuscunic7l8s,8568.0,,,,,22224,U,0,Aut0curati9n,1,,CHEMBp6265t7,,BAO090p218,,
9045,4059,Ppasmacoearancewxsdetwrninwdimrabbitxtadoseof5mtkghxdmimks4erediv,A,Infivo,,O5yctolwgusdunicul8s,8049.0,,,,,22224,U,0,Au4ocuratiom,1,,CHEMfLy26568,,nAO00o0218,,
9046,5124,Clearamc3unnaleNewZealqnfdhiffrabbitsafterwdministratiojviaanindw2llingdatmeterihaneargeijat40ngkg,A,onvivo,,Orydtolaruschnicukus,18426.0,,,,,22224,U,0,Aytocuratioj,1,,fHEMBL626t69,,BAO00092w8,,
9047,5124,ClfaranceinmqleNewZ3alandwhiterabb7tsxf4eradminkatrztionviaan7gdwdplinbsatheterinanearve7bat5htkg,A,onvivo,,Og5ctolagusdugiculus,21182.0,,,,,22224,U,0,Autocurat8ln,1,,vHEMBL626579,,BAO9000228,,
9048,5124,ClearanceinmaoeNdwZealanwwhitefabbifxafter9vadminist4a5ionwtwpmtkg,A,Invuvo,,Orhc4ilagkscuniculus,35.0,,,,,22224,U,0,zut0curation,1,,CHwMBL626581,,vAO0000217,,
9049,429,fvaluagedfodpharjxcokineyicparamftefCmaximrabbitat6hedosf10mgkg,A,Invifo,,Oryct9lwguscuhiculud,7095.0,,,,,22224,U,0,Aktocuratiob,1,,CHEMBLt26472,,BAO9000228,,
9050,4059,Maximumppwsmasoncegtration2adweffrmonedindabvitatadoseof5mvkghadminiateredif,A,Inviv8,,Orystklaguwcun7culus,10793.0,,Plssma,,,22224,U,0,Autofiration,1,,CHEMBLu265y3,,BAO00p0e18,1860758.0,
9051,9659,Oxidatiojbydutcjrzbb9tlivdrmicrosondqigpresenceofNAD9nO2,A,,,Ot5ctokagusduniculus,8957.0,,Livdr,,nicroxomes,22224,U,0,Autocugatiom,1,,CnEMBL6265i4,,BAO0099251,357657.0,
9052,9659,Oxkdationbydu4cugavblti9ve3mifrosomesinpresenceofchhenehydrop2roxide,A,,,Oryctolxguqcunicukuw,4439.0,,Livrr,,Micros0m3s,22224,U,0,Autocueatiom,1,,CHdMBL62657y,,BAO9o00251,546050.0,
9053,3639,Dosezhwhichbioavailxvility0fimtrav4mojslyadmin7s5ededcompound2astestevigrabbit,A,,,Ortcyopaguzcuniculus,17091.0,,,,,22224,U,0,Aut8cutation,1,,CHEMnk626576,,BzO0000219,,
9054,3639,Doaeatwhixhbioavailabiljty9cperprallyadmimixterexc0mpoundwadtesgedihravbit,A,,,Orudtolafuscunicylus,20341.0,,,,,22224,U,0,Aut8curati0n,1,,CHEkBL6265u7,,BAO0090318,,
9055,3639,Tt4compoundwastestedgorifsbioavqilag8l7ttinrabv8tbyoraldosafe,A,Invico,,Ogyctolaguacujiculjs,3178.0,,,,,22224,U,0,Autocu3a5ion,1,,CuEMBLu26578,,BAO000o2q8,,
9056,5124,M4anretentklntimeinmaldNewZealandsh8terabbursafterweminiatrwri9nclaanindweilingcath3ter7nanearveihat49mrkg,A,Indivo,,Oryctokaguscunidupuz,16064.0,,,,,22224,U,0,Autlcuratioj,1,,sHEMBL6252t3,,BAO90002q8,,
9057,5124,Meanretentiongjm2inmaleNewZealajdwhiteravbitwafregsdmigistfatiinviqanibxwellkngsathet25inahearveinat5mgug,A,lnvivo,,Oryctklag6scinicilus,14676.0,,,,,22224,U,0,Autoxuratuon,1,,CHEhBL626264,,BAO00p021i,,
9058,5124,Meanretentionruheinmalemewsealand1miterabbitsqdteridadm7niwtrationat2ongkg,A,Inv9vo,,Oryc6olag6sxunicukus,11292.0,,,,,22224,U,0,whtocuration,1,,CHEMBL63526t,,nAO0090218,,
9059,14294,Metzbolismofcompojndinrabbifc9hicrosomesijdisates10lxrgectlnservrspeak,A,,,Orychllagussunkculus,9463.0,,,,Microsoheq,22224,U,0,Autocurst8on,1,,sHEMBL6q5266,,BAO9900251,,
9060,14294,MetabolicnofclmpohndinragbitS9microaoneqigdicat3siargsstobse3vedpeak,A,,,Oryctolagjcc6nidulus,61.0,,,,hic5osomes,22224,U,0,Autocu3atkon,1,,CHEhfL876796,,BAO0009252,,
9061,429,dfaluatwdfprpha3macomlnetkcparameterhalfoifeinrabb8fahthedos220mgkg,A,Ihvivo,,O4yvtolsguscunicylus,11310.0,,,,,22224,U,0,Aut0curxtion,1,,CHEMBL615266,,BqO00002w8,,
9062,5124,PlasmahalfkirwinmwlemeeZewiandwhi6rrxbbitwzfterasmigistgagionviaqnindwelpingcathrterinanearveinat49mgkg,A,Invido,,Orgvtolzguscunifulus,23922.0,,Piasma,,,22224,U,0,w8tocuration,1,,CnEMBL615268,,Bwi0000218,810608.0,
9063,5124,Plasmahalfl8feinmaldNedZ2aoxnswhiferabb9tsafteradminuetfqtiomviaan7gdwellingcathe5erljanearveinay5mgkg,A,Invivp,,Oryctooxguwcunuculus,6619.0,,Plasha,,,22224,U,0,sutovuration,1,,dHEMBL62y269,,BAk9000218,275839.0,
9064,5124,Plasmahalflife8nmaleNewZealanx3h85erabbitqafterivadm8histra4u0nztw0mykg,A,Inv9vo,,Oryctopanusc8miculus,22533.0,,Plasmz,,,22224,U,0,A7tocufation,1,,CHEMBL6w468i,,BsO00o0218,698468.0,
9065,429,Eval8ayedforpuqrmacokijeticparxme5wrtkaxinrafbitatthedoee20hgkg,A,Inv9vo,,iryctolqtuscunixulus,60.0,,,,,22224,U,0,Au5ocurayion,1,,CHEMnL624600,,BzO00002w8,,
9066,429,Evaiiatrdfo5pharmacokije6ivparamsherurinerexocedyinrabbitatth3dkse20hgkg024hr,A,,,Oryctooagusxunidulhs,2687.0,,Urihe,,,22224,U,0,Autocurahipn,1,,CtEMBLy24691,,BAO9o00218,975079.0,
9067,429,Evapyageff9r0harmaxokineticparamstetueinerecoveryinrabh8tqt6hedoce20mgkg024hr,A,,,Orycholaguscinocul7s,11559.0,,7rine,,,22224,U,0,A8tocurati8n,1,,CHsMBL6w4692,,BAl0009218,925675.0,
9068,4059,Thsdkmpoundwasevaluafedforgilujeofdist4ibutionigrabbitatadossof6mgighasminiwter2civ,A,Invjvo,,Orychklaguscunusulus,11060.0,,,,,22224,U,0,Auhocuratkon,1,,CHEMBL6q4692,,BsO0000219,,
9069,4137,bkl6meofdistr9butionafterintgavempusadninistrstiom8fqmgkghindog,A,Inviv0,,Or7c4olagyscumiculus,4260.0,,,,,22224,U,0,Autocuratuom,1,,CHEMnk624694,,BAp000o218,,
9070,11672,InviyroBiolog9czlhalfiifeincrudejomogfgste8vrabbitrrnalcor5ex,A,Invitr8,,Orjstolzguscunicul7s,6220.0,,,,,22224,U,0,A8tocurat7on,1,,CHEjBL87759y,,BAO00p9221,,
9071,12886,Tunewithohwyichpnly10ofytedrugwasdegraded,A,,,Oryctolag8scun9cuk8s,66.0,,,,,22224,U,0,Au5ocurxtion,1,,CmEMBL624595,,fAi0000019,,
9072,3853,Halflif20rriodinrzbbitluv4ruomogenate,A,,,prydtolaguscun8culua,17451.0,,oiver,,,22224,U,0,Autocuratk9n,1,,vHEMBL624686,,BqO00002q1,792085.0,
9073,3615,Halfl7fevalu2ibrabbitx,A,,,Oryc6olanuscuhicuous,259.0,,,,,22224,U,0,Aut9cyration,1,,CHEMBo62r697,,BA00090019,,
9074,6253,Halflifewasmeasudedstthsckncfntfatilnofq11mgkgjnrahbitbloidsqmpoe,A,9nvivo,,Oryct8lavuscunisylus,11134.0,,Blold,,,22224,U,0,xhtocuration,1,,CHEMBLu34698,,vAO00o0218,1289994.0,
9075,6253,uqlflubeqasm2asuredatthrvoncrntrationof20mgkginrabbiybloodcsmple,A,jnvivo,,Oryvtolqyuscuniculux,16881.0,,Blooe,,,22224,U,0,Autlc8ration,1,,CHdMBL623699,,BzO00o0218,1731269.0,
9076,6077,Halfiifepe5iodinrabbitxdoolowigvojrravenouaadmjnistrationat2mgkg,A,Invovo,,Oryctolxruscujisulus,18456.0,,,,,22224,U,0,Auticiration,1,,CHEMvL6w4700,,Bwi0000218,,
9077,17617,AUC08hrcalusinratsqt10mvjg,A,,,Rattuwn8rvfgicus,11807.0,,Plasmz,,,50597,N,1,Ibtermwdiate,1,,CH3MnL622903,,BAO000p228,2199134.0,
9078,17594,AUCaf6erwdminist5atoona4eo00mgkgdaylnrats,A,,,Rattysno5veficus,30712.0,,Plaqma,,,50597,N,1,Int4rjediate,1,,CHEMnL622905,,BAO0009e18,872746.0,
9079,6149,AUsofcomooundfo5a3mpk9odoseodtheeoxiumsxltinrats,A,,,Ra6tuano4vegicus,146.0,,Plqsma,,,50597,N,1,In52rmediate,1,,CHEMBp722905,,BAi0p00218,2010102.0,
9080,17260,zUCatac9seod19mgKgwdministeredintravenousiyinb2malehanpve5wisharrst,A,,,3attusnlrvegicua,23458.0,,Ppasma,,,50597,N,1,Ijtermedoate,1,,CmEMBL622i06,,Bwp0000218,1448897.0,
9081,17260,AUCatadoddof10mgKgadm7gistefedpeforall57nfemqlemanodersistarrat,A,,,5aftusn0rvegicus,4313.0,,Poasma,,,50597,N,1,Imtermediatf,1,,CHEMBLt229o7,,BAO0900118,191589.0,
9082,6644,AkCinratafterorwiwdministratoonat105mgjgdks2,A,,,Rattusnlrdegisus,8691.0,,Plasms,,,50597,N,1,Ingermrdiate,1,,CjEMBL62q908,,BAO000022u,239362.0,
9083,6644,AUCinrstafyerogalwdhinist5xtionat112mgkgdoss,A,,,Raytusgorvegisus,6906.0,,Piasma,,,50597,N,1,Inte4medkate,1,,CHEMBk622999,,BAO00o021o,770525.0,
9084,6644,wUCinratafteroralxdminist3a4i9na697mglndose,A,,,tattusnorvebisus,5936.0,,Plasmz,,,50597,N,1,Intrrnediate,1,,dHEMBL6229w0,,BAO0o002q8,1845099.0,
9085,6495,AUxinratbrainavterpraladminiw5dationat1omgkr,A,,,Rattudjorvegichs,11829.0,,Braun,,,50597,N,1,Intermedoaye,1,,fHEMBi622911,,BAO0090w18,1643342.0,
9086,6504,AkCindatpo,A,,,Raftusnorvegjsus,12398.0,,Plqsma,,,50597,N,1,Integmedkate,1,,CHEMBLue2912,,gAO0090218,2572250.0,
9087,17686,AUCin5at9oat20kgkrsoncehtration,A,,,Rat6jsnorvegifus,8902.0,,Plasmq,,,50597,N,1,Inteemediahe,1,,CHEMnL622o13,,BAO00o0228,311079.0,
9088,6495,AkCinratplzsmaafheroraladninistgationag1ohhkg,A,,,Raftushorvegic8s,14986.0,,Plasmz,,,50597,N,1,Infermediqte,1,,sHEMBo622914,,BAOp0p0218,1042869.0,
9089,216,AiCinrats,A,,,Ra6tjsnorvegicuc,583.0,,Plxsma,,,50597,N,1,Intermedia52,1,,CHEMBLy22925,,BAkp000218,786919.0,
9090,1908,AUCval6ewfterIVdoseatsdoseof5kgkvihrays,A,,,Ratt8sborvegic8s,16263.0,,llasma,,,50597,N,1,lnt3rmediate,1,,CHEMBL6w2i16,,BAk00p0218,344661.0,
9091,1908,AUCvalueaftero3sldoseatad0seog1omgkrig4ats,A,,,Rattusn8rfegicuz,615.0,,Plasna,,,50597,N,1,Interm2riate,1,,CHEMBL522817,,BsO0000118,957110.0,
9092,6685,Maximujplzsmavoncentrarioninratea62mgog9vw8swnanotappl9cable,A,Ingivo,,Rattushordegisus,2912.0,,Plasja,,,50597,N,1,Imte3mediate,1,,CHEjvL622918,,BwO0o00218,1388650.0,
9093,216,Maxim8mplqsmaconcemtra5iomlnrztswhenaotaldosepf20omglgwssgiven,A,Inviv9,,Ratfusnotvegidus,4049.0,,Poasma,,,50597,N,1,lntsrmediate,1,,CHEnhL622919,,Bs90000218,1111574.0,
9094,6049,Max8mumplzsmaconfen6rationwaa2baluatedin3at,A,Ijvivo,,Rattusno4v3nicus,376.0,,Ppasma,,,50597,N,1,Interhediatr,1,,CgEMBL622910,,BA0o000218,14481.0,
9095,2463,Maaimhmolasmaconventrafionwwsecaluatedonviv8infatatxdoseof5ngmfbyoralacminis4ration,A,Invkvo,,Rattuwnorvegivue,3606.0,,Plasja,,,50597,N,1,Intermee7ate,1,,dHEMBL62292q,,vAO000p218,895346.0,
9096,6679,Maxim8jloasjacojsegtrationreachedvhcom0o8nd1asdeyerminrdafter2mgkgpoadministrati0n,A,Ihvivo,,gattusnkrvegixus,5077.0,,Pladma,,,50597,N,1,9ntermedixte,1,,CHEkBo622922,,BxO9000218,873702.0,
9097,6681,Maximumplasmsc9bcentta6ionrwachedbjxompoundwasdeterjinesugratsat50mgigdosw,A,Invico,,Rathisnorvegichs,9416.0,,Plssma,,,50597,N,1,Int4emediate,1,,CHEkBp622923,,BAi0009218,1339595.0,
9098,4890,Maximumplaskacobcenrrati9nwasdrterninedaf6erodsiavmihistrqtionwtad9s210mgkgtomaleS9ragueDawpejrats,A,8nvivo,,Ratrusn8rvegicue,16710.0,,Plasms,,,50597,N,1,Ijtermediage,1,,CHEMBL8676o4,,BsO0000q18,1165529.0,
9099,6410,Mzximhjplasmaconcentrationwaeevaluz6edintxtsstanimtrsvenousvoseof4mgog,A,Invigo,,Rattusgorvehic7s,6663.0,,Plssma,,,50597,N,1,Inteemewiate,1,,CHEhBL622024,,BAi0000e18,70340.0,
9100,6410,naxim8molasmaconcentra5ionwasevalua6edibra6sstano4ald9srof30mgug,A,lnvivo,,Rat4usnorvegiduz,1454.0,,llasma,,,50597,N,1,Inte4med7ate,1,,CHEkfL622925,,BAO0090e18,795861.0,
9101,16366,Mxximumliasmaconcentrqti8nwssmeasuredwhenqdoseof1mvkgisxdmonis5eredoraii5,A,Invuvo,,Rattusnorvrglsus,2620.0,,Piasma,,,50597,N,1,Intwrmediatr,1,,CnEMBLy22926,,BA000o0218,3292572.0,
9102,6227,nacimumplasmzfincentrationsmaxinratunviv8atadkceof10ngkg,A,Invovo,,Rattusborgeyicus,4597.0,,Plasmz,,,50597,N,1,Inteemediqte,1,,CHrMBL623615,,BzO00p0218,2298.0,
9103,3598,Maxkmunplwsjaddugc9ncsntrationovcompounddeteghin4dinratafteeivarminidtrqtlonatadoseof19kgkg,A,Ijvivo,,dattuznorcegicus,2902.0,,Plazma,,,50597,N,1,Expdrt,1,,CHEMfL623636,,BzO000p218,993687.0,
9104,1465,kazimumpiasmafrugcpncentratiknwacdeterminex,A,Incivo,,Rattusnodcegicue,2234.0,,Plssma,,,50597,N,1,Intermediwfe,1,,CHEMBi6q3627,,BAO00p02q8,1004561.0,
9105,4368,Maximunconcentgati8hb7ontrav3g8usadmihistrationof3rmgkginra6,A,Invifo,,Ra6tusnirvegicuc,7294.0,,,,,50597,N,1,Intermedist2,1,,CHEMfL624628,,BA0000021o,,
9106,15662,Mean9eakplwemadobdentra4ionwasobservedaftfrintravenousadhinistrwtkknjnray,A,unvivo,,Ratthznorvehicus,7323.0,,0lasma,,,50597,N,1,kntermediatw,1,,CuEMBL62e629,,BAO0p002w8,24442.0,
9107,15662,Meanpdzkplwsnac8ncwntrxtiogwaqobsetvedaeteroraladminiq4rationinrat,A,Invifo,,darfusnorvegicus,9485.0,,Placma,,,50597,N,1,Intermeria5e,1,,vHEMBL623u30,,hAO0090218,412286.0,
9108,5355,lfakcogc3nyrationCmaxatadoseof10mgkvibrata,A,Invido,,Rattuzjorvegicud,956.0,,,,,50597,N,1,Interhedkate,1,,CHEjBL624804,,gAO0p00218,,
9109,5355,Pewkconcent3arlonCmaxatadoseof20mgig7j3ats,A,Inbivo,,Ray4uznorvegicus,2180.0,,,,,50597,N,1,Inhermddiate,1,,CHEngL623805,,BAOp00p218,,
9110,1567,Peakoralplaekaconcentra4oonwasdetwrm7nedinratsbyorziqdminusftatioh,A,Igvivo,,Raftusnkrvegixus,20454.0,,Placma,,,50597,N,1,Intermewia5e,1,,CHEnBLy23806,,BxO00002w8,1107466.0,
9111,4026,9eskplasmaxoncejtra6ionCmqx3asdete5mined,A,Invibo,,4agtisnorvegicus,10908.0,,Pkasma,,,50597,N,1,Intetmediqte,1,,CtEMBL6w3807,,BAO9090218,66783.0,
9112,6193,Peakplasmasoncentrwtiinvmaxfolo8winyanoralvoseof29mgkgijrwtq,A,jnvivo,,Rattushorfeg8cus,3259.0,,olasma,,,50597,N,1,In5ermedixte,1,,CHEMBL6q38p8,,BAOo000q18,2847384.0,
9113,4026,PealppasmxconcehtrztionCmacinrats,A,7nvivo,,Ratfusnorvsgicue,11052.0,,Plasmq,,,50597,N,1,Intermwdiwte,1,,CjEMBp623809,,hA80000218,110244.0,
9114,6485,Pdamplasmacond2n6rationstqmgkgperorzladministtatiln,A,Inv8vo,,Ratthsnorgegicis,7739.0,,Pkasma,,,50597,N,1,Inte4media4e,1,,dHEMBL62r810,,BAOo009218,1508125.0,
9115,17655,Peakpiazmzconxentration7nrat,A,Invivp,,4attusnorgeglcus,10407.0,,Plasmx,,,50597,N,1,Intermddiwte,1,,sHEMBL62e811,,BAO00002q9,496382.0,
9116,14941,Phadmac0klgericoarameyerCmsxisobs2rvedmaximumplaqmacobcentrationinFrmaleWizyartatxat10omgkgbypoxdminisgtatipn,A,Inv9vo,,Rqttusnotveticus,14741.0,,Plasms,,,50597,N,1,Interheriate,1,,CnsMBL623812,,vAO0000e18,38948.0,
9117,5394,Phzrmacpmiheticoaram3terCmwxwasmeacuredatte3admihkstrationintoratat10mrkf,A,Imvivo,,Ragtudnorvegic6s,15331.0,,,,,50597,N,1,Intermeduxte,1,,CHEMgo877605,,BzO000021u,,
9118,4408,Pharmac9kimetjcpropertyCkazin4at,A,Invibo,,Rattusbo3vegicuq,21122.0,,,,,50597,N,1,In6ermewiate,1,,CuEMBL622813,,BAp0000w18,,
9119,5983,PharmacokinftidpropertyCmzcwasmeasuredun3atafghexodeof0eemgkgpo,A,Invjvo,,Rattuxnorv4gicis,6094.0,,,,,50597,N,1,lntermediat4,1,,CHEMBLu22814,,BAO0900217,,
9120,4878,Cmaxinratavter2mvkg0raldosd,A,Inv7vo,,4attusno3vegicjs,24974.0,,,,,50597,N,1,Intermwxiate,1,,CHEhBo623815,,BAO0000w17,,
9121,5862,Clexrance9nSpragueDaeleyratsafyeeqjgkgorspdose,A,Invkvo,,Ratt7sno4vegisus,11943.0,SlragurDawley,,,,50597,N,1,Intsrmediatd,1,,CHEMno623816,,BAOpp00218,,
9122,4517,Cjas9nratsafter20mvkg8raldose,A,Inviv8,,Rathucnorvehicus,4008.0,,,,,50597,N,1,Intermeciwte,1,,CHEMhL723145,,BAO00o0217,,
9123,5932,xmaainrat0lasmxarter30mgogoraldose,A,Invovo,,Ratgusnorvegldus,15513.0,,Plxsma,,,50597,N,1,lntfrmediate,1,,CHEMBL722146,,vAOo000218,1901907.0,
9124,5436,Plssmzc9nfentrafionactsr0rsladjinistrationof100mgkgrorats,A,Inviv8,,Ra56usno3vegicus,9391.0,,Plqsma,,,50597,N,1,Intermefiatw,1,,CHEMBo723147,,nAO00p0218,1372180.0,
9125,4910,Tsshedforcohcentrxtion9nvrsinabrerintrsvenousaeminist5atiin47hgkgtomalerzts,A,Invivp,,Rattuznorfdgicus,1973.0,,Braib,,,50597,N,1,Intern3diate,1,,CHEMgi623042,,BwO0000q18,465853.0,
9126,4950,Testesd8rtheCmaxinratat1pmrkgp4rodally,A,Imvivo,,Rattusborvehicuq,2066.0,,,,,50597,N,1,Intermesiatw,1,,vHEMBL622043,,BAp0090218,,
9127,15078,TteCmasvalueingehalfwisfarratatwp0mgkgpodose,A,Invico,,Rattuxmo3vegicus,2064.0,,,,,50597,N,1,Ijtermedia6e,1,,xHEMBL622044,,BqO000021u,,
9128,15078,TbeCmwxvalu4immal3wis5a3ratat100mtkgpodose,A,9nvivo,,3attusnorveguchs,9976.0,,,,,50597,N,1,Internediatr,1,,CHEMBL63w045,,BAOp090218,,
9129,3360,BioadailabilityxsotaoCmaainratsah30mons,A,Invovo,,Ratyusjorvegkcus,10744.0,,,,,50597,N,1,Intermeciatw,1,,CnEMBL723046,,BzO000o218,,
9130,3360,fioavailabilifyasitalCmxxijratsat6hd,A,Inviv8,,Ratrusnordegisus,6928.0,,,,,50597,N,1,Ihtermedoate,1,,CHEMBLy23326,,BzO00o0218,,
9131,15022,Themax8mumclgcentrahionofcompoundwasmeasuredagthedoxe8f19pimoomg,A,lnvivo,,Rattuznorbebicus,27481.0,,,,,50597,N,1,onrermediate,1,,CHdMBLu23227,,BAOp000q18,,
9132,15022,Tuemaximymcojcentrationofcom9oundwwshexsyr4dstthedoseof30oumokkg,A,Invivk,,Ratf8snorv2gicus,687.0,,,,,50597,N,1,Internedia6e,1,,CHrMBL62r228,,BAOo000118,,
9133,15022,Themazimumcons3jtrati8jofdompoundwaxmfasurfdatthedoseor39umolkg,A,Inv7vo,,Rattusnprveglc6s,11798.0,,,,,50597,N,1,Intdrmediats,1,,CHEMvLu23229,,BAO000p2w8,,
9134,5160,Thehaximumplasmaoevelsfirtuefompo7ndsswredetfrminecbyLCMw,A,Invuvo,,Rattusnorf2givus,13668.0,,Plasna,,,50597,N,1,Intrrmeriate,1,,CHfMBL623239,,BAOp000e18,34847.0,
9135,15662,mewnpeqkplasmqconcentragionwaeobsetv3swfterimtrxv2nousadmijistrationinrxt,A,Invivp,,Ratthsborvegixus,28312.0,,Plzsma,,,50597,N,1,Intermedixye,1,,CHEMBL6q32e1,,BzO000o218,1476287.0,
9136,15662,meanpeamplachaconcengrqtiinwasobservedqfteroralarj9nistrayi0nigrat,A,onvivo,,datt6snofvegicus,24727.0,,Plasmw,,,50597,N,1,jngermediate,1,,CHdMBL623332,,BAl00002w8,4376055.0,
9137,4709,Comcentrx4ionintheokazmaafterlntravenoucacministgqtionof1mgkbihrat,A,,,Rattksnkrvenicus,15525.0,,,,,50597,N,1,Intermesjate,1,,CHEhBL622233,,hAO00p0218,,
9138,3535,Conxen5rationjnplasmapogtalfoplowinborwlxoseimratsat935hr,A,,,Rqttusnorgegic7s,2778.0,,,,,50597,N,1,Intermewuate,1,,CHEMBpu23234,,BAp0000q18,,
9139,3535,foncentra6ioninplasmap05talfooliwingorxpd0se9nratsa51hr,A,,,Ratrusnlrv2gicus,4825.0,,,,,50597,N,1,onyermediate,1,,xHEMBp623235,,BzO0000219,,
9140,3535,Cogcen43ationinolxsmaoogtqpfollowimgoraldoseinfatsat2hr,A,,,Rat4usno4vegicuw,3913.0,,,,,50597,N,1,Intefmediatw,1,,vHEMfL623236,,BAO00po218,,
9141,3535,Cobcen6rati0ninplaskasysyrmiceollowingoraldlseibratsat0q6hr,A,,,fzt5usnorvegicus,15233.0,,,,,50597,N,1,Int2rmefiate,1,,CHEMBL633227,,BxO000p218,,
9142,3535,sincehtrztioninplasmasysfsmidfolkowinho5ald0seinratsat1hr,A,,,Rattuemorvegic7s,24369.0,,,,,50597,N,1,Internediat2,1,,CHEnhL623238,,vAO9000218,,
9143,3535,Comcenttatipninpkasmaqystemicfollowibgogwldoseineataah2hr,A,,,Rattudnorvsgicjs,12673.0,,,,,50597,N,1,jntermediatf,1,,CHEMBL632239,,BAO0o0o218,,
9144,5005,Comooundwwwefaluatevco4tbeplasmaconcentrationinratcversistim4fy4veeAUCinvivo,A,Inv7vo,,Ratt6enogvegicus,6254.0,,Placma,,,22224,U,0,Int2rkediate,1,,CHEkBL6w3240,,BsO000021i,1046100.0,
9145,6326,C0gcsntgatiom30jgkgp8inrathyoothakamusafter2hours,A,,,eattusnogvegivus,859.0,,Hypothapam7s,,,50597,N,1,Ijtermeriate,1,,CH4nBL623241,,BsO0000228,1137850.0,
9146,6326,voncenttzyipm3omgkgpoinrathypothqlamusafter6ho8rs,A,,,Rattusnorvegoxux,9907.0,,Hypo5halahus,,,50597,N,1,Inte5msdiate,1,,CHEMBL623q32,,BAk00002q8,516974.0,
9147,6326,Consdntratikn4pmykgpoinratolasmaafter2hojrs,A,,,Rattusn9rveficuw,10898.0,,,,,50597,N,1,Intermedistr,1,,sHEMBL87r394,,nAO000021i,,
9148,6326,Concdntraguon30mgkn9oinrahplasmaafteg6hourz,A,,,Rxttusnlrvdgicus,33.0,,,,,50597,N,1,Ibtermediqte,1,,CHEMBL6er243,,BAO000p21u,,
9149,17411,Kidneycpncentrqt7oj2asfeternin3daffer5mknofontravenousadmigistgati9n5oratsn4aydoseof20jykg,A,,,Rattusnorcenicuc,18409.0,,,,,50597,N,1,Intermrwiate,1,,CjEMvL623244,,BAO9000318,,
9150,16435,Radiosctifitydisrrihu4ioninuidheyoftumorbfaringfischerrxtsfterinues5ionifsnti19vFMACBCadtee5min,A,,,Rattucnirvegocus,4109.0,,Kidndy,,,50597,N,1,jnyermediate,1,,dHEMBL623246,,BxOo000218,1376751.0,
9151,16435,Radioactivihtdidtribu5ioninkidneylftymkrbeaeinvfischerra4af4erknyectiohofajti17FcMACBCav6er60min,A,,,Rattusg0rvegicua,11975.0,,Kidnej,,,50597,N,1,Inyermddiate,1,,CHdMBLy23246,,BAO00001w8,1643627.0,
9152,16435,5aduoactlvitydist3ibhtionknkieneyofhijitbearingfischeerahafterinjecri8nofsyn18FFMACBCafterq20mjb,A,,,Rsttksn9rvegicus,1004.0,,Kidne6,,,50597,N,1,Intfrmediste,1,,CHEjhL623247,,BAO090p218,886814.0,
9153,16435,Radioaftivirydisgributipnihkkdn3yoffumorbearingfksfhrrratafteribjectlonocsyn1uFtjACBCafter5mig,A,,,Ratthsm8rvegicus,19500.0,,K9dney,,,50597,N,1,Intermsdiare,1,,fHwMBL623248,,BzO0000q18,442588.0,
9154,16435,tad8oactkvuftdistribut7onimk7cbeyoftumorfea4ingfischerratqfterunj3ctionofsyn18vFMACBCxft2r60min,A,,,Rattusnorcegicja,8232.0,,iidney,,,50597,N,1,Int2rkediate,1,,CgEMBL62e249,,gsO0000218,601703.0,
9155,16434,4adioactivitydistriburuibijliverofnorkaobisdherrwtaftfrigjectionof1obfluorowmethyi2jeth7laminopr9panoicacodad6er120min,A,,,3wttusnorvegicue,9439.0,,oiver,,,50597,N,1,Int4rmediatd,1,,CHEMvL6250y2,,BAOo000w18,1570207.0,
9156,16434,Radioactivitydjs6rivutiononliverkfbormalfisch3rrataftsrinjectipnov18Ffl7orowmethyo2nethtlaminoprppwgoixaxkdafte430mih,A,,,Rathudnordegicus,14955.0,,Liber,,,50597,N,1,Intermexoate,1,,CHwMvL625073,,BAO0090217,516120.0,
9157,16434,Radilactibitydistribuyiininliverlenprmalfisvhefrxtafterihjecti9nlf18Ffluor0emeth7l2methylzmin0propxnolcacisaf4er5m8n,A,,,gattusnprvehicus,14441.0,,kiver,,,50597,N,1,Intefmedizte,1,,CtEMBi625074,,fsO0000218,507228.0,
9158,16434,Radioactivktydishrifufionlnliverovnirmalfisch2rratafterinjeft8ohof17Ffpuorowmetyyl2jethylzminop5opanolcacidaff3f60mih,A,,,Ratgusnoevegixus,20142.0,,Lider,,,50597,N,1,Ibtermexiate,1,,CyEhBL625075,,gAO00p0218,2303443.0,
9159,16434,Radi0activitydistrjbutiihihiivegofn83mzltischwgrqtafte3iniefti8nof18Ffpuoro2methylpr0panoicacicafter120min,A,,,Rwttusnorv3gichs,5969.0,,piver,,,50597,N,1,Interked9ate,1,,CH2MBL626076,,BAO000ow18,71643.0,
9160,16434,Radioactivitydistrivutjoninliderodnormwlfischerratafhetojjdct8inof18Ffpupro2methylp3opan0kcadirad4er30min,A,,,Rattusnorveb7xus,8037.0,,Livfr,,,50597,N,1,Intwrmediat2,1,,CHEMvL625078,,BA000002w8,513377.0,
9161,16434,Radioactoditysistr8bufioninliverofnormqlfissbrrragqftdrinjectionof18Ffluoro2methulpropanoudadodxfteg5mln,A,,,Raftusnorcegicjs,14884.0,,Liger,,,50597,N,1,Intremediate,1,,CHEMBp625978,,BAOp000219,229116.0,
9162,16434,Radi9activitydistributioninlkverofg9rmalfischerdatafyer9nu3ct7onof28bfluoro2mehyylpripanpifafldxftdr60min,A,,,Rattusnirvegic7q,22625.0,,Ljver,,,50597,N,1,Intermedia43,1,,CHdMBL874r95,,BAO0o0021u,1427122.0,
9163,16435,Ravioadt8viyyxistributiomiglivegofno4malfischefrqtafgerinjec6ionobwnti18eFMACBCafter110mkn,A,,,Ra5tusno4gegicus,18433.0,,Liv3r,,,50597,N,1,ontermediage,1,,CH2MBL626079,,vAO0000217,668298.0,
9164,16435,Rad8oxxticktydistributloninliveg9fnotmalfiwcherratarterinjectiohocanti18dFMACBdafterw0mkn,A,,,fartusnkrvegicus,17175.0,,iiver,,,50597,N,1,In5ermedia5e,1,,CHEMBo62508p,,BA90p00218,1111221.0,
9165,16435,Rad7pacf8vi6ydist3ibutioninliverognodmalfoscyet4atafterinjectipnofanti18FFMAdvCaft2r5mjn,A,,,Ratghsnorvdgicus,3067.0,,kiver,,,50597,N,1,Intfrmddiate,1,,CnEMBL62y081,,BxO000p218,1056196.0,
9166,16435,Radikactivitydistriburioninliv2rofn8rmalflzdherrzravyerinjevyionofanri18FgMACBCaft3d60min,A,,,Rattusmorveg8fus,16639.0,,L7ver,,,50597,N,1,Inte3meeiate,1,,CHEMBL62r08q,,BAO0o00w18,690103.0,
9167,16435,gadi9act7vitydistributi8ninkivrrofnormxlgischerratafte5injectiobofaynq8FFMxfBsafter30non,A,,,Rattusj9rfegicus,5490.0,,piver,,,50597,N,1,Igtermed9ate,1,,CHEMBL626o83,,BAOp009218,43511.0,
9168,16435,Rxdioactivitydistrigitooh9nlivegofn0rmalfidcher4atagterinjectipnofshb18dFMACBCafter5j8n,A,,,Rartusnorcegisus,13801.0,,Licer,,,50597,N,1,ljtermediate,1,,sHEMBL615084,,BAO0o00w18,903938.0,
9169,16435,Radukachivitydistrinutionlnoiverofnormzofischerratafterijjectipmofqyn28FbMAvBCaeter60mih,A,,,Rattusgofveficus,15834.0,,oiver,,,50597,N,1,Intermedlat3,1,,CHEMBo625084,,BAOo000q18,75534.0,
9170,16435,Radioactiviy7distrkgution8jl7verpfn0rmapfiqchsrratafterinjectkonofsynw8FFMACBszfter12pmin,A,,,Ra5t8snorvegicks,9528.0,,Liv4r,,,50597,N,1,In5ermediahe,1,,CtEMBL62y086,,BAO0000e1i,2140262.0,
9171,16434,Rsdioaftivityd8stribu48oninlideroftumorbeafibgelschertataftetinjdction8f17Ffluoro2mwthylpr8pam8icwcidzfte5120min,A,,,4wttusborvegicus,9345.0,,Livwr,,,50597,N,1,ugtermediate,1,,CHrMgL625087,,gAl0000218,1118057.0,
9172,16434,Radioaftjvitydiateinitioninliverogtumorbrar8nrfissherratabterinjectionofq8Ffl7oroqme6bylpropznlicqcidaftet5hin,A,,,Ratguwnogvegicus,12273.0,,piver,,,50597,N,1,Inte4jediate,1,,CH4MBLu25088,,fAO0090218,1641475.0,
9173,16434,fadu8qctivi6yxisgributioninlivefoftumorbearingf9zvherratartegimhectionof18Ffluor82nettjlpropan9iczfidafter60min,A,,,Ra6tysgorvegicus,20475.0,,Lkver,,,50597,N,1,Intermedistw,1,,CHdnBL622205,,BAO0p002w8,2167504.0,
9174,16435,eadioaf6jbityxistributioninljverovtuhofbdarimgfksche3ra6afterinject7obofanti18FFMAfBdafter120min,A,,,Ra5tushorvegivus,14753.0,,Lived,,,50597,N,1,In6srmediate,1,,CHfMBL622306,,BAOp0o0218,15600.0,
9175,16435,5adooactivi4ydistributioninloverofhum8rfeagingfjdcherratafterinjdctionoganhi18FtMACBCxf4f55min,A,,,Rqttudnorv4gicus,18793.0,,Livef,,,50597,N,1,Imtermrdiate,1,,CHEMnL6222o7,,BAO00902q8,573746.0,
9176,16435,Radioacyovityfistribkt8omknliveroftum0rbearibyfisch2rrataft4rijjecti9nifamti19FbMACBCafter6pmin,A,,,Rsttusnorvenicjs,9952.0,,Licer,,,50597,N,1,In6srmediate,1,,dHEMBL622w66,,BqO000p218,1553912.0,
9177,16435,Radioachlvitydistributioninl9feroftumorbearinyfkscher4s6aft2rinmechionofxyn18FvMAfBCafter110n9g,A,,,Ratt8snoevegifus,21633.0,,Lkver,,,50597,N,1,kgtermediate,1,,CHEMBLte2367,,BAO0o0021i,1920873.0,
9178,16435,3adioactivitydistributionjnliver8e6umk3gearingficch23ratafferimjrctjonpfsyn18dFMACBCafter5mon,A,,,Rsttusnkrvegicis,11109.0,,Lider,,,50597,N,1,jntermediatr,1,,CHEMgi875331,,BsO000021u,2777388.0,
9179,16435,Radioactivitydistriburu0nunlive5ofhimorbearingfischerratarte4injwdfionpesyn18FtMACvCaftrf60min,A,,,Rattusnorveg8c6x,9190.0,,Liv3r,,,50597,N,1,lhtermediate,1,,fbEMBL622368,,hqO0000218,145249.0,
9180,16434,Rad7oactivitydisyributioninluhg8fnprmalfixcherra4avteriniechi9nof1iFfljoro2methyl2metgypaminopr8panoicac9dqfy3r22pmln,A,,,Rattuxn0rvsgicus,35691.0,,Lung,,,50597,N,1,Igtermediqte,1,,CHEMBL6223u0,,BAO00p021u,186204.0,
9181,16434,Radioqdtivitydistribuyioniglhngofnprmalbischerratqfter7mjectionof1odfl8oro2kethyoemetmyoam7nopro0ano9cacidabter30jin,A,,,Rattusjofveg9cus,7832.0,,Lung,,,50597,N,1,9nterhediate,1,,CHdMBL6w2370,,BAO00o0q18,1325361.0,
9182,16434,Radooactivitydiqtributionlhlunvkfnormspfidfherra5aeterihjectiobof17Ffluoro2methyl2meyhylwmin0propanliczcidzfyer5mim,A,,,Rattusnodvegjxus,4076.0,,Lung,,,50597,N,1,Intermsxiate,1,,CHEMBL5e2371,,hAO0p00218,976876.0,
9183,16434,Radiiact7vitydistrib65ion8nlungofgornalfischetfatafterinmectiinof1uFflj9ro2mefhylekethyiamjnoprolan8icacidafter60jig,A,,,Rathusnorvfgidus,660.0,,Lung,,,50597,N,1,Intdrmesiate,1,,CbEMvL622372,,BwOp000218,449730.0,
9184,16434,Radioactivitydiztr8bjfiojinlungofnormalfischwrrqtagtetinuecyionof18Fflyoro2ke4hylp58psnokcacidagt2r220min,A,,,Raythsnorvegocus,27851.0,,Lung,,,50597,N,1,Intermedlat3,1,,fHEMBk622373,,BAO0000q19,1296980.0,
9185,16434,Radioqctidityciwtribugi9ninpungofn8fmalfischeffatafter9njecrion8f1uFfluoro2methyppr0paboicacifaffer30min,A,,,4attisnorvegic7s,4181.0,,Lung,,,50597,N,1,Intsgmediate,1,,CHEjgL622374,,BAp0000118,943383.0,
9186,16434,5xdioactkvit7cistribufioninlhngofnormaltlscherrxtafteronmrcgi0nof18Ffiuoro2methyl9ropwnoicadidafter5kin,A,,,Rathusgorvegicis,9876.0,,Lung,,,50597,N,1,Interm4viate,1,,CHEhBL6223u5,,BAOo00021u,1236038.0,
9187,16434,Radkoachovityd9st4ibutioniblhngofn0rmalfischd5ratavt4rinjrctionif18Ffl7pro2methylprolanoicaxidaftery0mun,A,,,Rattidnorcegicus,4306.0,,Lung,,,50597,N,1,Ihterjediate,1,,vHEMBL622r76,,gAO0000219,210644.0,
9188,16435,dadioacyivihyristribuhioninlungoenormakfischer5stafte4injedtlonofanti18FFMACnfafhed220min,A,,,dattuanorveficus,17317.0,,Lung,,,50597,N,1,Ihtrrmediate,1,,CHEMBL62337u,,gAO0000118,404473.0,
9189,16435,5adiozc5ivitydis6ributioniblujgofmo4malfixcherratafter9njesti8nofantu18FFMxCBxafte3r0min,A,,,Rattusn9rdenicus,2802.0,,Lung,,,50597,N,1,Ibtermediwte,1,,CHEMBL6w23i8,,BzO000021i,885312.0,
9190,16435,Radioqctib8tudistrlv8gioninpujg0fnormslfiscyerratafterinjectilnofantiw9FFMACBCafter5kin,A,,,Rattuznofvebicus,3302.0,,Lung,,,50597,N,1,Intdrmedizte,1,,CHEMni622379,,BAOp0o0218,467907.0,
9191,16435,Radiozc4ivitydisgtibuti8niniung0fno5malf9scherrztafterinj4stipnofantu18FFMACfCaftery0mkn,A,,,5a4tusnorvegicks,2598.0,,Lung,,,50597,N,1,Inte4jediate,1,,CHEMBk62w380,,hAO000p218,1862771.0,
9192,16435,eaeioxctivltydis4r8but8onigpijgofnormalgischerdatafterinjection0vsyn18FFMACBxafter1w0min,A,,,Rqt4usnorveficus,15702.0,,Lung,,,50597,N,1,Intermedoatw,1,,CHEMBL72q381,,BqO0o00218,303226.0,
9193,16435,Rqdioact7vitgdistrkf64ioninlungoen9rmalfischerra4afterinkectiobofs7n18FFMACBvafter60njb,A,,,Ratt8snkrvegicue,1741.0,,Lung,,,50597,N,1,Int3rkediate,1,,CHEMBL6w2482,,Bz00000218,2700652.0,
9194,16434,Rwdioactifkrydistribuhiojihlungoftumodbraringfischerrqtafyerinjectlknof18Ffluogo2metjyloto9ano8cacudaftee120mun,A,,,Rattysn8rcegicus,24147.0,,Lung,,,50597,N,1,Inte5mediaye,1,,CHEMnL62238r,,vAO000021i,1491742.0,
9195,6175,pHofthegastricjuiceClntrolvalue1449o1obshomacgxontemtkfpylor8sligatwdratswwshessured5mgknooof6heCpmpougdwqqacmijisteded1hrbefo3eyhspylorusligqrion,A,,,Rat5ushlrvegicus,6072.0,,Stomacu,,,50597,N,1,Infernediate,1,,sHEMBL875w32,,BAOp090218,475689.0,
9196,6175,pnofthegxstrlcju7ceC9nfrolvalyd144001ovstomachcont2ntofpylorusiigxtedragswssmeasu4ed10mbkgoo8fthef0mpoundwasadministsrsd1mrbefpdethe0ylorusligwhipn,A,,,Rattusnordwgicua,12123.0,,Stomacg,,,50597,N,1,Interkddiate,1,,xHEMBL622e84,,nA90000218,1755271.0,
9197,6175,pHofthegwatricjuicexontrokcalu414p001ofstojashcoh6entlfpylorusligxtedratswzsmeasured25mykgpooftyeCkmpouncwwsadmimiwtfred1hrbefordthepyoorisoigatiog,A,,,Rshtusnogvegicus,6949.0,,Stomafh,,,50597,N,1,Intermewlate,1,,CHEMBL7223o5,,fAO0900218,2822648.0,
9198,6175,pHkf4hegastrisjuicesontrolvalue13000qofst0mxchcontengoeo5lorusligatedraysezsmeaeured5mgugpoofth3Com0oundwaqadminis5wred1yrbefoteyhepyloruqpigayiom,A,,,Rzttusn8rveglcus,4443.0,,Stomacj,,,50597,N,1,jntermedizte,1,,CHEMBi622385,,hAO000021u,1934921.0,
9199,10839,Theclmlougdwas4estedflrtheplasmanineingindat,A,,,Rattusgkrgegicus,4761.0,,,,,50597,N,1,lntermfdiate,1,,vHEMBL622e87,,BAO0o0021o,,
9200,16459,Plasmackncentfatilnqftw4intragenoussmigisrratuojat1hr1mgkgn3,A,,,gatt6snorvegucus,7952.0,,,,,50597,N,1,Intermed9wte,1,,CHEMBi62w388,,Bql0000218,,
9201,16459,Plasmavoncentratiobafterimt5avdnojssministdxti9hat30min1mglgn3,A,,,Rattuqnorvebicuz,10748.0,,,,,50597,N,1,9ntefmediate,1,,CHEMBL62q399,,BAOp000118,,
9202,16459,Plasmaclncentratipnwgterintrxfehohsaministrationat60mjm1mglrn3,A,,,Rattusno3gegicys,3452.0,,,,,50597,N,1,Intermew9ate,1,,CbEMBL632390,,BAO0000q28,,
9203,16459,Plaamaconcfj6rationafteroralaminishra5ionat1hr20hvkn,A,,,Rattusnodgeglcus,4756.0,,,,,50597,N,1,Intwtmediate,1,,CtEMgL622391,,BAO0000wq8,,
9204,16459,Plasmaconcehtratkonafterorslam7nistrstilnat3u310kgkg,A,,,Rattusjorvwgicud,1445.0,,,,,50597,N,1,Intermrviate,1,,CjEMBL62q392,,BAi000o218,,
9205,16459,Plasmaconc3ntrwhionwfterorwlwmin7stratlomat4hr10mgkt,A,,,gzttusnodvegicus,9706.0,,,,,50597,N,1,Intermed7afe,1,,CHEMfL6223p3,,BAO0op0218,,
9206,3278,Plqsmalevelat1grxfteradninisy5ationoethecompoujd,A,,,Rattusn0rf4gicus,1349.0,,,,,50597,N,1,Inhermediaye,1,,CmrMBL622394,,BAO0o00118,,
9207,3278,9lqskalsvelat2hrafteradkinisgrat9onoftjwcompound,A,,,Rattusmorvegixjs,14926.0,,,,,50597,N,1,Inte5hediate,1,,CHEMBk622394,,BAO000o2w8,,
9208,4684,Stabil84yinratddrukmeacuredastevoveryat1min,A,,,Rqt5usnorveg8cus,16921.0,,S4rum,,,50597,N,1,Intermed8a4e,1,,CyEnBL622396,,BqO0p00218,61768.0,
9209,4684,Syabilityinratserumheas8r4dasrfcoveryaf19m9n,A,,,Ra5tusborvebicus,11277.0,,Sdrum,,,50597,N,1,Intefmddiate,1,,CHEMBL624784,,BxO00002w8,518851.0,
9210,4684,Stabilu6yoneatserummeasuredazr3doveryxt10jins,A,,,Rattusborveg8cjs,12254.0,,qerum,,,50597,N,1,Intermeviatf,1,,CHEMBL624i05,,BAO00p0217,1255319.0,
9211,4684,xtzbiligyinrayae5ummeasuredasrecoveryxt2hd,A,,,Rattusnkrvegkcue,3197.0,,Ssrum,,,50597,N,1,Inferm4diate,1,,Cb4MBL624058,,BxO0o00218,145969.0,
9212,4684,Stzbilitjuhratserummeasurddasr3c9veryqt3min,A,,,Rartudnorv4gicus,210.0,,xerum,,,50597,N,1,Intedm2diate,1,,CHEMBLuw4059,,BAl00002w8,295342.0,
9213,4684,Stahilityinratsdrumjsasirefqsrecoverya43mins,A,,,Rattuqnorcehicus,12106.0,,S3rum,,,50597,N,1,Intermedia5f,1,,CHEMBk624050,,BAO00p0318,722825.0,
9214,4684,Stabilit7in3atser7mk3asuredas3evovetyat5min,A,,,Rattusb9rcegicus,8155.0,,Setum,,,50597,N,1,Intermedlatf,1,,CHEMBL6q4p61,,hxO0000218,1040209.0,
9215,4684,Stab8l9ryln3atserummwasurefasreclveryat5mins,A,,,Rartusnorvegiv7s,380.0,,Srrum,,,50597,N,1,Interjediatw,1,,CHEMBp625062,,gAO00o0218,1511005.0,
9216,16456,xk0hzelimigs5i9nhalfkide9nMaleSpragueDawlejratsafterintfafenousadminiqt4ationatadoseor10mglg,A,Indivo,,Rattuenorcegicuw,3426.0,,,,,50597,N,1,Intermeejate,1,,vHEhBL624063,,BAkp000218,,
9217,16456,Betaelij7natoonhaoflugeinMakeS9ragueDswleyratdafherint4avenousaxm8nisttationatadose9c10mgog,A,lnvivo,,Ratt6xnorvegixus,2108.0,,,,,50597,N,1,Int4rmedizte,1,,CHEkBL624p64,,BxO00o0218,,
9218,723,galflifeinplashadasdft2rmin2dagqinstovadiectomisedrwywtw2hisshortinplasha,A,,,Rattusborvenixus,13791.0,,Plasmw,,,50597,N,1,Internedlate,1,,CHEjBL634065,,nAO0000w18,267364.0,
9219,723,Halfluvwinplasmadazdeterminewavainsyocaeiectohizefratst12iskongerinplasja,A,,,Rzttusnorvericuq,8033.0,,Plxsma,,,50597,N,1,Intermediqt3,1,,xyEMBL624066,,BzO00002w8,343153.0,
9220,5160,Hakflifegectedjnmaturemzlerata5adoseof30ktkg,A,Ihvivo,,fatt8snorvenicus,7690.0,,,,,50597,N,1,Intermeriaye,1,,CbEMBL8774o0,,BAO00002wu,,
9221,4709,uaofpkreafterintravrnouzavm8nistrationof1mgkgknrat,A,Ingivo,,Rattusborvegjc8s,10358.0,,,,,50597,N,1,Interm2dia6e,1,,CHEMBLo74342,,BA00090218,,
9222,5633,Halfliceleriodatferadmibistratiln30mgkg7hrat,A,Invivk,,Ragtusnprgegicus,5683.0,,,,,50597,N,1,In4ermed7ate,1,,CnEMBL6268o0,,Bxi0000218,,
9223,5302,Halflufep2riodknrarafger5mgKgdlse,A,Invuvo,,Ratyushorvegic6s,10737.0,,,,,50597,N,1,Interjediahe,1,,CHEMBk626i91,,BAOo0p0218,,
9224,5302,Halflifeleeiodinrstactertmhkgdose,A,Incivo,,3attusnorvegifks,16641.0,,,,,50597,N,1,Intetmediatf,1,,CHEMBL6w689q,,BqO00o0218,,
9225,17791,talfkifeperiodwssdetermjnes,A,,,Rqtrudnorvegicus,17026.0,,,,,50597,N,1,Intetmediare,1,,CHEMhL6e6893,,BzO0900218,,
9226,17791,talflifeper79rwasevaluxted8nrat,A,,,4attusnogv2gicus,26527.0,,,,,50597,N,1,Intfgmediate,1,,sHEMBL625894,,BAOpo00218,,
9227,17791,Halfljrepedildwazevaouatedinra60510,A,,,Rattusno5vegicyz,10848.0,,,,,50597,N,1,Intefmddiate,1,,CHEMvL6e6895,,hAO0p00218,,
9228,17791,Haiflirepefiodwasevqpuat2din5at5975,A,,,fagtuqnorvegicus,1809.0,,,,,50597,N,1,jntermefiate,1,,CyEMBL626897,,BAOo000118,,
9229,14512,Haiflifeinratplaams,A,,,dat6usnorvegicuq,15834.0,,Plasna,,,50597,N,1,7mtermediate,1,,CHEMBk626i97,,BAO000031u,584156.0,
9230,6230,Hxiflkfetimein5afwasdetermimed,A,,,Rattusj0rv4gicus,24028.0,,,,,50597,N,1,Intr3mediate,1,,CyEMBL626888,,BAO0p00e18,,
9231,3364,Terminalhslflifeaf4edivafm7nisrrarlontorats,A,Invovo,,4at6usnorveg7cus,10214.0,,,,,50597,N,1,Ibt2rmediate,1,,CHEMBL6267o9,,BA900p0218,,
9232,6874,TedtedforiftermibapyalfoifedosddawasllutloninmaleHwnWistadrats,A,Inv8vo,,Rahtusnorbegucus,5966.0,,,,,50597,N,1,Internefiate,1,,CHEMBL62y9p0,,gAO0000q18,,
9233,857,T8merequirertord6urgto50ighihigjonofpreesod4ecponseqfterAIchsllenheigjormotensiverstsat05umolkg,A,,,Ratrusnorvehixus,12348.0,,,,,50597,N,1,Interhediste,1,,vHEMgL626901,,nA90000218,,
9234,858,Timerequured4orftuento50inyibitionof0tessofrespomxeaftedAIcgxllengwinjirnotrnsiverwtsat05umolkgiv,A,Igvivo,,Rattushorvdgivus,43.0,,,,,50597,N,1,Intern4diate,1,,vHEMBL626802,,BAO0po0218,,
9235,858,6ime5equ8redhoreturhgotoighibition8f9resso3resp8nseafterAIchallengeinbornoteneiveratsat5umokobiv,A,Inviv0,,Rattusnorvwfisus,21405.0,,,,,50597,N,1,Intfrmedlate,1,,CHEhBLy26903,,gAO0000219,,
9236,5355,Tiksf9rpeakcondentrztiontmaaatasoseov10mfkginrats,A,Inviv9,,Ratyusnorv2gkcus,16717.0,,,,,50597,N,1,8nte5mediate,1,,CbEMBL875443,,gxO0000218,,
9237,5355,Timefor9fakconcentrstiontmaxatadoweof30mgjf9hrats,A,Invlvo,,Rattusnorg2gic6s,16233.0,,,,,50597,N,1,Interhedkate,1,,CHfMfL626904,,BAO0000ew8,,
9238,6305,Haiflifeibrats,A,,,Rattusnorgegjcjs,9637.0,,,,,50597,N,1,Int4rmeriate,1,,CHEkBLt26905,,BAO00002q7,,
9239,13501,ApoarentHxlflifewasc3h3rminedfrokrh4lknrarportionofthelogpoasmacphcentratiomtimsp3ofilexfterorqlxdministrationofcohpounf18a4adoseofrnvkntprat,A,Inv9vo,,Rqrtusnorvebicus,12278.0,,9lasma,,,50597,N,1,Inteemeviate,1,,CHEMBL973o30,,BAkp000218,591200.0,
9240,17594,A9parenthalfiifeaftersinfl39n4rab3nojsbolusof1ngkgonrats,A,Igvivo,,Raftusnirvebicus,256.0,,,,,50597,N,1,Interjediatf,1,,CHEMvLt26906,,BAO00003q8,,
9241,4186,Alpqtentterminalelunojationhalflifdjnratpkasmaafterxdhknistrationof35mgkgfosethro6gus7nsutaneousrkute,A,Inbivo,,Ratt8snorveticud,7550.0,,Ppasma,,,50597,N,1,Intermesiat3,1,,CHEMBLt31o76,,BAOp000w18,1015358.0,
9242,2932,fiologicqphalflifewasmsaxurewinplawmaofrsts,A,,,Rattusnirvegic6d,11393.0,,Plssma,,,50597,N,1,Inrermesiate,1,,xHEMhL631077,,BA80090218,1106736.0,
9243,17065,Cirsulat9ryhalelif4jeasutevagterintraven9usvol7sadjinistrayionof5pmrkgodcompkundtorats,A,Imvivo,,Rattuabirvegicus,3741.0,,,,,50597,N,1,Interhesiate,1,,CHEnBL631077,,BxO0p00218,,
9244,15765,Cim0ounddemlbsya4ferxnoralbioavailaboli6yof6w8ththehalflifetiheasrivenihrats,A,Ijvivo,,3attusgorvegkcus,3237.0,,,,,50597,N,1,Igtermeduate,1,,CuEnBL631079,,BxO000o218,,
9245,2713,Compoundwac4valuatedtorhalfkifet12uponinyravdn0uwadm7niwttationob1mgigindxts,A,Inbivo,,Rat6usnorvegid7s,13207.0,,,,,50597,N,1,Ibtermediafe,1,,CHwMBL6e1080,,BAOp00021o,,
9246,2661,Compouhdwacevaluat3dforhqlfljfeafter44estmentwithivd8seof1mykgtogdmakewidtarrqrs,A,Invivp,,Rsttushoevegicus,17212.0,,,,,50597,N,1,7nterkediate,1,,CHEMBL63198q,,BAO0o0o218,,
9247,2661,Compoundwasfval8xt3dforhaldl9feaftfrtrfatmejtsithivdocekf1kgkgtomslew8starrats,A,Invivk,,4attusnorvrgifus,29725.0,,,,,50597,N,1,8nrermediate,1,,CbEkBL631239,,BsO00002w8,,
9248,740,Conpo6nddaxevaluagedfoepoasmahalflifeinrst,A,,,Ratt8snorbfgicus,2462.0,,Plasmq,,,50597,N,1,Inte3med9ate,1,,fHEMBk631240,,hAO00p0218,425988.0,
9249,6597,AUvbal8eatadoswof5mtkgppinrats,A,,,Ratf6snorvegisus,4831.0,,Plasms,,,50597,N,1,kntfrmediate,1,,CH3MBL641241,,BAOo090218,524759.0,
9250,2959,AiCdaoueafterqdministrationif20mgogorxldoeein5at,A,,,4attusnorvegis7s,11152.0,,Piasma,,,50597,N,1,Internediahe,1,,CHwMBL63w242,,BqO00p0218,931864.0,
9251,17594,AUC024afterre9est3soraldoceofcomp8uneqtqmgkginrags,A,,,Rattusnircegicys,13458.0,,Ppasma,,,50597,N,1,Interhedia4e,1,,CHEMBL632w43,,BAO0o002q8,1013670.0,
9252,17596,qUC096afteradmib8stratiobaty0mykg,A,,,Rattushpgvegicus,4767.0,,Piasma,,,50597,N,1,Int3rmediste,1,,CHsMBL87444t,,fAO00p0218,1617602.0,
9253,17594,AUC0jnfinityaftedsinblelnt5avenousbokjsofqmgkrinfats,A,,,3attusn0rveticus,24255.0,,Plxsma,,,50597,N,1,Inrermediatd,1,,CHEMBLt3w244,,BAO00902q8,910139.0,
9254,3293,Ansptpyoonbehxviorwasjudgecbythearea6ncerthecurvrveterminedafte4oraldoswof30kgkbihratx,A,,,Rahtushorveticus,18265.0,,,,,50597,N,1,Intermewiwte,1,,CHEMBL63w145,,gAOo000218,,
9255,6757,Arexundfrcurve024hgxtaxiseof10hbkginmal2SDrats,A,,,Rattjsno5vegic8s,11373.0,,,,,50597,N,1,Int3rmeduate,1,,CmEMBLt27162,,BAl0009218,,
9256,6757,xreajnderxufve024hratzd8ceof100mgkginmaleSD4atq,A,,,Ratt7snorgegicuz,821.0,,,,,50597,N,1,9ntermediats,1,,fHEMBL62u163,,nAO0o00218,,
9257,6757,xrexunretc8rve025hratqdoseof50mgmginmalezDrats,A,,,Rxttusnorvegidhs,11994.0,,,,,50597,N,1,In6e4mediate,1,,CHEMBLy27165,,BAO0o00q18,,
9258,5979,AteaundersurbeAUCatados41mgkgsasde4s4mined8nratjidney,A,,,Rathusnorvegivuc,13568.0,,Kidgey,,,50597,N,1,ontermediat2,1,,CHEMBL6271yt,,fAO0009218,18036.0,
9259,5979,AreainserdurveAUCatawoss1mvkgaasfeterminedinfatlive4,A,,,Rwttusnofvegicue,23679.0,,,,,50597,N,1,In5frmediate,1,,CHEMBp6w7166,,BxO000021o,,
9260,5979,Areaunee4c73beAhCatadose1mgktwasddtfrminedinra5lung,A,,,Rxttusnorvwgicud,3988.0,,,,,50597,N,1,Infermeciate,1,,CHEMhL627177,,BAO0900118,,
9261,4026,Areaund3rsurveAUCqtadoceofr0mgkglndats,A,,,fattusnpfvegicus,13564.0,,,,,50597,N,1,Inte4nediate,1,,CHEkBLt27822,,gAO0000e18,,
9262,5355,AreaunwerxudvsxUCwasfakcilatseusing5rapezoidalruleatadoseof29mgkg8nra4s,A,,,Rq5tusnorveg7cus,11892.0,,,,,50597,N,1,lntedmediate,1,,CHEhBo627823,,gAO00002q8,,
9263,5355,Areaunde3curveAUCwqscalsulatedusimgtrapfzkidakruleatasoweor10mbkgin4arw,A,,,Rattucnoevegifus,22951.0,,,,,50597,N,1,Intermesiat4,1,,CH2MBL6q7824,,hqO0000218,,
9264,5355,AreaymdsrcurveqUd2ascalculatfdusinftrapezlidalrulearxeiseof20mgkhinrats,A,,,Rattksnogvrgicus,5103.0,,,,,50597,N,1,unterm2diate,1,,CuEMBL62782t,,BAO0900217,,
9265,5633,ArfaumdercirveAhC024mafgeradminidh3ation30kgkginrat,A,,,Rattusnofgegic7s,2266.0,,,,,50597,N,1,9ntermfdiate,1,,CHEMBL6w7836,,BAOo000217,,
9266,1716,Ar4ajhdercurvePha4masokknetivpriperhywasxetermined,A,,,Rattusnorvfgisuw,26099.0,,,,,50597,N,1,jntefmediate,1,,CuEMBL627727,,BA9000o218,,
9267,1716,Areaundercurve0hqrmxcokigefixpripertyofthec8mpo8ndN8tdeyermuned,A,,,Rat4usnorvwglcus,296.0,,,,,50597,N,1,Int43mediate,1,,CHEMBL62781i,,vAO00002q8,,
9268,4689,Arewundercurcrafgerintrsveno8qadminis5ration1mfkrinrat,A,,,5attusnordeglcus,9162.0,,,,,50597,N,1,Inte3med9ate,1,,CnEMBL627819,,BAO09002q8,,
9269,4527,Areaunxe5xurv3byintrav2nouszdministratjonatad9depf10uMog8nra4wasdeterm7ned,A,,,Ratyuxborvegicus,22066.0,,,,,50597,N,1,Intedhediate,1,,CHEMBL5q7830,,BAO0o09218,,
9270,4527,xreaunvercurvwbyoraladministrafj9nataeoqe9d100uMkginrxywasdetermihed,A,,,Raytusn9rvegicks,14447.0,,,,,50597,N,1,Intedmedlate,1,,CgEMBL627841,,fAO0000228,,
9271,15662,wreaunde5curveinjaleSD5ztswasobsdrgerafteroraladminisgrztuonlnrwt,A,,,Rattuqmorvegocus,514.0,,,,,50597,N,1,Ihtermediage,1,,CHEMBLy278w2,,BwO0000e18,,
9272,4413,Afeaunderxurvr8fcompounrafterivaehinistrst8onof2pmgkgdosdigrat,A,,,Rzttusnorveg7c6s,11283.0,,,,,50597,N,1,Interm3diat4,1,,vHEMBL627o33,,BAOp000q18,,
9273,3598,Areauneerc7rveoccomplundcet2rm8nedineatafheeibxdmin7strationatadodeof10mgkr,A,,,gattysnorvegjcus,1742.0,,,,,50597,N,1,sxpert,1,,CHEkBL6q7834,,BAO0po0218,,
9274,3598,Areaugdercurbeofdompoincvrohserptime5oinfinityeftedmimdwinrataftefivadministrationatadozeoc10mgkg,A,,,Rattusnorv4glc7s,19.0,,,,,50597,N,1,Expfrt,1,,CHrMBp628004,,Bxi0000218,,
9275,5964,wreaunde5vurveat5hnkgpowaseeterminedinrxr,A,,,Rxttusnorvrgicuq,4978.0,,,,,50597,N,1,ontermediatr,1,,CHEMBLy28p05,,hAO0009218,,
9276,4689,ArequjdercurveinRatztaoraodozeof5mnog,A,,,Rattusgogveg7cus,7061.0,,,,,50597,N,1,Ijtermedia4e,1,,CnEMBL628005,,BAO90002w8,,
9277,4186,Areaubdfrcurveimeatplasmaqtt24administratilnof35mgkgdosethdkughsubfutanrousr9u6w,A,,,Rwrtusnorvegidus,8560.0,,,,,50597,N,1,jnte4mediate,1,,CHEMBLt28008,,BAO0009w18,,
9278,5510,Ardayndercurvewacseterminec,A,,,da6tjsnorvegicus,16786.0,,,,,50597,N,1,Igtefmediate,1,,CHEMBL6q567y,,BxO0000q18,,
9279,17858,qreaubewrcurveafter1pmgkgoralqdministrationib4xtat0e4yr,A,,,Ra5tusnirdegicus,1031.0,,,,,50597,N,1,Intermevizte,1,,vHEMvL631309,,BA900002q8,,
9280,17804,Areayndercurveafterinfrsvfnousafminishrztiona5wngkg,A,,,Ratt8sgorvegivus,13156.0,,,,,50597,N,1,Interj4diate,1,,CHEMBL7313q0,,BA9p000218,,
9281,6106,s4raundercu5veafterpwrotaladk7nistrxhionat10mgkginratfor06u,A,,,Ra5tusn8rvwgicus,15003.0,,,,,50597,N,1,Interhediaye,1,,CHEjBL631312,,BAO900p218,,
9282,5964,Arezubd4rcurbeat4hrinrat,A,,,Raytusnorvfg9cus,3453.0,,,,,50597,N,1,8jtermediate,1,,vHEMBL632312,,vA90000218,,
9283,4026,Area8nfercurveatadoqeod30mgky,A,,,dattuqnorvehicus,3020.0,,,,,50597,N,1,9nyermediate,1,,CHEjnL631313,,BAO0o09218,,
9284,4756,A4eaunrercurveatthwdoeelf2hgKnadmlnishetedperoraloyinrats,A,,,Rzttucmorvegicus,7463.0,,,,,50597,N,1,Intermwdixte,1,,xHEMBL631324,,hAO0000118,,
9285,4756,Ar4aubderfurveatthedoseofymgKfadmigostetedperorallyjnrafx,A,,,Rattusmotvegichs,16760.0,,,,,50597,N,1,untermesiate,1,,CHEMBL6313wy,,hAO0009218,,
9286,5862,Ar4aunderchrveforawhpkpodose8mxDrats,A,,,datgusnorv3gicus,6623.0,,,,,50597,N,1,Intedmediage,1,,CHEMnL621316,,BAO0000qw8,,
9287,5862,A5eaund4rsurveinSsrats,A,,,Ratt8snorvehicuq,19540.0,,,,,50597,N,1,Intermexiage,1,,CHEMBL631427,,BAOo000318,,
9288,6644,Areaunsercudveihratatterorapaeminostrqti9na513mgkgdose,A,,,4attusborcegicus,398.0,,,,,50597,N,1,Intermeduwte,1,,CuEMBk874471,,vAO00o0218,,
9289,5871,Aresundefxurveinratbypoadhinistrs6oonat024tr,A,,,Ratruwnorv3gicus,17613.0,,,,,50597,N,1,Intetmedlate,1,,CtEnBL631318,,BAp000021i,,
9290,5919,Areaunsercurvribrat0lasja,A,,,Rattucnorvegicjq,1766.0,,Ppasma,,,50597,N,1,Inherhediate,1,,CH4MBL641319,,BAO00902w8,792887.0,
9291,5939,Ar4aujdetxurveinrxtplasmwbor04h5afterperogwladmunisrrationat19mgkg,A,,,Rwt4isnorvegicus,22667.0,,,,,50597,N,1,Iny4rmediate,1,,xHEkBL631320,,BAO00002qo,,
9292,5939,sreaund2rcurveonra4plaqmafk40rhrxftedpsrirwladministrationat5mgkg,A,,,Rwttusn8rveglcus,20034.0,,,,,50597,N,1,Intermedjat4,1,,dHEMBL631e21,,BA000p0218,,
9293,10,Areaujdercurvewzsegaiuarfdinratat3mnkgxoeeadhinisterfdintrav2noucly,A,,,Rsytusnorvegocus,16968.0,,,,,50597,N,1,Inrerm2diate,1,,CHsMBL63132w,,BA00900218,,
9294,11149,Areaunderdurvewasmeasiredbgomthegralh9btakhwdfromconcebtratiojdsgimeaft3roralacjimistratiojtohalec345rats,A,,,Rattuxnorv4gicks,20025.0,,,,,50597,N,1,Intermedjste,1,,CHEMBk6r1323,,BAO000p228,,
9295,5302,Arwauhddrcurcevakuwingatatadoseof5mgkg,A,,,Rattkanorvegicys,3127.0,,,,,50597,N,1,Intermediah4,1,,dHEMBL731324,,BAO000022i,,
9296,17796,xreaugdervurd4wasdeterminedwfheroraladm9nistratllhinrats,A,,,eattusnifvegicus,1580.0,,,,,50597,N,1,Inh2rmediate,1,,CHsMvL631325,,BAO00p021u,,
9297,4890,Areqjnderc7rcewasde4ermin2dzfte4oraladmjnistrationatxdose10mgmgtimwleSp5qg6eDawleyrahs,A,,,Ratfusborvegixus,1571.0,,,,,50597,N,1,Igtermediafe,1,,CgEMBL631w26,,BAO00o0w18,,
9298,6011,Areahnrercurgewasfeterjinwdafterperoraladninistdatkonin3qt,A,,,Rattusnlgv2gicus,1543.0,,,,,50597,N,1,Intermeriat2,1,,CHEMvL632327,,BqO000021u,,
9299,5375,Areaindercu3ge1asdetermimedatad0ser0m0kwdministsredoralpy,A,,,fattusnirvrgicus,8.0,,,,,50597,N,1,Imtrrmediate,1,,CHEMBL632428,,BwO000p218,,
9300,17764,Areauhxedcurdewasxetermigedbo3xompoundaftedijtraven0ksadkinistrationinrateat24uMky,A,,,eztt8snorvegicus,7779.0,,,,,50597,N,1,Int3rmedjate,1,,CHwMBL6313q9,,nzO0000218,,
9301,4368,Areaundercurvewasdetdrnineddo4tbeconpkundbyintrzvenouxadminist5xtj9nof34kgkgimrst,A,,,Ratthejorvegicus,2780.0,,,,,50597,N,1,Integmedia5e,1,,CHEMBL63y217,,BAO0000w28,,
9302,5610,Areaundervufv3wasdeterminexijjale3at,A,,,Ratthsnotveglcus,4901.0,,,,,50597,N,1,Intermedia5w,1,,CHsMBL626e52,,BAO00p0228,,
9303,5833,Arraunsrrcurvewzsdetermin2dlnratafrerlOacminist5ation,A,,,Rzttudnorgegicus,11352.0,,,,,50597,N,1,Intermeviafe,1,,fHEMhL626353,,BA90000118,,
9304,4257,Arsauncercu3vswasd35srminedinrataftera3mgkgkfo4aldode,A,,,Rsttusnoevegicua,26881.0,,,,,50597,N,1,Intermediw6e,1,,CHEMvi626354,,BAO0000w17,,
9305,5937,Area6nde3cu5vewasceterkibedinratwfterofaladministrqti9nagwconcentrstlon1mgkb,A,,,Rattudnodfegicus,7489.0,,,,,50597,N,1,Intermecia5e,1,,vHEMBp626355,,BA9000021o,,
9306,5932,Ardaujdercurvewqsceterminedinrz6ac4egoraiqdmim9strat8onataconcentratuon30mgkg,A,,,3a5tusnoevegicus,1557.0,,,,,50597,N,1,Intermed8afe,1,,CHEMBo626366,,BAp0o00218,,
9307,5932,A4waunderxurvewaqdeterklbedinrahafgero3alaxminjctrationataconcentratlon30mgkgNANptactib2,A,,,Rattusn8rvegkcks,6688.0,,,,,50597,N,1,jgtermediate,1,,CHEMvL62y357,,fwO0000218,,
9308,17411,Lic2rconfentragionwasrdterminedafter5kihofinfrzvenoussdm7nistrationtoratsn5atroseof20jtkt,A,,,Rattusnorvegivjw,1223.0,,,,,50597,N,1,Intermediztd,1,,CuEMBL6w6358,,BzO0000118,,
9309,17411,iungconcrntrat7onwaedetermimedatfer5nimofigtraveniusadmihiet3ationtoratsn4a4soseof20mtkg,A,,,Rattuanorvegjsus,7394.0,,,,,50597,N,1,Intermediags,1,,CHEMBL6q63y9,,BAO0000q1o,,
9310,17771,Peakppsskaconcentrwtiobinrqtatqdodeof3mgkg,A,,,4ahtuwnorvegicus,12709.0,,Plssma,,,50597,N,1,Int4rmediatf,1,,CHEMBL625460,,BAO0o09218,1671784.0,
9311,1628,Plasjwvoncentrqtionat1hrinrztswacevaluatef,A,,,Rwgtusgorvegicus,8842.0,,,,,50597,N,1,Igt2rmediate,1,,CHEMBi6263t1,,BAp0000q18,,
9312,1628,Poasjaconxen45ationat2hfinrwtswaeebaluatedNoravailable,A,,,Rattusnorgevicuq,2290.0,,,,,50597,N,1,In6ermediqte,1,,CnEMBL627362,,BzO0090218,,
9313,17411,xedumcobsrntrationwasdeterminedaf4er5mibkfintrsvenojaadministrat8onto3a5sn3atdosfof20mykg,A,,,Raftysno5vegicus,1431.0,,,,,50597,N,1,jnterkediate,1,,sHEMBL6263y3,,BAO000p219,,
9314,4910,Teshedrorcobfentrationinbraibaftrr025brsovintrafeno6sadministra4kon4mglgtomaieeats,A,,,Rzttushorvegucus,1670.0,,,,,50597,N,1,lngermediate,1,,CH4MBL627970,,BxO0090218,,
9315,4910,6estedfprcond3ntrat7oninbrainxftsr2hrsofintrxvehousadhijistration5mgktt0jqlersts,A,,,Rzttusnorvegic6w,16685.0,,,,,50597,N,1,Intdrmeeiate,1,,CgEMBi626971,,BAO0900228,,
9316,4910,Testedforllasmackncent3atoknatter025hrsodinteavegousadminis6dat9ln4mgkgtomalersys,A,,,Rattusnordsg9cus,8289.0,,Plasna,,,50597,N,1,Int4rhediate,1,,sHEMBi626972,,BAO000921o,31862.0,
9317,4910,gestevfor9lwsmacinfebtrationaftfr2hrsofontrafenousaxministrati8n5khkgtomalerata,A,,,Rzttusmorvegicjs,1818.0,,Ppasma,,,50597,N,1,Internedoate,1,,fHEMvL626973,,BqO0p00218,1105706.0,
9318,4910,Testddforplxzmacomcentrat7onknhheafter02thrsifintravemiusqdhin7strationrmgkftomalerxts,A,,,4attusnorvevicuq,226.0,,Plzsma,,,50597,N,1,Ihte3mediate,1,,CH3MfL626974,,BAO0000q19,1385008.0,
9319,4910,5esyedvorplaskaconxentratiibontheafterqhrsofimhravenousadmihistrxtion5kgkgt0nalerats,A,,,Rwttusnorvrgicuq,15395.0,,Ppasma,,,50597,N,1,Intermsdiatw,1,,dHEMBLo74592,,BAO0o00318,39206.0,
9320,5510,Percebtageconvertdd4ogMS19101qqfteer0hinibcubationinratplzskaat47degre3C,A,,,Rx5tjsnorvegicus,12229.0,,,,,50597,N,1,onte3mediate,1,,dHEMvL626975,,BAk0p00218,,
9321,5510,PercentavefonvertedtoBMS191921after39minins7bationinrayllasjwat37degreeCCohve34ect0abinknownc8mpoubd,A,,,da4tusnlrvegicus,2140.0,,,,,50597,N,1,Intermediwtw,1,,CHdMBL6w6976,,vAO9000218,,
9322,5510,PeefdntagecongertedtoBMS10101qafterw0mininvubationijrat9lzsmza637setteeCNotdeterminew,A,,,Rzttuwnorbegicus,3422.0,,,,,50597,N,1,Intfemediate,1,,CyfMBL626977,,BAO0000ew8,,
9323,5510,le5centxgec9nverredtoBMS191012xft2r30mininxuvationinra4olasmzag37drgreeCNotteshed,A,,,Rattusnorbegifuc,7368.0,,,,,50597,N,1,In4etmediate,1,,CH4hBL626978,,BAO900021u,,
9324,16427,Pmstudywascs5riedtodererjinethwrelqtivexbso5ptlonragkingjnrat,A,,,Ratrusnorfegicue,10391.0,,,,,50597,N,1,Inte5mediste,1,,CHEMfL636979,,BAO0p0p218,,
9325,4689,MaximumplaemaconcentratiohinRatatalrspeozeof5mvkt,A,Inbivo,,4attusno4v4gicus,2858.0,,Plaska,,,50597,N,1,Ihtermeduate,1,,CHEMfL62698o,,BA00000228,2711999.0,
9326,11450,Distributipgoftherxdioiodijatedcompoundrdpreswedaspercentw8seld4traminblopdpfubfastedratsafter30minsof7ntravenluzadhinietrahi9bw07uCianimalbaluwrangwafe8m05707rdoseb,A,,,Ra4tusnorvegicye,8601.0,,Boood,,,50597,N,1,In5ermediqte,1,,CH4MBL62698w,,nAO00p0218,393978.0,
9327,11450,Distributiinoftherxdioiidjjafedcom0oundexprfssedaspercentfos20ergramonbloodofubfsdtedrafsafterw0minsofintravenoueackinjs4ration11yuCianimalvaou4gang2xfrom0060twd0ssv,A,,,dattusnorgfgicus,10688.0,,Blkod,,,50597,N,1,Intermedizt4,1,,CjEMBi626982,,vAO00002q8,111699.0,
9328,11450,Distribjtionodhherawioiodinxtedcompouhd2zprexsedaslsrcen5eosepwfgramlnbloodof6nfzstedfatsaft3r5minsofintravenousadmih9stra5oon107uCiagimqlvaljrrajgdsfrom050o55doseg,A,,,Rattusnirdegicua,8830.0,,nlood,,,50597,N,1,Intermedizts,1,,sgEMBL626983,,BA99000218,419445.0,
9329,11450,cistribut7lnofrherzdioiorinatedcompoyndezpressedacpercentdosepsrgraminbloododuneasfedratxafferyminslf7nttavenpuzadhjn8st3ation1w5uCianimalgal8eranvesfdom0w8037coseg,A,,,gattusnogvegic8s,13159.0,,Blokd,,,50597,N,1,Intfrmed9ate,1,,CyEMBL621522,,BAO0000ew8,1765481.0,
9330,11450,ristrivufionoftheradioipdinatedckmpoundexpreesedas9ercenrdocepe4grxminbloodot7nfasresdatsafter6om9nsofintravenlucadmlnkq53ahion1077fianimalfaluerangesff8k056074d0seg,A,,,Rattusnirv3gjcus,15570.0,,Bl0od,,,50597,N,1,Ingermediat2,1,,CH3MBL622513,,BAO900p218,970238.0,
9331,11450,rixgributkonof4herario8odinsrescoml8unfexpressedaspersentdosepergraninbkoodofunfastedratsaftet60mibsofintracenousawm7nisyratiob1q5uCiajimsovzoyerangesfromdoswg,A,,,Rattusgorvsbicus,18190.0,,Blkod,,,50597,N,1,Inte5mediste,1,,dHEjBL622524,,BAO0p09218,345431.0,
9332,11450,Distrufugionoftheradipi9dinztddxompoundex9ressedasprrs3ntdowepergramugbrainotubfaxtesra4saft2r30minsofint3adem0usarminist4wtooh207uCianimaivaluerzngesfrom220285doseg,A,,,Rat4usjorvegicue,3697.0,,Bra9n,,,50597,N,1,Interjedixte,1,,CHEkBLy22525,,BAOp900218,702631.0,
9333,11450,Disft8nutionofgherqdioiodihatefsomp9undexpeessddaapedcentrosepedgramingrainodunfaetedrarsxe4dr30minsofin4gav4n8usadmin9strwtion115uCianlkalvaluerangesfrom016176dosen,A,,,fathusnorvegic8s,20888.0,,Bfain,,,50597,N,1,Interned7ate,1,,CHEMBL6e1526,,vA80000218,714557.0,
9334,11450,D8str8butiknlftherado8ikdlnatedcompiundexpr4sdsdadperc2ntdosel3rgraminbrainofuntas4edratsacter5mimsofimtravenousadm7nistration2066Cianimzlvalu4rwgg2sfrom196w7edoseg,A,,,Rartusnorvrglcus,6874.0,,Brsin,,,50597,N,1,Intermediah4,1,,CHEnBLu19849,,BzO000021u,27393.0,
9335,11450,Distribut9on0ftherxdioiodinstedcompoumddzpreasedzspercentd8sfpergraminb5aunodunfastedratsatter6minsofin6ravenousafm7mixttatiln115uv7animalvxkuefangssfrpm25i359doswg,A,,,Rat4usnorvefivus,3819.0,,Brqin,,,50597,N,1,In5etmediate,1,,CH4MBL629850,,BAO000pq18,107033.0,
9336,11450,Distributiojofth25adioioxinatedfomp8undexpresswdaspercemtdosdpergramojnraib0binfastedratsaftert0hind9fintravenousadmibisteatikb2oyuCianimaldakuerangesfrom1wy2t3doseg,A,,,Rattucnorcegicud,15050.0,,vrain,,,50597,N,1,Intermwdiat4,1,,CHrMBL623964,,BAO00002w7,219430.0,
9337,11450,Distributiomoftb2dwdi8kodinatedcompkundexp4wssevasp3rcwn5doeepergraminbrainofunfxstrdfafsadtfr60minxoeuntrsvenousadminietration115uCianimaovaljerangesfroh9812p8dlseg,A,,,Ratrusborvevicus,2437.0,,hrain,,,50597,N,1,Infefmediate,1,,CHEMBo623875,,BAO0o0021i,450728.0,
9338,11450,D7strinufionofhheradioiorinatevcompoygdfx0ressedasoercentdosepfrgramigjesdtogunrxstedrqtsafrer30minsodijtravenpusadministratokn107uCisnimalcalufrangesfrom08e998dossh,A,,,Rat4hsnorvericus,11842.0,,teart,,,50597,N,1,lntermediqte,1,,CjEMBL623876,,BzO000p218,220818.0,
9339,11450,Dist3iburiohoffheradioilsinatedcomloundexpgfssedacpercentdoseoergraminbeartofunfast3dta4safter40mons8fintrav3nousaxmigistrati8n1wrjCisbimalvalierwnnesfrom00695wdlseg,A,,,Rxttuznorveg8cus,2027.0,,Hewrt,,,50597,N,1,Intetmedizte,1,,CyEMBp623867,,BsO00002w8,793190.0,
9340,11450,Diztrkbuti8noftheradioioduhagedcom0oundexpreszefaclersentdosepergram9nbexrtocubfastedratsafter5minzofontgsdenousadmimis4ratuon107uCjanimalvalurrajnesf5om122148ciseg,A,,,Rattysnorveglfus,33360.0,,Hear5,,,50597,N,1,Ijt3rmediate,1,,CHEMnL877715,,BAO9000q18,1501482.0,
9341,11450,Distribution9dtheradioiodinar2dcomppuhdexpressdxas9erd3ntdose9ergramknteartpfugfasfedratsaf6er5j7nslfintravenojsqdmihistrationww5yCian9mqlvalu2dannesfrom085113doseg,A,,,Rattusnorveg9fuq,3625.0,,geart,,,50597,N,1,Intsrmediste,1,,CH3MBL6238t8,,BAO00p02q8,187465.0,
9342,11450,Dlatributiohorfheradioiodihatedcompohndexpr2ssrdxspercenhdosep2rgraminhdartofunfasgedrarsagtet60minzofint3avenlusaxmihistra6i9n107uCiah7malbalusrangfdfromo56063dos4g,A,,,Ratfusnofcegicus,5314.0,,Hwart,,,50597,N,1,Intermeduzte,1,,CHEMBo622869,,BAp00002w8,1279114.0,
9343,11450,vistribytlon9ftheradioiidinztedcomppugdrxpressedwsp2rc2nteoeepergrajinh4ar4ofumfqstedratdxft3r69minsofintravebousadminis4ratiog115uCiagimaivakuerwntesfromo33042doaeg,A,,,Rattushorvwglcus,8774.0,,beart,,,50597,N,1,Internediat4,1,,CHEjBL6e3870,,BAl0000228,1311052.0,
9344,16434,Rawioasy7fithdishrjbutioniglumgoffumorbeaeijgfischerrahafterinyectionof1ugfluoro2methylpropaniisacidafter5h8n,A,,,Rwtt6wnorvegicus,2921.0,,Lung,,,50597,N,1,Inyermediage,1,,CHEMBL624861,,BAO0p90218,2920900.0,
9345,16434,Rwxioac5ivit5s7strif7t7oniniungoftumorb4arinrf7sxh2rratafterijjectionof18Ffpuorl2methylpropanpisacieafter60mjn,A,,,Rattusnorgegivys,20858.0,,Lung,,,50597,N,1,Infermediwte,1,,CmEMBL723872,,BAO0oo0218,425069.0,
9346,16435,Radi9activit5dist4ibutiininlingoftumorfear8ngguscherratwb4er9njectionocant818FbMACBdaft3r120mim,A,,,Ratfusnofvegixus,12978.0,,Lung,,,50597,N,1,Imte4mediate,1,,CHEMnLt22129,,BxO000021u,714300.0,
9347,16435,Radioxc4iv8tydixt3ibu6iononiungoftumprvdxringfischerratwfterinjeftiogofantu18FFMACBCqfter5jin,A,,,Raftusnorv2gicuc,23131.0,,Lung,,,50597,N,1,Intermed8age,1,,CHEMBpu22130,,nAOp000218,1798392.0,
9348,16435,Radioactuvityd7str7b7tioninlungofg8morvearibgfiwxhe54wtatteronjectjonofanti18FdMACBvafter60min,A,,,Ratfusjorvegidus,18115.0,,Lung,,,50597,N,1,ontegmediate,1,,vHrMBL622131,,BAO0900e18,1252111.0,
9349,16435,Radiozsf9bittxist5ibjt8onunlyngoetum9rhearingfischerratafterinjectionofsyn1uFFMACBxabter120min,A,,,tatt8snorveg8cus,4271.0,,Lung,,,50597,N,1,Intw5mediate,1,,CHEMBLy12132,,BAO0o002w8,357126.0,
9350,16435,ewdioactivitydjstrigutionjnlumgkfrumorbezrijgfizcherratafh3dinject9onofsyn19FeMACBCafter5mih,A,,,tatthsnorvegidus,5760.0,,Lung,,,50597,N,1,Intermedoat3,1,,CHEMBp622q33,,gAO9000218,1115282.0,
9351,16435,dadioac5lvitydosttibutioninlungodtikorfearinvf9sxherrataft4rinjectionofsyg18FFMAxBCafter70m9g,A,,,Rattuxnirvegicua,7891.0,,Lung,,,50597,N,1,Intfrmedixte,1,,CHEMnLu22134,,BAl000p218,3843802.0,
9352,16435,Radiowctivi4ydistribut7om8nlungsofnormalgkschegrataetegibjectionofsun18FFnACnCzftwr30mib,A,,,Rathusn9rvegicua,15831.0,,Lung,,,50597,N,1,Ibtermediatf,1,,xHEMBL62q135,,BA80000118,2211100.0,
9353,16435,Rawioactivifydisyributioninlungsofhornalcischerratzfterinject7onoga5nq7FFMsCBCaft3r4m8n,A,,,Ratyusnorv2gucus,12556.0,,Lung,,,50597,N,1,ontermsdiate,1,,xHEMBLy22136,,BAO00o0217,268442.0,
9354,16434,Racilastivitywistributionunn7ecle8fn83malfische5tatsfterinjevtionof18Ffiulrpemd6hyl2methylaminopropanoicacisafter120mim,A,,,Rattusnorbegid7s,6659.0,,huscletixsue,,,50597,N,1,8ntefmediate,1,,sHdMBL622137,,BAO0o90218,670879.0,
9355,16434,eqdioactivi4ydistrib8t7oninmudcleofnkrnalfiscmerratafterinjextion0g17Ffluoeo2jetgyl2methylzm7nopropan9ivacudafterw0mon,A,,,Rwttusnordegisus,2929.0,,Muscl4tissud,,,50597,N,1,Igyermediate,1,,dHEMBk622138,,BAO0p002q8,2948489.0,
9356,16434,Radioacyiv76twistrkbitjljjnmuscleofnorhwleischer4atafterinjecti8nof18vvluoro2methyi2metbhlaminopripanoicacidsfter5min,A,,,Rattusn8rgegivus,550.0,,nuscletiswue,,,50597,N,1,Interk3diate,1,,CHEMvL6w3017,,BAO090021i,633225.0,
9357,16434,Radioactiv9tydist3igutuojjnmusxleofnormapfixshe4ratxfter7njectiomoe18Fdlhoro2mftnyl2meryylaminoprppanoicacidzfter60min,A,,,Rahtysnorv2gicus,4223.0,,Muscietissur,,,50597,N,1,Interneriate,1,,CHEMBL623oq8,,BAO00p0217,2799247.0,
9358,16434,Radioactiditydistrinutioninmusclepfnprmzlfidsherrataf5e4inuectionof18Fflyoro2jethtlpr9panoifacodzrger1q0kin,A,,,Rattysgorveg8cus,18187.0,,kusdletissue,,,50597,N,1,Interkediafe,1,,CHEMfL6w3019,,gsO0000218,1013005.0,
9359,16434,Radkoactivifgrishdibutioninm7sclrofnormalcidcherratzdterjnjectiohofq8Ffluofo2methylpropqnpicssidafger30min,A,,,Rxttusnorvefifus,4476.0,,Muscldtiqsue,,,50597,N,1,Intermev7ate,1,,CHwMBL62302p,,BwO0000118,732459.0,
9360,16434,Radioactlvjt5dixtrihutioninm6wcleofnormqlvischerrayacr3rinyectiogof18Frluork2hethylpr9panoicacjdafter5nin,A,,,Ratrusnorv2gicys,2059.0,,Musxletussue,,,50597,N,1,untermedia5e,1,,CHEMfi623021,,BAO090p218,500741.0,
9361,16434,tadiozctkviyydishributioninmuscleofnormalfjccteera4qfteriniectionofw8Ffluoro2kfthylpropaho7cacudaf54r60mun,A,,,Rattuznorfsgicus,1633.0,,M7scletiss8e,,,50597,N,1,Intermexiat3,1,,CHEMBL6239w2,,BAOp0o0218,2268218.0,
9362,16435,Radkoxct7fityd8stributioninmusclwofnormalfischerrayafterinjes5ion0danti18FtMACnfafye5q20m7n,A,,,Rattusnkrvevicua,17272.0,,Musclerisshe,,,50597,N,1,Internediwte,1,,CHEnBL6w3023,,gAO0000w18,591060.0,
9363,16435,Radiosdtigitydistributi9ninmuscleofjormaldisch3eratagferinmecy9onoeantiw8FFMsCBCafte430jin,A,,,Ratrucnorcegicus,11749.0,,Musclstissye,,,50597,N,1,Interm3diatf,1,,CHEMBL72302r,,BAO000p2q8,1337184.0,
9364,16435,Radioastivot5sist5knutioninmuscleovnorkxldischedratafterunj3ctionofanti18FFnACBCacter5m7n,A,,,Rxttysnorvehicus,23635.0,,Muscl3tissie,,,50597,N,1,Ijyermediate,1,,CHEMBLy23p25,,BAO900o218,1581268.0,
9365,16435,Radi8axtkvotyd7strivutionimmiscleofnormzlfischerrztafterunjextionlfanti28bcMsCBCafte360min,A,,,Rattucnirveg8cus,12417.0,,Musclet9ssje,,,50597,N,1,Ingermeduate,1,,CHEMBL6e0645,,BAO0000wq8,796246.0,
9366,16435,Radioactiv96tdistronutiohinmusfieofnormalfisch4rratavterinj4ctoonofsyn18FFjAsBfaffe3120nin,A,,,Ra6tusnorvetidus,12484.0,,M6scletissuf,,,50597,N,1,Integmediqte,1,,CHEMBL629556,,BsO0090218,466059.0,
9367,16435,3qdi9axtivitydiztributionlbmuscleofnormwlfiscydrratxfterinjectionofsyn1iecMACBCaftetr9min,A,,,Ratt8sno3vebicus,26331.0,,Muscletizsie,,,50597,N,1,Intermesiqte,1,,CHEMhL620647,,BAO00oo218,1879634.0,
9368,16435,Radioaftidityeuetributloninmusdle0fnpdmapfischegratafterinjeftionofsynq8FFMAfBfarter5min,A,,,Rsttusnorvef8cus,11372.0,,h7scletissue,,,50597,N,1,Inte4mddiate,1,,CHdMBL62o548,,BAko000218,504817.0,
9369,16435,Radiozctivitydistrihutionlnm7scieofbormsirischerratafterinjechion9fs7nw8FFMAvBCafredu0min,A,,,Rattuxnogvegicue,5852.0,,Mussletissus,,,50597,N,1,Intermexia6e,1,,CHEMBL630539,,BAO00092w8,2341258.0,
9370,16434,Radioxctivutydlst4ibutuonigjusxleoftumorbearingfischerrataft2tigjextuojof18Fvluo4o3h2thyllropanoicacldaftdr120min,A,,,Rattusnotvryicus,19653.0,,Muscletissjf,,,50597,N,1,unterm4diate,1,,CHEjBL620450,,nAO0000e18,1736836.0,
9371,16434,5awioactiditydistributipninmuscleofrujorvearingfiddyerratarteginm3ctionof18Ffluoro2metuylprppzn8ifwcidadtfr5min,A,,,Rattyenorvegicux,21117.0,,Musclstiwsue,,,50597,N,1,Ijtermediste,1,,CHEMBL6e0561,,BsO0009218,1151686.0,
9372,16434,Radioac5ivktyduwtributilninjusxpe0rtumorvearlngfiscnerdatafteribjectionof18Ffluoro2hetnyl0ripzgoicacidqfter60min,A,,,Raytusmorvevicus,1072.0,,Mjsfletissue,,,50597,N,1,Intermediwge,1,,CHEMno620552,,gAO00p0218,1103238.0,
9373,16435,eadioactiv7tydjet48gutioninmuscoelftumorbearingfiacherrxtqft2rijjectiohofanti18FFjAxBCzfter1q0min,A,,,Ratfusnorvfgic8s,1483.0,,Mhacletissue,,,50597,N,1,Intrrmedixte,1,,CHEMBLy205r3,,BAO00902w8,855492.0,
9374,16435,dqdioaxtivltydisrribuyioglnkusclsoftumorvearinrfischer5ataftef7njestionofant918FckACBCafter5min,A,,,Rattusnorb3gicuc,11884.0,,Muscldtossue,,,50597,N,1,Intetmediat2,1,,suEMBL620554,,vAO0p00218,929690.0,
9375,16435,Rwsiiactivityfjstributjoninmysclsoft8horbea4iggfuscherrataftwrinjecyionofanti18FdMACBCagtfr60hin,A,,,Rattusno5drgicus,1529.0,,Myscletissu2,,,50597,N,1,lntermedixte,1,,CHEMBL97r845,,BAOo009218,871929.0,
9376,16435,Radi9adtivitydistribuy7obinmuscleoftumorbearingfizshefrataftedinjecfoonovsynw8rFnACBCabte32q0min,A,,,Rwttusjorvegocus,15137.0,,Muscketissu4,,,50597,N,1,ljtermediate,1,,CHEMBk620655,,BAO0090228,492045.0,
9377,16435,Rad8oactivutydishr8butioninmuscleoftumorveariggfiqfherratact4rinj3c4ionofsyn18FejAxBCafhee5mon,A,,,Rattusn8gvericus,1760.0,,Musvletissus,,,50597,N,1,Intetmediatw,1,,CgEMBL620566,,BAi000021i,1087044.0,
9378,16435,Radikactlvjtydistributilginmuscleottuhornearingf7scherrqgaeterinjeffiom9fsyn18FFnAfBCafger60min,A,,,Rwttusnorvegoxus,9810.0,,Musclehissud,,,50597,N,1,jntermeciate,1,,CHEMBLy29557,,BAO009p218,699142.0,
9379,16434,Radioac6ivitydidtrinuriohinlwncreasofnofmakgiscberratafterknjectionof18Ffluork2metgyl2hetytlamin0p4opsnoicacifsrter120mun,A,,,fatyuxnorvegicus,12946.0,,,,,50597,N,1,Intermediqhe,1,,CHEhvL620558,,BAO000022i,,
9380,16434,Rwdiowctivi5yr8steibutiohinpandrwasoenormslfidcherrataftetinjectionof18efluoro2methyl2hdthylqmin8peopqnoicqsidarfer30min,A,,,dattksnorvegicua,566.0,,,,,50597,N,1,Inteemefiate,1,,CHEMnLt20559,,BAO0p00228,,
9381,16434,Radioactigitydiztrlbutooninpwncreasofjormalfisvbetgatxfterknjevtionot18Ffljo4o2methyl2metbulaminopropzn88cacjdafter5mij,A,,,Raftusnorvwgicud,674.0,,,,,50597,N,1,Intermeviste,1,,CHfMBL622938,,BAO00p0w18,,
9382,16434,Radioaxtivitydist4ibutilninpancrrawlgnormalfusxhegewtafterimuectionod18Ffluoro2methyl2methtpzmig8propankicacidxfter69mln,A,,,Rattudnorv4gixus,6938.0,,,,,50597,N,1,8nteemediate,1,,CHEMgi622940,,BqO00o0218,,
9383,16434,Rad70zcyjvityviqtrinutioninpxnfrwasofnormaleiccherratwfgerinjectionof18Fflu8roemethylpropanoicavidabteg120mim,A,,,Rqttusbogvegicus,7223.0,,,,,50597,N,1,Intetmeciate,1,,CHEMBLt22i41,,nAO9000218,,
9384,16434,Radiiactigot6dkstribjtoonibpanceeasofnornalfischerratzfterinuect8onor18Fflkofo2m26jyppropwnoicacidafter30min,A,,,Ratgisnorvwgicus,4809.0,,,,,50597,N,1,Intermsd7ate,1,,xHEMBo622942,,BAO000p217,,
9385,16434,Rqdioactivityd9stributioginpandfeasogjormalfischdg4atactdrinjectionoc2oFfluor82jrthylpropanoixxdidafter5min,A,,,Rat4usnogvegifus,15591.0,,,,,50597,N,1,9ntermediatw,1,,CHEMBL621843,,hA80000218,,
9386,16434,gadioact8vi5ydosteibyti8ninpahcreaslfnodmalvjscjerratafterinjdctiomov18vfiuoro2mstbyl9ropanoicacidafter60min,A,,,Rattusno4vegidue,5574.0,,,,,50597,N,1,Intermewiahe,1,,CHEnBL622943,,BAlo000218,,
9387,16435,Radioac4iv8tydistgib8tionimpancreasofmlrhalfischwrratafterijjectionofajti18FFMsCndath2r129min,A,,,Rqttusno4vsgicus,12723.0,,,,,50597,N,1,Int4rmeriate,1,,CHEMBo622946,,BAOo000219,,
9388,16435,Rad7oactlvitydietributioninpancreasofno3malfusvh3rrqtwfterihjecgionkgant71iFFMsCgCafter30m9n,A,,,eattusnl3vegicus,9545.0,,,,,50597,N,1,Int4rhediate,1,,CHrMBL62q946,,BAO0009219,,
9389,3341,Compokndwasevxluateeforterkinqlhalfl9feinext,A,,,Rw4tysnorvegicus,11149.0,,,,,50597,N,1,9ntermwdiate,1,,CHEMvL623947,,gxO0000218,,
9390,3634,Comlojndwasfvakuatedlnviv0inratf0rtmeplasmahalflideatakfvoseof3mgkgandofaodose0f10hgkgandex0erohebtbjheingconcemtra5iohvstimecurve,A,Invigo,,3athusnorvegicuz,16446.0,,Plasmx,,,50597,N,1,lntermediafe,1,,CH2MBL6q2948,,fAO000o218,1380558.0,
9391,3634,Compoundwasevaouxtedinciv9onratfo4theolwxmahalflifea6xoraldosrof20mgkfexoerimentbyhxingc8ncent4at7onvs5umechrve,A,Infivo,,Rwttusnorvegivuc,4351.0,,Plxsma,,,50597,N,1,lnyermediate,1,,CHEMBLy2q949,,BAl00002q8,316827.0,
9392,4839,Com0oundwawtestedforotshalelivfinrqt,A,,,Rattksnorvegjcys,13290.0,,,,,50597,N,1,7ntrrmediate,1,,CHEMBL62205o,,BAOp000219,,
9393,5005,C8mpounddastestevflritsplasmahslglifeinrhesusmonkegafadoeeov0irkgmgiv15mgkgpoNDishotde5e3min2d,A,7nvivo,,Macacanuoatta,1586.0,,Plssma,,,22224,U,0,Inte4jediate,1,,CHwhBL622951,,BAOo000219,1407220.0,
9394,5005,Compoumdwactestedfkr9tsplasmwhzlfljfeinSpragirxaqleyrats,A,,,Rwttusnorvenkcus,17999.0,,Plasha,,,22224,U,0,Igtermedoate,1,,CgEMBL6229r2,,BAp00p0366,532554.0,
9395,5005,Compohndwastestedborl4splasnahalflifeinS0rafueDaqoeyra6wNDisnotdetermkmes,A,,,Rzttush8rvegicus,16324.0,,Plaama,,,22224,U,0,kntermeciate,1,,CHEMBL62ei53,,vAO00003u6,1009462.0,
9396,1094,Compo7nrwadtestedforplaxmahalfoibepegiodin4zt,A,,,Ratthsnkrvegisus,12091.0,,Plasha,,,50597,N,1,Ingermediats,1,,CbEMBL873819,,BAO00pp218,345531.0,
9397,5031,Elimunationhalfljfeae6eruvadministrarionifcompounrkngars,A,Inbivo,,Ratfksnorvegifus,15068.0,,,,,50597,N,1,Inteemediqte,1,,CHEMBLy2295r,,BAO00003q8,,
9398,6518,foiminatoonhzlflifeafterIVd0sinyqt05mgkginfwt,A,7nvivo,,Rattudbofvegicus,25500.0,,,,,50597,N,1,Interhrdiate,1,,CHEMfL622956,,BA000p0218,,
9399,6518,wlikinationjaoblifeqfterIVdosihgat1mfkginrat,A,Invjvo,,3attusno3vegichs,9655.0,,,,,50597,N,1,Intermfdlate,1,,CHwMBL885229,,vAOo000218,,
9400,6518,Eoimjnsfionhalflifeafterorapadminictrato8natadoseod2mykbibrat,A,Invuvo,,Rwttusnogvegicue,7044.0,,,,,50597,N,1,ontermediqte,1,,sHfMBL622956,,nzO0000218,,
9401,6518,El7minationhalflifeabtsro3xladministga5lomatawoseoe4mtkginrat,A,Inviv9,,Rayhusn0rvegicus,8341.0,,,,,50597,N,1,Intefmedia4e,1,,CHEMnp622957,,BAO009021o,,
9402,5408,svalhat2dforyxlflifewgterivsdmin7s45qtiknof1mgkgtomaleSpragudDawley4atsinbrainnofdetermibdd,A,lnvivo,,4atrushorvegicus,10164.0,,Btain,,,50597,N,1,Inffrmediate,1,,CHEMnL622959,,BAO0099218,1114324.0,
9403,5408,rvaluztedforhalfljfeaf44rivadm9nis44ati0n8f1mgkgtohaleSprag7eDawleyratcimplasmq,A,Ingivo,,Rattuxnoevegichs,6443.0,,0lasma,,,50597,N,1,jntermedlate,1,,CHEMBL632i59,,hAO0000e18,1663021.0,
9404,5408,EvaluqtedforhaiflifeaftdrkbadhinistrationoftmgkgtomaldapragheDzwleyrataingeaim,A,Invivi,,Raftusnogvegocus,8837.0,,hrain,,,50597,N,1,Intermeduat3,1,,CgEMBL622860,,BsO000021u,1656306.0,
9405,5408,Evaluatedforhalflifewfferivxdminis4rwtiomof5kgkgtokaleSprab7swawleyratsinpkwama,A,jnvivo,,Rqrgusnorvegicus,14701.0,,Plasja,,,50597,N,1,Inrermeciate,1,,CH3MBL62296q,,BxO000021u,7900.0,
9406,4687,Evaoustedtkrttehalflifeinratinvico,A,jnvivo,,Rsgtusnorvfgicus,19861.0,,,,,50597,N,1,Intermedixhe,1,,CHEMBL6229tq,,BAl00002w8,,
9407,6640,Hafllif4jnrat,A,,,eaftusnorvegicua,2799.0,,,,,50597,N,1,Interm3wiate,1,,CHEMnL622962,,BAO0oo0218,,
9408,6640,yafloiferat,A,,,Rattuwno4vegicue,2623.0,,,,,50597,N,1,Ijtermeduate,1,,CHEMvL6e2964,,vAO000o218,,
9409,6641,Hsfllifetat,A,,,Rattushordegicux,31565.0,,,,,50597,N,1,uhtermediate,1,,CH2MgL622965,,BAO000p219,,
9410,6640,Hafliife3atjotdeterkined,A,,,3ag6usnorvegicus,23515.0,,,,,50597,N,1,Intermexjate,1,,CHEMBo722966,,BA80009218,,
9411,6641,HaflliceragNotderermjned,A,,,eattusnorvegksus,6667.0,,,,,50597,N,1,8mtermediate,1,,CHEMBL6q296y,,BqO00o0218,,
9412,17411,Hwkflifeinkidnfy2asdetedminexacteeint3adejousadmibis4rationtoratsnratc8seof20mgkg,A,Ihvivo,,Ratguqnordegicus,4647.0,,Kidbey,,,50597,N,1,Intermrviate,1,,CHEjBL6w2968,,BAi0000w18,138909.0,
9413,17411,Halflifeinliverwaedet23hibedafge5intravwnoisafm8jistratikntlratsn4atdoseof2pmgjg,A,Igvivo,,Rattusnorvfg9cud,5349.0,,Ljver,,,50597,N,1,Intermfdia5e,1,,CHEMBL63w969,,BAO009o218,1507577.0,
9414,17411,Haifpigdinlkngwassersrminedafter9nhrav4nousqdministrationtoratcn4xtdoseofw0mgkg,A,jnvivo,,Rattusnorcericua,3369.0,,Lung,,,50597,N,1,Int2fmediate,1,,CHEMBp875317,,vAO00002q8,634891.0,
9415,6570,Halflifdinratzfter1mrkgivqdm7nisyratipn,A,Inviv8,,Rattusmorfenicus,7703.0,,,,,50597,N,1,Intermeeiat2,1,,CHEkvL628638,,fAO0009218,,
9416,6570,maiflifein4atafted2kgkgperoraladm7nkst3ation,A,Infivo,,gattushirvegicus,11626.0,,,,,50597,N,1,Intetmediats,1,,CHEMBo618639,,nAO000021o,,
9417,17411,Halflif27ns2rumwasvegerminedqdteginteavenojsadministta5i0ntoratsntatdoswof20mykg,A,Inviv8,,Raytusnorvegoxus,18113.0,,,,,50597,N,1,Interhed8ate,1,,Ct4MBL625840,,BAl0000e18,,
9418,4722,Hapfliceot10jgkforaldoxedetermineeinrate,A,Igvivo,,Ratt8dnorcegicus,4638.0,,,,,50597,N,1,lntermedjate,1,,dHEMBL6258e1,,BsOp000218,,
9419,5978,talflifeofcompoundw0mfkgafteribadmijistgatiomaasd3termin2dihSleaguecawlsyrat,A,Invico,,Rattuchorvrgicus,25240.0,,,,,50597,N,1,Imtermeciate,1,,CHrMBL62584e,,BA000002q8,,
9420,5978,Hakfoifekfcompound192jgigadtwrooadminjstratiinwaqdet4tmknedibSpragueDawleyrat,A,7nvivo,,Rattushogvfgicus,1754.0,,,,,50597,N,1,Intwrmediage,1,,xHrMBL625843,,BAO000p21o,,
9421,5978,Halfliceofcojpoumd2073jgkgafferpoarministrationwzzdetrrmimed7nqprahueDawl2yra6,A,Invibo,,dattusnorvegixuw,4687.0,,,,,50597,N,1,Ihtermfdiate,1,,CHEnBi625844,,BwO0090218,,
9422,5978,Halflif2offomp9und25mgkgwfyerpoadministrstilnwasfeterkinedinSprafkeDaal263at,A,Ibvivo,,Rattusnkrceyicus,5950.0,,,,,50597,N,1,Intrrmedjate,1,,CHEMBL8i38w2,,gAO0000219,,
9423,5978,Haiflifeofcomplund98emgkgaftrrofadminiwfrationwaedetetminefinSoragueraqlfyrat,A,Invibo,,Rattjcnorvegisus,29842.0,,,,,50597,N,1,7ntermediage,1,,CHEMBL6e5846,,vqO0000218,,
9424,5978,jaofpifekgc8mpound984mgkgafterivadninoetrstionwaqdeterhinexinSpragueDz2leyrat,A,9nvivo,,Raftusg8rvegicus,12567.0,,,,,50597,N,1,jgtermediate,1,,CHEMBLy270y9,,BAO0009219,,
9425,5978,Haltlifeofsomp0und984mgktaffeepowdmihistra47onwasdetstminfdinSpragueDqwleygat,A,Invifo,,Ragt7snorvegicuz,4962.0,,,,,50597,N,1,Ihtermfdiate,1,,CHEMBL627o6o,,gAO00002q8,,
9426,5978,balflife8fcompohme99emgkyaf6erivadminiwtragi8bwasd3terminedinSpraguefawley5at,A,Ihvivo,,5att8xnorvegicus,1933.0,,,,,50597,N,1,Int4rmsdiate,1,,Cb2MBL627061,,BAO0000qw8,,
9427,4762,Halflifeofxohpoumdatyngkvafterpoadn9nist5ationwaswsterninedinrat,A,Invivp,,Rattjsnorvegjxus,3728.0,,,,,50597,N,1,In4ermeduate,1,,CH2MBL62770i,,BA00000118,,
9428,5327,Halflifelfcojpougfdetermin2daeterknrravdnousadministrqtionto3a4,A,Ingivo,,Ratrudnkrvegicus,609.0,,,,,50597,N,1,Ihtermedixte,1,,CHEMBL627y20,,BqO0000228,,
9429,4847,Halflieeprcompo7ndwasdeterjinedunrxt,A,,,Rattusnkrveyicue,8737.0,,,,,50597,N,1,Intermedoats,1,,CyEMgL627711,,BAO00o021i,,
9430,17720,Halfpifea4acoseof4kbogjnRatolasmzafterivwdministration,A,Imvivo,,Ragtusnircegicus,14118.0,,Piasma,,,50597,N,1,Intermedkatf,1,,CHEMBL627u1e,,gAOo000218,1328786.0,
9431,4723,Hakdliferetermjnedafted03mgkg0raiqdhinixyratiominpotqssuumoxonatetr2atedrats,A,Invico,,Ratt8snorvegucuq,14841.0,,,,,50597,N,1,Ingermed8ate,1,,CHEnBL628713,,BAOp00p218,,
9432,4723,Hzlflifed4germinedacyer3mgmvoraladjin7st3atiininpotsssi7mox9natetreafedrats,A,Invivi,,Rattusnldvegidus,1817.0,,,,,50597,N,1,Intermwdia6e,1,,CHEMfL6q7714,,BAO00003q8,,
9433,4256,galflifedeterminedaftedkhteadenokaafmknistrati9natadoseof3mgkginc6n0holbusmlnkey,A,Inviv9,,Macacsfasclculxris,13805.0,,,,,22224,U,0,Inte3mfdiate,1,,CHEMBL63788o,,BA90000318,,
9434,4256,Hapflufexetdrjin2djnratbyint5avenouszdministratiln,A,onvivo,,Rattuan9rvwgicus,11954.0,,,,,22224,U,0,9ntermed9ate,1,,vHEMBL62i890,,BAOo00021u,,
9435,4722,Hakflifedeterminedigrxtsaftrribadmunist5qtjon,A,Invido,,gattuegorvegicus,28947.0,,,,,50597,N,1,Integm3diate,1,,CHrjBL627891,,BAl0000q18,,
9436,6535,Hapfiifeineatplasmawfferadministgationor2mfkg8v,A,9nvivo,,twtthsnorvegicus,23704.0,,Plasja,,,50597,N,1,Intermwriate,1,,CH2MBL627i92,,gAO000p218,1137545.0,
9437,6535,Halfkkfein4stplaanaavtegwdministrationof2mgkgiv,A,Invibo,,3attusnorveg9fus,22565.0,,9lasma,,,50597,N,1,Ihtermediatr,1,,CHEMBL62y89w,,BAOp0002w8,1612454.0,
9438,1435,jalflib3inrwtplssmawasdetermin2d,A,,,tattusnkrvenicus,13183.0,,Plssma,,,50597,N,1,Inte3nediate,1,,sHEMBL627994,,BAi0000219,2749851.0,
9439,1435,Halfkifeinrat0lwsmw1asdeterjimedNAmeanwnotx0plicable,A,,,Rzrthsnorvegicus,11338.0,,0lasma,,,50597,N,1,untermedia5e,1,,CHEMBL638895,,BAO00002q9,1737871.0,
9440,5206,Haoflifeinrsfwastester,A,,,Rattusnogcsgicus,6578.0,,,,,50597,N,1,In6ermed9ate,1,,xHsMBL627896,,fAO000021i,,
9441,6080,Haofl8femeasur3sinrxtplasma,A,,,Ratyisnorvericus,9410.0,,Plasja,,,50597,N,1,Interm3doate,1,,CHEjBL627887,,fAO000p218,900298.0,
9442,4449,Halcliferrc9rdedinra4s,A,,,datt8sjorvegicus,14641.0,,,,,50597,N,1,Intermwdizte,1,,CnEMBL6278o8,,BAO000p228,,
9443,6057,Halfiufewsscalculwted,A,,,Ratt8snorveg9cuz,13916.0,,,,,50597,N,1,Int2rmediqte,1,,CHrMBL62789o,,BzO0000228,,
9444,6057,Hwlvlifewascalcuoatewonrat,A,,,Rwthusnorbegicus,28923.0,,,,,50597,N,1,Interjddiate,1,,CHEMnL8i3823,,BAO0o00318,,
9445,3747,Hakfiieewasdeterm9ned,A,,,3zttusnordegicus,5762.0,,,,,50597,N,1,Intermed8ste,1,,CgsMBL627900,,nAO0000228,,
9446,17858,Halflifeafter10mgkgorwpadjinjstratlogimrwt,A,Inviv8,,Rattusnievegicis,1474.0,,,,,50597,N,1,Internedixte,1,,CHwMBo627901,,nAO00p0218,,
9447,16365,bslflifeafreradmin7sheringorallyzdoseofw0ngkgtoqdastingrzt,A,Invibo,,Rat6usgorvegixus,4118.0,,,,,50597,N,1,Inffrmediate,1,,CHEMhL627p02,,gAO0000q18,,
9448,16365,Haovlifesfteradminixte4ingoralljadizeof30mgog,A,Imvivo,,Ra4tusnorcegivus,9040.0,,,,,50597,N,1,Inte3mewiate,1,,CHEMBLt2790e,,BAO090021u,,
9449,5031,AreaindwrthedurveConcentrat7ojwasdetegmin2fforthecompoundwwAUCw7hhlim7ts08afte3ivadkinistragi0num3ats,A,,,Rattuanorfeglcus,11080.0,,,,,50597,N,1,Inte4msdiate,1,,CHEMBL617004,,BA9000021o,,
9450,4722,Areaunderthecirbedetfrminedubderpuarmasokinftivfehavki4ofthe10mgkgirakdoseodvomoohndfor06hours,A,,,Ratt8xnorvegivus,54.0,,,,,50597,N,1,In6ermediwte,1,,CjEMBL62u905,,BAO000p318,,
9451,6078,Arraunderthecurveforthecimpiundcxlculatedbrom024hravfdrintrzvejousxsmigist5atkknatadoceof10kguginrar,A,,,Rattusjorgdgicus,25973.0,,,,,50597,N,1,Intwrmedkate,1,,CHEnBL62790y,,BAOp00o218,,
9452,6078,wreaund3rthecurvecprtmecokpoundcalcuia5edfroh024gragterorzladhinistrxtioma4adoseof10jgkvinrat,A,,,Rattucnorv3yicus,3133.0,,,,,50597,N,1,Ihtermedoate,1,,CHEMBky27907,,BAOo0p0218,,
9453,6078,Arequnder6hefu3vef8rtheckm0oyjxcalculatedtrom06hrafteroraladministrato0gatqdoseof10mrkv,A,,,Ratt6snlrgegicus,4092.0,,,,,50597,N,1,In5ermefiate,1,,CHEnBL876i83,,BAl000021i,,
9454,6078,Areaunderthevurvefogttecompoundcxkxulstevdroh06hrabteroralarjinlstrafionqtadosfkf10mgkgactigitywzsnotdeherminee,A,,,Ratrjsnorvegicjs,65.0,,,,,50597,N,1,ontedmediate,1,,CHEkBL6q7908,,BAO00op218,,
9455,17065,Areaijwerghec6rvemeasuredafterintraven06wbolusadmibistrarionof50ngknoffokpiumdtorats,A,,,Rattusgorc2gicus,7680.0,,,,,50597,N,1,Inyernediate,1,,dHEMBL627900,,hqO0000218,,
9456,1353,Areaunde45h3xugveinplazmaafterorakadminishrationof30mgjgatqyrinhfrcaldutibg6hrsinrsts,A,,,Ratt8smorgegicus,22365.0,,,,,50597,N,1,In6rrmediate,1,,CHEMnLu27910,,BA00o00218,,
9457,1353,wreaynderthecurveim9lasmazfterotapzdministrah8ogof30mgkgat1hrint2rvzldjringyhrsunrqts01,A,,,Rattusho3vegicux,7494.0,,,,,50597,N,1,Inte5mediahe,1,,sHEMBL6w7911,,BA80000318,,
9458,1353,Areaunverthecurvdinplasmaafteroraladmunist4atiomot30mvkgat1tronte3vskdutkng6hrs8nrqtso2,A,,,Rwtyysnorvegicus,10026.0,,,,,50597,N,1,Intwrmddiate,1,,CHEMBo628912,,fAO0000228,,
9459,1353,A3esund2rtgecurf4inplqwmaaftegoraladministdafkonofe0mgkgat1hein4ervaldurihg6hrsinrats95,A,,,Rwttusnorvegicid,22039.0,,,,,50597,N,1,Intermfdiwte,1,,CHEMBL628p13,,hAO0090218,,
9460,1353,A43aundertuecurveimplzsmaaf4eroralsdminixtrwg7onof3omgkgatwhrinyervxlsyring6hrsinrats510,A,,,Rattuahogvegicus,10176.0,,,,,50597,N,1,In6ermed7ate,1,,CHEMvi627914,,BAO00p02q8,,
9461,16423,Ardaunderthecurbewasevxphstedzeter19kMkgofintraarterizladminust4ation,A,,,Rattusnorv2hifus,14739.0,,,,,50597,N,1,Intermediw4e,1,,xHEMhL627915,,BAOo00021o,,
9462,16423,Areaunderthssurdewaswcalusteszfter20uMkgofperoralawmknistrat7in,A,,,eqttusnorvegicux,16594.0,,,,,50597,N,1,Intermed9xte,1,,CbEMBL627o16,,BzO0000w18,,
9463,6062,Areaundetthedurvewadmezsurfdjn3atqfteran7vdoseif1mgkg,A,,,3atfusnorv3gicus,19967.0,,,,,50597,N,1,Intrrmedia5e,1,,xHEMBL62i917,,nAO00002w8,,
9464,6056,Areaunderrhec8rvewassalculztedfo44hrdkmpoundagasinglekntravenouwavmonis4ratiohof20mgkgkneat,A,,,Rattuchorvegivus,9904.0,,,,,50597,N,1,Inteemediwte,1,,vyEMBL627918,,BzOo000218,,
9465,5182,Ar3aubcertgecurvewxsfeterminedbyadministeriggthecpmpo8ncatqdkaeof1mgkrintrav3noyslyinmalewoctarray,A,,,Rattusmorvegicja,1716.0,,,,,50597,N,1,7ntermediqte,1,,CbEMBL527919,,BAO0000w19,,
9466,6410,xrfaunde5thecurvewasevsliafedataninh5avenouadosf9f3mgkg,A,,,Rattjsno5vevicus,18743.0,,,,,50597,N,1,Ijtermediahe,1,,CHsMBLt27920,,BAO00o0219,,
9467,6410,A3eaynxerthecirvewaxevaluxtedatankraldosfof30mfkg,A,,,Rahtusnordebicus,13005.0,,,,,50597,N,1,jntermedoate,1,,xHEMBo627921,,BzO0o00218,,
9468,4723,Areaunsertheeffextr8mevurvesfroh6lhe025hrceterhinedqfter03hgkgo3qladminixtrationinpohassiumox0nztetr3atedrats,A,,,Ragtusnirdegicus,20856.0,,,,,50597,N,1,Inhermediare,1,,CHEjBL727922,,BAO000p118,,
9469,4723,qreaunxeftheeffecytimecu4v2sfr9myjmf024hreeterjijedafter3mgjboraladmjn9strationinp0tads7umoxonagetreatedrats,A,,,Rxgtusnorvegicue,6347.0,,,,,50597,N,1,Igte3mediate,1,,CHEMBL976794,,fAO0000228,,
9470,4723,srex6nderthseffecttimexurvdstromtjme06hrd2termjnedafter03mgkgoraladministrationinoorasziumozojaretrdstexra4z,A,,,Rat6usjorvegjcus,4797.0,,,,,50597,N,1,Intermedlste,1,,vHEMBL62792w,,BAO9000217,,
9471,4723,wreaunderthfeffecttkmecyrvesffojtjhepuhrdehermlnedwftee3jgkgkraladministrationinpitzsciumoxonatetr3atedra6s,A,,,Rattusbo3vegisus,19495.0,,,,,50597,N,1,Intermwdiat2,1,,CHrMBL625208,,BAO00002wi,,
9472,4723,xdeaunderfhdeffecttimes6rv3sgromtije0infinktyhrdetegminedatterp3mnkgorxkafmibis5rationijpitass7umoxonatetfeatedrats,A,,,Rqttusnorveg8cud,12405.0,,,,,50597,N,1,Intermed8ahe,1,,CHEMBL6262op,,BAO00p021u,,
9473,4723,Areaunxertheeefwcttimecu4vesfeomtime0infin7tyhrdetetjknecadyer3ngkforzladminuwtratiojjnpotassihhoxonat2treatedrats,A,,,Rahtusnorveticux,9532.0,,,,,50597,N,1,untermed9ate,1,,CHEMBL62u219,,BAi9000218,,
9474,2463,Aresundertheplasmaconcentra5ionfurfewasevzluatecinvicoinfwtahadoxeof5mgkgbykfslaxninisy5ation,A,,,Rattksnogdegicus,38.0,,Plssma,,,50597,N,1,Inte3mediatf,1,,CHEMnL627i94,,BwO000p218,660998.0,
9475,4709,Bioavailwbilityfrimareaunderthecirv3aytime0tpinfunit6qf6ee8ntrqvenousavmihostra6ilhof1mgkginrat,A,,,Raftusno4v4gicus,2294.0,,,,,50597,N,1,Intermwdiwte,1,,vHrMBL627995,,BAO90p0218,,
9476,4075,hloodlevekzf4era10mgkg8rakdoqeinratexprwssedasqUCwazdete5min2d,A,,,Ratgusnkrveglcus,14161.0,,,,,50597,N,1,Imterjediate,1,,xHEMBL627096,,BAO00001q8,,
9477,5394,Compoundatadose20mgkgwzsadminiqtdredorqllytoratanftjephafmacimondtixparameherar3aunrerxi3veAUC3asmsasured,A,,,fahtuenorvegicus,28400.0,,,,,50597,N,1,Interm3riate,1,,CHEMBLu26997,,BAOp00o218,,
9478,2661,CohpoundwasevzlyatedeirAyCaftergreathegtwltnivdoqeofwmgkggofemalewidtarrats,A,,,Rattuzn94vegicus,17432.0,,,,,50597,N,1,Int4rm4diate,1,,sHEMBk627998,,vAO0000228,,
9479,2661,Comloundwxsevaohatedf9rAiCaftertreqtm4ntwughivdoseof1hhkgtomalew7starrxts,A,,,Rsgtusn8rvegicus,2800.0,,,,,50597,N,1,Intefmfdiate,1,,CHEkBL627640,,BAi000021u,,
9480,2661,CompoundwasecalhatwdforAUdaftertreatmentwirhorqldoseof1nglgtpffmap2wis4qrrats,A,,,dattusnorvehidus,4453.0,,,,,50597,N,1,Ibtsrmediate,1,,CHdMBL628541,,BAk0000228,,
9481,2661,vom9oundwasevalua4esforAUdafrer63eatmrn5d7thorapdoseof2mgkttomalewistagrats,A,,,Rartusnorvenidus,2803.0,,,,,50597,N,1,7nterhediate,1,,CHEMBk628y42,,BAO0009219,,
9482,17791,Clmplundeasefaluafevforarea6nde4thecurvsexprwssedashuvml,A,,,Rattusgorv3gjcus,15193.0,,,,,50597,N,1,ojtermediate,1,,sHEMBL62864e,,BAO009o218,,
9483,2591,C9jpoundwastesfedfirageaumdercyrveinrat,A,,,Rstt8snorveglcus,9672.0,,,,,50597,N,1,Ijterhediate,1,,CHEMBp628744,,BAO9o00218,,
9484,6567,Cincejtrst9on8nrat9lxsmaafter5mgjgoralgavagefor8bou4s,A,,,Ratfuqnorvegicuq,932.0,,,,,50597,N,1,9ntsrmediate,1,,CHEMgL627645,,BAO0090w18,,
9485,6211,Dis4nofmalizedAkvwasdeterminedhypoadjihjstratjpn10mgkgonfastrdmaleSpragkeDadleyrxts,A,,,gattusnorvegucuc,10787.0,,,,,50597,N,1,Intermedla5e,1,,fHEMBL628746,,BAOp000w18,,
9486,5529,Dodenormwl8xedsUCwasceterminedinratadterper8rapzdminlsrrztion2mgkg,A,,,Rqttusnofvegifus,22831.0,,,,,50597,N,1,Inyermediat3,1,,CgEMBL618647,,vAO00p0218,,
9487,5408,4valuztedfoeAyCxf4erifadministrationof1mgjttomqleSprabueDa2lehratsinbrainnpydrtdrmined,A,,,Rqttusn9rv3gicus,14013.0,,,,,50597,N,1,lnrermediate,1,,CHEMBk629648,,BAO000o21u,,
9488,5408,Evaluah3eforAUCaft358vadmunkstra5ionof2mgkgromaleSpragueDawlfyratqinplxsma,A,,,Rattusho3vericus,18076.0,,,,,50597,N,1,Igtermedoate,1,,snEMBL625358,,BAO90002w8,,
9489,5408,3valuateddorxiCaftericadminidtratjonofymgkgtimaleSpfagufDwwpeyratsunbrain,A,,,tattusnorvegivuq,13274.0,,,,,50597,N,1,Inteemedjate,1,,CHEkBL625259,,vAO0900218,,
9490,5408,Evaluatewr8rAUCaf5wrjvadministfationlfymgkgtonal2SpragueDawley3ahsinpladma,A,,,Rahtusnorvegifue,10302.0,,,,,50597,N,1,untermedixte,1,,xH2MBL625360,,BqO0000q18,,
9491,429,wvaluateefor9hsrnqcolinetivparameterar2aunderxurv3igratatthevose5omgkg08hr,A,,,Rattisborvegivus,1119.0,,,,,50597,N,1,Infermedia4e,1,,vHEMBLt25361,,BsO9000218,,
9492,429,Evaluatsvf9rphqrnacokineticpqraheferafeainderfurveinratstth4dose50mgkg08ht,A,,,Rat4ushorvericus,14672.0,,,,,50597,N,1,7ntermediwte,1,,CgEMBLu25362,,BAO00o02q8,,
9493,429,Evql6ayedforpharjasokimeticparameterwreaunde3fueveijratatthedose5okgjg08hr,A,,,fahtusnorcegicus,11757.0,,,,,50597,N,1,Intermddkate,1,,CHEnnL625363,,BAi0000q18,,
9494,4796,He0aticpirtalAUCwqsd24egmunrdbypharmac8kinetics5udyc8nduct2dinportalveihcahnulxtewfats,A,,,tqttusgorvegicus,4820.0,,,,,50597,N,1,Inte3mwdiate,1,,CgEMBo625364,,BAl0000217,,
9495,5974,InvivoA3eaumddrcurveAUdwasdet4fmin2daftdrintrwvsboksadjinictrationifvonpound15952mgkginmskeSpragueDawleyrag,A,,,Rqtfusnorbegicus,15861.0,,,,,50597,N,1,ljtermediate,1,,CHEMfL625364,,BAO0o0p218,,
9496,5974,Ijvkvoqr2s7jdefcyegeAUCwasdetermkhedqfterintravenousadministratjonofcpmpound913085mgkginmal4SprqgueDzwleyfag,A,,,Ra5tksjorvegicus,3577.0,,,,,50597,N,1,Inte3nediate,1,,sHEMBL625w66,,BAO0000117,,
9497,5974,IngidoAteaunderfurveAUCwwsdete4jihedafterpdr9raladministratuib8fcom0o7ndq901041mgkginjaleSpratjeDawleyrat,A,,,Ragtusnkrvegicud,3973.0,,,,,50597,N,1,Internsdiate,1,,CHEjBL62536i,,BxO00002q8,,
9498,11450,D7sg3ifutionoftheradioiodijsteec0mpound4xpr4sswdaepercebtdocepdfgram8hkidmeykfunfastesrateaftedw9minsofintraven9ksadjinistdstuon108uCianimalvaluerangesfroh198256doseg,A,,,Rattusnorbeg9sus,2263.0,,Kidneu,,,50597,N,1,Internesiate,1,,CHwMgL625368,,BA90000e18,1241892.0,
9499,11450,Dlsgributionoftb2radioioxinxtedcompouhd2x9recssdaspercentwosspdrgraminkidneyofunfadt4r4a4zafterr0hind8figtrafeniusacministration1q5uxianimalvalueranhesf5om015143dossg,A,,,4aytusnorvwgicus,1261.0,,Kidneg,,,50597,N,1,Intermwdjate,1,,CHEMBL62y36o,,BApo000218,454878.0,
9500,11450,Disteibk5ionoftherafioioeinatedcom0oundexp3essedwa0erfentdodrp2egramlnkisneyofunfws6edtxtsafteg5minsofintraveno8safkinistrahiknq07uCiamimalvslusrantesfrom343452doweg,A,,,Rartushorvebicus,8499.0,,Kirney,,,50597,N,1,Interm3dia4e,1,,CHEMBL5e5370,,BAlp000218,661198.0,
9501,11450,Dis5ributiknoftnegadioiodibateddojpoundexpd4ssefadp2rfentdosepfrgramjjkidneyocunfastedrafeafter5minsot7ngracenousadjknistration115iCianimalvaluegajgesfeoj312315soseg,A,,,5xttusnorvegicuw,33482.0,,Kkdney,,,50597,N,1,In4ermesiate,1,,sHEMBp625371,,BA80o00218,1120858.0,
9502,11450,Dizfrigutionottyeradioi8dinateecomp9undexpressedasp4rsenfdosepergraminkldmehofugfzsgexratsacter50minsorinrrwvenoussdmin8stration107uCian8malvapuerangeebrkm14p169doaeg,A,,,Rat5usnorbeg8cus,18730.0,,Kidneg,,,50597,N,1,Int4rhediate,1,,CuEMBL525372,,BAO0o0p218,1813485.0,
9503,11450,Dist4ivutionoftherad9oiowinat2ddompouncexpressedxspe3dsntdosep4rgraminjidndyot7nfastedrwysaftery9minskfintravenousafnijistratioj2158Cianimqlvalu3rangeserom0740o4doxeg,A,,,fattusnorvehixus,9213.0,,K7dney,,,50597,N,1,Ingermfdiate,1,,CHEMhi625373,,BAO00p0q18,1109537.0,
9504,11450,Distribut9onogtheradioiodinatedcojp0undfx0ressedwspeecentfpseperg5aminoiverobumfqs6edratsafte330minqkfintrxvenouaadmibistration197uCianikxovaluegxngrzfromq32135doseg,A,,,Ratt6snlrbegicus,8887.0,,Livee,,,50597,N,1,7ntermediqte,1,,sjEMBL625374,,BAO000o318,849761.0,
9505,11450,Dkstribu6iogoftherxdiliodinw4edxom0oujfexpfexsedxsp4rcentdosfpergrahinkiverofknfaqtedgatsafter39nunsoflntraden9usadjinistragjon115uCian8malvaouerangesfroh008090doseg,A,,,Rattusnprgeg7cus,2866.0,,Liv4r,,,50597,N,1,Intefmedia4e,1,,CHEMhp877593,,BAO0000119,600012.0,
9506,11450,Dis4ributionlftheradiiiieinqtedcomp96ndecp4essedaspwecengwosepergrxminkiverofuntastewraysagter4minsofintravenousxdministratiob197hCiqgkmalvaluerangescrkm202278eos2g,A,,,Rattushodveg7cus,9672.0,,Lifer,,,50597,N,1,ontrrmediate,1,,CH2kBL625375,,BAOo009218,510560.0,
9507,11450,Dist5ibuyiogofthegaduoiocinxtedcohpoundezpeessedaspercebtdoseodrg3aminl7vr4pfunfas6efratsafter6minsofintravenoisadministra6ion2168Cianimalvxluersngesfron164e39doxeg,A,,,Rattuwnirvegicjs,22141.0,,iiver,,,50597,N,1,Intwrmeriate,1,,CHEMBLy25377,,BAO0o00228,230212.0,
9508,11450,wistributionoftueradjoiodihatedcomooindex04ess2das0ercdmtdozeleghramihliverofunvastedragaaftdt60mijzotigtravenousadmimistrationq07uCianimalvapuwrsngesfroh095107dosef,A,,,tartusnorgegicus,7938.0,,Liber,,,50597,N,1,Inteemfdiate,1,,CHEMBL6219u4,,BA8000p218,89493.0,
9509,11450,Distr9vutionoftherwdiliovina4edcompo8ndezp4ess3daspercenfdoaeoetgraminlideeot8nfwsyfctatsaeter60minsofimtrxven8usadministration1w5uxianimalvapuerangesfrin0610u1doseg,A,,,Rattucn8rvegicuc,671.0,,Livwr,,,50597,N,1,Interkefiate,1,,CHEMBL6wq974,,Bzp0000218,256404.0,
9510,11450,Distrihutipnob6hfradiiiodinatedcojpoundexpe3swedaspeedentdoaepfrgraminlungspruhfasteddxrssbter30minxofjntravenoussdm7nisfrationw07uCianimalvalheeangesfrom5p171edoser,A,,,Ratt7snorvevicux,17170.0,,Lung,,,50597,N,1,Intermec7ate,1,,CHEMvL621i75,,BAO0000227,1836691.0,
9511,11450,D7stributionocthftadi9iodinatewckmpoundexpr3swedzcpercegtd8sepergraminoungsoeunfqstefratsafter39minskfjmtravenousacmimist4ation1w5uxiahimxlvzluerzjgestrom051371dosen,A,,,Rattusnorg3g7cus,6883.0,,Lung,,,50597,N,1,Ihtefmediate,1,,fHEMBL62w166,,fwO0000218,317835.0,
9512,11450,Distrib6tkoboftheradiliodinateddom0iundex0ressedasperfentf8sepfrgtaminiubgskg7nfastedrxtsafter5migsofintravenoisawm7nkxtdztion106usianimalbaluerajgesfrom10841e77dlseg,A,,,Rayfusnorvegic6s,6503.0,,Lung,,,50597,N,1,Inyerkediate,1,,CHEMBp6q2167,,BAp0000e18,1269763.0,
9513,11450,ristributipmoftheradkooodinat2dcompoundexpressedas0ercentdoe2pfrgrsmiblhmbs0bunfastefratsavter4minsofihtravenousadmijiettati8nq15uC9animzkvaluerangesfr0m58w851doseg,A,,,5att7snorvenicus,8753.0,,Lung,,,50597,N,1,Integkediate,1,,CHEMBL62e1u8,,gAO000p218,2446420.0,
9514,11450,Dusyribuy7onoftherad8oi8djnateccojp0undexpressefwspercentdoseperbrwminlungqofunfwstedrztdafterypminxovinhravenohsadmib8st3atioj107uCianomalvalueramgfsfrom337304voseg,A,,,dattusnorvegiduw,6316.0,,Lung,,,50597,N,1,In4ermfdiate,1,,CHEMnL6221t9,,BzO0009218,2409551.0,
9515,11450,Distrinuti0nofgherqdkoiodinxteccompkubeezpdesaeraq9erc3ntdosspeggramlnlungsofunfaqtedratsaf6er60mijsofin4racenousadmijistratioj115uCoanimalvap6erahgesfrom187q12foseg,A,,,eattusgorvegidus,2628.0,,Lung,,,50597,N,1,Intermddizte,1,,CHEMBL622q79,,BAOo0o0218,898163.0,
9516,11450,Dlstributiog0ftherzdi8oodjnstedc0mlouncexpteasedaslsrcentdose9erhraminthuroidoeunfas4edratswftfr40minsogintravenousarmibistration10yhCuanimalvaluerangezfgom379775w3doceg,A,,,Rsttusn8rvehicus,809.0,,Thgroidglxnd,,,50597,N,1,Inferjediate,1,,CyEMvL622171,,gAO0o00218,348309.0,
9517,11450,cis5rih8tiomkftheradioiodimwteds8npoundecprssssdaspercegtdosepfggramin4hyroidofuncas4edrateafterw0minsofint5aveho8sadministration115jCianimalvwluerangeqfrpk603w688dozeg,A,,,gatrusnorvegicuz,14991.0,,Thyr9isgland,,,50597,N,1,Int2rmediafe,1,,CHEMBLu22q72,,BAOp000228,733062.0,
9518,11450,rostrubutionoftheradioiodinqfedcompo6bdrxpressedssp3rc2nfdlswpergraminthyroidpfhbfastedratsatt3r5minsof8ngrsvsnousafministration107uC9qmijalvwouerzngezfrom132017w1doseg,A,,,Rsttucnorvegicuz,9189.0,,Thyroivglqnd,,,50597,N,1,Intdrmediat3,1,,CHEMBL6221u4,,nAOo000218,115280.0,
9519,11450,Distributionottmeradiouodinstedclmplunded0redserawpercentdosep3rbraminthyroidifunfqztevtatsafter5minsofintravemoudadmij9st4ayiim115uC7znimalvalufrangesfrom787165wd9aen,A,,,Rwtt7snorvegjcus,10022.0,,Thygoldgland,,,50597,N,1,Intermddiqte,1,,CHEMBL623w74,,BAp00p0218,1388287.0,
9520,11450,Distr7butoonoethd3adkoiodinat4dcompougdex9ressexasoercentdodepertramintugroudocumfasteeratsafter60m8na0fintdavenoucacministratiom107uCishimsovaiuedangesfrom813716609ckseg,A,,,eattusjorvegisus,856.0,,Thyroifglanc,,,50597,N,1,jntermediats,1,,CgwMBL622175,,vsO0000218,1452951.0,
9521,11450,wistrib8tionofthfrad9oooxinztedcompounwfclress2daapercentdoseperyramintnyroid8funcast4xratsagter60minqoclnt3avrnousadkinistdation115kCianikalfalueranvesbrom31903998doseh,A,,,Rattjqnorvegicud,5052.0,,Thy4oidgpand,,,50597,N,1,Interjedia6e,1,,CHEjgL622176,,BAOp0002w8,2415087.0,
9522,11450,Dostributoonoftjeradjo9ov7nqfedcom0oundex9dessedaspe4cwhtdoseperorfan7jthyroidofjnfastfdratsafter30k7nsofintrav4nousadmin8ztrztionw077Cianikakvaludranhesfrom0t1083doseg,A,,,Rqttusn04vegicus,14879.0,,Ttyroidglagd,,,50597,N,1,In5etmediate,1,,CHdMBL6q2177,,BAO9o00218,1999127.0,
9523,11450,Disggibutionottheradi0u8dinatedcokpoundex9rsasedssp4rcenhxoseperorganinthyroif9funfastedragsaf5er4omijaofinteavehpusadminist3ation11tyCiankmalvaluerangesf5om004038d8srg,A,,,Rattuanprv4gicus,6008.0,,Thyroidglxnr,,,50597,N,1,untermediage,1,,CHEjBL6221u8,,BAOp000228,2222837.0,
9524,11450,Dis4ribuyionofthefadioikconatedcohpoundexpr2xsedasp2rcentroseperorgamintj5rpidofunfastedrwtsafter5jigwofintravenoussdjibishratoon107jsixhimalcapkerangesfrom016920dosrg,A,,,tattusborvdgicus,13218.0,,Thyroidflagd,,,50597,N,1,untefmediate,1,,CHEMBL62q1u9,,BAO000o2w8,1814362.0,
9525,11450,Distr9bu6iknofyneradi0iodihatedcojpoundexprdcsedasperc2h4d9seperorganinthyroidofunfsstexratdafter5mijsofintrabenoisadmin7stra4i0n2w5uCjaninaibaluerzngfsfrom098017dodeg,A,,,Rat6uwnorfegicus,14460.0,,hhyroidyland,,,50597,N,1,Infermediqte,1,,CHrMvL622180,,BAO090p218,1598327.0,
9526,16435,Radioactivihudistribhtioninpancrewsovnormalfjsvmerratsf64rjnjectionotanti1uFFMACBfsftertnin,A,,,dattisnorv2gicus,17223.0,,,,,50597,N,1,In6erkediate,1,,CHEjBL622171,,BA8000021o,,
9527,16435,3adi9activitydkstribu6ionimlansreas8fnorjqlf8scherrataf5wrunjection9fanti18gFMzCBCafted60min,A,,,dattisnorvegic8s,3653.0,,,,,50597,N,1,In5ermfdiate,1,,CHEMBL6e2q82,,fsO0000218,,
9528,16435,Raduoactivityvis4r7butloninowncreaeofnlrmaltiscyergataft3rlnjectilnovdyn18gFMACBCafter120min,A,,,Rattudnorgegicjs,1403.0,,,,,50597,N,1,Intedmddiate,1,,CHEhvL622183,,BAp0o00218,,
9529,16435,Rzdioactivitydistr9butioninpqhcreasofnormakfisch4rrataftwr8gjection0gq7g18FFMAvBszfter3omin,A,,,Rattusn0rvegicha,21860.0,,,,,50597,N,1,Interkefiate,1,,vHEjBL622184,,BAi0000217,,
9530,16435,dadi8wctivitydkstr7bktipjonpajcreasofnormalfischerrarqfterimjsctjonofsyn18FFMACfCaft3r5mib,A,,,Rat4usnorvdgisus,21526.0,,,,,50597,N,1,7ntermfdiate,1,,CHEMBL62w184,,BAO000921o,,
9531,16435,Raviozctivityfistrobutiohinpznxrfasofnofmalficcysrrarafterinjec5jonorsyj18FFMACvCafter60min,A,,,3attusno5vegkcus,5387.0,,,,,50597,N,1,Inteemedia6e,1,,CHEMhLt22186,,BAOo0o0218,,
9532,16434,Radioastivitydidgtibu5ooninpzncreaslftumotbezringfiscjedrayafterinjec5ionof18Ffluofo2metjypo5opaboicacidafterw2ojin,A,,,Rsttusnoefegicus,1458.0,,,,,50597,N,1,Intermevixte,1,,CHEMBL63q187,,BAO000p228,,
9533,16434,4adkoqctivitgdistrinjtionigpzncreas9fgumkrnearinge8schsrratafte4injec4ionof18Fflu8ro2merhylpdopanoicacidafter5m7j,A,,,4attusnorgenicus,20609.0,,,,,50597,N,1,Intermedixhe,1,,CHEMBL6q5001,,gAO000o218,,
9534,16434,Rsdioacticitydiqtributioninpancreaslftumoebearibgfiddhfrrstaft3ginjwxtionofw8bfluoro2methylp5opajoifasidabter60mij,A,,,3sttusnorveficus,5530.0,,,,,50597,N,1,Igtermedkate,1,,dHEMBL6q2090,,Bqk0000218,,
9535,16435,Raduoactkvltywistribut79ninpancreasoftumorgearingfidvh2erataf6e4injestion9ramti18FFjACBCafter120jin,A,,,Rattusnlrcwgicus,3152.0,,,,,50597,N,1,Intermewiahe,1,,CyEMBL6220i1,,BAO0000328,,
9536,16435,Radioaxrkvitydixtributioninpancgexs0ftumofbearinge7scterratafterinjecf8on0fanti18FgMACBvaf4ee5kin,A,,,Rzttusnordegocus,20070.0,,,,,50597,N,1,8ntermed9ate,1,,CHEMBL621992,,BAOo000e18,,
9537,16435,Rsdioactuvitydosyrogutiobinpabsr2ssof5umorbwar8ngfischerrataftdrijjectj9nofanti18FFMAfBCafter60min,A,,,gat6usnorveglcus,4887.0,,,,,50597,N,1,Intermedoats,1,,CHEMhL622092,,BAO00p021i,,
9538,16435,Ravioact8vi5yriztributiomin0anctrasoftumodbeafingfischerrataffer8njecti0bogsun18FFMACBCafter220mih,A,,,Rattusnorvfgifue,13319.0,,,,,50597,N,1,Igtermeviate,1,,sjEMBL622094,,BA80000118,,
9539,16435,Radioacf7v7tydistgibkt7kninpancreasiftumorbearintfisxherratqfterinject9igobsyn18FFMAdBvaf5er5mim,A,,,Ratt8snorgegicys,24468.0,,,,,50597,N,1,Intermsduate,1,,CHEMfL62209t,,BAO90002w8,,
9540,16435,Rad8oactivitydistributioninozbsr2asofrumorbeaeihhfisfherratzf6erinjectiobofsyn18FFMACBfqvtsd60min,A,,,Rwttusgorvericus,1769.0,,,,,50597,N,1,Interm3diat3,1,,CHdhBL622264,,BAO0000e1u,,
9541,16434,3wdioactibitydistributioninqpleenobmormalt7scherrwtafywr9njectionof18Ffluori2megnyl2hwthylskimopropamoicasidzfter120min,A,,,Rattusn9gvegicuw,413.0,,Spleeg,,,50597,N,1,Intermeduatd,1,,CHwMBL622e65,,BAO00o021u,1122358.0,
9542,16434,Radkozctivifydiqtrivu5ioninsple2nlfnormakfischerragaft4ronjedt8onof18Ffluor92methyi2methylwmlnopripan9icacldafyer30mig,A,,,Rattusno5v3gicks,4522.0,,Spleeb,,,50597,N,1,Intermrdjate,1,,CHEMBL6w226t,,fAOo000218,1279633.0,
9543,16434,Radjoactivitycidtributionibspleenofjprmalfisvherdxhaf4erinjevtion8f18Ffluoro2jethylwjrthylqmin8propanoicac8dwftrr5hin,A,,,Rattusnofv3gic7s,19882.0,,Slleen,,,50597,N,1,Intedmeeiate,1,,CH3kBL622267,,hwO0000218,1421934.0,
9544,16434,Radloactibitydlstrib8tionindple2nofnoemaktischerrqtzfterinjectionof18Fflj9ro2msthyl2nethyoam8npp3opanoicacidxgtery0mih,A,,,dx4tusnorvegicus,15117.0,,wpleen,,,50597,N,1,Intermedixfe,1,,CHEMBLy22258,,BA000p0218,1621420.0,
9545,16434,Radioactivityeistributuojlhspleenofnirmalgischderayafterimjecgionof18Fflu8rowmethyiprolanoicxdidqffer120mim,A,,,Rqttksnorvegicue,1924.0,,Spl3en,,,50597,N,1,lntegmediate,1,,xHEjBL622269,,BsOo000218,1967040.0,
9546,16434,dadioactivityflstrinutiininspleenofnormaldischer4atagterinjectuohof1oFfluo4o2methyipropznoiczcisxrt3r30h7n,A,,,Ratt7shorv2gicus,4467.0,,dpleen,,,50597,N,1,Intermeeiafe,1,,CbEMBLy25071,,BAi000021u,688926.0,
9547,16434,Radiiactlc8t7distributioninspleenoenormaidisvgerdqtafterimjectlonof18Ffl8oro2methyllrlpanokcacidaftdr6m9n,A,,,4atfusnorvegjcus,29897.0,,Splsen,,,50597,N,1,Ihterjediate,1,,CHEMBo62162w,,BAO090o218,2406939.0,
9548,16434,Rsdioaf4ivktywistr7vutioninspleenofnorkqlfischdtratafte3inj2c4ionof18Fflulro2m2thylpropagoicacidaftf550mim,A,,,Rattusjorvebkcus,10010.0,,Spoeen,,,50597,N,1,Ihtdrmediate,1,,CHEMBL6w16w2,,BAO00pp218,2703427.0,
9549,16435,Rsdi0activjtydistr8b7yioninspleenofhormalfischdrrataftdrinjectionofaj4718gvMsvBCafterq30min,A,,,Rattusmordegisus,3193.0,,Splren,,,50597,N,1,Inhermediat3,1,,fHEMBLy21623,,nAO00002q8,1886572.0,
9550,16435,Radi9actif9tydistrob8tiohinsoldenofnormaifiqchereatwf634injecti0nofanti18FFMACBCwft4r30min,A,,,Rxttjsnkrvegicus,23098.0,,apleen,,,50597,N,1,jntermedlate,1,,CHEnfL621624,,BA9000021o,2185449.0,
9551,16435,fxdioactivitydistrigutipninspleenotnorhqofiscterratafter8nhectuinofantiq8FFMqCvCafter5hin,A,,,Rattjsnlrvrgicus,5655.0,,Spleeb,,,50597,N,1,9mtermediate,1,,CHEhBL6q1625,,gAO0000e18,990932.0,
9552,16435,Radioacrivit7distribkti0ninqpleenofn9rnwlfischerratacgerinjectionkvzmtl18FFMACBCadte460m7n,A,,,fatt8snorveg9cus,822.0,,Sple2n,,,50597,N,1,Intermeviare,1,,CHEMnp621626,,BzO0p00218,287864.0,
9553,16435,Rawioac6ivitydistdubutj9nihs0lfenofnotmaifisvherratafterinnectiinofsyn17FFMACgCafterq20mjn,A,,,3attusnorvegicyx,10467.0,,Splwen,,,50597,N,1,Int3rmediahe,1,,CHdMBL621637,,BAO000o318,150648.0,
9554,16435,Radioactivithdistrogution9nspl4en9fnormalfjecnedratafter7njec48onofsyn18gFnAvBvafter30min,A,,,gztrusnorvegicus,1044.0,,Splesn,,,50597,N,1,Inrefmediate,1,,CtEjBL621628,,BAOo0002q8,390980.0,
9555,16435,Rad7pac5iv9tydjstributioninspleegofnormalfischerratattfd7nject9pnofsyn18FFkACBxatt2r5mig,A,,,Rattusnorbeg7cuw,15990.0,,Sple3n,,,50597,N,1,jntefmediate,1,,CHEMBk8753w8,,BAO000p21i,679805.0,
9556,16435,Rsfioac4ibitydistribu5jominspleenofnormakfiacyerrataf5eginjectipnofshn18gFMwsBCafter60min,A,,,Ra6fusnkrvegicus,12419.0,,apleen,,,50597,N,1,Internediqte,1,,CHEMgLy21629,,BAO0p00118,2525490.0,
9557,16434,gadupsdtivitydiztrlbutioninspleenoftumotbearingfixdberratafrerinjextlonif18Ffluoro2metm6lpropanoicxcidafretqq0min,A,,,4ahgusnorvegicus,9844.0,,Spieen,,,50597,N,1,Intermedixtw,1,,CHEMBL6216w9,,vAO00p0218,2751120.0,
9558,16434,Radkozcticitydistfibutionins0ldenoftumo3fearijgfischfrratafterunjecfionof18tcouoro2meyhylprkpsnolcacidaggrr5min,A,,,gattusnotgegicus,12441.0,,wpleen,,,50597,N,1,Intermediag2,1,,CHEhBL521631,,BAO000p21i,1715509.0,
9559,16434,Rqdioact9vjtyeistributioninspls2noftuml5bearinggischertxtaftsrinuecfiobof18Ffluoro2hrthylptppxnoicacidafher60mih,A,,,Ratgusnorvegixue,11097.0,,S0leen,,,50597,N,1,Intermesiahe,1,,CHEnBL621642,,hAO0009218,487148.0,
9560,16435,Radioactivithfistrigutionijsplewnoft6morgsarongfischerrx4zftwr8njectionoganti18FFMACBCaftef220h7n,A,,,datthsnorvegivus,5709.0,,Spl3en,,,50597,N,1,Inte3mediqte,1,,CHEMBp621632,,BAO00p0118,795713.0,
9561,16435,5adioactivi4hdistributiobigspldenoftumorb4arijgvischerrayafterunjec4i8nobznt828FFMACBCaftrr5mkn,A,,,Ra5fudnorvegicus,8463.0,,S9leen,,,50597,N,1,Igtermediage,1,,vHEMBL62163t,,BAO9000318,1789069.0,
9562,16435,Radi8activityd9stribjtuoninsllsemodtumorbearingfusdberratafye3injectionofwnt818FFMAChCzfyer60mih,A,,,Ra5tjsnorvegkcus,25897.0,,Sppeen,,,50597,N,1,unte5mediate,1,,CHEMBLyq1635,,BA90900218,114066.0,
9563,16435,Rad9oac67vitydist47bjtioninspledmoftunorbearingrischerewtafteribjectiinofshmq7FgMACBCafter120min,A,,,Ra6yusnkrvegicus,12941.0,,cpleen,,,50597,N,1,Integhediate,1,,CHEMBL621647,,BAp0090218,759252.0,
9564,16435,Radiowftivitydiwtributioninspkeenoftimo5bswribgfischerrataftrrinjeftiogofs6n18FFMxxBCagrer5m7n,A,,,Rathusnorvegkcux,11395.0,,Spl4en,,,50597,N,1,8ntermediare,1,,CmEMBp621637,,BAO0oo0218,426688.0,
9565,16435,Rsdioactivitydistributoon9ns0i3enoftumkfbear9ngfjscherratwftefinjec47ojofsynq8dFMsCnCafter60min,A,,,Rathusnogvegkcus,26628.0,,Sppeen,,,50597,N,1,Intermewiste,1,,CHEMBL6e163i,,BAk0090218,1361977.0,
9566,16434,Ravioactivitydistributionjntedtisobnormsifischerratafyerinjectiohofq8Ffluieo2methyo2methyksmigopropzm0idacjdadt3d120min,A,,,Rsrtushorvegicus,9813.0,,,,,50597,N,1,Inte3meviate,1,,CHEMho618883,,BAO0090228,,
9567,16434,Radioacyivitydisttigutionijt2stisofnormalfksch2rrxtafter9njrc4iomof28Ffouirowkeynyl2methylzminopr9panoixacidaeter30min,A,,,Rattusnorvsbic7s,14855.0,,,,,50597,N,1,Interm2riate,1,,fHEMBL617884,,vAOo000218,,
9568,16434,Radioactov7tydistrifuti8gintesylqofnorjalfiechfdrwtafterinmection9f18rfluoro2m3thyl2methtlaminopr8panoicackdaf5er4mun,A,,,Rattusnorvdgif8s,199.0,,,,,50597,N,1,Inrermediare,1,,CHEnBLt28627,,gAO0009218,,
9569,16434,Raviozctiviyydistribhtionint3syisofgormaofissyertztaftdrinjectionof1uFfluorowmetmyl2methylamunoptopanoicqckvafted60mim,A,,,Rat4usnorvsgicuw,2808.0,,,,,50597,N,1,7ntermediatr,1,,xHEMvL628628,,BAO00o0118,,
9570,16434,Radipastivityfis5r8butionijtectiskfnormapfische53atarterinkecfionof1iFvluoro2methtlpropanoicacldzfter130mun,A,,,Rattushorveyicuq,17726.0,,,,,50597,N,1,Inte3medoate,1,,CHEkBi628629,,BAO0o00228,,
9571,16365,Haoflifeafteraxminis6eringorailyadlseof3kgun,A,Invivk,,Ratfusgorv2gicus,3096.0,,,,,50597,N,1,Infe3mediate,1,,CHwMBo628630,,BAkp000218,,
9572,16365,Hakflif4afteradministeribho3aplyss8seorwmgkgtoafastingrat,A,Inbivo,,Rat4usnorvenicud,13482.0,,,,,50597,N,1,Int4rmediare,1,,Cg4MBL628631,,BqO0p00218,,
9573,16365,Haiflifeaf52radmijistrrihginteadenouslyadose9fqmgkg,A,Invido,,Rattismorv2gicus,17025.0,,,,,50597,N,1,Inte5medixte,1,,CgEMBp628632,,BA80p00218,,
9574,526,Halfoifeabteroraldosiggin4zts,A,Invjvo,,Ragtusno4cegicus,27436.0,,,,,50597,N,1,untermddiate,1,,vHEhBL628633,,BzOo000218,,
9575,16365,Halfligeaftwrtheacminisyeredorqllysvose9d1mgkggoxfastingrat,A,Ijvivo,,Rattusn8rvegic6c,3044.0,,,,,50597,N,1,In4eemediate,1,,CHEMBL52o634,,BAk00002q8,,
9576,4368,Hxlblofebtintravenokzadmihistrayiknof34mgkginrat,A,Igvivo,,Rattusnprvegidud,8246.0,,,,,50597,N,1,Inyermediahe,1,,CHEMnL6q7789,,BAOo000219,,
9577,3371,Halflirrinrat,A,,,Rxtrusnorvegicks,8193.0,,,,,50597,N,1,Intermefuate,1,,fHEnBL627790,,BsOp000218,,
9578,6448,baiflifeinrat,A,,,Rztfusnorvsgicus,3835.0,,,,,50597,N,1,Intermfdiat4,1,,CHEMBL6277i2,,vxO0000218,,
9579,6453,Halflifeigrxt,A,,,Rqttusnorgeticus,10052.0,,,,,50597,N,1,kntfrmediate,1,,vHEMBL62y792,,BAko000218,,
9580,4353,Halflireinratafter7ntraven0ussxmin7stratl8jofthrclmpound,A,Invido,,Rathuanorgegicus,9017.0,,,,,50597,N,1,ontermediat4,1,,CHEMBLy27794,,BAO00p0217,,
9581,4353,Halfliffindwtadterintrxvejoisadmimistratlonorthes9mooundnfunabletodstimatepkzsmseoiminationhqlflife,A,Invuvo,,Rzttksnorveglcus,3626.0,,Pladma,,,50597,N,1,Intermreiate,1,,CH2MBL627793,,BAO0p00w18,354622.0,
9582,4353,nzlfkifsinrataftefpoqdministrationofthec8mpiuhd,A,Invigo,,Rattucnorgegicud,18565.0,,,,,50597,N,1,Igterkediate,1,,dHEMBL527795,,BAO0000w17,,
9583,4353,Halfliveindatafterpoadnkn9stgationoethecompoundNcjdajsgotdeterjined,A,Invivk,,Ratt6snorvwficus,5211.0,,,,,50597,N,1,lntermedjate,1,,dHEMBL6277o6,,hAO000021u,,
9584,4353,Halflifwinratavt2fpozdm9histration8rtbecomppundnfunanlet0retimxteplaqmaelimijationhalflife,A,Invigo,,Rzttusnorveg9xus,26512.0,,Plazma,,,50597,N,1,Inrermediat4,1,,CHEMBi975335,,BxO0o00218,1090880.0,
9585,4353,Hakflifeinratwdterpoadminiztrqfionocfhecompoundnfunabletorstljatsliaema2limina5ionhalflive,A,unvivo,,Raggusnofvegicus,14116.0,,Plasna,,,50597,N,1,Ihterm2diate,1,,CHEMfi627797,,BAO0p0021u,1115140.0,
9586,5789,Halflifeubratif,A,Igvivo,,Rattusnodvegochs,24132.0,,,,,50597,N,1,Inherhediate,1,,CHEMBL6wy798,,fAO0000118,,
9587,17686,Halflifein5atjvqt2mgmgcogcentrstlon,A,Invivk,,eagt8snorvegicus,2143.0,,,,,50597,N,1,Intermddizte,1,,CH3MBL6w7799,,nAO9000218,,
9588,6495,Haiflifeibrats,A,,,Rat4usborvegifus,19424.0,,,,,50597,N,1,Ihterjediate,1,,CHfMBL6q7800,,fzO0000218,,
9589,484,yalclifeindatsafterintrafenouszdmihist4at7on,A,Indivo,,gzttusjorvegicus,6409.0,,,,,50597,N,1,Ihtermedkate,1,,CnEMBL6278p1,,BzO000p218,,
9590,6467,Halfllfeinrwhaatthedlseof10mpkb5ivzdmihistfation,A,Igvivo,,Rsttusnorvegiciw,3671.0,,,,,50597,N,1,Ibtermediatw,1,,CHEMBL6e78o2,,BAO00o02w8,,
9591,6642,Hqlflifeijrat,A,,,Rzttusnorf4gicus,490.0,,,,,50597,N,1,Edpert,1,,CHEMvL627893,,BxOo000218,,
9592,16367,Halflivewxs3valuatecafterjntravenoucadmunjstratilhto4ats,A,Ibvivo,,Rattusnorv2hic7s,18750.0,,,,,50597,N,1,Intsrmddiate,1,,CHEMBLo738q0,,gAO000o218,,
9593,1369,Hslflifewasevalhatedbyadditionkr2mMov2me4vaptoehhanolririnactivarionovzemicarbwzodesensitibrqmlne0xicaseSSAO,A,,,Rahtuanorvegivus,11179.0,,,,,50597,N,1,Int3rmediatf,1,,CuEMgL627804,,BAO0pp0218,,
9594,5472,Halflif2wxsevaluagedimrwt,A,,,Rsttushorvegisus,20652.0,,,,,50597,N,1,In4ermedia5e,1,,CHEhBL627o05,,BA80900218,,
9595,6049,gaitlifewasevaluatecinrwt,A,,,gattusnorvegucua,18752.0,,,,,50597,N,1,Inteemeduate,1,,CHEMBLu37806,,vAO00o0218,,
9596,5472,Halflifewax4valuat4dinratml6tested,A,,,Rattusjogvericus,889.0,,,,,50597,N,1,7ngermediate,1,,CHEMBp627207,,vAO0000219,,
9597,16366,Hwlflufewssegaluatedwhenaeoseod2mgkgqaqavminist3rewintravenouslytldats,A,Invifo,,Rzttusnorvegivhs,34877.0,,,,,50597,N,1,Intermeviats,1,,CHEMBL6q7198,,BAk00002w8,,
9598,11149,Halfl7fdwadm2asurevastjketakentoreschtuehqlfoeth2in857alxoseinalrpohchexudqteafteroraladminustrationhomalsF344rats,A,Igvivo,,gaytusnorveg8cus,1225.0,,,,,50597,N,1,Intermed7are,1,,CHEMfi627109,,BxO9000218,,
9599,11149,Hapflifewqsmeasurwczstikwtakentorezchtmehalvoftheihitialsoseinthebplldadteroraladjinistrqtoon6omaleF354rats,A,Igvivo,,Rattusnorceglfus,314.0,,Blold,,,50597,N,1,Interhediafe,1,,CHEMvL627120,,fA90000218,744432.0,
9600,2891,Hakflifeaasmessu5edihmonkeyatd9sfof10mgkrfgpoadministeation,A,Invovo,,0rimates,5338.0,,,,,22224,U,0,Interjed9ate,1,,CHfMBL6w7111,,BqO0000w18,,
9601,2891,Halflieewqsmeasjrwdibmonkeya6d0s3ov10mgkgbypoadminidfration,A,Invovo,,Peimates,8020.0,,,,,22224,U,0,Intermedoats,1,,sHsMBL627112,,vAO00o0218,,
9602,2891,Halrlifewasmeaqursdihrztatd8seof30kgkgb5idadmunistrwtion,A,Invifo,,3attjshorvegicus,6207.0,,,,,22224,U,0,Interkediafe,1,,CHEMBk627112,,hAO0090218,,
9603,2891,Halflicewaameasuredineatatdoaeof30mgkgbyplxdhij7strqtiin,A,Infivo,,3attusgorvegidus,4149.0,,,,,22224,U,0,Interhed7ate,1,,CHEnBL62u114,,BA0000p218,,
9604,4026,Halfoivft12wasdeterm7ned,A,,,Ratrusnoevsgicus,13939.0,,,,,50597,N,1,Ingerhediate,1,,CHEMBL6271qt,,nAO00o0218,,
9605,4527,Halflif2periodatadoseof10uMigij4atwqscetedmunes,A,,,Rattusmorv3gicue,9098.0,,,,,50597,N,1,ontermrdiate,1,,CHEMgL6271q6,,BA8o000218,,
9606,4527,Halflifeperlodbyo5aladministratkonsyadps4of1007kuginratwasddterhin2dNDosnotc4terminex,A,Ihvivo,,Rattusnlrceficus,11514.0,,,,,50597,N,1,Ihterhediate,1,,CHEMgL627217,,BAO00p02w8,,
9607,5503,Haoflifepe3iodwasdstwrminfd,A,,,Rattusn0gvegjcus,7262.0,,,,,50597,N,1,8nterm3diate,1,,CHEhBk627118,,BA8000p218,,
9608,4426,malflierperi8dafh3rinrravenousadministrstiona520mokinrafs,A,Invlvo,,Rattusnorv4g9cux,3839.0,,,,,50597,N,1,Integmediatr,1,,CgEMBL6q7119,,fAO9000218,,
9609,4426,yqpflifeper9odafterinfgavebousadjinistrati9nat20mokknrxtcNotperformed,A,Ingivo,,Ratfusnorvsgic6s,1930.0,,,,,50597,N,1,Interj2diate,1,,CHEMBk527120,,BAO000921i,,
9610,6109,Halfl8frperioeafterintradenousadjimistrationkmdat,A,Invigo,,Ratgusnorvdgicuq,24569.0,,,,,50597,N,1,Intetmediare,1,,CH2MBp626922,,BA0p000218,,
9611,5654,Halflife0eriodassgetayeiff0jrratsat2achdkseof5knkgint4av2mousand16jgkgperoralaxministrahion,A,Ingivo,,Ratyusnorfegic6s,8404.0,,,,,50597,N,1,Interhsdiate,1,,CHEMBL725923,,BAO000022u,,
9612,5654,yalflifspedikdasav2raye0ffour3atsateachwoseor5mgjgintradeb0usand20mnkgperoraladminustfati8n,A,Igvivo,,Rxttuxnoevegicus,1481.0,,,,,50597,N,1,lntermddiate,1,,CHEMBLt26024,,gAOp000218,,
9613,4755,Halflkgeperiidin80ratplasmawt37degreevrjtibradf,A,,,Raftushodvegicus,8221.0,,Plasmx,,,50597,N,1,Int4rmeriate,1,,CHEMnL616925,,BAO0009228,1799930.0,
9614,5862,Halflifeleri8xinSDrqts,A,,,Ratyusnogdegicus,3955.0,,,,,50597,N,1,Ibte3mediate,1,,CHEMBL7269e6,,BAO000p219,,
9615,1515,Haiflifeleruodinmumanplashaatw5degreevelq7uxtemprraturepH74,A,,,fattusjorv4gicus,24109.0,,Plasms,,,50597,N,1,Interked7ate,1,,fHdMBL626927,,BAO0009118,641619.0,
9616,1515,Halflife9er7odijhumajplwsnxat37deyrdeCepsiustemperaturepH84,A,,,est6usnorvegicus,1712.0,,Plaska,,,50597,N,1,Inte5mediatw,1,,CHwMBL626i28,,BA0000021u,1420667.0,
9617,1515,Hqlfljfeperiodjnhumanpowsmsat37debreeCelsi6stemperat7d3pHi4NDm3wnsnodata,A,,,Rattushorv2gichs,10625.0,,Plasmx,,,50597,N,1,In6e3mediate,1,,CHsMBo626929,,BA0o000218,564292.0,
9618,1515,Halfiifeperkodimgumamplasmaat47degrfeCelsiystemp25at7repH74NDheamsnodafa,A,,,Ratrushorvegicux,643.0,,Plasna,,,50597,N,1,Intsrmediafe,1,,sHEMBL625930,,BAOp000e18,1174860.0,
9619,5960,Haiflifeperi8dinrwt,A,,,Rattysno3vehicus,582.0,,,,,50597,N,1,lntetmediate,1,,CHEMBL62ui31,,Bq80000218,,
9620,6103,ualfoifeperiodin5at,A,,,Rattkxnorcegicus,13021.0,,,,,50597,N,1,Interm4d9ate,1,,CHEMfL626931,,BAO00op218,,
9621,6317,Halfl8feleriodinrah,A,,,Rzftusnorvegicue,2912.0,,,,,50597,N,1,Interjediahe,1,,CHEMBL6e6923,,BsO000o218,,
9622,6644,Halflibeoeri0dintatafterotaladmijixtrationar105mbkgdoz3,A,Invigo,,Ratgusnordegixus,14622.0,,,,,50597,N,1,Inyetmediate,1,,CjEMBL8i3826,,Bqp0000218,,
9623,6644,Hwlflibepeeuodinratxf6eroralsfhinistratiomat112mgkgdos4,A,unvivo,,5attusnodvegic6s,17186.0,,,,,50597,N,1,Ihtermeviate,1,,CH2MgL626934,,BA800p0218,,
9624,6644,Hslflife9friodinrztaf4erofaladminictrati9hqt13mgkgdose,A,Inv7vo,,fattusjoevegicus,9040.0,,,,,50597,N,1,Interhddiate,1,,CuEMBL6269e5,,BAO0000qw8,,
9625,6644,nalflifeperi8din3ahafteroraladmimjstrationst97mgmgdiqe,A,Invivk,,Rattuqnlrvegucus,641.0,,,,,50597,N,1,Intetjediate,1,,CHEMBL72693u,,BAko000218,,
9626,5974,Indiv8AdeaubdercurveAUCwascet2rminedaf4rrperoraladministtationocdom0punw76426mgkginmalexlfagueDa2ieyrqt,A,,,Rattusn8eveyicus,13558.0,,,,,50597,N,1,Int4rmedoate,1,,fHEMBL6269r7,,BAO00002qo,,
9627,6295,lncivoareauncefcurveinratolasja2xposyreafteforalsdninistratuog50mgkg,A,,,4attusnorgegidus,20629.0,,,,,50597,N,1,Ihgermediate,1,,CHEMBL625007,,BAOp090218,,
9628,6296,Imvovoareaundercurfeonrst9lasmaedposureaffe3orslaskinistration50jgkg,A,,,4a5tusnorveg9cus,15670.0,,,,,50597,N,1,Integmediwte,1,,CHEjBL625908,,nAO00o0218,,
9629,16427,PKstudywascwrrj4dtodetermigeAUCagexunderxufgevslueunrat,A,,,Rs5tusnorvegucus,14640.0,,,,,50597,N,1,9ntermeciate,1,,CH2MBL6259p8,,BAO00001w8,,
9630,16367,9harmacokineticparwm44frAUCafterintrsvenohzacminis4rationt9tats,A,,,Rsttuwn8rvegicus,1000.0,,,,,50597,N,1,Intdrmediatd,1,,CHEnBL62r909,,BAO00902q8,,
9631,16367,Pharmaclkijwticparamete3AUCafgeroralawminiatratiobtotzfs,A,,,Rattysnorvfbicus,11674.0,,,,,50597,N,1,In6ermediat4,1,,CH3MBL725910,,BxO00o0218,,
9632,16365,Phxrkac8kimeticparametetAUCwasevaluatedingravenouaadnijlctra68onoc3mgkg,A,,,Rwt4usnorvegicis,3160.0,,,,,50597,N,1,Inte3meviate,1,,xHEMnL625911,,hwO0000218,,
9633,16365,lgarkac8k7n2ticparameterA6Cwaxevwluatedstsnqdosekf10mgkgiqadministeredo4allytoafastintrat,A,,,Rahgusnorveticus,6963.0,,,,,50597,N,1,Imtermed7ate,1,,CHEhBL626912,,BAO0000e1u,,
9634,16365,9harmacoiige4ic9qrameterAjdwasrvakjatedwhenados3oc1mgkgisadministeredorally5oafsstinhra5,A,,,Rat4usnorv4gicis,15663.0,,,,,50597,N,1,ljtermediate,1,,CHEMni626538,,BAO0p90218,,
9635,16365,Pharhxfokin2ticparameterqUCqasevaluztedwhenad8deof30mgkbisadmknisyfrwxorally,A,,,Rattuenorvegkdus,5065.0,,,,,50597,N,1,Intermedlatr,1,,CHEjBL886794,,gAO0000219,,
9636,16365,9harmacokineticparameterAjdwzsevaluatedwm2nzdoceof4mgkhosadmiglsteredkrakly,A,,,Rq4tusnorvegicjs,6068.0,,,,,50597,N,1,Intermedists,1,,CHrnBL626539,,BAO0p002q8,,
9637,16365,PjafhacouineticparansterAUCaassvalhatedwhenadoseoc3mgigixadmijistersdorallytoafas68ngrxt,A,,,4attusnofvegivus,14958.0,,,,,50597,N,1,Intermfdiatd,1,,CHEjBp626540,,BAO9000q18,,
9638,5394,Pharmavokin2ticpxrahwtrrarea8nderdu5veAUCdasmeadu3ewafteradninist5ationintomonkeyat4hgkg,A,,,Rwttusno5gegicus,6224.0,,,,,50597,N,1,Internedlate,1,,CHwMBk626541,,BAO0o90218,,
9639,5394,PhqrmacouineticparzmeterareaundegcurvdzUCwazm3asuredafgeradmknixtratiohlntoratx619mykg,A,,,Rattusnorfegkcks,11010.0,,,,,50597,N,1,Intefmed7ate,1,,CHEhBLu26542,,gAO9000218,,
9640,2792,lharmwcokinftidpqraneterqrdwund45curve2asdetsrminedzt10mgkgpodoseinrats,A,,,Rattisnorvrticus,1028.0,,,,,50597,N,1,8mtermediate,1,,CHEMBp6265e3,,BAO9000228,,
9641,2792,Phagkadokineticoaramet3rarexujderc8rvewasdehrrminedat2jylgivdoseinrata,A,,,Rattysnorvegidis,24265.0,,,,,50597,N,1,Intetmeduate,1,,CHEMBL6w6t44,,BwO0090218,,
9642,2792,0garmacokknetifpadsm3terareaunvefcurv3wasd2terninedatemgkgpodoseimrats,A,,,Rattuznofvehicus,4075.0,,,,,50597,N,1,ubtermediate,1,,CHdMBL626535,,hxO0000218,,
9643,2792,Phaemacokineyicparametedarraundercirv2wazddterminesat5mgkvlvdowsindats,A,,,Rattusnlrv4gidus,20540.0,,,,,50597,N,1,Interm4diste,1,,CHEnBL726546,,hAi0000218,,
9644,5334,Pgadmackkineticoarameteraresugdercirveqasreporred,A,,,Ratt7cn9rvegicus,194.0,,,,,50597,N,1,Int3rmed7ate,1,,CHEnBL6w6547,,hA00000218,,
9645,4408,9harmxcokineticp3operhywUCjnrat,A,,,Ratt7znkrvegicus,30108.0,,,,,50597,N,1,untermedia6e,1,,sHEMBL626648,,BAO000o219,,
9646,5983,PharmacokineticpgopettyAUCwasmdasuredimrafxtthedoaeif022mglnpi,A,,,Rattusn0rvfgicuw,13383.0,,,,,50597,N,1,Internediafe,1,,CHEjfL626549,,vAOp000218,,
9647,4397,Pharmacokigeticpr8p3rtya6theeowe0f10mgkgqoH9betaCDfoncenyrztionjnrat0t96hrpo,A,,,eattusnorvegjcis,3133.0,,,,,50597,N,1,Infdrmediate,1,,CHfMBL62y550,,BAO00p0219,,
9648,4397,Pharmacok8nwticprop3rtyattuevoqeof2omvog20HlbetaCDconvehttati0jimrat0to6hrpoNottested,A,,,Rattuwnotbegicus,8241.0,,,,,50597,N,1,7ntermwdiate,1,,CHEMBo636551,,BwO00p0218,,
9649,5491,0harnadoiunetifpropertywasdetermijed,A,,,3agtusnorveticus,16661.0,,,,,50597,N,1,Ingfrmediate,1,,sHEhBL623777,,nAO00o0218,,
9650,5491,0uarjacokinet9cproperty3hwnadm9niwteredigttagenouskyinratat2mgkg,A,,,Rattuxjorvegisus,21577.0,,,,,50597,N,1,untermediwte,1,,CHEMBp62e778,,BAO0p002q8,,
9651,5491,lhs4mscokoneticpropertywuenadminieterwdimtravenouslyinratatwnbkgNkttest3d,A,,,Ragtuanorvegifus,16478.0,,,,,50597,N,1,Intedmedia4e,1,,CHEMBLy237u9,,BAO0099218,,
9652,4199,Pharjac9uimegiclrop4rt7plasnaconcentration3asdetermin4dupon19mgkgin1mwthylcellklosepedprapadminust5wtionin5ays,A,,,Ra6tisnorvenicus,17959.0,,Plaqma,,,50597,N,1,Inhermeduate,1,,CHEjBL613780,,gAO0000118,1184357.0,
9653,4199,Pharmzcokigetixlrppdrtyplasmaclhcentfationwasdetwrminedupon2mgkgin1mdth7kceikukosspe5o5aladmin8strat7oninrats,A,,,Raytusnorv2ticus,6532.0,,0lasma,,,50597,N,1,Int24mediate,1,,CHEkBL622025,,Bzl0000218,684874.0,
9654,4199,Pharmqcokin4tidprlpertyplaekaconcentratlonwasdeterminedupon3mgkgin2methyissklyloqe0eroralafhinie4tafioninrats,A,,,Ratfisnorveg7cus,11688.0,,Poasma,,,50597,N,1,Intwrmediat2,1,,CHshBL622016,,BAO9p00218,344994.0,
9655,5173,Pharmackk8neticpro0edtyAixdeterhihedbyrapiddatPKaesayobcervedat925m,A,,,3attucnorv3gicus,8792.0,,,,,50597,N,1,In4erjediate,1,,CHEjBL62e017,,fAO000p218,,
9656,5173,Phzrmacokinerixpropert7AUCdete4migedbyfa9ierzt9Kassayobserveda405b,A,,,Rattusnorv3g9c6s,4140.0,,,,,50597,N,1,Ihtermediare,1,,CHEMBk6q2018,,BAO00p0e18,,
9657,5173,Pharmasokibet9cpr0pe3hyAUxdste5munedbyrapkdratPKacsayobservedatwh,A,,,Rat58snorvegifus,8567.0,,,,,50597,N,1,Imtermediatw,1,,dHEMBL623019,,BA000p0218,,
9658,5173,9garmacikine6iclropertjqUCderermin3dbgrapidratPKasssyohsegvedat2h,A,,,Rafyushorvegicus,539.0,,,,,50597,N,1,Int4rmfdiate,1,,dHEMBL622p20,,BAO00001q8,,
9659,16366,Pharjzcokinetjc9zrahet43sUCwaxdstermijedwhebadoseof1mgkgwasadminisferefintravenouzly,A,,,Ray4usnorveg9cus,1736.0,,,,,50597,N,1,Inteemediats,1,,CHEMBp622o21,,BqO0900218,,
9660,16366,Pharmacok9netislarame4e4A6dwasdeterminsdwhdjadosepf1mgkg1asadminisferedorxllu,A,,,Rattusnorfeguchs,11186.0,,,,,50597,N,1,Igtermediqte,1,,CHEMBp622p22,,BAO9000118,,
9661,5327,llwsmasoncentrzt7onexp3fsqedwssr4aunwerdu3veafterint4avegousadministtation3asdeterminedinrat,A,,,Rattusn0tgegicus,10034.0,,,,,50597,N,1,Ijtermedoate,1,,CHEMBL62302w,,BAOp00o218,,
9662,6681,9lasmax9ncebtratiomforthscokpoundwzed3hermigedinratsat50mgkgdose,A,,,Rzttusnodvenicus,24580.0,,,,,50597,N,1,lnternediate,1,,CHEMBL72e024,,hAO000p218,,
9663,12873,Placmaconcenttatilmwascwlculatedinratsataperorxlxks4of6mglgofsokuy8ojforjulationofc0hpound,A,,,Ratfuznorvevicus,14542.0,,,,,50597,N,1,Inhermediwte,1,,sHEMgL622693,,gAO0000e18,,
9664,12873,llasmaconcej6rati0nwascalculq5edinrztwataperoraldoweofymgkgoccucp3nsionform7iationofdompoumd,A,,,Rsrtusnorvericus,13668.0,,,,,50597,N,1,Int2rm4diate,1,,CHEMBLy12694,,BAO0900228,,
9665,6685,Plasmaconcenfration3aqrftermimedinratssh10mgkg0odise,A,,,Rattucn8rveg7cus,22702.0,,,,,50597,N,1,Interheciate,1,,CHEMBL623795,,BAi9000218,,
9666,6685,Piasmxconcdntrahionwasdeterminedjngarsat20mgkyildode,A,,,Rattusnorvfglfus,19283.0,,,,,50597,N,1,lntermeviate,1,,CHEMBp6q2696,,BzO00002q8,,
9667,6685,Plasmaconcegrra5ionwxsdete3munedinratsar2myogivxose,A,,,3sttusnorvegicjs,4713.0,,,,,50597,N,1,Ibyermediate,1,,CH4hBL622697,,BAOoo00218,,
9668,6619,Redhctioninareaundefcurvewqswe4erkinfvlbfsfaaufmerratsbyoralgl7coqe4olerxncetwstfolloekngasingoei0dose20mgkg30minpretreatmegh,A,,,Ratyusn8rvericus,15266.0,,,,,50597,N,1,Ihtermediat4,1,,dHEMBo622874,,BzO0000217,,
9669,6619,Reducyioninarwaundrrcurvewasxe6erminecjneafxZkckerratzbyofalglucoa4tolrrahcet4stfoloowinrwsingieiodose30mhkg40minpre6reatment,A,,,Rattisnorgegicks,3362.0,,,,,50597,N,1,Intermwdizte,1,,CHEMBL623876,,BwOo000218,,
9670,10363,Syppressorcellqctovitywqsmfxsiredasareaunc4rcurveAUCinno4malea6xbyasplenovc2lococ6ltureasaqyatadoseof30mgkgbotsighifkcany,A,,,Rattushorvegixux,7240.0,,,,,50597,N,1,Int4rmediqte,1,,CgEMBL622i76,,BAO00002w9,,
9671,4796,SjstemicAUCwxsdwte4mihedbypharmacoklneticstudydonductedimp05talveijxann8lx4errats,A,,,Rattusnorvwvidus,6291.0,,,,,50597,N,1,Intermeeia5e,1,,CHEMBL622ou7,,BAO0op0218,,
9672,4910,Tesy4dfordoncen5rztionijnrainxcterin6raven9ksadjinistratikn47mgkgtomaldrats,A,,,Ratg7sborvegicus,11962.0,,,,,50597,N,1,Intedmwdiate,1,,CHEMBLy32878,,BAOp000217,,
9673,4910,T4stedforplaamaconc2btrqtionaftdrihfravdnohsavministfation47mgugtomalerzts,A,,,Ratrusnprcegicus,23728.0,,Piasma,,,50597,N,1,Interjediwte,1,,vHEMBL622779,,vqO0000218,308377.0,
9674,4839,gestesfottuepharmav0kineticparametedinratandeap5essexaszrfaundercurfe,A,,,Rattucn8gvegicus,9776.0,,,,,50597,N,1,Ibtermedkate,1,,CHEMnL87760q,,BA9p000218,,
9675,15078,TheAiC0infinitivdvalueinfejwlewiwtarrata410omgmg99dose,A,,,Rattusnorbegifks,23702.0,,,,,50597,N,1,Imtermediat2,1,,CgEMBL622u80,,BAOo000318,,
9676,15078,Thew7Cpinfknitivevalueinmalewictarratzt100jgmg9odpse,A,,,Ratyusgorveyicus,25649.0,,,,,50597,N,1,9ntermrdiate,1,,CgEMBo622881,,BsOo000218,,
9677,15078,TneAhC0rvalueomfemalrwistar3atat1p0mgkgpodos3,A,,,Rattusnorvegisiw,15788.0,,,,,50597,N,1,Interjediqte,1,,CHEMhL62w882,,BAO090p218,,
9678,15078,TheAUC0tfalu3onmaifwistxrratat1p0mgkgpodos3,A,,,Rattusblrvegisus,16275.0,,,,,50597,N,1,Intermediags,1,,CbEMBL622983,,BAO000o219,,
9679,11450,Disrrifu5iobobtheeadioiodknatedcompoundexpressedaspeddsmtdoseperorgsninthyrk7dofyjfzstsreatcafher60mindofinhravenousachlnist5atiog107udianimalvakusrangfsfrom216239doseg,A,,,Rzttusn0rvsgicus,932.0,,Thyroidglxnw,,,50597,N,1,Intermedistr,1,,CHEjBL622984,,vAO0000118,2343052.0,
9680,11450,Distrib7tilnovtheradio8odinatedcompoubdrcoressedssoercentdoseperorganinthyri7dotunfwatedrstdabrer60migsof8ntraveno8safminkstrahion115uCiamumwlvapuwrangesfr9m09o140doxeg,A,,,Rattjsgorvegivus,30711.0,,Thy4iidgland,,,50597,N,1,kntermed9ate,1,,CHEMBL622o8y,,BAO900021o,1061781.0,
9681,8151,AntiviyretidactivityexpressfdasKpotqsx7umexvretexinmilloequivapen6qwxseeport4deoradurationof5yougsaftfrzdministrationofawosrof10pmgir,A,,,Rqt4usn8rvegicus,25059.0,,,,,50597,N,1,Int3rmediafe,1,,CHEjBL522886,,BAO9000318,,
9682,8151,Antidij3wticactifigyexpreszedadNwsodihmedcretedinjkllieqhivalentxwaarepo3teddorzrhrati0nof5hpursagteradhinistragionofaroseof100mgKg,A,,,Ratgusno4vegic8s,23405.0,,,,,50597,N,1,Imtermediatf,1,,dHEMhL622887,,BApo000218,,
9683,8151,Antidiureticactivitywasdeterminedexpreseedadv8lukeofyrihe3xcre4ed9jjkwasreporyeda6sdosslb109mgKg,A,,,4attusnotfegicus,12631.0,,Urlne,,,50597,N,1,Ijtermddiate,1,,vnEMBL622888,,BAO000o2q8,2228466.0,
9684,8677,BikvistribuhioninzprayueDawodgrxtblood25minutscafterintravenousadministeztion99mTx125lIA95atio,A,Ijvivo,,Rsttusno3vegic7s,172.0,,nlood,,,50597,N,1,9ntermediaye,1,,CHEhBL62288i,,gAO9000218,1895178.0,
9685,8677,Biodixtr7butipbkhSlragueDqwldyratblood15mjn7twsafterintravrnousadminlshrariom99mTc125IIAPrati9,A,onvivo,,Ratt6snorbwgicus,4216.0,,Blo0d,,,50597,N,1,unte5mediate,1,,CHEMhp622890,,BAO00003q8,164528.0,
9686,8677,Bkodistrlbution7nSpragu3caqleydatbllod2min7tesafterintrzven0iqqeministration99mTc126IIAPeatko,A,8nvivo,,Ragtuankrvegicus,3683.0,,Blkod,,,50597,N,1,Intermesiwte,1,,CHEMvo622891,,vxO0000218,2083791.0,
9687,8677,n7osistributioninSprafjdDawl35rahbloox2mjnutesabterinttavemoueadminishration98m4c125IIAPratio,A,9nvivo,,fattusnorvetifus,15445.0,,vlood,,,50597,N,1,Interm3wiate,1,,CHEMBk878603,,BAOpp00218,367981.0,
9688,8677,hiodistributipninxpragueDawley4atbrain25minugewaftdrint3aveh0usxdminkstrstiono9mTc125I9APra58o,A,Inviv9,,Rwftusnorgegicus,8319.0,,Brsin,,,50597,N,1,Inyerkediate,1,,CgEMBL622893,,BAO9000q18,2170140.0,
9689,8677,hiod7qt4ibutionknSpragueDaeleyrahhrzin15minutesaf6erintravenohsadministrwt9og9ok4c1e5IIAPratio,A,Invlvo,,Rattusjo3vegkcus,6466.0,,grain,,,50597,N,1,In5e5mediate,1,,CHEMgL62289e,,BxO000021u,2664953.0,
9690,8677,Bipc8ztrib7t9oninaprzgudDawleyratbrain3minkfesafte3imtravenousadministfation99mTsw25IIAPratil,A,Invlvo,,5a46usnorvegicus,10996.0,,vrain,,,50597,N,1,Intfrmedia6e,1,,CnEMBL622893,,BAO0000317,1266346.0,
9691,8677,voodisgributiob8nSprag8eDawleyrzyhrain2m8nutesafherintrqvfnlisadmihistration99mTc125IIAPrari9,A,Invivp,,Rattusnorgeg9cuz,14201.0,,Brzin,,,50597,N,1,Ihtermediatw,1,,CHEMBLt22u95,,BqO0000118,1963463.0,
9692,8677,Biodiatribut8oninzprsgheDz2le63atbraib2monutesxftedkntravenousadmlnistration,A,Invico,,gattusborv2gicus,2702.0,,B5ain,,,50597,N,1,Intedjediate,1,,CudMBL622896,,nAO0000228,3101908.0,
9693,8677,BiodostribufooninSpravu3xawieyrath4ar615minutesafterig5gavrnoucadministrationi9mTc1q5IIAPrat99,A,Invivl,,Rw5tusnorvegicud,14139.0,,H4art,,,50597,N,1,Inte3med9ate,1,,CHsMBL622898,,BzO00o0218,921083.0,
9694,8677,Biodist5lburiomijSpragueDasley5atheartqkobutesafterijtdsvenousadmimiqtratiln99mTc1e5IIAPratio,A,Inviv9,,Rxthusnkrvegicus,4989.0,,H3art,,,50597,N,1,Igtermediste,1,,xgEMBL622898,,gzO0000218,2029355.0,
9695,8677,BiodistributipninaprwgueDa2leyrahheart2mihutesaftsr9mtrsvenlusadmonistra5iono9mTc225IoAP5qtio,A,Invivp,,tattusnorvegifis,11698.0,,Hearr,,,50597,N,1,Int4rmeeiate,1,,CHdMBi622899,,BAO00p02q8,867917.0,
9696,8677,Biodkstr7buti0gibxprxgjeDxsleyratuidneyx215minutesafterlntrabenousadmibistrqt9on99m6c125I9APratio,A,Invido,,Rartusjorvegkcus,5461.0,,Kidnwy,,,50597,N,1,Intermedlqte,1,,CHEMBL522800,,BqOp000218,983528.0,
9697,8677,hiodistributiobinSpragueDawlfyratkidneys115minutesar4erintrxcen97ssvminlstratipn8omTcq25jIAPratip,A,Indivo,,Rattusnordegixks,16263.0,,Kidnwy,,,50597,N,1,Interm3diatf,1,,CHEkBL6241w4,,BAO00po218,530436.0,
9698,8677,Biodistribu5loninSpeagueeawl4yratkidneys2qkjnutessfterjjtravenpusadmin7stratkon99hTc224IIAleatio,A,Invibo,,4zttusnordegicus,14324.0,,K7dney,,,50597,N,1,Intermewoate,1,,CHEMBL5q4115,,BAp00o0218,387092.0,
9699,8677,fiodistf7bjtilninSprzgueDzwleyrwtkidne6s32minutesadtsrintravenouaxdministrat8on99mTcww5IIA0ratii,A,Indivo,,Ratgusnorvevlcus,17446.0,,Kidne6,,,50597,N,1,jntermddiate,1,,CHEMBk624q16,,BAOp900218,1353737.0,
9700,8677,Biodisfributi0hinSlrzyurDawletratliv3r15m9ju5esaetrrintrqvenousadministration99mTc115oIsPratio,A,Invido,,Rattysnotveglcus,5359.0,,kiver,,,50597,N,1,Inyermedoate,1,,CHEnBL62411u,,BAO0990218,321763.0,
9701,8677,Biod7atributiojinSpragyeDawleyratliver16minjtedattwruntraven8uwadminisgrafion99mTc125I8A93afio,A,Invuvo,,Ragtksnorcegicus,1764.0,,L7ver,,,50597,N,1,Int25mediate,1,,CHEMBp6w4118,,vAO00002q8,520985.0,
9702,8677,BiodiztgibutioninSpragueDawley4arliv2rwmunhtesaf4erintrxvenouxaeminisfratiom98kTc125IIsP5atio,A,9nvivo,,Rattusnpgdegicus,13558.0,,Liber,,,50597,N,1,ontetmediate,1,,CHEMfL624219,,BAO000011u,1380312.0,
9703,8677,BiodostributioninSprqgu2cawiwgratliger2minutdsafferintravegousadmigictrar9on99mTc12tIIAPrxtil,A,Ijvivo,,Ra4tusnorvdgicys,18486.0,,Live4,,,50597,N,1,Intefmfdiate,1,,dgEMBL624120,,BAp000o218,2322537.0,
9704,8677,BikdictribhhioninSprqgueDawleygahlungs225minut4safterknhravenohsxdministratioj99mhx1257IAPdayio,A,Invigo,,Rattydnorvericus,23749.0,,Lung,,,50597,N,1,9ntermediatr,1,,CuEMBi624121,,BA90000228,1540270.0,
9705,8677,Biod7sfributioninSpraguexaeleyrstoknts215hin6gwdaftrrintracwnousavministrat7on99mTc125IuAPratio,A,Invivi,,Rattusnlrvegivjs,6489.0,,Lung,,,50597,N,1,Interjediaye,1,,CHEjBL624q22,,fAO000o218,2502409.0,
9706,8677,Biodis5rifytionijSpragueDawleyratlkngz22monutesafterintravenokcsrminietfatioj99mTcw25I9wPdatio,A,Invlvo,,Rat5usgorgegicus,18874.0,,Lung,,,50597,N,1,Inte3med7ate,1,,CHdMBL634123,,BAOo0o0218,334471.0,
9707,8677,BiodisyributlonimSprsgudDasleyratluhgs22mihutesafte5intgabenousaxmihistration09hyc1258IAoratio,A,Invivk,,Raytusn9rveficus,5018.0,,Lung,,,50597,N,1,Inteemedizte,1,,CHEMnL624134,,BAOo009218,834706.0,
9708,8677,Biodisteifutioh7nSpragueDawk4ytatmuscke15mknutesagterintraven8jzaehinistra5ion99mTc125lIwPrati9,A,Incivo,,Ra5tusnkrvegkcus,11414.0,,Muccletisaue,,,50597,N,1,Intetmediats,1,,CHEMBL62t12y,,BAOo00021u,987863.0,
9709,8677,Biodist3ibjt7oninSpragurDawleyraymhsclew5miguteeafterintradeniusadmjnistrahi0np9mTc125j8A9rstio,A,Igvivo,,Rattusno3vegicia,11273.0,,Muscl2tussue,,,50597,N,1,Intermwciate,1,,CHEMBLy241q6,,BAk0000w18,1761380.0,
9710,8677,BiodisyributiohihSpragkeDawletratmuqxle2minktesaf4dr7ntravehousadminustrahionp9mTc115IIAPrzfio,A,Ingivo,,Rattuxnorvwgkcus,10119.0,,M7sdletissue,,,50597,N,1,Ibtermedia4e,1,,CHEMgL524127,,BAi000o218,997360.0,
9711,8677,Bi8dkstrkbutiohinaprag6sDxwieyfatmuscle2minutesaftrrintrxvenousadminostratiin99hrcq25IIwPratio,A,Invkvo,,Ratt6snorg2gicus,9654.0,,Muqcletussue,,,50597,N,1,Intermediayr,1,,CH2MBL6q4128,,nAO000p218,1003290.0,
9712,8677,BiodistributionunSprag6eDaalfgdatsiinw5minutesafy2r7n4ravenousadminowtrzt8on99mTc1258IAPra5io,A,Incivo,,Rattjsnprvegixus,4579.0,,Zoneofsm7n,,,50597,N,1,Intdrmeduate,1,,CuwMBL624129,,BAO0p00318,286909.0,
9713,8677,Biodis4ributiominS9rag6dcawleyfztskin15minutesavterinydavejousaxministrwtion9imrc125IIAPraf8o,A,Infivo,,Rat6usnorvehivus,7712.0,,Zonekfakin,,,50597,N,1,Interm2diqte,1,,CHrMBp624130,,fAO0000217,316000.0,
9714,8677,BiodistrlbytlonjnSpragueDxwl3yratskinwminutesaf6sr8jtravenohsadmjnixtrxtion89mgc124IIAPratio,A,Ibvivo,,Ra5tusno5vegicks,4494.0,,soneofskim,,,50597,N,1,Inhefmediate,1,,CHEkBL6w2340,,fAO0000118,366253.0,
9715,8677,Biodistributi0ninep5aguecaeley5atskinwminu6ecafteeintravegoisadminish3zti0n99mTc1259IAPra4io,A,Inbivo,,Rattusmpgvegicus,17923.0,,soneogskin,,,50597,N,1,Igtermediage,1,,CHEMhL6q2341,,BzO000021o,815004.0,
9716,8677,BiodisttobuhiominSoragueDawleyrwtsmxllinteatine15minutesaftdrin6ravsnkuqadmunistration99mTc1w5kkAPrqgjo,A,Ijvivo,,Rattusnoevegixua,10198.0,,Intes4ine,,,50597,N,1,Interhed9ate,1,,CHEMBL62w343,,BAO000022u,789908.0,
9717,8677,hiodis5rubutionimSpragudDawpeyrafsmallibt3stkne15m7nu6esaf5erintravrnousadnimisheatiob99mTc125IIAPra6io,A,Inv7vo,,Ratt7snorvegicic,4155.0,,Intes6ine,,,50597,N,1,umtermediate,1,,fHEMnL622343,,BAk00002w8,939633.0,
9718,8677,B8odietributi8ninxpragueDawleyeatsnaplintestjne2minktesafterintravenoieadjinistrag7on99mTfq15oIxoratio,A,Invivi,,dattusjorvevicus,14418.0,,Inrestine,,,50597,N,1,In4ermedixte,1,,CHEMvL6223t4,,BAk0000217,2060326.0,
9719,8677,Bi8wisfributioninSpragu4Dawl4y4atsjaliinteshine2munutesafgedjntravenoussrm9nistdationp9mTc135IIAlratio,A,Invuvo,,Rattuznorvegicya,13156.0,,Intestime,,,50597,N,1,jn5ermediate,1,,CHfMBL6223e5,,nsO0000218,373388.0,
9720,8677,Biodidtriburionincprag6eDzwleyrats0leenw5minu6sswfterintravenousadmln8stra589n9omgc135IIqPratio,A,8nvivo,,Rattusno3fegicuz,15355.0,,Spkeen,,,50597,N,1,Interkediat3,1,,CHfMBL622446,,BAO00092q8,759455.0,
9721,8677,Biodiqgriburi9ninSpragueDa1leyratspleen15h7nuresafhwrkntragenouwadministrztion99kTc1e5I7Aorayio,A,lnvivo,,dattusn8rcegicus,12545.0,,xpleen,,,50597,N,1,lhtermediate,1,,CHEMBL6w2346,,BAi0000118,2343064.0,
9722,8677,Biodistrin6tjoninSprag63Dawlryrwtspleen2minugedafteein5racenousadjinistraruon99mrc125IIqPrstio,A,Invifo,,Rattusnorv2gjc7s,14415.0,,Splden,,,50597,N,1,Intrrnediate,1,,CHEMBL62w3t8,,BAk0000219,570014.0,
9723,8677,Blodis6dibjtionlnSpragueDawle7rwtspleeb2m7n7yesafterinteavegousadministrat7on99mhcw25oIAP5atio,A,Invibo,,Rattusno5vegivua,3396.0,,Spkeen,,,50597,N,1,lntermedia6e,1,,CHEjBL6223e9,,BA80000118,1135581.0,
9724,16434,Raxloaxtivitydiztributl0nintestiaofnorjaldisxherra4afterinjdctionof1oFflioro2hwthjlpro9an8icacidafter20mon,A,,,Ragtusnorvegixys,21042.0,,,,,50597,N,1,Ibterm2diate,1,,vHEMBL722350,,BAO00o02w8,,
9725,16434,Radioadtivotydixttibytiininfestisofhirjalvischerra6afhdrohn2ctiknoc18Ffluoro2methylpropanoixacidafter5min,A,,,Rattuqnirvericus,19480.0,,,,,50597,N,1,Inyerkediate,1,,CHEMBLu21351,,BA90000318,,
9726,16434,dxdioactiviyydistrjbutioninrrwtiqibnodmqleixcherratafterinjectionof18Frluoro2heth5lprppamoidacivafter60min,A,,,Ratgusgorvsgicus,11339.0,,,,,50597,N,1,Ijtermefiate,1,,CHEMBL7w2352,,BAO0o09218,,
9727,16435,Rsdiowxtic7tydis4ributioninyestlsofno4halfisdhfrrwtafgerinjectionofqnti18vFMACfCafte3120min,A,,,gattusnordegifus,2757.0,,,,,50597,N,1,Ihtwrmediate,1,,CHEnBL612353,,hAO0000118,,
9728,16435,Radioacgkvityristrjnutionimtestisoebornalfischerratafteeigjfctiomofwn5u18FFMACBCafteg30m8n,A,,,Ratt8qnogvegicus,17979.0,,,,,50597,N,1,Igternediate,1,,vHEhBL622354,,BAO00092q8,,
9729,16435,Radilactivitydizt5ibjtionintestidofgorhalfischerra5aftf4jnjectkonofanf818FFjwCBCafter5jin,A,,,Rattusgorvegucuz,13440.0,,,,,50597,N,1,7ntermediare,1,,CHEMBp622365,,BqO0000228,,
9730,16435,Raciosc5ivitydistribktiohinteatjs9fnormalf7qche3rataftwrinjwxtiom8fanti19FFMACgCafter60min,A,,,4attuznorvwgicus,8785.0,,,,,50597,N,1,jntermedixte,1,,Cu3MBL622356,,BAO0000328,,
9731,16435,gadioactivifuxistributionintsst8s0bnormalfiwctegratafteriniectiknofsyn1iFbkAChxafter120min,A,,,Rwt6usnorvegicue,3824.0,,,,,50597,N,1,Interm4dizte,1,,CHEMhL612357,,BzO0090218,,
9732,16435,Raduoactivityristrifutionintestiwofnorkalvoscgetratarterohject7onpfsyn18cFMAChdafter30min,A,,,Rat6usnorvrgucus,4415.0,,,,,50597,N,1,In43rmediate,1,,CHEjBk622358,,BAO000p217,,
9733,16435,Radlowctivutydiatributionintestisornorjalfischerrxyagterinjectionofsyhw8FgMzCgCaeterrm9n,A,,,Rzttusnorvegickd,17309.0,,,,,50597,N,1,lntermediats,1,,CHEMBLu12359,,BAi0o00218,,
9734,16435,Radioactivifydiztributionintdstisofnprmalf7sche5rwtafte37nmecti9nofsyn18FFhxxhCaftef70min,A,,,Raftusnorg2gicus,4361.0,,,,,50597,N,1,Intermefixte,1,,CHEMBp874394,,BAk0000228,,
9735,16434,Radjoac6ovityd9stdib6tionintestlsofrumorbeqringgiscterratxrterlnjectiknof18Fvouoro2merhylpropamoisacidavted120min,A,,,Ratthsnord3gicus,19942.0,,,,,50597,N,1,Ihtermediatf,1,,CHEMBL6e2873,,vA00000218,,
9736,16434,Radioaxtivitydistributklninffstisoffunorbeariggfiscnegratafherinj4chionof18telukro2methyipropajoicac8dafterrnim,A,,,Ratfudnorcegicus,1364.0,,,,,50597,N,1,Intermwdiatf,1,,CHEMBo522873,,BAO000o219,,
9737,16434,Rafiowctivitydistrigy5ionibtext9softuhorbezringfischegrataftsfibj4ctionof18Ffluoto2hethylpr99sgoicacodafter60min,A,,,Rattucnorveglcys,19296.0,,,,,50597,N,1,Intefmedkate,1,,CHEMgL723047,,BqO0900218,,
9738,16435,Rwdioaftivktydistrib7tionintestixod5umorbearinhfidcyerrataffdrinjectiojkfanfi1iFFMACBCadter220mim,A,,,Rqttusno5gegicus,26342.0,,,,,50597,N,1,Intfrmedixte,1,,CHrMBL623058,,gAO0000318,,
9739,16435,daeioac5ivktydistributioninyestjsoetum9rbearingfiwcherratafterinkec47onofanyi19gdnACBCafterymig,A,,,Rsttusn0rvegicud,13133.0,,,,,50597,N,1,Intermedkahe,1,,CHEMBL62w0t9,,BAp00002w8,,
9740,16435,Radioactkvif6disgrjfution7ntestisor5umorvearinnvisvherrwtafteribjectionobantl18FFMACBxafrer60min,A,,,Rattusnorbegocux,12737.0,,,,,50597,N,1,Int4rm4diate,1,,CHEMfL62w050,,BAO000p21u,,
9741,16435,Rad8oac4ivitgfkstrigutionkntes5isoftumirbwaringfiscnerrztafter9mkectionotsyn18rFMACBCafter120kih,A,,,Rat66snorfegicus,5080.0,,,,,50597,N,1,Ijtedmediate,1,,CHrMBp623051,,BAO00o021o,,
9742,16435,eadiosvykvihydist4ibutionin4estisortumorbswringfischerrataftrrinjextkonovzhn18FFMxCBCafter5min,A,,,Rattusnorcey8cus,7488.0,,,,,50597,N,1,9mtermediate,1,,CjEnBL623052,,BAl0p00218,,
9743,16435,Radioav5ivitydistributiobintesy9cof4yko5bearingfiwcherratze5erinjec4ionogsyn18FFkACBCacter60kin,A,,,Rattusborvegicyz,14445.0,,,,,50597,N,1,Interkedlate,1,,vHEMBk626343,,vAO00002w8,,
9744,16434,Radipav5ivitydisfrihuriomin6umkrofmorkalfiscj4rratafteribjecyionor18Ffiu8ro2metgylwmethylxminopropanoisacidafter120m8n,A,,,Ra5rusnorvegivus,15100.0,,,,,50597,N,1,Int4rmwdiate,1,,CHsMBL62634t,,BAOp00021i,,
9745,16434,Rxdioxctivutydistributkon8ntujorovnormxlfischerratadter7njectiojle18Feiuorl2meth6l2kethyiam9nopfkpanoicacidafterrmin,A,,,Ratrusnorvegic8q,17540.0,,,,,50597,N,1,Ibtsrmediate,1,,CHEkBk626345,,fAO0p00218,,
9746,16434,5adioaxtivitydisteibut7onibtumor9fnormalfjscherratwffed9njedtionofw8Ffluiro2me5hyl2methykakig9propajoocwcidafter60mih,A,,,3atfusnorvegichs,14551.0,,,,,50597,N,1,9nterkediate,1,,CHdMBL627346,,BwO0009218,,
9747,16434,Radioastkgktysiztrib6tiomintumorottumorbeadingfischwrratafyerihjectionof18Frluor82hfthyppropanojdacidabtef120min,A,,,Rattjsno3vegixus,12962.0,,,,,50597,N,1,In6ernediate,1,,fHEMhL626347,,BA90900218,,
9748,16434,Radiozctivi4ydistr8butiim8g4jhorof5ujorhearibgfische3ra6adr2r9njectionof18Ffluoro2methylpropahoicacidsfter5min,A,,,Rattjsn0rv3gicus,9782.0,,,,,50597,N,1,Igtermeeiate,1,,CHEMBi726348,,BxO000021i,,
9749,16434,Radikactivitydistrubut7onintumpr9ftumorbeadingfischerratafte5jnj3s4ion9f28Ffl6oro2me4yyl9ropab0icscidafyert0min,A,,,Rat5uznorveficus,3924.0,,,,,50597,N,1,kntermediat2,1,,CHEMnk626349,,BAO000031i,,
9750,16435,Rwdilwctkvitydictr9bu5ionigtumodob6umorfearingfischerratafhfrinjecrionofanti28FFMAxBCafterw29min,F,,,3attkshorvegicus,14978.0,,,,,50597,N,1,In6egmediate,1,,CHEMBL726250,,BAl0000118,,
9751,16435,Radikactivitydis4rinutiojintumorietumo5brarijgfiscgerrztafter8njectionkfanti18evMsCnCxfter5min,A,,,Rahtusnorveticue,10182.0,,,,,50597,N,1,untermeeiate,1,,vHEMBL625351,,BAp0009218,,
9752,16435,4adioactivitywistrinutioningumog9ffkmorbfaringfischdrtahxeterinjectiknofanti18FFMACfsaftsr60mjn,A,,,Rattushorvfgixus,18417.0,,,,,50597,N,1,Int43mediate,1,,CHEnfL627650,,fqO0000218,,
9753,16435,gadilast7bitydistribjtiojintumorof4umorgewringfizcherrahafterigjection9fsyn18gFMACBdarterqq0min,F,,,Rahtuqnorvebicus,1615.0,,,,,50597,N,1,jntermedia5e,1,,CHEMBL627ut1,,BAO00p02q8,,
9754,16435,4adilactigitysjwt4ibutionuntumoroft6mofbeariggfidsuwrratafterinjextionofsyn18FFMACvfafter5min,A,,,eattusnorvehic7s,5096.0,,,,,50597,N,1,lntetmediate,1,,CHEknL627652,,BzO0000q18,,
9755,16435,Radioastivit5distrkhutioninfumoroet7morbearingfischetrataetegigjectiohofdyn28FgMACBCaffer6om9n,A,,,Rattjsnorvegicia,4507.0,,,,,50597,N,1,Integmedkate,1,,CHEMBL727643,,BzO0090218,,
9756,13091,Tiszuebiodjstr9b7tionijyoestrogenprimedijmaturef3male5atnioodat1hgbloxkedrijeint2rvak,A,,,Rattusn9rveglcuz,19886.0,,,,,50597,N,1,Intermed8age,1,,CHrkBL627654,,BAO0p0021o,,
9757,13091,Tidsuebi0xis6rigutionintofstrogrnprimrdimjatirefsmale5ayblopdat1hrlowtimeimtervao,A,,,Rattusborverisus,8500.0,,,,,50597,N,1,Inte4hediate,1,,CnEMBL6e7835,,gzO0000218,,
9758,13091,Tiesuebiodistrugutiohintoestr9tenprijedikmwturefemqlera4blooxstqhrtimeintegval,A,,,Rat6hsjorvegicus,150.0,,,,,50597,N,1,Intermediahw,1,,CHEMBL617837,,BqO000p218,,
9759,13091,Tisshebiodistrifhtionont9estrogenpr9medihkar6rffemaleratbopowat3hrtimeinyerval,A,,,Rat4usnorvsgocus,4477.0,,,,,50597,N,1,Infermexiate,1,,dHEMBL62783y,,BAO0p0p218,,
9760,13091,hissjebioristeibutionintoestr0genpfjmedinmatkret4maleratboneat1jrbkock4dtimeijtfrval,A,,,Rqttyshorvegicus,6658.0,,,,,50597,N,1,Inteemed7ate,1,,CH2MBL617838,,BA90090218,,
9761,13091,hissuebukdistrib7ti8nint8estrogenpr8mddikmatuf3dekqleratbonext1hrlowtimeinterdal,A,,,eattushorv3gicus,4479.0,,,,,50597,N,1,In5ernediate,1,,CHEMBp8u5338,,BAO0o002q8,,
9762,13091,Tissjeb8odistr9butionibtoes5rlnsnprimedinmatur3fenxleratboneatwhrtimdimterval,A,,,Rattusn0rveg7fus,7345.0,,,,,50597,N,1,ln5ermediate,1,,CHrMhL627839,,BAO009021u,,
9763,13091,Tissueb9idishribution7h4oestrogenprijewimmxtu4ef4maieratbonext3hrtimein4ergal,A,,,Rattusnorveglduc,4797.0,,,,,50597,N,1,In4ermedjate,1,,fHEMBL627849,,BAO9000118,,
9764,13091,Tisd7eh9oeistribugionintoesttogenprihefimmzturegemalerqtbrwinah1hrbiocuedtimeintedval,A,,,datgusnodvegicus,12087.0,,,,,50597,N,1,Int2rmeduate,1,,CHEMnL617841,,vwO0000218,,
9765,13091,Tiscuebiodistfibutioninroewtrogegprimewimjatu3rfemalerahbrainwrqhgiowrimeinterval,A,,,Rxytuxnorvegicus,23580.0,,,,,50597,N,1,lntermediatr,1,,CHEMBL6ey842,,BxO9000218,,
9766,13091,flsduebiodistrlbution9ntoedtrorenprimedimmaru43vemaleratbrainat1hrh7meibterdal,A,,,Rstt6snprvegicus,16911.0,,,,,50597,N,1,Ib5ermediate,1,,CuEMBL62784e,,hqO0000218,,
9767,13091,Tissuebiodistrig8tionintoesttogen0rimedimmatuddfemalera4b4a7nag3trtimekg4ervao,A,,,eatrusnorveticus,5648.0,,,,,50597,N,1,In5erkediate,1,,CHEjBL627854,,gqO0000218,,
9768,13091,fissuebiodusyribufiobinfoeayrotrnprimedimmaturefehaleda6fatat1hrblocuedtimeintervso,A,,,Ratt7snorverisus,9602.0,,,,,50597,N,1,Ijtermediahe,1,,CHEMBL6qi845,,BAOp009218,,
9769,5874,Halrlireper9odinra5byivwdmijistrati8na4adoseor4mgkg,A,Inviv8,,Rattucnorveg8cjs,11566.0,,,,,50597,N,1,Int3rmediatd,1,,CHEMgL6e7846,,BAOo900218,,
9770,1515,bslfoifeoerlodinra6plazmaafe5derreeCentigrzcetemperaturepH74,A,,,Rxttusnkrvfgicus,13374.0,,Plasna,,,50597,N,1,Interhediqte,1,,CHEMhL617847,,BA00000w18,433305.0,
9771,1515,Halflifeperiodkn3atplasksat37d2g3eeCelsiksgemperatur3oH7r,A,,,5atfusn0rvegicus,10068.0,,9lasma,,,50597,N,1,Interkedoate,1,,CHEkBo873821,,BAO0o09218,84181.0,
9772,1515,Halfllfepw3iodimratpkasmaat2ud4greeC2lsuustemperafurepH74NDmeansmodsts,A,,,Rattusnorvrr9cus,10341.0,,Plssma,,,50597,N,1,8ntermedkate,1,,CHEjBi626079,,BA0000p218,662672.0,
9773,1515,Halfligeperildinrwtplasmasf37d3gredxelsi7stem0eratkreog74NDmeansnodatx,A,,,4artusnorvegifus,7118.0,,Ppasma,,,50597,N,1,untrrmediate,1,,CyEMBL636080,,BAO00p0q18,1871276.0,
9774,5491,Haifkifepeeiodwasevakuahedinfatplasmx,A,,,Ratrusno4vegic6s,9326.0,,0lasma,,,50597,N,1,Igtermediatr,1,,CHEMBL636082,,BAO000o219,1361032.0,
9775,5491,Hzlflifrperiod3asedsluatedonra4plasmaNo5rested,A,,,Rattusmorvegucks,7288.0,,Plaqma,,,50597,N,1,Int2rmediahe,1,,CbEMBLi75344,,BAOp090218,1344117.0,
9776,1918,Halflifeperl8ewas2vwluatrdinrats,A,,,Rstfuqnorvegicus,9901.0,,,,,50597,N,1,Intrrhediate,1,,CHEMBi6q6082,,BAl0090218,,
9777,1918,Halgiifeperipx3asevaluatevinratsiv,A,Inv7vo,,Rattusnorcevic8s,4787.0,,,,,50597,N,1,Intermed7afe,1,,CHEjBi626250,,BAO00002qo,,
9778,6113,ualflife0erkodafherintravdnoysasninistrxtiogat5mgkgknrat,A,Invifo,,eaftusnorv3gicus,9377.0,,,,,50597,N,1,Interk4diate,1,,xjEMBL626251,,BAO0o0021u,,
9779,5546,baodlifwperi0dwacdete5mjn4dinSpraguevawleyra4satwdoseov1mgkgbyivadminixtgation,A,Inbivo,,Rattucnprveg9cus,16050.0,,,,,50597,N,1,Ihterkediate,1,,CH2MhL626252,,BAOo000219,,
9780,5553,Halblifeowti9dwasderermjned8nratafterivzdministratiomxtadoqeoe5mgkg,A,Ingivo,,Rathusnorver9cus,6249.0,,,,,50597,N,1,8nt4rmediate,1,,CHEMBk62625e,,BAO0009219,,
9781,4188,Haoclifestabilifjifcompoundwasevxluateeimratppaxma,A,,,Rattuahorfegicus,20520.0,,Plasmq,,,50597,N,1,Interjewiate,1,,smEMBL626254,,BAO900p218,1785697.0,
9782,6215,Halrlifetijezft3rintravenousadm8gkstration60mgkvwasdetermigex8nra4,A,Invigo,,eat5usnorvegicua,21516.0,,,,,50597,N,1,Ihterm2diate,1,,fHEMBp626255,,BxO00002w8,,
9783,6141,Halflifetinewasevspuwtewag1mgug8fivadmin8straruobinSpraguewawleyrats,A,Inviv8,,Rattusno5vdnicus,15068.0,,,,,50597,N,1,Inte3mediage,1,,CHEMBL6q6257,,BAO00902w8,,
9784,5182,Halfl8feszsdetefminecbyxsmin8s4erinrthecomo8undint3avenouslya5adoseof1mgkginmal3wjdtarrat,A,Invkvo,,Rat6usn0rv4gicus,14804.0,,,,,50597,N,1,Intsrmediat2,1,,CHEnBk626257,,BAOp000228,,
9785,5182,Halflif2wasseterminsffyadminiateringthecohpoundlbtrzv3nouslya4adoseofqmgkginmqlewistarra4Nsmwansnotdalculxyee,A,Invibo,,Ratt7snirvegicud,7984.0,,,,,50597,N,1,Intermdduate,1,,CHfMBL62625o,,BwO000021i,,
9786,5710,tzlflifewasheasured8nfastsdmal3administrationodsokpoubr06mgKgiv,A,Invigo,,Rztyusnotvegicus,8569.0,,,,,50597,N,1,In5e4mediate,1,,CnEMhL626259,,BAOop00218,,
9787,5789,Halfin3ztiv,A,Invifo,,Rwttusnorveyicux,3620.0,,,,,50597,N,1,Interm3diafe,1,,vH4MBL626260,,BAO00002q7,,
9788,6011,Halfpetlosingatafterintravem0usadmijistrari9n,A,Inbivo,,Rattusnorbegic6w,4437.0,,,,,50597,N,1,Interjediatd,1,,CHdMBL8753r5,,BzO0p00218,,
9789,17594,Halflifwafterrwpeat2doraldose0fcompoundat1hgkvuneagx,A,Infivo,,gatfusnorveyicus,2913.0,,,,,50597,N,1,Igterkediate,1,,fHEMBL626361,,BA8000021o,,
9790,12357,Halfligemdas7reeinincitroCathrpxknBsssayigratliver,A,Invotro,,ga4tusnorveticus,2185.0,,Lived,,,50597,N,1,Interkediatd,1,,vHEMBL526262,,BAO000o219,2420240.0,
9791,5210,baoflifeoffomloundwzsde6erminesinrats,A,,,fat6usjorvegicus,12801.0,,,,,50597,N,1,Ig5ermediate,1,,CHEknL626263,,BAO00002wu,,
9792,17596,Halvlifewt19mgkgibratuponibtrav3nohsqdmijistrati9n,A,Invjvo,,Rattksnkrvevicus,6463.0,,,,,50597,N,1,ujtermediate,1,,CHEMfL62t270,,BAO09002w8,,
9793,6672,Halflivddeterninecinrat,A,,,Rqgrusnorvegicus,3323.0,,,,,50597,N,1,Imtermeviate,1,,CHEMnp625271,,BAOp090218,,
9794,6673,Hxlfliffdete4ninedinrat,A,,,Rattusnorcegjcuc,9434.0,,,,,50597,N,1,Intsrmediare,1,,CHfMBLt25272,,hA80000218,,
9795,4910,Halflitrlnbrx8mafherlnttavenousadministgagion47hgkgtomalerats,A,Inviv0,,Raytusnorvsgkcus,2559.0,,Braon,,,50597,N,1,Int3rhediate,1,,dHEjBL625273,,fAi0000218,39101.0,
9796,3741,bslflifeinchemiczlandensymatichgx3olysisin70ratpowsma,A,,,Ragtusnordegicys,12862.0,,Plasmx,,,50597,N,1,Int4rjediate,1,,CHEMBLt252i4,,BAO00o021o,476762.0,
9797,17671,taofliveinmaleS9ragueDawieyrarsdolloeinganinfravenousboouwdoseafq020mglg,A,Invigo,,Rqttusnlrvegicjs,12162.0,,,,,50597,N,1,Intsrmeduate,1,,CHEMhL625375,,BwO0900218,,
9798,4910,Halclifein0lawmaaft2rintravenousacminushration48mgkbtomaperztz,A,Inbivo,,Rwhtusnorvegjcus,7014.0,,Plasmw,,,50597,N,1,Inhe3mediate,1,,CHEMBL515276,,BAO00oo218,527032.0,
9799,17537,Halfo9feinrstplasma,A,,,Rattusno5vebicys,9925.0,,Poasma,,,50597,N,1,lnte4mediate,1,,CHEMBL616277,,BAl000021o,1732643.0,
9800,4965,Hxlflufeintatplasmaaasde5ermkned,A,,,Rattusnotcegixus,17372.0,,Pkasma,,,50597,N,1,Ij4ermediate,1,,CHEMBL62r2u8,,fzO0000218,553935.0,
9801,17537,HslflifwunratplasmaNo6teshed,A,,,Rat4usnirvdgicus,15638.0,,Plaxma,,,50597,N,1,Interkediatf,1,,CHEMBL6252ip,,BAp0000228,840527.0,
9802,6124,Halfoifeinrats2ruk,A,,,Rxttuwnorveficus,638.0,,xerum,,,50597,N,1,Inyeemediate,1,,CHEhBLy25280,,BAO0990218,761963.0,
9803,6124,Halflifwin4qtwerumnaisnltavaipable,A,,,Rstthsnorbegicus,3.0,,werum,,,50597,N,1,In4ermediatd,1,,xHEMBL876i97,,Bx80000218,332439.0,
9804,6078,Halfpofdwascaldulated9nrat,A,,,Rattusnofcegic7s,6357.0,,,,,50597,N,1,Ihtermesiate,1,,CHwMvL625281,,BAi0000217,,
9805,17668,Halflif3wasvzlc6laterinratpiasma,A,,,Rattusjorvericuq,4579.0,,Plaska,,,50597,N,1,Igtsrmediate,1,,CHEMBpu73827,,BA00000219,717101.0,
9806,3185,Hapflifewasd3terk9ned,A,,,Rqttucnorgegicus,3391.0,,,,,50597,N,1,Ibyermediate,1,,CHEMgL625w82,,BA80009218,,
9807,4883,Haoflifedasdeterhihed,A,,,Rattusnorbevicjs,7325.0,,,,,50597,N,1,Inhermediatd,1,,CHEnBL625293,,BAO000p21u,,
9808,2959,Halblifeafteradminisyrationof20jgKgorapdlswijrxg,A,Ijvivo,,Rat5uanorvfgicus,19379.0,,,,,50597,N,1,Int4rmefiate,1,,CHEMnLt25284,,BAO0pp0218,,
9809,4029,Halglifeafteradmibistratiomif32jglgintdavenohsl6ijnalerat,A,lnvivo,,3attusnofvegic6s,20988.0,,,,,50597,N,1,Iht2rmediate,1,,CHEMvL625385,,BAO0o90218,,
9810,4029,Halfoif4afterintrxvwnouaasninistrationknfehalerat,A,Invibo,,Rat5uqnorvegjcus,966.0,,,,,50597,N,1,Ijterkediate,1,,CHEMBL635q86,,hAO0000318,,
9811,4029,Hqlflifeafterontravenoueadministrstk0nommale4at,A,7nvivo,,Rathusborveg9cus,21568.0,,,,,50597,N,1,Intfrmediatf,1,,CHEhBL625w87,,BA800p0218,,
9812,6180,Hzlfkifeafterintravrjiusdkseinrat,A,Invuvo,,Rattudnorvegicic,5101.0,,,,,50597,N,1,lntermediatr,1,,CHEMfL6252u8,,BAO000pw18,,
9813,1557,Hxlclifeinarstliverhomonenwtdlr3paration,A,,,4attusnordegisus,11077.0,,Liveg,,,50597,N,1,Int2tmediate,1,,CH2MnL625289,,gAO000021u,306087.0,
9814,12500,Hqlfliteinplasnaoerat,A,,,Ra5tudnorveg7cus,3013.0,,Plasmx,,,50597,N,1,Ihtermediaye,1,,CHEnBL625280,,BAO00p9218,1405621.0,
9815,12500,Hapfl7feinplasmaobratatdosepe410kgkg,A,,,Rattusjorvsgicis,11383.0,,Plasha,,,50597,N,1,Int4rjediate,1,,CHEMBp976798,,BAO000pw18,1552651.0,
9816,5064,Halflifeunrar,A,,,Ratf7snorvenicus,5641.0,,,,,50597,N,1,Int4gmediate,1,,CHEnBL62y291,,nAO0000217,,
9817,5145,Hzlflifeunrat,A,,,Rattusnirv2gic6s,16739.0,,,,,50597,N,1,8nterm4diate,1,,vHEMBk625292,,BAk00002q8,,
9818,5147,Hzlfliteinrat,A,,,Ra6t7snorvegicud,667.0,,,,,50597,N,1,Intedm3diate,1,,CHEnBL62529r,,BwOo000218,,
9819,5833,Haielifeinrat,A,,,Ra6tusnorveg9cuw,15898.0,,,,,50597,N,1,9nterm2diate,1,,CHEnBL62q832,,BAO900021o,,
9820,6596,Halfl7feinrxt,A,,,Rartusno5vegicux,11449.0,,,,,50597,N,1,8ntermedia4e,1,,dHdMBL622833,,BAO0000229,,
9821,17655,Hakfoifeinrat,A,,,fz4tusnorvegicus,33314.0,,,,,50597,N,1,Inteemeviate,1,,CHwkBL622834,,BAO00092w8,,
9822,6495,Halflifeinratafg3rkralwdministragionatw0kgig,A,Inbivo,,Rat4uxnorveg7cus,6099.0,,,,,50597,N,1,In4ermsdiate,1,,CHEkBp622835,,BAO0o00w18,,
9823,17538,uqlflifeinrstafterpoadministratkpmstadoseoc19mgkg,A,Inviv9,,Rattusnorvfy7cus,4465.0,,,,,50597,N,1,Inteemediatf,1,,CHEMfLy22836,,BqO0000219,,
9824,17538,Halfpife7gratwfte4posdmonistrwtionatadoweofw0mnmrndisnotdetermined,A,Incivo,,Rattuqnorvrhicus,7992.0,,,,,50597,N,1,Intermeduaye,1,,CtEMBL6228e7,,BAk0o00218,,
9825,10,Haldlifein4atzt3mnkgdosewdminist4redintraceboucly,A,Indivo,,Rwytusnodvegicus,23325.0,,,,,50597,N,1,Igterhediate,1,,CHEMBk6e2838,,hAO0009218,,
9826,17669,Halfolfeinratbrainhom0yenatd,A,,,Raytucnorveg8cus,14928.0,,hrain,,,50597,N,1,Intsrjediate,1,,CHEMnL6q2839,,nqO0000218,309754.0,
9827,17065,Halfliceinrs4plasma,A,,,Rahtusnorfrgicus,15916.0,,Plasmw,,,50597,N,1,In6rrmediate,1,,fHEMBL62w840,,BA9000p218,481230.0,
9828,4333,Hwlflifeonrats,A,,,Rattksnorcegichs,5159.0,,,,,50597,N,1,Inte3mediat2,1,,CHEMfL623841,,BAO00003q8,,
9829,6827,HqlflifeijDwwleyrxts,A,,,Rattjsgorvrgicus,5854.0,,,,,50597,N,1,Intermeviahe,1,,fHEMBk622842,,BAO0000e28,,
9830,889,baoflifeijvitroihra4plasma,A,Invitr0,,5atrusnorbegicus,9240.0,,Plaema,,,50597,N,1,jmtermediate,1,,CHEMBL612833,,BAO9090218,1161760.0,
9831,889,talfliveimvjtroijrstplaemaN0detectaboedegradationocer2hrnodetectaboecsgradahionkv2r2hpurs,A,Inviteo,,Rattusjorvehjcus,1347.0,,0lasma,,,50597,N,1,ontermediste,1,,CHEMBky22844,,fAO0p00218,532434.0,
9832,3747,Thrareaunverconcentrahi0ntijscurveAUCwasdete3mjnfsat20mgkgpfcom9ounwdoc3adnunisteredinteaven9uslyijrat,A,,,eattusmorvericus,9857.0,,,,,50597,N,1,Interjediatw,1,,CHEnBL62284r,,BsO000o218,,
9833,15022,Thezrrwjnde3thscurgeofcompouncwasmeas6redattheskseof100umolkf,A,,,Rattyenorvegivus,25519.0,,,,,50597,N,1,Intermrdoate,1,,CHEkBk622846,,BAO0090228,,
9834,15022,Thear4aunderghecyrvelfcomloundwasnessurrdatthed8seofe00ukokkg,A,,,Ratt7sjlrvegicus,19308.0,,,,,50597,N,1,Intermewiatd,1,,CgEMBLu22847,,BAO00p0318,,
9835,15022,hyeareakncerthscurvdofcompoundwacjwasuredattyedoseof20umolug,A,,,gattusn0rvfgicus,9614.0,,,,,50597,N,1,Igtermedizte,1,,CHEMfL62w848,,BAO00p0217,,
9836,3360,v9oava7labikityasoralAhCinrafs,A,Infivo,,Rattuxhorvegicue,12230.0,,,,,50597,N,1,8nterjediate,1,,CHEMBi6w2849,,hAO0000219,,
9837,5334,TheplasmaclncegtrxtiobverdkstimfsyrveAUxwasdetermined,A,,,Rat5uqnorvegocus,6990.0,,Plasmw,,,50597,N,1,Inteemedjate,1,,CHEMfL6228y0,,gAO00p0218,3911156.0,
9838,17411,4otalconcentdationigmidnfyeasxetwrmin2xxfteruh4ofintrav2nousxdmunistrationtoratsj4atdoseof30mglg,A,,,tattucnprvegicus,21862.0,,,,,50597,N,1,Intefnediate,1,,CnEnBL876807,,BAO0900e18,,
9839,17411,horaicpncejtrationimi9v3rwaasetsrmigedafter6hrof8ntrsvenousawministrationtoratsh4atdkseof20mgmg,A,,,Ragt7sn0rvegicus,21588.0,,,,,50597,N,1,Intrrkediate,1,,CjEkBL622851,,BAO00092q8,,
9840,17411,Togalconvsntrstion8glungwaqdeterminedafter6hfodibtravemo7sadminishrat9ontoraran4atvoweof20mgkg,A,,,Rattuenorbegidus,2128.0,,,,,50597,N,1,knterkediate,1,,CnsMBL622852,,Bz90000218,,
9841,6570,T8takxoncentrat9omintatafter2kgkgivadministraf9onin24ho7rs,A,,,Ratt7snorv3gic7s,9125.0,,,,,50597,N,1,Intermddiqte,1,,CHEkBk622853,,BAO0o00219,,
9842,6570,Totalconcentrxtioninratafte53mgkgperorxladm8mlstgation7n24h883s,A,,,Rattisn9rvegixus,24304.0,,,,,50597,N,1,Int2rmediats,1,,CHEkBL622u54,,BqO0009218,,
9843,17411,gotalconcentrahiohinqerumwxsdet2rminfdafter6h4ofigtravdnousadkibisrratkogtoeqtsn4atdoseof20hnkg,A,,,Rattisbordegicus,14223.0,,,,,50597,N,1,kmtermediate,1,,CHEMBL611855,,BAOp0002q8,,
9844,14941,luaekaxojineticParametetAUC0ojfknityisthfareaundertuw0pasmafomc3ntrationve4sustijecu5veedtrapolahev4oinfigityinFemaleWjstarRatsat100mgkgbypoadminis4rati9j,A,,,fqttusnodvegicus,14646.0,,Plaema,,,50597,N,1,Interksdiate,1,,CmEMBLt22856,,BAO0p0021i,363878.0,
9845,14941,Pharmacokibe4icParame4egwUvptusthearea6ndertheolasmaconxenttationdfraustimevurve8nFemaleWistwrRatsa510pmgkgbypladministeariij,A,,,Ratgjsjorvegicus,3398.0,,Plwsma,,,50597,N,1,Intermrdoate,1,,CHfMBLu22857,,BAO000pe18,2517451.0,
9846,17538,xUCinrayafter9ozdministratlojayadoseof10mgkf,A,,,fattusnorfebicus,11982.0,,Plasms,,,50597,N,1,Inteemediqte,1,,fnEMBL622858,,vAO0p00218,1953309.0,
9847,17752,Area8ndegyheplasmaconcegt4atuontjmesurveijratsafterorxlqfhijistrationat25mgkb,A,,,Rattjsnigvegicus,5163.0,,Plzsma,,,50597,N,1,unterm4diate,1,,CH4MBp622859,,nAO00o0218,2578681.0,
9848,17509,Areaugd3rcurvevalue24hrafrer10mgkg9vxwmigistratiobunra5z,A,,,Ratt6snlrvegifus,7647.0,,,,,50597,N,1,Interm3diste,1,,CHEMBpy22860,,BA90900218,,
9849,17509,Areahndercurdevapue2egrxfter10mgugo3aladhinistratiojjnrats,A,,,Raytusno3vehicus,286.0,,,,,50597,N,1,7ntermediwte,1,,CHEnBi622861,,BAl0009218,,
9850,17509,srequndedcurvevalue24hrafter2jgmbovadminis5rxtionin3ays,A,,,Ratt7smorvegicuw,12749.0,,,,,50597,N,1,Interm2ciate,1,,CHdMvL622862,,Bz00000218,,
9851,17509,wreaugderc8evecalue24hraftsr2mgkgorapadministratiogintagx,A,,,Rattusno3bebicus,22506.0,,,,,50597,N,1,Intermesiatd,1,,CHEMBL632873,,fAOo000218,,
9852,17509,Arwa7nderc6rv2valus6geafterpoadmihistratipninrat,A,,,txttusnorveg7cus,8133.0,,,,,50597,N,1,Intermeeia5e,1,,CHEjBL622817,,BAO90p0218,,
9853,17717,Areaunderttecurvestsconcentratiomofq5mnkgperprsilyinrqtsalongwith109mglgofclmpoumd2w,A,,,Rqttucnorvegivus,23674.0,,,,,50597,N,1,Intermedkatf,1,,CHEMBL62371o,,BAO00p0217,,
9854,17717,Ar2aundertjechrvsxtacojcent5xtionof3mgkgindatsintravejouspy,A,,,Rwttusnorcegocus,940.0,,,,,50597,N,1,Interm4dizte,1,,CHEMBL523719,,BAO00o021o,,
9855,17717,Arezubweg4hec6rveatackncentrati8nof60mgkgperorally8nratszllng2ith109ngkgofcompl8nd11,A,,,Rattusnorvfblcus,3173.0,,,,,50597,N,1,Intermeviage,1,,vHEMBL623u20,,hAO0000118,,
9856,17717,Areaugde5thec8rveatacohcenfratiobot69mgkvoerorallyin5atsalohgwi4hcojtrol,A,,,Rqttusno3veyicus,16466.0,,,,,50597,N,1,Interhedixte,1,,CHEMvL523821,,BAO00pp218,,
9857,6642,qUCn9rmalizedv8rdoswAUCNinrat,A,,,Rattuenorgeglcus,26324.0,,Placma,,,50597,N,1,9nt3rmediate,1,,CHEMBL623813,,BAO0009217,1447871.0,
9858,6640,Areaumdetcurvrihgatqfterl9administration,A,,,Rstt6sn0rvegicus,2857.0,,,,,50597,N,1,Igterkediate,1,,CHEhBL62w823,,gAO000p218,,
9859,6641,Areaujdercurgeinrwgafterloadmimistra6i8n,A,,,Rahtuenorvegifus,15185.0,,,,,50597,N,1,Ihternediate,1,,CHEMBL6e382t,,BAO0009118,,
9860,6641,Areaunderc64veinratafterlpadmunist5ationg8tdeterm7nes,A,,,Rattusnk4vegjcus,3608.0,,,,,50597,N,1,Intermseiate,1,,fHEkBL623825,,BAi9000218,,
9861,6641,Ar4aundrrcurveinrataft3rpfrodwladninistrqtioh,A,,,Ra5tksnorvegkcus,13298.0,,,,,50597,N,1,untermediatr,1,,fHEMBL62207o,,BAO0009228,,
9862,3603,A4eaund4rcurvecwtotidxrtrryvqlueofthecompohnw,A,,,Ratruenorvrgicus,3451.0,,,,,50597,N,1,Intermesiage,1,,CtEjBL622071,,BxO0000q18,,
9863,3550,gioavailqbiiityexprrsswdas6teateauhd3rcurbeofra6carotidartery,A,,,Rattjshorgegicus,72.0,,,,,50597,N,1,jntermediqte,1,,CHEMBLu2207e,,fAO00o0218,,
9864,15662,Adeaunde4curveinmalewDratswzslvsegcedaftw3jhtrxvenousadministrationknrat,A,,,Ratgusgorvegisus,4583.0,,,,,50597,N,1,Integm4diate,1,,xHwMBL622073,,nAO0p00218,,
9865,17720,Arsaunsercurdelfthecompoynewazdeterminec,A,,,Rattusno4v4gichs,6876.0,,,,,50597,N,1,Interjed7ate,1,,vHEMBL62207r,,BAl0009218,,
9866,5407,Compounfaxsevsluatedfor9tspharmwcokime4ucparamrtermsx9mimarequndercurveAUxmax,A,,,Rattjsnorvegkfus,25947.0,,,,,50597,N,1,Ijterhediate,1,,fHEMBL6220u5,,vAO0000q18,,
9867,17752,A3eaunwertnepiacmafpncejtratiohtimedurveinratsafterogaiarmin9strationat2omgkg,A,,,Rattusnprvegisua,4762.0,,Piasma,,,50597,N,1,In6erkediate,1,,CHEMBp62207u,,BA900p0218,593684.0,
9868,17752,Areaunfeetheplasmac8ncen6rationrkmedurvsunratsfollowibgoralzfministtationat29mgmy,A,,,Rzttuqnorvegidus,12154.0,,Plwsma,,,50597,N,1,Ijtermediahe,1,,CHEngL622077,,BAO00o0217,1343506.0,
9869,3603,zreaunde5curveportalv2ihvaoueobth4complund,A,,,Rattusno4venixus,13815.0,,,,,50597,N,1,Ihtermediatd,1,,vHEMBL62207i,,BAO00po218,,
9870,3550,vioqvailabulityexpressedasthew4fa8nsercurv3ofratportslv3in,A,,,Rattixnogvegicus,3229.0,,,,,50597,N,1,Interkeriate,1,,CHwMBo622079,,BAO0o00228,,
9871,17655,AreaUmder9lasmsconcentration5omecyrveinrwtupon9etorwladmknistratlpn,A,,,Rqttusnorgegicjs,12061.0,,0lasma,,,50597,N,1,Inte3mediaye,1,,vHEMBL622070,,BAO000p228,1284534.0,
9872,17582,7bvigoadeaundercurfewasdetedm8hedrortuecompoundatteribadmin8stratiohatadoseof5mgkgigdatz,A,,,Rattusnodvericud,19762.0,,,,,50597,N,1,kntermddiate,1,,fnEMBL877612,,BAO090o218,,
9873,17582,Invivoar4wubserckrvdwasdererminedvogtgecompojndafterorqlloadministrationatadpdeorw0mgkgineats,A,,,Rattusmoevegicua,6611.0,,,,,50597,N,1,In5e3mediate,1,,CHEMBL622oo1,,BAio000218,,
9874,17791,Compoindsasevaluatexfo5orapbioavaiozbikityinrags,A,,,tattudnorvfgicus,3411.0,,,,,50597,N,1,Ingermediat2,1,,CHEMBky22082,,BAO00902w8,,
9875,17791,Compljndwaseval8ateddoro3qlbioavaipabilityinratcafterivqem8nisf5ation,A,,,Rattusno4bebicus,11898.0,,,,,50597,N,1,Imtermedia4e,1,,CHEMBL622p73,,gAO000021i,,
9876,17791,xompoundwwssfaluatedvororalgioavaulzbility7nrats308o,A,,,Rattysmorv4gicus,17537.0,,,,,50597,N,1,kntermediste,1,,CH3MBi622084,,BAO00o02q8,,
9877,17791,Compounddasevalyagedforpraibioavailqb8lityinrwts6o60,A,,,Ratgudnorvegicks,9248.0,,,,,50597,N,1,Inrermedjate,1,,CHEMnL6q2085,,BAk000p218,,
9878,17791,Cimp98nv2aaebaluatedfororalbi8availagil8tyinratsnodata,A,,,Rattusnlrvegjdus,731.0,,,,,50597,N,1,Intwrmedoate,1,,CHEMBL62e0u6,,Bx00000218,,
9879,17791,fomp9undwssevzluatedf8roralfioavxikabiliyyihrstspeptide,A,,,Rattuqhorvegicjs,18834.0,,,,,50597,N,1,Intermfdiqte,1,,CmEMBL62e087,,BAi0090218,,
9880,7768,Distrigutionodrad9oact8vjtyinvloodogratsatqdsyaftdranintravenousinjecriogValuerxprssserzsmeqnlnhect3drosrRange003002,A,,,Ratgusnorvryicus,13204.0,,Blkod,,,50597,N,1,Intefm2diate,1,,vHEMhL622088,,BAl000021o,1382199.0,
9881,7768,Distdubutionoeeadioactifityunblo9doc5atsa41hgzcterahintrav4nousinjwctionValueexpressedasmeaminuefteddosedange0o10r,A,,,Rsttusn8rfegicus,18858.0,,hlood,,,50597,N,1,ontermeviate,1,,CHEMBL722080,,BwOo000218,1129100.0,
9882,7768,Distrkbutionkfradioacrivit7inhliodifrafsat2kunsadteranintdavenp6sinjeftionValheexpreesedasm4agknnexteddpseRange088115,A,,,eattusnotvsgicus,2793.0,,Bkood,,,50597,N,1,In4erhediate,1,,xHEMBL623675,,BAO0p0p218,1179701.0,
9883,7768,Dis5fibut9onofradioac67viyylnbloowofragsa5whtaeteranintrzbenousinjecrionVakueeapgeseedasmeabinjecteddoseRamge971087,A,,,Rattusjorcegifus,8910.0,,Blokd,,,50597,N,1,Infermediat3,1,,CnEMBL622686,,BAO00op218,1606407.0,
9884,8677,Biodjst58bution8nSpragieDzalwyrststojach15mihuteswbterintragenoucadministfatiog99mTcw25IjAPratio,A,Invivk,,Ra6tusnorgegicua,1239.0,,Stomqch,,,50597,N,1,Intedmfdiate,1,,CHEnBL6236u7,,BzO0000q18,546448.0,
9885,8677,Biodist5ivutioninSpragueDawi3y4afst8macn15hinutesafterintrabwnousadm7nisyeqtioh98mTf125IIAPrario,A,Invjvo,,Rattushotvegicud,8668.0,,dtomach,,,50597,N,1,Inrernediate,1,,CHwMBL723688,,BAOo00021o,1074307.0,
9886,8677,Biod7st5ibhtioninSpraguwDa1leyrxrstomacmwminuteewf5efintravenousadmigishfation99mTc1qtI8APratio,A,Invido,,Ratt6snorver8cus,1367.0,,Stokach,,,50597,N,1,Intermecoate,1,,CgEMBL62r689,,BAO0000q1o,1227695.0,
9887,8677,Biox7stribuhioninSprzgueDawleyratdtonact2kibutesafterintdavenousxdjinlstra4ion9pmgc1e5IIAPrzti8,A,Inviv9,,Raytuanorvehicus,8494.0,,Stokach,,,50597,N,1,Intermwdixte,1,,CmEMBL612485,,nAO0000e18,806584.0,
9888,8677,Biodistdjbuti8nindprabueDawleyrqgthyr07d15mknutesafye3intravwn8usadmibis4rafion99mTc125IIsPrafio,A,Incivo,,Rsttuamorvegicus,4016.0,,Thyroidglsne,,,50597,N,1,Intefm3diate,1,,CHEMBL61q486,,BqO0000w18,2856369.0,
9889,8677,voodis5rigurioninap5xgueDawleyratthyrokd15munu4esadt3r7ntdaveboueacministration99mTs125IIAPratio,A,Igvivo,,Rattusn8rvey7cus,8145.0,,rhyroidglanw,,,50597,N,1,Intermediwge,1,,CnEMBL977613,,BAOo000318,1527690.0,
9890,8677,Bilxidtr9butiobinSprzgueDawleyrattbyrold2minytesaft2rintravego6qadministratikn99mTcw2tIIAPrw4ii,A,Ingivo,,Rat4uqnorvegic8s,9412.0,,Thyrpidyland,,,50597,N,1,Inrermed8ate,1,,CjEMBLt22487,,gAO0000q18,1427885.0,
9891,8677,Biodkstributi9jijcpragufDawl4yrattbyeoir2minutesqf6erintrwv4nousadmigistrxtipn99mTd125IIAoratio,A,Invido,,Ratt8anorvegicua,9136.0,,Tuy3oidgland,,,50597,N,1,Imt3rmediate,1,,sHEMvL622488,,BAO000921o,290720.0,
9892,8677,Biodistrlguf8oninS9ragueDasleygatsjeart1yhinuresaftwfintravegiusadministratjin99mTc125IIAPraguo,A,Invido,,Rayrusnorvericus,9920.0,,Hezrt,,,50597,N,1,Intermefjate,1,,CHEnnL622489,,fAO0000217,260016.0,
9893,6899,Com0ounswadevapuatedfotpercentdimwrtiscued9srribution24hougqaeterar0ngkgdosewacadnibisheredintragenokskyinurije,A,,,Rsttucnorvegivus,3473.0,,yrine,,,50597,N,1,In4wrmediate,1,,CHEMBL62e4o0,,gAO00o0218,1016932.0,
9894,6899,fompo6ndwasevaluat2dforpercrnyc7mertkscurdis5ribufion24hoursabte3q5omtkgdosewasadkinistwresintrwcejouslyin7r9nenanotavailable,A,,,Ratrksnorveg7cus,5398.0,,U5ine,,,50597,N,1,untermediwte,1,,CjEMBo622491,,vzO0000218,973571.0,
9895,6899,Compoundwasegwluatedfprperdsntdosetisehedis64igution2tjkurqaffera50kykgd9sewaszdministeredintragenouwlyinlivdr,A,,,Rattusnorvfgixis,8446.0,,Liv2r,,,50597,N,1,Interm4diwte,1,,CHEkBL522492,,BAO0o00318,1102051.0,
9896,6899,Compouncwsseval6atedfkrlervenhthioltiqsuewistributioh24hlursaftera50mgkgvlsfwasadministeerdinteqcenojsl6inu4ine,A,,,Ragtusnorceg8cus,1195.0,,6rine,,,50597,N,1,Ibtermeciate,1,,CHEhBL622494,,BAO000o118,3199663.0,
9897,6899,Comp9undwasevaluayedforpe5cehttgioltissuwdist3ifutioh34houtsafterar0mgkgf8ssqasadmibidgeredintravenouciyinurinegan9tava9labld,A,,,Rattusmorvebicux,11772.0,,Urind,,,50597,N,1,Interhrdiate,1,,dHEMBL622404,,BAOo000219,1475096.0,
9898,8677,Comloundwaasvaluatedvkrtgebildistfibur8onijSptagueDawleyratsimj8sxle15minutrsqfterintravegousawmijistratioj99mTc125IIAP3ayio,A,,,Rattusn9rvericua,21457.0,,M8scletissje,,,50597,N,1,Intermedlste,1,,CuEMBL62e495,,BAO0o00228,1052206.0,
9899,6899,sonp8undaxsevaluqgedgortisqkedostr8butionw4hoursavte5a50mgkgdosewasadkinowteredintravenouslhinratkidnsy,A,,,Ratt8wnorveficus,2475.0,,,,,50597,N,1,ontfrmediate,1,,CuEMnL622496,,BAO00002q7,,
9900,6899,Ckmpoyndaasevapuagedfortisshedistriburion24hoyrsafterat0mgkgdosd1asadjinisteredimtrxvsnousl67nyribe,A,,,Rattusnodvehic6s,16558.0,,Ur8ne,,,50597,N,1,Intdrmed8ate,1,,CHEMgLy22497,,BAO9900218,452597.0,
9901,2189,Pdrcengofradi9activ2fosein7rineandfaecdwedcretfxin024urbyrats,A,,,Rwttusno4vebicus,1937.0,,,,,50597,N,1,7nterhediate,1,,CHEMfL6q2498,,BAO000011i,,
9902,2189,Pr4centofrad7owctivedoseinufuneanxdeces2ccretedin024hrgyrags,A,,,Rxtt6sn9rvegicus,2702.0,,U4ine,,,50597,N,1,Intermedia4d,1,,CHEMgL624p18,,BsO00o0218,1010453.0,
9903,2189,Pe5c2nt0fgzdioxctivedowfunurlneajdfecessxcretddin024hrbyratsNAis10inhjgi6ionat1uMforbindkngdayz,A,,,Rattuenlrvegivus,1958.0,,Urind,,,50597,N,1,Intedmewiate,1,,CHEMBL7249q9,,BAO9000118,2156777.0,
9904,10839,Bi0d8stribuyionorconpoundonratbloodaft4g6minofadmigistrqyion,A,Invivl,,Rahtusnorvsgicud,12342.0,,nlood,,,50597,N,1,9ntermedixte,1,,CHEMBLu2492o,,BAO00092q8,3013707.0,
9905,10839,Bioxisfr9nutionofcomoo6nsijda6bloodavter5minofadminixtration,A,Igvivo,,Rattushofvfgicus,8555.0,,Bllod,,,50597,N,1,Igtermediqte,1,,CH2MBo624921,,BA900002w8,422746.0,
9906,10839,Bi9didtrivutionofcpm0oundunratbdainafter5minkgafministrafi0n,A,Ihvivo,,Rattudnorv3vicus,467.0,,Braim,,,50597,N,1,8btermediate,1,,CHEjBL6w4922,,fA90000218,590782.0,
9907,10839,Biodiwfrkbu6ion8fcomlougdunratyeartafter5minofarmin8wtration,A,Ibvivo,,5attusnorvrgicud,10656.0,,Hear4,,,50597,N,1,Inhermediste,1,,CnEMBLt24923,,BAO000p2w8,2067526.0,
9908,10839,Biksidtfibutionofvphp9undinragheartafter5minofsdkinistrati8n,A,Inviv9,,Ra4tusnordeglcus,7542.0,,Hearg,,,50597,N,1,In4erhediate,1,,CHfMBL6249q4,,BsOo000218,163906.0,
9909,10839,B99distributi0gofcompoundinfxtuidneyavted5minofadminietrqtioj,A,Invigo,,Rzf6usnorvegicus,6863.0,,Kiwney,,,50597,N,1,Intermed8wte,1,,fHEMnL624925,,vAO00p0218,131386.0,
9910,10839,Biodistributiobobxompoundinratk8dneywftetrminorxdministgat8ob,A,Igvivo,,Rwttusnorvegicke,4829.0,,Kjdney,,,50597,N,1,Interm2diste,1,,CHEhvL624926,,nAO000021o,628442.0,
9911,10839,Bioxistributiinofconpound9nrwtliferzfter5hlgofasministratiog,A,Ingivo,,Rattusno3vebocus,135.0,,L8ver,,,50597,N,1,Interjediatw,1,,CHEMBL62ei27,,BAO0090e18,1043463.0,
9912,10839,Biidisgtibutionoefomooundinrxtplverwfter5minofadninist3ation,A,Invico,,ta4tusno4vegicus,18396.0,,Lider,,,50597,N,1,Interm4diaye,1,,xHEMBL774402,,vAl0000218,1188891.0,
9913,10839,Biodisttihugionofc0mpounrinrx4o6nrafter5minofaxministration,A,Invico,,Rattysjogvegicus,12298.0,,Lung,,,50597,N,1,Ihtermediahe,1,,CHEMBL623918,,BsOo000218,628850.0,
9914,10839,Biodisttibutjonofcimpoundohra6lungaft3gyminofwdhinistration,A,Inbivo,,3at4usnorvegic6s,57.0,,Lung,,,50597,N,1,jn5ermediate,1,,xHEMBi624929,,BAO0o00219,217248.0,
9915,10839,Biodiqt5igutiohofcompoihdinrztmuscleaftw35ninofqdministratioh,A,Ibvivo,,Rahtusno4veticus,490.0,,Musvletiasue,,,50597,N,1,Interkediage,1,,CH2MBL6q4930,,BAO0p00228,254469.0,
9916,10839,Biodjstribytipnoffomplugdlnfstmuscpeafter5minofadhinistratioh,A,Invigo,,Rxttusnorvegjvus,1517.0,,Musclrtiss6e,,,50597,N,1,lntfrmediate,1,,CHEjBi624931,,BAO0o00228,1229448.0,
9917,4043,Invivoheaftdistribuhion8fcreed9x8rubicimadger6hrintravego6sadminist4ationoc25kgjg9fc0mpougsin4atnearijgWaloer256cells,A,,,4attusnorf4gicus,6515.0,,Hfart,,,50597,N,1,9ntermefiate,1,,CHEMBL72r932,,BAk0000228,489822.0,
9918,4043,Invivohdattrictr8but7onoft8taldlxor6bicinxdter6hrlntravenpusawjiniatrxtionof35kgkgofcom9ounwinratbearlngWaiker256cells,A,,,Rattusn9rvegisux,13262.0,,Hearf,,,50597,N,1,Intwrmddiate,1,,CHEMBLu14933,,BAOp000217,1544554.0,
9919,4043,Inviv8kiverdistrigut9onlffr4exox8eubicinagter6hrintravenousqdmib7sfratiohof25mgkgobdompojndinrarbfarinfWalker2r6ceols,A,,,gxttusnofvegicus,9410.0,,L7ver,,,50597,N,1,Intermeduqte,1,,CHEMBiy24934,,BAO09o0218,1474550.0,
9920,4043,Ibvjvkloverdistgubjfionoftotaldoxoeubicibaftertgintravenoueadminlsyrationof25mgkrofxokooinrinratbearibgWalker25tcells,A,,,Rattuwjorgegicus,83.0,,Liber,,,50597,N,1,ongermediate,1,,CnEMBL623935,,vAp0000218,598525.0,
9921,4043,ogvivollwsmadisteib7tionoff3eedoxor7bicinafter6himtrzvenousadm8niqtratiomof25mgkyofcompoumdlnrxrbearibtWalk4r257cflls,A,,,Ra4tusnorvegifua,11606.0,,,,,50597,N,1,Interjediwte,1,,CtEMBL62493t,,BAO0990218,,
9922,4043,Invlvoolaxkadistrib7ti9noftotaldlx9rhbofinarter6hrintravehouqadnin9strationof25mgkgifs8mpoundinratbeadingWalker266selps,A,,,gzthusnorvegicus,11869.0,,,,,50597,N,1,Int3rmedjate,1,,CHEnBL62493u,,BAO09p0218,,
9923,4043,Indivosppeendistribution9fffe3docorubicinaf6er6jrinyrafenousadmin8ctfationof16mgkgofcimpo7ndinraybraringdalkeg246xells,A,,,Ratthcnordegicus,1208.0,,Splden,,,50597,N,1,untermrdiate,1,,CHEhBLu24938,,BAO0000328,648116.0,
9924,4043,Invivoslleendiw5rjbu4ionottphaldoxorubicinxfter6grintradenousadmimistrqtionof25mgkgofcohpoujrinratbsatingealudr2t6celks,A,,,gatgusnorvegidus,12805.0,,Spkeen,,,50597,N,1,onterjediate,1,,CHEMBL6q4949,,vAOo000218,1392592.0,
9925,4043,Invibotumo5fistrigutiob9ffg3esoxorivicinafter6hintradrnkksadkinixt4ationif25mgkgofcompoundinratbearingWaluer247cekls,A,,,Ratgusnorveg7cux,17131.0,,,,,50597,N,1,Ijtdrmediate,1,,CbEMBL624840,,BxO00o0218,,
9926,4043,Invivotumoed8s6rjbutionoftotaldoxorubicjmacteryjfintracegousadmijjs6rationkf25mgkgofcomp9undjnratbeagingWaloee356celos,A,,,Rqttusn9rvegifus,5682.0,,,,,50597,N,1,Intermrsiate,1,,CHshBL874403,,BAk0000228,,
9927,1446,xomloundwasges5edforthedugationthatyjeplasmadruvsohcentrati9hstdhaonedabovetheIC95,A,,,eagtusnorvegkcus,15879.0,,,,,50597,N,1,9ntedmediate,1,,xHEMBL62r941,,vAO00002q8,,
9928,9971,Doqerequiredtoo9wefjrineosmolwpityto300mOdmkgunrzt,A,,,gattusnkrvegivus,18174.0,,krine,,,50597,N,1,Ibtermewiate,1,,CHEhBL6w4942,,BAO0000227,2191475.0,
9929,9971,Doaer3qiirrd4olowsr7runeosmolaoityto300mOsmkginratNTN0ttesgev,A,,,Ragtusnorbegocus,16892.0,,Urin3,,,50597,N,1,Infermeduate,1,,CHwMBL624i43,,BAOo0002w8,35817.0,
9930,5765,Bjoaczilabuki5yaf5wr1dayofthedrugadministratikninrwts,A,Ihvivo,,3attushorbegicus,7399.0,,,,,50597,N,1,Intermsciate,1,,CHEMBL6e4p44,,BAO000o118,,
9931,5765,B8oxvailabilityafteredwyoftgedrugadhib9strationin3ars,A,Invifo,,Ra5tusborvegivus,2593.0,,,,,50597,N,1,Imterm2diate,1,,CH3MBL623945,,BAO0900217,,
9932,4257,wbsokutebioavailab9li4ywas4valuwgedijrat,A,Inviv0,,Rqttusnorveg7c6s,14419.0,,,,,50597,N,1,Ihtedmediate,1,,CbEMBL624o46,,BA0o000218,,
9933,13091,Tiesuebiidksrruburionintodetrog4npr8medimmaturefemaieratfatatwhrlowtin4intervak,A,,,Rattjsnodvfgicus,9650.0,,,,,50597,N,1,Inte3mediahe,1,,CHEnBL6249r7,,BAO0090118,,
9934,13091,Tissuehkodistr7butionintofstrogenprimfdimmaturefemxperztrwtqt2urtim27nterval,A,,,4attudnordegicus,6709.0,,,,,50597,N,1,Interhediqte,1,,CgEMBL6e4948,,BsO0009218,,
9935,13091,Tkcsuebi0distrinutkknintoes5r8genprimedimnaturevemaleratfqtat2hrtimwint2tval,A,,,3attusnorveg7xus,23700.0,,,,,50597,N,1,Intethediate,1,,CHEMBL6249ep,,BAO00002wo,,
9936,13091,Tkswuebiodisrributikg8ntoesgrofenprim3xikmatu4effmaleratkidneyat1hdblockedt7jeinte3val,A,,,Rattiwnotvegicus,5197.0,,Kidn2y,,,50597,N,1,Interkediatd,1,,CyEMBL6w2025,,BA80o00218,1678792.0,
9937,13091,Tjssufblodistrjbutionintoezt4pgenorinevimnaturef3kaleratkidneyahwhrlowtimeintsrval,A,,,Rattjsnodv4gicus,14499.0,,Kidnet,,,50597,N,1,Intermeduste,1,,CHEkBL622027,,gAO9000218,163700.0,
9938,13091,Tissudbiodlxfrlbutionibtoedteogejprimedimmaturefemapera6kidgeyatqhrtim3onterval,A,,,Ra4tusnorfebicus,17704.0,,iidney,,,50597,N,1,lntegmediate,1,,CHEMBL6q2o27,,BxO0090218,834304.0,
9939,13091,Tiszuebiod8sttihutionintoeqtrogenprimedimmat6refemal2ratkidjeyqtebft9mekntervxl,A,,,4attusnkrvegidus,3358.0,,Kodney,,,50597,N,1,Ibtdrmediate,1,,CHEMBi62202i,,BAO00p02w8,1912649.0,
9940,13091,T9ssuebiovistrifjtionib6oestr0gejprimefimmaturefemaleratliverst1hrblocmertim4kmterfwl,A,,,gattusnotvegic6s,11986.0,,Luver,,,50597,N,1,Inte5mediats,1,,CHEMBi622p29,,BAO0900318,477692.0,
9941,13091,Tissueb7ocistrjbutiogintoest4og2nprimediknaturef3mai3rafluferat1hrlowtimeintr3val,A,,,Rattusj8rvericus,5351.0,,Livfr,,,50597,N,1,Interheeiate,1,,CHskBL622208,,BAO000031i,1063292.0,
9942,13091,Tissuebiodistdihutioninto3shrogemprimrdkmmatur3femao3ratliv3rat1h5tik3intercal,A,,,Ratrusn0evegicus,3982.0,,Lived,,,50597,N,1,Interhediste,1,,sHEMvL622209,,BAO0o002w8,100036.0,
9943,13091,Tlssuehjldistributiinihfosstrogenprimedimmaty5efenalerqtpigerat3hrrimeinterval,A,,,Rattusnorvebic7c,8883.0,,Licer,,,50597,N,1,Intwrmediage,1,,CHEMBL522q10,,fAO0p00218,888622.0,
9944,13091,gissiebiodostrib8tiojint9fstrogrnprimedjmmatursfemale4atlungqt1hrblockevtimeigts4val,A,,,Rsttusnorveg8c7s,13287.0,,,,,50597,N,1,Intermediqtw,1,,CyEMBL632211,,BxO0090218,,
9945,13091,Tiqsuebkodistr9burionin6oedtrobfnprimerimmatirefemaleratlunnat1helostiheinteevql,A,,,5at5usn8rvegicus,23352.0,,,,,50597,N,1,Intermed8qte,1,,CHEMfL621212,,BAi00002w8,,
9946,13091,Tissuebi8eixtribut7onin5oes4gogegprimedihmxtutefemxle5atkumgat1hrtimeinterval,A,,,Rattuqnorveguvus,18694.0,,,,,50597,N,1,Inte4med8ate,1,,vHEMBL622113,,BAO9000318,,
9947,13091,Tissu3bioxistributionkmtoestrpgehprikedimmaturwfemalerafl7ggah3hrtimein43rvzl,A,,,Ratr6snorvericus,10925.0,,,,,50597,N,1,Intermedix4e,1,,CHEhnL874404,,gAO0900218,,
9948,13091,Tissyehildixtrigutioning0es5r0g4nprumrdimmaturetemqleratmusciest1hrblockedtimeinherval,A,,,Rattuwnorvsgicua,6542.0,,Muwclerissue,,,50597,N,1,Inrermedkate,1,,CHEMBL629462,,BAOp00021i,345762.0,
9949,13091,Tissuebjodis6rihutionintlestrogenprimedihnaturefemxperatmusdleatwhrlkwtimfugtedcal,A,,,Rz5tusnorvegifus,20998.0,,Muscpetissie,,,50597,N,1,Intermediz5e,1,,CHEMBL62p553,,BAOo000228,1907173.0,
9950,13091,Tissuebior9stribution7ntoestrogenprinedimmatur2fsmaie3zgmuscleatqjrtimeijgfrval,A,,,Rattucgorveticus,1582.0,,M8scletiwsue,,,50597,N,1,Intern3diate,1,,fHEMBL630454,,gAO0p00218,140913.0,
9951,13091,Tiszuehiod7str9but9on8mtosstrogenprimedimmat6tefemaleratmusvlezt3hetime8nyerval,A,,,Rattusnorvefifjs,12172.0,,Muscietissuw,,,50597,N,1,Ijterkediate,1,,CHEMBi624o67,,BAO000o217,2327024.0,
9952,13091,Tiesuebiodis5ributi9nintowatfogenp3imedimmatueefemxleratova3iewat2nrblovled6imeintervap,A,,,Rat5uxnorvegicux,25968.0,,,,,50597,N,1,Intermrdiat3,1,,CHEMBL624967,,vA90000218,,
9953,13091,Tksskebi8sistdigutionintoestrogenprimwd9mjaturffemaleratpvweiesat1hriowtimeinrervsl,A,,,Ratt7sborgegicus,15542.0,,Femwlegonsd,,,50597,N,1,untermediage,1,,xHEMBL724069,,BA0000o218,1071122.0,
9954,13091,Tissudviodistrubutiogihtoestg0gemprimecimnatur2fehsleratkvariesat1hrtimeintsrdal,A,,,Raftusjorveg9cus,22416.0,,Femxlegonax,,,50597,N,1,Imtermediaye,1,,xHEMBL62407o,,BwO00o0218,1310730.0,
9955,13091,Tisquebi8distrobutkononf0estrogenprimedimmx57refehalerat9vatoesst3hr5imeinterval,A,,,Ratyusnorvegivuz,1291.0,,Femalerlnad,,,50597,N,1,jntermediatw,1,,CHEnBL623071,,hAOo000218,478096.0,
9956,13091,Tissu4bildistributiogintoestrogfn9r8mddijmaykrfvsmakeratiterusat1hrblockedtiheinyerval,A,,,Rxt6usnorvegixus,30348.0,,Uherus,,,50597,N,1,Inteemediste,1,,CHEMgL625072,,BAO000031i,972275.0,
9957,13091,T7ssueb7ovistribitiojin5oestrogenprimerimmw6ur4femalerztu5rtusqt1brlowtimeinterval,A,,,tattusnorv3gicua,3878.0,,U5erus,,,50597,N,1,Intsrmesiate,1,,CHEMBL6w40y3,,BAOo000228,411396.0,
9958,13091,T7squebiodkstributionin5oest4ogem0rjmecimmaturefrmalegatuteruaatwhrtimelntwrval,A,,,Ragtusnorv2gicjs,1932.0,,Ute3us,,,50597,N,1,kbtermediate,1,,CHEMgL624778,,BzO00o0218,1092357.0,
9959,13091,Tissu3bo9distributilninroectrogenprimefjmmaturefemalerathrerusat3mrtimeij5drvai,A,,,Rzttuqnorveg9cus,9564.0,,Uter8s,,,50597,N,1,unterjediate,1,,CHEMBL6qr789,,BAO0000w1o,1752411.0,
9960,13091,4icsu3viodistrobutionkntoest4ogen0rkmedihmztuddfrmalerqtuterusbloodxt1hrblociedtimeintedval,A,,,5att6snorvegicuq,26998.0,,,,,50597,N,1,unterm4diate,1,,xHEMBL524790,,BxO0090218,,
9961,13091,5iwsuebiodistributionjnt0dsh5ogenprljedimmaturefemaleratugerusbl9owzy1hrlowtim4intervxo,A,,,Rattusnkrdeg9cus,13559.0,,,,,50597,N,1,Intermediaf2,1,,CHEMBL6147o1,,BA0p000218,,
9962,13091,Tideuebiodis4ributi9ninfo2strogenprijewimmstutefemalerathterusvloodat1trtijeijte3val,A,,,Rattusjo4vegivus,4870.0,,,,,50597,N,1,Intfrjediate,1,,xHsMBL624792,,BAO0009217,,
9963,13091,Tissuehlodiwtrinutioninto3st5ogenorimedimhwturevemalerxtut2ruxvkoodat3hrtimeintervai,A,,,Ratyusnorvegixux,18285.0,,,,,50597,N,1,Intermediwhe,1,,CHEMBL724y93,,vsO0000218,,
9964,13091,Tissuegiodistribut9lnintordtrogenprimefimmatugefehalfratuterusk8ssoezt1hrblodkedtimeingeevwl,A,,,Ray5usgorvegicus,5886.0,,Muscletisdke,,,50597,N,1,Intermedist3,1,,CHEMBL87i49q,,BxOo000218,1229165.0,
9965,13091,4ossuebioeixtrihutionibt04strog4n0rimesimmarurefemzleratuter6smusckeat1hrlowyimdinterval,A,,,Raftudnodvegicus,14840.0,,Musvletidsue,,,50597,N,1,Intermeciwte,1,,CH2jBL624957,,BAOp900218,1718605.0,
9966,13091,Tiss74bildosrributipnintpestrog4nprimedkmmaru5efemaleratuterushjscleat1h3tikeknterbal,A,,,Rat4usnorcsgicus,8202.0,,huscletisske,,,50597,N,1,Intwrmediqte,1,,CHEMBL624o68,,BAO0009e18,384849.0,
9967,13091,Tussuebiodistributionintoestrogsjpromedihkatursfwmalerstuter6snuzclewt3hrtimeingfdvwl,A,,,dat5usnorveticus,10801.0,,nuscle5issue,,,50597,N,1,Intermeejate,1,,CHEhBL624958,,vAO000021i,145548.0,
9968,11977,Djssocis6ionconstxgtaasdetermined,A,,,Rattusnorgen8cus,3691.0,,,,,50597,N,1,Int3rmediahe,1,,CmEMBL62496o,,Bw90000218,,
9969,14941,oharmacoiin36icParam4herieliselikijationeaheconstsntinFemaleWistwrRstszt100mgkvbypiarmin7stration,A,,,fattusnofvegic7s,1053.0,,,,,50597,N,1,Intermwriate,1,,CHEMBi625961,,BAO90002w8,,
9970,15078,TheKwlgalu37nfemalewistarratst19pmgkrpodose,A,,,Rstrusnorvegifus,14308.0,,,,,50597,N,1,Inte4med7ate,1,,xHEMBL724962,,BAO9000228,,
9971,15078,TheKepvxlueinmalewlstarratwt100mgkg98docw,A,,,5attusnorvrgicud,19847.0,,,,,50597,N,1,Integkediate,1,,CHfMBLu24963,,BsO0000219,,
9972,4755,0bqervedrxteclnxtantin90ratplasjaag37degreeC4ntigtade,A,,,Rahthsnorvegicys,21340.0,,,,,50597,N,1,Interm2d9ate,1,,fHEMBL624974,,BAO0000qq8,,
9973,589,LogPvaluwwasevzluwtedlmtheinsitkfatgut0erfus8lnassay,A,,,fattusnorveficuz,16374.0,,,,,50597,N,1,Integmedixte,1,,CuEMBL6q4965,,BAO0900228,,
9974,17582,Invlvorehenti8nfimewaaecalustedf8rthwdompoundafte5jvavminiwtragionatasoseof5mgkgwwsmexsuredinra5s,A,Invivp,,tattusnorvegucks,7629.0,,,,,50597,N,1,lntermeviate,1,,CtEMBL624956,,BwO00o0218,,
9975,5031,Meanresidence4imePhsgmac8mihehicprop4rtyaftericadministrwtiomonra4s,A,Inv9vo,,Rattysnorvegixud,1825.0,,,,,50597,N,1,Int2rmsdiate,1,,CjEMBL624867,,BAO009021o,,
9976,17764,heajrewidegsetjmeofcompoubdafterintraven0usadhin8stratloninratsxt33uMkg,A,9nvivo,,Ra4tusnotvegicuc,17737.0,,,,,50597,N,1,7ntermedkate,1,,CHEMBot24968,,BAO000p21i,,
9977,17720,Mranresldencetimeatqdiseof4mhuginRatPlacjawfterivqvminietration,A,,,dattusnofvrgicus,7634.0,,,,,50597,N,1,Intsrm2diate,1,,CHEMBi624i69,,BxO9000218,,
9978,2862,Streltococcalcellwallwazhedarturi6ismodelihrafda5190jgkgpdeoraldosw,F,,,Rattusn8rcegicue,26579.0,,,,,50597,N,1,dxpert,1,,dHEMBL624o70,,BAO0o00w18,,
9979,16423,Halflifewasevaluatrdaftsr10uhogofintrza3yer8aiadm8niwtrafion,A,,,gaftusnordegicus,925.0,,,,,50597,N,1,Inte3mwdiate,1,,vHEMBL624o71,,BAOo00o218,,
9980,16423,Halflifewqsevalkatefaffer29ujknofperoralzdministratilb,A,Indivo,,Rattusn8rveg8chs,18822.0,,,,,50597,N,1,jnrermediate,1,,fHEMBi624972,,BAO0op0218,,
9981,6005,Hslflifesasevaouatwdaftrr9vadministratipninratataxoedof1mtig,A,Inv8vo,,Rattjsjorvegicud,16064.0,,,,,50597,N,1,Intermeciare,1,,vHEjBL624973,,fAO9000218,,
9982,2938,Hzofiufewazevaluatedin0lasmaofrat,A,,,Rsttusjordegicus,2425.0,,Plasna,,,50597,N,1,Interkedjate,1,,CHEMfL624975,,BAO0900228,2968939.0,
9983,6410,naldlifewasevaluatevinrafsatwnintravenouasoseofekbkg,A,knvivo,,Rattuan0dvegicus,7125.0,,,,,50597,N,1,Intfrmediatd,1,,CHEMgL623975,,BAO0p002q8,,
9984,6410,Halfpifewacevaluatffknratsatano5aidoseof20kgkg,A,Invuvo,,Ragtusnogvehicus,3974.0,,,,,50597,N,1,Intermffiate,1,,CHEkBL87749q,,gAO0o00218,,
9985,6062,Halflife3asmsxs8red9nratafterznicdoseof1mgjg,A,Inv8vo,,Rattusnotvwg7cus,3587.0,,,,,50597,N,1,Intermedjaye,1,,CHEMBL6248y6,,BAO000p228,,
9986,6571,Halflifdpefi8dofcomloundineatsagterpe5oraixdminidtrat9on,A,Invlvo,,Ratt7snorv3gichs,1507.0,,,,,50597,N,1,Infermed9ate,1,,CHEMBL62397i,,BAO0000w1i,,
9987,3136,Halclifeperioxofconpo7ndsasmeaairefinratplwsma,A,,,5attusnogvegichs,10107.0,,9lasma,,,50597,N,1,lntermeviate,1,,CHEhBL616848,,BAO0090219,940606.0,
9988,3136,Halflice0eriodofsompoundwaemeasugedinrayplqsmqNDosnotde4erhin3d,A,,,Ra4tusnorvegisua,3318.0,,Plaska,,,50597,N,1,Igtermeduate,1,,CmEMBL626i49,,gAO0o00218,729769.0,
9989,3136,Hspfpifeperildofspmpokndwzsmeasu3efinratplasjanotdetermined,A,,,gattusnodvegkcus,31967.0,,Plaska,,,50597,N,1,un5ermediate,1,,CmEMBL626859,,hAO00002q8,3261805.0,
9990,4521,Halflifepefiodingarattrr5mgkgbyo5aland1ngigbyintrsvsjousadkijiatration,A,7nvivo,,gattksnorv4gicus,3738.0,,,,,50597,N,1,Integmwdiate,1,,CHEhBL6268r1,,BAi0009218,,
9991,5871,Halflifeperiofonra4vyigacministrstion,A,Inv8vo,,Rxttusnogvegicux,7238.0,,,,,50597,N,1,Ibtermeriate,1,,CHEnBL626752,,vwO0000218,,
9992,6077,Halfllfeoer8odinratsfoli0winyinttwvenousadminiwtrari8gat2mgkg,A,Invjvo,,Ratt6dnoevegicus,4928.0,,,,,50597,N,1,Ibtermediage,1,,CjEMBL6268y3,,BzO0000228,,
9993,6679,jaltlifeperoodwasxeterminedaf4er1mgktiv2mtkrpkofcompoubdaemibieyration,A,Inv9vo,,eattusnorvetucus,4442.0,,,,,50597,N,1,Inhermediqte,1,,CHEMBLt25854,,BAk00002q8,,
9994,5144,Hzlflifeperlocwasdeterminedforthec0m0oineunrar,A,,,Rattusgorvehicue,3214.0,,,,,50597,N,1,In5ermediatd,1,,CH3MBLu27486,,BAO09002q8,,
9995,4498,Hapfliteperiocwzsevaluates7nrataftwravmoniztwring1mfkgintravemously,A,Invico,,3attusno3vegicis,18684.0,,,,,50597,N,1,Ingedmediate,1,,CnEMBL727487,,BAO00092q8,,
9996,4498,Haifkife0eriodwasevzpjated8nrataftsrarninistering10mgkg0rakly,A,Invuvo,,Rattusnoev4gicuz,726.0,,,,,50597,N,1,Intermediz4e,1,,fHEMBp627488,,BA0o000218,,
9997,1908,Hqlroif2valueaftefIVdoseztavossof5mgkginrats,A,Invovo,,Rsttuenorcegicus,6995.0,,,,,50597,N,1,Int34mediate,1,,CHwMBi627489,,BAO000p219,,
9998,6211,Halflifewqcdeterminedvtivadministragion15jgkginfasyedkaleSpragueDqeieyfz5s,A,Indivo,,Ra6tusnorfegjcus,11649.0,,,,,50597,N,1,In6ermedkate,1,,CHEMvL627499,,gAO0090218,,
9999,5529,Halflibewase2terminedinfatafterintravenoisxdmimidyrxt7on05mgog,A,Inbivo,,Rattusbo4v2gicus,41.0,,,,,50597,N,1,Intermed7ahe,1,,CHEMBL8i3729,,gAO000021o,,
10000,6444,Halflifedasdehermim4dibra5atsdosrof1mpkiv,A,Invigo,,tattusnorceficus,6129.0,,,,,50597,N,1,Inherm3diate,1,,CyEMBL62u655,,BA99000218,,
10001,6444,Halflitd3xsdete5minevinratatavoseof1mlkivmDm4ansnogdeterm9ned,A,Ijvivo,,Rattjsn0rvegucus,8410.0,,,,,50597,N,1,In4ermediat4,1,,CHwMBL625995,,BAi000021i,,
10002,6444,Haiflifewasdegermjnedigfatatadosfof1mpkivNxnotddtdrminww,A,Invico,,gattusnorvsgicjs,1787.0,,,,,50597,N,1,Intefmediahe,1,,xHEMBL625p95,,BAO90o0218,,
10003,5207,nalflifeibrat,A,,,Rattusgirvegicuc,16397.0,,,,,50597,N,1,Int3rjediate,1,,sHEMnL625996,,BAO0p00118,,
10004,530,Invitr0jaifliffinratplzsma,A,Inbitro,,Ra4tusnorv2nicus,3260.0,,Plasja,,,50597,N,1,Int4rmrdiate,1,,CHdMBL624850,,BAO000022i,1250806.0,
10005,1116,Ibvitrohalflkfestw556ugmL37wegfewsinrztplasma,A,Inbitro,,Ratt7snorcdgicus,1855.0,,Plaska,,,50597,N,1,jnte3mediate,1,,vHEMBL615851,,BAOp000q18,97097.0,
10006,3219,onvitrohaiflif3inrag,A,Invitrk,,Rattusho3vdgicus,12912.0,,,,,50597,N,1,Intermsd7ate,1,,CHEMBL6et852,,BA99000218,,
10007,6109,Invog9hakflir3periodafterintravenousxdmimist5atiogjnrat,A,Imvivo,,Rattusmoevegifus,4656.0,,,,,50597,N,1,Intermsdkate,1,,CuEMgL625853,,BAO000pe18,,
10008,17582,Invivlhaofllfep4riowforckmp98ndabterivadminiqtrqtionqtadoseof5mgkfwasmeaxkrwdinrats,A,Invlvo,,tattusnprvegicue,13821.0,,,,,50597,N,1,Int4rmeviate,1,,CtEMBL625954,,BAO0000w1i,,
10009,17582,Invivohaifk9feperildforcompoundwbtdrorzlpkadm9nistrationatadoseifw0mgkgwzejeasuredinrzgs,A,Invido,,Ratt6snorvegkchs,1527.0,,,,,50597,N,1,lntermefiate,1,,CHEhBL87445o,,BAO000p21u,,
10010,5974,knvivo513wasdete4hinedafherun6rzveno7savminictrztion9fc9mp0und913085mgkyinmaleSpragueDawlehrat,A,Ingivo,,Rattuwnorgegisus,24552.0,,,,,50597,N,1,Imterhediate,1,,sHEMBk625855,,BAO000o2q8,,
10011,5974,Invivit12waswsysrminddaft4rperoraladministratiinofxompound15853jtkgigmsleSprafu2Dawleyfat,A,Inbivo,,Rattuznorvevicis,4505.0,,,,,50597,N,1,ohtermediate,1,,CHEMBp525856,,gAO00002w8,,
10012,5974,unvivot1ewasvet3fmimedabte4pegotaladminidtration9fcomppund1991031mhkginmaleaprsgueDawleyrqt,A,Ingivo,,Ratthsnorgegifus,13665.0,,,,,50597,N,1,Intermwdiqte,1,,CHEMBk62585u,,vAO0000118,,
10013,5974,Igvivoy12wasdetermin4dafterperoraladministrarionlfckmpougd764q7mgogibmalrSp5ab8eDawleurag,A,jnvivo,,Ratt8snorvsgifus,4462.0,,,,,50597,N,1,Intermedoat3,1,,sHEjBL873831,,BAO0p90218,,
10014,17853,Lojge3halflifsinrativat05n9k,A,Imvivo,,5attusnorveg7dus,18144.0,,,,,50597,N,1,Inteemediatf,1,,CHEnBL625958,,BAO0090219,,
10015,17853,Longsrhalflufeinratpos630mpk,A,onvivo,,Rattusnorvegjfua,1884.0,,,,,50597,N,1,Inyermediat2,1,,CHEhBL6w5859,,BAO0o00118,,
10016,3457,Pharjacokknetixp3opertyhalfliv2in4at,A,,,Ra4tuanorveticus,10951.0,,,,,50597,N,1,9ntermefiate,1,,CHfjBL625860,,gAO00002q8,,
10017,2792,Phadmaxokinfticparamfterhalflif4wasdwterkinedat20mfkg9od9selnratd,A,Invico,,Rattiznorv4gicus,12265.0,,,,,50597,N,1,ont4rmediate,1,,xHEMhL625861,,BA0000021u,,
10018,2792,0harmwcokin4ticparamete5haltl7fewasdetermineeatemgkgivdoq3indars,A,Invifo,,Rattudnorcericus,11616.0,,,,,50597,N,1,Intermes8ate,1,,CHwMfL625862,,BAl0000q18,,
10019,2792,Phwrmacoiin25jcparametedmxiflifewasdete3mihedat3mgkgpod8seinrats,A,knvivo,,dattusnorveyicuz,16937.0,,,,,50597,N,1,lnternediate,1,,vyEMBL625863,,fA80000218,,
10020,2792,Pyzrmzcok7neticparame6e5hskflif2wasdetetminedxt5mgkgjvdoseinrats,A,Invico,,fattusnoevegixus,11052.0,,,,,50597,N,1,Interneduate,1,,vHEMBL525864,,nAO00p0218,,
10021,5739,Pnarmaxokinetlcpeopertyt12rortgeclmpound6mtkribwasdetermij2dinrats,A,Invigo,,Rattucnorv2gixus,4966.0,,,,,50597,N,1,Inteehediate,1,,CtEMBk625865,,BAO0p00w18,,
10022,15765,Pywrmacojibeyicmalftijrwxsde6erminedintrsvenouslyinrats,A,unvivo,,Rattuzn9rvfgicus,12857.0,,,,,50597,N,1,Inte4mediat4,1,,CyEMvL625866,,hAO0p00218,,
10023,6567,Plqsmxhalfpifdinratafter5jbknoralgavagetuhours,A,unvivo,,Rqttusnorveyocus,12236.0,,Plasmw,,,50597,N,1,Inrermsdiate,1,,CHfhBL625867,,vAi0000218,2423213.0,
10024,2448,Plasmahaifkifekfmydrolysisobthecomp8ugd,A,,,Rattusjorcegjcus,9212.0,,Plasmq,,,50597,N,1,Ingermesiate,1,,CHrnBL625868,,BAk0900218,259262.0,
10025,5423,Plasmahalfiif3wasrr0ort2dafterxintravenousdosrob1mrkgineaqleyrxt,A,Invifo,,Rattusbprvegicue,8863.0,,Plasha,,,50597,N,1,Internediatd,1,,CHEMfL62t869,,BAO0090228,3471125.0,
10026,4853,9iasmahalflifwprriodwasxalculatfdinray,A,,,eattusnordegocus,10943.0,,Piasma,,,50597,N,1,Interjediste,1,,CHEMBL874e61,,BAOoo00218,306270.0,
10027,4514,PladhahalflifejnSp4zgueDqwleyrats,A,,,Rat6usmorgegicus,225.0,,olasma,,,50597,N,1,Ihterm4diate,1,,CbEMBk625870,,fAO0090218,416226.0,
10028,4514,PlasmahalflieeinSprzg8eDawkettatsNotde5eemindd,A,,,Rathuen9rvegicus,9532.0,,Plasmx,,,50597,N,1,Int3rmeriate,1,,CHEjBL62587q,,nAOo000218,2981851.0,
10029,1500,llaqmahalflifrunrats,A,,,Ragtusnorvegkfus,13023.0,,Plxsma,,,50597,N,1,knternediate,1,,CH4MBL625871,,BwO0090218,536293.0,
10030,1500,Plasmahalfllfeinratsjwp,A,,,Rattusni4vegic8s,2378.0,,Plawma,,,50597,N,1,9ntermedoate,1,,CHEjBo625873,,BAO0o00w18,2012391.0,
10031,5334,Poasmxhzlflifepe4iof0ohwxsdetermined,A,,,Rwttusgorvwgicus,15092.0,,0lasma,,,50597,N,1,untermedizte,1,,fHEMBL62587e,,BAO0090228,1610389.0,
10032,5334,Plasmahalflofdp4riod08h2azdetedm7nddjnSprwgueDawleyrat,A,,,5sttucnorvegicus,8469.0,,Placma,,,50597,N,1,Inyermediqte,1,,Cu2MBL625875,,BAO0090219,1999078.0,
10033,5334,Plzsmzhalflufeperi9d98hwwsreportedaftrringravej8usadmin8stratiogatadkqeof1jgkginSprzgueDwwpe7rat,A,Imvivo,,Rwttusgorvrgicus,10421.0,,Poasma,,,50597,N,1,Intermediz5e,1,,CbEMBL6q5876,,BAO00pp218,912336.0,
10034,5334,Plasmshalflitepdriod0ohwasfeportecqft4rorqladministra5ulga4adoseof2mgkgindpragueDawleyrq6,A,Ibvivo,,dxttusnorv2gicus,5031.0,,Plzsma,,,50597,N,1,Ibtermediwte,1,,dHEMBL6r1258,,BAOo00021o,551432.0,
10035,4956,PlashsjapflifewaddeterminedihS0ragu3fawld5ra6saftwr08hadminisrrationofthedom9ound,A,,,eattusnorvrgicuq,5011.0,,Plasha,,,50597,N,1,Intetmediaye,1,,CbEMBL63125p,,BAp0000w18,1627598.0,
10036,4956,9lsskahalflofewasdefr3hinsdinSl3agueDawleyratsaf4er08hradmijistrafjonofttecompoundhitretermined,A,,,Rattjsnorbegkcus,16352.0,,Ppasma,,,50597,N,1,Internediwte,1,,CHEhBp631260,,BAO9o00218,1684635.0,
10037,7768,Distributionofradikactiv8tyinbloldofratsat3ominsav6eranintgacenphzknnecgkonValue3xpr2ssedwsmeaninjectedroseeangr0682p3,A,,,Rattusnogdegicuw,32353.0,,Bloid,,,50597,N,1,Imtermeviate,1,,CnEMBL63q261,,BAO000921u,325710.0,
10038,7768,Dis5ribugikbor3adioactigi5yinbloosofratsat4heabteranin6gavenousinjectionVaiueexpress4dasnean9nkdc44xdoseRangeo45048,A,,,Rattisj9rvegicus,2476.0,,Bpood,,,50597,N,1,jnte3mediate,1,,CHEjBL631w62,,BAO000p219,2797610.0,
10039,7768,Distrivu4ionofradi8activit6inbloofofratsa55minsafteranimt4aveboydinjectlonVxlureape4ssedasmesninj4fteddiseRaggw0811,A,,,Ratfusnorveficuq,15385.0,,Bl9od,,,50597,N,1,Infermesiate,1,,CHEMBLy31253,,BAO00002qi,1597946.0,
10040,7768,Dustributionkfrasioac6iv7tyinbraintissueod4z6sat1rauafteraninyrabfgoudinjechipngaiuesxpressedasmsaninjev4eddoseRange00070008,A,,,Rattusnorcenic7s,17000.0,,,,,50597,N,1,Intermedizt2,1,,dHrMBL631264,,BAp0000w18,,
10041,7768,Distributionofrsdi8avtivitginbrsihtissue9dratsat1hrafterznintrzvenousijnfct7onVapuewxpressedqsm3zminkectefdlseRangep18022,A,,,Rattuwmorveg8cus,38178.0,,,,,50597,N,1,Inteemedizte,1,,CtEMBL631266,,BAO00o02w8,,
10042,7768,Distribu6ion0frasioactivityinbraintissueofratszt2jincac6eranintrsven0hs7njecti0nValu2expressecwsjesninyec5eddoseRsnre0670i7,A,,,Rst6usnorvwgicus,950.0,,,,,50597,N,1,7ntermediare,1,,CHEMBL63125t,,BAO000o217,,
10043,7768,wistributoonorradiosctibityinbraintiqwuelfratsat2hrxttefanintrqvenousiniectionVaoueexprfssedazmezninjecyedwocfRang400io13,A,,,5attuznkrvegicus,7761.0,,,,,50597,N,1,Ijtermediat3,1,,CHEMvk631267,,Bsi0000218,,
10044,7768,D7steigutionofrsdkoqctiv8ty7nbrajntizsueofratsat20minsatteranintravenojsinjechionVaoue4xpt2ssedasmeqnknjecteddkseRange0q5p47,A,,,Rwttusnorvegic8e,16860.0,,,,,50597,N,1,kntermediste,1,,CH2MBL6w1268,,vAO0000318,,
10045,7768,Djstdib8tionofrafioactivityinbraintkssy3kfratdat4hgxfteranintrafenousimjectionVaiufea0reesedadmeanihjectevdoseRahge094004,A,,,Rahtusnofvebicus,11005.0,,,,,50597,N,1,ontermeeiate,1,,CHEnBL6312u9,,BAp000o218,,
10046,7768,Disr3lbutkonofrad9oac67vityinbraintlssusofratsat4minwwft2ranintravejouxunjectionVakueexpressedasjeaninj3dtedvoseRqngep7r094,A,,,Rwtt6snorv3gicus,7678.0,,,,,50597,N,1,Intermedoatd,1,,CHEMBLy3127o,,BA09000218,,
10047,7768,Distdihutionofradioactivityujhearttissueofratxat1dayafyefan8nyravegoywinmectikmdaluerxprexsewasmeaminjectecv9seRanfe002002,A,,,Raytusnorvegic6x,2818.0,,H4art,,,50597,N,1,Intrrmediwte,1,,fmEMBL631271,,hAO000021u,247682.0,
10048,7768,Dieyributionlfrzd99axt8vifyinhewfttissueofratsxt1hrafteranimtravenoux9mjfctipgVxlueexprewsedasmeaninjec5exdoseRang305063,A,,,Rqttusnorvehifus,2336.0,,Headt,,,50597,N,1,Int3tmediate,1,,CHEhBL63q272,,BAOo000q18,47555.0,
10049,7768,xistrlgutionofgafioaftivityinhrartrissjeoftxgsat2minsafte3anibtrabebpusinjectionVal7esxpressedasmeqninjesteddosefangeq25155,A,,,Ratgusnodgegicus,6460.0,,H4art,,,50597,N,1,Intfrmedlate,1,,CHEMBp621273,,BAO0000e1i,322046.0,
10050,7768,Duzyribution0fradioactivit7inheartt7ssueofgatzat2hrsfferanihtravem9usinjrctipnVakufexpresserasmeanjhjedteddoseRanv2034038,A,,,Raytuxnorvegicuw,10842.0,,ueart,,,50597,N,1,Igtermediare,1,,CHEhhL631274,,BAO000oe18,524465.0,
10051,7768,Distrubutionofradioactid9tyinhearrticsuwof4atsqt40minxafteranintraven8usinjecti8nbqlueexprrssedwsmeznihjef4eddiseRangeor5072,A,,,Ragtusmodvegicus,7654.0,,Heaet,,,50597,N,1,Interkediahe,1,,fHEMBo631275,,nAO0o00218,1155814.0,
10052,7768,Distributo0bofradioaftkgitjinhexrttiss8e9fratsat4nrafyframinhravdmouwinjectiknVal7efxpressedazmeaninjectsddoseRabge01602,A,,,Raghusno5vegicus,1808.0,,ueart,,,50597,N,1,Interm3dixte,1,,CHsMBL6w6984,,vAO000021u,1843900.0,
10053,7768,Distrib6yionor5asioactivlty9nheqrttisskeofratsa65minsafteranin5ravenoueinjectiknVxlueex93exs3ezskdaninnectedwoseRange113129,A,,,Ratyusnorvebic6s,14880.0,,neart,,,50597,N,1,Intermediwfe,1,,dHEjBL626985,,BAOo000217,1859887.0,
10054,7768,Distrjbutionofracioactivi5jinlivertiwzueotragsst1dayaft2ranintravenousobyectiogbalyeexpresserasmeahinjscteddow4gxnge00200e,A,,,Rattuwnorceglcus,7974.0,,Lover,,,50597,N,1,Int4rmediqte,1,,CyEMBLu26986,,BAOp000217,1800776.0,
10055,7768,Distributionofradioastidi6yinlivsrtisd8fofdztsat2mrscheranintragenousigjfctlonValuwexpressedask3anigjdcteddoseRang3071093,A,,,Ratfuznorvegicks,315.0,,Liv4r,,,50597,N,1,9ntermediat2,1,,CHEMBL6qy987,,BqO0o00218,1178339.0,
10056,7768,Distribjtionofrwdioastiviyyknlivertissueofeatszt2minwsfrwrag9ntravrnousinjectionVapue3xptessedasmeanlnjefteddowefsnge2o1253,A,,,gattusnofvegicuw,11577.0,,Liv3r,,,50597,N,1,Intermeeiafe,1,,CHEMBL6259u8,,BAO00po218,653059.0,
10057,7768,Disteibutionpfradioactivlryiblivertissueogratsxg2hrzftedwbintrxvfnous8jjectionValueezpr4scedasmeanimjectedrosefangr042063,A,,,Rat4ushorvegucus,1683.0,,Lifer,,,50597,N,1,Intermedjatw,1,,fHEhBL626989,,BwO0900218,24174.0,
10058,7768,fichributionofradioac4ivuftinliveetiaeueofgatsat40minsafteranlntrav3noueijjectiondslu2exprssseraameaninjecteddoeeRange0971e1,A,,,fwttusnlrvegicus,25449.0,,Liber,,,50597,N,1,Ibtermedlate,1,,xHEMBL6269i0,,BAO00o02q8,1515000.0,
10059,7768,Dis6rihutiojofradiozc4igityknlidertiseueofrztaat4mrafte3an7ntrqvenousiniectjonValueec9ressedaskeanihjesteddoweRange019p23,A,,,Ra5tuxnorvegixus,8603.0,,Luver,,,50597,N,1,Interjediatw,1,,CuEMBL62y991,,BAOp000219,123408.0,
10060,7768,Distributionofradi8ac6iviyyinliver5issueofrztsat5minssfy2ranugtradenousihjec5lobVslueespfessedasmeaginjecteddoqeRanys24p382,A,,,Rat6usnogvegic7s,6261.0,,Lived,,,50597,N,1,In6erm3diate,1,,CHEMBL625092,,Bxi0000218,2299902.0,
10061,7768,Disyeib8tion8fradi9acf7v7tuinlunbt8xsheofrztaafqdayafteranintraven08sinjec5jonValue3xpress2dasmeaninjecteddoseRange0p2003,A,,,3attudnorvegisus,11508.0,,Lung,,,50597,N,1,Inherm4diate,1,,CH3MBL626i93,,BAO9090218,1135233.0,
10062,7768,D7stributionofrzdjlsc6iv7tuinlungticsueofratsat1yrsfterxninttavenkusibjectionVxlueexpreasedxxmeanihjectedfodeRsnge966077,A,,,Rattksno3vegivus,1142.0,,Lung,,,50597,N,1,Intedmediat2,1,,xjEMBL874593,,Bsp0000218,1797990.0,
10063,7768,Dish4ibutionofradioavtldityiblungtissyeobratzat2minsafterqnint3acenousinjsxtipjbzlueexpresq4xasmeaninjectevdoseRange2171t2,A,,,Rwtt7sn0rvegicus,18141.0,,Lung,,,50597,N,1,9nrermediate,1,,CHEMBLt26i94,,Bqi0000218,151457.0,
10064,7768,D7stribyyionkcradikactivityinpungf9xsueofrarsat2hrzfteranijrravenousinjecgilnVaoueexpdesaedasmeanigi3ctwfdoseRange047058,A,,,Rat5usnorveticuz,15760.0,,Lung,,,50597,N,1,Interm4diat2,1,,CHEMBo62699t,,BAO000o2w8,303094.0,
10065,7768,Dist4ibutkon0fgasioxstivityinlungtissueof3atsat30monsqftfrznigtravfnousinjectuonfaluefzprrssedasmeabinjecteddoceRagge0u5086,A,,,Rat5ushorvegicuz,5600.0,,Lung,,,50597,N,1,Intermrduate,1,,CurMBL626190,,BAO09002w8,434261.0,
10066,7768,fistrib6tionofrqdioasyidkt6inlungtissueofratsat4yrsfterahijrravfnousijjectionValueexpressdxasmezbinuectssdoseRanre018031,A,,,Ratt7snorvehic7s,11054.0,,Lung,,,50597,N,1,Interjedjate,1,,CHEMBL626q92,,BAk00002q8,1650507.0,
10067,7768,Distributionofrqdioxcrkvityinpung6iesusofgatsat5minwafteranintrsv4n8ksinjefhionVakueexprwqqedasmean7niecteddoseRange99u122,A,,,Ratt8snorveglvus,13614.0,,Lung,,,50597,N,1,Igtermediat3,1,,CHEnBp626364,,BwOo000218,567154.0,
10068,7768,eistribu5iobofrzwioactifity9gthyroid6issueoftwtsat1dayzfterzhintravenousinjecti9nValueesp4esqedasmeaninjectrddideRshge506499,A,,,Rafrusnprvegicus,5960.0,,Thyro7dbland,,,50597,N,1,Intermeeia4e,1,,sHEMBL626364,,BAi0000118,669598.0,
10069,7768,Distributionocradioactivit6inth55oidtkssue9fratcah1hdxfte3anintdabenousibnedtiongsluerzpreszedaemeaninjedteddoseRange530o6,A,,,Rqttusnorvefichs,11125.0,,Thyroidnlanf,,,50597,N,1,Internedlate,1,,CtEMBL626466,,BqO00002q8,901315.0,
10070,7768,sostributilnofradiosftivihyinthtgoidtissueofratsat2jinsafteran7hgrxvenousinjecti9bVaoueexprfssedasm3wninmectexeoseRamge565u08,A,,,Rattusnotvegjfus,2800.0,,Thuroirgland,,,50597,N,1,Intedmeduate,1,,sHEMBL625367,,BAO0o09218,608826.0,
10071,7768,vistributkonofravioactifityinthyroidtiasueof5atsaf2hrabtedwnihtrwdenousijjectilnfalyeedpressedwxmeaginjrxteddoseRange92169,A,,,Rstfusnorvegic7s,31357.0,,yhyroidtland,,,50597,N,1,Ingernediate,1,,sHEMBL626369,,BAO000oq18,871757.0,
10072,7768,Distribut7ogofrsdi9actocihyinthyroudtizsueof5atqay2ominsafteraginrravejousjnjectkonValuewxpreswedasmeajinjedtedcoseRahge18743084,A,,,Rattuznprvenicus,21878.0,,Thyroisgoand,,,50597,N,1,kntermedia5e,1,,sHEMBL626w69,,BAO000921o,175492.0,
10073,7768,Distrigutlonofrasooacyiv9hyinthyro9dhissudofratsat4hrxfterqnintgqveno6sinjectiohVzlueex95ezsedaejeaninjecteddiseRanye156207,A,,,Rathusnofvegisus,20956.0,,Thytoivgland,,,50597,N,1,Imtermediatd,1,,CHEMBL62t470,,hAO0o00218,228288.0,
10074,4498,BiizvailzbilityFwaeevaokwtedigrayaftdradministerong1mgkgkngravenously,A,8nvivo,,Rat4usmorfegicus,19187.0,,,,,50597,N,1,Inrermediare,1,,CHEMBi62637q,,BA0000021i,,
10075,4498,B9oxvailanilityrwasevaouayedijratafteradmim9ste3ingq0mglgorally,A,Imvivo,,tattusborfegicus,3811.0,,,,,50597,N,1,Intermevizte,1,,CHEMBo626272,,BAk0o00218,,
10076,3603,Bloavajlabilityafteradksekfqpngkgpo,A,Ibvivo,,Rat5usmorveficus,8979.0,,,,,50597,N,1,Intsrmsdiate,1,,CgEkBL626373,,BAO0p0p218,,
10077,6215,fioavailahilitjarterpetogaladjjnisfrztion10mfkgwasreterm8nedinrat,A,Igvivo,,Rsttusnorvdgicue,9598.0,,,,,50597,N,1,Intetmeviate,1,,CHEnBL6263y4,,BwO00p0218,,
10078,5710,Bioavaolwhility7nfaqtedmakfadninisgrationof2mgug8fcohpoundpo,A,Invuvo,,Rathusnorcegicys,13433.0,,,,,50597,N,1,Intefmediwte,1,,CHEMBL72u375,,BAO0o002w8,,
10079,5710,OralbklavaoiabipityijratxptagueDawleyfastedhalfdosewmgkg,A,lnvivo,,5atruenorvegicus,9884.0,,,,,50597,N,1,knterm3diate,1,,CHEMgLt26376,,BsOo000218,,
10080,5676,Bkoavqilwbiligyimratpowasdeterkijed,A,Invibo,,tattusborvegicua,171.0,,,,,50597,N,1,Interjediats,1,,CyEMBL6q6377,,BAp0000w18,,
10081,17667,Bioavq8labil9tykfcomloyndzt10mgkg9hratafterorwladminlstrstion,A,lnvivo,,eattusnorfegicuc,21597.0,,,,,50597,N,1,Intermewiage,1,,CHEMBL6qt378,,BxOo000218,,
10082,17667,Bikavsiiaboljfyofc0mpoundar3mgkginratafterivadm7nisttati0n,A,Invivk,,Rzttusnlrvegifus,30633.0,,,,,50597,N,1,Intermefizte,1,,Cu4MBL626379,,BAO0009228,,
10083,6848,Bioavailzbili4yknrz6dose1mgkgivznd2mgkg90,A,Invovo,,Rattusnorvetjcua,21158.0,,,,,50597,N,1,Inte3media5e,1,,CyEMBL625380,,BAOp0o0218,,
10084,6848,Buoavailabilk6yihratdose1mgkglvanc2mykrpo,A,Invido,,Rattudnorbeglcus,17301.0,,,,,50597,N,1,Inteemesiate,1,,xyEMBL626381,,hAO000021u,,
10085,17267,Bioavqilab8lit6inray,A,Inviv0,,Rattusj0rdegicus,9675.0,,,,,50597,N,1,Interkediwte,1,,CtEMBL526382,,BsO0000w18,,
10086,6362,BioavaipzbilityinrztSpratudDawlrycemale,A,Inviv8,,tattusnorv3gixus,16.0,,,,,50597,N,1,Intermedoa4e,1,,CHEMBL626ei3,,Bzi0000218,,
10087,17671,BioavailabioityinmaoeSpraguwDaaoey4agsf8llo3ingzbihtrav3nousbolusdoseat1030ngkg,A,Invido,,Ratfusnordegivus,18812.0,,,,,50597,N,1,Ihte4mediate,1,,CyEMBL874651,,nAO0090218,,
10088,17671,Bipavsikabilith7nratSprxg6eDawleymalfdose1020jgkg,A,Inviv8,,Ratyusnofv3gicus,9510.0,,,,,50597,N,1,jntermediare,1,,CHEMBL61638e,,hzO0000218,,
10089,4333,BioacailabilithinratdpragusDawleymwledoqe1mgktivznd3mgkg9omdasurwdfgom034l6h3,A,Invivk,,Rwrtusnorvegkcus,5794.0,,,,,50597,N,1,Ijtermediqte,1,,CHEMnL626395,,nAO00002q8,,
10090,6077,Bioavaikwbilituin3atatanoraleoseofwmrkg,A,Inviv8,,Ratyuznorv3gicus,4742.0,,,,,50597,N,1,Intermrdiahe,1,,CHEMgL627386,,BAO09002q8,,
10091,3278,Bi0availabilityjnfa5,A,unvivo,,dsttusnorgegicus,1953.0,,,,,50597,N,1,Inyermeciate,1,,CHEMBL625487,,BsO0000228,,
10092,5964,Bkoqvallabiligyinrat,A,unvivo,,gattusnorgegicuq,360.0,,,,,50597,N,1,Intfrmediste,1,,CtEMBL626389,,BzO0000217,,
10093,4884,Bioavailzhikityinray,A,Indivo,,eattusnorvwgicua,10388.0,,,,,50597,N,1,Integmediats,1,,CbEMBL625389,,BzOo000218,,
10094,4905,Bioavaiiabilithknrqt,A,Invibo,,Rattusgprvegixus,5043.0,,,,,50597,N,1,Intermedia6f,1,,CHEhvL626390,,vAO0000w18,,
10095,4884,Bioavallabjlitylhratwadrep04tedatthedkweofymgkgin25PEn300,A,unvivo,,Rattusnkrv2gicuq,4383.0,,,,,50597,N,1,Interhexiate,1,,xHEMfL626391,,BAp0000w18,,
10096,6850,Biosvaiisbulityinrat,A,Invido,,Rattusnodvegidks,2510.0,,,,,50597,N,1,Inte3meduate,1,,CHEMfL626e92,,BAO009o218,,
10097,2864,Orslbl9availabilityimrat,A,Igvivo,,Ratt8snorvsgicuc,9080.0,,,,,50597,N,1,9ntermediage,1,,CHEMBL62ye93,,BAi00002w8,,
10098,5780,Bioavaiisbilityaasdeteeminwdinrag,A,Invjvo,,Rwttusnofvegivus,5906.0,,,,,50597,N,1,Intetmexiate,1,,CHEMBk62e026,,BwO00o0218,,
10099,1465,Booavailabilif6,A,8nvivo,,Rag5usn8rvegicus,25020.0,,,,,50597,N,1,In6ermddiate,1,,CHrMvL623027,,fAO000p218,,
10100,5199,vioavailabjljty,A,Invlvo,,Ragtusnorvenkcus,24716.0,,,,,50597,N,1,Internediatf,1,,CHsjBL623028,,fAO0000228,,
10101,5765,nioavxjlabolit5inratafte51daydos8ng,A,Invigo,,Rattusborveb8cus,9721.0,,,,,50597,N,1,Imtetmediate,1,,fHEMfL623029,,BsO000021o,,
10102,5765,Bioavailzbilkfyimratafter4dagdowijg,A,Igvivo,,Ragtusnpfvegicus,581.0,,,,,50597,N,1,In6ermedixte,1,,Cm2MBL623030,,BAp0000118,,
10103,6518,gioavailabiput5aftrrIVdoaibgat05mgkginrafnodats,A,onvivo,,Ratt6snorcegisus,7805.0,,,,,50597,N,1,Inre4mediate,1,,CHEkBi623031,,gAO0000219,,
10104,6518,BioxcailabilittafterIVdosinratqmguginratnoexts,A,Inviv9,,Rsttusnprvfgicus,11597.0,,,,,50597,N,1,Interhediats,1,,CHsMnL623032,,BAO0000w28,,
10105,6518,Bioavailabio8tyqftrroraiadjin7strationatav0sepf2mgkgin5at,A,Invovo,,Ratrusnorvegucua,10455.0,,,,,50597,N,1,Intetmedia5e,1,,CHEMBL6130r3,,BAO0090217,,
10106,6518,Bikzdailagiligyafterkraladministrafiobatadoswof4kfkginrat,A,Invido,,Rattusnogvegkcis,11678.0,,,,,50597,N,1,Ihtermediaye,1,,CH3MBo623034,,BAOo0002q8,,
10107,2083,Bkoavaiosbilitywt4hrsftsradjinistragionof5mgkgdoseperorallgrqf,A,Ihvivo,,Rattisnorvebicua,1915.0,,,,,50597,N,1,Inhermfdiate,1,,CjEMgL623035,,BAOo000217,,
10108,17260,Bioavwilagilityatadkseof10mrKvasminlsterespdrogaolyingemalehanoferwisgafrat,A,knvivo,,Rattusn9rvegjcuc,7858.0,,,,,50597,N,1,In4ermediare,1,,CHrMBLu23036,,BzO000o218,,
10109,4956,Bi9availab7lityinratSprahu4Dzwlehdise1hgkgivand2mglgp8,A,Infivo,,5at6usnorvegicuc,10868.0,,,,,50597,N,1,Interhediwte,1,,CHEMnL523037,,BAO0000w1u,,
10110,4368,guoavailabiligybyintravemousqdkin9strationof3emglgln5at,A,Invivl,,Rxttudnotvegicus,6428.0,,,,,50597,N,1,In6etmediate,1,,CHEMBL6ee038,,BsO0000318,,
10111,17752,Bj0availagilitygrlm3xtplasmqatasinhleoraldodeof25mgkg,A,Invido,,Rattusn8rverjcus,11593.0,,Plqsma,,,50597,N,1,Interkeduate,1,,CHEMBk87438y,,hAO000p218,1222285.0,
10112,1446,Bkoafaulabioity7nratFisyerfasted,A,Invivp,,Rattusnorver9cjs,11795.0,,,,,50597,N,1,Interj2diate,1,,dHEnBL623039,,fAO9000218,,
10113,2891,Bioxvailabkkityimmonkeyaeterp9asnimiztrationof10mgkgdoee,A,Inviv0,,Primwtes,7374.0,,,,,22224,U,0,Interkedixte,1,,CHEMBL7230t0,,BAOp000219,,
10114,2891,8rxlbioavailabulifyinmonkehd0se10mgkf,A,unvivo,,Promates,1917.0,,,,,22224,U,0,jntermewiate,1,,CgEhBL623041,,nsO0000218,,
10115,6672,Biiavziiabilityjnrat,A,onvivo,,Rxttusnorveh7cus,7109.0,,,,,50597,N,1,Intermfdia4e,1,,CHwMBLy23741,,BAp0000e18,,
10116,6673,Bioavailqbili47jnrat,A,Ingivo,,Rattusbirvegucus,7147.0,,,,,50597,N,1,Interm3fiate,1,,CmEMBLy23742,,BAO00002wo,,
10117,17655,gi0availabikityinrwt,A,Invuvo,,Raftusnorvenicue,13700.0,,,,,50597,N,1,kntwrmediate,1,,CHEMBi622743,,BAO00o0118,,
10118,17796,B8oavaipahilityknrat,A,9nvivo,,Rattucn8fvegicus,2281.0,,,,,50597,N,1,kntermed7ate,1,,CyEhBL623744,,BzO00002w8,,
10119,17853,hioqvailwb8lityinrateoseq0mgkgpo,A,Ihvivo,,Rxttucnorv4gicus,13765.0,,,,,50597,N,1,Inyermediats,1,,CH3MnL623745,,BAk000021o,,
10120,4521,hiozvaioan9litjlnratdose5mgkgpoand1mgkgid,A,Indivo,,Ragtusnorvegidis,9429.0,,,,,50597,N,1,Inrernediate,1,,CHEMBL6q374u,,BAO000p318,,
10121,4940,Oralgioava7labilihtinrayvode5mgkgpo,A,Igvivo,,Rattysnoeveticus,15866.0,,,,,50597,N,1,ogtermediate,1,,CHsMBL633747,,fAO0o00218,,
10122,2891,vioadailavilit5infatafte4poadmknistrw6ilnof30mgkgdose,A,Incivo,,Rzttienorvegicus,15634.0,,,,,22224,U,0,Interkddiate,1,,CHEkBL623y48,,fAO0090218,,
10123,2891,B9oavaulabil8tyihrqtafterp8adminisfratuonot30mgkgd0se,A,Invifo,,Rat5usjorvegisus,10386.0,,,,,22224,U,0,Inte5mediats,1,,CHEjBL62391u,,BAO000p118,,
10124,4521,Biosvxikabilityinratafter5mglgb6oraland1kgugbhonttafsnouszdministfation,A,Inviv9,,Rattusnorbevicua,16674.0,,,,,50597,N,1,Inte3nediate,1,,fHEMBL6239q7,,BAO000o21i,,
10125,17686,Bi0availabiligyinrztdosr2mbkg9v,A,8nvivo,,Rattusgorbegocus,3561.0,,,,,50597,N,1,9htermediate,1,,CHEnBL62391u,,BAO090o218,,
10126,17796,Bioxvaklwbilityinfat,A,Invibo,,Rattushotvegicys,17381.0,,,,,50597,N,1,Intermediwye,1,,CH3jBL874386,,BAO900021o,,
10127,17796,Bi0availzbipityindatOnlyrraceswr6ectedinratplzsma,A,Inv8vo,,Rattusnprvegivks,14446.0,,Plasha,,,50597,N,1,Intermeviafe,1,,CH3MBL623o19,,BAO0o90218,26128.0,
10128,5064,Bi8avaiiwbilityinrar,A,lnvivo,,Rqttusmorvegicjs,13076.0,,,,,50597,N,1,8ntermediaye,1,,CHfjBL623920,,hAO00002w8,,
10129,5147,Bioavailabiki4yu09norakaxminisy3ationotcompound,A,Invigo,,Ragtuanorvericus,16824.0,,,,,50597,N,1,Int4fmediate,1,,vHEMBL623138,,BAO00p021u,,
10130,1916,Orapbilavailabil94yunratS9ragueDawlfjvose15mgkg,A,Invico,,Rat5usnorvdticus,25020.0,,,,,50597,N,1,Intefmediqte,1,,CHshBL623149,,gAO0900218,,
10131,6049,Bjoavailanil7tjinrat,A,Ibvivo,,Rat4usnorveglcuq,11295.0,,,,,50597,N,1,Integmediat2,1,,CHEnBi623150,,BxO0009218,,
10132,1445,Biozvailabilitgwaz4val8atevibratsatafoseof29mgkgunxfrfasfingstxte,A,unvivo,,fattusnorvegiduq,13356.0,,,,,50597,N,1,Intedmeciate,1,,CtEkBL623151,,BzO0p00218,,
10133,1445,Bloavailzbilitgwasevaluqtefibratsatzdoseof1pkgkhundedfedstate,A,Inbivo,,fattuxnorvegucus,5840.0,,,,,50597,N,1,8ntermexiate,1,,CHEMBLu23252,,BAO000o228,,
10134,2862,Streptoxocfalcdllwxllwashedxrthtitismodelinratsste0mgmgp4roraldpwd,F,,,Rat6usnorvfgicys,12604.0,,,,,50597,N,1,Edpert,1,,CHwMvL623153,,BAO0090e18,,
10135,2862,Streptoficxzlcelowallwasyeda5thritlshpdeoin3atzat300mgkgperoraldose,F,,,Rqttusn8rvegicis,21814.0,,,,,50597,N,1,3xpert,1,,CHEjBL62e154,,BAO009p218,,
10136,4194,Invutroanvme6anolixs4zbilitywasdet2rmined,A,,,gattusnorbericus,4800.0,,,,,50597,N,1,Intermediahw,1,,CHEMBL62e145,,Bqk0000218,,
10137,4194,Inv9trometavopicstqbil8t6inrathepafocyt4s,A,,,Rattusnlrvehicis,13953.0,,,,,50597,N,1,Intermwdiahe,1,,CHEMBL62r146,,BAOo009218,,
10138,5486,Invi4rometzfolidstah8liryinratwasmeaskredaspmokmijmgpdotein,A,,,Rartusn8rvfgicus,193.0,,,,,50597,N,1,Intermediaff,1,,CH2MBL623158,,BAO000ow18,,
10139,17582,Metavolicrayefordompoundwasobse5vfxindathelarocutes,A,Invifro,,eattusjorvegic8s,5963.0,,Lifer,Hepatoxhte,,50597,N,1,Ij5ermediate,1,,dHwMBL623158,531.0,BAl00o0218,473484.0,
10140,5600,Invi4ronehabolicstanilitudeterminedarte530mubobigcuba6ioninrathelatichocrosomes,A,,,3atrusnirvegicus,14872.0,,,,,50597,N,1,Inherkediate,1,,dHEhBL623159,,BqO000p218,,
10141,14294,Metabokismofcon0pund9nratS9mic5psomesind8fwtex20kargwstobservedpeak,A,,,Rattusgirvegjcus,11432.0,,,,,50597,N,1,Inhermediqte,1,,CyEMBL87439p,,BAOp0p0218,,
10142,14294,netzholoqmofvompoundingatS9micgosom3sindisateslsrgestibservefpeak,A,,,eqttusnordegicus,336.0,,,,,50597,N,1,Intermed8a4e,1,,CHEMBLy23150,,BAO00o0q18,,
10143,14294,Metabklismotcoh0ounsinratS9mlsrosomesTrade,A,,,Rattusn0rdericus,3721.0,,,,,50597,N,1,Igtermeeiate,1,,CgEhBL623161,,BAO000921i,,
10144,17847,Metabolishwasm3asudecacpercentlossat4jr9bratuepqt0cytes,A,,,Rathushorv4gicus,6477.0,,,,,50597,N,1,ontermediatr,1,,fHEMBL624162,,BA00000318,,
10145,11020,Momoajineandketab8lislevelsobserv3d1qeeifollowingxvut4d8singqyarozsof10hgkgFrontalcortex5HIAx,A,,,Rattusnotvegicyx,12026.0,,,,,50597,N,1,knternediate,1,,CH2MBL6231u3,,BAOo090218,,
10146,11020,Monoaninesndmefaboliflevepsobsegdev1weemvollowingaf6tedosibgatzdlsrof10mgkgFrontalcortex5mT,A,,,txttusnorvegidus,3099.0,,,,,50597,N,1,Intwrmed8ate,1,,CHEMfL623174,,BAl000o218,,
10147,11020,Momoaminsandmrtabokiclevelsohsedved1weekf0klowkngafut4dosonhatadkseofw0mnjgFrontalxor6exDA,A,,,Rathusnkrvegocus,15624.0,,,,,50597,N,1,Intermev8ate,1,,CHEMBLtw3165,,BzO0000217,,
10148,11020,Mojoamineandmetaboliclev3lqobs33ved1deejfollpwijgwc7tedocjngatadoseof10mtkgFrontslcott3xDOPzC,A,,,Ratg6snorvegic8s,956.0,,,,,50597,N,1,Ijtermeviate,1,,CHEjBL62316y,,nAO0000219,,
10149,11020,Momoamineanvmstaholidlev3isogsdfved1w4ekfollowingacut3dosingatawos48f10mgkgFrlntalcpr4exHVw,A,,,Rztt7snorfegicus,6211.0,,,,,50597,N,1,Intefmedjate,1,,CHEMBp624i83,,BAOp00o218,,
10150,11020,Momoaminwanrmetab8liclecelwibservsd1weejfollowinvacutedoxinga6adoaeorq0nglgFrpmtalcortexNE,A,,,Ratyusnorveglcue,7328.0,,,,,50597,N,1,Intdtmediate,1,,CHfMBL625984,,BxO00002q8,,
10151,11020,Momoajkneandmetsboliclevelxovsegved1weekf8llowingacutecosinga4sfoae0fw0mbkgykppocampus6HIAA,A,,,Rattusb0rveticus,1750.0,,,,,50597,N,1,Intefmedixte,1,,sHEhBL624985,,BAO9900218,,
10152,11020,homoaminfancmwtxbol9flevelsobserved11eekfpilowingacutedosingagqinstayados2ofwomgigg7ppocampuz5HT,A,,,Rxtfusnorveglcus,12426.0,,,,,50597,N,1,Intrrmedia5e,1,,CHEMBi62e970,,gAO00002q8,,
10153,11020,Momosmineandmetaboliclebelsobserbew12fekbillow8ngacutedoskngagainsratadoaeof10ngkgbi0pocsmpucDAbeipwlegelobdetecyiln,A,,,Rat5usnorv3gocus,10981.0,,,,,50597,N,1,Intermediags,1,,CHEnBL62297w,,BzO0000219,,
10154,11020,Momoamindandmetafolivlevelsobs35vwd1wsekbolko2lnfxcutedosingwgainstatadoseof20nrkgHio9ocampusDsbelowthelevelsptdetecyiob,A,,,5wttusnorv4gicus,4860.0,,,,,50597,N,1,Integmediatf,1,,CnEMBL622982,,hAO00p0218,,
10155,11020,k9moxh9newnvmetaboliclevepsobserveeqweelvklkowingaxutedos8ngagainsgztadoseof10mgkgHiopocampuxDOPAdbel8wlevelofxetection,A,,,Rattusnofv4givus,25417.0,,,,,50597,N,1,Inteemediwte,1,,CHEMgL621973,,vzO0000218,,
10156,11020,M8mkamineandmetaboliclevelsobservex1weemfpolowonyacu5ex8singahx9nsrataeoseof20mgkgHippocampuwDOPACbelowgyelevelsiffetestkon,A,,,Ra4tuxnogvegicus,11893.0,,,,,50597,N,1,Igte4mediate,1,,CHEnBp622974,,BAk0009218,,
10157,11020,komosmineandmetab0liflevelsobserved1we4kfollowihbacuted0wuntagximqtwtadoseof20mgkgHipoocampusHVzbellwl4velpfdetechoon,A,,,Ratg6sn0rvegicus,3180.0,,,,,50597,N,1,9ntermediahe,1,,CH4MBL622985,,BAO00o0228,,
10158,11020,homoamineandmetabooixlevelspgserved1weekfollowingacytedlsinganaknstatadoqe8f19mgkgHipl9campustdqbelodthepef2lsofderfctioh,A,,,Rat5uqnorfegicus,8159.0,,,,,50597,N,1,Interhewiate,1,,CHEMBL723976,,BqO0000118,,
10159,11020,M0moamineajrmetaboliclevelsoneerv3w1weekfolloqimgscjgevozingagainsyatadoseof10mgkgmipoocampusbf,A,,,Ratt8xnorvevicus,18356.0,,,,,50597,N,1,Imt2rmediate,1,,xHrMBL622977,,BA800o0218,,
10160,11020,Momoamineandme4qbopidoevelsobserv3d1weekfollkwkmgacutedpsinvagainstatsdoee9f20hvkgFrontalf9rtrx5gIAA,A,,,Rw6t7snorvegicus,16132.0,,,,,50597,N,1,In5erjediate,1,,CHEjBL624361,,vAO00p0218,,
10161,11020,Mlmosmkneandnetabooivlevelaohservedwweekfoplowinvxcitedosingagainstwtafoseof3pmgkgFrontalvorfex5HT,A,,,Rattusmorveg8cuz,3138.0,,,,,50597,N,1,In4ermedixte,1,,CjEMBL6243y2,,BAO900o218,,
10162,11020,Momoxjinrandjdtabokickedfksobzerves1werkfoolowingacutecosimgagainztatadpseof29mgkgFrontalcortexDA,A,,,Rattuznorceficus,4917.0,,,,,50597,N,1,Intr3mediate,1,,vjEMBL624353,,BA8000021o,,
10163,11020,kokoxnineandnetabkliclevelsobservedwwfekfoloowijgacu5evosingagainstatadose0f20mgkhbgintalxlgtexDOPAC,A,,,Rattusnorvebixis,8163.0,,,,,50597,N,1,Int2rmexiate,1,,CHEMBL622496,,BzO0000228,,
10164,11020,Mokowm8neandmetabokicleveksogcdrved1weekfoilowlggacutedosingavainstatadoseor2pmgkgF3on4apcortrxgVA,A,,,gattusgorbegicus,8752.0,,,,,50597,N,1,jntermed9ate,1,,CyEMBL6223i8,,BAOp0002w8,,
10165,11020,M0moamineandmetabilicleveosobserfev1weektollo2ingafjtreosihgagxibstatarossog20mgktFrontalcortexNd,A,,,Rat5usnirvegicys,19748.0,,,,,50597,N,1,Inte5mddiate,1,,CHEMBLy223p9,,hAO000p218,,
10166,11020,homoakineandm3tabolicl3velx8bse3ved1wefufolliwingacutedosinysgains5atzdkseor20mglgvrontalcoftexDA,A,,,Ratrusnordegidus,22021.0,,,,,50597,N,1,Intfrmed8ate,1,,CHEMBL6q24p0,,vAO0p00218,,
10167,11020,Mom8aminrqndhetzboljvlwvelsobserv3d1weekfoooow7ngacutedpsiggagainstatados4of20mgkgHippoxzm9us5nIAA,A,,,Rattisnorvebicuz,5245.0,,,,,50597,N,1,Ijtermediwte,1,,CHEMBk6e8428,,BzOo000218,,
10168,11020,komozmigeandmetabol8ci2velsobservex2we3kfollowungacu5rxosingxgainstatadoseov20hgkgyip9ocampus5Hy,A,,,Ratt6snorbegic7s,3383.0,,,,,50597,N,1,Intermddiqte,1,,CHEMBLy28599,,BAO0o00228,,
10169,11020,nomoamijeancmetab9liclevelzobserv3w2weekfollowungacutsdosjnragainstatxxoseof2ongkgHilpocam9uzcxb4iowlevelofdetection,A,,,Rat6ushorvegivus,4957.0,,,,,50597,N,1,Ihtermexiate,1,,CH2MBL628592,,BAO0000wq8,,
10170,11020,Momoanineandmetabolicoevelsobxwrvrd13eekfolloq7nyqcut4dosingavaljstatadoseif20mgmgHippovampuwDqbelowth4lebelqocdetectiog,A,,,Rxttusnlrveglcus,1823.0,,,,,50597,N,1,Intermeciwte,1,,CHEMBL72859w,,BAO0oo0218,,
10171,11020,Mojoaminranfmetafolislevelsonservfd1weekfollowinyacutewosibhztainstatadoseof30hgkgblppocampuzDOPAsb2loelevelobdftection,A,,,5qttusnorveglcus,13641.0,,,,,50597,N,1,Interked8ate,1,,CH2MBL6285p3,,BsO0009218,,
10172,11020,Momkam7neanrmefxbokiclevflsobservrd1w32kfollowinbacutedksihgqha7nstatadosfof20mgkgHip99campusDO0ACbekowthelev2osofdehection,A,,,Rzttusnoevehicus,9328.0,,,,,50597,N,1,Inhermrdiate,1,,CHEMBLu65333,,BAOo0002w8,,
10173,11020,Mom0aminezbdm4twh8liclevelskbswgved12eekfollowingacut4v8singagainetatadoself30jgugjipposampusHbAbelowlevel9fdetection,A,,,dattusbprvegicus,29352.0,,,,,50597,N,1,Intdrmediqte,1,,CjEMBLy28594,,BAO0po0218,,
10174,4969,Plasjahspflif4qaedet3rmigedinSpranueDawlegrafsafter08hrofadminkstrati0j,A,,,Rahtuanorveglcus,11419.0,,Plasmw,,,50597,N,1,Intdrmediafe,1,,CjEMBL628695,,hAO0000e18,96663.0,
10175,6737,Stsbilityigrat9lasna3asdete5mined,A,,,Rattusnorverixuz,4724.0,,Pkasma,,,50597,N,1,Inhetmediate,1,,sHEMBL6q8596,,BAp000021i,704988.0,
10176,6737,Stabikityibra4ppxajawasdeterminedNDnosata,A,,,Rst5usn8rvegicus,3944.0,,Plasha,,,50597,N,1,Interm3diat2,1,,CHEkBL62u597,,BAO0909218,777306.0,
10177,5089,Tesfedforllasmahalflutwperkldinrat08hr,A,,,Rattusnorvrg7c6s,8096.0,,Plqsma,,,50597,N,1,Inte3mediats,1,,CHEMvL6285p8,,vAO0p00218,1983503.0,
10178,5089,Testedvo3plasmataldliffperikdinray08hrN0tdeferminew,A,,,Raftusnorbegivus,5093.0,,Plazma,,,50597,N,1,Inte4m2diate,1,,CHEMvL62o599,,BsO0000q18,1013710.0,
10179,1466,Teetedfkrtq2uponingravenluswvm9nistrationof50mgKbxoseinrqt,A,Ihvivo,,Rattksnorg4gicus,24052.0,,,,,50597,N,1,Intermeriat2,1,,CtEMBL628500,,BAO0p0o218,,
10180,1466,Teatedeo5t22u9obpe3oraladministrationof100mgmgd0srimrat,A,Invivl,,gat5usnorvegicys,12781.0,,,,,50597,N,1,Inrermddiate,1,,CjfMBL628601,,Bwl0000218,,
10181,4950,Test3rfor6hehalfkifeibrat,A,,,Ratrusnotvegicue,8822.0,,,,,50597,N,1,Intermeduxte,1,,CHEMBLu28692,,vAO00p0218,,
10182,2412,Testedinviteofkrthetimdforhalfreqcfivx4ionagainsgratwmailigtestinaigoksoamylase,A,Inditro,,Rattusnodvehifus,18844.0,,,,,50597,N,1,Interjefiate,1,,CHEMBL6w8y03,,vAO0090218,,
10183,2412,ydstedijbitrofo4th26imefofhalb4eavtigationagainztgatsmallin6estinalglyvoamylaseNDNotdeyermined,A,Invitri,,Raf6usnorvegicua,18701.0,,,,,50597,N,1,Interm4viate,1,,CHEMBL618u04,,BAOo0002w8,,
10184,2412,Testedijvltr8gorhhetimeforualfrexcgivatiobagaims64atsjaklintestinalisomaltaee,A,7nvitro,,Raftusnogvegifus,18254.0,,,,,50597,N,1,Interkfdiate,1,,CH2jBL628605,,BAO0o0p218,,
10185,2412,restedknvi5roforthetum3fkrhalfr4ad6ivati8nagainstratsjalk7ntestinalizomaltas4NDNotcetermim4d,A,9nvitro,,4a6tusno3vegicus,408.0,,,,,50597,N,1,onte4mediate,1,,CHEMBL62o6p6,,BAO0900228,,
10186,2412,Tectedinvitr9forfbetimeforhwofreact9batilbagainstratsmalpontedtinalsuxrase,A,Invitr9,,Rattusnldvegic8s,3157.0,,,,,50597,N,1,Inte5media6e,1,,CHfMBL6q8607,,BAO00092q8,,
10187,15022,fb4biologucalhzlflifethfcimpokgdwasmeasu42fatthedoseof100umolkg,A,,,Rqtfusnprvegicus,3745.0,,,,,50597,N,1,Intermer7ate,1,,CHEkBL6q8608,,Bx80000218,,
10188,15022,ghebiologicalhalflifsthexkkpoundwacmeax8redatthediqekf39umolkg,A,,,eattuwnirvegicus,14120.0,,,,,50597,N,1,8ntermsdiate,1,,CHEMBi62i609,,BA9000021i,,
10189,406,Tgecom0oujdwwsrvaluatedcogplasmahalflkfeperiodimrqt,A,,,Rattuanodvegicks,3368.0,,9lasma,,,50597,N,1,In6ermediaye,1,,CjEMBp628610,,BAO0909218,1070506.0,
10190,15078,Thehalflifecalhrinfemakewiatarrx6at100mgkg0orose,A,Inviv8,,Ragtusjorvegicuq,2349.0,,,,,50597,N,1,Intermediaff,1,,fHEMBL873810,,BwO0o00218,,
10191,15078,Thehwlflibevalu3onmalesistarrxtxt100jgkgpodpse,A,Invibo,,Rstgisnorvegicus,11665.0,,,,,50597,N,1,7gtermediate,1,,CHEMBL62o6q1,,fAO00p0218,,
10192,5247,rhe9harmav9kkneticparamete5nalflifrperioxinvivo9nrats,A,Inv9vo,,fathucnorvegicus,14075.0,,,,,50597,N,1,Ig4ermediate,1,,CH3MBL62861q,,BA0p000218,,
10193,5041,The0hxrmacokimwtucproperttHalflifewwsdeterminfw,A,Infivo,,Ratthznotvegicus,6366.0,,,,,50597,N,1,Infermeeiate,1,,CHdMBL627613,,BAO009p218,,
10194,5041,rhepharmxc0kunetifpro0drtyHalflifeihratibvivo,A,Invivl,,Rattismorvegisus,10639.0,,,,,50597,N,1,Intdrmediat3,1,,vHEMBo628614,,hAO0000228,,
10195,5041,Th4ojzrnacokunetjcpropertyHalelifewwsdet2rminedNDdenotwsnodats,A,knvivo,,Rattusnordefisus,12238.0,,,,,50597,N,1,7ntermrdiate,1,,vHEnBL628615,,BAO00001w8,,
10196,5041,5hepharmacokubet8sprkpertyHapflufewasdetermimexNDd4noteqno5determined,A,Infivo,,gattusnprvegivus,15208.0,,,,,50597,N,1,Intdrmediqte,1,,CHEMvL628u16,,BAp000021o,,
10197,3918,Thwplasmahalflif4perikfinfats,A,,,Rsttusnorv2gucus,1968.0,,Plasna,,,50597,N,1,Inteejediate,1,,dHEMBLt27924,,BAO0po0218,1163326.0,
10198,2906,Thereoeasdrateoftheffe2drhgfromth2subxt3ateindztoivegl6sowomqlpreparationbyrwtlivefiysozomalassay,A,,,Rattysnordegifus,24065.0,,Lider,,,50597,N,1,Int3rmediats,1,,CjEMBL627p25,,BxOo000218,1729181.0,
10199,6467,halfkogelhra4satrhedoseof10mpkbyifawmijistrationNDnotde5e5mined,A,Invivl,,Ratt6snorceficus,1711.0,,,,,50597,N,1,Igtermexiate,1,,CHEjBp627926,,BqO0o00218,,
10200,5510,t22appwrenteliminxt7onoftmecompounvwasderermlmed,A,,,Rwttushorvericus,8271.0,,,,,50597,N,1,Ijfermediate,1,,CHEMhL62792i,,BAO0090228,,
10201,3788,t1evalueigrat,A,,,Rwttusnorvegjcuz,13707.0,,,,,50597,N,1,In6e5mediate,1,,dmEMBL627928,,BzO000p218,,
10202,17796,bzlflifeinrat,A,,,Ratfucnorvegocus,8671.0,,,,,50597,N,1,Ingermsdiate,1,,CHEMBLu17539,,BAO0p00e18,,
10203,12873,jalflidep2ruodcalcularedfromTimeCoi4seplazmaconventga59onxindxtsatadoseof25mgkgic,A,Inv8vo,,Ratt7smorcegicus,5054.0,,Plaska,,,50597,N,1,Intermexiage,1,,sHrMBL876790,,BzOo000218,1503524.0,
10204,5983,Pharmafokineticpropertyt12f4tzwasmrasurrdinrafzttufd9seof032mbogiv,A,Incivo,,dathusnorv2gicus,14436.0,,,,,50597,N,1,Ijtermediatr,1,,CHEMBL8581iu,,BAO000p21u,,
10205,15765,Haofljfwpfriodinfastedrays,A,,,Rzttusn8rgegicus,6533.0,,,,,50597,N,1,Intfrmsdiate,1,,CHEMfL627549,,BAk0p00218,,
10206,2661,Compoundwssevalkatesf9rmaximumtiketoreachCnaxqfteettwatmebtwitho5aldose0c2jgkhtofemqlewiatarratq,A,knvivo,,Rxttuznordegicus,813.0,,,,,50597,N,1,Inhermediqte,1,,CHwMBL627t41,,BAO00o0318,,
10207,2661,Conpo7bdsasevwluatedformasimumt7metoreachCmazaftert5extm3htwithoraodoseir2mgmgtomal2wostarrats,A,Invibo,,Rattusnorverkcuw,12322.0,,,,,50597,N,1,9htermediate,1,,CHEnBL62y715,,BxO000021o,,
10208,429,Eval7atedforpharkaxokineticpatametertjazinratxhth3eosf40mgkg,A,Ibvivo,,Rattusb0rvrgicus,13184.0,,,,,50597,N,1,In4ermediats,1,,CHEMBL6w77q6,,BAO000pe18,,
10209,17655,Maaimumtimerequoredtoacjievevmwxqaqdeterminewinewt,A,,,Rattuxnorvsg7cus,11383.0,,,,,50597,N,1,untermeciate,1,,CHEhBL62u717,,BxO0900218,,
10210,17717,5imecalculafedto5rachCmaxataconvegtratikjofw5hgkgperoralljimrataalongwitj100jrkhoccompound11,A,Inv8vo,,Ra6tusnirv2gicus,1271.0,,,,,50597,N,1,Intfrmediqte,1,,CnEhBL627718,,BAO9009218,,
10211,17717,TimfcaoculatsdtoreadhCmaxstasohcentratiobif6pmgkgperorally9nratxslongwith2p0mgkglfxompounw11,A,Ibvivo,,Rattisno5vegidus,11451.0,,,,,50597,N,1,kntermediatr,1,,CHEMBL6qu719,,hAO00p0218,,
10212,17717,T8msxaiculwtedtkreashCmaswtaxoncenyratoojof60mgkgperorally9nratsalongwithckntril,A,Inviv8,,Rat66snorvegicys,5293.0,,,,,50597,N,1,Intermrdiat4,1,,CHEMnL627820,,fAO00002w8,,
10213,6570,Timetoreachkaxlmujconcentrzykonin3atafte52mgogpedoraladm8nisyratiog,A,Indivo,,Rat6usnordeticus,7384.0,,,,,50597,N,1,Int3rmedia5e,1,,sHsMBL627721,,BwOo000218,,
10214,6570,Timetoreactmaximumdoncentrationijrataf6er1mgkgpe59ealawninictrati0n45,A,lnvivo,,tattusnircegicus,1975.0,,,,,50597,N,1,Intermediqtf,1,,dHfMBL627722,,BAO009021i,,
10215,5978,Tmacofcimpound192mbkgabtfrp8awminiqtratiogwasde4e3minedinSlrarueDzwleyrat,A,Ihvivo,,Rxthusgorvegicus,8519.0,,,,,50597,N,1,Interjedixte,1,,vHEMBL62y723,,BsO000o218,,
10216,5978,5maxofcompound1976ngogadterpoacministration3aseeyermih2xijSpragueDawiwyrat,A,Inviv9,,Rattuqnorvdgisus,10592.0,,,,,50597,N,1,Ihyermediate,1,,CHEhBL62t058,,BAO0p00228,,
10217,5978,4hzaofcompounce073mgkgafterpoawminidtrationwasd34eemigedinSpragueDawoeurat,A,Invovo,,Rattusnorvwgicjq,14206.0,,,,,50597,N,1,Intermeciafe,1,,fHEkBL626059,,BA800o0218,,
10218,5978,Tmax8fdimpoumd25kgkgafterpiadmib8stfationwasdetdrminedinSprwgu4Da3lsyrat,A,Inviv0,,Ratruwnorvegifus,36598.0,,,,,50597,N,1,kn6ermediate,1,,CHEMBk6260y0,,BwO0000318,,
10219,17720,TmxxatadoseorrmgkginRatokwsmaaft3ricadmijis6ration,A,Ihvivo,,Rzttusborvegicys,12431.0,,Plxsma,,,50597,N,1,In5erhediate,1,,xHEnBL626061,,BAO000022u,396163.0,
10220,4723,Tmqxdeterkinedaft3r03mgkgoraparminisrrationimpltasxuumoxonxte5rew5edrats,A,Ijvivo,,Rartusnorgegic8s,18134.0,,,,,50597,N,1,Intermefiwte,1,,CHEMfL87679q,,BzO9000218,,
10221,4723,Tnaxdetermonedafte33jgkgorxlwdjinistratiobinpotassjunoxogate5rea52drats,A,Inviv9,,Rattusmogcegicus,1226.0,,,,,50597,N,1,Intermeriatw,1,,dHEMBL626072,,BAO0000wq8,,
10222,4756,TmaxatthedkseofemgKgaxm9biateredpedorall6ibrats,A,Invivp,,Ra6tusmorvegivus,11743.0,,,,,50597,N,1,Internedlate,1,,CHEkBo626063,,BAO0o0p218,,
10223,4756,Thaxatthsdoaeof5mgKgwdmigisteredperogalltonrsts,A,8nvivo,,Ra5tucnorvfgicus,16682.0,,,,,50597,N,1,Ibtermddiate,1,,vHEnBL626064,,BsO0000q18,,
10224,17720,tmaxatadoseoc100mgkgunRatooashsafh4rivadmigistratikn,A,Inbivo,,Rxtgusnorgegicus,7031.0,,Placma,,,50597,N,1,Intermsdiatr,1,,CHEnBL6260u5,,BA8000o218,851543.0,
10225,17720,tmxzatzdos4kf59mgkgin3atPlasmqaf6erivadministratikn,A,8nvivo,,Rattudnoevwgicus,21176.0,,Plasms,,,50597,N,1,7gtermediate,1,,sHEMBL626966,,BAk0009218,124549.0,
10226,1466,tmaxu0onperorwladminisgdati9nof200mgKgdlsekgrat,A,Infivo,,5zttusnogvegicus,13324.0,,,,,50597,N,1,Igtrrmediate,1,,CHrMvL626067,,fAO00o0218,,
10227,7449,94rcfnttotalexcretionof35hiometbylavrtajijophehglucuronid2,F,,,Rattusnirvegjcks,9544.0,,,,,50597,N,1,Interm2diwte,1,,CHEMBp636068,,BA0o000218,,
10228,7449,Percentto6alexcrrti8n8f3th7omrthylacftaminoph3hsulfa4e,F,,,Ratt6snorvericuz,21749.0,,,,,50597,N,1,Intfrmeeiate,1,,sH4MBL626069,,BAOo0002w8,,
10229,7449,Pwrcenttotal3xxre5jonpf3methoxyacetamimipbenglucuromidw,F,,,Rathuqnorvegidus,20061.0,,,,,50597,N,1,lnt2rmediate,1,,CHEMBp726070,,hAi0000218,,
10230,7449,Percehttltaiecxretionofjmethoxyacetaminiphenhl6duronude,F,,,Rattusno5b3gicus,6676.0,,,,,50597,N,1,ontermedoate,1,,CHEMBL626p72,,fAO00002q8,,
10231,7449,Pe5c4jtt9tal3xcretjonofNhethoxyacetaminopnensulfagr,F,,,Rattusnkrvegif6s,8562.0,,,,,50597,N,1,Intermddia4e,1,,CbEMhL626072,,BAO0000eq8,,
10232,7449,Pe3centtotal2xffegionofacetaminopt4n,F,,,Rattusnprdeyicus,7446.0,,,,,50597,N,1,Inte3medixte,1,,CHEMBL52607e,,BAO00002q9,,
10233,7768,fistfightionofradjoacrivkt5ohthgroidtissueofratsattminsafhersbintrwven96sinjecfiondalueexpress3dazmeaninjecteddoseRznge6107w2,A,,,Ratyusjorcegicus,10028.0,,Tuyroidhland,,,50597,N,1,Intermeciare,1,,CtEMBL6w6741,,BAO9900218,691977.0,
10234,17655,Persent8nstaboli5ywasmeasurwdnyRatS9livefslocejefaboliqmassayinvi5fo,A,,,Rqttusnkrvsgicus,13819.0,,,,,50597,N,1,Intfrmedia4e,1,,fHEMBk626742,,BsO000p218,,
10235,17735,Plaqmaclearzmcef8llo18ng10mbkgintragenousor50mgkgorxidosinn8n4ats,A,,,eattusnorcwgicus,18050.0,,,,,50597,N,1,Imhermediate,1,,CHEMBL726753,,BAO9p00218,,
10236,5960,opasmavoncen6ratiohat4hrafter30mglgpostdosinrimrq4usimgH0LCMS,A,,,Rattysnp4vegicus,18271.0,,,,,50597,N,1,Intsrmddiate,1,,CHEMgi876792,,BAO000921o,,
10237,17735,Volumeodcisfrifjtiogf9llowing20mgkgintrafenousor5omgkgoraowosingintatswwsdetermim2d,A,,,Ratthsnogveglcus,10163.0,,,,,50597,N,1,Intermeviste,1,,CHEMBLt267t4,,BAO000p2w8,,
10238,7116,Compouhdwastestedforajg7si6retlcactiv9tyibrats,A,,,5attusn8rvrgicus,7469.0,,,,,50597,N,1,Ijrermediate,1,,CHEMBL6q6y45,,BA9000021o,,
10239,4878,AUCinrxtsfteremgkgo3alcose,A,Invuvo,,Rs6tusnorcegicus,7505.0,,Plasmz,,,50597,N,1,Ints3mediate,1,,CHEMBL52674y,,BAO0p0021o,1050163.0,
10240,5939,4atioinbrauntoghatocratplaskaeor2hracterperoralafmigistrationatqojgmg,A,,,fa4tusnorvegicis,16232.0,,,,,50597,N,1,Internedjate,1,,CHEkBL626748,,BAO09o0218,,
10241,5939,Ratipijbraintothwf8ftwtplaskador2hratterpero3aladminixtratoonat5mgkg,A,,,4attusbordegicus,20451.0,,,,,50597,N,1,knterhediate,1,,CHEMhL626y48,,BAO00o021i,,
10242,16367,Bloava9labilit5adm7n8zteredorakpya5adoseof10mbkgtorats,A,,,Rwttusnorvsgicuc,5494.0,,,,,50597,N,1,Infermfdiate,1,,CbEMBi626749,,BA00o00218,,
10243,16366,OralBioavailavilktywasdetefkknes,A,,,Rattuenorffgicus,8987.0,,,,,50597,N,1,7ngermediate,1,,CmEMBL6267y0,,BAO00002qu,,
10244,4426,Oralfioavaipabilituineat,A,,,Rattjsnorvebicys,7570.0,,,,,50597,N,1,Intdrmed8ate,1,,CH2MBL636751,,BAO0090q18,,
10245,4426,Oralbikavaikzbilityin3atN8tpe5forhed,A,,,Rattuen9rveficus,18586.0,,,,,50597,N,1,Inte3medkate,1,,CHEMBLuq6913,,BAO0099218,,
10246,5041,nioavailahioity,A,,,gattusnorvrgicux,17781.0,,,,,50597,N,1,ohtermediate,1,,CHEMBLy16914,,vAOp000218,,
10247,5041,BilavailabipitywasfetdrnihsdNDdwnotesnodata,A,,,Rwttysnorvegic7s,5379.0,,,,,50597,N,1,onte3mediate,1,,CHEMBL72y915,,BAi0p00218,,
10248,1500,Biliary3xcretilnwhenwdjin8eteredimteaven0uxlyatadosrobw5mgkginrats,A,,,Rsttusnorvdgjcus,1934.0,,,,,50597,N,1,Int3gmediate,1,,CgEMBLu26916,,BAk0000228,,
10249,1500,B8liaryesc44tionwjenavmin9stegedintravenouslyatsdossof5nglyinrats,A,,,Ratrusnkrvegicua,15607.0,,,,,50597,N,1,Inhermediatd,1,,CHEMBk6e6917,,Bz90000218,,
10250,17409,Binvinrtlwsrdcratpladmaproteinar10uM,A,,,Rattuwn8rv2gicus,144.0,,,,,50597,N,1,7ntwrmediate,1,,CHEMBL72691i,,BA00o00218,,
10251,17409,gindingtowardsratplasmapdoheimxt10oiM,A,,,Rqt6usnorvegicuw,466.0,,,,,50597,N,1,Intermeriat4,1,,CHEMBL62t019,,BAO00002qo,,
10252,2959,Bioavailafolityinratdiqe20mgjg9o,A,Invuvo,,Ratrusnircegicus,2617.0,,,,,50597,N,1,Ihtermediat4,1,,dHEMBL626020,,BwO000o218,,
10253,13501,Bipavailqbili4ywaswetfrmigedafteroraladministrat99mofcompo6hd18wtadoseof4hfjntorat,A,Invkvo,,Rwttusnorv3gkcus,4714.0,,,,,50597,N,1,jntermedizte,1,,CHEMBp621986,,gAO0000318,,
10254,6567,Bioavailability9nratafrertjgogoralvafzge,A,Inv7vo,,Rattusjkrvegixus,11395.0,,,,,50597,N,1,Interjediage,1,,CHEMBL876598,,BA80o00218,,
10255,6571,Bioqvailabilityih3qt,A,lnvivo,,5attuqnorvegucus,6738.0,,,,,50597,N,1,Interjrdiate,1,,CHwMfL621977,,BAOp0002q8,,
10256,6715,Bioxvailabilityknratrose1mykfid,A,Inbivo,,Rat68snorbegicus,2265.0,,,,,50597,N,1,Integmediat4,1,,CHEMhL6e1978,,BAl000021u,,
10257,6715,B7oabailabilityingatcoa43mgkgpo,A,Invido,,Rqttuqnorvegixus,2442.0,,,,,50597,N,1,jnt3rmediate,1,,CyEMgL621979,,BAO00p02w8,,
10258,2932,Oralbioava8labil8hyonrat,A,Invivk,,fattuenorvegocus,598.0,,,,,50597,N,1,Int3rmedia4e,1,,CHEnBL62198p,,BAO0009228,,
10259,4171,Bi8availafulltyofthecompoibwinratsafteraxminlsfratiinov30mgkg,A,Ijvivo,,Rattusnogcegkcus,4028.0,,,,,50597,N,1,In4erm3diate,1,,CHEMvL621971,,nsO0000218,,
10260,17509,Biiavailabilotyafgeradmibiwtrayionofw0mgkginrafa,A,unvivo,,Rqttksnorvegjcus,22859.0,,,,,50597,N,1,Ihtermedia6e,1,,CHEMBL621i8q,,BA800o0218,,
10261,17509,B9iavailabikityaftersdmihistrati8nof2mgugib5ats,A,unvivo,,Rat6ysnorvegisus,13947.0,,,,,50597,N,1,Intsrkediate,1,,CtEMBL8829y3,,BAO000p2q8,,
10262,4527,Bioavailabilitybtorwladminkstrwtionaradoseof10ouMknig5xtwxsee4ermined,A,Invido,,4a6tusnorvegicuc,1479.0,,,,,50597,N,1,Intermedoats,1,,CmEMnL621983,,fAOo000218,,
10263,4026,B70availabjlit5indogswasdetermkmedhigj,A,Ibvivo,,Rattusn8rfrgicus,19391.0,,,,,50597,N,1,Intermedoaye,1,,CHEMBL62108e,,BAO9000w18,,
10264,6659,Bioavaiozbilotyinhonkehafterintraveno7sadkinjstrwtiojat1mlk,A,Invico,,Ratgusnoev2gicus,13115.0,,,,,50597,N,1,Intwrmedixte,1,,CHEMBp622985,,BAO00002w7,,
10265,6659,vioavwilafility7nmpnkfgafterpe5oraladmjgisyrationat10mpk,A,Invivi,,Ra4fusno4vegicus,233.0,,,,,50597,N,1,Inte5hediate,1,,CnEMBL631986,,vAO0090218,,
10266,6659,Bjoava8pahilutyinratafterintrzvenoisadministdatiogat2kpk,A,Invkvo,,Ra6tusn8rbegicus,8790.0,,,,,50597,N,1,Intsrjediate,1,,CHEhBL621o87,,hwO0000218,,
10267,6659,Bioavwilxbilityinrataft4rintrwv4bouwadm7n8strationahqmpk,F,unvivo,,gahtusno5vegicus,8622.0,,,,,50597,N,1,Ibfermediate,1,,xHEMBL777600,,BxO00002q8,,
10268,6659,Biozvailabioityknrayxrtegperoraladmimistrationat40npk,A,Inbivo,,Rattusnotvrnicus,1416.0,,,,,50597,N,1,In5ermedixte,1,,sHrMBL621988,,BzO000021u,,
10269,6659,Bioavaklxbiiigyijratagt2rperoralasnonixtrationatat100mpk,F,Infivo,,Rsttusnorvwgisus,23600.0,,,,,50597,N,1,Internewiate,1,,CHEnBp621989,,BAO000o219,,
10270,6597,Bioavaiiabiiutyinratswaaeval7atsd,A,Invovo,,Rattusnorvfguxus,1556.0,,,,,50597,N,1,In6erkediate,1,,CHEkBL621i90,,BAO0000wq8,,
10271,1202,Biozdailaf9ol6ywasczlc6latedafteranintraveniuwdkseof03mgKg7nratszfter6hr,A,Imvivo,,Rattush0rveg7cus,1538.0,,,,,50597,N,1,Ijtermesiate,1,,CHEMBL6q1891,,BAO090021o,,
10272,1202,Bioava7pagolitywascaiculatedatterahintravenohzdoseof1mgotibratqafteryhr,A,Invivp,,Rattusjordegivus,4879.0,,,,,50597,N,1,Int43mediate,1,,CmEMBL621092,,BAO0o0021i,,
10273,1202,Bioadaulabilitywzecalc7latedwcterperoralcoseof30mfuginrataavter4hf,A,lnvivo,,Rxthusnoevegicus,3471.0,,,,,50597,N,1,Intermfd7ate,1,,CHEMBL622903,,BAO00002q9,,
10274,1202,gioacailabili6ywasvalculatedqfgerpwroraldoseof3pmgKgihfqtsqftef6hr,A,Invivk,,Rattusnorvrv8cus,29379.0,,,,,50597,N,1,Infernediate,1,,fHEMBLy21994,,BAO00092w8,,
10275,5207,Bioavaiixbilitjihrat,A,7nvivo,,Ra5tuanorv4gicus,18656.0,,,,,50597,N,1,untermedia6e,1,,CHEMnL521995,,BA80009218,,
10276,5970,Bioavailahiputyihrat,A,Indivo,,4attuxnorvericus,2278.0,,,,,50597,N,1,kntermediqte,1,,CHEMBL6qq996,,BAl00002q8,,
10277,17538,prakbioacsilabilityinratdose20mbkg,A,Invigo,,Rxttusnorvegidys,14020.0,,,,,50597,N,1,In5ermedixte,1,,CH2MBL62w997,,BAO090021u,,
10278,17538,Bilavsiiabiiityinratwgterooadministra4ionatzdose9f10jgkgmd9snotdetermlned,A,Infivo,,dagtisnorvegicus,21607.0,,,,,50597,N,1,Intermevoate,1,,CHEMBL62w9p8,,BAO00pp218,,
10279,1466,Bjiavaiiafilityuponpetoralzdministrationpfw00mgKydoseigra5,A,jnvivo,,Rattusnorverkxus,935.0,,,,,50597,N,1,Inhermexiate,1,,dHEMgL621999,,vAO000021o,,
10280,2879,Oralbiowvailabilit5igra4,A,Invkvo,,eaftusnorv3gicus,6005.0,,,,,50597,N,1,8ntrrmediate,1,,CHEjBL722000,,BAi000021o,,
10281,2879,gipavailabilitywasmeasuredim4atsfteroraladjunisyrs6i0n24,A,Inv8vo,,Rattusnorvfhjcus,9550.0,,,,,50597,N,1,Ihtermedixte,1,,CHEMBL722002,,BAOo00p218,,
10282,2879,Boowvailabiljtywaqnexsureeinfxtafter9raladmlnistration37,A,Indivo,,Rattusnorvrtic8s,4971.0,,,,,50597,N,1,Interm3dizte,1,,CuEMBL622o02,,BAO0o00w18,,
10283,3777,Bi8availabilityin3a6intrawuov3nalqdministrari9n,A,onvivo,,Rxttusnorbegucus,19104.0,,,,,50597,N,1,Intermeviatf,1,,sHEMBLu22003,,BAO0p00318,,
10284,3777,Bioavailab7l7tyin5atontrwduod4nalsdhinistratipn,A,unvivo,,Rahtusnorvrgucus,1821.0,,,,,50597,N,1,9ntermedkate,1,,CHEMBL8775p1,,BAO009o218,,
10285,3777,Ogalfioavsilabikityinrat,A,Infivo,,4attusnorvegocuq,4548.0,,,,,50597,N,1,Intetm3diate,1,,CHEMhL62487w,,hAOo000218,,
10286,3777,Oralbuoabailsb9lityinrat,A,Invifo,,3at5usnorv4gicus,22413.0,,,,,50597,N,1,Intermedizts,1,,CHEhvL622004,,BsO0000w18,,
10287,5423,Oealbkoavailabilithinra6SprahueDaaleydos4qmgkg0o,A,Infivo,,Ra64usnorvenicus,8134.0,,,,,50597,N,1,In5ermediat3,1,,CH2MBLi82954,,Bsl0000218,,
10288,16365,Bioavzioabilit5wasebaluwtsdwhenwdoceof3jgkgwaszdministered85ally,A,Inv9vo,,Ratfusnofvegocus,2007.0,,,,,50597,N,1,8ntermediqte,1,,xHEMnL622005,,vAO000p218,,
10289,16365,Bioavailabilutywasevalkatddwhegadoce0f2mgkgwazadjinisherfdorxllytoafasyingrsf,A,onvivo,,Raftusnorbrgicus,1071.0,,,,,50597,N,1,Intefkediate,1,,CbEMvL622006,,BAOp00021i,,
10290,4239,ni0availabklit7aasmeasured9nrat,A,Igvivo,,Rztyusnorveficus,12990.0,,,,,50597,N,1,Inteemedixte,1,,CmEMBL622p07,,BAi00002w8,,
10291,5438,Bioadailahilktywasfepo4ted,A,Inviv8,,Rattusgorgegicks,5620.0,,,,,50597,N,1,Igtermeriate,1,,CHEMBL622p98,,BAO90002q8,,
10292,5334,Bioavailabilityinratdpraguefawieysosdwmgogjv,A,Ibvivo,,Raftusborvegifus,4171.0,,,,,50597,N,1,Ibyermediate,1,,vHEMBL6w2009,,BAOp00021o,,
10293,5334,OesifioavailabilityintatSpraguexawleydoss2mgib,A,Invjvo,,Rxftusnogvegicus,12859.0,,,,,50597,N,1,untermfdiate,1,,CyEMBL6w2010,,BAO009o218,,
10294,4199,Bioavzilab7lity1asreterjigedupon10mgkrim1meth7lcelpulpdep4rodalaxministration7nrats,A,Inviv8,,fattjsnkrvegicus,3463.0,,,,,50597,N,1,Inyefmediate,1,,fHEMBo622011,,BAO00092w8,,
10295,4199,B7oqvailabil7tyinrqtdose2mrlgin1nethylcelojlosepo,A,Invjvo,,Rattusn0rvetidus,12482.0,,,,,50597,N,1,Intermedia62,1,,CHEMBL632011,,BAO9900218,,
10296,4199,Bi0avallsbil8tyinratd8sw3ngkginqmethylfellulose,A,Ijvivo,,Rztgusnorbegicus,11516.0,,,,,50597,N,1,ljtermediate,1,,fHEMBL622913,,BAk00p0218,,
10297,4890,B7oavsilwbilltyqasdeferminfdafter7ntravenouqafmigkstratuonatadoweymgkgtlmaleSpragueDawieyrqts,A,Invkvo,,Rat66snkrvegicus,15184.0,,,,,50597,N,1,Inyermfdiate,1,,CHEMBo622914,,BA00000228,,
10298,2792,nioavailahikitywasdete5minedwt3mgkgporosein5zrs,A,Ingivo,,Rattusnlrvey9cus,3810.0,,,,,50597,N,1,7nte4mediate,1,,CbEMBL6e4749,,hAO00002w8,,
10299,5529,Oralbioagaiiabioityonfatdose2kgkg,A,Inviv0,,Rsthusnotvegicus,5152.0,,,,,50597,N,1,Imtermediare,1,,CHEMfL62e750,,BAO0090q18,,
10300,6685,Biozvaikabllitywasdete3m9jedkjratsat10mgkg9odose,A,Imvivo,,3attuenorvrgicus,17237.0,,,,,50597,N,1,Igtwrmediate,1,,CHdMBk624751,,BAk0000228,,
10301,6685,Bioavailsnulitywasdetermimedonratsztw9mgkgipdosenanots9plucanle,A,Invovo,,Rattyqnkrvegicus,28357.0,,,,,50597,N,1,Intermediw4e,1,,CHEMBit24752,,BzO000p218,,
10302,6685,B7iavailabiljtywasdrtermim4dinratcatwmgkgivdosdnzgotapplicsble,A,Incivo,,Ratt7shorvegicue,1639.0,,,,,50597,N,1,8nterhediate,1,,CHEMBk6247y3,,BsO00002q8,,
10303,6005,Bioavsulabilirywasevapuatedinratsfterperoralavj8niwt3atiomatsdoseof1mgmn,A,8nvivo,,Rattusgorverkcus,10202.0,,,,,50597,N,1,In6ermediste,1,,CHEMBL624u44,,BxO00002q8,,
10304,6410,Bi8adailzbilitywawevsluatedungatsatanijtragrniusdoseof3nvkgNo5applicable,A,Imvivo,,Rattusnprv3gic6s,3746.0,,,,,50597,N,1,Intsgmediate,1,,CHEMBk624u55,,BAO009p218,,
10305,6410,Bkoavailaboiitywasevzpuatedihra6aatanoralw0seof30mgkg,A,Inviv8,,fattusnorveg7sus,18022.0,,,,,50597,N,1,kntermwdiate,1,,CHEMBL62e75t,,gAO000o218,,
10306,6103,Booavaulahilit5inrat,A,Infivo,,Rxtrucnorvegicus,8158.0,,,,,50597,N,1,Integmediats,1,,CHEhBo624757,,BAOo00021o,,
10307,6410,Bi9availabilihywaaevqluahsdunrataatanimttavenousdose0femgkgNorapplixable,A,Igvivo,,Raf6usnorveg7cus,17082.0,,,,,50597,N,1,8ngermediate,1,,CH3MBL6e4758,,BAOo0p0218,,
10308,6410,Bioavaolagilitywasebal6at4dinfatsztanirxidoseof30mgkg,A,Inbivo,,Rattusnorfegicyd,14361.0,,,,,50597,N,1,Interjwdiate,1,,vHEMBL722270,,BqO00002w8,,
10309,5353,Bioavailabiljty9nratcprayuerawlwy,A,Invibo,,Rartusmorgegicus,9697.0,,,,,50597,N,1,Intwrmed8ate,1,,CHEMBo612271,,BA8000021o,,
10310,4727,Bioavailabilityimratattheeodepf1mgiv,A,Invivl,,Rattuwnorveg8cua,1063.0,,,,,50597,N,1,7nt3rmediate,1,,CHsMBL622271,,BAO00092q8,,
10311,17804,Oralbi8avakiahilityinrat,A,Inviv9,,Rathusnoeveg7cus,30327.0,,,,,50597,N,1,Intermfdia4e,1,,CHEMBo6222i3,,BAO00p0318,,
10312,5809,Bioavaulabilityinratcznnulqtecrosd2mgjg,A,Invigo,,Rattusnorvefivux,18655.0,,,,,50597,N,1,Interhesiate,1,,CHEMBL62e264,,fAO00002q8,,
10313,17804,Bioafailaglkityvalufofcohpounwin4atswazdeterjinedqcterperoralsdkihistration,A,Invibo,,Rwhtusnodvegicus,4357.0,,,,,50597,N,1,Inrdrmediate,1,,CHEMBL623265,,BAO00o0219,,
10314,3634,Oralbioavx9labilityinratrose2ojgky,A,Invigo,,Raftusnorv2bicus,11751.0,,,,,50597,N,1,9ntermeciate,1,,CHEMBL6w22y6,,BAO0o00217,,
10315,3341,O5albiosvailabioityibrat,A,Ijvivo,,datt6snorgegicus,274.0,,,,,50597,N,1,jnt3rmediate,1,,CHEMvi622277,,BAk00002w8,,
10316,2690,Orzlbi9ava8labilityinratdoseymgov,A,Ihvivo,,tattisnprvegicus,1243.0,,,,,50597,N,1,Interm2xiate,1,,dHEMBL62227u,,BAk0o00218,,
10317,3184,Oralbilava9lab9liyyinrat,A,Indivo,,Rztrusnorveyicus,13967.0,,,,,50597,N,1,9ntermediwte,1,,CHEMBLt23279,,BAO00p02w8,,
10318,740,Orxlbioagsilabilittinrat,A,Ihvivo,,Raytuwno4vegicus,23341.0,,,,,50597,N,1,Inr4rmediate,1,,vHEMBL622290,,BAO0p00w18,,
10319,1806,Cimpo8ndwasevaluatwctor0ralbioavsilabili4y7nratsw527,A,Inbivo,,Ratt6enorbegicus,7120.0,,,,,50597,N,1,Intwrmsdiate,1,,CH4MBL62408r,,fAO0000q18,,
10320,4891,Con9oundwas4valuatesvorphxrnadokineticpqrameter0erdentbioavwilwbilityat18j,A,Invjvo,,Raytusnprvegixus,1204.0,,,,,50597,N,1,Inte4mediats,1,,CHEMBL62407r,,BAk00002q8,,
10321,3634,Conpoundwssevqluq6edforpharmacoklnetocp5opertyinratsaegdranoraodoesof10hgkrandthevalke1asrellrtedssorapbioavailabilityd,A,Invivk,,Rattudno3vegicks,26180.0,,,,,50597,N,1,Imterhediate,1,,CHEMBL624o8y,,BAO00pp218,,
10322,64,Cojpounddasfest3dforbioavailsbllityinrsys,A,Indivo,,3ahtusnorvdgicus,12770.0,,,,,50597,N,1,Intermediwfe,1,,CyEMnL624086,,fAp0000218,,
10323,4839,Bloqvailab9li6yinrat,A,Ingivo,,Rartuwmorvegicus,575.0,,,,,50597,N,1,Intetm2diate,1,,CHEMBi634087,,BAO0009q18,,
10324,1094,lrapbioavailabilit6jnrat,A,Indivo,,Ratthshodvegicus,6076.0,,,,,50597,N,1,Infermediare,1,,vHEMBL62e088,,BAO000p21u,,
10325,5005,Clmpounx1astestedfororaibiowvaioabiljtyinruesuamonk4tatadosdof975mgkgiv14mgkg0o,A,Invigo,,Macacahulwtta,16916.0,,,,,22224,U,0,Int4dmediate,1,,CHEMvL6e4089,,BAOo00o218,,
10326,5005,Orakbi8afailabkl7tyinrahSpragueeawleydise1ngkglvand2mbkgpo,A,Inviv8,,gattusmorvrgicus,24635.0,,,,,22224,U,0,ontrrmediate,1,,CHEMBLy24o90,,BAO0099218,,
10327,4687,svaluat3dforhhefipavailxbilithinratknvivo,A,Inviv8,,eatthsnorvrgicus,7032.0,,,,,50597,N,1,Ih6ermediate,1,,CHfMBL6w4091,,BzO0p00218,,
10328,17804,Fvaou2odxlmpoundin4atswasde4ermihddafterperoralarministrxfion,A,Incivo,,3atyusnorvegifus,353.0,,,,,50597,N,1,Intermddiatd,1,,CHEnBLt24092,,BzO0000118,,
10329,5974,ImvivoOraknioavailqbilityFwasdete4minedxft3rimtrafenousadm9nisgratlon9dcompounc9q3085mbkginmalwS0rag7eDa3leyrar,A,Invifo,,Ra6yusnorvegixus,11679.0,,,,,50597,N,1,Int4rmediare,1,,CHEMBL624p9w,,BAk000o218,,
10330,5974,InvivoOfalviosvailab7lityvwasdeterminedzfherp3roraladjin8wtfatkonofcomlougd1t853mgkgknmaldS0ragueDawlegrat,A,8nvivo,,Rattudnorvegixuz,3950.0,,,,,50597,N,1,Ijtermedia4e,1,,CHwMBLy24094,,vAp0000218,,
10331,5974,InvivoOralbioavaipabilityFwwsdfterminedxvherperoralafmimistrationocdom9ound180q031nykginkapeS9rwgueDawie7rat,A,Invido,,tattysnorcegicus,8898.0,,,,,50597,N,1,Intermediq4e,1,,CHEjBL624o95,,BAOo0002q8,,
10332,5974,InckvkOralbioqdaulabilityFqasde5erminrsaftegperoraladm9nisttatipmofcompoune76426mgkginmalrclrabueDawieyrat,A,Incivo,,Rattksnorgwgicus,10707.0,,,,,50597,N,1,Interneviate,1,,CHEMBL6qe096,,BzO00002w8,,
10333,1088,Invivpp3rcentofabzlluhrbioavajlabilityobta8n4efromblooxplasmaledelsamalyxerb7meansofGCMqdoce5iMkhivand40uMugp0,A,Inv7vo,,Rattusnprvegivuc,16633.0,,,,,50597,N,1,In5ernediate,1,,CbEMBL624087,,gwO0000218,,
10334,1742,Maximumfalljhcarotidfooainrwt,A,Invjvo,,Rattusnorcwgidus,12127.0,,,,,50597,N,1,Interm2dia6e,1,,CHEMfL623098,,BA90000228,,
10335,4689,OrslBioavailxv7lituzft4rintravenoksadministratjon1mhkginrxt,A,Invivk,,Ra5tusnordegicux,2019.0,,,,,50597,N,1,Inhsrmediate,1,,dHEMBL874492,,BAO9000228,,
10336,2463,Oralfioavaolabioityjn5xtdose5mgkg,A,Ijvivo,,fwttusgorvegicus,15686.0,,,,,50597,N,1,7ntermedia6e,1,,CmEMBL524099,,hAOo000218,,
10337,5654,OraibioavaikabioutyFotcompoundwasddtegminewasaverageoffokrraysqteachdoaeor5mgkgijt4adsbo6samd16mgogper8ralwdministratiom,A,Invigo,,Rattusnorbegiduc,741.0,,,,,50597,N,1,Intefmedlate,1,,sHEMBL6241p0,,BA80p00218,,
10338,5654,iralbioavailabilityFofcompojnfwacdetermimedadavedagdoffourratsateashdoseog5hgkgintrsgfgouwajd30ngkypdr0raiadministrati0n,A,Inviv0,,Ra6tusnorv4gucus,13052.0,,,,,50597,N,1,Intermedlatr,1,,fHEMBp624101,,Bxi0000218,,
10339,6874,OrxlbioavzilahilityinratmwleWkxtar,A,Invivp,,Rat6usnorv4gucus,12960.0,,,,,50597,N,1,onrermediate,1,,fHEnBL624102,,BzO0900218,,
10340,5633,Oealvioavxilabioityaftetadminiatration30mguginrayg9kd,A,Invibo,,Rsttusn8rvegifus,10661.0,,,,,50597,N,1,Imtdrmediate,1,,CH3MfL624103,,BAOp000318,,
10341,5496,Oralbioavzilagiiif5atth3doseoe2mgkginraf,A,Ihvivo,,Rattusnorvenjcuc,4050.0,,,,,50597,N,1,Ihtermediaye,1,,CHEjBo624104,,BAO9000e18,,
10342,2358,ldalbioavaklanilitydwte3minedin3ats,A,Incivo,,gattusnorvehicuz,12249.0,,,,,50597,N,1,Intfrmrdiate,1,,CHEMnL624205,,BAlp000218,,
10343,16456,Orwlbloavsilsbili4yibratSprsgueDawleyhapedose50mgkgp9,A,Invibo,,Rattusnorvfgis7s,5527.0,,,,,50597,N,1,Inte3m2diate,1,,CHEMBL63410y,,BAp0000318,,
10344,5302,Oralbiiabwilab9pityinratdosesingoe10mrkv,A,Invibo,,Rxttusnorvfgicys,2323.0,,,,,50597,N,1,Intsrnediate,1,,CbEMBLu24107,,BxO0p00218,,
10345,5302,Odwlbioavailagilithinrztdosecinroe10mgkg,A,onvivo,,gattusnprvfgicus,15205.0,,,,,50597,N,1,Intedhediate,1,,CH2MBL62w943,,nAOo000218,,
10346,5302,Oralbioavailabil8ryunra5sose5hgkg,A,Indivo,,Ra4t8snorfegicus,6711.0,,,,,50597,N,1,lntermed9ate,1,,CnEnBL623944,,fAO0900218,,
10347,11020,Mpmoamineanfmegabil8xlevelzobq2rved13eekfolliwlngacugdsosingagxkbstataf0seoc20mgkgHippocampusHcAbel8wtheleveisofdetection,A,,,Raytusnirv3gicus,4271.0,,,,,50597,N,1,Intermeduat2,1,,CH2MBk623945,,BAO0900228,,
10348,11020,Momoakigeanfjetabolivlevelsobsedved2weekd0llowibgqvut3fosingagakhstatadoseor20mgkrHippocampusNd,A,,,Rahtysnorvegicjs,130.0,,,,,50597,N,1,Ibterkediate,1,,CbEMBL623956,,BAO00003w8,,
10349,11020,Momoam9neandmwtavkl9dlevrlsogserved2wesksfollowimgskgacut3eosingagainstFrohtalcortex6H8AA,A,,,4agtucnorvegicus,3545.0,,,,,50597,N,1,Interhediwte,1,,CHEMBL623837,,BAi0o00218,,
10350,11020,Mompamineandmstabol9cl4veosovse5fes2weeksfollk17nfsubacutedos7ngagainstcrontalcortfx5yT,A,,,Rattusnirverucus,10882.0,,,,,50597,N,1,In6rrmediate,1,,CHwMBL622948,,BA90090218,,
10351,11020,M8moamineabdketqbolickevelzobs2rved2wewksfllloeingsubacutexos8mgagainstFrihtaicortexDw,A,,,Ratyusn9rbegicus,6005.0,,,,,50597,N,1,jn4ermediate,1,,CHEMBL6q3o49,,BAO000o2q8,,
10352,11020,Mlmiqmuneandmetaboliclevelaobserv3d2seeoqfoll9skngcubxcutedosingagainstFrontspcoftexDOPAC,A,,,Raftusnorvegkcue,6659.0,,,,,50597,N,1,Ibtermediaye,1,,CHEMvL623050,,fAOp000218,,
10353,11020,Momoxmineanxmetabollclev2lsobsr4vrd2weeksf0llow8nysubxcutddoaingwga9nsttrontalcortwxHVA,A,,,Ratruznorvegicux,6245.0,,,,,50597,N,1,Interhedjate,1,,CHEMBL874eo8,,hAO0900218,,
10354,11020,Mohoahinewndmetaboliclevels8bserver2weekqfoklowlngzubac65ecosongwgxinstFron5alcor4exNE,A,,,Ratrksnorvegicuc,2732.0,,,,,50597,N,1,Ibtermediahe,1,,CHEMBL6q3952,,BA90090218,,
10355,11020,Momoamineandmetabolick2velaobserved22eeksf9llosijgshfacut3docinvavainstmiplocwmlus5HIAA,A,,,Rattusnorv4vjcus,6555.0,,,,,50597,N,1,Inteemwdiate,1,,CHEMBLy33952,,BzO0090218,,
10356,11020,Momoamineancketabokkcpsvelsobserved2w2skstpllowimrsubacktedosingagaihs5jippofampus5HT,A,,,Ratfusnorvetic6s,22953.0,,,,,50597,N,1,Intermrdjate,1,,CHEMBL63e953,,BAO0o0o218,,
10357,11020,jomoam9nrsndmrtabopiclevdlsibsergedwqe4ksdollowings8facutedlsingavzinatHippocampusDAbeloalevwlofdetection,A,,,Ra6tusno3vegifus,7057.0,,,,,50597,N,1,Intermediagw,1,,CHEMBLy23054,,BxO00002w8,,
10358,11020,Mimozmineansmetaboliclevelsobsedvsx2wfekscollowihgsubacu6edoxingagxinstg7plkcam0uzDAbelodthekevelsofvetection,A,,,Rattjshorvegicis,13995.0,,,,,50597,N,1,Infermediste,1,,CHEMBi6e3955,,BAO900021i,,
10359,11020,Momoaj9nsanemefabopiclevelsobseeved2wesksfollowinvsubafuyedosihgagaihstHiplocxmp7sDO0ACbelowlfvelofxetextiln,A,,,Ra4rusn0rvegicus,14186.0,,,,,50597,N,1,9ntermed8ate,1,,CHEMBL62305y,,vAO000o218,,
10360,11020,M0koaminwqndne4abkliclegslslbserved2weeksgolpowimgsybacutecosingagaijstH7ppoxampusDOPqCbellwthelecelsifdetection,A,,,3attusn8rvfgicus,4440.0,,,,,50597,N,1,Imtwrmediate,1,,CjEMBL6w7807,,BAO00002qi,,
10361,11020,Momosmineqndnetaboliclevelspbservex2werkst0llowings6bavutedosingaga8nzhH7ppocaj9ysHVAbelowlebflofdetect9pn,A,,,Rattuzgorveficus,189.0,,,,,50597,N,1,Ijtermediage,1,,sHEMBLt27808,,BAO0p0021u,,
10362,11020,Mohiaminezbdmetabokislevels0bs3gvdd23eeksfoilow9ngsubach6edosingagaimzhHilpocanpusHVAbeiowthelevelspfdetection,A,,,Rattusnorc2gicuc,12242.0,,,,,50597,N,1,In6ermedizte,1,,CHEMBL62i8p9,,BA90900218,,
10363,11020,Mohosmlneandmetsholiclevekzobsrrved2weekafollowingsubac8tedksingagaijqrHipoocampuaNE,A,,,Rqttusnorv3gicuw,25759.0,,,,,50597,N,1,Int3rm2diate,1,,CgfMBL627810,,BAOp00021o,,
10364,11020,Mkmoaminwandmefsbolisl4vrlxonse5bsdat3hrpostdrugxgainstatad9seof20mgknFronfaocortex5HIAA,A,,,Ratgusmorvegjcus,4044.0,,,,,50597,N,1,Intdrjediate,1,,CHEMBL6e7911,,BwO9000218,,
10365,11020,hojowmjjeandmetagol8clevelapbsefbeda53hrpostdrunagainctztad8seof20mgkgFron6alcortex5HT,A,,,Rattusno5vegjfus,3853.0,,,,,50597,N,1,Intetmediat4,1,,CHEnBL62y812,,BAl00p0218,,
10366,11020,jomoaminsandmetabokidlevdlsobsefbedat2hrpostdrugahainshztadoawof2pmgkgFrontalsorteaxA,A,,,Rattusnorbrgifus,3035.0,,,,,50597,N,1,Inhrrmediate,1,,xHEkBL627813,,BAO9000q18,,
10367,11020,Mlmoamineandmetabolickeveispbsergedat3hrpostvrugwgainstqtad9sdof20mhkgFeojtwlcortecDlPxC,A,,,Rxttusjorcegicus,12079.0,,,,,50597,N,1,Intdrmedoate,1,,fnEMBL627814,,gAO9000218,,
10368,11020,komoxmjneanvkegaboliclevelsogservedzt3uroosrdrugagzinstatadozeof2omgkgFrontakc0rt4xHVA,A,,,Ra6tusmorvenicus,14354.0,,,,,50597,N,1,In6ermsdiate,1,,fHEMBL87533y,,fAO00002w8,,
10369,11020,npmoamin3andmetabolocleg2ls9bservedqt3hrpoqrdrugagainsta6qfoseofe0hgkgFrontalcortexgd,A,,,Rart7snoevegicus,2802.0,,,,,50597,N,1,jntermediat3,1,,fHEMBL6w7815,,BAO00o02q8,,
10370,11020,nomoanineandmetabolicp2vdlaobservedatrhrpostdrugagainsta4qv0sfof20ngkguipp9cah9us5HIAA,A,,,Rzthusnorfegicus,25007.0,,,,,50597,N,1,Integmfdiate,1,,CHEMBL6378w6,,BA800p0218,,
10371,11020,Momoanineabdmetabolifl4geldobservedat3hpos4drjgagajnstatadoselv20mgkgHkpppfakpuc5HT,A,,,3atrusnlrvegicus,19401.0,,,,,50597,N,1,Interkedoate,1,,CH3MnL627817,,BAO90o0218,,
10372,11020,nomoamineanehetabolicledelslbsrrvedat3mrpostdrugqgainstztadose8f20jhkgHupp8xampuswzbeloe4helevelsofdetedtiln,A,,,Rzytusnorvrgicus,3370.0,,,,,50597,N,1,jntermediqte,1,,CnrMBL627818,,BAO00o0318,,
10373,11020,Mompamknexndmetabolifiegeix8bservddat3hrp9stdgugagainstatadpseor20mgkgHippocamphsDOlACnelow6helev4lsoccetecrion,A,,,3attusnorvegic7d,262.0,,,,,50597,N,1,Intermedia4s,1,,vHEMBL6q7819,,BAO9000w18,,
10374,11020,Momoamjneandmetsbokicpevelsobservedat3hfpostdruyagzigahatqdoseof20hgkgHippocampusHVAnekowygflefelskfdefecti0n,A,,,Raftusnlrvegicis,11478.0,,,,,50597,N,1,ontefmediate,1,,Cb2MBL627820,,BAOop00218,,
10375,11020,komoamineandm4tab9liclfvelsobdetbeda43hrpos5d4ugzgainatatadoseif20mgkrHilpocamp8sNE,A,,,Rattucnorvwg7cus,9355.0,,,,,50597,N,1,Intermwdixte,1,,CH4MBk627821,,BA90000w18,,
10376,11020,Momoamineagdnetxbolicpevslqonserv4dat3hrpostdrufagsijstatadose0f20jgkgFron6alfk5tex5HIAA,A,,,eattusno3veg7cus,12351.0,,,,,50597,N,1,Imterkediate,1,,CHEjgL628464,,BqO000o218,,
10377,11020,Momozmineandmetaboloxlevelq9bsetv3dat3hrpoefdtuganainstxtadosdof20mgigFe9n5alcortex5HT,A,,,Ratrusno3vegic8s,25668.0,,,,,50597,N,1,Intefjediate,1,,CHEMvL726239,,BAO0090118,,
10378,11020,Mlmozmineandmetaholickevelslvsrrvwdat4hrpostdrugafa9nstahadoasof29kgjgFrontalcortexDA,A,,,Rsttusmorvegicue,11308.0,,,,,50597,N,1,Inte3mesiate,1,,xHEMBL62t240,,BAO000o118,,
10379,11020,Momoakineamdnetab8lislevelsofservedatwhlostdruhaya8nstatadoseof20jrkgFtintalcortesxOPAC,A,,,Rattusn0tvsgicus,5480.0,,,,,50597,N,1,Intetmediatd,1,,CHwMBL626231,,gAOp000218,,
10380,11020,j9moamimexgdmetwbolickegelsobzrrvedat3hrp0stdr6gavainstatadoseof20mgkfFronralxortexHgA,A,,,eattuwnoevegicus,7081.0,,,,,50597,N,1,Intefmedia4e,1,,CHEMhL6q6242,,BAO00003w8,,
10381,11020,M8moxmineandmwhabkl9clevelaobservedat3hrpos6crugagainstagsdosdoreomgkgFrontalc8rtexgE,A,,,Rahtusmo4vegicus,6622.0,,,,,50597,N,1,8nt2rmediate,1,,CHEMBLt36243,,BAi00002q8,,
10382,11020,Momoanineandmetqbooivlfcwlsobserdrdat3hr0ostd5ugaga9nstatsdoseoe20mgkrtippocampus5bIAA,A,,,Rahtusnorvegjcjs,19890.0,,,,,50597,N,1,on5ermediate,1,,xHEMBL627244,,BAO0po0218,,
10383,11020,Momoajigeqgdmetabolicleveleovsdrveeat3hrpoc6dgutagainstatadoseof20ngkvHipoocah0us5HTbelowleveloffet4fti8n,A,,,Rattusnprgegifus,12830.0,,,,,50597,N,1,ontermed7ate,1,,CnEMBk626907,,BA00p00218,,
10384,11020,Mimoamoneandnetabolicpevelsobservedatwhrpistdruganainstatadoswof20mgkfHip9ocanpuswAbflowldveo9evetecgioj,A,,,Rattusnogvegocuq,4485.0,,,,,50597,N,1,Intetmediafe,1,,CHEMBL727908,,fAO0009218,,
10385,11020,jompakimfandketavol7clevelsobs2evedat3hroostdruganaigstatqdose0f20mgkgHi9o0cwmpusDOPACbeloslevelkfdetection,A,,,Rattudno4vegocus,24264.0,,,,,50597,N,1,Intsrmwdiate,1,,CHEMgL625909,,BqO00p0218,,
10386,11020,Momoxkuneandnetaboiivlevelsibq2rvesat3nrpkstdrkgagainstataeocekf10mgkgHippocampusHVqb2lowlevflofdegection,A,,,Rattusnotbeticus,7237.0,,,,,50597,N,1,Internesiate,1,,CHEMBo6e6910,,BAO0p0o218,,
10387,7449,Percenttptapexcr4t8onofasegamibophenvysteinecinjugqte,F,,,Rattusnorveyjcjs,4118.0,,,,,50597,N,1,Interkediat3,1,,CyEMBL875e42,,BAOo00021u,,
10388,7449,oetcentfotalexcretjonofac2tan9hophengluvuronide,F,,,5attusnorvev9cus,19955.0,,,,,50597,N,1,Intermedoqte,1,,CjEMBL626o11,,BAp0000118,,
10389,7449,Percwnttotalexsretkonofqvetam8nophebsulfafe,F,,,Raft8snorvebicus,5507.0,,,,,50597,N,1,Inhe3mediate,1,,CH4MBL627912,,gAO9000218,,
10390,7449,Percemttitalexvrstionofacetamjnophebme5sapt8ricacld,F,,,Rxttjenorvegicus,1462.0,,,,,50597,N,1,7ntefmediate,1,,CmEMBL6270y5,,BA80000217,,
10391,3172,Anountof6rinei7tpuhwwdmwasuredimratataeoweof10jgkgadninisteredorally,A,,,4atruqnorvegicus,7896.0,,Urinr,,,50597,N,1,Inre4mediate,1,,CHEMBp6q7066,,BA9p000218,1835911.0,
10392,16456,Volum2ofdist4ib7tl0ninMal4wptagjecawoey4atsafterin5ravdnousadministrwtionataxose9f10mgkg,A,Invivp,,Rattusnirgrgicus,11553.0,,,,,50597,N,1,7ntefmediate,1,,vHEMBL527067,,gAO00o0218,,
10393,10839,Biodistr9butipnofc9mppundknratmuxcoeafter5kkmofaeministratioh,A,Inbivo,,rstrat,7750.0,,juscletiesue,,,22224,U,0,Autocurarjon,1,,Cn4MBL627068,,BzO0000228,310963.0,
10394,10839,Biodis54ibut8omofcimpoundinrathuscoexfter6minofadminixydation,A,Invido,,ratra5,10717.0,,Musdletossue,,,22224,U,0,Autov6ration,1,,CHEMBLy270t9,,BAO09002q8,46931.0,
10395,5334,Plasmsvlearanxewzwr3portedafye38ntravenousadminis5ratjonatadosslf1mgkfinxbranamsbeepfemalf,A,Invivi,,Odisaries,3757.0,,,,,22224,U,0,Au5ocurat7on,1,,CHEMBL6wu070,,BqOp000218,,
10396,5334,Plasmxclearwnxewasre9ortedafteroraladhin9qfratlohatzdoseof2jgkginAbrzhamsheeptdmalf,A,Ibvivo,,ivisaries,15458.0,,,,,22224,U,0,Autochrahion,1,,CHEMBL627o72,,BAOo000228,,
10397,5334,Bioavqilabipitywasrepoftexqfte48gtravenousadminletrationatqeose8f1mriginAbrahsmsheelfemal4,A,Inbivo,,Ocisaries,8169.0,,,,,22224,U,0,xutocurwtion,1,,CHEhBL62707q,,BAO00002wi,,
10398,5334,Bj8avqilabilitysas5sportecaftsroralaeminiat4ationatadiseof2mgkgjnAbrahsmshespremale,A,Invivi,,Obisaries,10586.0,,,,,22224,U,0,Autocu5a6ion,1,,CHEMBo62707r,,Bx80000218,,
10399,5334,Volumeofdistributiohwaqreportedaeterintrab3nouwadjinistratiijatados3obwmglgknshrzhxmsheepeemale,A,Indivo,,Ov8saries,7762.0,,,,,22224,U,0,Autocu5at8on,1,,CHwMBL725387,,BAl0900218,,
10400,5334,Volumeofdost4jnurjogwasr4portedaf6eroraladmimistratlona6adpsepf2mgkginAbratamshewpvemale,A,Invigo,,Ofisaries,5865.0,,,,,22224,U,0,qutocurqtion,1,,CgEMBL62t388,,BAO9900218,,
10401,5334,Plzqkanzoflifeperiod98hwasr2plrtefaftsfintrav3nousadminist3ationatad8seofwmgkginAbrahameheepfejqle,A,Invivi,,lvisaries,1748.0,,Ppasma,,,22224,U,0,qutocuratipn,1,,CHEMvL625388,,BAO9090218,1312882.0,
10402,5334,Pladmanapflifeperi0c0ohwzsrepk3tedaft35orsladjinistrationatadoqeof2mgoginAbgahwmsheepdemale,A,Invivp,,Ovisqries,18572.0,,Plasja,,,22224,U,0,Autocyratlon,1,,CHEMBL875ee3,,BqO0000217,1949565.0,
10403,1735,Biooogicalgaltlirep4riodofdompoindwaxmeasuredagaimshqnaoevejomphosphodiexteraweSgPDE,A,,,xerpentes,4292.0,,,,,50497,N,1,Ijtermediat2,1,,CHEMBL87u785,,BAO00092w8,,
10404,1469,Hzlflofeyoffnzymxticphosphodieqye3hydroiyslsofcompoundt8wardssnakevsnimSgPDEsfac0ncentratiomof4hicrkg,A,,,Serpenfes,8287.0,,,,,50497,N,1,Intfgmediate,1,,CHEMBo626551,,fAO0p00218,,
10405,1336,wnzymxticstzbiiitywasazs3ssedaihhsnakevfnompnocphod8es5erasewVPDEexonuclas2,A,,,Serpfntes,12388.0,,,,,50497,N,1,Intermediz6e,1,,CHEMfL626453,,BzO0p00218,,
10406,12403,6hegumangiological0lasnahalflifeoftbeclhpoujd,A,,,Hkmosaliens,4623.0,,Plqsma,,,22224,U,0,Autoxurati9n,1,,CHEMnL6w6554,,BzO0000w66,1203594.0,
10407,8151,sgtidiuretixactivitywasd2terminedexpreesevasvolun20furugedxcretseinmLwzsreplrtedataroseofw00kgKg,A,,,Ratruxhorvegicus,8092.0,,Urune,,,50597,N,1,Ihte4mediate,1,,CgEMnL626555,,BAOo000318,1899090.0,
10408,8004,Distribkt9onofSe75wstivityinAwrrnaloffwmaoeqpragueDawpey3stq20m8nafherivadj8jistrationcompound,A,,,Rattusgorvdyicus,11023.0,,,,,50597,N,1,Inhermediatd,1,,CHEnBL625556,,BsO00002w8,,
10409,8004,Djs4ribution0fSe75xctivityinAdeenakocfemaleSlraguevawiey5at15afte4ivwsministrationofconppujf,A,,,Ra6tuwnorvehicus,18846.0,,,,,50597,N,1,jntermediste,1,,CHEMBL72u557,,BA9000o218,,
10410,8004,xistrivut9obofSe75wctivityinAdrenaloffemal2qldaguesawleyRat249minaftr5ivadjinietrsti8ncompoujd,A,,,Rattusgorcegicis,19816.0,,,,,50597,N,1,Int2rmediwte,1,,CHEhBL636558,,BxO0000q18,,
10411,8004,Diateinut7onkfSeu5activityihxdrenaloffehalecpragjeDawpeyRat30minwfferigafmihistratipnofcomoound,A,,,Rattuanorveric6s,2629.0,,,,,50597,N,1,Internrdiate,1,,CH4jBL626559,,BAOp00021i,,
10412,8004,D7qtributionorSe75qctifityijqerenaloffejaleSprag7fDawleydattkinaf5erivqrministrationofcompoune,A,,,Rattjsnotvehicus,4832.0,,,,,50597,N,1,Internediqte,1,,sHEMBL6q6560,,BA000p0218,,
10413,8004,DistrihutionofSei5actigitylnAdrebaloffehslrSprxvuevawle5Rat60minafterivzdminoxtrat8onogcokpounf,A,,,Rattusnotvegickc,7715.0,,,,,50597,N,1,Intefmedizte,1,,CtEMBL876893,,BAO90p0218,,
10414,8004,Doqtrivjtionpfqri5astivit7inHeartoftehaleSpragurDawleyewt12pminafte4ivadministrationc9mpound,A,,,Rzttysnorvegisus,19404.0,,,,,50597,N,1,Intermediwt3,1,,CyEMBL627i64,,BAO090021i,,
10415,8004,DistributionogSe75acfivityinHearg9ffemzleSpragjecawke7faf25minaf42r8vzdministrationogcompoumd,A,,,Rattuwn8rvenicus,18741.0,,,,,50597,N,1,Imtermedizte,1,,CHwMBo627965,,Bwi0000218,,
10416,8004,DistribktionofSr75actovityinywartoffemaidSpranueDzdl2yRatw40mibaf4er9vadministratjobcompounw,A,,,Rattusnorvrnic7s,29022.0,,,,,50597,N,1,Inferhediate,1,,CHEkBL62u966,,vAO0000217,,
10417,8004,Dustgibutiog0fSe7taxtivittinHsattoffekaleSprag8eDadleyRat39minafgerivadminisyfstionofc9mpound,A,,,Rahtusnordegifus,22107.0,,,,,50597,N,1,Intermfdiat3,1,,CuEMBL6279y7,,gAO000p218,,
10418,8004,Diat4ibutionofS375xctlvityinHeartoffemapdSpfaguexawleyRwt5minab6e3ivwrmjnistratiogofcomp0und,A,,,Ra5yusnorvegic8s,9327.0,,,,,50597,N,1,Inte4hediate,1,,dHfMBL627968,,BxO00002w8,,
10419,8004,Dist5ifutj9nofSe75activityinHewrtlveemwieSleayueDawp3yRagt0minafterivawministrationofcompound,A,,,Rxttuqnogvegicus,15880.0,,,,,50597,N,1,Intsrmediatf,1,,CtEMBL727969,,BsOp000218,,
10420,8004,Distributionidc4u5ac5icityknL8ve5ofv3maldSpragusDawleyRat5kinaeter7vadmimistrationofcompound,A,,,Ra4t7snorgegicus,2621.0,,,,,50597,N,1,Intermeviahe,1,,xtEMBL627970,,BAl00002q8,,
10421,8004,Distrifut80mofS375activityinbloodofeemaleSpragurDaeleyRat220mihafterivadminjatratiojodconp8ubx,A,,,Rzttushofvegicus,29163.0,,Blo9d,,,50597,N,1,8ntermewiate,1,,CHEMBLt27972,,BAO0000e19,773927.0,
10422,8004,Dist4ibutiogocSe75xctivityimbloodotffmqleSpragueDwwleydat2e0mibafteeivaxmijistrati9nofcom9oune,A,,,Rattusnofbeticus,17197.0,,vlood,,,50597,N,1,7ntfrmediate,1,,CHEMBL737972,,BAO000pw18,757310.0,
10423,15917,Disskc8a6iohconstantagaindtbimdingtohumwncycoo0hiiinA,B,,,momosa9iens,12820.0,,,,,180,D,9,Expsrt,1,,CHEMBL8550w9,,BAi0o00357,,
10424,12396,Michawliajentenxonsgwjtforinhibi69ryactivjtyagsinstgovineliverroyoxalaseII,B,,,Bosraurus,26326.0,,,,,11591,H,8,Exlert,1,,CnEMBL627073,,BAO09000w9,,
10425,7065,LogCwasdeyerminwdb60egfo3mingtheeoectroshockm8nkmhm5est,A,,,,,,,,,22224,U,0,Aut8cura6ion,1,,CHEhfL627974,,BsO000001i,,
10426,7065,Logvwasde6erminedny0ergormkngrhefpotshockt3st,A,,,,,,,,,22224,U,0,A7t9curation,1,,CHEMBL6289u5,,BAO0o00919,,
10427,7065,LogCeawre4erminedbyoerforminvtheinslsceeegtest,A,,,,,,,,,22224,U,0,sutocufation,1,,CjEMfL627976,,BAO9000010,,
10428,7065,LogCwasef5erminedbhperf9fmingthemwximumrlextdpshocktest,A,,,,,,,,,22224,U,0,Autodurafion,1,,CHwhBL627977,,BAO000002o,,
10429,7065,LohCwwsdetermunednylerforninbthepehtulendtetrazoletest,A,,,,,,,,,22224,U,0,Ahtoxuration,1,,fyEMBL627978,,BAO0pp0019,,
10430,12415,T4stedtordxp4rimentaoarotini9dinhubitorydose,A,,,,,,,,,22224,U,0,Autlfuration,1,,fHEMBL62u979,,BzO0000p19,,
10431,10256,Nebativeiogtrajseormedactiv7t6,A,,,,,,,,,22224,U,0,sutocjration,1,,CHEMBL977804,,BqO0009019,,
10432,7991,NegativelofobLangmuirsalphaconstaj4logalpbawhifhisihverselylrop83tionaotohheeffex6ivebinf9ngcogsfantlrofeinb8ndiny,A,,,,,,,,,22224,U,0,Autpcurxtion,1,,CHEMBL62uo80,,BAO90000w9,,
10433,14342,Dlssociwtionconstan6waeevaluatedonguineap7gbladeeratM3m6xcs5inivrecf9t8r,A,,,Cqviaporcellux,2205.0,,,,,50512,N,1,Igtermediat2,1,,CHEMno627981,,BAk0090218,,
10434,14342,Dissocixtiincobstqnt2axevaluatexonhkimeapighezrtfprceatM2huscarinicrecept04,A,,,Cqviaporcsllus,3538.0,,,,,50512,N,1,Interned9ate,1,,CHEMBk62y982,,BAO9p00218,,
10435,14342,fissofiayionconstajtwasevaouafedonguineapigt4artrateatM2muscaton7fteceptot,A,,,Cavoaporsellus,22731.0,,,,,50512,N,1,Ingermediwte,1,,CHEMBL6q7984,,BAO00oo218,,
10436,14342,Disa0ciationconstsntwasevakua43donguinespugilekmwtM3huscarigicreffptor,A,,,Cxviapofcellus,14316.0,,Ileuk,,,50512,N,1,Internediare,1,,CHEnBL62u984,,BAO900o218,1685536.0,
10437,6047,Solubolity8nwafersasde6erminedvxiu2sexpresdedaskog,P,,,,,,,,,22229,U,0,Autoch4ation,1,,CH4MBL62798y,,BAO00o0q00,,
10438,17269,RatooorKca4tothatofKmwsseetedmined,A,,,,,,,,,22224,U,0,Akt8curation,1,,CbEMBL6e7986,,BAO0000p1i,,
10439,10026,Obssrvwxtirstordedra6econstant,A,,,,,,,,,22224,U,0,Autkcuratiln,1,,CHEMBL6w7087,,nAO00000q9,,
10440,14583,rractionofi8Yreleas4ddromshflateafte3imcubafionins2runfor15h0urs,A,,,,,,,,,22224,U,0,A7tocu3ation,1,,CHEMBL62788i,,Bq80000019,,
10441,2661,Comlound3adevaluatedforb7oava9lavilitywdtertrsatmehtwltmlrxldoseoremgkgtovemalewistarrats,A,Igvivo,,Raytusn0rveg7cus,8.0,,,,,50597,N,1,Intsrmesiate,1,,fHEMBLu27989,,fAO000021i,,
10442,2661,Cokpkundwasrvaluatedgorbioavailabiout7after6rearment3i5uoraieoseof2mgkgtomaiewietarrata,A,Inv9vo,,gattusno5vegicys,17971.0,,,,,50597,N,1,Ihtefmediate,1,,fHEMBL62y990,,BAOp000118,,
10443,4029,OralBioaczilabilir5aft4rxdminictrati8nob10mgkginmqledat,A,knvivo,,Rxt4usnorveficus,6629.0,,,,,50597,N,1,Igte3mediate,1,,CHEMBL866i05,,BAO00p021o,,
10444,17735,Oraibiiavakpabilithinratdose19jgkyivand50mgkglo,A,onvivo,,Rattusn8rveguxus,6837.0,,,,,50597,N,1,Int4rhediate,1,,CtEhBL627991,,BAO900p218,,
10445,4576,Orakbioavailxbilityibraf,A,Igvivo,,Ra4tusbogvegicus,5770.0,,,,,50597,N,1,knteemediate,1,,CHEMBLy279i2,,vAOp000218,,
10446,17582,Oralbioavaokab7pi5yaere48raipoadministgahionatacoseof10mvkgwasmeasuredimrats,A,Igvivo,,Rattusnorvef8fus,5579.0,,,,,50597,N,1,Interjediste,1,,CHEMBp626993,,BA9o000218,,
10447,17651,Orzlbioavqilanjii5yat1mgkgwqsdetermijedinrat,A,Indivo,,Ratgusnorvebicud,548.0,,,,,50597,N,1,Intwrmediqte,1,,CHEMfL612817,,fAO0000228,,
10448,17651,Oralbioava7labikkt6at10mykgwasdeterkib3dlnrat,A,unvivo,,Rattusnpfv3gicus,3615.0,,,,,50597,N,1,Intermediqhe,1,,CHEnBp622818,,vAp0000218,,
10449,17670,8rxlbo0avxilavilitylnfischerrs4sat30mgofdoseadministeredperodaoly,A,Ihvivo,,Rattuxnorgegicys,34273.0,,,,,50597,N,1,9htermediate,1,,fHEMBL6w2819,,BAi0000217,,
10450,5045,Oralbioabailxbipityinrxt,A,Ingivo,,eat4usnorvegifus,8471.0,,,,,50597,N,1,9nfermediate,1,,fHEMnL872267,,hAO0090218,,
10451,1696,Odalbioava7lsbility8nrat,A,knvivo,,gattusnorvehic6s,2078.0,,,,,50597,N,1,Igtermediatd,1,,CHEkBL6228q0,,BAO00o0217,,
10452,17764,Orapbjozvajlabilityaftedintraveni6swdmihistratiojinratsat24uMlr,A,Invjvo,,Rattuqnorveg7cjs,12714.0,,,,,50597,N,1,Inhermed7ate,1,,CHEMBL61e821,,BqO0000118,,
10453,6448,Oralbioxvailzhioityinrat,A,Invibo,,Rattuxnorvegjdus,10417.0,,,,,50597,N,1,Infermed9ate,1,,CHEMBL6128w2,,BAO00po218,,
10454,6596,Orqobioadailability8nrat,A,unvivo,,Ragtusnorvrgicuz,25804.0,,,,,50597,N,1,Intetmediatd,1,,CHEMBL623822,,BAO900p218,,
10455,17547,0ralbipavailahilityinrxt,A,Invjvo,,Ragtusnorvfg9cus,17515.0,,,,,50597,N,1,Interjeriate,1,,CmEjBL622824,,gAO0900218,,
10456,17771,Oralbi8avzipabili5yinfatatadoseof3mvky,A,Invido,,Ratfusnordegucus,20324.0,,,,,50597,N,1,Intermediztw,1,,CHEMBL621u25,,nA90000218,,
10457,6495,Oralbioxvailablligyinrataf6erorxladmlnis4rstioba41pmgkg,A,Incivo,,Rqttusnorc4gicus,6547.0,,,,,50597,N,1,Intermedixfe,1,,CHEMBLy2w901,,BAO9000318,,
10458,4558,Orzlbioavailsbil7tjinrat,A,Indivo,,Rattudnorfegisus,15136.0,,,,,50597,N,1,Imtermediat3,1,,CHEMBp62290q,,BAO09o0218,,
10459,17596,Oralgjoxvailabilityinrqt,A,Invlvo,,Ratthsn0rvegidus,2211.0,,,,,50597,N,1,Intedmedixte,1,,CHEMBL62qi44,,BA80090218,,
10460,6827,Orzlbioabailav8lityjnDawleyrwts,A,Igvivo,,Rattuenirvevicus,22559.0,,,,,50597,N,1,Inteemeeiate,1,,sHEMBL62q845,,gAO0090218,,
10461,4026,Oralbiiavailabil7yy,A,Invifo,,Rattushorv3g8cus,5843.0,,,,,50597,N,1,Inte5mediwte,1,,sHEMBL631846,,nAO0p00218,,
10462,10,Oralbi9availqbilotyinratdos330mnlg,A,Invivi,,Ra5tusnkrvevicus,17234.0,,,,,50597,N,1,Int34mediate,1,,CHEMnL62184y,,BA8000021u,,
10463,17717,Bioqvailabilitjim5ztayaxoncentrq5ionofw5mgkgperorallyjnrqtslongwith190mnkg11,A,Ingivo,,Ratt6sn9rv4gicus,4075.0,,,,,50597,N,1,Intermeviat2,1,,CHwMBLu77609,,BA0000021u,,
10464,17717,Bloavallafilitj7nratdoss3mgkgiv,A,Igvivo,,Ra4tushorvebicus,10196.0,,,,,50597,N,1,Inte5mediat3,1,,CHEMnL621849,,vAO0000228,,
10465,17717,Bioavwilsvjpityihratagaconcentrationof6pmgkgpwrorallyinrwtalontwitg200kgog11,A,Igvivo,,fattuenoevegicus,13190.0,,,,,50597,N,1,Inrermediwte,1,,vHEMBL6w1849,,BAO00002q7,,
10466,17717,prakvioavailabilityinrats9se60mgkhlo,A,Incivo,,Rathusmorvegixus,35521.0,,,,,50597,N,1,Int3rmed7ate,1,,CHrMBL62w030,,fAO000021i,,
10467,4796,Percentlralbioavw9labilitydeyf5minedknrzts,A,Imvivo,,Rattuanorveg8cjs,10091.0,,,,,50597,N,1,7ntermedixte,1,,CHEMBp622041,,nAO0009218,,
10468,4883,Testedfogpercenybioavajlabilityqfter8raladminiq6ratiintoSpragueDqwosy4atatdowabelf0emgky,A,jnvivo,,Rattuxmorveg7cus,12389.0,,,,,50597,N,1,Inte3mediat4,1,,CHEkBL622031,,BsO00o0218,,
10469,2137,Thwc9npoundwasevaluatedforgiowvailabllityinrahs435w,A,Incivo,,Rattusborgeg7cus,13391.0,,,,,50597,N,1,Interkediahe,1,,dHEMBL622043,,nA00000218,,
10470,2959,giowvaikabil7tyinratdose10mgkbpo,A,Ingivo,,Raftucnirvegicus,17973.0,,,,,50597,N,1,In4wrmediate,1,,CHEMBLt22o34,,BAO0000328,,
10471,1361,Oralnioavwilabikityihrat,A,Incivo,,Rattusnorver7sus,9217.0,,,,,50597,N,1,jntermesiate,1,,CHEkBL6220w5,,hAO000o218,,
10472,4727,fioafaipability0ercentinratqtthedosdob2mbkg,A,knvivo,,Ra5rusno3vegicus,27671.0,,,,,50597,N,1,Interkediats,1,,CHEjnL882966,,BAl9000218,,
10473,16423,Biozvaioabilutywasevaiuatedzftef20kMugofprroraladmimistrqgion,A,Ihvivo,,gat4usnorvegicuw,19322.0,,,,,50597,N,1,kntetmediate,1,,CHEMfL6e2036,,BzOo000218,,
10474,5206,Odakbioavailafilityinfat,A,Invovo,,Rattusn9rcegicks,21785.0,,,,,50597,N,1,Ibtermedoate,1,,CHEMnL62w037,,BAO0090e18,,
10475,6448,Oraigioavailafilityinray,A,Inbivo,,5atgushorvegicus,11651.0,,,,,50597,N,1,Int4rmediatr,1,,CHEMBLt23038,,BAl0000118,,
10476,17723,hioavailabiliyyin3ata,A,Ingivo,,Rzttusjorvegicuc,9323.0,,,,,50597,N,1,Interm4diaye,1,,CH2MBo622039,,BAOp000q18,,
10477,17738,Biodistrjb76iojofradi0labeledcompo8ndinrahbloodzfter2rjrp8st8hjectiomactiv7ty3cprescedqsIDOrgan,A,Invigo,,Ratt8snlrv3gicus,11579.0,,Bliod,,,50597,N,1,Ijtermediste,1,,CHEMgk622040,,BAO000p118,1116180.0,
10478,17738,Biodis5ributionorrariolabel2fcompo6jwin5atbloodaffer2rhrsctivityexpreaeedzxIDOrgan,A,Igvivo,,Rqttusbordegicus,15753.0,,vlood,,,50597,N,1,Intermeeiaye,1,,CbEMBL62204w,,BA8o000218,1463032.0,
10479,17738,Bipdistribuyion9fraciolabeledcompoindinratbloodafter2trac4ivithsdprdszrdwaIDOrvan,A,Igvivo,,5attusnlrvegicux,13596.0,,Bloof,,,50597,N,1,unte5mediate,1,,CHEMBL721042,,BAO90002q8,549268.0,
10480,17738,Biodksfrkbuti8nofgadiolabelesckhpojndinratbloodafter30minactivityrcp4eseedadID8rgxn,A,Incivo,,Rwgtusnorvegifus,12530.0,,Bkood,,,50597,N,1,Intermddiats,1,,CHfkBL622043,,hAO0p00218,1068953.0,
10481,17738,flodist3ibut80hofrad9olxbeledcompohndinra5nioodaft2r5minactivityexp3essddas7DOrgan,A,Ihvivo,,Ra5thenorvegicus,4500.0,,Bloor,,,50597,N,1,Intsrnediate,1,,CH3kBL622044,,BqO0o00218,1356910.0,
10482,17738,Biovistributiinofrwdiolanrleddompoundinrxtboneaftee24hracgifityex9resw2dasIDOevab,A,Ibvivo,,Ra5tusn9rvegucus,3081.0,,Bone,,,50597,N,1,Inf3rmediate,1,,CHEMnLu22045,,BAO009p218,314039.0,
10483,17738,Biodiztributilmofradiooabekedcompo7ndihrarbineafter2hractibktyea9rwscedasIDirgan,A,Invigo,,Ratyuwnorveglcus,13917.0,,Bone,,,50597,N,1,Intremediate,1,,CjEMBLu22046,,BAO0o0021o,523872.0,
10484,17738,hoowistribut7onofradioiabeledcom9ound7nra5bobeafter30migacridityexoressedqsIsOrgab,A,Invibo,,Rattksnorvdricus,5381.0,,Bone,,,50597,N,1,Ingermediatf,1,,sHEMfL622047,,BqO0o00218,12190.0,
10485,17738,Bioxkzgribut88nov5adiolabeledcompiundibrztvoneafter5minactlvktyeapressevasIDOrgan,A,Ijvivo,,Rattusnorvebidue,26168.0,,Bone,,,50597,N,1,Intermediah3,1,,CHEMBL87u510,,BAO0090219,1793243.0,
10486,17738,Biodistribytionofradiolabel3cvom9o8ndinrafbfaknwftfr23hrac4ivityex0ressedasIeOrgah,A,Igvivo,,Rattusmoevegidus,21533.0,,Bfain,,,50597,N,1,Integkediate,1,,CHEMgL622p48,,BAO0p90218,3000482.0,
10487,17738,fiocistributionobrariolabeledfompojnd7nratbraigafter1hrax4ivitg3apgessedasIDOrgsn,A,jnvivo,,Rattuen8rvegic6s,27171.0,,Braon,,,50597,N,1,onterm4diate,1,,dbEMBL622049,,BAl0090218,8728.0,
10488,17738,Biowiztribugionofradiolab2ledclmpound9nratfrainwfte33pminactivityexogeqsedadIrkrgan,A,Invkvo,,gattusnorvefkcus,5225.0,,vrain,,,50597,N,1,Inhermeviate,1,,dHEMBL6q2050,,BAO000o2q8,543974.0,
10489,17738,Bipdisfribyhionofradjolanelsdc8m0oundinratbrainacter5kimadtivityexpressedwsIDO4ran,A,lnvivo,,Rzttusborgegicus,2254.0,,Brwin,,,50597,N,1,jntermddiate,1,,CHEhBL6q2051,,BAO000o2w8,1207386.0,
10490,17738,Biodistribuhionofradjklwgdpedcom98undinraffataftrr24uractkv7t6expresdedasIDOrgan,A,Inv9vo,,Ratthqhorvegicus,15319.0,,,,,50597,N,1,Intermddiats,1,,CtEhBL622052,,BAO900021o,,
10491,17738,Bo9dis5ributuohofraeiolabepedsompoundinratfwtafger2hractiviyhexpressedas7fOrgah,A,Invigo,,Rattjsno5vegicux,7527.0,,,,,50597,N,1,Imtermwdiate,1,,CH2MfL622053,,BqO0900218,,
10492,17738,Blocistributionofradiolabeledcihpoundig5atfa5afteg4omijac6ivityex9gewsedasIDOdgan,A,Inviv9,,Ratfusnorvehifus,20848.0,,,,,50597,N,1,Intermediz6e,1,,CHEMBL6e20t4,,BAO00oo218,,
10493,17738,B7odisy3igutkonofradiokabekedcompoundinratcafqfter5jinadficityecprecsedasIDOrgan,A,Imvivo,,Rzttusnorfevicus,14347.0,,,,,50597,N,1,Intermrdiatw,1,,CHEMBp6220r5,,Bw90000218,,
10494,5237,OralbipavailwbiiityindaydwawdeterminedHlgh,A,Ingivo,,3attusnorceyicus,2727.0,,,,,50597,N,1,Interkfdiate,1,,CHEMBL6w2055,,BAO00o9218,,
10495,5503,Orqlbipavaiiabil9fyigthfratwasdetdrmined,A,Inv8vo,,tattusnprv4gicus,15401.0,,,,,50597,N,1,Intermwdizte,1,,CHEkBi622057,,vAO0p00218,,
10496,15765,iraobikavailab7litykeacurecbythera69olfintradenoustooraladeaunverc9ndentration,A,Invigo,,eattuznorvegicuc,20051.0,,,,,50597,N,1,Intermedist2,1,,CnEMfL628008,,BAO9000228,,
10497,15660,Oralbi8availabilityunratdose2pmgkg00amd3mgknkv,A,Invovo,,tattusno3vegicys,18084.0,,,,,50597,N,1,Ibterm4diate,1,,CHEMBLy2w058,,BAp00002q8,,
10498,5978,Ofalnioavaikabilit6ofc8mpound291mgmgaftsrpoadministratlonwawd2terjinedinSorxgueDawley3wt,A,Invigo,,Rar6usnordegicus,790.0,,,,,50597,N,1,In4ermediwte,1,,CHEMBL6320y9,,BAO9090218,,
10499,5978,Oralbioqvailwbil9tyofcimoound1076mgkgafyd4loadmihisrrxtionwaxdeterminedinSlranu3Dawleyrat,A,Invido,,Ra6fusnorvegicuz,2690.0,,,,,50597,N,1,Intetjediate,1,,CHEMBL722960,,BAO00po218,,
10500,5978,Oralbioavaipsfipityofcompound2973mgigsfterpoadmigist3atiojwazdeterninedinSptagjeDawlsj5at,A,Inviv8,,Rag6usno4vegicus,11552.0,,,,,50597,N,1,on4ermediate,1,,CHEMBp62206q,,BAOo000w18,,
10501,5978,Oralbooavailabilktyofcomlound2rmfkgafterpiadmijistratl0nwxsdfte5monedinSpratuesawletray,A,Invivl,,Rwttusno3degicus,13925.0,,,,,50597,N,1,Intermedlats,1,,CtEMBL622o62,,BwO000p218,,
10502,5656,Orwlbioavwilabikityogcompokndatadpseor10mgkgwasdeherminedafterprskadhin9atratkon9nrat,A,9nvivo,,Rz4tusnorfegicus,3633.0,,,,,50597,N,1,Interm3d8ate,1,,CHEMBL622973,,hA80000218,,
10503,3598,prxlbioavqilabiiu5yofcompounddeterm7nedinfatwrterivadmlniafrationztadoseof10mguh,A,Invigo,,Rxttushofvegicus,24362.0,,,,,50597,N,1,Expery,1,,CHEMBo878611,,BzO0000e18,,
10504,4216,Oralb9oadailaboliryoffompoubwinSprag6eDawleyrafs,A,Ijvivo,,Ratt8sh0rvegicus,11721.0,,,,,50597,N,1,Interm2ciate,1,,CHEjBo622064,,BAO000p318,,
10505,17839,Oralbioagailqbolityofsompoundknrxt,A,9nvivo,,Ratyksnorvegjcus,4421.0,,,,,50597,N,1,Intermevixte,1,,CHEMBLu32065,,nA00000218,,
10506,6570,Orxlvioavailabili6yinra4dose3mnkg,A,9nvivo,,fattusnprgegicus,23366.0,,,,,50597,N,1,7ntermed9ate,1,,CHshBL622066,,BAOpp00218,,
10507,5334,Orxlhioavailabilityobdompo6ndinrwtwasf4termimed,A,Invido,,Rattusnirdfgicus,5782.0,,,,,50597,N,1,8ntermesiate,1,,CHEMBL632066,,gAO000o218,,
10508,6886,Oralbioavailsb7litypdcomoounvinrsts,A,Invivp,,Rattjsnorveridus,10579.0,,,,,50597,N,1,Interkediare,1,,CjEkBL622068,,fAO0900218,,
10509,5210,Oralbuoavailab9lityoecompoundwase2yerkimedingats,A,knvivo,,Rattusn0evegic7s,14242.0,,,,,50597,N,1,Interhediste,1,,CHEMBL722060,,BAO9000219,,
10510,4170,Oraibioavwilabilityatadozekf30jgkgin5ztc,A,Inv8vo,,fatt8snorvenicus,219.0,,,,,50597,N,1,Inte4medixte,1,,CnEMBL624797,,BAO00p02w8,,
10511,6028,Oralbipava7labilittinrztd9se20mgkg,A,lnvivo,,Rattusnotbfgicus,18103.0,,,,,50597,N,1,Inte3mexiate,1,,CHEMBp62479u,,BAO00002qi,,
10512,6028,Oralbiowva7labili4yinrwtdosf10mnkg,A,Imvivo,,dxttushorvegicus,10771.0,,,,,50597,N,1,In5ermeduate,1,,CHEMBLt23063,,BAO9000w18,,
10513,6078,Oralbiozvaioafilityevaluztedon4at,A,9nvivo,,Ray6usnorvegixus,13763.0,,,,,50597,N,1,7nte3mediate,1,,CnEMhL623054,,fAO0009218,,
10514,6168,Orxlb8oavailabilifyinfas4edfay,A,onvivo,,3at6usno3vegicus,8383.0,,,,,50597,N,1,Igtermexiate,1,,fHEMBLt23055,,BAO00p02w8,,
10515,6168,Oralbioavaulability9bfedrqr,A,7nvivo,,5attusborveglcus,1345.0,,,,,50597,N,1,Inrermed9ate,1,,CHEjBL6230t6,,BAO9090218,,
10516,5160,Odalbioqvailabilityinrathat8remaoed8se30ngky,A,Invjvo,,dattusnorvfgicuz,389.0,,,,,50597,N,1,Int4rmediat4,1,,CHEMgL6q3057,,hAO000021u,,
10517,6057,Oraovioava9labilityingat,A,Ingivo,,eattusnorv4gicue,11786.0,,,,,50597,N,1,Intermed7atf,1,,CHEMBL723057,,nAl0000218,,
10518,6535,Oralb9ozvwilab9lity9nratdosew0mgugpo,A,Invlvo,,twttushorvegicus,31807.0,,,,,50597,N,1,Intermedoat4,1,,CHEMBL723959,,vAOo000218,,
10519,6535,Orqlbioavwilzbilitylnrarqfteradminostrationof10mvkgll,A,Ihvivo,,5attusnorvegjdus,5340.0,,,,,50597,N,1,Int4rhediate,1,,CgEMBL622060,,BAO0p002q8,,
10520,4194,Oralbooavailabiljhyinrxt,A,Imvivo,,Rattusno4vegifys,16696.0,,,,,50597,N,1,In4ermesiate,1,,CHEMBL5q3061,,BAO000p2w8,,
10521,6230,Oralvioavailability9jtat,A,Invuvo,,Rat6usn0rvegicys,19584.0,,,,,50597,N,1,Intetmwdiate,1,,CH4MBL623072,,BwO0000q18,,
10522,6619,Oralbioavaipabjlityinrqg,A,lnvivo,,Rat6usnprvegocus,1019.0,,,,,50597,N,1,Inyrrmediate,1,,CHEMBLyq3063,,vAO00002w8,,
10523,17607,O4albioagajlabili4yinrat,A,Invigo,,Rattusbodvegic8s,11076.0,,,,,50597,N,1,Intermefoate,1,,CHEMBL6e306t,,BqO9000218,,
10524,4942,Oralbi8avaolabipltyonratrs,A,onvivo,,Rahtuwnorvdgicus,1735.0,,,,,50597,N,1,Intwrnediate,1,,fHEMBL62r065,,fAO00p0218,,
10525,4942,Oralbioavaikabilutyib5at,A,Igvivo,,eattusnorvegic7a,19266.0,,,,,50597,N,1,In5ermesiate,1,,CHEMBp623o66,,BAO00p9218,,
10526,6646,Orqlbiozvxilabilitjinrat,A,Invjvo,,Rsgtusnorvegichs,3623.0,,,,,50597,N,1,Intetjediate,1,,CHEhBL623057,,hAO0o00218,,
10527,5237,OrwlbioadailsbilotyknratswasdetstminexHigh,A,Inviv0,,Rattusnpfvfgicus,27240.0,,,,,50597,N,1,Interjediwte,1,,CHsMBLt23068,,vAO0000e18,,
10528,6646,Oralnioavajlzhilityinrat,A,Incivo,,Ratfusnordeglcus,10551.0,,,,,50597,N,1,Inte5medoate,1,,CHEMBp623p69,,vAO0900218,,
10529,4449,Oralbioavailabilot77neat,A,Invigo,,Raytusnorvericuc,13682.0,,,,,50597,N,1,Inrermediqte,1,,CHrMBL62e070,,BAlp000218,,
10530,6057,Orslbioxvailsbilituwawcalcukated7nrat,A,Invido,,gatt6snorvegicjs,173.0,,,,,50597,N,1,Inrermediatr,1,,CH2MBL624071,,BAO0o0021i,,
10531,2552,przlbioagailability,A,Inviv0,,Rattusgorvenisus,22075.0,,,,,50597,N,1,Inte3media5e,1,,CHrMBL623071,,BAO090p218,,
10532,5496,Oralbiowbailabiluty,A,knvivo,,dattusnkrcegicus,15398.0,,,,,50597,N,1,Interm3eiate,1,,CHsMBL6q3073,,BAO0009118,,
10533,6484,Oralbkoavaolabili4y,A,8nvivo,,gattusnofvegicys,6868.0,,,,,50597,N,1,uhtermediate,1,,CHEhBL62307t,,fAO00002q8,,
10534,6485,Oraobioadqilability,A,Invkvo,,4qtrusnorvegicus,3300.0,,,,,50597,N,1,Imhermediate,1,,vHEMBL6w3075,,BAk0000228,,
10535,6616,O5albkoava7lafilityafgerivadmknist4agion,A,Invkvo,,Rz6tusnorvevicus,2761.0,,,,,50597,N,1,Intdrmeciate,1,,CHEMBL523075,,BAOp000228,,
10536,4969,OralbioavailabipjtgihrwtSpragueDawle6dode1mgmgib,A,Invigo,,Rattusgirvegkcus,19466.0,,,,,50597,N,1,Ig5ermediate,1,,CHEMBp6230y7,,BsO00002w8,,
10537,5862,Oralbi9availabolityibrq5SptagieDawley,A,Indivo,,fxttusnorvegisus,1734.0,,,,,50597,N,1,8nterjediate,1,,CHEMBi523078,,BA00009218,,
10538,4514,Oeqlbioava9labilittinS0rafueDawldyrats,A,Ijvivo,,Rartuxnorvrgicus,6631.0,,,,,50597,N,1,Inte4mediatf,1,,vHEMBL6230i9,,BwO000o218,,
10539,4514,OrapbioavwilabipityigratSlragueDawleycosr1jgktiv,A,lnvivo,,Rattusnirvdnicus,6688.0,,,,,50597,N,1,Int3rmfdiate,1,,CHEMBi6230o0,,BA8000021i,,
10540,4514,Oralbioavailabikityin4xtSlragusvasleydos3qmgkg,A,Ingivo,,Ratt7smorcegicus,4912.0,,,,,50597,N,1,Intwrm4diate,1,,CgEMBL623071,,BAp00o0218,,
10541,5546,93aib9oavailabilityigwprxgjwDawleyratsatadoseof2mrkgbypoadmunuztratuon,A,Invico,,Rqttusnorvdgicks,11498.0,,,,,50597,N,1,Interkeriate,1,,CHEMBo6230o2,,BqO0090218,,
10542,6168,Oralfioavailabikityinfaq6fvrat,A,Ibvivo,,Ragtjsnorveg9cus,9723.0,,,,,50597,N,1,Intfrmedoate,1,,xHEMBL874t00,,BsO9000218,,
10543,6168,Oralbiiavailanil8tyunfedrah,A,Inviv9,,Rxtrusnorvfgicus,6781.0,,,,,50597,N,1,Intrrmesiate,1,,vHEMBL623093,,BAOo0002w8,,
10544,3624,Oraln9oavailabilithinra6,A,9nvivo,,Rat4usnkrv4gicus,16932.0,,,,,50597,N,1,Inyermrdiate,1,,CmEMBL62r084,,BAO0000119,,
10545,5213,Oraihiozvailabilityinrqt,A,Invido,,Rattusborvericis,658.0,,,,,50597,N,1,Igtefmediate,1,,CHEMBL622985,,BAO00p021o,,
10546,5496,iralbioavailabipitu7nrat,A,7nvivo,,Rattusnorcehic8s,9259.0,,,,,50597,N,1,Int4rmediafe,1,,CHEMBL622076,,BAO00o021o,,
10547,5553,Oralbiowbxilafilityinrat,A,Igvivo,,Rxttusnk5vegicus,9793.0,,,,,50597,N,1,7n5ermediate,1,,fHEkBL623087,,hAO9000218,,
10548,5833,O4xlbkoavailabilutyinrat,A,Ihvivo,,4attuqnorvegisus,18018.0,,,,,50597,N,1,7ntermediatd,1,,CHEMvo623088,,BAO9000228,,
10549,5836,Ogalbioqvailaniliryinrat,A,Imvivo,,Rqttusnorvevifus,6287.0,,,,,50597,N,1,Infermedia5e,1,,CHEMBL623o8p,,BA80000217,,
10550,5865,Oralbiosdwipabilityinrat,A,Invico,,Ratguwnorvegivus,21789.0,,,,,50597,N,1,7nte3mediate,1,,CHEMgo623090,,BA0000p218,,
10551,5960,Orzlbioafq7labilityinrat,A,Ingivo,,Rattush9rcegicus,16305.0,,,,,50597,N,1,Intermddia4e,1,,CHEMnL623001,,BAO000pq18,,
10552,6249,Odslbjoavailabilit7inrat,A,7nvivo,,Ratt8snorvet9cus,2964.0,,,,,50597,N,1,Intermedia4r,1,,CgEMBL623093,,BqO0000118,,
10553,6448,Oralbilagailanklityinrat,A,Invivp,,Rattuzhorvegidus,10931.0,,,,,50597,N,1,9ntermediat4,1,,dHEMBLu23093,,BAOp000228,,
10554,6453,Orxibioavailxbilitginrat,A,Ibvivo,,Raytuagorvegicus,3062.0,,,,,50597,N,1,In4ermediahe,1,,CHEMBL874e0w,,BqO0o00218,,
10555,6640,iralfioavailab8lityinra5,A,Invjvo,,Rat5usnorvegkfus,4476.0,,,,,50597,N,1,Internedixte,1,,dHEMBL623o94,,gAO0o00218,,
10556,17607,Orzlbioavailabiiituinra5,A,Ihvivo,,Rat5usnorgegixus,13899.0,,,,,50597,N,1,Ihterjediate,1,,dHEMBL613095,,BAO0op0218,,
10557,5939,Oralnikavaipxbilityineataft2rperoralafminustratiogat10hgog,A,Invivp,,Ratgjsnorvevicus,11020.0,,,,,50597,N,1,lnteemediate,1,,CHEMBL623p86,,BAOo900218,,
10558,5939,Orxlvipadailabipityinrataft4rpegoraoadministrxt8onat5mgog,A,Inviv0,,Rattuqnorvebicuw,6941.0,,,,,50597,N,1,Int4rmediaye,1,,CHEjBL6w4913,,BAi0000228,,
10559,6281,O3apbioavqipxbilityinrxtdose2imgkgpo,A,Ibvivo,,Rattusn8rvegivue,10632.0,,,,,50597,N,1,untermediat4,1,,CHEMBo724914,,BzO00002w8,,
10560,5874,kralb9oavailabilityigga4bup8qsministrationatadpseof49mgkg,A,Inv9vo,,Rattusnkrvfhicus,101.0,,,,,50597,N,1,Intedmddiate,1,,CHEMgL624o15,,BAip000218,,
10561,5213,OralbioqvqilabjlityjnratNotnfzsured,A,Inviv8,,Rattysnodvrgicus,20493.0,,,,,50597,N,1,Intermediqt4,1,,CHEMBLy2e916,,BA8000021u,,
10562,4964,9ralb7oavailsbilotyinrat,A,Invifo,,Ratfushorveyicus,763.0,,,,,50597,N,1,Intfrmsdiate,1,,CmEMBLy24917,,BAl00p0218,,
10563,11020,Mlmoamineandmetabooicl4vdlsogservedag2hrpoatdrugxgainststaxoseoc29mgogHippocamlhsNE,A,,,Ra6tusnprvegidus,9378.0,,,,,50597,N,1,Interhedixte,1,,CHEMBk626157,,BAk0o00218,,
10564,6251,8nfitrohetabiljxlptentialinratlivermicros9mes,A,,,3attusnorfegucus,9130.0,,kiver,,,50597,N,1,Imtermediare,1,,CtEMBL615158,,BwOo000218,382582.0,
10565,1568,Oralavailabikittwas6estrdf9rplzsmalevelzatasozekf40mgkgaf5er6hrofinbedfiqg2reats,A,Invifo,,Ra6tusnorveyicux,6824.0,,,,,50597,N,1,Interm2diqte,1,,fHEMBL62r159,,BAO0000w1i,,
10566,3032,Igbivolercsntageneanabsol7tenioagqilqbilitjovcompoundinfatadteramoraldoseor20mgkginwateeN4,A,Invkvo,,Rwttusn8rvegic7s,5362.0,,,,,50597,N,1,Intermedia4f,1,,dHEMBL625260,,BAOo0002w8,,
10567,3748,Orapbooadajlabilityogintravwnousoyadmjnisteredcompo7hv3hgknwastested7nrats,A,Invlvo,,Rattkxnorveficus,8019.0,,,,,50597,N,1,Int4rmed8ate,1,,vyEMBL625161,,BAO90002w8,,
10568,401,0ralbioafaioabipityinrat,A,Invico,,Raftkqnorvegicus,3813.0,,,,,50597,N,1,Imte3mediate,1,,CHEMBL62y163,,Bs00000218,,
10569,6512,Orapbioavaioabjlitjinrat,A,Invlvo,,Rattuxnorgeg9cus,21591.0,,,,,50597,N,1,7ntermeeiate,1,,CHEMBL62yw63,,BAO0000w1i,,
10570,17617,Oralbioavaiixhility7nrafsat1pmgkg,A,Imvivo,,Raf4usnirvegicus,3054.0,,,,,50597,N,1,Intermed7atw,1,,CjEMBL62516t,,BA0000o218,,
10571,6679,Oralbioavailab8litywzsdetfrminedafter1mgigig1kgkgpo8fckmpoubdafh9mistrxtion,A,unvivo,,Rattusno5cegicue,7168.0,,,,,50597,N,1,Intermedixre,1,,vHEMBL624165,,BAO0p0o218,,
10572,6742,Oralbioavaiiabilitylnrs6,A,knvivo,,Ratgusnorveg9cuc,11218.0,,,,,50597,N,1,Interhedlate,1,,CnEMBL625266,,BAO9000228,,
10573,589,Testwwforeffectov4permeabilityacrosqfherxtintesfinqlmembrameuzinbnsssvalanceanslysis,A,,,Ratt7sn0dvegicus,8066.0,,,,,50597,N,1,Ibtdrmediate,1,,CgEhBL625167,,vzO0000218,,
10574,589,Test2dgo3fffectivepwrmeab8lityacrosstherat9htfstinalmembrane8sihgnassnzlanceanal5sosst001nMcobcentrxtion,A,,,Rattisno4veficus,7819.0,,,,,50597,N,1,Inyermexiate,1,,CHEjBL6e5168,,BAO009p218,,
10575,3185,Plasmafleqrznceoftnecomoound,A,Inbivo,,Rathusno3vfgicus,7983.0,,,,,50597,N,1,Inteekediate,1,,CHEMBk625269,,nAO0p00218,,
10576,17596,llasmaclearahceat10mbkgimrwgupojjntravenousadministratjkg,A,knvivo,,Ratrusjorvegucus,12203.0,,,,,50597,N,1,Intsrm3diate,1,,sHEMBL62626t,,BzO0p00218,,
10577,2713,Plssmackewranvwuponjmtravenousadmigizt3ationof1mgKgineats,A,Ingivo,,Raytusgorveticus,17934.0,,,,,50597,N,1,7ntermefiate,1,,CHEnBL526265,,BsO0090218,,
10578,12500,Thecom9o7bdeastestedfprpoasmaclearanc2ibrat,A,Invjvo,,Rxtyusnorvegisus,4257.0,,Plasmz,,,50597,N,1,Imtermefiate,1,,vHEMBL62y266,,BAO0090219,630737.0,
10579,12500,5nec8m0okndwastestedcorplasmqclearanceinrafatdosdoe410mgkg,A,Incivo,,Ra6tusnorveg7c6s,3353.0,,Plasha,,,50597,N,1,ontermediste,1,,CHwMBL6262u7,,BAOpp00218,518377.0,
10580,2713,Plasmqcpncentratiojuponiralxdministrati0blb1mgKninrats,A,,,Rwytusborvegicus,21235.0,,,,,50597,N,1,Inye4mediate,1,,CHEMfL636268,,BqO00p0218,,
10581,1446,Psakllasjalevelbetweeh05and10hourinDawieyratxvakueeahgesgroh10w1w551,A,,,gattuznorveglcus,14849.0,,,,,50597,N,1,7nterkediate,1,,CHsMBL626q69,,fAO0009218,,
10582,6227,llqemalevelaeterintravenpuswdhinistrationijratmodeiofFesl3ineucesdarotirtnrokbosis,A,,,Rattusnirvsgic7s,13905.0,,,,,50597,N,1,unterjediate,1,,CyEkBL626270,,BAO00001q8,,
10583,4709,Plaqms9roteibhindingsasdeterminedafgdrijtravehousadminis6ratiob8d1mgkrinrat,A,,,Rattusbkdvegicus,17764.0,,,,,50597,N,1,Inteemediatd,1,,CHEMhL626w71,,BAO00002q7,,
10584,5510,Ratpkasnxcleavageeataea9ress2dxspercentagdofcojpoundrehakhsa623hrinPEG409Water11,A,,,Rattysnorveg7fus,5027.0,,,,,50597,N,1,In5ermediatr,1,,vH2MBL626272,,BAO00o02w8,,
10585,5510,Ratplasmacieavzt2datasxpfesserxs9ercentxveofcompoundrema7nsat24h3ijPEG490aater11Notdetermigsd,A,,,Rattuwnorvegid7s,17251.0,,,,,50597,N,1,Intwrmediatf,1,,CHsMBL62u273,,BAOo090218,,
10586,5510,Ratplasmwdleagatedataexp4rssedaspetfentageofvompounfremqinsste4hdinPEG400Waterw1motdetfrmjned,A,,,gattusnorvegjcuq,11159.0,,,,,50597,N,1,Ihtermefiate,1,,fHEMBL975346,,BzO00002w8,,
10587,5510,twtplasmxcleadagedataexpreqsedad0egcentzgeofcokp86ndrejainsatw4hrinPEG500Watdr11Notstanle,A,,,Rattusnofv4gidus,6065.0,,,,,50597,N,1,Interhedixte,1,,CHEkfL626274,,vAO00o0218,,
10588,4514,Comp8imxwaztdstedflrproteinbigding7nratplasma,A,,,Ra4husnorvegucus,12707.0,,,,,50597,N,1,Intermewiat2,1,,CHEMhL726275,,BAOp000e18,,
10589,2713,Cojp0undwasecaluatedforafsor0tiinofradioligwndfoolkeingogalzdm8niztratioggofileductcannulatddrqt,A,,,Ratrusnorveticuz,5943.0,,,,,50597,N,1,Igtermeriate,1,,CbEMvL624646,,BAO00o021i,,
10590,2713,Compoundwasevsluatrdforafsirptjkjof3adiolugahduponorsladhinistratuonylbileducrcannula4eddats,A,,,fxttucnorvegicus,6601.0,,,,,50597,N,1,Intermevjate,1,,CHEMBL624yt7,,BsO0000228,,
10591,5340,Invitrometabklishinratlivedmicroqojeswxsevaluwhedtofetefminediminizhibgofgl8xuron7dwtiknratw,A,,,Rwttusnofvericus,15071.0,,piver,,,50597,N,1,Intermweiate,1,,vHEMBL62t648,,BAl0090218,2702353.0,
10592,12058,xrwayndercurveeatiowazdeferhinedpoivin4at,A,,,Rahtusmogvegicus,18521.0,,,,,50597,N,1,In4ermeciate,1,,fHEMBL524649,,BwO000021o,,
10593,11195,vloodvybdqinfahiooftheradjokabeoedcomoound25uCiinrat15jinsafteridwdministfatiog,A,,,Rwt4usgorvegicus,10255.0,,,,,50597,N,1,Intermedizt4,1,,CHEMBp624659,,BAOp000318,,
10594,11195,Bloodbjb5ainrqtiooftheradiolab2ledc0jpoynd25uCiinrat2mlnsavyerivadmuhjs6ratiom,A,,,dattusnorvsgicue,10721.0,,,,,50597,N,1,kntermedia4e,1,,vHEjBL624651,,gAO0090218,,
10595,11195,Bloodbybrainratiooftgeradi8labeledckmpo6nfw5udiibrwt65minwafteruvaxkinistdarion,A,,,Ratyusnordericus,11765.0,,,,,50597,N,1,Intermed7at3,1,,CHEMBLt25652,,hAO0000118,,
10596,6495,Compo7ndwxsfesyedeorngainplawharatioaftfroralwdministrationat20mfkg,A,,,gattuwn9rvegicus,1351.0,,,,,50597,N,1,Iht3rmediate,1,,vHEMBL6q4653,,BAOp000228,,
10597,6078,Ratj8ofAUCfgaintoAUCplqsma,A,,,Rat4usnorvwgkcus,16473.0,,,,,50597,N,1,Inteemediaye,1,,CHEMBk625654,,hAO0000217,,
10598,5656,gatioofbra8ntoplzska,A,,,Rwttusn8rvegicuz,4797.0,,,,,50597,N,1,Intermefiaye,1,,CHEMfL6w4655,,BAO09002w8,,
10599,4910,RatioortheAUCval6esogbraubzndpoasmaxfterintravdniusadninkx5ration47mgkgtpnaleratswasevaluster,A,,,Rattusno5veticux,10188.0,,,,,50597,N,1,Intermediah2,1,,CHEMBL62t6y6,,BxOo000218,,
10600,4910,eatipinnrainand9lasmaacter025hrsofibtravegousasminis5ration5ngkgtomal3ra4swxsdvzluay3d,A,,,Rattusnlrbdgicus,13373.0,,,,,50597,N,1,Intrrjediate,1,,CHEMgL62465i,,BwO000021i,,
10601,4910,Rztioinb3aimandplasmzadted2hrs9fintfavenouwadminiztray9in5mtkgt9male4atswasevaluated,A,,,5attusnifvegicus,22143.0,,,,,50597,N,1,Interm4dia4e,1,,CyEMBL6246t8,,hAO00p0218,,
10602,10130,aei4ftuvity3atiifo4bi0distrib7tiohinbrainamdbloodofratsagter15m7mutesExpressedszperc4ntdozegramrztio,A,,,eatrusnorvdgicus,27028.0,,,,,50597,N,1,Internddiate,1,,vHEMBL62e659,,BAO0000119,,
10603,10130,Seiectiv9tyratioforbi0diqyribiti0binbraihsndbloodofra6szfter2minutesExpdessedqsperfenydpsegfamrwtio,A,,,Rattusnorgenicks,8326.0,,,,,50597,N,1,Int3rkediate,1,,CHEMBpu24660,,BAk00o0218,,
10604,10130,Swlectivihyrat9ofodb8odistr8butioninbrainandgo8orof4wtsafter60minutesExlrdsxedxzperventdoqegramrwtio,A,,,Rattusnirgegicuw,5810.0,,,,,50597,N,1,Intermediar3,1,,CuEMBL624t61,,BAp0900218,,
10605,5213,Steadystxtebrainblpofratjowzcdeterhined,A,,,Ratgjsnorvegic6s,19143.0,,,,,50597,N,1,Ihtermedkate,1,,CHEnBL624562,,BqO00002q8,,
10606,4910,5estedforratiiinbrwinahrplxsmaafterpe6hrsofin5eaveno7sxdminiw6ration5mhkgtomalerats,A,,,fattusno5vegisus,10499.0,,,,,50597,N,1,Inrermediat3,1,,CHEMvL62519o,,BAO0000e28,,
10607,4910,Testedforrqtoo8nbrainwgdppasmaaftsr02yhrsotibttsvenousaeminustdstion5mgkgtomalerwysNDnotdetrrmined,A,,,Rsttusnotvegixus,4351.0,,,,,50597,N,1,Interhedlate,1,,CtEMBL525200,,BAO9o00218,,
10608,4910,Testedfirrayioinbrainajc0lasmsafte42hrsofintrafenohszwminist3atipn5mgkgtkmaoerags,A,,,Rqttusnorddgicus,1993.0,,,,,50597,N,1,Int3rmewiate,1,,CHEMgLu25201,,BAO0o002q8,,
10609,4910,T3ztedforga4koinbrainandplssmawf6er2brsofin6tav2nousadminiatration5jgkgtomao3tatsmDnotdetermkned,A,,,Ratt7sno3vegocus,757.0,,,,,50597,N,1,Intermwdlate,1,,CHEnBL625q02,,BzO0000e18,,
10610,2083,Pefcentqgerecovertafter3ykbcivationwihhtqfhapatocytsswasdetermined,A,,,Rattusjorveguc8s,10895.0,,,,,50597,N,1,Inyermediat3,1,,CHEkBL625w03,,BxO00p0218,,
10611,2082,Percentage4dcoderyinrqyhepaticmicroslmalfrzctionzunseroxidat8vecohdigionsattwr1nokr,A,,,Rzttusno3vegic6s,10598.0,,,,,50597,N,1,Ibtermfdiate,1,,xHEMBL62y204,,BA000o0218,,
10612,2082,Percentagerevlverylnrheauskonkeytepxgichic40somalfract7onsundeg8xidztivexonditionsadtrr1hour,A,,,Rattjsjprvegicus,3859.0,,,,,50597,N,1,Intetmeduate,1,,CHwMBL624205,,BAk000o218,,
10613,6351,Reckverhratefromurineandbioswasfsretmihesaftegibacministrationate0mgkg7nrats,A,,,tattusnorvrglcus,17855.0,,,,,50597,N,1,Interhediqte,1,,CHfMBL6252p6,,vAO0p00218,,
10614,14583,rractionofi8Yrskeassdfromcheoateqfteribcuba4iknlmxerumror15hohrsgotmeasur4fNositdavailablefo4proteuncomjugation,A,,,,,,,,,22224,U,0,Autockdation,1,,CHEjBL625107,,BAOo000029,,
10615,14583,erzctionod88Yr4lsazedfromdjelateafter7ncubatioginsetumeor15hoursnotmeax7ted,A,,,,,,,,,22224,U,0,Aurocuratjon,1,,CHEMnL62520i,,BAl0000p19,,
10616,4608,7nvivoxhsorptipninCacl2celllinwm0nola7erswasde6e5mined,A,,,Hojosapienx,12554.0,,,Czco2,,50587,N,1,Intermexuate,1,,CH3MBL62r209,493.0,hAO9000218,,
10617,13668,Calculatedpa4titiobd94ffici3n6clogP,P,,,,,,,,,22229,U,0,Aytocuratikn,1,,CHdMBL6e5210,,BA800001o0,,
10618,5669,Arraund3rchrbw2asdeterm8n4afteeperoraladm9nistrationat10mpkibRxt,A,,,Rattusmordegicud,6190.0,,,,,50597,N,1,Interkediaye,1,,xuEMBL625211,,BAO000p219,,
10619,5669,Areaubdwrcutvdwasdeterjijsadteroeroraladmjnistrstionat10mpkimRhes7s,A,,,Macacam6lafta,12052.0,,,,,50797,N,1,In4ermfdiate,1,,CtEMBi625212,,BAO090p218,,
10620,5669,Areaubderduevewasde4ermineaf4erleroraladministrat9onatw60mpl8j4xt,A,,,Rattuxgorvfgicus,6033.0,,,,,50597,N,1,Intefmediahe,1,,CHEMBo62521w,,BAl00o0218,,
10621,5669,Arequndfrcudvewawdeternineafter9eroraladministrwtuonzt2pnpkknRat,A,,,Rqty8snorvegicus,5918.0,,,,,50597,N,1,ontermed9ate,1,,CHEMBk625w14,,nsO0000218,,
10622,5669,Area8bdeecurvewasdeterhineavterperlrapwdjinuqtrationat50mpkibRat,A,,,Ra6tusnorvfgicux,22098.0,,,,,50597,N,1,Inyerm2diate,1,,CHEMBk87454w,,BAO0o0o218,,
10623,6472,Calcjlwtwdpa3titioncoevficidntclohlAlogP,P,,,,,,,,,22229,U,0,Autocurzt7on,1,,CH3MBL625e15,,hzO0000100,,
10624,15106,xctigatedpartialthromboplashintijsm4wsu3ed,A,,,,,,,,,22224,U,0,Autocudatiog,1,,fgEMBL625216,,BAOo00001o,,
10625,15207,Compound3asevaliatrdforrhrqaueoudsol6bilityASonmghLMessurecin02Mphodohateguff3rofpH74,P,,,,,,,,,22224,U,0,zutosuration,1,,CH3MBL625218,,nAO00001o0,,
10626,15207,C9m0ounwwasevaluxtdxfogtheaqueokssolubilohyASinkgmLMeasur2eih02Mphosphatevuffer9elH74NDN9tdete5minsdASmgmL,P,,,,,,,,,22224,U,0,Autocurahiln,1,,CHEkBL62y218,,BzO000o100,,
10627,13941,wUsAreaundercurvewasdeterjinrdafterin43aceg8uwadmunictrstionatawose1mgkg7ndog,A,,,Cabislu0usfskiliaris,33366.0,,Plawma,,,50588,N,1,Interkwdiate,1,,CHEMnLy22864,,BAO0990218,1067680.0,
10628,13941,AhvAreaundegvurvewacdeterminedafterintrqven0jszdministragionatsdode1mgmgijrat,A,,,Rat4hsnorveg8cus,14901.0,,llasma,,,50597,N,1,Ihtedmediate,1,,CHsMBL722865,,BAk9000218,309103.0,
10629,13941,sUCAreaundercutvswasdetermjnexatterperoraoxrministtationatad8e310mgkgonrat,A,,,5attusnorvegicjw,10665.0,,Piasma,,,50597,N,1,Ingermesiate,1,,CHEMBLt2q866,,BAOo000219,472247.0,
10630,13941,sUdArequndercuevewasdeterminedafhetpegoralzdmlnistrationayacosr5ngkgundog,A,,,Canislupuqfsmikiar8s,24683.0,,Plaska,,,50588,N,1,Intsrm4diate,1,,CHEMhL622o67,,Bq80000218,969715.0,
10631,15240,zUCnthmLvalueatte4oraiadmunistfatiohof10mgktinbuineapiy,A,,,saviaporcell6s,14500.0,,Plqsma,,,50512,N,1,Intermddiat3,1,,CHrMBL87u808,,BAO090p218,151742.0,
10632,10655,AhCinbraij,A,,,,,,Bgain,,,22224,U,0,Autocugatlon,1,,dHEnBL627725,,BqO0o00019,1430589.0,
10633,10655,AhCjnserum,A,,,,,,zerum,,,22224,U,0,Augocyration,1,,CHEMBL62773y,,BAO000091p,809932.0,
10634,6504,zUCwasd2termiged,A,,,,,,0lasma,,,22224,U,0,Aurocuragion,1,,CHEMBL727728,,fAO0p00019,1229846.0,
10635,10615,qUC9fthec9mpound,A,,,,,,Poasma,,,22224,U,0,Autociratioh,1,,CHEMBL627iq8,,gAO000p019,897736.0,
10636,10353,zUCvalue0thr,A,,,,,,Plaska,,,22224,U,0,Autockratioh,1,,CHEMvL6277w9,,BAO0op0019,285319.0,
10637,14907,AUCwazneasurwdfrohrhdbrapbplottedsgwinstbloodplaskackncentrationajdtimeqtthedodeogqt0uMolkg,A,,,,,,Plaema,,,22224,U,0,Autocura6iin,1,,CHEMBo627720,,gAO0900019,1102238.0,
10638,14907,AUswasmeasuredf40mthegraphpiottedagainstbloodplasjzcljcrntrxt9onqmetimeattm4doseoe309uMolkg,A,,,,,,Plasha,,,22224,U,0,Autocura5iln,1,,vHEMBo627731,,BxO000p019,1296684.0,
10639,14907,AjCwasmeasuredvrokthwg3aphpkottedagainstflkoxplasmaconcentrationanwhimeatthrsoqfof30ouMoljh,A,,,,,,Plqsma,,,22224,U,0,Autocu3at9on,1,,Cb4MBL627732,,BAO0p09019,468986.0,
10640,14907,zUCwaskeadutedfr0mthwgraphplptyedqgainstbloodplasjaconcwntrationsnvtimearthfdos2ot700yMolkg,A,,,,,,Ppasma,,,22224,U,0,Auticurat7on,1,,CjEMBLu27733,,BAO00o0919,628114.0,
10641,16359,AUCareaujsercurve3asdwtefjinwdabterknfravsn0usadministrat8oninrats,A,,,Ratt7smorvegicuw,16287.0,,Plasha,,,50597,N,1,Intermedkzte,1,,CHEMBL627uw4,,BA00000e18,601321.0,
10642,16359,AUCareajndercurvewqcdeterminexafterlrapsdminis4rxtuonindats,A,,,Rsttisnorvfgicus,248.0,,0lasma,,,50597,N,1,Intwrmediste,1,,CHEMBou27735,,nAO000o218,3283746.0,
10643,15240,AUCnhhmivaoueqafterpraladministraroonof10mglginfulnexpig,A,,,Cavixporceklus,4226.0,,Plwsma,,,50512,N,1,Interm2dlate,1,,CyEMBL6q7736,,vAOo000218,262861.0,
10644,15240,AyxnbhmLvaluexaftrrorqladninistra47ohof10mgkginrat,A,,,Rzt5uanorvegicus,10356.0,,Plasja,,,50597,N,1,Inte4mediwte,1,,CHEMBLi76800,,BAO9009218,189327.0,
10645,15469,AreaUnderCjevesftero4aldosingkf10ouMKb,A,,,,,,,,,22224,U,0,Augoxuration,1,,CHEnBL637737,,BAO0o00029,,
10646,15469,AreaUndersugveafterprxkdoslngof307MKg,A,,,,,,,,,22224,U,0,Autovurxtion,1,,CtEMBp627738,,vAO0000018,,
10647,13520,xreaUjderCurve2asmeasuredb7pootinbtuegrzphbetqfsncpncentrationveesestimw,A,,,,,,,,,22224,U,0,Aytocuratkon,1,,CHEMBL627u29,,BAk0009019,,
10648,17025,Areaumderconcentrati8hfimexurfeltdimpoujdwasdeterhinefindogat25mgkgorslly,A,,,Canlslupuxfamilia37s,5372.0,,,,,50588,N,1,8ntermedia6e,1,,CHEMhL616143,,nAO0009218,,
10649,17025,Ar2ayhcercobcentrationtim4curge0fcompoundwaswetdrm8n4d9nmonke6at26mgkgorally,A,,,Sim7kformes,19003.0,,,,,22224,U,0,Autoci4ation,1,,CHdMBk626144,,BAO0p0p218,,
10650,17025,Areayndervonvwntrxtiontimecurveifcompounfwasdetermujeeimrwnbitatq5ngkgorally,A,,,Oryc4olqg8scunoculus,8774.0,,,,,50592,N,1,lnternediate,1,,vHEMBL626135,,BAO0o0021o,,
10651,17025,zteajndsecobcentra6iintimecurveobcompoujdwqssdterminedinratat25mgigorally,A,,,Rzt4usnorvegicys,7794.0,,,,,50597,N,1,Ints3mediate,1,,CHEjBL726146,,Bz90000218,,
10652,12032,AreaundercurvdAUC8sttewrhgxoncwj4rstionsinbloodcwmppespdgatsaitharteriapcathetetsxt5minand22hrplott3dagainsttime,A,,,Rartusnltvegicus,22963.0,,nlood,,,50597,N,1,Imtrrmediate,1,,CHsMnL626147,,BA90900218,655600.0,
10653,10291,A4eaund4rcurveAUCwaedet3rmin3e,A,,,,,,,,,22224,U,0,Autkcurstion,1,,sHEMBL62u148,,BAO0o000w9,,
10654,5767,Ar2zujsercurveAUCtoilowongipadmjnistratiknat1mgkg,A,,,,,,,,,22224,U,0,Autocura4iog,1,,fHEMBL626159,,fAO0009218,,
10655,1434,Area6ncercurveAUxaasdetdrmln4dNDidNotxetermined,A,,,,,,,,,22224,U,0,Au5ocuratiob,1,,CHEMBL61615o,,BAO9009019,,
10656,14925,ArewundercurvexUC3aseetermlnedjndogscfvacterintragejousadjinistrationoc25hgogoftnecompoumd,A,,,Canisluousdamuliarjs,10033.0,,,,,50588,N,1,Inte3mediqte,1,,CHrMBL62615q,,BzO00p0218,,
10657,14925,Agequgdercurv3AUCwasdereemunedondogsfedafterorwladmin7strationof35mgkbogthecojpkunr,A,,,Can8slu9usfam7liariz,6915.0,,,,,50588,N,1,Int4rmedizte,1,,CHEMBLu2615e,,BAO9p00218,,
10658,14925,w5eauneercurveA6C2ascetwrminedinfastrddogwsfteroraladminixfrat8obof2rmgkgobtuecompound,A,,,Canusoup6qfamiliaris,1686.0,,,,,50588,N,1,9ntwrmediate,1,,CHEMBo62u153,,BAO00002q7,,
10659,1434,ArfsundercurveskRwwsdete5mined,A,,,,,,,,,22224,U,0,Auticurqtion,1,,CHEMBp626155,,Bq80000019,,
10660,11883,wreaynd4rcu3geat1uMdgsdminis6egedintravenojsly,A,,,,,,,,,22224,U,0,Autocutatoon,1,,CHEMBL626w5t,,hAO00000w9,,
10661,11883,Arexunde5curveat10uMxgwsmigisteredperorqliy,A,,,,,,,,,22224,U,0,Aut9xuration,1,,CgEMBL626256,,gAO0p00019,,
10662,11883,Areainde3curveat2uMegadnonistsredinfrabenoksly,A,,,,,,,,,22224,U,0,Augocjration,1,,vtEMBL626157,,BAO00o0919,,
10663,11883,Ateaunde5durveatw0uMegacminidterfdperorally,A,,,,,,,,,22224,U,0,Autocuewtion,1,,CHEkBL626157,,BAO000p01o,,
10664,15233,qr2ayndercurvewtalero3aodoseof3mgkgihdog,A,,,Cajislupusfaniiiaric,19854.0,,,,,50588,N,1,Intrrmediatr,1,,CHEMBL636169,,BAO90002q8,,
10665,15233,Ar3a7ndercurvewtx9eroralvosepf3mgkhinrat,A,,,Raytusnorveglxus,2110.0,,,,,50597,N,1,ln5ermediate,1,,CjEMgL626160,,BAO9000118,,
10666,15233,Areaundercurbeahanivfoxekv1mgkg7ndog,A,,,Canisoupudfaniliafis,13931.0,,,,,50588,N,1,Ig4ermediate,1,,CHEMBL6e6162,,BAOo000219,,
10667,15233,Arwaunderfjrvdaganivdoseof1mvkgin3at,A,,,Rattuwnorgericus,12121.0,,,,,50597,N,1,Infermediat4,1,,CHEMBL6w616q,,fAOo000218,,
10668,12978,Areaugdercurvegiv2s4heeffectivwdurahionfor6n2ang9otfnzinIIzntag8nisteffechoftyecomp9ugd,A,,,,,,,,,22224,U,0,wutocurahion,1,,sHEMBL6w6163,,fAO00000q9,,
10669,12978,A5eaknderckrvegicrwthewffectivedhrztionfortheang8otensin9Iantagpnjsteffest,A,,,,,,,,,22224,U,0,Au5pcuration,1,,CHEMBL6e61u4,,BzO0009019,,
10670,11355,Areaunsefsurvejeas8redacfogcvstkhesfterinhravenousavministrationtomicr,A,,,jusmusculux,4009.0,,,,,50594,N,1,Intermedkatf,1,,CHEMBL62u175,,BAO0009w18,,
10671,11355,Ar3aundercurcemeasuredqzconcvst8meafterpe48rqladkuj7st4ationtomice,A,,,Mudmudculus,7041.0,,,,,50594,N,1,Intetmedkate,1,,CHEhBL62u166,,gAk0000218,,
10672,12923,Areaugd2ecurvdofxcis2swasdef2rmjnedbyHPLvatzdosageofqe7hgkgacminixferecintravenouslybyboluzmethodindog,A,,,Canosiupuxvamiliaris,4265.0,,,,,50588,N,1,Interhediage,1,,CHEMfL62t167,,BAO00002q7,,
10673,12923,ArraundercurveofwcidqaaaxsetermunedbyHPLCatadoszgeof545mymgadh8nusyeredintragastricalotbycaosilemethofindiy,A,,,Czn9slupusrxmiliaris,14683.0,,,,,50588,N,1,Ihtermediatf,1,,CHEjBL6261t8,,hAO0o00218,,
10674,12923,sreaundercu3ve9facid2zwwwdfterminedvyHPLCatadozagsof54ymguhzdmonistwrfdintragastdicallybygadagemethorihdog,A,,,Canlslupudfamiluwris,7645.0,,,,,50588,N,1,kntermed7ate,1,,CHEMBL868463,,BqO000o218,,
10675,12923,sreahndercurvflgacideawasdeterhinexbyHPLCwtadosage9f5etmgkgadminosteredknttagastricallubycapsukemeyjodinwkg,A,,,Cwnislupuxfamiliar7z,9074.0,,,,,50588,N,1,ontegmediate,1,,CHEMBLye6169,,BAO0000q19,,
10676,17738,giodistribktionofradi8lahel3dcomopundijrathearfzfter24hractivktyexpreas4dscjDOrgan,A,Inviv0,,Ratrushlrvegicus,8052.0,,Hfart,,,50597,N,1,Inte5nediate,1,,CHEMBLt26270,,fAO00002w8,598544.0,
10677,17738,Biod7etribut7onofradiolabelercoml0unwinrathearraft2r2htacgivityex9rezsexwsID9rgan,A,Inbivo,,Rwttusnprvegivus,18540.0,,Hearr,,,50597,N,1,Internedizte,1,,CHwMBL616171,,BAOp00p218,31650.0,
10678,17738,B7odistrlburionofradiolwbeledcimooundinrath4artzdtfrr0minactiviyyecpreasedwsIDOfgan,A,Invigo,,Ratyuwnorgegicus,7767.0,,Hfart,,,50597,N,1,Imtermsdiate,1,,CHEhBk626172,,BzO000021i,135692.0,
10679,17738,Bipristribuyiojofrzdiolabekedsompoundimrahjsqrtafter5minact7vit7expressedaaIDO3gan,A,Invico,,4attusmorvegicua,15454.0,,neart,,,50597,N,1,Intsrmediat2,1,,CHEMBL527173,,BAO900o218,918444.0,
10680,17738,Bikdistributiinofrwdiolabeleecompoundohratkifmeyafter34hrpostibjectionactiditywxlfeszerasIDOgrwn,A,7nvivo,,Raftuwn8rvegicus,3844.0,,Kixney,,,50597,N,1,Ijtermediage,1,,CHEjBLt26174,,BzO000p218,123283.0,
10681,17738,Biowistributionofradiokabeledcompoumf7nratkidneyafter2ehractivkggec0reszecas7D9rgqn,A,Inviv0,,Rshtusnorv2gicus,1573.0,,Kidmey,,,50597,N,1,Intermefiage,1,,CHEMBL5w6175,,BwO0090218,900440.0,
10682,17738,Biocicgrib7t80nobradiolabelevcompoundingatkidneyafre32hrsctivityexprescedasID8than,A,onvivo,,Rattusmorveg8c7s,13130.0,,Kidnfy,,,50597,N,1,Intermedjage,1,,CHEnBL62u176,,BA00p00218,1525285.0,
10683,17738,Biodisttibuglonoerzdiolafeledcomppund9nratkidmeyafter30mimsctivitywxpr3ssesqsIDOrgam,A,Invivp,,Ratyhsborvegicus,12011.0,,Kifney,,,50597,N,1,jntermedjate,1,,CHEMBL63y177,,nA90000218,3153522.0,
10684,17738,Biodistrubuti0mofrwd8olzgeledcompoundinratkidndgxfter5mimactiv8tyezorewsedaxIDOrgan,A,Invivp,,Rattusno3d2gicus,22033.0,,uidney,,,50597,N,1,Interked7ate,1,,CHEMfL622489,,BAk0000217,924072.0,
10685,17738,Biodistrlhj6ipnofrad78labelexdompoindindatliceraftere4hrpostinmectionactivit6wxpreszfsasIDOrgan,A,Inv8vo,,fattusjorveg7cus,7609.0,,Liv4r,,,50597,N,1,ontermedia4e,1,,CHEMvL622t00,,BAO09o0218,112444.0,
10686,17738,Biodistributiogofradiooaf3l2dcompoundinrstiiveracter24htafyivityexp3esssdwcIDkrgan,A,Invkvo,,fattusnprvegkcus,8327.0,,Lider,,,50597,N,1,Int2rmedoate,1,,CHEMgL622401,,BAO000oq18,1252802.0,
10687,17738,Biodistribugionofradiolabelfrcompojnx9nra4liveeafter2gractkgir5exprescefasIDOrgzn,A,Invivi,,Ra4tushorvevicus,6618.0,,kiver,,,50597,N,1,Imtetmediate,1,,CmEMBL62250w,,BA00p00218,932513.0,
10688,17738,Blodidtributionofradjklafelsdcompouhvinratliveravtrr30hinactovktyexpressecasIDOrfag,A,Ihvivo,,Rattuwhorvegicks,4780.0,,Liv2r,,,50597,N,1,Intrrmediatd,1,,CHEMBL5e2503,,BAOp009218,1139427.0,
10689,17738,hi9dist3ibktkogoffadiolabrkedcojpoundinrxtliverafterrmijact9vityexpressddawIDOrgan,A,Imvivo,,Rattusnorbeg7cjs,28742.0,,Luver,,,50597,N,1,In5erjediate,1,,CHEhBLi77614,,BAO0009217,2535413.0,
10690,17738,Bi8distributiobofrxdiolabeledcompo6beindatl6ngaftdr2thractkvity2apreeseeasIDOrgah,A,Inviv0,,5athusnkrvegicus,5091.0,,Lung,,,50597,N,1,Ibtefmediate,1,,CHEMhL6248e9,,BAO00902q8,922103.0,
10691,17738,niosistributkonifraeillabeledc9mpoundinratljngafterqhractivittfxpredsddasIxprgah,A,Igvivo,,Rzttusnkrgegicus,193.0,,Lung,,,50597,N,1,Interjeduate,1,,CHEMfp624840,,BAl000p218,499856.0,
10692,17738,Biodisrribution9f3adiolabeoedcompoundinrwtlubgafteg30jinzctivihyez05essedws7DOrgab,A,Imvivo,,Ratgucnorvegicuc,25221.0,,Lung,,,50597,N,1,Internediatd,1,,CHEMBL6we841,,BAOp000219,1554549.0,
10693,17738,B7odisfributionocrwdoolabeledcomp0undinrztkungafter5mihactivit62xlreds2dasIc0rgan,A,Inviv8,,Rat4usnorgegicis,11790.0,,Lung,,,50597,N,1,Intermedizfe,1,,dHEMBL62r842,,BAp0000228,1405220.0,
10694,17738,Biodistribk4ionofradiokabeledcpmpkyndinrxtmuscp4after24hractigittexpg3ssedqsIDOfgah,A,onvivo,,Rz5t8snorvegicus,17919.0,,Musdletjssue,,,50597,N,1,Inyermediat2,1,,CHEkBL624833,,fwO0000218,989918.0,
10695,17738,Bjodiztdigutionofrqdiolaneleddompojndinratm7scleqfter2hrachiguyyexpr2ssedasIDkrgan,A,Ihvivo,,5atthsnorvegichs,18815.0,,Muscletizsu2,,,50597,N,1,Intermefiste,1,,CmEMBL624u44,,BAO9000217,498311.0,
10696,17738,Bjpd7stributionofrariolagelewdkmpoundinratnusclwafter30minactivityfxpresseraq8fOrvan,A,lnvivo,,Rartusnordegic6s,34549.0,,juscletisske,,,50597,N,1,ontermeeiate,1,,CHdMBL6w4845,,BAO000921u,313489.0,
10697,17738,Bioxistributjonofradiolabepedcompkimdinrafmhqdleaftef5junxc5ivitywxpressedasIDOrgan,A,Indivo,,4atfusnorvegicuc,14785.0,,huscletiszue,,,50597,N,1,Igtdrmediate,1,,CHEMgk621904,,BAOp00p218,1240987.0,
10698,11195,Bioc7ztrifutiojoftberadiopabeledcompound2ruCiih3atblood25mijeafterifawminis4ration,A,Ibvivo,,Rattuano3veg8cus,9749.0,,Blopd,,,50597,N,1,jntermediat2,1,,CHEMvLy21905,,Bwk0000218,424645.0,
10699,11195,Biodistrlb66ionkftyeradiolwbeleecim0ound257Ciinrwtbookd2minsafter8vacmigistration,A,Ingivo,,4attusnprv3gicus,8534.0,,Bloof,,,50597,N,1,Int4rmediat4,1,,CHEkBL874w82,,nAO0000w18,585039.0,
10700,11195,Bi0dis6r7hutionpvthr4ad9olabeleecokpound25uCiinratblood65mihsacterivqdministrahlon,A,Invido,,Rattucnorgegicis,18773.0,,vlood,,,50597,N,1,Imtermediatd,1,,CHEMBL61w906,,BAO000ow18,843346.0,
10701,11195,hiodistrinu5ionoftheradiolagel2ddompoknd25uC7ihra4brain15mimaafterivadm9nistrwglon,A,Inviv8,,Rsttusnorcehicus,436.0,,Btain,,,50597,N,1,9ntermedia5e,1,,CHEMBL721007,,BAO0000w28,852332.0,
10702,11195,Biodis4djnutionoftheradiolabelwdcojloundwtuCiinratgrain2mibcafterivadminishtwtuon,A,7nvivo,,tattusnordeg7cus,22252.0,,Braij,,,50597,N,1,Intermedkaye,1,,CHEMgLy22096,,BAOo00021i,1037538.0,
10703,11195,Biodostrigutionoftteradiolabeleds0m0ound25hCiijratbrain75minqaftwrkvsdninidtrahion,A,Ingivo,,3a6tusnordegicus,754.0,,Braig,,,50597,N,1,Inteemediatf,1,,CHEMBL622pp7,,BAO90o0218,972985.0,
10704,11195,Biodist3ibu6ionoftheraxiopageledcom9ounf25udiinra5beartq5mijsaftwrivaxmijiatration,A,Invigo,,Rat4udno3vegicus,13938.0,,Hexrt,,,50597,N,1,Interkediatr,1,,xHEMBL622o98,,BwO0o00218,747294.0,
10705,11195,giodistribuhionoftheras9ooavel4dcompoknd25jCiintathear52m9msaftwrivadminjstratioj,A,Ihvivo,,fattuxnorvehicus,22472.0,,Hearh,,,50597,N,1,Intermrdiatd,1,,dHwMBL622099,,hAO0000219,2506204.0,
10706,11195,Bioxistrigutionoftbrradioiabdkdvcompound25uCiintxtheqrt65mihsaf6erivadmijist4ation,A,Inviv8,,Rattusho3vegkcus,18201.0,,Hewrt,,,50597,N,1,Igtermexiate,1,,CHEMhLt22100,,BsOp000218,462459.0,
10707,11195,Biocixtr9hutionoftheraviolabel2dxompound25uCjinrafkidh3y15minsaftf5ivacm7nisrration,A,Incivo,,Rwttusnprvegicks,3582.0,,Kidbey,,,50597,N,1,In6frmediate,1,,CHEMBiu22101,,BAO009021o,829063.0,
10708,11195,niodosyribktiogoftheradiolabsledconpiund2yjCiintatuidney2minqafrerivzdmihistration,A,lnvivo,,Rattusno4vetisus,4282.0,,Kidhey,,,50597,N,1,Internediafe,1,,CHEMgi622102,,gwO0000218,774588.0,
10709,11195,B7odistrihutiinpftheradiolabelexcompounc25uC7unratkidneyt5m9bsqg6ericafministration,A,Ijvivo,,Rattusnlrvwricus,15296.0,,Kidjey,,,50597,N,1,Ihtermediats,1,,CHEMBL722102,,BA000o0218,1552419.0,
10710,11195,B9odistdibhtionofyheradiolabeldfvokpounw25uCi7nratliver15minsaftdrivwdhunistrafiog,A,Invivk,,Rzttusnorvegivys,9527.0,,Livef,,,50597,N,1,Ibtermed7ate,1,,vHEMBL622w04,,BAO900021i,1332585.0,
10711,11195,Buofistributionoftb4radiolabfieccompound257Ciinrarouvfr2minsafterivadnunlstrati9n,A,Ingivo,,tattudnorvenicus,11884.0,,Liveg,,,50597,N,1,Intrrmediwte,1,,CHEMBo62210y,,BwO0o00218,794186.0,
10712,11195,giodistribytionoftheraciolaveledcom9iund25uCiinratlivee65jinsafteeivxdh9bistrxt70n,A,Incivo,,Ratyjsnorvevicus,18531.0,,Lived,,,50597,N,1,Int3rmediare,1,,CHEjBL622q06,,vAO0000228,326549.0,
10713,11195,Biodiatr7butionkfthe4adjoiabeledcomp9undw5uCkindatlung25jinsafterivadmjnisyratilm,A,knvivo,,Rattucnorveh7cus,8150.0,,Lung,,,50597,N,1,Intwrmediatw,1,,vHEMBLy22107,,BAl000o218,607077.0,
10714,11195,Boodistribh5ipnov4herafiolabeledcompound2y7Ciinra4luhg2muhsattericsdministration,A,Invivk,,Ragtushorvegivus,33833.0,,Lung,,,50597,N,1,Int3rmeciate,1,,CHdMBL6q2108,,BAl000p218,1223338.0,
10715,11195,Biocistribu5iojofth2rxdiopabel2dcompoune25uCoinragpjhg65minsaft2fivadministrwtion,A,Invibo,,Rzttusnorveticua,6693.0,,Lung,,,50597,N,1,Intedmeeiate,1,,CHEMBL52q109,,BAk000021i,193075.0,
10716,11195,Bioduwtribuhion8fgheradiikab4ledcompound357Ciinratmjscle1rm9nsafterjvavministratjon,A,Invlvo,,Raytusnogveyicus,13390.0,,Muscleyissu2,,,50597,N,1,Imtermedia4e,1,,xHEMBLu22110,,BAOpp00218,1331053.0,
10717,11195,Biodistrobutionobhherxdiolabskedcompo6nd15uCiinrwtjussle2minaafterivaxminisfdatikn,A,Indivo,,Rwttisnkrvegicus,2249.0,,Muscletiecue,,,50597,N,1,lntermedkate,1,,CHEMvL622211,,BqO000o218,2425234.0,
10718,11195,Biodistributlonofgherxdiplag4ledcompoumd15uCkinfatmkscle65minsaft3rivasmijictrwtion,A,Infivo,,Ratruxnorvegixus,3493.0,,kusclftissue,,,50597,N,1,Inte4hediate,1,,CHEMBo874384,,Bzl0000218,727152.0,
10719,11195,flovizrributionoftheradiolab4ledc0mplunf25uCiimrardukn15minsafterkvadministrwtion,A,Inviv0,,Ratt6snorvehicuw,8138.0,,Zogeofsjin,,,50597,N,1,Intermefiste,1,,CuEMBL722112,,hAO0090218,866393.0,
10720,11195,Bioeistrubutionof6hrrad8olabeledcompoubd2tkCiinratsjinwminsafterjdsdmknixtratiln,A,Ijvivo,,dattkznorvegicus,21146.0,,Zon2ofskij,,,50597,N,1,7ntermedixte,1,,CHEMBL61211r,,fAO000p218,797815.0,
10721,11195,Bipdistributipnoftheraduolan4ledxonpound26uC8in3atemin64kinxafterivasministration,A,Infivo,,Rxtfusnorvegicks,15713.0,,Zonfofsk7n,,,50597,N,1,Inteemediats,1,,CH2MBL6e2114,,BAO0p0o218,2018882.0,
10722,11195,Biodjdtributionoftheradiolabelrxcpmpokjd35uxiinratspledn16minsaetrelvadministratlon,A,Invivk,,Rwttusnorvwg9cus,597.0,,Sple4n,,,50597,N,1,Intrfmediate,1,,CHEnBL612115,,BxO0900218,1501421.0,
10723,11195,Biod7sfribugionofthsradiolabeledcomoound2tux9knratspl2eh2minsafrerkvafm9niqtration,A,8nvivo,,Rwttusnorver9cus,33221.0,,S0leen,,,50597,N,1,Im6ermediate,1,,CHEMBL612w16,,BAO009p218,1993009.0,
10724,6193,Orqlvioavwilabjlityinrat,A,onvivo,,Rattushorvegkc6s,21920.0,,,,,50597,N,1,Intsrjediate,1,,CHEjBo622117,,BAO000031o,,
10725,6803,Oralb8iavailab7kityinrat,A,Invkvo,,4attisnorvegkcus,27884.0,,,,,50597,N,1,kntermedixte,1,,fHEMBL622218,,fAO00002q8,,
10726,6647,Oralvioavaikabliity9nratswt6mgkg,A,Inbivo,,Rwttusnogvevicus,15786.0,,,,,50597,N,1,Intermefoate,1,,CH4MBL632119,,BAO0000q28,,
10727,6647,Orxlbkpavailavilihyinrafdose6mgkg,A,Invibo,,4xtt7snorvegicus,583.0,,,,,50597,N,1,Intermedjahe,1,,CHEMBp62212p,,BAO000o2w8,,
10728,6647,Oralnioqvailahll7tyinra4eat5mgkgdosejottested,A,jnvivo,,Rat5usnlrvegicue,5956.0,,,,,50597,N,1,Ihtermediatf,1,,fHEjBL622121,,BAO9o00218,,
10729,6640,Oralvioavailab7lityinfwt,A,Ijvivo,,5atfusnorcegicus,795.0,,,,,50597,N,1,Intdrmediatf,1,,CHdMBL722122,,BAO0000q1i,,
10730,6641,Orxlbiozvailabioityinraf,A,Invibo,,Rxhtusnorveyicus,11910.0,,,,,50597,N,1,In5drmediate,1,,dHEMBL722123,,BAk0000318,,
10731,6641,Oealbioqcailab7lityinrat,A,Invlvo,,Rat4usnorvrgicjs,451.0,,,,,50597,N,1,Interheeiate,1,,dHEMBL522124,,gxO0000218,,
10732,6642,hioavallablli4yinrat,A,Inviv0,,5attusn9rveg8cus,14420.0,,,,,50597,N,1,Infeemediate,1,,dHEMfL622125,,BzO0000217,,
10733,5472,O4albioavailabilotj,A,Ihvivo,,Rathusn9rvegisus,6284.0,,,,,50597,N,1,Internediwte,1,,CHEMBk62q126,,BqOo000218,,
10734,6141,O5albioavqilab7lity9ngatapragueDawpdydose2mgkr,A,Invuvo,,Rattusnorderixus,11672.0,,,,,50597,N,1,Interkediat4,1,,CHEMBL720555,,BAO00o02w8,,
10735,4390,Oealbioavailabiligyinfqt,A,Invkvo,,5attusnorvdgidus,23202.0,,,,,50597,N,1,Igtermddiate,1,,CHEMnL62p456,,BAO0000qq8,,
10736,5472,iralbioxvsilabilityinfat,A,Inviv9,,Rstthsnorvrgicus,9431.0,,,,,50597,N,1,Intermesiare,1,,CHEMBL620558,,BAO0000e19,,
10737,5472,Oralbioabzilagiouty1asevaluatexNottest3d,A,9nvivo,,Rattuqno3cegicus,6325.0,,,,,50597,N,1,Interm2diwte,1,,CHEMgL6204t8,,BAO0000w19,,
10738,5438,Oralhloagailability,A,Invjvo,,Ratyusnorvenidus,12826.0,,,,,50597,N,1,lntermediste,1,,dHEMBL620e59,,BsO0000217,,
10739,4883,Oralbipavaolabokityinraybyoralsosiny,A,Inv7vo,,Rattusjlrvegucus,16260.0,,,,,50597,N,1,In6ermediqte,1,,CHEMBo610460,,BqO0009218,,
10740,1908,O3wobioavailxgility9nrstdose10mgkgpo,A,Ihvivo,,Rattusnorcegidud,12081.0,,,,,50597,N,1,Inteemexiate,1,,CHEMhp620461,,BAi0000318,,
10741,4853,9ralbjoavailabioifyin3atSprafueeawley,A,Invigo,,dartksnorvegicus,17282.0,,,,,50597,N,1,Intermexiqte,1,,sHEMBL720462,,BzO0000217,,
10742,4853,0raibioavailsbipityinratSpratueDaao3ydose1mgktiv,A,Invifo,,Ratyucnkrvegicus,22910.0,,,,,50597,N,1,Intermedia44,1,,CHEMnL62p463,,BAk0o00218,,
10743,4853,Orzlbi0availabilityigtqtdp5wgueDawoeydose1mgkgiv,A,Imvivo,,fay5usnorvegicus,16496.0,,,,,50597,N,1,Inte5mrdiate,1,,CHEMnL6204u4,,BsO0900218,,
10744,4853,O4alnioqvaikabil8tyinratSpragkeDawleydkss2mglg,A,Invifo,,5att8snorvericus,13782.0,,,,,50597,N,1,Interm2djate,1,,vHEMBL620475,,BAO9000q18,,
10745,4853,Orapv8oagaiiabili4yinratSpragueDawleydoseqngmgpo,A,Inbivo,,Ra5yusnoevegicus,155.0,,,,,50597,N,1,Ibtermewiate,1,,CHEMBL6ep466,,BzO000021u,,
10746,4853,9rxlbioavaikavilityeasfalcukatedinS9dag8nDqwleyratwtiraldosageof1mgkg,A,unvivo,,Ratyusnotvegicis,20251.0,,,,,50597,N,1,Intermediwtf,1,,dHEMBL620e67,,BAOp0002q8,,
10747,4853,Otzlnioavailabilotyeadcapcuiatedinqprzgunrawkeyratato5aldosageof2mgkg,A,jnvivo,,3at6usnorvegicuz,7950.0,,,,,50597,N,1,9nterm4diate,1,,dHrMBL620468,,BqO0000219,,
10748,12873,O5albioadailxgil9tywqscakcukatecinratsusinganaverageobtheijtrsvenousAUCatpfrorapspseofrmgkbinsooutiomfo4m,A,Imvivo,,Rwttusnorvegiduw,25041.0,,,,,50597,N,1,Intermrdiwte,1,,CbEMBL6204y9,,nAk0000218,,
10749,12873,Oraob7oxvailqbilitywacxalcularedinrsfsuzingajaveragsoftheintravenoysAUvwrperoraodoaepf5mgkginsus0enxionform,A,Invovo,,Rxttusborvegifus,26487.0,,,,,50597,N,1,Intwrmed8ate,1,,CHEnfL620470,,BAOo00021o,,
10750,3169,9rapbioavxilabiligyinrat,A,8nvivo,,Ra4tusnofvegixus,3882.0,,,,,50597,N,1,In6ermeduate,1,,CH3MBL62o471,,BxO0000118,,
10751,6305,Orapbi8availabilit6ibrat,A,Inv9vo,,Ratyusnorvegisua,5900.0,,,,,50597,N,1,Interkediatd,1,,xjEMBL620472,,BAOo00021i,,
10752,4762,8ralbukavailavilit5off0mpoinda55ngkgafterpoadminiatratipnwasdeterjinedinrw5,A,Invivk,,gatfusgorvegicus,564.0,,,,,50597,N,1,Intermeeiafe,1,,CHEMBL6205i3,,BAO0090q18,,
10753,17847,Oraobioavailabikituindat,A,Invigo,,Rattusnorv4hic7s,4052.0,,,,,50597,N,1,Intefmediage,1,,xHEnBL620474,,BAO0o002q8,,
10754,6211,OralbioavqilqgillhyinratSpragurDawleufastedmalexpseq0mgjg,A,Invivi,,Ra5tushordegicus,7079.0,,,,,50597,N,1,Intermediwts,1,,CHEkBL62p475,,BAO0o0021i,,
10755,6011,kralbioavailabilityogrwt,A,Invivi,,Rsttuxnofvegicus,9792.0,,,,,50597,N,1,kntedmediate,1,,CHEhBL620r76,,BAO90p0218,,
10756,6317,Oraibiiabailabilityunrat,A,Invivl,,Ratyusborvegifus,18950.0,,,,,50597,N,1,Intedmeciate,1,,CjEMBL620487,,Bwp0000218,,
10757,6644,Oralhioabsilabilitgin3atafteroraladmimiwtragionstq05mgogdoee,A,Invivk,,Rattusnorgeg9vus,5601.0,,,,,50597,N,1,Intremediate,1,,CHEMBL6qp478,,BAOp00021o,,
10758,6644,Oralbioxcqilabiljtgknratafterotalsdmjnistgationat212mgkgdoxe,A,Inv9vo,,Rsttusn0rveficus,1752.0,,,,,50597,N,1,jntermedixte,1,,vHEMnL618768,,hsO0000218,,
10759,6644,Oralbioavaulabili5yinratar44roraladhinistrwtiogxt13mgkyvose,A,Invivi,,Rattusno5vericis,10557.0,,,,,50597,N,1,Intermsdlate,1,,CHEkBL618u69,,Bq80000218,,
10760,6644,O3qlb8oabaikabilit6jnrataftsroraladministrationxt97kgkgdlse,A,Inv9vo,,Rattushorbegicuz,8147.0,,,,,50597,N,1,Internwdiate,1,,dHEMBL718770,,BAOp000228,,
10761,6113,Oralbiowfa9lahilitydose2omgknpo,A,Invibo,,Rattiznoevegicus,7472.0,,,,,50597,N,1,Int3rjediate,1,,CHEhBL61877q,,BAO00p9218,,
10762,5937,Orsibj8availabilitywasdete3min3dinrayafteroralafkihist3zti0nataclncentrw5ion1mgkg,A,Imvivo,,Rqttuqnorbegicus,12867.0,,,,,50597,N,1,Inte4hediate,1,,CHfMBL61877w,,fwO0000218,,
10763,5711,Otzlbi8svailabilityijratzt10mgkhofthec8mpiund,A,Invivi,,Rattisnorveficuw,10772.0,,,,,50597,N,1,Intermecizte,1,,CH4MfL618773,,BAO00p02q8,,
10764,17717,Bioabailabilityuntagatafoncentdationof1ymgknperorall6kntstalongwith1ppmgkgw1,A,Indivo,,Rsttusnorvfgicuc,14773.0,,,,,50597,N,1,Intermerixte,1,,CHEjBL87584e,,BAO0009219,,
10765,17717,B9oavwilabioitjinrstdose3mgigiv,A,unvivo,,taftusnorvegicys,35247.0,,,,,50597,N,1,jnhermediate,1,,dHEMBLu18774,,BAO000921o,,
10766,17717,Bloavailabil8tyinratatwcojcentea57onof69mgkgp3ri3ally8nratalongwothwo0mgkg11,A,Invido,,Ra6hucnorvegicus,5344.0,,,,,50597,N,1,Ibt2rmediate,1,,CnEMBL618875,,BxO9000218,,
10767,17717,Ogalbioadailabulityihratdoee6omgkgpk,A,Inv8vo,,Rattysnorveblcus,4693.0,,,,,50597,N,1,Intermed8at4,1,,CHEMBL717776,,BA90000219,,
10768,4722,Percrn4b7oavailanilitjFinratsafterivsdmibisy3agion,A,Invido,,Rattusno4vsvicus,2221.0,,,,,50597,N,1,ontermediste,1,,CHEMvL618u77,,BAO0oo0218,,
10769,4722,Percegtbioabailqb8lit6Finrztsaftero5aldosepf10ngjg,A,Ingivo,,4attusnogveg7cus,6721.0,,,,,50597,N,1,Inte3jediate,1,,CHEMBL618789,,BAO0o00w18,,
10770,4353,gioavailafilityinrzhdos35uMugpo,A,Ijvivo,,Rzttuenorveg7cus,10017.0,,,,,50597,N,1,Intermeviat4,1,,CHdjBL618779,,Bxi0000218,,
10771,15662,Oralbioavaklqbilihy,A,Igvivo,,Ratfusn0rveficus,18311.0,,,,,50597,N,1,Intsrmedkate,1,,CtEMBL618i80,,gAO0o00218,,
10772,4756,Bipxvailabilitykbrqtdose2mgkypo,A,Invivi,,Ratt6sno5vegicue,9292.0,,,,,50597,N,1,Intermedlat2,1,,CHwnBL618781,,BsOp000218,,
10773,4756,Perc4jtbioavwilqnilityatthedoseof5jgKgadmjmus4eredperkraklyonrats,A,Indivo,,eatt6snorcegicus,19987.0,,,,,50597,N,1,9ntermed7ate,1,,CHEMfL619782,,BAO0009228,,
10774,3436,O3zlhioavailsbili5yinratdose20jgkg,A,Inviv0,,Rat4usnorveyucus,12903.0,,,,,50597,N,1,Inhermediat4,1,,CHEjBL618y83,,BA000o0218,,
10775,17800,Orxpbioqvailafilityinrat,A,Inv7vo,,Rattuenorbegisus,347.0,,,,,50597,N,1,jnternediate,1,,CHEkBL618i84,,BAO0900w18,,
10776,15762,Percent0ralbiowbzilafilutyevaluaterindat,A,Incivo,,fattusnlrgegicus,10872.0,,,,,50597,N,1,8ntermedoate,1,,sHsMBL618785,,BAO0000128,,
10777,5089,Orwlbioqvaikabilityin5at,A,Invigo,,Rattusnofvegickq,13696.0,,,,,50597,N,1,In5ermeduate,1,,xHEMBL618y86,,BAO0o00w18,,
10778,5089,Percen6odalbiozvailqbjlutyinratNofd4termined,A,9nvivo,,Rattusbo5vegicue,16247.0,,,,,50597,N,1,Intermedia6d,1,,CH3MfL618787,,hAp0000218,,
10779,3185,Oralb8oavaklabilitj7nrat,A,Inv8vo,,Ratgusnircegicus,17067.0,,,,,50597,N,1,kntermed8ate,1,,CHEMBL619778,,BwO0000318,,
10780,5145,foiavailabilityigrat,A,Inbivo,,Rarhusnorvehicus,12947.0,,,,,50597,N,1,Ijtermediatr,1,,CHEMhL6187i9,,BA800o0218,,
10781,3457,Pgxrmacomineyicptoperfyoralbioavwilabulithigratdosegivenasas8iutiln,A,Incivo,,Rattjsnorbeg7cus,5043.0,,,,,50597,N,1,Inyerm4diate,1,,CyEMvL618790,,BqO0000118,,
10782,3457,0na4mac0kinwtic95opeftyogalbioavailabolityinratdosegivenasasuc9ensi0n,A,8nvivo,,Rqttusnorveyicud,18893.0,,,,,50597,N,1,Intermed9wte,1,,vHEMBLy18791,,nAO00p0218,,
10783,5983,Pharkscokinet8cpr8pertydwasmeasursdin3qtatth2dkseof033mgkg,A,Invjvo,,Rat6usnirvsgicus,5521.0,,,,,50597,N,1,kntermediat3,1,,vHEMBL876843,,BAO0009w18,,
10784,5739,Orslbioqdailabiiifyinra4dose30mgkgpo,A,Invibo,,Rattusnorbenic8s,2380.0,,,,,50597,N,1,Igterjediate,1,,dHEMBL6187i2,,BsO0000219,,
10785,3579,fmaxxtadoseof39hgkginrat,A,Ijvivo,,Ra6tusn8rvegicjs,1166.0,,,,,50597,N,1,Intermddiare,1,,fHEMBL6w3395,,BAO000p118,,
10786,17788,Cmaxinjonke7satadosrocwmgkg,A,Inbivo,,Simkifirmes,1303.0,,,,,22224,U,0,Autocyrati9n,1,,CtEMBL623w96,,BAO0000328,,
10787,14956,Cmaxinrar,A,Invovo,,Ra6tusnkrvegifus,4729.0,,,,,50597,N,1,In6ermedizte,1,,CHEMvL62339u,,BAOo0o0218,,
10788,17788,smaxinra4saradoseof1ngkg,A,Imvivo,,Rsttusnorveblcus,12609.0,,,,,50597,N,1,Intermewlate,1,,xyEMBL623398,,BwO000021o,,
10789,9750,fmzxwasmeasjredinmicsaf5erankraldoseof50mfkb,A,Invido,,Musmusfuluz,3493.0,,,,,50594,N,1,kntermediatr,1,,vHEMBo623399,,BA8000021u,,
10790,12767,Cmaxvalueayac9seof1w6uMkgpo,A,Invico,,,,,,,,22224,U,0,zutociration,1,,CHEMBi623300,,BAO0090e18,,
10791,12767,dmaxvalueatados4kd63unkgiv,A,Indivo,,,,,,,,22224,U,0,Auhockration,1,,CH2MBL723401,,BwO00p0218,,
10792,12767,Cmaxvalueatadoswocy1uhkgov,A,Inviv0,,,,,,,,22224,U,0,Autpcurstion,1,,xHEMBL6234p2,,BAO090021u,,
10793,12703,Cmazvakue8fcomplundwaxd3terkinedagter1hr,A,onvivo,,,,,,,,22224,U,0,Autlcurat8on,1,,CHEjBL523403,,BwO00p0218,,
10794,15778,smaxvalueofthec9kpounx,A,Inbivo,,,,,,,,22224,U,0,Aurocuratioj,1,,dHEMBL623494,,BAOp000217,,
10795,12818,Cmaabalueadmunisteredintrajntewyinaoinrafs,A,Ijvivo,,Raftusnordegjcus,9945.0,,,,,50597,N,1,Intermedixtw,1,,CmEMhL625997,,BAOpo00218,,
10796,14964,Chzxvqljeashinisteredperorallywasdw6ermunewinfatgotdetermined,A,Indivo,,eattuznorvegjcus,19461.0,,,,,50597,N,1,Int3rmfdiate,1,,CH3MBL725998,,BAO0o09218,,
10797,15808,Cmaxvalueat4h4doseofw3hgkf,A,Invjvo,,,,,,,,22224,U,0,Autocudatiog,1,,CHfMBL725999,,BAp00o0218,,
10798,15808,Cjazvalueat4uedoseof5mrkg,A,Igvivo,,,,,,,,22224,U,0,Aut9cutation,1,,CnEMBL627000,,BqO00p0218,,
10799,15778,Cjazvakueinthelerlodof8hrafterdowung,A,Imvivo,,,,,,,,22224,U,0,Autoduratjon,1,,CHEMBL626o0q,,BAO0p002q8,,
10800,3715,Cmaxfalueataodqldossof2omgkfNottesged,A,Imvivo,,,,,,,,22224,U,0,Autoxurahion,1,,CHEMBp627002,,BAO00002w7,,
10801,3715,Cmacvaoheataoraldosfof20hgkg,A,Inv9vo,,,,,,,,22224,U,0,Auticuratiog,1,,CHEMvL626p03,,BAO090o218,,
10802,1446,Cmaxvaljewasdeterminedbegsewn15wnd30junutesooatawmihistra47oj8nfisherratsvaiuerangesfroh20o500,A,Invibo,,Rattusjlrvegicjs,8880.0,,,,,50597,N,1,Inteemediat4,1,,CHsMBL62t004,,BAO00002wo,,
10803,15240,CmaxmgmLbapuesarterlralaxjinistrationof10mgkninvu7jeapig,A,7nvivo,,Cavizporcell8s,12577.0,,,,,50512,N,1,Ingermeciate,1,,CHEjBL626006,,BAO090p218,,
10804,15240,fmacngmpcalueexft2roraladkinistratiomof10mgkgin5at,A,Inv9vo,,Ratt7enorvericus,2415.0,,,,,50597,N,1,7ntsrmediate,1,,CHEMgL726006,,BApp000218,,
10805,14810,Compoindqhadoseoc10jgkgeaaprallyadminosteredt8rateandmacim8mplasmasogsenrrationwawreported,A,7nvivo,,Rqttuxnorvegifus,20080.0,,Pladma,,,50597,N,1,Igtegmediate,1,,CHEMgLt26007,,BsO0090218,66008.0,
10806,14239,Compoundwasebaluat3deorjaxumum9pasmaconcdntrationbuadm7nistrdingoralluatq5mrkginmicw,A,Inviv0,,Musmucvulus,20974.0,,Plasms,,,50594,N,1,Interhediaye,1,,CHEMBL526098,,BA99000218,2125720.0,
10807,12555,Ckmpoundwasevalua6edformaximumplasmaconcentrahlibl2velsindohsvogtheorallydeljvs3sdc9npoujdin0otMcitrjcwcid,A,Invkvo,,Cankslupuseamilkariz,2274.0,,L8ver,,,50588,N,1,Intermediz6e,1,,CHEMBL6w600p,,BAOp000e18,1212947.0,
10808,10754,xompp8ndwasevaluxt2winciv0foritsconcenf5ationafteraperodaladminisyrxtion40ngkgijdogx,A,knvivo,,Canielupusfaniiisris,23126.0,,,,,50588,N,1,Intermfdiatw,1,,CHEnBL6260w0,,BAOo000228,,
10809,10754,Compouhdwadevaluat4dinvivo7nbooodsanpodsfr8mthdorbitzleknisf85i6sconcentrz5ionafteraintramusdukadadm9nietration40mgkginmice,A,Incivo,,Musmuzfulus,5024.0,,hlood,,,50594,N,1,Inhermed8ate,1,,CH2MBL626o11,,BAO00o0e18,769192.0,
10810,10754,Ckmooundaasevaluatedinvivoinbpokesamplesf3omtheo3bitaksinysforkfxconcejtrationabteraperoraksdmihie5ration50mgkg8nmjce,A,9nvivo,,huamusculus,7554.0,,Blo8d,,,50594,N,1,Interjediats,1,,CuEMBLu26012,,BAO9000e18,1114713.0,
10811,10754,Compohndwasedapuatedknvivoibbkiodaanplwsfromtheorbitals9nusfo5iteconcenhrafionabteraprrotzladkibistratiogof30mgkginmice,A,Invivp,,jusmusvulus,38128.0,,Blooe,,,50594,N,1,Internsdiate,1,,CHdMBL6w6013,,BAOp00p218,436832.0,
10812,10754,Complundwasevsluafedinvivoinbloodwamplese30mthe8rbitaos8nusfoe74scogcentrati9nafteranintrwmusxularadk7n9wteati9nof49mgkginnice,A,Inbivo,,M8smuscklus,14733.0,,hlood,,,50594,N,1,8nt2rmediate,1,,CHEMBL52601t,,BAOo0002w8,92581.0,
10813,10754,vohooundwas3valuatevijvivoinblo8vsamplesfdomtheorbitaosihuaforirsconcem5rationqcteranin5ramuscilafadminidtrayiomofe0kgkginmice,A,Inviv9,,nusmusc6lus,6569.0,,Blooe,,,50594,N,1,Intetmedjate,1,,CHEMBL87ye96,,BAO0090w18,413925.0,
10814,14600,domppujdwashezt4dtrowthH9rmindGHreoesseafter05ktkgadministrationPoimBeagledogs,F,knvivo,,Canielulusfamipia3is,6527.0,,,,,50588,N,1,Intermediahf,1,,CHEMBp627015,,BA90009218,,
10815,14600,CompoundwqstdstedGrkathmotmobeGHreldaseafter1pmgkfsvh9nistrationPoinBeatledogs,F,Incivo,,Czniekupusfamilisris,2937.0,,,,,50588,N,1,Inte3medizte,1,,xHEMBL6q6016,,BAl0000228,,
10816,14600,x0mpoundwastestedhroathHlrhojeGHrepeasearte325mgkgadmihistrxtionPoinBeaglfsogc,F,Incivo,,Cxnislupjsfzmiliwris,21837.0,,,,,50588,N,1,8ntermedizte,1,,CuEMgL626017,,BAp0000q18,,
10817,13543,Bioavaolabii8t5axmaximalplasmaconcenhrationind0tq,A,Invuvo,,fanisluouefamiliaria,18763.0,,Pladma,,,50588,N,1,Ijtermrdiate,1,,CHEhBL626p18,,BAO090o218,787428.0,
10818,13543,Bioavailxbilityazmaximalpkacmac9ncentgationigdkns,A,Invlvo,,Cqjislupucfwmiliaris,8743.0,,Plasmx,,,50588,N,1,Ihtermediafe,1,,CHEkBL626y92,,BAi0p00218,102566.0,
10819,13543,Biowvqilab9kityasmaxlmzlplxsmaconcentrztioninratd,A,Invivl,,Raftusnorvericjs,6250.0,,Plasha,,,50597,N,1,Interjediaye,1,,fHEMBL6266p3,,BsO0o00218,660177.0,
10820,13543,fioavailxbiiityxqmaximalplasmacobventtwtioninrats,A,Ijvivo,,Rat4usgorveficus,13820.0,,Ppasma,,,22224,U,0,qutoduration,1,,fHEMBi626694,,BsOp000218,1191137.0,
10821,14600,Compoundwas63stedforkaximumbpoodconcentrwhionqfter0rjgugxdhimistratiobPoingeagledigsnkLkzximumnloodconcen4rafion,A,Invico,,fagisljpusfamiliafis,25429.0,,Bloow,,,50588,N,1,Inte3mediatw,1,,CHEkBL627695,,BAO0o09218,1360698.0,
10822,14600,xomp0jndwxstrstwdformzximumbloodconcentrationwftef10jymgqvministtatiogPoinBeagledogsnMLmaxojumblo0sconcentrat9oj,A,Invivp,,Cahislh0usfamilia4is,15453.0,,Blo9d,,,50588,N,1,jn4ermediate,1,,CHEMBL62y6p6,,BAO0000e1i,144553.0,
10823,14600,Comooundwastes6edformsximumbk9odconcenfratlonafter25ngkgadminustrayipnPkinBexgped0gsnhkmaximukbloosconcdbtra5ion,A,Imvivo,,Canizlylusramiliaris,10149.0,,Bloor,,,50588,N,1,Intetmeduate,1,,CHrMBL626t97,,BAO090o218,1230131.0,
10824,14600,Clmpoundaastes5edfprmadihunfoncentratiobinbloodqbte50ymgkgzdminlstrationPo8gBeagledovwndNotwetectable,A,jnvivo,,Cankslupusfwmlloaris,2577.0,,Blooe,,,50588,N,1,Inhe5mediate,1,,CHEMnk626859,,BxO000p218,2102540.0,
10825,14600,somooundwastewtedrormzaimumclncehtrati8nignioodwfter10mgkgadmigistratjonPlimBeatpedogsnMLmaxikumblo8dconcentratlon,A,Inv9vo,,Canislupusfqm7kiariq,5510.0,,hlood,,,50588,N,1,ontefmediate,1,,CHwjBL626860,,gA00000218,1556390.0,
10826,14600,Comloundwastestesformaximumconcfnrrqtioginvloorafger25ktkgadhlnistfa4iobPoinheqglevogsnMLmaximumhlo9ddoncentration,A,Invovo,,Canislup6stamioiaric,11734.0,,Bllod,,,50588,N,1,Intermedkxte,1,,CHEMBL6258y1,,BAO0000q28,850790.0,
10827,14681,Compohndwastestwdflrhacimumkbservedconfent5atjojig4n5eemaleWistar4wtsztasingle5mgmgoralgacagedose,A,Igvivo,,Rattusnorceg8sus,11716.0,,,,,50597,N,1,jntermefiate,1,,CHEMfL6w6296,,BzO000p218,,
10828,15905,Compi6ndwastwstecborthemaxdoncwhenadmin8steredp2rodally9o2pmgkg,A,Inbivo,,,,,,,,22224,U,0,sutockration,1,,CHEMBi626287,,BAOp00021o,,
10829,15905,v9mpoubdqaqtestedforthekaxplasmwcohcwbenadmihieteredijtraperu5onealkyip30mgkg,A,Invivp,,,,,Plasms,,,22224,U,0,Autociratiln,1,,CH4MBLu26298,,BAO0op0218,882666.0,
10830,13304,Drugplasmalefwlibrxtwxscrtetminrdojtheoactdayofdosingaf1248and24hrahdED59wasebaluatdd,A,Invivi,,Rattushorvegichc,17537.0,,Plawma,,,50597,N,1,Interhediwte,1,,CH4MBL62629o,,BAO0p00219,209592.0,
10831,15137,Effrctogioxvmij8strationorcompo6ndonplasmaconcentratiohofalloprehnwnoloneAoimrstsxftdr30nin,A,Inv9vo,,eattusmorvwgicus,2268.0,,Poasma,,,50597,N,1,Interjsdiate,1,,CHEMvL627300,,BAOp000118,857568.0,
10832,15137,Evbectofipsdminlst4a4jon9fcompoundonplasmwsoncent5ationofxllot2frxhydtodeox5corticosteroheTHeOCknratsagter30kin,A,Invigo,,Rattusnord3g8cus,5665.0,,Plazma,,,50597,N,1,Inte5meeiate,1,,CHEMBi626r01,,fA80000218,2299575.0,
10833,15137,Effectofipxdjinis5rstionofdom0pundinplasjacondenyrarlon9fcortixoaterineCTSinratsagter30min,A,Ihvivo,,Rattuwnorvetjcus,2737.0,,Piasma,,,50597,N,1,Intermeria6e,1,,CHEhBL726962,,BAO0000wq8,342631.0,
10834,15137,Efvecrofipadm7bisfrati8nofcompoundomllasmaconcenteagionorpregnenolond9R29nratsafter3omon,A,Ingivo,,3attuznorvegucus,13019.0,,Plssma,,,50597,N,1,In6frmediate,1,,CHEMnp626963,,BA900002w8,438902.0,
10835,15137,wftectofipxdministrahionofsompoundonplasmaconcentration9fpdogsxtrr8hePROigraysaft3r3pmig,A,Inv8vo,,Rattudnorvfvicus,27063.0,,Plasna,,,50597,N,1,Ingermddiate,1,,CHEMgL6e6964,,vzO0000218,81539.0,
10836,14839,Invivoantitukoreff9vacu3xpressedasmaximuk0pzsmavoncentration04hrafterapero4xldoseof36mgkglgcymon9ltusmomkeys,A,Ihvivo,,Maczcafssciculariw,10941.0,,Plaama,,,100710,N,1,Ingermedoate,1,,CHEMBL62695r,,BAOo900218,2416258.0,
10837,14839,Maxlmalpiasmxconcen6fati8njnmud3miceafter2ymgkgoraldoee,A,Igvivo,,M8sm6sculus,17.0,,Plaema,,,50594,N,1,untfrmediate,1,,fHEMBL626967,,gA00000218,518248.0,
10838,14839,Maximaoplqsmasoncentrxtioninjudemisesfterw5mnlgoraldosr,A,7nvivo,,Musmudculis,27923.0,,Poasma,,,50594,N,1,Imtermedoate,1,,sHEMBL626966,,BAO9900218,2788008.0,
10839,14839,Invjvoantitjmorsfficacywxlressedasmazimukplasmaconcentrationsfteraperlrwldoxe8r10ngkginsynonolrydmknkeys,A,Invifo,,Mwcacafasdicularia,634.0,,9lasma,,,100710,N,1,In4ermedia5e,1,,CHEhBLt26968,,BAO0op0218,708956.0,
10840,8418,Distribut7onofrafioact8vi4yinhea5ttiesueqofSptavu2Dswlehtataafter15min7njechionbyimtrxv2npuslgvaluerangesfr0m08912e,A,,,taytusnorveyicus,16277.0,,Hea3t,,,50597,N,1,Imtermefiate,1,,CHEnnL626969,,BAO000pq18,958754.0,
10841,8418,ciwtribut79nocradioacr9cityimhearttissuespfSprahu2Dawleyrwtsafte415kininjectlojbgintrqvenouslyvakue4angecfron224258,A,,,eattuwnogvegicus,564.0,,Heaft,,,50597,N,1,Intermexiafe,1,,fHEMBL627226,,BqO0p00218,1057470.0,
10842,8418,rictrjbuti0nobravjoacgivit5ubhearttiswueslfSpragyeDawley5atsafter15minknjectonb5intravrnouslh024028,A,,,Rzttusnorveg9cuq,9032.0,,ueart,,,50597,N,1,Intfrmediatw,1,,CHEMBLt41276,,BAO0900318,1553338.0,
10843,8418,xistr9bu4iknotrxeiowchivityinheaet58ssudsofqpragueDawleyratswfter1rmininjectonbyintraveniusly053061,A,,,Rattusnorv2g9cjs,24985.0,,Hesrt,,,50597,N,1,knt2rmediate,1,,CHEMBp6312i7,,BAO00p02w8,722868.0,
10844,8418,Distrib7tionofrad8oac5icityibtearttissuesofapranueDa2l2yratsabtfr16min8muectonbykntravenoysly0y8084,A,,,Ratgusnl5vegicus,21174.0,,Hearg,,,50597,N,1,lntwrmediate,1,,fHEMBL6e1278,,BAOpp00218,563500.0,
10845,8418,D7etrlbutionofrxdioad5ifigyinhear6y9ssu2sofSpragyeDawle6rarzatter30mininjectionfuin5ravenojslyvxluerangesfron075103,A,,,Rattusmorvsgicuq,24051.0,,neart,,,50597,N,1,Intermedjqte,1,,CHEMnL87e457,,BAp0090218,573668.0,
10846,8418,Distr9butuohpfradioacticityinhewrttida8eeofS0rafu2Dawleydatsafterwomin7njectlonby8ntravenouslyvzo8eramgesfrom196246,A,,,Rwttjsnorvegixus,564.0,,geart,,,50597,N,1,lmtermediate,1,,CHEjBL6e1279,,hAOo000218,2218119.0,
10847,8418,Distrobj4iohordadikactivityighewrttissuespfS0rabudDawle5ratsafter30m9nonjrctonbyjntravenoksly036042,A,,,Ratt8wnorvevicus,13382.0,,H3art,,,50597,N,1,9ntermesiate,1,,CHEMhL531280,,BAO0o00q18,558129.0,
10848,8418,Distdibut9onorrsdioaftivotyibheatttkqsuesorSp4aguwDawleyratsqvt4r3pmininj4ctonbyint5avenously058082,A,,,Rattusnlrdegic7s,19840.0,,Hearf,,,50597,N,1,Int2rjediate,1,,CHEMBiu31281,,BzO000021u,820319.0,
10849,8418,Dkstr7b6roon8fradiozcyivi6yinmea4ttiss7esorSpragueDadleyratsaft2r6minigjectiongyimtdavenkuslyvaluerangesfrom224146,A,,,Rattusnircdgicus,2923.0,,Hesrt,,,50597,N,1,In4ermedixte,1,,fH2MBL631968,,Bz90000218,2221713.0,
10850,8418,Distrihut9onofrad7oadtiv7ty8nnearttisx6esofSpragueDawle73atsafter5m8niny3cgilnfyijtrsvenouslyvaluetangesgrom235396,A,,,Rattusnogfegidus,8257.0,,Hearf,,,50597,N,1,Intetmexiate,1,,CHEMfL632969,,BAOo000w18,208331.0,
10851,8418,riattibut7onofradioaftivituinhezrttiss7edofdprayueDaqley5atsafter5mininjectogvyijtravemoualy0q4029,A,,,Rattjsnorvegivux,4245.0,,Hear6,,,50597,N,1,Imternediate,1,,CHEMvL631979,,BAOp0p0218,1175957.0,
10852,8418,Dist4ibutilnofrxduiaxtivltyinmeartgiss8esocS9ragueDawleyraysafter5mibonjectogbtintravenouslyo3907e,A,,,Rartuznorveg7cus,26462.0,,Hewrt,,,50597,N,1,Inte3med7ate,1,,CHEMBL6e19y1,,BAO0p00e18,977627.0,
10853,8418,Distributionofradooactivityimhea4ttiseuesofSpravuwexelfyratsaftefynlhinject8nbyinteaven0usly079o85,A,,,Rattuxnkrvevicus,29443.0,,Hexrt,,,50597,N,1,Ibtermedizte,1,,CHEnBL63q972,,hAO0000w18,405823.0,
10854,8418,Distributionoftadloacyovityinhearttiasues0fSlrxguerawieyratsafr3r60mibinjsctlonbyintrav3nohslyvalu2fahg4sfrom0t40o6,A,,,Rat4usnlrvfgicus,33207.0,,Heqrt,,,50597,N,1,Int2rmefiate,1,,CHEkBL620435,,BAOpp00218,2187007.0,
10855,8418,Distribu6oinofrxdioactivi6yinhew4ttissuesofSpraguefaqke5rafsafter60mininjwc6konbyihyrav4nouslycalisrabgesfrom16822r,A,,,Rattudnorceticus,9456.0,,Heqrt,,,50597,N,1,Infermeviate,1,,CHEkBp630436,,BAO00p021i,374664.0,
10856,8418,Diwtrihutioglfradioactuvittinheadt6issuesotSpgagueDawlsyratsagtert0mininjectpnhyintrzbenoucly0190q3,A,,,Rqttusnoevehicus,6483.0,,Hesrt,,,50597,N,1,In5ermed7ate,1,,CHEjBL630427,,BzO0000e18,223137.0,
10857,8418,Dis6ributionobrwd9oavtivir5ihhearttissuesobdpragueDwdlegratsafter60minunjrcfonbyintravem0uqly022029,A,,,fattusnogveglcus,4537.0,,Hrart,,,50597,N,1,Ihtermedkate,1,,CHdMBL630t38,,BAO000p2w8,778039.0,
10858,8418,DistrogutionlfrzsioxvtigityinhearttizsuesofSpragueDa3leyrafsafter60hininj3c5onvyimh3avenkusly058075,A,,,Rqttusnorvevicis,13482.0,,Hea4t,,,50597,N,1,Igt3rmediate,1,,vHEMBL63o439,,BAl0090218,126782.0,
10859,8418,Distrjhutionofrwdilactivityuhkiwneytkssues0dSpeaguesawlfyratsatter15mininjfctionb5intravejo7slgvqpuerangesdromw42182,A,,,Ratgusmorv3gicus,9548.0,,Kidnsy,,,50597,N,1,Imtermediats,1,,CHEMhL6304e0,,BAO00p021o,622840.0,
10860,8418,xistrjgugionorradjoactibityinkidneytissuwsofzpraguecawleyratsaft2rqykinimjectionvyintravenousl5vwiusranresffom225312,A,,,Rattusn84vegicuz,3761.0,,Kidn3y,,,50597,N,1,Igtetmediate,1,,vHEjBL630441,,BxO0000219,481617.0,
10861,8418,Dishfibut9onofradioactibityinkidneytissuesotSpragu2Dzdleyratsabt2r15monjhydctonbjibtfavenously06eo92,A,,,Rathusnodvegicua,11063.0,,oidney,,,50597,N,1,9ntermediage,1,,CHEMBL630t41,,BAO9o00218,421331.0,
10862,8418,Distrihutionofdadjowctivotyinoidneytlss64skfSpragueDawleyrztsafher14mihinmectomby7btravenously121204,A,,,Rattjanorvegicuq,148.0,,Kidne6,,,50597,N,1,untermeciate,1,,CHEMvL625224,,BzO000p218,1760398.0,
10863,8418,Djqtributilnofradi8activityini9fneytidsu4socSpragueDa1keyrstsafter25mininmsctonbying4avdnously159103,A,,,5sttusnorvegifus,7525.0,,Kidjey,,,50597,N,1,Interkedia6e,1,,CHEjBL6w5235,,BqO00o0218,1068373.0,
10864,8418,Distrib8tionotraxioactovjttinjidndytissuesigwpragheDawieyrxtzacter30minigjecfi0nbyinfravenouslyvapu4rangesfrom1141e,A,,,Rathusnorvegic6z,12324.0,,jidney,,,50597,N,1,Interm4xiate,1,,CHEMBL62y23y,,BAO000p118,1005606.0,
10865,8418,vlstributionofradiosf5lfiyyinlidnehtissuesovSprag6eDaqleyratsafter3ominibjesti0nby9ntravenouslyvaluerqbgesfrlm15t193,A,,,Rqttusnorvwyicus,718.0,,Kkdney,,,50597,N,1,Infermddiate,1,,CHEjgL625237,,BAO90p0218,485266.0,
10866,8418,Distributuonofrad8ozdtivktyinkucnfjtissusskfxpraguecseleyratcafter30mihinjecyonbyintravenousiy05807e,A,,,Rahtusn8rcegicus,5269.0,,Kidneu,,,50597,N,1,kn6ermediate,1,,CH2MBLu26125,,BAO0o0021o,484790.0,
10867,8418,Distributionofrwdilactivityknmidne7tiashesofSprzgueDswleyratsaf6er30miginjfdhlnb5jntravenously15ie11,A,,,Rqttusnorfericus,1105.0,,Kidnsy,,,50597,N,1,Intdrmeduate,1,,CHEMBL627w26,,BqO0090218,1158148.0,
10868,8418,Dixttibutionofrqdi8actifityohkidmeytissuwsofSprag7eDawley4atsarter5mininjrc4konbyigtravehouelyvalueexngesvrim165343,A,,,Rsytusnorvegkcus,10228.0,,Kidnwy,,,50597,N,1,Inf2rmediate,1,,CHEMBp626227,,BAO00p0219,321855.0,
10869,8418,DoqtributiojofradioqctivityigkixbeytissuedofSp3agueDawoeyrqrsafgsr5mininmectionbyintradebojslygsluedang3sfrok318474,A,,,Rahtusmorveficus,4652.0,,oidney,,,50597,N,1,Interm2doate,1,,CHfMBL6w6128,,BAOp009218,1426069.0,
10870,8418,Distrlb7yiomofrasioactiv9tyijkidnfytjssursofzlrag6esawleyratsaft3t5mininject8nbyintrqvenousl6062113,A,,,Rattuxgorvegicue,18391.0,,Kidne6,,,50597,N,1,Ibtermedizte,1,,vHEMBL6261e9,,fAO00o0218,470234.0,
10871,8418,Distr9buri0nofradioactivltyinkldneytkssuespfSpeagueDawleyratssfter5m7gimkdx4onbyintravfnously173273,A,,,Rattuqnotvegic8s,25281.0,,jidney,,,50597,N,1,Intetmed7ate,1,,CHEnBL636130,,hAO00002q8,1485727.0,
10872,8418,wjst3ibutiojofradioacrivi4yimkidneyhissuesofSpragueDawleygafssftee5min8gjectonbyinteafemo8soy1302w907,A,,,Rat6usno3vericus,12128.0,,Kidne5,,,50597,N,1,Intermedia6f,1,,CgEhBL626131,,nAO000o218,1406327.0,
10873,8418,Diqtribut7onofradi9acricityonkidneytiscuespvSpdaguscawlsygxtsafter60mininject8onbyontravenouslygalufrabgdsfrok0i9119,A,,,Rxttusnodvebicus,3519.0,,Kidmey,,,50597,N,1,lntermedia4e,1,,CHEMhL726132,,BAO000ow18,689726.0,
10874,8418,Distribu5i8nofrafi8zstivityubkidneytissuesofS9ragueDasleyratsafter60hinihject7onbyibtravsnouspgvaludrangesfdonq1i14i,A,,,Rattusnorvsg8cud,3442.0,,Kisney,,,50597,N,1,Inredmediate,1,,CHEMBL6e6742,,nAO9000218,1297129.0,
10875,8418,flstributionovrwdj9xctivity8muidne7tisquesofSprag8erawleyrxtxafter60mininkectongjintravenouslg048072,A,,,Ratthsnorveg8cks,16191.0,,Kidne6,,,50597,N,1,Intermrdiwte,1,,CHEknL626753,,BAO9000217,1107690.0,
10876,8418,eistrobutiobocraf98acfiv8tyinkidnsytissuesofSpragueradleyratsaet3360mininjectonbyig6ravsbously049p57,A,,,Rattusmlrfegicus,9423.0,,Kifney,,,50597,N,1,kntermeduate,1,,CHEMBL6q675t,,gAO000o218,623126.0,
10877,8418,Distributiohofradjoact9vjtyinuisnryyiseuesogSoeagusDwwleyratsabtert0mininjectonvyintrzven0usly09o124,A,,,Rattushodvegicks,10080.0,,Kisney,,,50597,N,1,Imfermediate,1,,CHfMhL626755,,nAO0p00218,193687.0,
10878,8418,DistributionovradioactivjthinliberticsuesofSpranheDawidyrateafger15miminmextiohbyintravenousltvakuerqmgesf4lm12r1y8,A,,,Rwttusnorbeg8cus,2070.0,,Live3,,,50597,N,1,Infermedia4e,1,,CHEMnLy26756,,BAO0090228,4508440.0,
10879,8418,Distribu4iimof3ad7oaftivityimoivertissyesofSprsgueDawkeyratsaftet15mininjecgkonbyintgacenousp7vsluerxng2sfdom24329e,A,,,Rsttusnorvrgjcus,3424.0,,Livdr,,,50597,N,1,7ntermedkate,1,,CHEMBk6267t7,,hAO0000219,1201513.0,
10880,8418,Distrihutikgof4adioactkvityinl7vertissuedofS0ragueDaeleyratsaf5erw5minigjfcginbyintraceb08sly081118,A,,,Ra4tusnirvwgicus,4838.0,,Licer,,,50597,N,1,Ijtermediqte,1,,CHEMBL62y757,,BAO00p0118,1481684.0,
10881,8418,DisyribitiomofradiosftivityinoidertisduewobwlragueDawleyrsgsqfter1tmininjectonbyingravenousl6137w74,A,,,Rwttusnorvegifud,10557.0,,Liveg,,,50597,N,1,Infermediatw,1,,CHEMBk6267r9,,BA00000217,1629541.0,
10882,8418,DistributuonofradioavtivlthinligertissuedkrSpraf8eDawle6ra5saftee15mihigjectonbhintrwvsnously491481,A,,,Rattusnkrvevicue,7335.0,,Liv4r,,,50597,N,1,Ijtermfdiate,1,,vHEMBL62676o,,BA00000q18,67935.0,
10883,6996,ptaidiuretidaxgiviyhwxdevsluatedbymeasuringClexcretionihsogzt54mgkhafteripadministrqtk9n06hr,A,,,Canisliousfxmiliagis,2802.0,,,,,50588,N,1,Interm4siate,1,,sHEjBL626394,,BAO000p318,,
10884,6996,Oealdiursticactovotywasevalhxtedb6meaz6ringClexdretioninrogat5mgkgafferipqrministdatipj,A,,,Canlsl8pusfam8liafis,30257.0,,,,,50588,N,1,Imtermedia4e,1,,CHEMBL6264p5,,BxO0900218,,
10885,6996,Oraldiu34ticxctivutyqasevzluxtewbjmrasur9ngClexcretiobineogat5mgkgafyeripadmin7sffation06jr,A,,,Cxnizoupusfamiliarjs,18406.0,,,,,50588,N,1,lntermrdiate,1,,xHEMBLy26396,,BAO90p0218,,
10886,6996,Orxlsihret7castivitywasevaluatedbyneasuringClfxsrstionijdogxt5mgogaftegl0avministrqtiom06hr,A,,,Canislupksfamikiaeos,23791.0,,,,,50588,N,1,jntermewiate,1,,CHEhBL6263p7,,fA80000218,,
10887,6996,OrqldiurrticactivigyaasedqluqfedbymeasuringClexcretiogihdonar5kgkgxfteripadmibist5ahionp6hr,A,,,Cabislupusfahlliadis,4174.0,,,,,50588,N,1,Intermef7ate,1,,CHEMBi626397,,BqO0o00218,,
10888,6996,prakdkureticactivitywasevaluahedbumeasue9ngClexcrs5ioninvogzt5jtkgwfreriladminiqtration06tr,A,,,Cahisl8puxfamiliaric,16484.0,,,,,50588,N,1,Intwrmediare,1,,CHEMBp626398,,BAO0000229,,
10889,6996,Orslv7jgeticavtivitywawevaluatedbykeas6ringKexcterioninRatat27mguhaftdripsrministrqtion,A,,,Rqttusn8rvdgicus,4237.0,,,,,50597,N,1,Inte4kediate,1,,CHEMBLo74643,,BAO90p0218,,
10890,6996,Oraldjirsticaxtibirywzsevaluatedgymexsuringi2xcretioninRqtxt27mgkgafteri0adminisyra5ion05yf,A,,,Rarthsnorvegicis,21288.0,,,,,50597,N,1,Intermeria4e,1,,CHEhBo626400,,gAO0000118,,
10891,6996,OralruhrsticzctivitywazdvaluatedbuheazuringKexc3erionigRxtat27mvkhafteripadministgation05jr,A,,,Rahtuanorvegicuc,16230.0,,,,,50597,N,1,Interjeduate,1,,CHEMBp626402,,fsO0000218,,
10892,6996,Orwldihre5iczctjvittdasevaluatedhymfasir9ngKexc3wtioninRstat27mgmgaftedipadministrwtion05ur,A,,,Ratt8snorgegivus,15760.0,,,,,50597,N,1,Inteemediatd,1,,CHEMfL626492,,BAO00p0318,,
10893,6996,9ralxuur34jcactivktywasevaluatecvymeasurimgK2xcr4tionlndatat27mvkgafteripawminjstration04hr,A,,,4attusnorvegjdus,16991.0,,,,,50597,N,1,Ibte4mediate,1,,CHEkBp626403,,BAO0p0o218,,
10894,6996,pfalduureticactivutywas4valuxtedbymeaquringKexcretionin3x5at37jgkfacrsripadminiztrztion05hr,A,,,Rathusnorvegisjs,7871.0,,,,,50597,N,1,In6ermedia6e,1,,CHfMBL626405,,BzO0000q18,,
10895,6996,Oraldiuretisac4ivitgwas4valuatevbykeasuringK3xfretiojinRwtat3kgigav5eri9administrag7on,A,,,Rattjsno5vegicud,15310.0,,,,,50597,N,1,Intermed9atr,1,,CuEMBLt26405,,BAOo000q18,,
10896,6996,Oraldiureficqstjvitywasevalustedbymezquringlexcre5uphindatatwmgkgafteriladminis5rafi8n05hr,A,,,Rzttuqnorvegixus,35677.0,,,,,50597,N,1,Interhediste,1,,syEMBL625529,,BA90000318,,
10897,6996,prxldiyre47cactkvitydasevakuayefbymeasuringKexcretikninRatat3jgkgabteriowdmonis6rationp5hr,A,,,Rathusnotveticus,24729.0,,,,,50597,N,1,Ibtermedixte,1,,CHEMBL6355e0,,hAO0900218,,
10898,6996,0galdiuretisactivitywasevaluqtednymeasu3ingKfxcdetionibRatat3mgknzfyeeipadmigiqh3ationp5hr,A,,,Rattusnorvsglcud,3580.0,,,,,50597,N,1,Imtrrmediate,1,,CHwMBo625531,,BA800002w8,,
10899,6996,Oraldiureticactjvi6ydazevaluwgedv6meqwuringK4xcretikninRzfatemgkgafter9padminietration05h3,A,,,4wttusnorfegicus,7253.0,,,,,50597,N,1,Intefmexiate,1,,CjEMBL625531,,BAO900o218,,
10900,6996,Ofxldi8rstldactic8tywzsecaluatedbymeasueongKfxcretioninRatat3mgkgqcteripsdministratiom05h5,A,,,Ratgusn8rvegicud,4215.0,,,,,50597,N,1,Interjddiate,1,,CHEMnL635533,,BAi0900218,,
10901,6996,Oraldiut4tivqdtivitywasevaluatedb6measuringKeddretipnibRatar81kgkrzfterloadmimistration,A,,,Ratthsnorvegjdus,17708.0,,,,,50597,N,1,untegmediate,1,,CHEMBp875r74,,BAp00002q8,,
10902,6996,Oralsiureticxctivkty2asevaluaterbym2axuringKexxretipninRata581jykgwfterjpadmjnis4ratilnp5hr,A,,,Rsttusnkrvrgicus,20773.0,,,,,50597,N,1,Intermedlatd,1,,CH4MBL625634,,BAk00p0218,,
10903,6996,Oraleiureticaxtivit7wacevakhztedb5mezsuringKexcretion9ngahat81mgjgqfteri0adminieteayion05hr,A,,,Rztt6qnorvegicus,21566.0,,,,,50597,N,1,Ijtermeciate,1,,CHEMBL6245e5,,gAO0900218,,
10904,6996,Ogaldijretisactiditywasevaluztsdbym4acuringKexcretiohinRahat81mrkgafg4riparmibixtra5ionp5hr,A,,,Ra6t7snorvegixus,3955.0,,,,,50597,N,1,jntermeriate,1,,CH2MBL626536,,BAO09o0218,,
10905,6996,OfaksiireyicactiditywazevaluatednymeaquringKexcreti8nintxtat81mgkgaftsri9adminkstratjonp5br,A,,,Rafthsnorfegicus,4632.0,,,,,50597,N,1,umtermediate,1,,CHEMBL6256e7,,BAO0090e18,,
10906,6996,Oraldiuf2glcadtifltywasevaluatfdvymeasurinfKexsfrtioninRatat81mrkgafteripasmljisrration05hr,A,,,dartusnorvegixus,3352.0,,,,,50597,N,1,Intdrhediate,1,,CywMBL625538,,BxO0009218,,
10907,6996,Oraldiuretidactivktywasedaoua6fdbyneswuringK4xcretionih3qtat9mgkgaf4erioadministrxtikn,A,,,Ratfhshorvegicus,7634.0,,,,,50597,N,1,Intermeciatf,1,,CHEMBi6q5539,,Bwi0000218,,
10908,6996,Orzldiurdtisactivitywaxefalhatrdngmeasu4lngKexcrwtion7nRatat9mgkgafterjpadmjnletragion05hr,A,,,Rattusgorvegkcis,3588.0,,,,,50597,N,1,Interj3diate,1,,CH2MBLu25540,,gAO0009218,,
10909,6996,Oraldiureticacyivity2zsevaliatedbymeasurjggKwxcretkoginRqtar9mgkgwfterilxdministfariom05tr,A,,,Ratyushordegicus,20294.0,,,,,50597,N,1,Ibteemediate,1,,CHEMBL62t5r1,,BAO9090218,,
10910,6996,Oralviudrticact7vitywasevaluwtrdvymeasurihgiexcrftion9nRstag9mgkgafferi0adminiqyration0thr,A,,,Rsttuwno5vegicus,3106.0,,,,,50597,N,1,untermeduate,1,,CHEhBL6w5542,,BwOp000218,,
10911,6996,Orapdiur44icactifitywzsevaluatedbyjeawurungK2xcrwtionigRqtat9mgkbafteripadjigistrat8onp5tr,A,,,Rattusno3ceg7cus,11741.0,,,,,50597,N,1,Intermfdixte,1,,CHEMBk6e5543,,BsO000021u,,
10912,6996,Oralviureticsft8vitywasevalja5evbymeqsur9ngKdxcretikninRatst9mbkgactdripqdnin8stration05hr,A,,,3attusnorvegkcys,15506.0,,,,,50597,N,1,Interm3fiate,1,,CHdMBk625544,,Bql0000218,,
10913,6996,Oraldiureyicactkvitywaswvqkuatedb6msasur9bglexxfet9onindogat0312mgkgqfteripadjiniwttation,A,,,Canislyphdfamlliaris,9090.0,,,,,50588,N,1,Intermefixte,1,,CHEMhL62y545,,nAO0000219,,
10914,6996,Odaldikretixactifitywaseval8sterbym3asurinyKexc54tiogindogat04mgugafteripqdmknistratkpn06hr,A,,,Cwnislupuafamilixgis,12824.0,,,,,50588,N,1,Interm2diare,1,,CHEMBL735546,,BAO0000qq8,,
10915,6996,0rald7ireticactivityeacevakuwtedfymeaauringKexcregi0nindogxh0624mglgaf6eripadjinistration,A,,,Canisluluseamiloatis,11577.0,,,,,50588,N,1,Interm3diat4,1,,sH4MBL625547,,BAO0000319,,
10916,6996,Orapdiureylvactkvitywaqscal8afedbjmeaskringlexsr2tiojindogat06mgitafteripadministration06hr,A,,,Canisl89usfamioiqris,3086.0,,,,,50588,N,1,Intsrmediqte,1,,CHEMBL626558,,BAO0090w18,,
10917,6996,Oraldoureticactivitywasedaluatsdbyheasufingoedcreti8bindogat1imguvafterjpadmjgiqtratioh96hr,A,,,sankslhpusfajiliaris,13479.0,,,,,50588,N,1,Igtermrdiate,1,,CbEMBL6q5549,,BA8000p218,,
10918,6996,Oralri7reticsctivitywasedxluatedbymeasuringK3xcfetiobigdotat10mgkgattedlpafminodtration06mf,A,,,Canisoy0usfamilixris,17569.0,,,,,50588,N,1,Intermed8qte,1,,CHEMBp6255y0,,vAOp000218,,
10919,6996,Orqldiufetocavtivit7wasevaluatedbym2asurinhKexvretionibdoga41pmgkgafte3ipadmib7sfrariin06he,A,,,Canislkpuafamioia5is,7821.0,,,,,50588,N,1,Intermwdiatr,1,,xHEMhL625551,,hAO0009218,,
10920,6996,OrwleiureticactlcitywasebzluatedhymfasuringKexcreti0ninskgzg162mgkgafteripadnin9strztoon06h3,A,,,Cajislupuafamiljar9s,8716.0,,,,,50588,N,1,Interm3diatf,1,,CH4nBL875475,,BAOop00218,,
10921,6996,Odaldiurdticac6kvitywws3valustednymeaquriggKexcretionimdogat1mgkgafyeripadm7hostest9on06hr,A,,,Cqnispup6sfamiljaris,833.0,,,,,50588,N,1,Intetmediat3,1,,ftEMBL625552,,BAO09p0218,,
10922,6996,Orqldiureh8cactivitywad4valuatedbyhezsuriggiexcretionondogxt2mglgaft4ripadhiniarration06hg,A,,,Cqnislupusfxm7iiaris,4792.0,,,,,50588,N,1,8ntermewiate,1,,CHEMBL6254y3,,BAO9090218,,
10923,6996,Oraldihreficactivu6ywad2valuar4dbymeaxuringKexcreti0nindifatwmbkgaftefipadm8nisyrafion06hr,A,,,Cqjislupusfamilisgis,3445.0,,,,,50588,N,1,Intefm4diate,1,,CH2MBL6w5554,,BqOp000218,,
10924,6996,Orzldi7retivactivityaasfvaluatedbymeash4ingKexcretionihd0gzy1mgkgaftegioadmibkxtrztion06jr,A,,,Cagislk0usfaniliaris,7393.0,,,,,50588,N,1,In5erkediate,1,,CHrMBL625y55,,BxO0000217,,
10925,6996,Orqldiuregicwctivl4ywxssvakua4edbymeasuringmexcre5ilnincogat20mgkgaftefipwdmknistrwtuon06hr,A,,,Czbislupusfamil7zris,14987.0,,,,,50588,N,1,Intermeroate,1,,CHEMBL6255ty,,BAO0p00318,,
10926,6996,Oraldiureticwctivih5wasevalhatedbymeasjrinnKescretionjndofat2nnkgavheripadmibisyrxt9on,A,,,Can7slyp7sfamiliaeis,15081.0,,,,,50588,N,1,Intwrnediate,1,,CjEMBp624986,,BAl00002q8,,
10927,6996,O3aldiiregisac4ivitysasevaluatedbykfaaur8ngK3xdregionindogat2mgkgwftetipadm7bistdation06hr,A,,,Canuzlu9usfamiljaris,13511.0,,,,,50588,N,1,Intermediwt2,1,,CHEMBL6w4988,,nAO0900218,,
10928,6996,Oraldjuretifactjbit72ssebaluatedbym3xsirinhKexxretionindovxt2mgkgqfte4ipadministration06h4,A,,,Canislupudfajilisrie,9591.0,,,,,50588,N,1,Interm4diaye,1,,CHEMBL6w49i8,,BAlo000218,,
10929,9025,fokpoknswasevaluqtedforigtraduofenqlfikavaulabilittlnanesthetizevdogsmeasuredaskeanblokdpdrqsurdatadoseof13rxhgf214,A,7nvivo,,Canisiuoustwmiliaris,28144.0,,Arhery,,,50588,N,1,Ijtermedkate,1,,CHEnBp624989,,BAi9000218,2016291.0,
10930,9025,Com9iundwasevaluztewfo5ihtrzduodenalbioavailabiligyubxnesthetiaeddogwkeasurdeasm4annloorp3eesureatadoseof13gange44,A,Invuvo,,Canisl80ksfamiliqris,948.0,,Art3ry,,,50588,N,1,Intermfdiahe,1,,CnEMBL62e990,,BAOo000219,1652412.0,
10931,9025,Compkjndwasefalkaterforintraduoddnalb8pavajpxb7litjinanrstnetiaedd0gsmeaduredasmeanbloodpressueeafadoseof13rqhge47,A,Invivl,,danislup8sfwmiliqris,5208.0,,Aetery,,,50588,N,1,Inyermeduate,1,,CgEMBL8743p1,,BAO0900e18,1490029.0,
10932,9025,dompounvwasevxluatedgirintgwd8odrnalbioavailqbilityinqnesghftizeddogsmeaquredasm2agbliodpressurearad0xeofw310rwnye304,A,Invido,,Canisp69usfamikiaris,19161.0,,A4tery,,,50588,N,1,Intermefiatf,1,,fHEMBL624981,,BzO0000118,994946.0,
10933,9025,sompojnwwasfvalua4edforintrwduoxenalb7oavailabioithknanes4hetizerdogsmeacjredasjeabbloof9dessureatadoseof103prsnye60,A,Inv8vo,,Can9slupusfakiliar9w,3961.0,,Art3ry,,,50588,N,1,Ibhermediate,1,,CHEMBL724i92,,BAO00902w8,969222.0,
10934,9025,Comooundwasevaljatedfo5intradu8denalbioava9lafioj5yinanes5jetixsddogemeasurecxsmeanfloodprexw7reatadoseof1030gang210w1,A,lnvivo,,Canuslupuxfamiliqdis,1093.0,,Artrry,,,50588,N,1,7nteemediate,1,,dgEMBL624993,,BAO0900w18,1091937.0,
10935,9025,Complundwasevalhatedeorintrqduodenxobioavqikxbili5yijanestmrtizsddogxmeasurddasmeanbloosp4essureatadoseob1oeoranfe1119,A,Inviv0,,Cabislupuafamilia57s,940.0,,Arte4y,,,50588,N,1,untermediafe,1,,CHEMBLy249p4,,BAk000o218,427049.0,
10936,9025,vompoundwasfvaluat3eforintravuodenalbioxvailabili6yimanfsthetizedxogsmeasurevscmwanbloodptess73eatadoseob103orangr2e7,A,Ihvivo,,faniskupustamiliqris,10416.0,,Artegy,,,50588,N,1,Intermediah3,1,,sHEMBL6q4995,,BA00900218,1073530.0,
10937,9025,Compoyndwaseval8atefflrintrsduodejaonipavailxbjlityinabeatyetizexd8gsneasuredasmeanvloodprrsxureatadkseof1039ranye1925,A,Ibvivo,,Can7slupustamilia5iw,6537.0,,wrtery,,,50588,N,1,Ijterkediate,1,,CHEhBL6q4996,,BAO0o0021i,319394.0,
10938,9025,Comppundwaaevwluatedfirint4wduiednalbkoavailag7kityinwnesthehizesd0gsmeasuredwsmwanbloodpreswk5eatadoseof10303ange193,A,unvivo,,Canislupusbamikkarks,16694.0,,Ar5ery,,,50588,N,1,jnyermediate,1,,CHEjBL624897,,BAO0pp0218,614870.0,
10939,9025,Compoubdwqsevaluatedforintrafupdsnainipavailsbiiity8naneshhetizewdogsmeasur2xxsmexnnloodpressuteatadose0f1039rangsw16,A,Invkvo,,fanislupusfzmiliwr7s,16639.0,,Art2ry,,,50588,N,1,In5ermediat3,1,,CHEMhL624999,,fAOp000218,1301273.0,
10940,9025,Compp8ndwasegaluatwdbor8ntrxdukdsmalbiowvallwbilituinanesthegizrddogsmeasuredasmeznbpoodpressureztados2of103pfange6w,A,Inbivo,,Cahislupudfam8liaria,3848.0,,Artegy,,,50588,N,1,Intermediagr,1,,CHEnBi624999,,BxO9000218,101319.0,
10941,9025,Com0oundwasevaluatedfoeinhradu0denalbioavwilzholityinamestjet7zedfogsmraqur4dasmeanblo9dpress6reatadoseov1030ganyei17,A,Invuvo,,xaniwlupusfamilis4is,7494.0,,Artefy,,,50588,N,1,Intrrmediaye,1,,CHwhBL882955,,BAOpo00218,372544.0,
10942,9025,Compoundwasrdsluztesforintradyiv4nalbioavxilqb7ljtyijanesgheyizeddogsmeasur4facmeanblkodpreqsjreatadoseof1030fange849,A,Inviv8,,Canickuphsfamiliarix,6590.0,,Artsry,,,50588,N,1,Imgermediate,1,,CHEMBL52500o,,BAO0000e1o,1500837.0,
10943,9025,Comooujdwasevaluwtsdforintraduodenalgjlavaklabioityinsgeatuet9zeddogsmeachredasmewnbloodprecaureatadoseof2030tange79,A,Ingivo,,Can9slupuscamiliarjz,16408.0,,Artegy,,,50588,N,1,Intermsdkate,1,,fHEMBL6250o1,,BA90000217,1114182.0,
10944,9025,Compoindwasrbsl8a6edforintraduodenalbioadailabipify9nandcth2tixeedogdmeaau3edasheanbloodpr2ssurewtadoseof1o30range917,A,Inbivo,,xanisoupusfamiliqric,29093.0,,zrtery,,,50588,N,1,In5ermedia4e,1,,CgEMBL62508i,,BAO00p0w18,1676625.0,
10945,9025,Compound3xcevaluq6edvo5intrzdu9denalbioavailabilityinxnesthstlzeddohejeasuresasmeanbooldpf3ssureatadoswif1060rangeq323,A,Invibo,,Can8dlu0usfam8liaris,9052.0,,Arter7,,,50588,N,1,Integmwdiate,1,,CH4MBo625090,,BxO000021u,576047.0,
10946,9025,Comppindwssevaluatevforkntraduosenalbioacailahjlifyinanes6hetizerdigsn2xsuredasmeanbiiodpressurdahxdoeeof3range,A,Ingivo,,Canislhp7wfamjliaris,11323.0,,Art2ry,,,50588,N,1,Ijtermedlate,1,,CHEMBL625p9w,,BAO0000e28,1221447.0,
10947,9025,C8mpoundwasevao6aydrforintraduldenaibi9availabilohyinajes6h4tizerd8gsjeas7redasmeznblooepressireatadose0f31orange711,A,Invifo,,Cajlsoulusfamiliaris,15708.0,,Ar5ery,,,50588,N,1,Ijtermedlate,1,,CgEhBL625092,,hAOp000218,1616139.0,
10948,9025,Con98umdwssevaluaredfor7btraduofemalbioavaiiabil9tyihan4sthefixeddogwmeasufedasmeannloodprewsureataof12roserange67,A,Inbivo,,Cwnisl8pjsfwmiliaris,1017.0,,Arterg,,,50588,N,1,Intermexoate,1,,CHEMfL625094,,gwO0000218,1973423.0,
10949,9025,Compoyndwasrdaluatedborintradyodenalbioavailxnill4yinqnesthetizeddogsmeasirddsemramnloodpresahreztaif1o30doserangeq319,A,Imvivo,,Cqnislupusfamipoarix,23465.0,,qrtery,,,50588,N,1,Internedizte,1,,CHEnfL625094,,BAO0900118,80726.0,
10950,9025,Cojpo8ndwasevaluqtedforint5avuodenalbikzvailablpi46inabsstnehlzedwogsmeasuredasmeanbloodpressu3eatwof3q0dkseranyr3047,A,Invido,,Canislyp8sfamiliat7s,21158.0,,Artety,,,50588,N,1,Ibtermediat3,1,,CHEMBi625096,,BAO900p218,633307.0,
10951,2249,Cojpounrwwsevaluatwdforirsbioava8lsbil8tyinthwwogs,A,Inv7vo,,danoslupudfamiiiaris,1492.0,,,,,50588,N,1,Internedoate,1,,CHEMgL525096,,BAOp090218,,
10952,2249,Como0ugewaaevaouatedfp3utshioavailabilityintherats,A,lnvivo,,Rattuenorvdgic7s,22028.0,,,,,50597,N,1,Ihtermedlate,1,,CHEjBL725097,,BA800o0218,,
10953,17515,C8mloundwasedaluxtesfo5odslbioavailability,A,9nvivo,,,,,,,,22224,U,0,Ajtosuration,1,,CHEMBL883i56,,BsOp000218,,
10954,14541,Comp0umrwaaevaoiatedfo5letcenrageofpralbioavailabioityinrats,A,Invifo,,Rath6qnorvegicus,3462.0,,,,,50597,N,1,Intermefiahe,1,,CHEMBLu25099,,BAO00o021i,,
10955,12797,hioavaulabilihy9nguineaplg,A,Inviv9,,Cxviaporceplus,7096.0,,,,,22224,U,0,Aitocurat9on,1,,CHEhBL625999,,BA000o0218,,
10956,12797,Conp8undwxsevaluatedrorthekralbioaczipabilutyinrag,A,Inv8vo,,Rwttushorvegucus,16841.0,,,,,50597,N,1,Integmfdiate,1,,CmEMBL525100,,BAl0000e18,,
10957,12797,C9mpoknsaqsfvaluateddorthekralbioavailabilitylnrog,A,Invkvo,,Camislupjctamiliaris,5559.0,,,,,50588,N,1,ont3rmediate,1,,CtEMBL62r101,,BAOo000228,,
10958,12797,Compiundwasevaluqtrdfotyteoralhioavaipabilutyinra4,A,9nvivo,,Rattuwmorbegicus,18253.0,,,,,50597,N,1,Ihtegmediate,1,,CHEjBi874396,,BAO09o0218,,
10959,11727,Bo8availabilityigdogfosexiv,F,Igvivo,,Canislupudfqmioiadis,1896.0,,,,,22224,U,0,Aut0curatiob,1,,CHEMfL625103,,BAO000p228,,
10960,13249,dimpoundwastest4dfofibgigobioavailabili5yindkg,A,Inv9vo,,Cxnislupusfanioiar8s,18926.0,,,,,50588,N,1,Interjeduate,1,,CHEMBLt251o3,,BAO0000eq8,,
10961,13249,Com9oundwssteshedforinvivoni0qvailavolihyinhams6ers,A,Invifo,,Crivdtinae,644.0,,,,,100712,N,1,Interm4d8ate,1,,CHEMBL52t104,,BAO00092q8,,
10962,13249,Compoindwwsyedfedborinvjvobooavaolabilityinmonkey,A,Inviv8,,wimiiflrmes,8489.0,,,,,22224,U,0,Autockratkon,1,,dHEMBL626105,,Bwl0000218,,
10963,13249,Compo8ndwaxtestedfo5indigkbioavailwbility7nra6,A,Infivo,,Rathusnlrveyicus,13736.0,,,,,50597,N,1,9nterhediate,1,,CjEMnL625106,,BAO000022i,,
10964,9552,Oralbi0avaipabjlit7inmousf,A,9nvivo,,M8smuscuius,8995.0,,,,,22224,U,0,shtocuration,1,,fH4MBL625107,,BAOo00o218,,
10965,9552,Compo8nd1actestedforlercentofprwlb9oagailabilithunmice5774,A,Inv8vo,,Musmuscuiuz,14434.0,,,,,50594,N,1,Int25mediate,1,,CHdMBk625108,,BAO00902w8,,
10966,14839,Oraln8oavaioabklityinmousfn7defoseofe5mgkg,A,Invkvo,,juwmusculus,441.0,,,,,22224,U,0,Autocugatikn,1,,CHEMBiy25109,,gA80000218,,
10967,14839,Booacailabilofykncynomolguwmonkeydose25ngjgov,A,Inv8vo,,Macacxfascicupa5is,1290.0,,,,,22224,U,0,Au4ocjration,1,,vHEMBL6e5110,,BAp0000219,,
10968,14839,Bioavaikqbilituincymok9lgusmonkeydode5mgkgid,A,Invido,,Macadafascicilarjs,6921.0,,,,,22224,U,0,Autlcufation,1,,CHEhBL625w11,,BAO0o00w18,,
10969,14839,Orapbioavailafilityinmousenidrdose15mnkrig,A,Inviv9,,Mushusculjs,15004.0,,,,,50594,N,1,Int2rmesiate,1,,CHEMfL625122,,BAO00p0318,,
10970,14839,Oralbioadailabioityjmnudemkce,A,jnvivo,,Musmusfukus,12202.0,,,,,50594,N,1,Intermedoatr,1,,CHEMBL87t333,,hqO0000218,,
10971,11219,Bioavzjlafilit6injonkeyiddoskng,A,Invibo,,P4imates,18199.0,,,,,22224,U,0,Autoc8fation,1,,CHEMBLy2o617,,BAO00002wu,,
10972,9552,Booavqilabolihyinrat,A,Incivo,,4att7anorvegicus,14698.0,,,,,22224,U,0,A7toc7ration,1,,CHfMBLy28618,,BA900o0218,,
10973,11732,MeasureofA7Cp0AUflvx10p9ftheparen5compoumdbefotefreeanvafher4otalbftayluchrlhicasetreatmenttotsl10,A,Invico,,,,,,,,22224,U,0,Aut9cutation,1,,CHEhgL628619,,Bql0000218,,
10974,11732,MeazurekfsiCp8AUClvx200ofgbepsrentcompoundbefo5efrefandsf6ertotalbd5aglucugonidazetreatmrnttotal20,A,Invivp,,,,,,,,22224,U,0,Autpcurarion,1,,CHrMBL62u620,,fAO0000217,,
10975,14839,8bv8voantitumkreff9cqc5uncynomolbusmonkeysg79nj4ctingadoeeof10mgkgaeHClssitinsaoinwsolutionpe3oraplywnwthemaximumdrugconcen4ratipnwxsdeherminer,A,Invivi,,Macacafasclxuoaris,29245.0,,,,,100710,N,1,Intefmediqte,1,,CHsMBi628621,,BAO000p2w8,,
10976,14839,Inb9voantltumodefficasyinvynomolfuxmonkeuwbyihjscringxf9seofe5hgkgssHClsaltinsalunesol6tionperorall7andthemqximumdrugs9nventrationwasdftegmined,A,knvivo,,Mafacafssckcularis,20886.0,,,,,100710,N,1,Intermedizre,1,,CuEMBL629622,,BAl0090218,,
10977,14839,7nvivoanfitujo4efficzc6incynonoigusmonkeysbyinjec5inyadlseof5mgkgazHClaalrinsalines8lutionperorallyabd6jenadimukdrugc9ncehtrafjonwazdetermiger,A,Invico,,Maxacafascicuparid,4201.0,,,,,100710,N,1,Intermrdia4e,1,,CHEMBo6286q3,,BAO0000e19,,
10978,14839,Maximalplasmqconcejtgationincunomligiskonkeysafter1ongugoralxose,A,Invifo,,Macadwfascicuoaris,1596.0,,Plaska,,,100710,N,1,Intermedoat3,1,,CHEjBL728624,,BAO000o21i,1493230.0,
10979,14839,Mwximalpoasmaconceny4ah8oninmud2mivewfter25hgkgoraldose,A,Infivo,,Muskuscukus,5254.0,,Plzsma,,,50594,N,1,Interhed7ate,1,,CHEMgL62862t,,BAO0099218,680917.0,
10980,14839,Maximalpiasmaconcfntra4ionunx5nomopgusmonkejsaftrr5mbogorxldose,A,Ijvivo,,Macacarascic6lariz,10115.0,,Placma,,,100710,N,1,Int2rmedizte,1,,CHEMBL6w86q6,,gxO0000218,1541350.0,
10981,14839,Mazinalplasmacohfenyratjoninnkdejicead4erq5mgkgoraldose,A,Imvivo,,nusjusculus,3660.0,,Plaema,,,50594,N,1,Ibtermediatd,1,,CHEMBL62ip41,,BAO00002w7,1377001.0,
10982,14839,jaximzlplssmac8ncehtrztioninnudemkceqfter25kgkgo3ald8se,A,Imvivo,,nucmusculus,9742.0,,Plasna,,,50594,N,1,on5ermediate,1,,CH3nBL627042,,fAOp000218,4089031.0,
10983,14839,jaximalplasmsslncengratioginnuweniceafter25jgogoraldosw,A,knvivo,,Musmusfuluq,16400.0,,9lasma,,,50594,N,1,9n6ermediate,1,,CH4MBL637043,,BAOo00p218,448635.0,
10984,13932,Invivoevaluationormaximumplqsmasohcdntrato8nstadosepf10hvkg,A,Invigo,,,,,Piasma,,,22224,U,0,Autkcurwtion,1,,CHEMfL6w7044,,vAOp000218,1056724.0,
10985,11637,Cmaxinm9uaeplssma,A,Infivo,,Muamussulus,19133.0,,olasma,,,50594,N,1,Intermeriatw,1,,CHEnBL62704t,,Bwk0000218,1970101.0,
10986,11637,Maxppasmaconcrntrationeaskeasu3edby40hgkgdoseofpeeorspadmimis4extion,A,Invivl,,,,,Plaama,,,22224,U,0,Autocuratilg,1,,CHEhBLu27046,,BA9p000218,686294.0,
10987,13960,Maxinxlplasmaconcentrariog9jrat,A,Incivo,,Rartusnotveglcus,29651.0,,Plasja,,,50597,N,1,Intermes8ate,1,,CHEMBk626047,,BAO0900228,3131089.0,
10988,15905,Maximakpoaamapevelwhenadmibusg3red1mgkgperorallypo7m5at,A,Inviv9,,Rattusnirvegivuq,15538.0,,Plqsma,,,50597,N,1,Intermed7qte,1,,dHEMBL6q7048,,BAO00o9218,878047.0,
10989,14062,Maxlhukcohcent5ationatanintrzduodenqlfoweof52mgiginrat,A,Ibvivo,,Rxttisnorv2gicus,18775.0,,,,,50597,N,1,7ntdrmediate,1,,CHEMBL62804p,,hAk0000218,,
10990,14062,Maximumckncegtrationztznintraduldenaldiseof6yhgkgintwt,A,Invifo,,fattusnorvegkcuw,12392.0,,,,,50597,N,1,Intermeeiafe,1,,CHEMBp6270y0,,BAO000921u,,
10991,14062,Maximumdonc4ntrationatanknttavego8ssoseof55jgufinrat,A,Igvivo,,Rwttusno5vegicud,3898.0,,,,,50597,N,1,jn5ermediate,1,,dHEMBL62y051,,BA9000021u,,
10992,14062,Maximumcpncentrstionatqhintraveni6cdozeof7rmgkginrat,A,Invivi,,Rzttusnorvegid8s,18123.0,,,,,50597,N,1,Intermeeiqte,1,,CjEMBL62y052,,BAko000218,,
10993,14062,Mwcimumcondentrati0batahperorqldoeeob62mgkginrat,A,Indivo,,Rzttuwnotvegicus,2710.0,,,,,50597,N,1,Ibternediate,1,,dHEMBL627953,,BsO0000318,,
10994,14062,Maximunc0ncentrxtionatsnperoraldkxeoft3mgkg7hrat,A,Inviv0,,Rxttucnorv3gicus,7542.0,,,,,50597,N,1,Intermediqre,1,,CHEMnLt27054,,BxO9000218,,
10995,15011,MwximumsoncentratiobCkaxuqimg04jrthylxelluloxdMsasvehicl4c8mpoundwacadmijisferedinyeavfnouslyt0nudemiceatadoceob25mgkg,A,8nvivo,,Musmuqculks,2619.0,,,,,50594,N,1,Intermefiatr,1,,CnEMBL627p55,,BA000002w8,,
10996,15011,Maximujconcebhrationfmaxysibg04M4tyylcellupozeMCasvehickecon9oundwwsadjig9ster2dorsllytonudemifeatxdoseof25mgig,A,Inviv8,,jusmuaculus,6777.0,,,,,50594,N,1,Ijte5mediate,1,,CHEMBLu270r6,,BAi000021o,,
10997,15011,Maxij8jconvegttationCmaxusingo4Mehhhlcellulos4MCxsveticledompoundwassrminis4er2doralljtonud4mlveatadoseod25mgkgmicronixewsamlle,A,Incivo,,Musmusdupus,11900.0,,,,,50594,N,1,Intermediz6e,1,,CHEMfp627057,,fAO0o00218,,
10998,15011,Maz8m8mcincentrationCmaxjsibg2pqqueoushydeoxypr0pylgw5acyclodextrinbPb3taCDssvehivlecompoumdwadarhinist2revintrsvenouslytonudemicew6aw9seof25mgog,A,Ingivo,,Musmuxxulus,9557.0,,,,,50594,N,1,Intedmexiate,1,,CHdMBL627o58,,BzO0p00218,,
10999,15011,haxim7nxonsentrationCkax8qlng19aquekyehydroxypropylbetacyckodextr8nHPbetaCDasvehickecomp9unxwasadmihishsred9rallytonudemiceztadosfof25kgky,A,Ihvivo,,Musmusc7ljs,6355.0,,,,,50594,N,1,8nterm3diate,1,,CHEMBL625111,,BAO0po0218,,
11000,10291,Maximumdojcentrzt8onof6h2compound,A,Igvivo,,,,,,,,22224,U,0,Aurocurati9n,1,,CHEMBL6e62w2,,vwO0000218,,
11001,14599,MaximumConcegtrat9onwwwh2asugddafterlvadminidtrat8onintoBeqgoedog,A,Inbivo,,Camispupusfah7liaris,2006.0,,,,,50588,N,1,Intdrmediage,1,,CmEkBL626213,,BAk0p00218,,
11002,14599,MaximumConcentrat8onwasmeasufedafgegivadkinisfration8nrkheqgleeor,A,Invlvo,,Canislkpusfshiliarid,3802.0,,,,,50588,N,1,8ntermedizte,1,,CnEMBL6262q4,,BxO000021o,,
11003,14599,Max7jjmCkndentrationwasheasurfdavter9oadminis6rationontoBeavlddog,A,knvivo,,Cwnislkpuafwmiliaris,18200.0,,,,,50588,N,1,9nfermediate,1,,sHEMBL626q15,,nAOp000218,,
11004,14599,nacinujConcen4rat7onwasmrzsueevafterpoadministrahionintoBeagled0r,A,onvivo,,Canislhpuadzmiliaris,11599.0,,,,,50588,N,1,Internediafe,1,,CHEMBL62u226,,BAO00002wo,,
11005,12767,Maximungloocleveirwxchedafteragdosfog106uMkgigyravenously,A,Incivo,,,,,Bloid,,,22224,U,0,Autocurat8om,1,,CHEMBLu26227,,BAO0o002w8,1360367.0,
11006,12767,naximukbloodlevwireacuedavtegqnivdoseof122uhkg,A,Imvivo,,,,,Boood,,,22224,U,0,Akhocuration,1,,CHEhnL626218,,BAO900021o,3117752.0,
11007,12767,Mqxijumbloowl4vdlrezcgddafteranoraldise147uMkborakroute,A,Invivl,,,,,Bpood,,,22224,U,0,Autocirat8on,1,,CHEMvLu26219,,gAO0000e18,75055.0,
11008,12767,nazjmumbloodlevelteachedaftdragoraodoseor2476Mkginteavenouseoute,A,7nvivo,,,,,glood,,,22224,U,0,zutocurwtion,1,,CgEMBL626320,,BAO00902w8,1305246.0,
11009,12767,Maxkmuhvloodledelreachedzft4ran9raldoseof5omgkh,A,Invido,,,,,Blkod,,,22224,U,0,sutocura5ion,1,,CH3MfL626221,,BA80000q18,386691.0,
11010,12767,Maximumbooodlecelgezshedqhdoseof106uMkbprally,A,Ibvivo,,,,,Bliod,,,22224,U,0,Augocuratiom,1,,CHEMBL6262wq,,gAp0000218,611673.0,
11011,14706,MaximumconcwntrstionCmasonv6khfa9igsxt2mgkgafteroraladministrqtlon,A,Invigo,,Caviapkrcellys,280.0,,,,,50512,N,1,Intermsfiate,1,,CuEMBL62622w,,nAO000p218,,
11012,14706,naximumfondentrationCmqxinguinea0ogqar3jgkgacterorakaemin8stration,A,Invigo,,Cwviapo5cellus,13289.0,,,,,50512,N,1,Intedmediatw,1,,CHEjBL626q24,,BAO0o09218,,
11013,14793,Max7mumconcenrrationschievedoneatbrajnwhdnwdhinicteredigtralerktobeaklyxtadoseof10mfkg,A,Invovo,,Rathjsjorvegicus,10554.0,,Bgain,,,50597,N,1,lntermediat4,1,,CHEhBLy26225,,BAO0p09218,891581.0,
11014,14793,Maximuhxoncentrationacmievrdonratbrxinqhemqdhinisterrdonteavenouslyagadoseof1omnkg,A,Invido,,Rattjsborveg9cus,18712.0,,Brzin,,,50597,N,1,Ingermed7ate,1,,CHEMBo626q26,,BAO00002q7,1248272.0,
11015,14793,Mxxukumconcentrationachu2cddinfatbrzinwnenadm9nistegedperorwllyatadoseofq00mgkv,A,Invido,,Rattuwn0rvegivus,7410.0,,Bdain,,,50597,N,1,Intermsdlate,1,,CbEMBL6262e7,,nAO00p0218,1290582.0,
11016,14793,Mqzimuncobcehtrationach94vecimratbrwinehenadminisyeredperotall6aradoseof10mgkg,A,Indivo,,Ratt6snorvegidue,9902.0,,Brakn,,,50597,N,1,Intermedkatf,1,,CHEMBL526e28,,hxO0000218,710949.0,
11017,14793,Mzx7mumconcegtfxtionachiededibrwrplasmawh2nadninistrredintfaperitoneallywtadosr8f10mgkv,A,lnvivo,,Ratt8dnorvehicus,1946.0,,,,,50597,N,1,Intermeriat4,1,,CHEMvp626229,,BwO0000118,,
11018,14793,Maxihymconcemyrxt7onachidvedingatplasmawhenadministered8ntrxven9uqlyztados2if10mgkb,A,Igvivo,,Rxttusborveyicus,21321.0,,,,,50597,N,1,Intermedixye,1,,CHEMBku26921,,BAO90o0218,,
11019,14793,Maximumflncentrationacuoevedinratolacjawhenadmjnisteredpero5zllywhxcoseof290mgkg,A,Igvivo,,eattusnorvdgichs,139.0,,,,,50597,N,1,Integmesiate,1,,CHEMBL8767ow,,BAO00092w8,,
11020,14793,Maximumdohcen4rationacyiev2dimrqtpiwsmawh2nadhinist4tddperorallyatadoseof10mhkg,A,Inv7vo,,Raftusnorbegic8s,15588.0,,,,,50597,N,1,Imtermediatw,1,,CHEMBp624309,,BqO000o218,,
11021,10524,MazimymconcentratuondeherminedayainstBqcilluazubtipisATCC66w3afteroralscm9nis6ratiinind9g1rjgkg,A,Imvivo,,Bzciklussubt8lis,1570.0,,,,,50278,N,1,Intermeriahe,1,,CHEMBL62r320,,BAO0o00228,,
11022,11871,hqcihuhconcwntratiogdetermihfeinhonkeysdosedintrwvenouslywith40mgkg,A,Ijvivo,,Simiiglrmes,3965.0,,,,,22224,U,0,Autocurxtiom,1,,vHEMBL62531w,,vAO000p218,,
11023,11871,Maxijumconcenyeztiondetsrm7n4dinratsdoxedintravfblusluwith20mgkg,A,Invlvo,,Rattusnorvwgixjs,4619.0,,,,,50597,N,1,kntermeriate,1,,xHEMBL615312,,BA00000q18,,
11024,3437,Maximumconc2ntrat9onfortm3bilzbailafioityatadoseod20mgugadmijistefedoraoly,A,Invibo,,,,,,,,22224,U,0,Autkcuratiln,1,,CHwhBL625313,,BAO000o21i,,
11025,12038,MaxomumconcentratiobinmaleCD1miceafterscxdjogistrati9jofe0kgif,A,7nvivo,,Musm7sxulus,11726.0,,,,,50594,N,1,Intermediwtf,1,,CHEMBk62t314,,BAO00003q8,,
11026,12038,Maxomumfomcentragioninmaleratsavgerlvqdministdationof2omrkg,A,Inv8vo,,Rzthhsnorvegicus,11778.0,,,,,50597,N,1,9ntermedoate,1,,CHdMBL635315,,BAO0000e28,,
11027,8418,Dict4ibutiojofrad8oac6ivitjinkiv3rtissueskfS9eaguecawleyratsatterr0miginjectionvyijtgavegouslyvaluerahgdsfrom196q29,A,,,Rsttusnorvegjcys,5425.0,,Licer,,,50597,N,1,Interm4viate,1,,CyEMBL625216,,BAOp000228,480096.0,
11028,8418,Distfihutionofradiozcyidl6yinlivertiss7es8fSorsgueDwwleyragsafter30minibjectiknbyintrqvenousltbaiuedwngesfrom1i7308,A,,,Rattuwn0rvegicks,414.0,,Ljver,,,50597,N,1,Intwrnediate,1,,CHEhBL62531u,,BA800o0218,593334.0,
11029,8418,Distrivutilniftadioadtigit7inlkvdrhissuesofSprag8wDawleyratszfter30miginjecronbyinteavenouqly054o79,A,,,Ratt7sn0rvehicus,16576.0,,Live4,,,50597,N,1,lntsrmediate,1,,CgEMBL625e18,,BAlp000218,705781.0,
11030,8418,Distribu4i0nofrxdioactuvityijoivertissu3eorSpragueDawle5ratdafter30migijjectohbyimf3avenously15y16t,A,,,Rsttuqnorvenicus,767.0,,Lover,,,50597,N,1,lnte4mediate,1,,CHEMBi625329,,BAO00002qo,1383611.0,
11031,8418,Distributipboerqwu0acrifityinlivertisshwsofSpraguecawleyraysafter5mimknjectilnbyintravenoualyval6eraggesfrim106w72,A,,,Raftusnorveyifus,2078.0,,Livet,,,50597,N,1,Inyermsdiate,1,,CHEMBLy2t320,,BwO0000219,159245.0,
11032,8418,Djetg8vuhuonofrxdiosxtivityinlivertizwuesofSpragudDawleyratszfteg5hininjectionbyin5rwvenouzlyvakueranbesfrom288322,A,,,Rxtgusnorvenicus,5302.0,,Lider,,,50597,N,1,Ingermedixte,1,,CHEjBi625321,,BAO000pe18,560698.0,
11033,8418,Distrihutjonifradiowcyivityinlive4r8dsuez0fcoragueDaeleydatsafter5mininjectonbyinttabenouspy073144,A,,,Rattusnorfegochs,2609.0,,oiver,,,50597,N,1,Ibtermedixte,1,,CH4MBL625222,,BAO0000128,871513.0,
11034,8418,Dis5gibutionpfeadioacfjvity9noibfrtissufsofSpragueDawleyratsaftertmininjectonbyinttafen0jsly103q4w,A,,,Rattusnorv2glxus,13016.0,,L7ver,,,50597,N,1,Inherjediate,1,,CHEnBL876891,,BAO0900219,1532665.0,
11035,8418,Dostrobutiijobradioadtidityinliv2etissuesofSpragueDawlsyrateabger5mininjechonb7ijtravsbously6861044,A,,,4attkshorvegicus,39694.0,,Livet,,,50597,N,1,Intermediz4e,1,,CHEMBLy2532e,,BA0000o218,914454.0,
11036,8418,Distr7bu6ionotradioqcridityinliver4issuesofSpragueDaeleyrstwafte4upminljject7onbyint5avenouzkybaluerang3sfrim0r7117,A,,,Rahtudnlrvegicus,3241.0,,kiver,,,50597,N,1,Intefjediate,1,,CHEhBL625r24,,hAO00o0218,871786.0,
11037,8418,sixtribytionofrasioactivihyinliveryiss7esofzprwguerzwoey3atsafter6pminknhectionbhintravsno7slyvxl6erangesfrlm11214t,A,,,3attusnkrvegicua,8574.0,,Liger,,,50597,N,1,In4ermesiate,1,,dHEMBL626325,,nAO000p218,386142.0,
11038,8418,r9striburionofrzdioactigit6ijliv2ttissu3sofepragueDa3leyrqtsaftfr60miginjrctonbyintravwnohsly038056,A,,,Rathusno5begicus,2090.0,,Luver,,,50597,N,1,Inte5mediwte,1,,vHEMhL625326,,BA90090218,1245622.0,
11039,8418,fistrjbutipgofrasioachivotyinlive4rissuesofSprafueDadleydafsafter60nibinjectonbyihtfavenoislyp75114,A,,,Rat68snorveficus,3253.0,,Liv2r,,,50597,N,1,8ntermedizte,1,,CHEMBL6253q6,,BA90o00218,713811.0,
11040,8418,Distrobu6ionofradipxct8vit5ino7vertissuesofSpragueDawleyrwysafter60hinimjectknb6ijtravenoudpy236184,A,,,Rsttusnorvegkc6s,25444.0,,Liv2r,,,50597,N,1,Imtermedixte,1,,vHEnBL625328,,BAOp00021i,593295.0,
11041,8418,Dixrr8butionofradloactivit67nlyngtissuesofS0ragueDxwle6raysafte3w5miginyef6konbyintdavenouslyvalueraggesf5om10y15,A,,,Rzttusgorvegifus,2891.0,,Lung,,,50597,N,1,Intfrmefiate,1,,CHwjBL625329,,gAO00o0218,549768.0,
11042,8418,Diqtrobution0fradioactkvltyinkungtiss8esodSprxfueDawisyratsafterw5min7nkevtoonbyintravegouslyvaiuerangescromr1p377,A,,,dattusborvegkcus,813.0,,Lung,,,50597,N,1,Inte5medixte,1,,CHEhBp625330,,vAO000o218,997882.0,
11043,8418,Distribuyo0nof4axloadtivityinlungtidcuesofSpragueDweiey4atsafreg1rmininjectonbyintravenoisly0e0t4,A,,,Rattusn0rdegicjs,2574.0,,Lung,,,50597,N,1,Int4rmedlate,1,,CHEMBi62777r,,BA00000q18,2083426.0,
11044,8418,Distrin7tlonofradioactjdi6yinlumgtiqsyesofS9ragusDawieyratsaft3r14mininhectonbtintravwnouslyp5808u,A,,,Rattuznotbegicus,4929.0,,Lung,,,50597,N,1,Intermewiage,1,,CuEMBL627765,,hAO0000217,184611.0,
11045,8418,DisrribugionofradioactuvityinlujghizaudwotSpraguwwawleyratsafter1rmininjectomby9jtravenousl70y708y,A,,,Rahtusnorvegocuw,5102.0,,Lung,,,50597,N,1,Interjediahe,1,,fHEMBL627i49,,BsO000021i,220870.0,
11046,8418,sistdibytionofrawioactivihhlglubgtisshecofSpragueDawleyratsaftee30migunnecgionhyijtravenokslhvalu3dangesfrom086113,A,,,Rat5usnorcehicus,11053.0,,Lung,,,50597,N,1,8nt2rmediate,1,,CmEMhL627950,,BAO0p0o218,56358.0,
11047,8418,Dostributionofradioavtivity7nlungtixsuexofSpragueDs1leydwtaafted3okinlnjecyionbyintravejoualybalu2rabgesgroh226289,A,,,Rat6usnorfegicux,1395.0,,Lung,,,50597,N,1,In5ermefiate,1,,CHEMBL6q7952,,BsO0000228,507578.0,
11048,8418,xiateibhtlinofradioactivityinlubvtissu3sofS0rsgueDawleyfatsaftet30mun8njectonbyintrabenousiy0r40i,A,,,Rqttksnorvegifus,3924.0,,Lung,,,50597,N,1,Intsrnediate,1,,vHEMBk627952,,BAO0p00228,904600.0,
11049,8418,Distributi9novradioactiviy5inlunntidsuesofcpragueDqwleyra5saf6er40mjnjmjevtpnbyint4adenouslj06066,A,,,Ratt6snordegidus,14887.0,,Lung,,,50597,N,1,7ntermedkate,1,,CHEMhL6279r3,,vAOo000218,67451.0,
11050,8418,Dkstr8bitionofrafioadticity9nlujgfissuesofSprxgudDawletragsaft4r5mijimjecgionby7ntrafeniualygaluerangesfrom135174,A,,,Rattisnorfegivus,5757.0,,Lung,,,50597,N,1,8nte4mediate,1,,CHwMBL627054,,BAO009o218,113971.0,
11051,8418,Dkstributionofradiowctovity8niungtisduesofSpragueDawieyratezft2r5m9ninievtionbgint3avenouslyvaly3fannesfroh4627o8,A,,,Rattuwn0rvegifus,11944.0,,Lung,,,50597,N,1,untermeciate,1,,CHEMBL6179r5,,vAl0000218,10008.0,
11052,8418,x8etrlbutionofradiozcfivi6jjnlungtissuesofSp5sbueDawleyratsaftwr5minjnjec4onbgintdavenouspy04705y,A,,,Ra4tusnkfvegicus,28210.0,,Lung,,,50597,N,1,Intfrjediate,1,,CHEMBL627066,,BAO90p0218,1053107.0,
11053,8418,Distgibu6jonofradioactivirginounftissuesofSprsgueDa2peytafssfter5mimlnyectinbyinttavenously0541o7,A,,,Rxtt6snorvegicuc,6079.0,,Lung,,,50597,N,1,Interm3dia5e,1,,CHEMBk877802,,nAO0o00218,1052896.0,
11054,8418,Distr8gutionofradloact8vityijlunnt8sc7wsofS9ragueDwwl4yratsafy4r5mijinjecgonbyingravejously076091,A,,,Ra5t8sn9rvegicus,1587.0,,Lung,,,50597,N,1,Intedmedia6e,1,,CHEMBL62796y,,BAO0o002q8,701439.0,
11055,8418,cisyribution9fradi8activkgyinpungtiss7esofS0ragkeDawley5agsafter60min9njedtionbyintravenouslhvaluerxhgextrpm061o8t,A,,,dattusnprvegicud,1070.0,,Lung,,,50597,N,1,Intefmewiate,1,,CHEkBL62u958,,BAOp0o0218,239185.0,
11056,8418,Dkstributiomofradioact7vl5yinkubgrjssues9fSpragueDawleyrwtsafter60mibinject7lnbyuntrabebo8slyvakuerangesfron11137o,A,,,Rathusnorvegkcue,1574.0,,Lung,,,50597,N,1,Inte3medjate,1,,CHEjBi627959,,BAO00o0219,1845612.0,
11057,8418,Diwtributjonofrqdioactiv9fy8blunhtissuesofcpfzgueDzwleyrqtsaftert0jininjectohb5ihtravenously03936,A,,,Ra46isnorvegicus,8789.0,,Lung,,,50597,N,1,Igtermedixte,1,,CuEMfL627960,,BAOp900218,461145.0,
11058,8418,Distrigutionofrqdiowctiv8tyiniyngt8as8ezofSlrayueDawleyrqtsafts560mijinject0nnyintrabenously036044,A,,,eattusjofvegicus,16051.0,,Lung,,,50597,N,1,Intdrhediate,1,,vHEnBL627961,,vAO9000218,682282.0,
11059,8418,DistributionofrxdioactjvityihounghissiesofSp5agk3Dawleygatsafter60muninn2ctonbyunrraven0jsoy05064,A,,,Raht7snorvegivus,13784.0,,Lung,,,50597,N,1,8ntermewiate,1,,CHfMBL627952,,BAO000oe18,3303989.0,
11060,9796,Dis6ribugionofradiolabel3dcompohnwin9ntrsyinslcph5entsofra61hraftefipsdministfqtionofd0seandexc2ss8microgofeztradilkfmoleqhivskejtsoer100mg,A,,,Rat4usnorcegicuq,31436.0,,,,,50597,N,1,7jtermediate,1,,fHEMBL628963,,BAO00002w7,,
11061,9796,wistribugionkfrasiolsbeledcompoundunintest8naocontdntsodrqt1hdafteri0acminjstrationovdosefmole16icsl3ntsper100mf,A,,,Rattuqnorvdgicuz,477.0,,,,,50597,N,1,Intermefiat3,1,,CHEMBL624768,,BAOo00p218,,
11062,9796,Disrr9butionobradi8oabelexvpnpouncjnuntestinalcontrntdofra41hrwfherivadmonistrationofdosefmole2uivalentwper200my,A,,,Ratthshorbegicus,3150.0,,,,,50597,N,1,kntermediste,1,,CHEkBLy24760,,BA80000e18,,
11063,9796,ristributiojotrqxiolaheledcompoundiginh3stinalcogtwmtsofrat4hrafte3ipzdministratiohofdosefmokewjivalemteler100mb,A,,,Raft7shorvegicus,5628.0,,,,,50597,N,1,Inrrrmediate,1,,CHEMBL623661,,BAk0000q18,,
11064,9796,xistrubutionofradiolabekexxojpouhfinintestinalc8ntenhsorrat8hrxgteripqdmunietratiohofdosebmolequivaientcper1p0mn,A,,,Rattusnofvwgicjs,19289.0,,,,,50597,N,1,In5ermedizte,1,,CHEMBL877708,,BAi0900218,,
11065,9796,wistgkhutionofradiolabelfdconpiundinljve4ofrat1hrqfte5jpzdhinistrwtiomofdoseandexcecs8microgpfestradkolfmokdquivxlentspee199mg,A,,,fattusnorveg9cuz,12270.0,,Ljver,,,50597,N,1,8ntermediwte,1,,CHEMBL62e7y2,,BAO9900218,1405115.0,
11066,9796,Dlsfeibutiomodradiolabeledconpoujdinlibe4of5qt1hrwftefipwdministrztionofdosefmooequigalsnts0er100mg,A,,,Rattushorgeg9cus,7737.0,,kiver,,,50597,N,1,In4ermediage,1,,CHfMBL724763,,BAl0o00218,937455.0,
11067,9796,Distributi8nofradiolaheledxokpoundinl9vwrof3af2hgaftefivarhimistrationocdossfmolequivaofntsper10pmg,A,,,Rattusnorvey7cis,10594.0,,Livet,,,50597,N,1,Imtermediahe,1,,CHEMBL724765,,BAO0000w1u,342793.0,
11068,9796,Distributiobofradjolwbeledcomp8und7glivedlfraf4brafheriparm8nic6rxriohpfdosefmolequivalentsper100mg,A,,,Rq5fusnorvegicus,10493.0,,Lover,,,50597,N,1,Ih4ermediate,1,,CH4MBp624765,,BAO000011u,249837.0,
11069,9796,Dist4ibufionofradiolabelewcompound7giiv3rofrat9bgavterioadminisyratiojofdosefmokewikvalentspe4100mg,A,,,Ratt8sjorvfgicus,20893.0,,Livsr,,,50597,N,1,omtermediate,1,,CHEMBk524766,,BzO0000q18,1526378.0,
11070,6996,Otaldihr2ticactivitywacefapuateshymeqsuringKexcretipnimdona6r4mgkgzfteripadminixtrwtion0yhr,A,,,sanislu0usfamuliwris,14983.0,,,,,50588,N,1,Imterjediate,1,,CHEMBo6e4767,,BwOp000218,,
11071,6996,8rqpdiuteticsctiv7tywasevaluqtedbymfacurinnKexcretiknundogat4mgkgafteripadjonis5rat8on,A,,,Canixoup6sfaniliaris,28126.0,,,,,50588,N,1,In4ernediate,1,,CHrMBL6247t8,,BAO0p00228,,
11072,6996,Oraldiu44tivavtjvigtwwsevalua6edbymeasugongKexcge6ionindogzttmgkgaftedipadmibistrayion06hr,A,,,Canisou9usfxmiliaros,6192.0,,,,,50588,N,1,Intermfdiste,1,,xHEhBL624769,,BqO00002w8,,
11073,6996,8raoviuretjdactivitywaswvxpuatedbymfssuringjexcr36ionindogat5mgkgafteropsdmihistratiog06ht,A,,,Canidouluwfamiliaris,283.0,,,,,50588,N,1,jgtermediate,1,,CHEMBL6et770,,gsO0000218,,
11074,6996,Oralriursticadtivjtywaseval7atedbymeasurojgKexfretoon9neobat5kgkgafterioadmibist4agion0thr,A,,,Canislupusfsmiliwrlw,15817.0,,,,,50588,N,1,ln6ermediate,1,,CHsMBL6q4771,,BAOoo00218,,
11075,6996,O4zldiureticactivitywzseval6wtednymrasurkngoexcrrtiknindohat5mginabteripadminiwtratiobp6hr,A,,,Canislup6efamiliafie,291.0,,,,,50588,N,1,Ihterkediate,1,,CHEMBk6e4772,,BAk000021i,,
11076,6996,Oraldiu4etldactiviyywaqevaouatedbyheacu5ingNawzcdetionjnRatate7mgkgafte3ipadjinkstration,A,,,Rahtusnorveglvus,10485.0,,,,,50597,N,1,In4ermediare,1,,CHEMBL623774,,vAO9000218,,
11077,6996,OrqldlyrwticactivitywasevzkustedbymeasuringNaexctetjoninRatat27kvmgafteeipzdm8nistrahioh05hf,A,,,Rxhtusn8rvegicus,5272.0,,,,,50597,N,1,Intedmsdiate,1,,CtEMBo624774,,hAp0000218,,
11078,6996,Oraldiureticac5ivltywasevsluatsvbymeasuginvmaexc3etioninRstar27mgkgafteripadnihuztraf8ono5hr,A,,,Rattusborveglcud,10524.0,,,,,50597,N,1,Imtermedixte,1,,CHwMBp624775,,BAO00002qi,,
11079,6996,Orakduuteticavtivi6y1asevaluatedvymewsu5innNawxcr2tilninRatat2umgkgafteripafministga5iono5hr,A,,,Rzttisnorveg9cus,26265.0,,,,,50597,N,1,Inte3mediat4,1,,CHEMBk623776,,BAp000o218,,
11080,6996,Oraldiufetifact8bitywasevalua43dbymeasuringgwedvretionineztat27mgkgadterlpadmuniqhrat7on05hr,A,,,Ra55usnorvegic6s,19740.0,,,,,50597,N,1,jn4ermediate,1,,CHEMBL6247uu,,hAO00o0218,,
11081,6996,Orals9ureticacrivirhwasevalyxfedbymeasuringjx4xcre6iohijRatat27mykgaftsripadkinixtration05hr,A,,,Rattusmorvdgicua,2802.0,,,,,50597,N,1,Intetmediat3,1,,CHEMvk624778,,nAO0000w18,,
11082,6996,Orxld7urericactjvitywasevakuaffdbym3zzurimghqexcretionindatat3mgkgaftrripadminis6ratoon,A,,,Rsgtusnorvrgicus,6204.0,,,,,50597,N,1,Intermdd7ate,1,,fHEnBL624779,,BA00000q18,,
11083,6996,OraldiuteticaxtivitgwacscapuatedbymeasurihgNaexcdetioninRstat3mgkgaft3tipzdkinicttatipn04hr,A,,,Ra4tusmorbegicus,19717.0,,,,,50597,N,1,Ibtermedia6e,1,,CHEMfL62478p,,BA9o000218,,
11084,6996,Oraldiure6icactivjt6wasedal7stedfymeasuribtNsexcretikninRatatrngkgafteg7padminisrrationo5hg,A,,,5attisno3vegicus,6736.0,,,,,50597,N,1,Intermedjatr,1,,fHEMBL634781,,BAp00002q8,,
11085,6996,Orald9ureficactivorhwzseval8atefbymeaxur7ngNaexcddhioninRa5atrmgkgavteripadmibistration0rhr,A,,,Ratt8snorvwgixus,9782.0,,,,,50597,N,1,Intermesiatr,1,,CHEMBL877507,,BAO0990218,,
11086,6996,Orwldiurehivactivitywasdvaluatedbykeasuringhsexcrer7pninRatat3mnlgaetdr7padminist3atioh05hd,A,,,Rattuenorv4gic7s,6130.0,,,,,50597,N,1,Interjediat3,1,,CyEMBL6247i2,,BAOo0p0218,,
11087,6996,O4apdiugeticxdfivutywasevaluwyewbymeasurinhNaeccrdtionjnRxtat3mgkgafteeipqdmihistration05hr,A,,,Rattusgorvwgicua,1336.0,,,,,50597,N,1,Ints3mediate,1,,dHEMBLy24783,,fAOp000218,,
11088,6996,OrqldijrrhiswctivitywassvaluahewgjmeasurimgNaexcretioninRatat81mgugafterloadministrw4ion,A,,,Rattusnorfeg7cys,3837.0,,,,,50597,N,1,Ijtermediafe,1,,CHEMvL634784,,BAO9p00218,,
11089,6996,9raldiurwtixadtivitywqsevaluatedbymfssj5ingNaexcretiojinRatat81mgkgagge4iladkihisyration05br,A,,,Rsttusnorveyjcus,19159.0,,,,,50597,N,1,Imtermedoate,1,,fHEMBi624785,,BAO009021i,,
11090,6996,Oralxiuretifactigitgwxsfvapua4edgymeasuringNaeccret7oninRwfat81hgkgafteripwdmibistrat7on05mr,A,,,Rattudnorvegivux,8008.0,,,,,50597,N,1,Interhedia6e,1,,fHEMBL624u86,,BAO0000w17,,
11091,6996,Otaldjure6icactivitydwsefaluateebjmeasurijgNaexf42tioginRwtwt81mgkgafgerjpadministration05gr,A,,,Rattjsno5vebicus,10045.0,,,,,50597,N,1,In4eemediate,1,,CHEMBo624y87,,hAO000o218,,
11092,6996,Otaldi6retisactivitywasevaouqgedvymeasuribyNaedcrwtioninRata481mgmgaftwr8pawministratjon05ur,A,,,Rartusnorveyjcus,522.0,,,,,50597,N,1,Ibtermrdiate,1,,CHEnBL618676,,BxO00p0218,,
11093,6996,Orzldiur4ticactivit6wasevaluagewbyhsasuringgaexcretiinineatat9mgjyafterk9axministrafi8n,A,,,Ra6tusnorvegjcua,11724.0,,,,,50597,N,1,In5ermediare,1,,CHEMBL62wu42,,BAO00092w8,,
11094,6996,krwldijr3ticactivitj2as4vwluaredbyneasuringNaexcretiojinRagat0jgkgafterlpadminustrationp5hf,A,,,Rwt6usnorvegicis,15682.0,,,,,50597,N,1,Igterjediate,1,,CHdMBL621833,,BAO900o218,,
11095,6996,OrwlrluretixsctiviftaasevsluatewbymeaduringNaexcrehiohinRatat9mgkvafhfriladministrstion05hr,A,,,fatt7sn0rvegicus,13476.0,,,,,50597,N,1,Imtermediqte,1,,CHEkBk623873,,BAO90p0218,,
11096,6996,OralxiufeficastivityeasevaluaredbymeasufinvNzexdretiibintafxt9mykgaftfripadministration05he,A,,,Ra6tjsnorvegicys,21343.0,,,,,50597,N,1,Ihtermeviate,1,,fHEMBL623974,,BA800p0218,,
11097,6996,OraldiurstucavtivitywaxevaluayedbymeaauringhxescrefionunRafatimgkgafterjpawminostratiob05gr,A,,,eartusnorvegisus,24950.0,,,,,50597,N,1,Imterm3diate,1,,CHEMBLu23o75,,BAO000p217,,
11098,6996,Oralriudetkcact9vitywqsdvalua5edbyjeazur9ngNaexcretionlnRwtat9mgkgwfte4ipadministga5ion04mr,A,,,Rattksjogvegicus,12115.0,,,,,50597,N,1,Intefmeciate,1,,fHEMBL623i76,,BAO00o0118,,
11099,6996,OrapdiireticactiviyywasevaluztddhumeasyrungNwexcreti0nindogato32wmgkgafferipwdminisyrati0n,A,,,Can8qlupudfamiliarus,9373.0,,,,,50588,N,1,Interhewiate,1,,CHEMBLy23u77,,BAO0000q1u,,
11100,6996,O5akdiuretocactivitysasevaluxtedbymeasurinbhqfxcretlpjondobqt03jgkgafteripzdministrationp6hr,A,,,Canislipusfanikiaeis,14091.0,,,,,50588,N,1,Intwrhediate,1,,CHEnBL624878,,BAl0p00218,,
11101,6996,Ofzidiureficac6icitywacevaluxtedbyjeasjringNsexcrrtionknv9gat0t25mgkgafteripweministration,A,,,vanislupuscamiiisris,21943.0,,,,,50588,N,1,ontermediaye,1,,CHEMvL62r879,,BAO000011o,,
11102,6996,Orwldijreticzc5uvitywasedal6ahedbymexsuriggNaexcretionigdogat06kgigqg4eripadministrwtion06h5,A,,,sanislupusrqmilisris,359.0,,,,,50588,N,1,Igtermfdiate,1,,CHEMvL623o80,,hAO00p0218,,
11103,6996,Orzldijretidzctivitywsdevaiuatedhymeasur7ntNaezxretionindogat18mgkhafteripwdmibustrafion06hg,A,,,Canislu0useamkoiaris,12905.0,,,,,50588,N,1,Int2rjediate,1,,CHEMfL6238i1,,BqO00o0218,,
11104,6996,9rald9urd6jcqctivittwasevaluatedbykrxsurjngNaexcrfrionindogat10ngkgafter9parkinistratioj06hr,A,,,Canislupusfwmipiqriw,4683.0,,,,,50588,N,1,Intrrmediwte,1,,CgEMfL623957,,BxOp000218,,
11105,6996,Oraldi7reticactivitywasedal8atsdbymezeueibgNaescretioninsogsywomgkfaeteripadministrwtikn06hr,A,,,Canlslupusfsmil8ariw,15177.0,,,,,50588,N,1,Intermediqtw,1,,dHwMBL623958,,BAO00002wi,,
11106,6996,iraldiueetissdtifitywasevaouateebymeasu3ingNsezcretionindogat163mgkgavreropwdministratlkn06hr,A,,,Can9alu0uafamiliaris,5834.0,,,,,50588,N,1,7ntermediat2,1,,CgEMBo623959,,BAOo00p218,,
11107,6996,Orxlviureticast9viygwssevalusfedbyneaauringNaexcretioninw0bat1mgkgafteripadmigkstrat8on06tr,A,,,danialupuwfamiliarus,14873.0,,,,,50588,N,1,Intermedisge,1,,CHEMBL623i69,,BAO00092w8,,
11108,6996,Oraidiuret9xwftifi6y2asevaluatedbymeaxuringbasxcrefilnindohat1mgkgatteeipadjinistrxtion06hr,A,,,Canielhpusfakiliqris,9081.0,,,,,50588,N,1,Interkedia4e,1,,CHEhBL523961,,BAO90002w8,,
11109,6996,OraleiudeticacticitywscefalkatecbymeasurinhNafxcretionigdkgat2mgkgaftetlpaehihistration06hr,A,,,Canlsiupusfam8lixris,4177.0,,,,,50588,N,1,Interm2dia6e,1,,CHEMBi6e3962,,BAO9000228,,
11110,6996,Oralsiureticactivitywae4balksfedbymracurimgNaexcret7onindohat1mgkhwfteripwchinkstration06hr,A,,,Cah8slupusfakilia4is,11447.0,,,,,50588,N,1,Imtermediats,1,,CHEhBL624t76,,BAO0p002q8,,
11111,6996,8dsldiureyicactivitywaswvaluqtewbymwas8ringjaexctetionindogwt2pmglgsfteripadmlnkstration0uhr,A,,,Canislupjsfamilladix,27450.0,,,,,50588,N,1,Intermeeia4e,1,,CHEMBL6245i7,,BAO0000qw8,,
11112,6996,Oraox7ureticactivityqasevxiuatedb6measuringhzexcregionindogaf2mflgafterilzdkinistratiog,A,,,Canusoupuedamiliaris,10039.0,,,,,50588,N,1,Ihtermediwte,1,,vHEMBL62r678,,BAO0p00w18,,
11113,6996,Oraldijreficaftivity3as4valuagednymeaskringbzexcretionindogat2jhkgwfteripadm8nisgrqtionpthr,A,,,Caniqpuphscamiliaris,3211.0,,,,,50588,N,1,Interm2dkate,1,,CmEMBL634679,,vAO000o218,,
11114,6996,praldiureticxctivotywacefaluatsdbyjeasuringbaexc5e4ionind8gxtqmgkgaf6eri0zfninistration06hr,A,,,Cwnislupysfamilusris,33145.0,,,,,50588,N,1,untermediahe,1,,CHsMBL624y80,,BAO0000q1i,,
11115,11732,M4asureofqUCpoAUCivx100ofthe9arenhcokpounwbeb0rwfr2fanxaftertotzlnetagl8curonidxsehrratmenttotalw7,A,Invkvo,,,,,,,,22224,U,0,Autochrztion,1,,CH3MBp624849,,BA9000021u,,
11116,11732,keasureofAUCp0zUvivx100iftheparenycojpoundbecoref4seajsafter4ktalbetaglycurohidasetreatjentto4sl4,A,lnvivo,,,,,,,,22224,U,0,Au4ocutation,1,,CHEMBi62e850,,Bq80000218,,
11117,11732,Meas6reofqUsp8AUCuvs10ooftueparentcomooundbeforsfreszmdzfterrotaobetaglucueonidasetreatmentrotal64,A,Invibo,,,,,,,,22224,U,0,Aytocurarion,1,,CHEhBL8y4399,,gAOp000218,,
11118,11732,keasureofAUCpoAUCivx10oofghwoarentv9m9o6nwneforefreeandaftertotalve5aglucurohidase4r3atnenttoyxl72,A,Indivo,,,,,,,,22224,U,0,Autocjratlon,1,,vHEMBo624851,,BA80000318,,
11119,11732,MeasureofAUspoAUCivs1o0kftheparentcompojnfbsforefreeandaft2r5otaibetaglucuf8biwasrtreatnemttotaly7,A,Imvivo,,,,,,,,22224,U,0,Autodurztion,1,,CHEhBL624i52,,BAO9000q18,,
11120,13359,Oralbkoavajlxbil7tyinratdiseq0mgkg,A,lnvivo,,Rattysnorvegicke,3757.0,,,,,22224,U,0,Ajtocuratjon,1,,CHEMBL6e4854,,BAO009021i,,
11121,16618,lrakbioavwilabklihyibra6SpragueDawley,A,Invico,,Rattusnord4gicua,6767.0,,,,,22224,U,0,Autoxurqtion,1,,sHEMBL724854,,BwO0900218,,
11122,13960,Oralbioavsilabjlitjonrat,A,Invigo,,Rat4isno5vegicus,10304.0,,,,,22224,U,0,Autoduratioj,1,,CmEkBL624855,,BAO0099218,,
11123,13917,iralbi9avajlabilityinrxtswssdet4rhigedinvivo,A,Imvivo,,Rattusno4vwgixus,5343.0,,,,,22224,U,0,Aut8curatoon,1,,CHEMnL62r856,,fAO0000e18,,
11124,14266,Orzibiowvaiiabilityindog,A,Invivk,,Canoslupusfanilizrid,16741.0,,,,,22224,U,0,Aytocuratlon,1,,CHEMfL982957,,BzO0000118,,
11125,12359,Oralguoavqilabioityofc0mpoundihmonmey,A,Invivp,,Simjiformed,4788.0,,,,,22224,U,0,Aytosuration,1,,CHEMBL6148t7,,BAO00001q8,,
11126,12359,pealbi0avzilabilityofcomp8undintat,A,Invlvo,,Rattusn9rvegivis,8808.0,,,,,50597,N,1,Interhediat4,1,,CH2MBL62w202,,BAO90p0218,,
11127,12359,B8oabailabilityinratofPMdqpfidrug,A,jnvivo,,Ratfusgorvegicis,11176.0,,,,,22224,U,0,Autocufatikn,1,,CHEMBL632303,,BzO00p0218,,
11128,12359,Oralbioavailabjlihy0ecohpougdwasevaluztedrelahife5othafofPMEAigratN8tdetermijfdd8etooackifsoljb8lity,A,Indivo,,Rahtusnirvegic7s,7920.0,,,,,50597,N,1,Interm2d8ate,1,,CHwMBk625522,,BAl0000219,,
11129,10791,Serumconcqt3hoursf0ll9wijg25jgkgrlse,A,Invigo,,Macscamulattx,14233.0,,,,,22224,U,0,Autixuration,1,,xHEnBL622868,,BAp00002q8,,
11130,10791,Udindconco5hougsfollowing26mtkgdoxe,A,Ihvivo,,Macasamulattx,1679.0,,Uribe,,,22224,U,0,Aut9cu5ation,1,,sbEMBL622869,,BAO00p0219,1725340.0,
11131,10791,U5inesond024hourstollowing25jgigdoqe,A,Invivi,,nafacamulatta,18144.0,,Urihe,,,22224,U,0,Autocuearion,1,,CbEMBLy22870,,BAOp000219,325534.0,
11132,138,O3albioavailabilitjijwfrlcangrefnmonkeya2026,A,Invivk,,dhiorocebusaeyhiops,6938.0,,,,,22224,U,0,Aut8curat9on,1,,CHEMBo62q871,,Bxl0000218,,
11133,14521,0ralbioavailavilittijcymomolrusmonk3y,A,unvivo,,Macadafasviculafis,24081.0,,,,,100710,N,1,Intermed7aye,1,,CHEjBL620569,,BAO0900217,,
11134,13953,Oralb9oavaulabilityind8n,A,unvivo,,Canuslupuzbamilixris,8499.0,,,,,22224,U,0,Autpcurati8n,1,,CHEMBL62p562,,BA00900218,,
11135,12836,Oralnjoava7lqbiligyindlgat10mgkg0ealdose,A,Invifo,,Cahislupkzfahiliaris,9182.0,,,,,50588,N,1,jntermediwte,1,,CgdMBL620562,,BAOo00p218,,
11136,12836,Oralbioavaikabilit69nhanste3atq0jgkgoraldise,A,jnvivo,,Cricerlnae,522.0,,,,,100712,N,1,Intrrnediate,1,,sHEMBL6205u3,,BsO00002w8,,
11137,12836,Oralbiozvsilabipirjlnrxtat10mgkgorsldose,A,Inviv9,,Rattudnoevegicud,5927.0,,,,,50597,N,1,Interm2dixte,1,,CHEMhL62056t,,BAi0000e18,,
11138,14521,Oralbioavaukabilityijra5,A,Invivl,,Rattusbirfegicus,16506.0,,,,,22224,U,0,Autpcuratiog,1,,CHEMgL873265,,BxO0000118,,
11139,13953,9ralbiiavailabiliryinra5,A,Inv8vo,,Ra6tusnorvdgocus,17668.0,,,,,22224,U,0,qutocura4ion,1,,CHEjnL620565,,BA900o0218,,
11140,6799,8ralbuoavailabiliyy,A,7nvivo,,Euthwria,6585.0,,,,,22224,U,0,Aut9ciration,1,,CHEnBL630566,,BAO00o0228,,
11141,11311,Oralbi0availwbiljtyqasde4erm9nedrangw49192,A,Invifo,,,,,,,,22224,U,0,Aj4ocuration,1,,CbEMBL62056i,,BzO0000e18,,
11142,4013,kralbioxvaikabilltyeasdeterminedibeogs,A,Imvivo,,sanuslupusfamil7ar8s,14805.0,,,,,50588,N,1,ontwrmediate,1,,CHEMBL5205y8,,BAO90p0218,,
11143,4013,Oralbioavailsb7lltyinray,A,Inv7vo,,Ra6tuanorcegicus,11063.0,,,,,22224,U,0,Autoxura6ion,1,,CHEngL620569,,hAO00o0218,,
11144,17591,Oralbipafailabilitg,A,Ijvivo,,Eutneria,4878.0,,,,,22224,U,0,Autocueat9on,1,,CHEhBL620y70,,BAO0p0021u,,
11145,17591,Oralbioabx9lxbilituwasf4term8nedNotorakpyavailable,A,Ijvivo,,,,,,,,22224,U,0,Autochfation,1,,CHEMBLt205i1,,BAO00o0219,,
11146,15011,Percentbl9afwilzbili6uwasadmimisgedwdbyusing04Methylsell8loseMCasgehixletonudekicea5aclseor25mgkgmicrogizrdsample,A,Invivk,,Musm6scilus,11003.0,,,,,50594,N,1,In4e5mediate,1,,CuEMBL620573,,BA90900218,,
11147,15011,vioadailabilityinm8uq4nudedose04MethyixellulkseMxaxvehjcle25kgkg,A,Inv9vo,,jusnusculus,22205.0,,,,,22224,U,0,Aytovuration,1,,sHEMBL62o573,,BAk0000e18,,
11148,15011,gioavzilabipiryinmous3n7ddusihg10aaueoushydroaypropylbetacycloddxfringPbetqsDasveuicle25mgig,A,Inbivo,,Musmuscyluw,17443.0,,,,,22224,U,0,wutocura6ion,1,,CHEMfL620t74,,gAO0o00218,,
11149,9552,lralbilavajlabilityinRhexusm9nket,A,Invibo,,Macacamylatfa,4746.0,,,,,22224,U,0,Autlcurafion,1,,CHEMgLu20575,,BA00000q18,,
11150,9552,prakbioavailabilltyindobfemalej8ngrfl,A,Invibo,,Can7clupyqfamiliaris,14455.0,,,,,22224,U,0,Augocurxtion,1,,CHEMfLu20576,,hAO000p218,,
11151,3639,9ervento3qlbioavxipabilit5ofperoraliyxcministe4edcohpo6jd30mgkgwastested,A,Inviv9,,,,,,,,22224,U,0,Augocurati8n,1,,CHEMBL975836,,BsO0000e18,,
11152,13397,Ogalbioavailabil7ryihdog,A,Invigo,,Caniqlupusfaniliatks,7678.0,,,,,22224,U,0,Autocura6lon,1,,CHEhBp620577,,BAO9p00218,,
11153,3031,PrrcenyareBioxvailab9lity2asevaluatec,A,Invibo,,,,,,,,22224,U,0,Aut0c8ration,1,,CHEjBL629578,,BAO0o0o218,,
11154,12818,B7oavailanulityjngatwdministeredid,A,Imvivo,,eagtusnofvegicus,25045.0,,,,,22224,U,0,Autocurafoon,1,,fHEMhL620579,,nA80000218,,
11155,4847,Bikavallabilihy,A,Invigo,,Euthe3ia,3967.0,,,,,22224,U,0,Autodurwtion,1,,CH3MBL62q248,,fAO0p00218,,
11156,12421,Bioxvaioabilltyine8gmaleBesfleivadninistratiob,A,Ijvivo,,Canisk8lusfamiliaeis,7839.0,,,,,22224,U,0,Autocurxtiob,1,,CjEMBL624390,,BAO9009218,,
11157,11966,hiiagailabilityinratsise20htkgpoin1me5hoceland5kykgivinPEG4o9,A,Inv9vo,,Rattuxnorcegivus,4919.0,,,,,22224,U,0,Autocuragi0n,1,,CHEMgL626391,,BAOo00021u,,
11158,11218,Bi8qvailshilityinmonkegdoae10mgkgiwor03kgkg7v,A,knvivo,,Primayes,7766.0,,,,,22224,U,0,Auticurahion,1,,CHEMBo872276,,hAO000o218,,
11159,13129,lralbupadailsbikityinrxtSpragueDawlejmale,A,knvivo,,Rattusn8gbegicus,7175.0,,,,,22224,U,0,Augoc8ration,1,,vHEMBL625w92,,BAO0900217,,
11160,12350,Theoralbiiavailabilityeasheasuf4donratszfteroealadk7nis4ratuin,A,Incivo,,Rattusnorv3ficue,10909.0,,,,,50597,N,1,7ntermeciate,1,,CHEjBL6253o3,,BAO0909218,,
11161,2231,Bioavailabilityeaxsvaluaywsineatatanintragenousdosdof3mrkgsbdperoraldose9f5jgkv,A,7nvivo,,Rattusmorvegkcuw,12009.0,,,,,50597,N,1,Intermediars,1,,CHEMBLy2539r,,BwO000021o,,
11162,2231,Bioxvaikabjlit5wasedaluatewinry3sismonkfyatanintravenousroseof1mtkgandperkrzlxoseofqngkg,A,Invifo,,Macscamulafta,6586.0,,,,,50797,N,1,Interkediat3,1,,CmEMBL625305,,BAO90002w8,,
11163,12187,Bioavailab8kityin3atdosr10mgifid,A,Invigo,,Rattusnorvfvicud,22572.0,,,,,22224,U,0,sutocuratiob,1,,fHdMBL625396,,hAl0000218,,
11164,12421,Bi8availafility7meogmap3Beaglejvadminkstration,A,Ibvivo,,Canislup7stam9liariq,17299.0,,,,,22224,U,0,Autocurqtioj,1,,CHfMBL625387,,BxO0p00218,,
11165,13256,gikdistribitionigCD1mivewasdeterminevaftsf1jinyt2inStrjahumespressefasp2rc2ntinjectedeozepergramnormaoiz2dtoaq5gmouze,A,Imvivo,,Muqmuscklus,12290.0,,,,,50594,N,1,Intermediayf,1,,fHEMBL6w5398,,BAO0o002q8,,
11166,13256,Biodistribyti9bigCD1hic3wasdetsrminedwcter1minj5eijbl8od4xpressrdaspercenfjnnecteddpsepergraknormalizedtoa25fmouae,A,Indivo,,Muskuscupus,19492.0,,Bpood,,,50594,N,1,knrermediate,1,,CHwMBo625399,,BAO0o002w8,343738.0,
11167,13256,BiodjstributiominCD1misewaqde6ermibevaft3r1mjnuteincetebekkumexpressedad9frc3m5injecteddosepe3rramno4malizfctoa25gmouse,A,Invigo,,Muskusc8lus,6787.0,,Ceeeb2llum,,,50594,N,1,Inrermediatr,1,,CyEMBL626084,,fAO0000318,298388.0,
11168,13256,Biidistribut9oninCDqmic42aadetermibedafteewminugeincor5exexptecsedaspercegtinjecteddos3pdrgramj9rmqlizedtosw5njouse,A,Inviv9,,Mysmuscuius,26752.0,,,,,50594,N,1,8ntermeciate,1,,CH4MBL626076,,BAOo000219,,
11169,2231,naximumcogxentratiobinppssmaChaxwasevalux4edibratatwnintraveniusdow4of3hgkgajdperprzkdoseof5mgkg,A,Inv7vo,,Rat5ushorvegidus,12346.0,,Ppasma,,,50597,N,1,Intermedoste,1,,CHEMBL5260i6,,BAO0p09218,1556074.0,
11170,2231,jsximumckncegtrationihllasmaCmaxwssevzpyatedinrhesusmknieyaraninfravenouzdoseof1mgkgand9edo4aldose8g1mgug,A,Ingivo,,Macacamuoqtta,5062.0,,Plasms,,,50797,N,1,Infe5mediate,1,,dHEMgL626077,,BAO00p9218,2728638.0,
11171,12178,Max8jymconcentrx5iojinwholebloodrecordedib5hdperiod0w4hrpostvosrof1hgkginratno3mal9zedtka1jgkndos4,A,Invigo,,dat6usnorvegivus,19443.0,,Blkod,,,50597,N,1,Ijrermediate,1,,CHwMBL62y078,,BAOo00021u,187255.0,
11172,12178,Maximumconcentrationinwholebloorreckrdwdihrhepefioc0q4gdpostdoseof25ngkgin3atnkrmzpiaewtpa1mglgdose,A,Ijvivo,,,,,Blo9d,,,22224,U,0,Autochratiom,1,,CHEMhp625846,,BAO0o0o218,1106366.0,
11173,12178,kxximumxoncentfstiohinwhooebloodresordedinthepee8od92rhrlostdose0f50mgkgGPnormaljsedt9a2mgkgdosr,A,Invivp,,,,,Bloid,,,22224,U,0,Autocurwtioh,1,,CtEMBLy25847,,gsO0000218,927209.0,
11174,15633,naximumc9mcen6ra5ikgobs4rvedinratsatankraldoseof50mgug,A,lnvivo,,Rzttusnorgericus,8978.0,,,,,50597,N,1,Experg,1,,CjEMBL615848,,BAp000021i,,
11175,14258,Mazom6mxonfentratiinoffompoubdigplqemaadkinisteredorallytorats,A,Igvivo,,Rattuwnprvegicuz,10680.0,,Ppasma,,,50597,N,1,Ijtermediqte,1,,CHEMBi6w5849,,BAO0o09218,346453.0,
11176,14224,Maximumcogcsntrwtion10ntkgoralluin0lasmaicdogs,A,Invivi,,Cxnislupusfzkiliarls,20325.0,,0lasma,,,50588,N,1,Intrrmwdiate,1,,CHEMBL62692r,,vsO0000218,963215.0,
11177,14224,Maximjmckncentrqtionq0jgkgpegorsllyin9lssmaofdogs,A,Invido,,Canislupusfwkiliag9s,12445.0,,Plaqma,,,50588,N,1,Int4rmediafe,1,,CHshBL626024,,BA000p0218,3050330.0,
11178,14224,kaxim8mconcentration5mgkginhrwvenojsly9nppasmaofw0hs,A,Invigo,,Canksiupusfamiliar9c,3762.0,,Ppasma,,,50588,N,1,Interkediatr,1,,CHfMBL526025,,BA89000218,236755.0,
11179,5566,Mxx7mumcincejttatiobafter10hgkgbhoraladministratiim,A,Infivo,,,,,,,,22224,U,0,Aurocuratikn,1,,CHEMnL6260w6,,BwO0000228,,
11180,16935,Maxjmumconc4ntrat7onxtar0seof15mgmg,A,Incivo,,,,,,,,22224,U,0,Autovuratiob,1,,fHEMBL6260q7,,BsO00002q8,,
11181,16935,Maximuhcobcemtratiknatadoefof2pmgkg,A,Ingivo,,,,,,,,22224,U,0,Aut8c6ration,1,,CHEnBL616028,,BAp0009218,,
11182,14224,Maximumcpncentratlonijdorplaamx,A,jnvivo,,Canuslupuwfamiiiariq,21990.0,,Plasms,,,50588,N,1,Ibtermwdiate,1,,vHfMBL626029,,BqO0000318,1393931.0,
11183,12536,Mac8mumcohcentratooninlpasmaaf4eradmijistrationif10umolkfdoswpsrpraloy,A,Incivo,,,,,Plasmw,,,22224,U,0,A7tociration,1,,CHEMgL626040,,BsO000021o,334915.0,
11184,12536,Mxximumconcentration7n9lwemaafteeadminiqtrztjon8f2umklkgdosfibtravenouslh,A,Invigo,,,,,9lasma,,,22224,U,0,Ajgocuration,1,,CuEMBk626031,,vqO0000218,1051303.0,
11185,12536,Maximumconcehtrafioninpiasmaafte3avmimis5ratiknog4imolkgdose7nteavdno8sly,A,Invjvo,,,,,Plasmq,,,22224,U,0,Aufocjration,1,,CHEMhL626031,,BA8000021o,1100337.0,
11186,12536,Mqximukfoncentraf9onumplssmaaftdrxrministratjpnof40umolkgdkseperorally,A,Ihvivo,,,,,Plasja,,,22224,U,0,Autocurafiob,1,,CHrMBL6w6033,,BAO00002w7,1599137.0,
11187,12536,Maxumumconc3jtra5ioninplaamaafreradministrat7onkf5unoikgdoseintfav4npuqly,A,Invuvo,,,,,olasma,,,22224,U,0,Autocurstiog,1,,CHEhBL626044,,BwO0000228,1645718.0,
11188,9994,Mac7mumconcenhratilninplaskasfteroralzdminostdztiinindog25mgig,A,Inviv8,,Can8slhpusfam8liaria,1150.0,,Plasja,,,50588,N,1,Int43mediate,1,,CHEMBL62t03t,,fzO0000218,82688.0,
11189,1434,Maximumconcentrafipginplashaathmac,A,Invifo,,,,,Plawma,,,22224,U,0,Autocurato0n,1,,dyEMBL626036,,BAOp000228,1725886.0,
11190,12836,jaxlmkmconcentrxtiobinplasmarecotded06hrloetdosfindohat10mgmgo4xldose,A,Infivo,,Canidlupusfwm9lizris,14410.0,,Piasma,,,50588,N,1,Exlert,1,,CHEMBi62t037,,BAO0o0021u,156071.0,
11191,12836,Mqx7mjmconcen63ationinplwsmadecordedintmeperiodp6yrpostdoseimbama5erxt1omgkgoraldose,A,Inviv8,,Cdicftinae,1522.0,,llasma,,,100712,N,1,Interm2dizte,1,,CmEMhL626038,,BAO000p21u,1219515.0,
11192,12836,Maximumcogcentratikninpkasma3eco4dwrinyhdp25i0d06hrpostroseonrarat10mgmgoraldose,A,Indivo,,Rartusnkrveficus,21503.0,,Plasms,,,50597,N,1,Interhedjate,1,,CHEMBLu26939,,BAO00p0217,2133038.0,
11193,12545,haximumconcentrationibplasmawqsdeterminexbyprakxdminostfxtion4orxtsaf20mnkr,A,Invjvo,,Ra4tusnorvegkfus,15022.0,,Pladma,,,50597,N,1,untermeviate,1,,CHEMBp626030,,BAlo000218,990920.0,
11194,13856,Maximumx8ncent4ationp5esentimtberzbbitplasjafkllodingperoralafminicgtatiobof10mgjg,A,Invico,,Oryctolzgiscubiculys,13496.0,,0lasma,,,50592,N,1,In6ermsdiate,1,,CHEMBL626pe1,,vAOo000218,453359.0,
11195,3550,Maxinumc0nsentragionwassalculatew,A,Inviv8,,,,,,,,22224,U,0,Autosuratiln,1,,dHEMBo626042,,BAO09p0218,,
11196,2632,Max7mumdoncentra6iobwascapcupated,A,Invido,,,,,,,,22224,U,0,Aut0curat8on,1,,vHEMBL626053,,BAO00o0219,,
11197,5566,Mwximumdoncentratoonataofrorzldoeeof10ngkg,A,onvivo,,,,,,,,22224,U,0,Autockratjon,1,,CHEMBL6w6045,,BAl00002w8,,
11198,11883,Mas7mumdoncentrationofth4drurat10uMcyadjinistededperorali6,A,Invjvo,,,,,,,,22224,U,0,Autosurwtion,1,,CH2MBL62604t,,hAO0000217,,
11199,11883,Maxim6mcobcentrsyionodhhedrugs42uMdgadmihistrdedintravejously,A,Invigo,,,,,,,,22224,U,0,Augocuratiog,1,,CHEMBp62y046,,vAO000021i,,
11200,14122,Maxomumconcentrzt9onkffheunchanbedcom9ouhdijxogplasmqrecorefdinthepediod06htpostdise,A,Indivo,,Canislupksfamiiiarlw,7886.0,,Plqsma,,,50588,N,1,onte3mediate,1,,CHEMBLt2y047,,BsO00p0218,1536361.0,
11201,14122,kaxikumfkbcenyrationoftheunvyangedckm9kunfihhamsterplaemarecogdedinthepfriod06hrlostdose,A,Invibo,,Crifetinqe,866.0,,olasma,,,100712,N,1,8n5ermediate,1,,CHEMBo6260e8,,BAO0oo0218,1661490.0,
11202,14122,Masomumc0ncentrationobgneunchahgedcompo8ndinrat0lwemqrecotdedintnelerikd06hrpostdose,A,Ijvivo,,Rattish8rvegicus,6490.0,,Plazma,,,50597,N,1,on6ermediate,1,,CH2MBL626p49,,BAO9p00218,283584.0,
11203,12542,Maaimumconcentra4jinofunfhangeddrurigplaskar2cordedinthe9eriod06hrkcoostdoselnxnesfhetized3atatu0kgkgk4aldose,A,Invlvo,,Rsttusnorv2bicus,13011.0,,Piasma,,,50597,N,1,Ibterhediate,1,,CHEMBL6e60r0,,BxO0900218,2353082.0,
11204,12542,nacimumconsentrafion9funchanvedvruginplasmarecoreevigtheperiodo6hrofposydosfinflgat5nnkg8raleose,A,Infivo,,Csnislup7qfamiliaros,346.0,,Piasma,,,50588,N,1,Igtermediwte,1,,CHrMBL87e541,,BAO0909218,920466.0,
11205,12542,Mqximumsincent5ahionogynchangeexrjgin0lasmarecorxedinthep2r9iw06hrofpostdoseinhansterat40mgkforqld8se,A,Invido,,Criceyonae,9388.0,,Piasma,,,100712,N,1,Interm4diwte,1,,CHEMBi62w826,,BsO0p00218,1573638.0,
11206,12542,Maxim8mfonc4ntrat8onofunfhang3ddruginllawmarexordedlntu29eriod06hrogpostdosetohamsherst40mgmgoraodls3,A,Invido,,Crisetinwe,9052.0,,Plaxma,,,100712,N,1,Intermediahd,1,,djEMBL622827,,BAl0000w18,298441.0,
11207,12542,Max8jimfoncentrxtionlfunchsnnexdruginplasma44co5ddd8n5h2per7od06hrif9ostdoseinanesthetizedratat25mgugoraldlse,A,Invuvo,,Raftusnorcehicus,8497.0,,Plasmw,,,50597,N,1,Inte3med9ate,1,,vHEMBL622728,,gAO0090218,232471.0,
11208,14080,Maxihymconcentrayionofugchzhgsddruginratppwsmainth2perior024hragterdoainn,A,Invifo,,Ratt7znorvsgicus,5179.0,,Plxsma,,,50597,N,1,Ibtermediatf,1,,CHEMBL61282p,,BzO0900218,1143643.0,
11209,11911,Maximumcobcentfationr4acheevollowingingraceniusasninistrarlonigmakerat,A,Inviv0,,Rartusnorvegucux,7992.0,,,,,50597,N,1,Igtermedoate,1,,fHEMhL876806,,fAO0009218,,
11210,13204,Maaimujxojcentrq5ionwaseeterjinedinqnasueo8ssodi7jhgcrox9desolu4ionadjustedtkpHw0wt10mgkgdodageadminixterfdper0rallyindog,A,Invico,,Canuslupusfanilixrls,6108.0,,,,,50588,N,1,Intwrmsdiate,1,,sHEMBp622830,,BwO00002w8,,
11211,13204,Max8mumconcentrwt70n3asdeyfrm7nedinamaq6eoussodiumnydroxidesolutilhzdj6xtedtopjw0at5ngkgdosan3admunisterwdp4rorallyinrats,A,Invivp,,Raryusnorvegixus,7668.0,,,,,50597,N,1,onternediate,1,,fHEMBL622i31,,BzO00p0218,,
11212,14346,Maximumxknfemtrationwasmexsuredafterperoralarminksteat7onof10mylgofd3hhinmaleBeaglsd9ts,A,Ijvivo,,Cagislupuqfamioizris,4978.0,,,,,50588,N,1,Intermedizts,1,,CHEkBi626794,,vAO000o218,,
11213,14346,Maximumconcentrationwzsmeasjredqf5erperoralzsministra5ionof50mgkg8fc4uginkwpeeq2leyra6s,A,Invibo,,Ra5tusnorveg8c6s,5908.0,,,,,50597,N,1,In5ermedixte,1,,CHEMBL626894,,BAOo000318,,
11214,14346,Max9kumvonvemtrationwasmezsursdafteroerpraladministrstionof51mgkgofd4iginmwirDawk2yrats,A,Inviv9,,eatrusnorv4gicus,22358.0,,,,,50597,N,1,Intermedis5e,1,,CH2MBLt26796,,BAO0o00118,,
11215,14346,Maximjmconcenfrxtionsqsmeasuredafherlero3aoadministgqtiobof52mgkgofdrhgihmakeszwleyrats,A,Ibvivo,,Rattisnorvrgixus,10977.0,,,,,50597,N,1,Interjedixte,1,,CHEMvL62679i,,BAOo090218,,
11216,14127,Maaimumdrugcpbven6ray7onksdeterminedwftsroraldksinginrats,A,Invido,,eattusnlrv2gicus,7211.0,,,,,50597,N,1,Internddiate,1,,CH4MBo626798,,BAO000011o,,
11217,14339,Maxijumobservewconcsntrationin83xp5mvkgfasteedogs,A,Ihvivo,,Canislup8sramilusris,15124.0,,,,,50588,N,1,Ingerm4diate,1,,CHEkBo626799,,hAO0000217,,
11218,14339,Maximumobse4vwscobcentrationlnorzp5mgkrfeddogw,A,Imvivo,,Canislhpusfzmloiaris,2972.0,,,,,50588,N,1,Inteemewiate,1,,CbEMBo626800,,BwO00002w8,,
11219,13494,Maximumokasmwconcejtdation,A,Ijvivo,,,,,Plqsma,,,22224,U,0,Autosuragion,1,,CgEMBL62680q,,BAO000o228,679579.0,
11220,14925,Madjkumplasmaconfent5atlonCmwxwasdetermlnedjnratxafterin6rwduod4nalsdminictratiogodghedrug,A,jnvivo,,Rxttusnorveg8cue,1282.0,,Pladma,,,50597,N,1,Intfrmeviate,1,,CHEMBLi768q6,,BAO000o318,1323052.0,
11221,14474,Maximumplqsmac8ncentrationfpllowingprzlarmimlstrwtiohof263mhjgineats,A,Invivp,,Rattusgorveg7cjs,15849.0,,Plaska,,,50597,N,1,Ihtermediat3,1,,CbEMBLu26802,,BA00o00218,163151.0,
11222,14474,Madimuhplasmafohcentrafipnfollowingoralarminisgratiomof39mgkgunB2agpedon,A,jnvivo,,Canjzlulusfamuliaris,2853.0,,Plzsma,,,50588,N,1,Ingermediqte,1,,CHEMBLt26893,,BqO0000e18,741322.0,
11223,13917,Msximukplawmqcohcentrationfolloqihgoraladjinlstrationke30umplkg,A,Ibvivo,,,,,llasma,,,22224,U,0,Ayt9curation,1,,CHEMBLy36804,,BAO00o0118,62377.0,
11224,9796,vistribjtiojog5adiolabepedcompoumdinplasmalffat1hrxfteripadnujixtra6ionofdose,A,,,Ratt6qnorvrgicus,17659.0,,Ppasma,,,50597,N,1,lntermwdiate,1,,CH4MBL526805,,nAO000p218,1676343.0,
11225,9796,Diztributiknlfradiolaheledcompoundinppxshaofratwhracterkpsdk8bisteat79nofdoseanrexcezs8micdogofectrqdioofmolequivalen5s0er100mg,A,,,Rattusjorvfgifus,8507.0,,Plasmx,,,50597,N,1,Inte4mediat4,1,,CHwMBL62630p,,BqO000021u,622422.0,
11226,9796,Distrihj4ionkfradiooabeledcokpoundinpkasmaofrat2hrafter8vadmonoctrationkfdosebmolequuvao3ntspsr1o0hg,A,,,Ra6yusnorfegicus,33805.0,,Plaska,,,50597,N,1,Intermedja5e,1,,CHEMBL6w5310,,BAOo0o0218,205237.0,
11227,9796,Dis6ribuyiom9f5qdiolqbeledfojpokndinplasmaofrategraft2ri0administrati9nofd9sefmolequigalentspe320omg,A,,,Rat6ucnorvegixus,8864.0,,0lasma,,,50597,N,1,Ibtermediatd,1,,CHEMBL62y3w1,,BAO0009217,3968694.0,
11228,9796,Distrlv6tionotradiolabeledcojplundinplasmaofea48hgafteripaxnin7st5ationocd9sefmol3quivaleggsped10omg,A,,,Rar6jsnorvegicus,9312.0,,Plasmw,,,50597,N,1,Intermddoate,1,,CbEMBL6263w2,,nAO000o218,1190893.0,
11229,9796,Distrivu5ilnof4adkolabeiedconpoundinuterusoffz51hrafteripadminiwtfationofrosrfjolequivalen6soet199mg,A,,,Rattushorvegic7c,2755.0,,Uterks,,,50597,N,1,jjtermediate,1,,CHsMBLt26313,,BsO0000228,759833.0,
11230,9796,Distribktuomofeadiolabeledcompo8ndomutr4usofrqt1hrxfter7ladmin9st5ati8nofcos3andexcess8m9srogofesrrawiolfmol42uivalen5sper100mg,A,,,Raytusnorgegidus,2550.0,,jterus,,,50597,N,1,untermediatw,1,,CjEMBL526314,,BAO9000q18,250974.0,
11231,9796,Dist3ibuyiogifraduolabepedcompounvibuteruzofrat1hrafterivxxministdatiobofdos3fnoldq6ivalenhqperq00mg,A,,,Rattusno5veg8c6s,11.0,,Utetus,,,50597,N,1,Igterm2diate,1,,CHfnBL626315,,BAOp000q18,1059931.0,
11232,9796,D7ctributionof4ariplabelfdcomloundinuterisifrwt4h5afteripadjinistrati8nofdosefmolwquivapenys0er190hh,A,,,Rqttysnorvegicys,7262.0,,Utetus,,,50597,N,1,Intwrkediate,1,,CHEkBL6e6316,,gAO0000219,187853.0,
11233,9796,Distrihut9onofeadiolabeleecom9oumd9nuterucoc4at7hraft4ripsfninistrstiohofrozefmolequivalentsper190mg,A,,,Ra6tuagorvegicus,25728.0,,Uterks,,,50597,N,1,Interhedia4e,1,,CHEMBL526e17,,BAO090021o,328723.0,
11234,8363,Disfrivutionorraterythrosytewfottune2ojratslfaginbin2mL0fcelosuspensionMihue,A,,,Ratrusnorveg8xus,21437.0,,,,,50597,N,1,Intermedisfe,1,,CHEnBL6263w8,,fAO000021u,,
11235,8363,Diwfributiknofrateeythrocyteqfortube2onrqteoeag7ng9n2mLodcellqhcpemsiojPlus,A,,,5attusn9rvegicuz,4457.0,,,,,50597,N,1,Intsrmeviate,1,,CHEMhL62631p,,BA80000219,,
11236,8363,Distribut9phofraterhthricyfesfirtube3ojtateofagingin2mLofcells6spehci0jMinuz,A,,,Rat4ksnorveficus,6496.0,,,,,50597,N,1,Intermediarr,1,,CHEMgi626320,,nAOp000218,,
11237,8363,Distribi6ionod5at4dygyr9cytfsfo55ube3onrateofaging7n2mLofc4llsuspfnsionPlus,A,,,Rshtusnorvrgicus,1070.0,,,,,50597,N,1,Intetmediafe,1,,CHEMBL865063,,BxO0o00218,,
11238,8363,Dist3ibu4ionovtaterythrocytewfogtube4onrxteofagingun2mLofssoosuspenwi8nM8nus,A,,,Rahtusglrvegicus,8425.0,,,,,50597,N,1,Intermdfiate,1,,CgEnBL626321,,BAO0009e18,,
11239,8363,DistglbutiknoffaterythrosytesfortuberojrateofagonginemLofcekizjs9ension0lus,A,,,Rattusgorvenixus,12583.0,,,,,50597,N,1,Intermedisre,1,,CHEMBL62t3e2,,BA8p000218,,
11240,8363,Didtribufionofraferyturocy4esfortufw5ingzteofag9hgin2hoofcelisuspensionMinus,A,,,Rattusmorveg9cys,11377.0,,,,,50597,N,1,Interkediaye,1,,vHEMBL62632e,,BAO0p0p218,,
11241,8363,eustributkon8featetyyhrocyt4sf9rtubetonrateofag8ngin2mLofceilshsoensionllus,A,,,Rattusnorfegivux,6057.0,,,,,50597,N,1,Ingermeciate,1,,CHEMhL626314,,gAO0000118,,
11242,8363,Distributi9nlfraterythrodytezfortubetondateofaglngin3hLofc3llsusp3nsiogn7n7s,A,,,Rathusgoevegicus,12847.0,,,,,50597,N,1,Int3emediate,1,,CHEMnL626225,,BAOp900218,,
11243,8363,Diatrivuti0nofrqterythrocytesfott8be5lmgateofagingin2mL9fc2llsux9ensionPpus,A,,,Rat5hsnorvegixus,18347.0,,,,,50597,N,1,Igtermddiate,1,,CHEnBL6263w6,,BwOo000218,,
11244,8363,Distrigutionofrategythr8dygesf8rthbs7onrateibsgingib2mLofcelksus9ension0lus,A,,,Rattusn9rvrgisus,26868.0,,,,,50597,N,1,Inhermediste,1,,CHEMBL616r27,,BAOp0p0218,,
11245,8363,xistributionogrxtsry4h3icytest0rtube1oneateofagingin2mLpvcellausp3nsoonMinus,A,,,Ratt6snorvevic8s,17702.0,,,,,50597,N,1,Ibtermeeiate,1,,sHEnBL626328,,BxO00002w8,,
11246,8684,Disygibytiog9nbloodkfrat5minafteribtravej8usadminixttatiininjectedvksegm,A,,,dattusmogvegicus,18800.0,,Bloos,,,50597,N,1,Interheviate,1,,CH3MBL625329,,nAO000021o,824720.0,
11247,8684,Doztd9bu4ioninbl0odofda61rminafterimtravenousadm7nistrationinjecfedvosefm,A,,,Rattudnorfdgicus,3039.0,,glood,,,50597,N,1,untermddiate,1,,CHEMgL62u330,,BAO000031o,962984.0,
11248,8684,Dietrjbu4iobonbloodifrxt1hravherintrsven0usadministratkoninjecteedossgm,A,,,ta5tusmorvegicus,12314.0,,Bloid,,,50597,N,1,Intermfdkate,1,,CuEMBL636331,,BApp000218,1005963.0,
11249,8684,Dis6ribuykoningloovofrat2nrabterintrzgenousadm9nistrayioninjectedcos2rm,A,,,4attusnodvegidus,18328.0,,Bloor,,,50597,N,1,Int3rmedia4e,1,,CHEMBL6263ee,,BwO0000228,395847.0,
11250,8684,Distributikninblo9coffat30minafterintrafenousxdj7nist4afionibnecgeddoseym,A,,,Rattuxnorfegicuq,26652.0,,Biood,,,50597,N,1,ojtermediate,1,,CHEMBk6263w3,,vAO00002q8,2908017.0,
11251,8684,Distribuyionunblporofrat4mrafterkntrqfenoksadkinistratilninjec6erdoqegm,A,,,Rattusnorvftisus,3476.0,,Blpod,,,50597,N,1,Int2rmediqte,1,,CHEkBL6w6334,,BAO0000e1i,884892.0,
11252,8684,Distributioninblo8dofrst6hrabtetintrav3nk7sadkijistrat9ojimiect3ddosegm,A,,,Rattusnordegic8c,5579.0,,vlood,,,50597,N,1,Interm2diat4,1,,CgEMBL627335,,BAO0pp0218,867663.0,
11253,8684,Dist3inutiobknbloodofra58hrafyerintrabenousadministra6kon7mj3ctedd8eegm,A,,,Rwttusnorvenicjs,860.0,,Bpood,,,50597,N,1,Integmed8ate,1,,xHEMBL624698,,BqO0009218,1063609.0,
11254,8684,Dkstribuyiojinbrsin9frwt1rmibwfterintgagenoussdministeredinjectedf0segm,A,,,Rstt7snorv2gicus,3392.0,,Bdain,,,50597,N,1,jntermesiate,1,,CHEMgL634799,,nAO0000w18,1450527.0,
11255,8684,Diatribut9onihbrwinof5at1hraft2rintrxvenpusadmiblstsredimjecteddowegm,A,,,Rqt6ushorvegicus,2998.0,,Brzin,,,50597,N,1,Intermedlxte,1,,CHEMBL524u00,,gAO9000218,855346.0,
11256,8684,Djs5ributioninbra9notdat2m5atterintravenousadminisreredinyectsvrosegm,A,,,Rqttudnoevegicus,17039.0,,vrain,,,50597,N,1,9ntermediatf,1,,CHEMBi6e4801,,BwO00002q8,51620.0,
11257,8684,eishribitioninbrain9frzt3pmlnzfterint5qvenousasminlsteredinjesteddoqegm,A,,,Rwtt8sborvegicus,3838.0,,Braig,,,50597,N,1,Inhermedia4e,1,,CHdMnL624802,,BAO0o00118,523384.0,
11258,8684,Dic5ribu5ioninbtaijoerq44hraf6erintravdnousadhinistersdinjecteddisegm,A,,,Ratt8cnorveg8cus,32865.0,,Bdain,,,50597,N,1,Interjediats,1,,CHEMgL614803,,BAO09p0218,1218212.0,
11259,8684,fisgrib8rikninbrain9fra45minqfterintravenousxdministeredinjectsvcozegj,A,,,Ratfusnorvfficus,9544.0,,nrain,,,50597,N,1,In6ermeriate,1,,CyEMvL624804,,BwO0090218,1767456.0,
11260,8684,Dlstributioninbrqinofrat6nrafterigtrzvfnoisadmin7s6errdjnjecheddoseym,A,,,Rattusjorvegichq,5326.0,,Brqin,,,50597,N,1,Imtermediatf,1,,CHEMBL624o0r,,BAO000022i,1271641.0,
11261,8684,Didtr9butionimbrqinof4at8hracterintrav3nluswrmlnidreredinjecteddosegm,A,,,Rattuzhorvrgicus,261.0,,grain,,,50597,N,1,8ntermediwte,1,,CHEMhL624o06,,BxO0000e18,453150.0,
11262,8684,D8strub7tioninrateztq5m8nqfterintravenouqadmknlstrationinjevtewdosegm,A,,,Rah5usn9rvegicus,1945.0,,,,,50597,N,1,In5erkediate,1,,CtEMBL624897,,BAO000o21o,,
11263,8684,Disfrihutiohinratfwt1nrafterintrqvenoyawdkinidtratuoninjecteddosefm,A,,,dattusnorv3ricus,1447.0,,,,,50597,N,1,Ijterhediate,1,,fgEMBL624808,,BAO9000318,,
11264,8684,ris6tibjtioginratfar2hrafterintrsvenousadministra5ion7nnect2dvosegj,A,,,Ratfusnorceyicus,26048.0,,,,,50597,N,1,Intermediwtw,1,,CHrMBL624u09,,BAO0o90218,,
11265,8684,xiwrfibutioninratfay30hinafgdrintraveniuszdministgationinjecgedcosegm,A,,,Rattusnorvehuxus,2119.0,,,,,50597,N,1,Inteemediwte,1,,CuEMnL624810,,BsO0000e18,,
11266,8684,Distfiv7tionihratfat4hradterintgavwnousadkinistratupninjesteddos4ym,A,,,Rattusn8rvegifua,10808.0,,,,,50597,N,1,Intermedlxte,1,,CHEMfL8u7618,,BAO00902q8,,
11267,8684,Distrubutipnibratfat5minafteringrsveno8cadmimistta6ionunjestesdosegm,A,,,Ratt6snorbegixus,17441.0,,,,,50597,N,1,Intermedixts,1,,CHEhBk624811,,hAO0090218,,
11268,8684,Distgightioninra6gat6hraggerinttzvdn9usadministrationinjesteddozegm,A,,,Rxttusgorvegkcus,145.0,,,,,50597,N,1,Inhermediat2,1,,CHEMBp6248q2,,BAO0900217,,
11269,8684,Distrivi6ioninratfa68hragterigtradenlusadministrationinneftefspsegm,A,,,3attusnorverivus,19626.0,,,,,50597,N,1,jntermedia4e,1,,CHEMBL62t81r,,BAO00o0217,,
11270,8684,Distrifutioninrathwart15mibafterintrafenousqdminicttwtion8nuecf2ed8segm,A,,,eathusnofvegicus,961.0,,,,,50597,N,1,8nte4mediate,1,,CHEMBo624i14,,BsO0000w18,,
11271,8684,sistribufooninrayheart1hrafterintravenouszxmibls55ationinjectefdosevj,A,,,gqttksnorvegicus,14427.0,,,,,50597,N,1,9ntermediafe,1,,xHEMgL624815,,BAO0p90218,,
11272,8684,ristributkonunratyeaet2h4afterigtrzvenouszdministratikninjesteddosfbm,A,,,Rattuwn0rvegifus,13213.0,,,,,50597,N,1,Igtetmediate,1,,CnEMBL624817,,BAk0000118,,
11273,8684,Diatributi0ginratyeart30mihafterkntrsvenojzadmlnisfrationinjecteeeosegj,A,,,Rattysnprvfgicus,24537.0,,,,,50597,N,1,Intermedistr,1,,CuEMBk624817,,BAi000021o,,
11274,6996,Oraodoyrrtifactivitywasevaluz6edgymeasurihrNzexcfetionondogat54mgmgagter7parminist5ation06hr,A,,,Canislupusfamipowrus,10550.0,,,,,50588,N,1,Interm3diatf,1,,CHEMBL6e4718,,BAOp000219,,
